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 How to Use This Book?
This is a book that deals with the daily practice of rheumatology! We did not 
write it just to make another book! It is not a book to be added to the list that 
already exists on the shelf! It is a small practical one, in which we rather 
focus on the skills that the physician, the patient, or caregiver might need to 
take care of rheumatologic complaints and diseases!
Many junior staff start working in Rheumatology or see patients with 
arthritis may find themselves incompetent in basic skills while evaluating 
such patients. This book provides a comprehensive yet simple guide for 
junior or senior staff to deal with rheumatology patients.
You do not need to read the whole book to get its benefits nor do you need 
to read it linearly. You just need to read the relevant section you are interested 
in. For example, if you just need to know how to examine the small joints of 
the hands, you can go directly to musculoskeletal (MSK) examination chap-
ter: hands examination or if you need to know details about a biological drugs 
used in Rheumatology, you can go directly to the pharmacology chapter: bio-
logical drugs. In other words, you may determine in advance what you need 
to master each time you hold the book!
The book consists of three parts. The first part is about basic skills in rheu-
matology. There is a comprehensive approach to history taking of patients 
with arthritis. We suggest this approach on the basis of differential diagnosis. 
Any patient with arthritis needs a comprehensive MSK examination, labora-
tory evaluation, pharmacological drugs analysis and radiological assessment. 
(You may just need to know what drugs are the patient taking especially if he/
she has an established diagnosis of arthritis?). We put special emphasis on 
low back pain, as there is a distinctive approach to this complaint. There is a 
significant delay that may reach 7–10 years before one can diagnose a patient 
with diseases characterized by inflammatory back pain like ankylosing spon-
dylitis (AS).
The second part of the book is designed to address common medical prob-
lems affecting patients with arthritis. It is truly said that to be good in rheuma-
tology you need to be good in internal medicine! Rheumatologic diseases are 
systemic diseases affecting nearly all body systems. This comprehensive 
approach to common medical problems should emphasize the reader’s skills 
not only in Rheumatology but also in general internal medicine. A reader can 
approach this part at any point. If a systemic lupus erythematosus (SLE) patient 
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has anemia, there is a hematology chapter one can go to directly to; or if another 
SLE patient has headaches, stroke, and/or other neurological complaints, just 
read the chapter that deals with how to approach neurological complaints that 
contain elegant flow chart, tables, and diagnostic algorithms. There is also a 
chapter about pediatric Rheumatology highlighting the essential issues in deal-
ing with rheumatic diseases in this young age group.
The last part of the book is a compilation of recent recommendations for 
management guidelines and current classification criteria in Rheumatology. 
Lately, there has been a tremendous progress in the practice of Rheumatology 
worldwide. This has resulted in the introduction of new recommendations for 
the management and classification criteria. We tried to bring in this part all 
efforts that have been produced to enhance the practice of Rheumatology. 
However, if you need to read further details about the management of a par-
ticular disease beyond the guidelines, you would need to read from recent 
medical literature.
To sum up: this book is a practical guide designed for building your skills 
in dealing with Rheumatology patients. We focus on diagnostic approaches to 
medical problems. You may find more than one style in the different chapters 
you are going to read. This is because each contributor thought about the best 
approach to deliver the contents. This may explain partly the variations in 
writing styles in some chapters. Dealing with a patient with a skin condition 
in rheumatology may not have the same approach as when dealing with a 
patient with shortness of breath. We offer variety of approaches to entertain 
the reader.
We hope that medical students, interns, residents, fellows, general practi-
tioners, and rheumatologists appreciate the efforts put into making this book 
a useful aid to deliver a better care for patients with arthritis.
The objectives of this book are as follows:
 1. To compose a comprehensive approach to managing patients with arthritis.
 2. To perform MSK examinations for the most commonly involved joints in 
inflammatory arthritis.
 3. To interpret autoantibodies in the appropriate clinical settings.
 4. To discuss indications and contraindications of the most common drugs 
used in rheumatology practice.
 5. To order appropriate imaging modality for assessing patients with rheu-
matic complaints.
 6. To construct a diagnostic approach to common medical problems affect-
ing patients with rheumatic diseases.
 7. To review recent classification criteria and treatment recommendation 
guidelines in rheumatology.
We hope you will enjoy reading this book. We welcome your comments 
and feedback.
Makkah, Saudi Arabia Hani Almoallim
Jeddah, Saudi Arabia Mohammad Cheikh
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History taking in rheumatology is the most impor-
tant skill needed for proper handling of a patient 
with a rheumatological complaint. Obtaining a 
good history will help you to reach almost 90% 
of your diagnosis. However, history taking is 
mostly depending on experience and practice 
rather than theoretical recall. Here in this section, 
we provide you with the most important points in 
history taking you should use while dealing with 
rheumatological patients. There is an approach to 
history taking in rheumatology started as with the 
classical approach in history taking like any other 
disease. There is much focus on rheumatological 
aspects related to the onset of joints pains, pat-
terns, symmetry of joints involvement, number 
of joints involved, and ultimately rheumatology 
review of systems. We summarized the classic 
symptomatic correlations with certain rheumato-
logical diseases. We present briefly a suggested 
approach to your presentation of the entire case.
1.1.1  Objectives
 1. To compose a comprehensive and organize 
history for patients with rheumatological 
problems.
 2. To recall the most important points in eliciting 
history for certain rheumatological diseases.
 3. To construct a differential diagnosis in 
rheumatology.
 4. To develop an approach for monitoring 
patients with arthritis.
1.2  Approach to History Taking 
in Rheumatology
This approach is based on the assumption that 
majority of patients with rheumatological dis-
eases present at the beginning with joint(s) 
pain. Rheumatological diseases are systemic 
diseases affecting almost all body systems 
with no system that is preserved. You may 
have patients with neurological complaints 
(like hemiplegia because of ischemic stroke) 
end up with the diagnosis of a rheumatologi-
cal disease like systemic lupus erythematosus 
(SLE) and secondary antiphospholipid syn-
drome (APS). Here the initial presentation was 
not joints pain, but yet the final diagnosis was 
rheumatological. This concept emphasizes the 
point that good foundations in general inter-
nal medicine is essential to the rheumatology 
practice.
L. Alharbi 
Medical College, Umm Al Qura university,  
Makkah, Saudi Arabia 
Department of Internal Medicine, Skåne University 
Hospital, Malmoe, Sweden 
H. Almoallim (*) 





The approach to joints pain for any new 
patient should establish two basic issues: the 
personal data and then full analysis of the pre-




 3. Patterns of joints affected.
 4. Symmetry.
 5. Number of joints affected.
 6. Associated symptoms.
 7. Constitutional symptoms.
 8. Functional impairment.
 9. Relieving and aggravating factors.
 10. Rheumatology review of systems.
This should be followed by the classical com-
ponents in any history taking in internal medicine 
(past medical and surgical history, family history, 
drug and allergy, and social history).
Here is a brief description about each one of 
the above.
 1. Onset: The patient should determine whether 
joint(s) pain have started suddenly or gradu-
ally. This is essential as the top differential 
diagnoses that should be ruled out for sudden 
Ia- Classical approach for a new patient
A-Personal Identification B-History of presenting illness
(joints pain)
1-Onset
(When did you first notice this problem)
X X X X X
2-Duration
- Acute: < 6 weeks
- Chronic: > 6 week
Sudden (hours to few days):
- Septic arthritis (bacterial
  arthritis, viral arthritis
  (e.g. parvovirus 19 and
  rubella)




  rheumatoid arthritis.
- Inflammatory arthritis like:
  rheumatoid arthritis (RA),
  psoriatic arthritis (PsA),
  reactive arthritis (ReA),
  systemic lupus erythematosus
  (SLE),
  juvenile idiopathic arthritis
  (JIA),
- Chronic bacterial infections
  like mycobacterial and fungal
  arthritis,
- Degenerative arthritis like
  osteoarthritis (OA),
- Rare: most cases of
  neuropathic arthropathy
  (Charcot's joints), tumors,
  infiltrative diseases
Gradual (weeks to months):
Fig. 1.1 Approach to history taking in rheumatology
L. Alharbi and H. Almoallim
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onset of joints pains are septic arthritis and 
crystal-induced arthritis (after excluding 
trauma as a possible cause for joints pains) 
(Fig.  1.2). Gradual onset joint pains have 
long list of differential diagnoses including 
the classic rheumatological diseases like 
rheumatoid arthritis (RA) and SLE (see 
Fig. 1.2).
 2. Duration: It is essential to determine 
whether the joint pains have been present 
for less or more than 6 weeks. Classically, 
arthritis caused by acute viral illnesses like 
parvovirus B19 infection can cause RA-like 
arthritis in distribution but with less than 
6  weeks duration. Duration more than 
6 weeks is an essential criteria to diagnose 
RA based on 2010 classification criteria of 
RA (see Chap. 25).
 3. Patterns of joints affected: Each rheumato-
logical disease has a pattern of presentation 
that should be recognized from this early 
stage. Each pattern has a differential diagno-
sis (Figs. 1.3 and 1.4).
Predominant small joints involvement 
(like in pattern A) particularly the wrists, 
metacarpophalangeal (MCP), proximal 
interphalangeal (PIP), and metatarsophalan-
geal (MTP) joints is a classical presentation 
for RA. Other disorders like SLE, psoriatic 
arthritis (PsA), polyarticular gout, and reac-
tive arthritis (ReA) can present in a similar 
way. The commonest joints involved in RA, 
for example, are wrists and MCP (2nd and 
3rd). It has to be noted that distal interpha-
langeal (DIP) joints involvement is rarely 
ever involved in RA. These joints (DIP) are 
Make sure the origin of the pain is from the joint itself, NOT from the periarticular sructures. One tip is to
ask the patient to point the site of the pain by his/her finger!
Fig. 1.2 Identifying the site of the pain
Joints
Symmetrical polyarticular MCP
PIP and MTP joints
RA, SLE, PsA, Polyarticular gout
and ReA.
DIP joint(s) PsA, OA
Bony swellings of DIPs or PIPs or 1st
CMC joint (base of thumb)
OA
Proximal girdle joints Polymyalgia rheumatica and RA
Asymmetrical large joint oligoarticular
disease
ReA, PsA, ankylosing spondylitis {AS)
Acute monoarticular disease Infection, gout, pseudogout
Chronic monoarticular PsA, RA, AS, OA and chronic infection
(e.g. tuberculosis (TB))
Axial, sacroiliac and girdle joints AS
Axial joints Lumbar & cervical spondylosis/OA
Dactylitis (sausage digit) PsA, ReA, AS, TB, sarcoidosis,
sickle cell disease.
Differential DiagnosisFig. 1.3 Patterns of 
joints affected
1 History-Taking Skills in Rheumatology
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a RA
b Reactive Arthritis c AS
d Psoriatic Arthritis e Inflammatory OA of the hand
Fig. 1.4 Each rheumatological disease has a pattern. (a) Rheumatoid arthritis. (b) Reactive arthritis. (c) Ankylosing 
spondylitis. (d) Psoriatic arthritis. (e) Inflammatory osteoarthritis of the hand
L. Alharbi and H. Almoallim
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predominantly involved in patients with PsA 
and inflammatory osteoarthritis (OA) of the 
hands. Classical presentation of inflamma-
tory OA of the hands (pattern E) involves 
DIPs, PIPs, and first carpometacarpal joint 
just at the base of the anatomical snuff. It has 
to be noted as a physical examination caveat 
that the swellings of the joints in inflamma-
tory OA of the hands are bony! It represents 
the degenerative changes happening in the 
cartilage with osteophyte formation. 
Predominant large joints involvement in the 
lower limbs (pattern B) is a classical presen-
tation for ReA. A group of disorders called 
spondyloarthritis (SpA) (include ankylosing 
spondylitis (AS), PsA, ReA, and arthritis 
associated with inflammatory bowel diseases 
(IBD-related arthritis) and undifferentiated 
spondyloarthritis) (see Chap. 23 for detailed 
classification criteria) has particular predi-
lection of large joints of the lower limb. 
Sacroiliac joints can be involved in an asym-
metrical fashion (pattern B) in ReA or can be 
symmetrically involved (pattern C) with 
inflammation of all the insertions of tendons 
and ligaments to the bones of the back (this 
is called enthesitis, and such inflammatory 
process in the back is called spondylitis). 
Therefore, (pattern C) is a classical presenta-
tion for AS.  Spondylitis per say can be a 
manifestation of any disease of the SpA 
group of disorders. Large joints like proxi-
mal girdle joints (shoulders and hips) can be 
involved predominantly in diseases like 
polymyalgia rheumatica and RA.  There is 
one feature that is quite classical for PsA and 
crystal induced arthritis. It is the inflamma-
tion of all articular and periarticular struc-
tures in one digit (dactylitis). This is not a 
feature for RA.  It has to be noted then, 
involvement of small joints like in (pattern 
D) with predominance of DIPs, dactylitis, 
and asymmetrical sacroiliac joint involve-
ment is classical for PsA.
For acute sudden monoarticular joint 
involvement, a septic process and/or crystal- 
induced arthritis should be ruled out. The 
knee joint is the commonest joint involved in 
septic arthritis, while the first metatarsopha-
langeal joints are the commonest joint 
involved in gout. For chronic monoarticular 
joint involvement, a chronic infectious pro-
cess should be ruled out like tuberculosis or 
brucellosis. However, systemic rheumatic 
diseases like RA can rarely present with a 
monoarticular joint only.
 4. Symmetry: This might have been covered 
partly in the above section. It has been 
included here to help the evaluator  remember 
it all the time and consider it while compos-
ing the differential diagnosis. There are dis-
eases like PsA that can present in several 
different ways including symmetrical arthri-
tis like RA and asymmetrical arthritis involv-
ing only few joints like the DIPs. Symmetrical 
arthritis does not include in the differential 
diagnosis only known rheumatological dis-
eases like RA and SLE. There are less com-
mon diseases like sarcoidosis, and 
paraneoplastic syndromes can present with 
arthritis (Fig. 1.5).
 5. Number of joints involvement (How many 
joints affected?): Again, this feature has been 
covered partially above (Figs. 1.6 and 1.7). 
The emphasis is on a monoarticular single 
joint involvement when it should be consid-
ered a medical emergency. If a septic mono-
articular joint was not diagnosed and treated 
properly, it will lead unfortunately to irre-
versible damage and lifelong disability if not 
death from disseminated infection [1]. It is 
hard clinically to separate between oligoar-
ticular and polyarticular in the initial workup 
as will be shown in Chap. 3. A list of possible 
differential diagnosis is provided for you just 
to give a knowledge background base to 
 proceed further in the history from patients 
with joints pains.
 6. Associated symptoms: Obtaining history of 
redness, swelling, and morning stiffness is 
essential in any patient with joints pains. Any 
severely inflamed joint will cause obvious 
swelling observed by the patient. Keep in 
mind that sometimes, swellings of the small 
joints can be detected by physical examina-
tion only as the patient did not notice any 
1 History-Taking Skills in Rheumatology
8
Symmetry of the joints
 Symmetrical arthritis
Inflammatory: - RA, PsA, SLE, JIA (systemic
  and polyarticular types),
  adult onset Still’s disease,
  Sjögren’s syndrome
- Other systemic rheumatic
  diseases: SLE, mixed
  connective tissue disease
  (MCTD), adult onset
  rheumatic fever,
  polymyalgia rheumatica,
  erosive inflammatory
  osteoarthritis, calcium
  pyrophosphate deposition
  disease (CPPD) (pseudo-RA
  type)
- Viral arthritis especially
  parvovirus arthritis
- Lyme disease





- Primary infiltrative/paraneoplastic: 
  Leukemia
- Chemotherapy induced
  (classically post breast






- Oligoaricular or 
  polyarticular gout
- CPPD disease
















(More than 4 joints)
DD
- Traumatic
- Inflammatory:  
  Pauciarticular JIA,
  crystal-induced
- Infectious: bacterial,
  fungal, TB, viral (AIDS).
- Neoplastic
- Infiltrative: one type of







- Inflammatory: RA, JIA
  (polyarticular and Still),
  adult Still, Sjögren’s
- SLE and other connective












Fig. 1.6 Number of 
joints involvement (How 
many joints affected)
L. Alharbi and H. Almoallim
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because of its small size. Redness is one of 
the cardinal signs of inflammation. Active 
RA does not cause redness usually unless 
there is a superimposed infection in that joint 
that it is red. Therefore red and swollen joints 
are caused classically by septic arthritis and/
or crystal induced arthritis (Fig. 1.8).
 7. Constitutional symptoms: Obtaining these 
symptoms in any history obtained from 
patients for whatever symptoms presented is 
essential. Fever and arthritis are common clin-
ical association. Again, septic arthritis whether 
in a monoarticular or polyarticular presenta-
tion should be ruled out. There is a full outline 
for this combination: fever and arthritis in 
Chap. 11. Apart from fever, the following 
symptoms should be obtained: weight loss, 
loss of appetite, night sweat, and fatigue. It 
has to be noted that patients with inflamma-
tory arthritis often feel a general malaise. 
Fibromyalgia patients often report feeling ill 
(if I go shopping I am wiped out for the next 
3 days). On the other hand, OA patients may 
be a bit tired but not really unwell.
 8. Functional impairment: any inflamed joint 
will affect the functionality of the patient. 
The followings should be obtained:
• How has the arthritis affected your daily 
ability to self-care?
• How has the arthritis affected your ability 
to sleep well and to do things at home, 
work, and leisure?
 9. Relieving and aggravating factors: Here the 
focus should be mainly on the effect of activity 
on the symptoms. Activity tends to aggravate 
joint pains caused by a degenerative process of 
the interarticular cartilage, i.e., OA, to be a 
reliving factor for inflammatory back pain as 
going to be shown in Chap. 6 about low-back 
pain. Use of nonsteroidal anti-inflammatory 
drugs (NSAIDs) tends to relive symptoms in a 
remarkable way in patients with inflammatory 
arthritis in comparison with patients with 
degenerative arthritis (OA) (Fig. 1.9).
 10. Rheumatology review of systems: After your 
full analysis of the joints pain(s), now it is 
time to think which rheumatological dis-
eases might be the top in your differential 
Single red hot joint in RA: It should be remembered that the uncommon occurrence of a red hot joint in
the context of RA may be due to superimposed septic arthritis and not to the disease process itself.
Monoarthritis in SLE: The occurrence of monoarthritis in a patient with SLE suggests infection
or osteonecrosis.




- Infections (gonococcal or
  non-gonococcal septic
  arthritis)
- Crystal induced arthritis
  (gout, pseudogout)




Fig. 1.8 Associated 
symptoms
1 History-Taking Skills in Rheumatology
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diagnosis. All rheumatological diseases are 
systemic diseases with significant involve-
ments of other body parts (Fig. 1.10). Some 
patients may not correlate the relationship 
between numbness, tingling sensations, and 
joints pain(s) (some patients may present 
with arthritis and mononeuritis multiplex 
like in vasculitis or RA). Others may not 
remember to mention history of skin disease 
like psoriasis. Obtaining obstetric history is 
extremely important for any childbearing 
female patient as there are many complica-
tions in pregnancy related to SLE and/or 
APS (see Chap. 17). For all of these reasons, 
it is your rule to review all possible  symptoms 
that might be present and help you in com-
posing your differential diagnosis. All possi-
ble symptoms are complied in an approach 
from head to toe just to help you mastering 
this part of the history.
• Past medical history:
 – History of any rheumatic disease (RA, 
SLE, gout, psoriasis, etc.).
 – History of recent infections (think of 
ReA!).
 – History of chronic diseases. There are 
some rheumatological associations 
with diabetes mellitus (see Chap. 21).
• Family history:
 – Ask if similar condition happened in 
the family.
 – Any family history of RA, SLE, pso-
riasis, etc.
• Medications and allergy:
 – Detailed medication history.
 – Any allergy from food and/or drugs?
• Past surgical history:
 – History of any previous operations.
 – History of blood transfusion.
• Social history:
 – Marital status and occupation (tendini-
tis in typist!). How many children? 
Where do they live?
 – History of contact with TB or jaun-
diced patients: essential prior to start 
of disease modifying anti-rheumatic 
drugs (DMARDs) and biological 
therapy.
1.3  Historical Correlation
Some patients may present initially with symp-
toms suspected for a certain disease. Then you 
need to check other symptoms related to this dis-
ease that might help you to make your diagnosis 
from historical grounds only! This is different 
than rheumatology review of systems mentioned 
above. Actually, as your skills in obtaining his-
tory from patients with joints pain grow, you will 
notice yourself combing this step with rheuma-
tology review. For example, you are evaluating a 
young female patient with joint pains. You have a 
suspicion for SLE as you are proceeding in your 
history; then during your history taking, you 
should cover all common presentation of SLE! 
Factors that relieve the symptoms:
- Rset: OA.
- Activity: classical relief in AS!
- Medication (NSAIDs): symptoms
  are relived more in inflammatory
  conditions compared to degenerative
  conditions.
- Activity: classical aggravate of OA!
- Food e.g.: red meat: gout.
- Medications: thiazide: gout.
Factors aggravate the symptoms:
Relieving and aggravating factors
Fig. 1.9 Relieving and aggravating factors
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The common symptoms for some diseases have 
been complied for you (Figure 1.11a, b, c historic 
correlation). Some of the questions may not be 
related to symptomatology! It might just address 
risk factors. If you are assessing a patient with 
pain in the first MTP and/or with a red swollen 
knee joint and you are suspecting gout as a pos-
sible diagnosis, then you need to check for risk 
factors for gout: prior history of uric acid renal 
stones, alcohol intake and use of diuretics, etc.
SYSTEMS SYMPTOMS SHOULD BE ASKED
1- Hair Hair loss, alopecia, psoriatic rashes (in the hair line)
2- CNS: History of stroke, weakness, seizure, psychosis: SLE.
Mononeuritis multiplex, peripheral neuropathy: vasculitis, SLE
Lymph node enlargement in the neck: SLE, lymphoma with sjögren syndrome
3- Eyes: Dryness: sjögren syndrome.
Redness (uveitis): AS
Pallor: anemia from many causes in RA or SLE.
4- Face: Cheek:
Photosensitivity: SLE
Red cheeks (butterfly rash): SLE
Scaring hyperpigmentation: SLE




Ulcer: SLE (painless), inflammatory bowel disease (IBD), Behcet’s, RA (from
methotrexate use)
4- Chest (Respiratory
    & Cardiovascular
    systems):
SOB, chest pain, palpitation: SLE, RA
History of PE/DVT: SLE, antiphospholipid antibody syndrome (APS)
History of bronchial asthma: Eosinophilic granulomatosis with polyangitis
(EGPA) (Churg- Straus)
5- Gastrointestinal tract
    (GIT):
Ask about all symptoms of GIT!
History of jaundice: viral hepatitis.
History of recent gastroenteritis or bloody diarrhea: ReA
History of IBD: enteropathic arthritis.
History of dysphagia: scleroderma
History of HBV: vasculitis.
History of HCV: chronic HCV can present as RA!
Ask about risk factors of HBV, HCV and HIV prior to start any disease modifying
antirheumatic drug (DMARDs).
6- Urinary system: Frothy urine: lupus nephritis.
Hematuria: lupus nephritis, anti-glomerular basement membrane disease
(Goodpasture).
7- Sexual and obstetric
    history:
History of recent STD’s: ReA.
History of oral/genital ulcers: Behcet’s disease.
History of still birth at any age and/or history of three recurrent abortion: APS
8- Lower Limb: History of non-palpable purpura, lower limb edema, nodules: vasculitis
9- Ask about Smoking
    and alcohol intake.
Smoking predisposes to RA, decrease response to DMARDs and biological therapy
Adjust alcohol intake in patients recieveing methotrexate
Alcohol is a risk factor for gout
Fig. 1.10 Rheumatological review of systems
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Diseases
1- Patient with suspected SLE
2- Patient with
    suspected vasculitis
Ask about the following symptoms:
Ask about the following symptoms:
3- Patient with suspected
    myositis
4- Patient with suspected gout
5- Patient with suspected
    Sjögren’s syndrome
6- Patient with suspected
    Spondyloarthritis
7- Patient with suspected
    Septic Arthritis.
Ask about:
Ocular: dry eyes
Mouth: dry mouth, decrease salivation, drinking fluid while swallowing, difficulties with speech, change in
taste and parotid enlargement
Ask about the following risk factors:
Ask about the following symptoms:
Ask about the following symptoms:












- Detailed obstetric history
- Claudication: Takayasu’s arteritis
- Fatigue, fever, myalgias, headache, diplopia, jaw claudication: giant cell arteritis
- Wight loss, myalgias, peripheral neuropathy (numbness), abdominal pain, livedo retieularis:
  Polyarteritis nodosa (PAN)
- Sinusitis, saddle nose deformity, hemoptysis, chest pain, hematuria, uveitis, history of DVT or PE,
  granulomatosis with polyangiitis (GPA) (Wegener’s) or microscopic polyangiitis (MPA).
- History of Asthma, granulomatous vasculitis, eosinophilia: EGPA.
- Abdominal pain, palpable purpura, polyarthralgias, microscopic hematuria: IgA vasculitis (IgA V) (Henoch-
  Schonlein).
- Oral/genital ulcer, uveitis, erythema nodosum: Behcet’s syndrome.
- Weakness: gradual, progressive, painless, symmetrical and proximal. It may involve shoulder, pelvic girdle
  and neck flexors, but no involvement of facial or ocular muscles!
- Dermatologic: erythematous rash on sun exposed skin, heliotrope rash over upper eyelid, Gottron’s papules
  over the dorsum of PIP and MCP joints.
- Myalgia and arthralgia.
- Dysphagia and dysphonia.
- Raynoud's phenomena.
- Symptoms suspected of malignant conditions: weight loss, fatigue, bleeding per rectum, smoking and chronic
  cough .. etc.
- Drugs.
- Pain in 1st MTP (sudden onset), may involve ankles, feet and knees, bursitis (olecranon, patellar).
- History of previous attack of gout, chronic tophaciuos gout (deforming arthritis).
- Risk factors: uric acid renal stones, history of hyperuricemia, chronic renal disease, myelo &
  lymphoproliferative diseases, increase meat, seafood and alcohol intake, use of diuretics and pyrazinamide.
- Alcohol.
- Family history of gout.






- GVHD (graft versus host disease)
- Red eye (uveitis)
- Psoriasis
- Recurrent/previous infections: gastroenteritis, STDs, tonsillitis
- Dysphagia
- IBD
- Inflammatory back pain
- Lower limb joints pain
- Plantar fasciitis/Achilles tendinitis
- Joint pain,
- Joint swelling or history of joint edema,
- Fever,
- Sweating and Rigors (I)




- Urinary symptoms, GI symptoms.
- History of wound infection or abscess.
Certain historical points
Fig. 1.11 Historical correlation
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1.4  Physical Examination
This is just to remind you about the particular 
approach of physical exam techniques that should 
be performed and then presented (Fig. 1.12). A 
comprehensive approach to joints examination is 
presented in Chap. 2.
1.5  How to Present your Case
You are ready now to present your case! You have 
built an organized approach to history taking from 
patients with joints pain(s). You have performed 
a comprehensive physical examination focusing 
on evaluation of these joints and whether there is 
true articular process like arthritis or periarticular 
process like tendinitis (see Chap. 22). Simply you 
need to present your history and physical exami-
nation in the same manner mentioned above with 
focusing on positive findings and important nega-
tives. After your history and physical examination 
presentation, it is required from you to sum up all 
your information together. It is better to start with 
your impression (summary of the case) and then 
your problem list and differential diagnosis.
1.5.1  Impression
This (age) who is (known to have (chronic dis-
eases)) presents with:
• History (usually presenting complain).
• Physical exam(mention obvious findings).
• Lab results (mention the important results 
related to the case) (if it is known to you).
1.5.2  Problem List
In this section you have to make a list with all 
your patient’s problems or complains starting 
with the most serious and important one. This 
should guide you to reach the diagnosis easily.
This is a suggested approach on how to write 
a problem list:
Regarding the first problem:
 1. Write your differential diagnosis for this issue 
and mention which diagnosis is more relevant 
with your case and why.
 2. Write your management plan, if further inves-
tigations and/or referral are needed.
Physical Examination Details
1- General Appearance
    and Vitals sign
As usual.






Nails (pitting, periangular erythema)
3- Specific exam for
    any joint
I-   General appearance:
     Deformity , swelling
II-  Inspection:
     Skin: redness, sacrs and rash
     Ligaments and tendons
     Muscles
     Bones
Ill- Screening Exam:
     Check for range of motion (ROM)
IV- Palpation:
      Effusion, tenderness, warm and crepitus.
V-  Range of motion:
      Active and passive.
VI- Special tests.
4- Examination of the
    other systems
CNS, CVS, Chest and Abdominal exam.
Fig. 1.12 Physical 
examination
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See the diagram below for more details 
(Fig. 1.13).
1.6  Follow-Up Patient
Established patients with rheumatological diseases 
have frequent visits to outpatient clinics. They 
come for routine visits for assessing the progress 
of their disease and review the management plan 
of their chronic disease. Here are suggested tips 
for you to help you deal with these patients.
You should ask about:
 1. Pain (how he/she is doing since last visit).
 2. Which joints are particularly affecting you 
today?
 3. Associated symptoms (morning stiffens 
(mins), swelling).
 4. How well controlled do you feel the arthritis is?
 5. What drugs are you taking? Your adherence? 
Do you get any benefit?
 6. Any functional impairment?
You should not forget to:
 7. Do not forget to examine his/her all joints.
 8. Do not forget to review all his/her medications.
 9. Do not forget to review his/her previous inves-
tigations (Fig. 1.14).




1.7.1  Boolean-Based Definition [2]
At any time point, patient must satisfy all of the 
following:
• Tender joint count ≤1+
• Swollen joint count ≤1+
• C-reactive protein ≤1 mg/dl
• Patient global assessment ≤1 (on a 0-10 
scale)+.
1.7.2  Index-Based Definition
Simplified Disease Activity Index score of ≤3 [3].
Definitions for some of the outcome measures 
in rheumatology are compiled in Fig. 1.15. Further 
Problem Lists
DD:
1 → because of ........ However this is not
typically a feature of ...
2 → because of ......
Plan:
1-further investigations:
Labs, imaging, ivasive (biobsy)
Plan:
2-Non-pharmacological measures:




1-Drug: why? Explain side effects,
monitoring, baseline screening, prophylaxis
Plan:
4-Other referral.
X1 X2 X3 X4
Fig. 1.13 Problem lists
CDAI SDAIDAS28
Outcome measures of the diseae activity:
Fig. 1.14 Outcome 
measures of the disease 
activity
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reading is required from you to know more about 
the implications of its use in the management of 
patients with RA (Fig. 1.15 outcome measures of 
disease activity in RA and their interpretations).
Outcome measures
of the disease activity
1-DAS28
a. How many Tender
    joints?
b. How many Swollen
    joints?
c. ESR or CRP level.
a. How many Tender
    joints?
b. How many Swollen
    joints?
c. The PGA represents the
    patient’s self-assessment
    of disease activity (0 to 10 scale)
d. The EGA represents the
    evaluator's assessment of
    disease activity(0 to 10
    scale)
a. Tender joint count (using 28 joints)
b. Swollen joint count (using 28 joints)
c. PGA (0 to 10 scale)
d. The EGA (0 to 10 scale)
e. CRP level
1- DAS28 <= 2.6: Remission
2- DAS28 > 2.6 and <= 3.2:
    Low disease Activity
3- DAS28 > 3.2 and <= 5.1:
    Moderate Disease
    Activity
4- DAS28 > 5.1: High
    Disease Activity
1- CDAI <= 2.8: Remission
2- CDAI > 2.8 and <= 10:
    Low disease Activity
3- CDAI> 10 and <= 22:
    Moderate Disease
    Activity
4- CDAl > 22: High
    Disease Activity
1- SDAl <= 3.3:
2- SDAl > 3.3 and
    <= 11: Low
    Disease Activity
3- SDAl > 11 and
    <= 26: Moderate
    Disease Activity
4- SDAl > 26: High




Fig. 1.15 Outcome measures of disease activity in RA and their interpretation
Abbreviations
AIDS Acquired immunodeficiency 
syndrome
AS Ankylosing spondylitis
CDAI Clinical Disease Activity Index
CMC Carpometacarpal joints
CNS Central nervous system
CPPD disease Calcium pyrophosphate dihy-
drate disease
CVS Cardiovascular system
DAS-28 Disease activity score
DIP Distal interphalangeal
DVT Deep venous thrombosis
EGA Evaluator Global disease Activity
GVHD Graft vs. host disease
HBV Hepatitis B virus
HCV Hepatitis C virus
IBD Inflammatory bowel disease
JIA Juvenile idiopathic arthritis
MCP Metacarpophalangeal joints
MCTD Mixed connective tissue 
disease
MTP Metatarsophalangeal





PGA Patient Global disease Activity
PIP Proximal interphalangeal
RA Rheumatoid arthritis
SDAI Simplified Disease Activity 
Index
SLE Systemic lupus erythematosus
STDs Sexually transmitted diseases
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Hani Almoallim, Doaa Kalantan, Laila Alharbi, 
and Khaled Albazli
2.1  Introduction
Musculoskeletal (MSK) symptoms are one of the 
most common reasons for patients to seek medi-
cal attention. Despite the high prevalence of mus-
culoskeletal disorders in all fields of clinical 
practice, doctors continue to describe poor confi-
dence in their musculoskeletal clinical skills. 
Here in this chapter an overview of the epidemi-
ology of MSK disorders and the current status of 
MSK competency skills among clinicians will be 
discussed. Then a general approach to MSK 
examination will be introduced. The rest of the 
chapter will address detailed approach to upper 
limb and lower and back joints examination. 
Each section will start with a brief approach to 
pains originating from each site. Good history is 
part of the MSK examination.
2.1.1  Objectives
 1. To discuss the current status of musculoskel-
etal (MSK) examination competency skills 
among clinicians.
 2. To construct a diagnostic approach to single 
joint pain.
 3. To demonstrate a comprehensive approach to 
MSK examination of all body joints.
2.2  Epidemiology of Rheumatic 
Diseases
MSK symptoms are the most common health com-
plications requiring medical attention and account-
ing to 20% of both primary care and emergency 
room visits. MSK conditions affect one in five 
adults [1]. In a health survey, MSK disorders were 
ranked first in prevalence as the cause of chronic 
health problems, long-term disabilities, and con-
sultations with a health professional [2]. In Saudi 
Arabia, MSK disorders are the second major cause 
of outpatients visit in primary care centers and pri-
vate clinics. This is corresponding to findings in 
several other reports from different parts of the 
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world. Low back pain is the most prevalent of mus-
culoskeletal  conditions; it affects nearly everyone 
at some point in time and about 4–33% of the pop-
ulation at any given point [2].
MSK disorders are a very common cause of 
health problems. They result in limiting work in 
developed countries. Besides, up to 60% of peo-
ple on early retirement or long-term sick leave 
claim a MSK problem as the reason [1].
2.3  Current Status of MSK 
Examination
A continuous neglect is observed in musculo-
skeletal examination skills in clinical practice. 
Thus problems of patients with complaints 
about bones and joints are often ignored and 
underestimated by doctors. Many studies sug-
gest that training in MSK disorders is inade-
quate in both medical schools and most 
residency training programs. In Saudi Arabia 
and in many parts of the world, undergraduate 
and postgraduate medical teaching of MSK 
disorders is currently brief and not directly 
relevant to the knowledge and skills com-
monly required for management of these con-
ditions in an outpatient setting [1, 3]. 
Educational deficiencies in MSK disorders 
have been reported extensively in undergradu-
ate curricula and postgraduate training pro-
grams (Box 2.1) [3].
Box 2.1 Educational deficiencies in MSK examination skills
Causes of musculoskeletal (MSK) examination 
skills deficiencies [2] Solution of MSK examination deficiency [2]
  1.  Vague training of MSK disorders in 
undergraduate programs.
  2.  Examination of the MSK system is often 
regarded to be complex in comparison with 
other organ systems.
  3.  Underestimation of the prevalence of MSK 
conditions and their impact on individuals and 
society.
  4.  MSK disorders are not considered to be main 
competencies of medical graduates because 
they are not life threatening conditions.
  5.  The lack of standardized approach to the 
clinical assessment of MSK problems, whether 
pertaining to primary care, rheumatology, or 
orthopedics.
  6.  Lack of proper standard teaching in MSK 
disorders results in the low competence in 
MSK examination skills.
  7.  Lack of summative evaluation of MSK 
examination skills contributes to low level of 
competency among medical graduates.
  8.  The disparity in the approach to examination 
between rheumatologists and orthopaedic 
surgeons mostly lead to poor performances in 
MSK examinations.
  9.  The lack of appropriate teaching and 
evaluation in MSK disorders; clinical teachers 
are not usually skilled in MSK examinations 
and thus bone and joint diseases are not 
screened.
1.  To define competencies that should be mastered 
while dealing with MSK disorders.
2.  To agree on what MSK skills should be mastered 
by medical students.
3.  Standardized approach to the clinical assessment of 
MSK problems (Figs. 2.1 and 2.2).
4.  Experts in various specialities work more closely 
together and look for the commonality of approach 
when treating a patient as they often treat the same 
patients but from separate angles.
5.  Another solution would be an integrated MSK 
disease course for medical students, bringing 
together orthopedics, rheumatology, and physical 
medicine and rehabilitation. This approach has 
been found to be effective.
6.  The method of teaching MSK examination skills 
should follow interactive approaches and hands-on 
teaching sessions where learners are involved in the 
teaching process.
H. Almoallim et al.
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As there is no standardized approach to the 
clinical assessment of MSK problems, one of the 
direct solutions for this is to have unified approach 
to MSK disorders. The approach should consist 
of screening examination (this is basically active 
range of motion testing (ROM)), inspection, pal-
pation, ROM, and special tests (see below). The 
other direct solution is to have a clear objective 
from each MSK examination encounter based on 
historical facts obtained from patients. Each cli-
nician should have then an objective for the MSK 
examination, whether signs of arthritis to be 
sought or signs of periarthritis with soft tissue 
inflammation (ligaments, tendons, bursae, carti-
lage, etc.). For example, a young female patient 
with small joints pain for 6 weeks should have a 
different objective for the MSK examination than 
a young male with knee joint pain following a 
football match. The objective for the MSK exam-
ination for the female patient with small joints 
pain should be to look for signs of arthritis, while 
the objective for the MSK examination of the 
male patient is to look for signs of periarthritis 
mainly ligamentous or meniscus injuries in his 
knee. This is not to underestimate the compre-
hensive approach to any joint with performing all 
steps (screening, inspection, palpation, ROM, 
special tests) but rather to get more focus on the 
techniques that should yield the signs suggestive 
of the preliminary diagnosis that was made ini-
tially based on the history obtained from the 
patient.
A number of different medical specialties are 
usually involved in treating patients with muscu-
loskeletal complaints. This comprises general 
practitioners, family physicians, internists, ortho-
pedic, and surgeons. However, the various practi-
tioners may work in teams with other health 
professionals, but they often lack a multispecialty 
focus which results in treating the same patients 
in a segmented manner and from different incon-
sistent angles.
Based on a literature review published with 
details in reference [2], Box 2.1 shows some 
summarized causes of MSK examination skills 
deficiencies. Some suggested solutions were 
mentioned as well. One of these solutions is to 
have a standardized approach to MSK examina-
tion (see examination of the hand and wrist 
joints) (see Table 2.1.)
2.4  General Approach to MSK 
Examination
Clinicians have perceived the MSK examina-
tion across the world as complex and difficult to 
perform. This can be solved if the approach to 
MSK examination across different disciplines 
were unified. This approach starts by initiating 
the MSK examination using the following 
steps:
• Inspection: The basic anatomical structures 
overlying joints should be inspected for any 
changes. This includes inspection of the skin, 
tendons, muscles, and bones (joints). Skin 
changes like redness, rashes, and color 
changes should be noted. Loss of skin wrin-
kling may indicate swelling in underneath 
structures. Synovial sheaths covering tendons 
might be swollen. Muscles might be wasted. 
Bone and/or deformities might be obvious to 
observe.
• Screening exam: this is basically an active 
range of motion (ROM) testing to assess for 
gross pathology. The patient performs the full 
range of movement of the examined joint by 
own effort. If the active ROM was entirely 
normal without any limitation and/or pain, the 
joint examined can be considered normal. 
This step is introduced early on in this 
approach in order to focus the detailed MSK 
exam in joints with significant abnormal active 
ROM testing. The screening exam might be 
normal for arthritis affecting small joints of 
the hand and/or feet particularly in early stages 
of arthritis.
• Palpation: this is basically palpating for ten-
derness over different anatomical structures 
(bone, joint, tendons, bursae, fascia). 
Tenderness over the joint line (where two 
bones forming the joint are meeting) might 
indicate arthritis. There are special approaches 
to palpate small and large joints that will be 
explained in this chapter. Palpation for one of 
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the cardinal signs of inflammation, hotness 
(warmth), should be considered as well.
• Range of motion testing: there is active and 
passive ROM testing. If you have done the 
active ROM during the screening exam, you 
may now just perform the passive form or 
repeat it again. In cases of true intra-articular 
disease process (true inflammation of syno-
vial membrane as in case of inflammatory 
arthritic disorders, for example, rheumatoid 
arthritis or psoriatic arthritis), the active and 
the passive ROM will be both restricted. 
While in cases of periarticular disease pro-
cesses (affecting tendons, ligaments, bursae, 
fascia) the active ROM will be restricted and/
or limited with tenderness, the passive ROM 
should be entirely normal. It is normal 
because you exclude the contribution of the 
affected tendon or ligament in the movement 
by doing it passively. However, there are 
exceptions to this general rule. Handling of 
the joints during MSK examination is essen-
tial. You should avoid assessing ROM while 
you are holding the joint itself. You should 
hold the assessed joint from distal and proxi-
mal areas trying also to hold other joints. You 
should mainly assess the ROM by holding 
bony structures forming the joint rather than 
the joint itself. This is not to cause pain over 
the joints from your holding. An issue might 
interfere with your ability to evaluate the ori-
gin of the pain; whether from the ROM or 
from your holding that causes stress over the 
joint results in pain.
• Special tests: these tests are conducted to 
examine for possible causes of the joint pain 
particularly soft tissue structures around the 
joint. As a general rule to examine for tendon- 
and/or ligament-related problems, you need to 
“stretch” the tendon to assess if this stretch 
can aggravate the symptoms and/or to “stress” 
it. If the function of tendon that you are assess-
ing is extension, for example, to stress it you 
need to exert your force as an examiner in 
flexion while the patient is maintaining his 
joint in extension and resisting your flexion. If 
there is tenderness while performing this test, 
it might be due to tendinitis.
• Complete your exam: the MSK exam for any 
particular joint is not complete without evalu-
ating other joints (above and below the joint 
being examined). In addition, a neurovascular 
evaluation is essential to exclude any possibil-
ity of neurological and/or vascular origins of 
the joint pain. Assessing peripheral pulses, 
examining the motor system, and evaluating 
for sensory loss are essential for comprehen-
sive evaluation.
There are two important steps that should be 
addressed for any patient with joints pain. The 
first is determining in your history the location of 
the pain whether it is anterior, posterior, lateral, 
or medial pain. This could be achieved by simply 
asking the patient to point by his/her finger to the 
site that is causing pain at the joint. Each one of 
these sites has its differential diagnosis as a cause 
for pain. This should lead to the next step that is 
considering the anatomical structures at the site 
of the pain determined by the patient. You should 
continue taking your comprehensive history 
addressing the risk factors and trying to rule in or 
rule out the possible differential diagnosis you 
created by now from these steps.
After completing your history, you should 
determine now the objective of your MSK exami-
nation. Examining a young female who presents 
with small joints pains should have different objec-
tive than examining a young college student who 
presents with knee joint pain after a soccer game! 
For the young female patient, your objective 
should be looking for signs of arthritis: small joints 
pain swelling and/or tenderness. You may base on 
your history to look for signs of systemic lupus 
erythematosus, for example. While the objective 
of MSK examination for the college student should 
be to look primarily for signs of soft tissue injuries 
in his affected knee. This is not to underestimate 
the value of performing comprehensive MSK 
examination for the affected joint. It is rather a 
process to construct an approach to diagnosis uti-
lizing historical findings and combining it with an 
objective-oriented MSK examination.
The following section is divided into three: the 
upper limb, the lower limb, and the back exami-
nation. Each section starts with a brief review of 
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the anatomy and then a description on the 
approach to pain origination from that particular 
joint. This is followed by a stepwise approach to 
examination of that joint using the inspection, 
screening exam, palpation, ROM, and special 
tests approach. The reader should realize the 
importance of applying the knowledge learned 
from this chapter into practice. This continued 
practice is the assuring way to the mastery level 
in competency skills in MSK examination.
2.5  Musculoskeletal 
Examination of Upper Limb 
Joints (Fig. 2.1)
The joints included in upper limb are hand and 
wrist, elbow, and shoulder. There is a brief review 
of the important anatomical landmarks that 
should be mastered because it has clinical corre-
lations. This will be referred to as the first step. 
Then an approach to pain originating from this 
joint will be discussed focusing on anatomical 
differential diagnosis. The second step will be to 
follow the stated approach in MSK examination 
with descriptions whenever it is necessary. 
Illustrations have been used sometimes as a self- 
explanatory toll.
2.5.1  The Hand and Wrist Joints
2.5.1.1  First Step: The Anatomy
 Anatomy of the Hand Joints (Fig. 2.1)
Each hand consists of 27 bones: 8 carpals, 5 
metacarpals, and each finger having three pha-
langes except the thumb which has only two 
phalanges (Fig. 2.1). The joint is the articulation 
between two bones, so between the two phalan-
ges there is interphalangeal joints, proximal 
(PIP) and distal (DIP); between the phalanges 
and  metacarpal bones, metacarpophalangeal 
joint (MCP); between the metacarpals and car-
pal bones, carpometacarpal joint (CMC); and 

















Fig. 2.1 Anatomy of 
the hand
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There are around 62 muscles in the hand divided 
as intrinsic and extrinsic muscles. The intrinsic 
muscles are thenar, hypothenar, and interosseous 
muscles. The extrinsic muscles are flexors in the 
volar of the hand and extensors in the dorsum of the 
hand. There is also the synovial sheath, which is 
always involved in inflammatory arthritis.
The hand is innervated by three important nerves, 
which are radial nerve providing sensory supply 
to the dorsum of the hand, median nerve provid-
ing sensory supplies to three, and half finger and 
ulnar nerve sensory supplying the little finger and 
half of ring finger. All the small muscles of the 
hands are supplied by ulnar nerve except (LOAF) 
the lateral two lumbricals, opponens pollicis, the 
abductor pollicis brevis, and the flexor pollicis 
brevis. Be aware that the extensors of the thumb 
are supplied by radial nerve.
 Approach to Hand Pain





In the history, you should ask about the loca-
tion of the pain whether it is located in the dorsal, 
volar, radial, or ulnar sides of the hand (Table 2.1). 
Then you should think about the anatomical 
structures in each one of these sites and what pos-
sible diseases might cause the pain.
If the patient presents with dorsal pains, the 
anatomical structures that might be included are 
MCPs, PIPs, DIP joints, or wrist joint. The  diseases 
that affect these joints are mainly arthritic disor-
ders. Detailed approach to history taking should be 
undertaken as it was explained in Chap. 1. Tendons 
can be involved which result in tendinitis or, if the 
entire finger is swollen, dactylitis.
The anatomical structures included in patients 
presenting with volar pains are flexor tendons 
causing flexor tenosynovitis or what is known as 
trigger finger. Palmar fascia involvement results in 
Dupuytren’s contracture. Median nerve compres-
sion as it passes below the flexor retinaculum 
causes a condition called carpal tunnel syndrome.
If the patient presents with radial pain (the 
thumb), the anatomical structure are snuffbox 
area. This is surrounded laterally by tendons of 
extensor pollicis brevis and abductor pollicis lon-
gus muscles, medially by tendon of extensor pol-
licis longus muscle and in the roof the scaphoid 
bone. The classical diseases affecting this area 
are de Quervain’s tenosynovitis and first carpo-
metacarpal osteoarthritis. Other diseases like 
thumb fracture and extensor carpi radials tendini-
tis are less commonly observed.
Ulnar pain is rare. Possible diseases affecting 
this site of the hand could be originated from 
ulnar nerve compression, tenosynovitis of flexor 
carpi ulnaris, and/or traumatic injuries.





• Range of motion.
• Special tests.
Table 2.1 The differential diagnosis of wrist and hand pain according to the location of the pain
























•  Tenosynovitis of extensor 
carpi radialis
•  Trauma: Thumb fracture
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 Inspection
Nails: evidence of psoriasis, vasculitis.
Skin: redness, scars, rashes.
Muscles: wasting, atrophy.
Bones and joints: swelling, deformities.
 Screening Exam
The aim is to screen for gross pathology.
• It is basically active ROM testing.
• First, extend fingers and wrist (palmar aspect 
upward). Make a fist, and then extend again. 
Make a tuck position, and then extend again. 
Make a prayer sign and then wrist flexion with 
all fingers facing the ground opposite of the 
prayer sign. Lastly, assess grip strength 
(Fig. 2.2).
 Palpation
The major aim is to look for evidence of arthritis 
in the form of warmth, effusion, and joint line 
tenderness.
Palpate: joints, bone, and soft tissue.
Start with dorsum of the hand for nodules; 
palpate MCPs with a scissor technique and PIPs 
and DIPs with four fingers technique, follow the 
third metacarpal bone to feel capitate and the 
joint line of the wrist; and then feel scaphoid in 
the anatomical snuff box and other bones for 
tenderness.
Make a scissor-like shape with your fingers, 
joining the index and middle fingers together and 
joining the ring and little finger together. Hold 
the patients hand from the sides at MCPs level. 
Flex the MCPs to 90° and with your two free 
thumbs from both hands, feel the joint line for 
every MCP joint to assess for effusion, swelling, 
and/or tenderness (Fig. 2.3) [3].
This technique is called four fingers because 
you should use your four fingers which are the 
thumb and index finger of each hand (Fig. 2.4). 
With your thumb and index fingers of one hand, 
hold each PIP from the side and press firmly. 
With your other hand’s thumb and index fingers, 
hold the same PIP joint from an anteroposterior 
direction and push intermittently in and out, 
looking for effusion, swelling, and/or tender-
ness [3].
With your thumb, follow the third metacarpal 
bone on the dorsal aspect of the hand until 
reaching a dimple at the capitate level (Fig. 2.5). 
Your thumb should exert a firm, continuous 
pressure on this point with your other thumb 
pushing intermittently in and out, just half an 
inch away from the other thumb on the wrist 
joint line, looking for effusion, swelling, and/or 
tenderness [3].
Remember:
• Always inspect dorsal and palmar 
aspects.




Wrist Flexion Wrist extension
Fig. 2.2 (a) Wrist 
flexion and (b) wrist 
extension
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Range of motion
• You have done active ROM in your screening 
exam.
• Do it again for the wrist joint: extension, flex-
ion, ulnar deviation, and radial deviation.
• For passive ROM of the wrist: hold the distal 
forearm with one hand, and grasp the palmar 
aspect with the other hand. Avoid holding the 
hand from the MCP site as this might be pain-
ful if there is arthritis.
• Now move the wrist passively to extension, 
flexion, ulnar deviation, and radial deviation.
You should observe and comment on tender-
ness, stiffness, and/or limitation of movement 
and end-range stiffness. All these are expected 
signs of arthritis.
Special tests
• This is to assess stability of the wrist joint. 
This is important particularly in pain in wrist 
joint following traumatic injuries.
• For de Quervain’s tenosynovitis: do 
Finkelstein’s test (Fig. 2.6). This is simply a 
trial to overstretch the tendon and examine for 
tenderness if it is elicited with this technique 
to suggest the diagnosis. To stress the tendon, 
push the extended thumb to flexion and ask 
the patient to resist your flexion. If there is 
pain, this would confirm the diagnosis.
• Carpal tunnel syndrome is reviewed thor-
oughly in “Diabetes and Rheumatology” 
Chap. 21.
Fig.  2.3 Scissor technique
Fig.  2.4 Four fingers technique
Fig. 2.5 Two thumbs technique
H. Almoallim et al.
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2.5.2  The Elbow Joint
2.5.2.1  First Step: The Anatomy 
(Figs. 2.7 and 2.8)
The elbow joint is composed of three bones, 
which articulate together to form three joints, 
three ligaments, and muscles. The bones that 
form the joints are the distal part of the humerus, 
the proximal part of the radius, and the ulna lat-
erally and medially. They articulate together to 
form three joints, the humeroulnar joint, the 
radiohumeral joint, and the proximal radioulnar 
joint. These joints are held together through a 
network of ligaments; the major three ligaments 
are the medial collateral ligament, the lateral 
collateral ligament, and the annular ligament. 
What makes the elbow flex, extend, supinate, 
and pronate are the muscles of the elbow joint, 
such as the biceps muscles and its tendon, the 
triceps muscles, the brachioradialis, the flexor 
forearm muscles attached to medial epicondyle, 
and the extensor forearm muscles attached to 
lateral epicondyle. Branches from median, 
ulnar, musculocutaneous, and radial nerves 
supply this joint.
 Approach to Elbow Pain





In the history you should determine the location 
of the pain by simply asking the patient to point 
to the tender spot in his elbow. Lateral elbow pain 
is the most common site for clinical presentation. 
Other sites are medical and posterior elbow pains. 
After determining the site, then a simple standard 
approach should be followed including the onset 
of the pain, its duration, severity, radiation, aggra-
vating and reliving factors, and history of trauma. 
The occupation of the patient as well as detailed 






Fig. 2.6 Finkelstein’s 
test
















































Fig. 2.8 Elbow Joint 
anatomy: nerves and 
ligaments
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Repetitive minor trauma from overuse might pre-
cipitate epicondylitis with micro tears affecting 
the common tendon insertion. You may ask also 
about functional limitation, swelling, and/or 
instability of the joint. A swollen elbow should 
lose its ability to be fully extended. History of 
shoulder and/or neck pain should be obtained as 
pain in the elbow may be simply a referred one 
from these sites.
 Differential Diagnosis
Depends on the location of pain (Box 2.2).
2.5.2.2  Second Step: The Approach
 Inspection
Expose the upper arm completely and examine:
• Skin: rashes, abrasions, erythema, redness, 
scars, subcutaneous nodule, subcutaneous 
psoriasis.
• Muscle: wasting, atrophy.
• Bones and joints:
 – Swelling: localize over olecranon bursae, 
e.g., olecranon bursitis or diffuse particularly 
in area between olecranon process and lateral 
or medial epicondyle, e.g., elbow arthritis.
 – Deformity: assess the carrying angle 
(Fig. 2.9):
Ask patient to extend arm in anatomical position 
(palm facing anteriorly), the longitudinal axes of 
upper arm and forearm from a lateral (valgus) 
angle at elbow joint known as the carrying angle 
(5°in male, 10°–15° in female).
 Screening Exam
• The aim is to screen for gross pathology.
• It is basically active ROM testing (Fig. 2.10).
• A quick way to evaluate this is to ask patient to 
comb the hair and watch any abnormal moment.






Should include palpation of:
• Skin and soft tissue: muscles, ligaments, ten-
dons, and epitrochlear lymph nodes. This 
lymph node is located just 1 cm above medical 
epicondyle in the antecubital fossa and then 
1 cm distally on the shaft of the ulna. It is hard 
to feel in obese patients.
• Bony landmarks that should be palpated:
 – Medial epicondyle: any tenderness sugges-
tive of medical epicondylitis.
 – Medial epicondylar ridge: any tenderness 
suggestive of elbow joint arthritis?
Examine both elbows for asymmetry
Box 2.2 Differential Diagnosis of Elbow Pain
Lateral elbow pain
Common:
  1.  Lateral epicondylitis




  2.  Radiohumeral bursitis
  3.  Radial tunnel syndrome (posterior 
interosseous nerve entrapment)
Not to be missed:
  1.  Osteochondritis dissecans.
Medial elbow pain
Common:
  1.  Medial epicondylitis
  2.  Medial collateral ligament sprain
Less common:
  1.  Ulnar neuritis
  2.  In children: Avulsion fracture of the 
medial epicondyle
Not to be missed:
  1.  Referred pain
Posterior elbow pain
  1.  Olecranon bursitis
  2.  Triceps tendinopathy





• Range of motion.
• Special tests.
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 – Lateral epicondyle: any tenderness sugges-
tive of lateral epicondylitis?
 – Lateral epicondylar ridge: any tenderness.
 – Olecranon process: any tenderness sugges-
tive of olecranon bursitis?
 – Superficial surface of the ulna (as far distal 
as the wrist).
 – Radial head.
• Elbow joint line: palpate for tenderness, effu-
sion, and/or nodules.
Start by palpating the posterior aspect: the 
three palpation landmarks (the medial epicon-
dyle, the lateral epicondyle, and the apex of the 
olecranon) form an equilateral triangle when the 
elbow is flexed 90° and a straight line when the 
elbow is in extension. The points between the 
olecranon process while the elbow is in 90° of 
flexion and the medical or lateral epicondyle rep-
resent the joint line of the elbow joint (Fig. 2.11). 
If there is tenderness elicited while palpating 
these points, it indicates elbow joint arthritis. 




Fig. 2.9 Abnormality in 
carrying angle: (b, d) 
Cubitus valgus. (a, c) 
Cubitus varus (gunstock 
deformity). Effect of 
swelling: it holds the 
joint in partial flexion 
[4]
Ulnar nerve: runs in capital groove behind 
the medial epicondyle.
H. Almoallim et al.
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 Range of Motion
• You have done active ROM in your screening 
exam.
• Place one of your examining hands just above 
the elbow joint holding the distal end of the 
arm. The other hand should be holding the dis-
tal end of the forearm just few centimeters 
above the wrist joint. Examine passive range 
of motion for the following actions:
 – Flexion: bend the patient’s elbow slowly by 
bringing both of your hands together.
 – Extension: move your hands away from 
each other to extend the patients elbow. 
Note that some patients particularly 
females may have hyperextensible joints 
that may cause few extra-degrees of elbow 
hyperextension.
 – Supination: with the hand holding the dis-
tal forearm, bring the palm of the patient to 
let it face upward.
 – Pronation: now let the palm face 
downward.
Presence of tenderness, limitation, stiffness, 




This is to test for medial epicondylitis.
Ask the patient to have their elbow and fingers 
flexed. Palpate the medial epicondyle with one 
hand, and grasp the patient’s wrist with the other 
hand, and then ask the patient to flex the elbow 
and wrist against resistance (Fig. 2.12). A posi-
tive test would be a complaint of pain or discom-
fort along the medial aspect of the elbow in the 
region of the medial epicondyle.
Tennis Elbow Test
This is to test for lateral epicondylitis.
Ask the patient to have their elbow and fin-
gers extended. Palpate the lateral epicondyle 
with one hand, and grasp the patient’s wrist 






Fig. 2.10 Active range 
of motion of the elbow 
joint
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extend the elbow and wrist against resistance 
(Fig.  2.13). A positive test would be a com-
plaint of pain or discomfort along the lateral 
aspect of the elbow in the region of the lateral 
epicondyle.
Elbow Flexion Test (Ulnar Nerve)
This test is to evaluate for cubital tunnel syn-
drome (Fig. 2.14).
Ask the patient to hold their elbows fully 
flexed for 3 min with their wrists in neutral posi-
tion and their shoulders adducted at their sides. 
The test is considered to be positive if paresthe-
sias were elicited within the ulnar nerve distribu-
tion of the hand.
2.5.3  The Shoulder Joint
2.5.3.1  First Step: The Anatomy 
(Fig. 2.15)
The shoulder consists of three bones, four artic-
ular surfaces, muscles, and ligaments. The 
bones include clavicle, proximal humerus, and 
scapula. The articular surfaces include sterno-














Fig.  2.11 Some anatomical landmarks in the elbow joint. O: olecranon process, M: medial epicondyle, L: lateral 
epicondyle
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humeral joint, and scapulothoracic articulation. 
The muscles of shoulder are rotator cuff which 
includes supraspinatus, infraspinatus, subscapu-
laris, and teres minor. The subscapularis muscle 
rotates the humerus internally, while the infra-
spinatus and teres minor rotate the humerus 
externally. Abduction of the humerus is accom-
plished by supraspinatus along with deltoid 
muscle.
For the ligaments of the shoulder, they are the 
glenohumeral ligaments which are superior, mid-
dle, and inferior glenohumeral ligaments.
 Approach to Shoulder Pain
Shoulder pain represents either intrinsic or extrin-
sic pathologies. Intrinsic pathologies account for 
85% of the cases and include traumatic, acute, 
and chronic causes. While extrinsic pathologies 
account only for 15% of the cases which repre-
sent referred pain that can be of cardiac, respira-
tory, gastric, or diaphragmatic in origin. The 
approach to patients present with shoulder pain 




Start analysis of the shoulder pain by first 
determining the site of the pain. To assure accu-
rate workup you may ask the patient to point one 
finger to the site of the pain by one finger. 
Shoulder pain can be classified into three catego-
ries according to the site: anterior, lateral, or pos-
terior (Table 2.2).
Lateral shoulder pain is the most common, 
and it is classical for rotator cuff tendinitis. 
Anterior shoulder pain is classical for glenohu-
meral arthritis. Posterior shoulder pain, which is 
the least common, usually represents referred 
pain.
Following this step you need to cover other 
aspects of pain history to help you narrow the dif-
ferential diagnosis according to the anatomical 
location and other important pieces of  information 
you are going to collect from the patient. This 
should include the duration, nature, aggravating 
factors (with lifting, reaching or pushing) and 
Fig. 2.12 A special test for medial epicondylitis
Fig. 2.13 A special test for lateral epicondylitis: see text
Ulnar nerve
Fig. 2.14 Elbow flexion test
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relieving factors, radiation (shoulder pain that 
radiates past elbow can be due to cervical pathol-
ogy), history of trauma, and sports activities. Past 
medical history: diabetic and patients with thy-





































Fig.  2.15 Anatomy of 
the shoulder joint
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2.5.3.2  Second Step: The Approach
 Inspection
• Skin: redness, scars, rashes.
• Muscles: wasting, atrophy of deltoid (squar-
ing sign).
• Bones and joints: swelling particularly anteri-
orly obscuring the coracoid process area; this 
is in case of glenohumeral joint effusion, 
deformities (acromioclavicular (AC) joint, 
clavicle), scapula elevation (back), and asym-
metry posteriorly (look at back exam for 
asymmetry).
 Screening Exam
The aim is to screen for gross pathology.
• It is basically the active ROM testing 
(Fig. 2.16).
• Ask the patient to abduct (ABD) shoulders to 
90°, then supinate forearms (externally rotat-
ing (ER) the shoulders), continue abduction to 
180°, do painful arc by bringing both shoul-
ders to zero position again (if the patient 
develops pain, it indicates positive painful arc 
test suggestive rotator cuff tendinitis (RCT)), 
then ask patient to bring his hands behind the 
neck (ER + ABD), and then move hands back-
ward over the back internal rotation (IR) and 
adduction (ADD) (IR + ADD). Then try bring-
ing your thumbs on your back as high as pos-
sible (Apley’s scratch; Fig.  2.17), and finish 
with forward flexion and extension.
• Shoulder elevation, protraction, retraction, 
and circumduction.
 Palpation
• Remember: shoulder (or glenohumeral joint) 
effusion is usually detected anteriorly (this is 
not a common finding).
• Palpate for bony and soft tissue structures: 
start with sternoclavicular joint (SC joint), 
then move to feel clavicle, AC joint, acromion, 
subacromial bursae (a lateral structure just 
below the acromion) (tenderness indicates 
RCT, greater trochanter (GT) (rotator cuff 
inserts here, you are feeling the capsular 
attachment of glenohumeral joint (GH joint) 
medially feel bicipital groove (long head of 
biceps), coracoid process where the short head 
of biceps inserts (it is painful!)
• Palpate for crepitus by simply feeling over the 
joints while moving the shoulder.
 Range of Motion
• The aim is to differentiate between intra- 
articular and extra-articular pathology.
• In intra-articular pathology (arthritis), active 
and passive ROM are limited due to inflam-
mation of the synovial membrane that moves 
during both active and passive ranges. There 
is usually effusion that might limit the ROM 
whether it was  passive or active. Even if here 
was no effusion, the inflammation of the 
synovial membrane itself would limit the 
ROM passively and actively because of the 
pain.


























–  Referred pain
•  Diaphragm
•  Gall bladder









• Range of motion
• Special tests
Remember:
• Always inspect anteriorly, laterally, and 
posteriorly









Fig. 2.16 Range of motion testing for shoulder joint
Fig. 2.17 Apley’s 
scratch test
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• In extra-articular pathology (periarthritis), the 
active range is limited only. Here, there is 
synovial membrane inflammation to limit any 
kind of movement in the joint. Instead, there is 
pathology in structures around the joint like in 
RCT or subacromial (subdeltoid) bursitis. Here 
the active ROM will be limited but the passive is 
not.
• You need to test two components to determine 
with accuracy the cause of the pain.
• Active ROM was assessed during the screen-
ing exam.
• For passive ROM: watch the location of your 
hands!
• Place your right hand on the right shoulder 
over AC joint firmly. This is to stabilize the 
scapula in order to do isolated GH joint move-
ment without scapular elevation. The other 
hand should hold the proximal forearm.
• Do shoulder abduction up to 90°. This is a 
pure GH joint movement. Normally, there 
should be zero scapular elevation. Then do ER 
and IR, while the shoulder is abducted at 90°. 
Then adduct the shoulder back to zero posi-
tion where the forearm and the elbow are just 
beside the body. Then do extension. Then 
remove your right hand on the right shoulder 
and do forward flexion.
• You can assess ER + IR while at zero abduc-
tion with arms on the sides.
• Repeat the same approach for the left shoulder 
with your left hand stabilizes the scapula over 
the left AC joint.
 Special Tests
Several MSK examination techniques will be 
described to assess for specific diseases 
affecting the shoulder joint. The emphasis 
should be as stated earlier on the combined 
evaluation for any patient with MSK com-
plaints of the history and MSK examination 
findings in order to reach to a correct diagno-
sis. The diagnostic accuracy for majority of 
these tests is limited [5]. However, combining 
careful history taking skills with competent 
MSK examination findings should help 
improve the diagnostic accuracy at least to 
narrow your differential diagnosis rather than 
reaching an accurate diagnosis.
For RCT
• Painful arc (as described above): from 120° 
to 60°.
• Isometric resisted abduction while the arm 
is in zero degree. If there is pain develop-
ing, this could be due supraspinatus 
tendinitis.
• Empty can sign:
(Shoulder abducted 90° + forward flexion 
30° away from the body on horizontal line + 
thumb down (IR)—supraspinatus) (Fig. 2.18).
 Infraspinatus and Teres Minor
• Isometric resisted ER (elbow flexed 90° with 
the arm at the side).
• In the same position, you can assess isometric 
resisted IR for subscapularis tendinitis 
(Fig. 2.19).
Principle
To assess tendons you need to stretch the 
tendon (impingement) and/or stress it!
Fig. 2.18 Supraspinatus examination (“Empty can” test)
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 Left off Test
This test is performed with isometric resisted IR 
while the patient adducting his shoulder and 
internally rotating it. Presence of pain while 
resistance may indicate subscapularis tendinitis 
(Fig. 2.20).
 Hawkins Impingement Sign
Shoulder horizontal adduction in 90° of flexion 
then adduct shoulder more with passive IR; this 
should reproduce symptoms (Fig. 2.21).
 Drop Arm Test (Fig. 2.22)
This is to test for complete supraspinatus tear. 
Sudden push to an abducted shoulder may result 
in arm drop if there is complete supraspinatus 
tear.
For AC joint:
• Painful arc (as described above): when it pro-
duces pain from 180 to 120. It is usually due 
to AC joint pathology rather than RCT.
• There is another test called cross-body adduc-
tion test (Fig.  2.23). The patient simply per-
forms horizontal adduction with the shoulder 
in flexion. This might reproduce pain due AC 
joint pathology.
• For bicipital tendinitis:
 – Speed’s test: resisted shoulder flexion at 
90° with elbow extended and forearm 
supinated.
 – Yergason’s sign (Fig. 2.24): resisted supina-
tion of the forearm with elbow 90° flexion. It 
Fig. 2.19 Infraspinatus and teres minor examination
Fig. 2.20 Left off test
Fig. 2.21 Hawkins’ test for subacromial impingement or 
rotator cuff tendinitis
H. Almoallim et al.
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has to be noted that rupture of the long head 
of biceps is rarely associated with significant 
weakness in elbow flexion. This is probably 
due to the fact that 85% of elbow flexion is 
from brachioradialis and short head of biceps 
rather than from long head of biceps.
• For glenohumeral joint instability:
• Anterior apprehension test (Fig. 2.25) (supine, 
90 ABD and 90 ER, apply gentle forward 
pressure to posterior aspect of humeral head).
2.6  Musculoskeletal 
Examination of the Lower 
Limb Joints
The joints included in lower limb are ankle, knee, 
and hip. As in the upper limb section, there is a 
brief review of the important anatomical land-
marks that should be mastered because it has 
clinical correlations. This will be referred to as 
the first step. Then an approach to pain originat-
ing from this joint will be discussed focusing on 
anatomical differential diagnosis. The second 
Fig. 2.22 Arm drop test
Fig. 2.23 Cross-arm test for acromioclavicular joint 
disorder
Fig. 2.24 Yergason test for biceps tendon instability or 
tendinitis
Fig. 2.25 Apprehension test for anterior instability
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step will be to follow the stated approach in MSK 
examination with descriptions whenever it is nec-
essary. Illustrations have been used sometimes as 
a self-explanatory toll.
2.6.1 Ankle Joint
2.6.1.1  First Step: The Anatomy
• Bones of the Foot (Fig. 2.26)
• Ankle and foot consist of 26 bones, 33 liga-
ments, and more than 100 muscles and ten-
dons. The main structures are:
• Bones: tibia and fibula and tarsal bones, which 
are calcaneus, talus, navicular, and cuboid, 
and three cuneiforms bones, five metatarsals, 
14 Phalanges (proximal, intermediate and dis-
tal), and two sesamoid bones.
• Joints: ankle joint, subtalar joint, metatarso-
phalangeal joints (MTP), and interphalangeal 
joints.
• Ligaments: anterior and posterior tibiofibular 
ligament, anterior and posterior, talofibular 
ligament (ATFL and PTFL) and deltoid liga-
ment (Figs. 2.27 and 2.28).
• Muscles and tendons: anterior tibialis, pero-
neal, extensors, and flexors muscles and ten-
dons (Fig. 2.29).
 Approach to Ankle Pain





The first step in any history of a joint pain is 
determining the site of the pain. This simply can 
be achieved by asking the patient to point out by 
one finger the site of the pain. The following 
steps should focus on comprehensive approach 
to pain analysis including duration, progression, 
aggravating and relieving factors, and history of 
trauma. Here, it is important to ask about and 
examine the patient’s shoes. RA classically 
affects MTPs and ankles. The first MTP joint 
can be affected classically by gouty arthritis. 









Medial (1st) cuneiform bone
Metatarsal bones
Middle (2nd) cuneiform bone







Fig. 2.26 Bones of the 
foot
H. Almoallim et al.
39
ing and redness is diagnostic for gout. Acute 
gout might mimic cellulitis as it may cause soft 
tissue swelling and redness as well. The first 
MTP joint can be involved chronically in osteo-
arthritis. The interphalangeal joints can be 
involved in psoriatic arthritis (PsA) that might 
give identical presentation to RA.  In addition, 
PsA might cause diffuse swellings in one or 
more than one toe called dactylitis. It may cause 
Achilles tendinitis and/or plantar fasciitis. 
Subtalar joint is classically affected in osteoar-
thritis. History of trauma- related pain should 
direct the attention immediately to soft tissue 
problems (periarthritis rather than arthritis). 
Table 2.3 lists the possible differential diagnosis 
according to the site of the ankle and foot joints 
pain.
2.6.1.2  Second Step: The Approach
Inspection
Expose both ankles and feet and examine for 
asymmetry. Then follow the standard approach in 
inspection as it was explained at the introduction 
of this chapter.
• Nail: evidence of psoriasis.
• Skin: scar, redness, rashes, wart, ulcers, blis-
ter, calluses, corn, erythema, ecchymosis, 
change in color.
• Muscle and tendons: wasting, atrophy, and 
swelling posteriorly for Achilles tendinitis.
• Bone and joint: swelling, deformity (hammer 
toe, clawing or crowding of the toes, hallux 
valgus of forefoot), arch of the foot.
Screening Exam
• The aim is to screen for gross pathology.
• It is basically the gait and active ROM testing. 
For any lower limb joint examined, gait exam-
ination is a mandatory step.
• Ask the patient to walk in a straight line and 
then on toes and on heels.
• Ask the patient to run a short distance (if it 
possible, this is of great value in assessing 
periarthritis).
• Ask the patient to hop five times on each foot 
(if it possible) and then squat and stand from 
squatting position.
• This quick screening tool actually has assessed 
the neuromuscular integrity for the lower 
limb. Walking on the toes, for example, 





• Range of motion
• Special tests
Remember: Always examine anteriorly, 
















Fig. 2.28 Bones and ligaments of the ankle 
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arthritis in these joints, the patient will not be 
able to perform this. In addition, walking on 
toes assessed plantar flexion in ankle joints 
and extension of knees and hips. Squatting 
and standing from squatting position have 
assessed, in addition of joints, the strength of 
proximal muscles. Walking on heels is an 
excellent screening for plantar fasciitis. The 
different steps applied in this screening exam 
assessed as well almost all the nerve roots for 
the lower limbs.
Palpation
The major aim is to look for evidence of arthritis in 
the form of warmth, effusion, and joint line tender-
ness. Tenderness might be felt laterally and/or 
medially if there is ligamentous pathology:
• Palpate skin and soft tissue (muscles, liga-
ments, and tendons).
• Determine joint lines and palpate for tenderness:
 – Ankle joint: (tibia, fibula, and talus joint) 
perform plantar flexion/dorsiflexion to 
locate joint line or just medial to the strong 
tendon of tibialis anterior as it passes over 
the ankle joint to be inserted at the base of 
first metatarsal bone.
 – Subtalar joint (talocalcaneal joint): per-
form inversion/eversion or adduction/
abduction of the midfoot to locate this 
joint. Usually, it can be palpated below and 
anterior to lateral malleolus.
 – MTPs: Press firmly and intermittently with 
your thumb and index finger over these 
joints to illicit tenderness. It is much more 
reached from plantar aspect than the dorsal 
aspect of the feet.
 – Medially: Palpate the big toe at the site of 
the first MTP, and move along the first 
metatarsal to feel the metatarso-cuneiform 
joint. Palpate the navicular tubercle, the 
head of the talus, and the medial 
malleolus.
 – Laterally: Start palpating the fifth metatar-
sal bone to feel the styloid process, and 
then reach the cuboid bone to the calca-
neus. Palpate for the peroneal tubercle to 
the lateral malleolus.
Achilles tendon
Medial (and lateral) subcutaneous








Fig. 2.29 Achilles tendon and plantar fascia
Table 2.3 Differential diagnosis according to the site of 





Lateral –   Peroneal tendinitis, rupture, or 
subluxation caused usually by 
rheumatoid arthritis
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 – Posteriorly: Feel the Achilles tendon and 
follow its insertion at the calcaneus for any 
tenderness. Just lateral and medial to the 
insertion of the Achilles tendon, feel for 
retrocalcaneal bursitis on both sides (lateral 
and medial) of the tendon.
 – Inferiorly (plantar aspect): Feel for tender-
ness at the insertion of plantar fascia under 
the medial side of the heel.
Range of Motion (Fig. 2.30)
• You have done active ROM in your screening 
exam, but you may repeat active ROM now 
for detailed examination.
• Examination includes passive and active ROM 
for the following actions: plantarflexion, dor-
siflexion, inversion, and eversion of the foot 
and flexion and extension of the toes, particu-
larly the big toe.
• Hold the distal leg with one hand while the 
knee in a flexed position. Then hold the feet 
from central position just between the ankle 
and the MTP joints. Now, perform slowly full 
dorsiflexion (20° from neutral position) by 
bringing the ankle to the leg, and then push the 
ankle away from the leg for plantarflexion 
(50° from neutral position). Now, grasp the 
feet and perform inversion and eversion. In the 
same position, you may perform midfoot ad 
duction and abduction as well. Note any limi-
tation of movement, tenderness, stiffness, and/
or end range stiffness.
Special Tests
• Squeeze test (Fig.  2.31): This test aims to 
stress the MTPs looking for tenderness due to 
arthritis. Simply squeeze the sides of MTP 
joints at the level of the heads of phalanges.
• Peroneal subluxation test:
• This is to assess the peroneus longus tendon 
rupture or instability. Ask the patient to sit down 
and actively dorsiflexes and everts the foot 
against resistance; and simultaneously palpate 
the peroneal tendon posterior to the distal fibula. 
Pain, clicking, or sensation of instability may 
indicate subluxation of the peroneal tendon. 
This test is abnormal when 3–5 mm transloca-
tion is present compared with the opposite side.
• The anterior drawer test (Fig. 2.32):
Evaluate stability of the anterior talofibular 
ligament (ATFL): stabilize the anterior por-
tion of the distal tibia and fibula with your 
hand, and use your other hand to cup the heel 
of the patient foot and pull it toward yourself.
• The inversion stress test (Fig. 2.33):
• Evaluate the stability of the lateral ligament 
complex (the ATFL and the calcaneofibular 
ligament (CFL)).
 – Stabilize the anterior portion of the distal 
tibia and fibula with your hand, and use your 
other hand to cup the heel of the patient foot.
 – The ATFL is evaluated by maximally plan-
tarflexing the ankle and then inverting the 
rear foot.
 – The CFL is evaluated by maximally dorsi-
flexing the foot and then inverting the rear 
foot.
 – The test is considered abnormal when 10°–
15° more inversion is present, compared 
with the opposite side.
• Test for Morton’s neuroma:
• Grasp consecutive metatarsal heads and com-
press them together. If a click, as well as 
reproduction of the patient’s pain, occurs, a 
Morton’s neuroma should be suspected.
• Thompson test (Fig. 2.34):
Ask the patient to lie in prone position with 
the foot hanging off the table, and then squeeze 
the gastrocnemius muscle. If the foot does not 
plantarflex, rupture of the Achilles tendon 
must be considered.
2.6.2  Musculoskeletal Examination 
of the Knee Joint
2.6.2.1  First Step: The Anatomy 
(Fig. 2.35)
The bones and articulation of knee joints consists 
of four bones, which are femur, tibia, fibula, and 
patella. There are three articulations: medial tib-
In assessing dorsiflexion: the knee must be 
flexed for proper evaluation







Fig. 2.30 Range of 
motion of the ankle joint
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iofemoral, lateral tibiofemoral, and patellofemo-
ral articulation. The knee joint has many bursae: 
in the anterior aspect suprapatellar bursae, prepa-
tellar bursae, and superficial and deep patellar 
bursae and in the medial aspect pes anserine. 
Cartilage and ligaments of the knee are anterior 
and posterior cruciate ligaments, medial and lat-
eral collateral and medial and lateral menisci.
Approach to Knee Pain





Fig. 2.31 Squeeze test
Fig. 2.32 Anterior drawer test
2 Approach to Musculoskeletal Examination
44
The first step is to determine the site of the pain. 
This is achieved by asking the patient to point by 
one finger to the site of the pain. In some condition 
like anserine bursitis, the location of the pain is 
totally away from joint line. Determining the site of 
the pain is extremely an important step for reaching 
accurate diagnosis. Detailed history including 
duration, progression, and aggravating and reliev-
ing factors should follow. History of trauma should 
be clearly outlined particularly if it was sports 
related. There are many soft tissue structures that 
can be affected with traumatic injuries. The knee is 
the most common joint involved in septic arthritis. 
Symptoms suggestive of an infectious process like 
fever should be obtained as well. The knee as well 
is a common joint in osteoarthritis and crystal 
deposition diseases (like pseudogout).
Table 2.4 provides a classification of the knee 
pain according to the site of the pain and its dif-
ferential diagnosis.





• Range of motion
• Special tests
Fig. 2.33 The inversion stress test
No movementAnkle plantarflexes
Fig. 2.34 Calf squeeze 
test
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Inspection
• Skin: redness, scars, rashes.
• Muscles: wasting (note medial fibers of quad-
riceps), atrophy.
• Bones and joints: swelling, deformities – genu 
varus (common in osteoarthritis of the knee 
joint) and genu valgus deformities.
Screening Exam
• The aim is to screen for gross pathology.
• It is basically the gait and active ROM 
testing.
• Ask the patient to walk and comment if the 
gait is normal or abnormal.
• Ask the patient to walk on toes, heels, and 
squat and stand up from the squatting position 
(see details in ankle joint exam above).
Palpation
• The major aim is to look for evidence of 
arthritis in the form of warmth, effusion, and 
joint line tenderness.
• Palpate for tenderness over the patella, patel-
lar tendon, suprapatellar bursae, prepatellar 
bursae (housemaid knees), anserine bursae 
(medially below joint line, just 2 cm from tib-





















Fig. 2.35 Anatomy of the knee
Table 2.4 A classification of the knee pain according to 
the site of the pain and its differential diagnosis









–   Tibial apophysitis 
(Osgood-Schlatter 
lesion)




Lateral –   Iliotibial band 
tendinitis
–   Lateral collateral 
ligament sprain
–   Lateral meniscal 
tear
Posterior –   Popliteal cyst 
(baker’s cyst)
–   Posterior cruciate 
ligament injury
Medial –   Pes anserine 
bursitis
–   Medial collateral 
ligament sprain
–   Medial meniscal 
tear
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patellar tendon inserts, it can be tender in 
patellar tendinitis).
• Palpate for crepitus, osteophytes, and popli-
teal cyst.
• The maneuvers used to detect effusion:
 1. Bulge sign:
 – Milk the knee with the palmar or dorsal 
aspect of your fingers 1–3 times from 
the tibial side to medial side of the 
femur. Wait for a few seconds.
 – Now with your fingers, milk the fluid 
down from the femur side to the tibia 
laterally. Note the bulge of fluid on the 
medial side. This method detects mild 
effusion.
 2. Patellar tap test:
 – Compress the suprapatellar pouch with 
one hand. With the tips of the fingers of 
the other hand, give a sharp downward 
push on the patella. Feel the patella’s 
clunk against the femoral condyles. 
This method detects moderate effusion.
 3. Balloon sign:
 – Compress the suprapatellar pouch with 
one hand. Place the thumb and index (or 
long) finger of the other hand on either 
side of the patella at the level of the joint 
line. Now if you press with these fin-
gers, you should feel the fluid pushing 
away the other hand. This test is positive 
for large effusion.
Range of Motion
The aim is to differentiate between intra-articular 
and extra-articular pathology.
• In intra-articular pathology (arthritis), active 
and passive ranges of motion are limited (see 
explanation in shoulder joint exam).
• In extra-articular pathology (periarthritis), the 
active range is limited only.
• You need to test two components: active and 
passive ROM.
• Ask the patient to bring both heels toward the 
pelvis as much as possible (flexion), and then 
ask the patient to put his knees flat on the bed 
(extension).
• For passive ROM testing, ask the patient to 
relax. With one hand covering the entire knee 
anteriorly and the other holding the heel, flex 
the knee and then extend it. You should 
 comment on tenderness, stiffness, end of range 
stiffness, and/or limitation of movement.
Special Tests
• The aim is to look for the integrity of menisci 
and ligaments around the knee.
• For menisci integrity, you can use the 
McMurray test (Fig. 2.36): hold the knee with 
one hand, while the patient is in supine posi-
tion. Bring the knee to full flexion. Now, 
extend the knee slowly with applying valgus 







Fig. 2.36 McMurray test and Apley compression test
H. Almoallim et al.
47
are holding with your hand, while the other 
hand is externally rotating the knee from the 
ankle. The test is considered positive if there is 
pain and/or popping sound.
• Apley’s compression test: here the patient lies 
in prone position with the knee being exam-
ined flexed at 90°. You should stabilize the 
knee by placing your leg pressing over poste-
rior aspect of the patient’s thigh. Apply now 
compressing pressure over the knee from the 
ankle with external rotation force. The test is 
considered positive if it produces pain.
• For cruciate ligaments (CL), you can use the 
anterior drawer test (Fig. 2.37): you should sit 
on the patient’s feet for stabilization the flexed 
knees to around 90°. Place your hands on the 
tibial plateau from medical and lateral aspects, 
and then try to push tibia anteriorly over the 
femur toward your side (anterior drawer test) or 
posteriorly (posterior drawer test). Any dis-
placement particularly when compared with 
the other knee is considered positive for cruci-
ate ligament instability. The Lachman test: the 
patient here is in supine position. You should 
place one of your hands above the knee joint 
line with a good grasp, while the other is just 
below the knee joint line. In around 20–30° of 
passive knee flexion, try to apply contradicting 
forces by two hands; one pushes anteriorly 
while the other pushes posteriorly. Any exces-
sive displacement is considered positive 
(Fig. 2.38). The validity of these tests has been 
questioned [5]. In general, this test is more sen-
sitive than the anterior drawer test [4].
• For collateral ligaments, you can apply valgus 
and varus stresses, while the knee is held in 
40–70° of flexion to assess for medial and lat-
eral collateral ligaments, respectively. With 
positive result, there will be laxity and wide 
openings of the joint.
2.6.3  Musculoskeletal Examination 
of the Hip Joint
2.6.3.1  First Step: The Anatomy 
(Fig. 2.39)
The hip joint is formed by the articulation between 
the round head of the femur and the acetabulum. 
It is a ball and socket joint with one part, the ace-
tabulum, which is fixed in the body. Three bones 
compose the acetabulum: Ilium, ischium, and 
pubis. Femoral neck, Greater Trochanter (GT), 
and lesser trochanter are bony structures of ana-
tomical significance. Femoral neck is vulnerable 
site for osteoporotic fractures. This site is used to 
measure bone mineral density to diagnose osteo-
porosis. The insertion of hip abductors and exten-
sors are at the GT. While the hip flexor (iliopsoas) 
inserts at the lesser trochanter. An important bur-
sae covers the GT which can be inflamed and 
cause symptoms. Symphysis pubis is a fibrocarti-





Fig. 2.37 Anterior drawer test
Lachman test
20°-30°
Fig. 2.38 Lachman test
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 Approach to Hip Pain
It is important to determine the site of pain. This 
is an essential step in the history of any joint pain. 
True hip joint pain (due to arthritis of head of 
femur articulating with the acetabulum) can be 
felt only anteriorly in the groin region. In the case 
of hip arthritis, you can expect to find, in addition 
to groin pain, severe limitation in the ROM 
actively and passively. Hip joint is a deeply seated 
joint; for this reason aspiration is always per-
formed under fluoroscopic or US guidance. Pains 
that felt elsewhere in the hip region could be due 
other structures around the hip joint and still 
called by patients as “hip pain.” Trochanteric bur-
sitis is a classical example of a lateral hip pain in 
moderately obese female. Here there is tender-
ness by palpation in the lateral hip, and the active 
adduction and/or abduction may be painful, but 
usually the passive ROM is intact. In meralgia 
paresthesia (lateral cutaneous nerve entrapment), 
there is usually pain in the anterolateral hip 
region with entirely normal ROM.  There are 
many structures posteriorly that can cause pain. 
Sacroiliac joint gives rise to posterior hip pain 
and usually referred to by some patients as but-
tock pain. Lumbar radiculopathy is another dif-
ferential diagnosis. The patient should be asked 
then to point to the site of hip pain by one finger 
to exactly determine it. Table 2.5 summarizes the 
most important differential diagnosis of hip pain 
according to its site.
2.6.3.2  Second Step: The Approach
Inspection
• You should start inspection from standing 
position and inspect anteriorly, laterally, and 
posteriorly. Then you can continue your 
examination after screening exam and palpa-
tion, while the patient is in supine position.
• Standing:
 – Back:













Fig. 2.39 Anatomy of 
the hip joint
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Bones and joints: assess symmetry and 
pelvic obliquity – inspect posterior supe-
rior iliac spine (PSIS) (dimples of Venous) 
as they should be align to one level. 
Asymmetry may give clues to cases with 
chronic low back pain without apparent 
etiology. Inspecting gluteal folds, tip of 
scapula can assess symmetry.
 – Lateral: inspect for lumbar lordosis and 
possible swelling or redness over greater 
trochanter.
 – Anterior: symmetry can be assessed by 
inspecting anterior superior iliac spine 
(ASIS). Rarely, fullness in the groin region 
may indicate hip arthritis. However, signif-
icant hip joint pathology can occur without 
apparent swelling. Inspect also for rashes, 
redness, and scars.
Screening Exam
• The aim is to screen for gross pathology.
• It is basically the gait and active ROM 
testing.
• Note position: external rotation (ER) indicates 
hip joint pathology as internal rotation (IR) is 
lost first in arthritis.
• See ankle joint exam above for details of gait 
assessment. Simply you should ask the patient 
to walk/turn/walk on toes/on heels/squat (if 
possible) and stand from squatting position. 
This is a comprehensive evaluation of the neu-
romuscular integrity of the lower limb. 
Walking by itself is a good screening for hip 
flexion and extension. Squatting position is a 
good screening again for hip flexion and 
extension.
• Assess Trendelenburg sign: ask the patient 
to stand on the affected side that has classi-
cally hip joint arthritis (diseases like osteo-
arthritis) with week hip abductors and 
extensors. Then ask the patient to raise the 
normal side. Normally, the pelvis in the 
unsupported side will be raise due to the 
tone of strong muscles from the other sup-
ported side. In this sign and because of 
weakness of hip muscles from arthritis, the 
muscle tone here cannot support the pelvis 
in the other unsupported side, and this will 
result in pelvis drop in the unsupported side 
with positive sign. Trendelenburg gait is 
basically the same explanation, but when 
the patient needs to walk, bending laterally 
toward the supported side will raise the 
dropping unsupported pelvis producing the 
classical waddling gait with bilateral 
involvement of both hips.
• Note the type of gait (Fig. 2.40).
Palpation
• You can start palpation, while patient is still in 
standing position.
• Back: palpate paraspinal muscles, sacroiliac 
joint (SI joint) (1 inch medical + inferior to 
PSIS), iliac crest, and ischial tuberosity (IT) 
• Apparent leg length: from xiphoid carti-
lage or umbilicus to medial malleolus
• True leg length: from ASIS to medial 
malleolus
Table 2.5 Classification of the hip pain according to the site of the pain and its differential diagnosis









Avascular necrosis (AVN) of the head femur




Greater trochanter pain 
syndrome
Referred pain from 
lumbar spine
Fracture of neck of femur
Nerve root compression
Tumor
Posterior Sacroiliac joint disease,
Lumbar radiculopathy
Inferior hip joint osteophytes 
associated with hip arthritis
2 Approach to Musculoskeletal Examination
50
(you may ask the patient to step on a stool 
using the limb under examination), feel GT, 
and feel sciatic nerve between the IT and GT.
• Lateral: palpate trochanteric bursae (Fig. 2.41).
• Anterior: palpate groin region – lymph nodes, 
pulses, hernia, ASIS, hernial orifice, pubic 
tubercle (where adductor longus originates), 
symphysis pupis – note any discrepancies in 
leg length.
• You may continue your palpation now, while 
the patient is in supine position.
• Quick screening: “frog” leg position—exter-
nal rotation (ER) + abduction (ABD) + knee 
flexion—then compare both sides. In this 
position you may feel adductor longus tendon 
by asking the patient to adduct the hip against 
resistance and then just follow the adductor 
longus tendon until its origin from the pubic 
tubercle. Eliciting pain here may give you the 
diagnosis of adductor longus tendinitis.
• Flex hips and knees then extend them and look 
for leg length discrepancy.
Range of Motion
• You have done active ROM in your screening 
exam for two important hip movement flexion 
and extension. Now, you need to do compre-
hensive assessment of ROM (Fig. 2.42).
• In supine position: ask the patient to flex hip 
as much as possible; you may combined hip 
Normal abnormala b
Fig. 2.40 Types of gait: 
normal (a) and 
abnormal (b)
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Neutral position
Flexion with knee bent Flexion with knee extended


















Fig. 2.41 Trochanteric 
and iliopsoas bursae
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and knee active flexion by asking the patient 
to bring the knee to abdomen. Back to supine 
position and ask patient to abduct the hip lat-
erally to as much possible and return to each 
hip one at time and ask the patient to cross 
midline. This is adduction. Back to supine 
position, and ask the patient to bring both 
plantar surfaces of both feet together facing 
each other with both knee flexed. This is exter-
nal rotation (ER), and it is called “frog” leg 
position. The opposite of this position is the 
assessment of internal rotation (IR). The other 
position for active ER and IR is while patient 
is sitting at the edge of the bed with the knees 
and hips flexed. Bringing the leg away is IR 
and toward the midline is ER. The same tech-
nique can be done while the patient is supine. 
Extension can be assessed while the patient is 
in lateral decubitus position with the hip 
moved posteriorly.
• Active: Flexion 120°
 – Abduction 50°
 – Adduction 30°
 – Frog leg (for ER) 45°
 – Opposite of frog leg (for IR) 35°
 – Or in prone position: do active ER + IR
 – Assess ER + IR through leg rolling while 
hips are extended.
• In lateral decubitus position: you may palpate 
trochanteric bursae and perform active exten-
sion 30°.
• The passive ROM can be assessed, while the 
patient is in supine position. Flex the hip and 
try to bring it to patient’s abdomen. Back to 
neutral position, and while putting one hand on 
the pelvis, take the hip to abduction, and use 
the same technique for the other hip. Perform 
passive adduction by crossing midline. For 
ER, flex hip and knee to 90°, then hold knee 
with one hand and the heel with the other hand, 
and then bring heel medially. For IR: bring 
heel laterally. Assess passive extension in lat-
eral decubitus position or in prone position.
Special Tests
• Hip fixed flexion deformity:
• Thomas test: bring both knees to patient’s 
abdomen and then extend one hip. If it failed 
to extend fully, there is fixed flexion hip 
deformity.
• Trochanteric bursitis:
• Tenderness over GT with pain elicited by 
resisted abduction.
• Radiculopathy:
• Straight leg raising test and slump test (see 
back exam).
• Piriformis syndrome:
• Resisted abduction while hip is flexed at 90° 
and adducted (Fig. 2.43).
• Tightness in iliotibial band (Ober’s test):
In lateral decubitus, neutralize hip and knee 
at 90°, and then abduct hip: a tight iliotibial 
band prevents the hip from adducting pas-
sively (Fig. 2.44).
2.7  Back Examination
2.7.1  First Step: The Anatomy
• The spine represents the axial skeleton of the 
back, and it is composed of 32–33 small 
bones, called vertebrae (7 cervical, 12 tho-
racic, 5 lumbar, 5 fused sacral, and 3 or 4 coc-
cygeal) (Figs.  2.45 and 2.46). The vertebrae 
bear the majority of the body weight and 
transfer it to lower limbs and also provide pro-
tection and support to spinal cord. A typical 
Fig. 2.43 Testing for piriformis syndrome
H. Almoallim et al.
53
vertebra is consisted of anterior body and pos-
terior arch enclosing the vertebral canal where 
the spinal cord extends from the brain to the 
area between the end of first lumbar vertebra 
and top of second lumbar vertebra (L1 or L2 
vertebral levels). Between each vertebra is a 
cartilaginous joint, called intervertebral disc. 
The discs limit the movements between the 
individual vertebrae and also act as a shock 
absorber (Fig. 2.47). The vertebral bodies are 
strictly attached to the intervertebral discs by 
two main ligaments: anterior and posterior 
longitudinal ligaments. Each pair of vertebrae 
is also connected by a synovial joint called 
facet joints. This is formed by the inferior 
articular process of one vertebra joining the 
superior articular process for the vertebra just 
below it. The facet joints give the spine its 
flexibility as there are two facet joints between 
each pair of vertebrae, one on each side. While 
the joints allow flexibility, the mobility of the 
spine is provided by the surrounded paraspinal 
muscles extended laterally along the spine.
• In the vertebral foramen posteriorly, the spi-
nal cord extends down to the end of the sec-
ond lumbar vertebra. Below this level, the 
spinal canal forms a group of nerve fibers, 
called the cauda equina. This group of 
nerves goes to the pelvis and lower limbs. 
Attached to each segments of the spinal 
cord, there is a pair of 31 spinal nerves exit-
ing the vertebral foramina through vertebral 
notches of the adjacent pedicles. The spinal 
nerves exit the intervertebral foramina in 
relation to vertebral levels as the following: 
nerves of C1-C7 exit superior to the pedi-
cles of the same-numbered level, C8 nerve 
inferior to C7 pedicles, and then T1 and 
below exit inferior to the pedicles of the 
same- numbered level.
• Different injuries and diseases may affect the 
components of spine and its surrounded para-
spinal muscles resulting in back pain 
(Figs. 2.48 and 2.49) (See Chap. 6).
2.7.2  Second Step: The Approach
2.7.2.1 Inspection
You may start your examination by explaining to 
your patient the steps of your exam. After proper 
exposure, start your inspection, while the patient 
is standing. You may ask one of the family mem-
bers to be around.
Always inspect the patient posteriorly, later-
ally, and anteriorly.
• Alignment: you should be familiar with the 
normal alignment of the spine. This is to help 
inspect for abnormal alignment that may give 
rise to chronic back pains: kyphosis, scoliosis, 
and exaggerated or lost lumbar lordosis. In 
patients with ankylosing spondylitis (AS), 
lumbar lordosis is usually lost from spondyli-
tis. This also can be lost due to severe muscle 
spasm over the lower back.
• Skin: Inspect for erythema, hair patch, café au 
lait spots, nodules, and/or scars.





• Range of motion.
• Special tests.
Fig. 2.44 Ober’s test



















































































Fig. 2.45 Bones of the 
spine [6]
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• Symmetry: check symmetry of the back by 
assessing whether tips of scapulae are at one 
level or not. Also for the iliac crests and gluteal 
folds. Inspect PSIS (dimples of Venous) as 
they should be align to one level. You may ask 
the patient to flex the hip and observe while 
you are standing behind the patient the sym-
metry and whether the asymmetry is corrected 
or not.
2.7.2.2 Screening/Gait Assessment
• Gait: straight walking while watching for 
abnormal flexion (suggestive of spinal steno-
sis or facet joint pathology), abnormal exten-
sion (suggestive of disc pathology), or 
Trendelenburg gait (Fig. 2.50).
• Screening for neurological integrity: walk-
ing on toes (L5, S1) and then on heels (L4, 

















Fig. 2.46 Structures of 
lateral spine
1 Superior articular process
2 Posterior tubercle



















Fig. 2.47 Structure of a vertebra
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to squat and stand from squatting position, hip 
flexion (L2, L3), and hip extension (L5, S1).
• Position: watch as patient changing position.
• Asses Trendelenburg sign (see hip joint 
exam): the patient stands on affected side and 
then raises the normal side, and in a positive 
test, the unsupported side will drop.
• Note the type of gait: normal gait passes 
through two phases stance and swing phases. 
The stance phase consists of heel strike, mid- 
stance, and toe off. The swing phase has an 
acceleration and deceleration components. A 
common gait abnormality in rheumatology is 
antalgic gait which is simply short stance 
phase gait due to pain in one of the lower limb 
joints.
2.7.2.3 Palpation
Start palpation while patient is in prone position. 
Palpate spinous processes over the midline from 
cervical down to sacral regions (Fig. 2.51). You 
may percuss to illicit severe tenderness that might 
indicate discitis. You may palpate now the para-
median spinal structures including muscles (for 
tenderness and/or spasms as majority of low back 
pain is caused by muscle strain and/or spasm), 
interspinous or supraspinous ligaments, and facet 
joints. Keep in mind the low specificity of these 
techniques. You may palpate now iliac crests for 
tenderness suggestive of enthesitis a hall mark 
feature of spondyloarthritis, while palpation 
observe any skin and/or soft tissue fluid collec-
tion suggestive of an abscess. Palpate the dimples 
of Venus at the level of S2 as the sacroiliac joints 
lie beneath them. It can be severely tender in sac-
roiliitis. You may ask the patient to stand and put 
his feet on a chair or a stool and you can posteri-
orly identify by palpation two bony prominences: 
the ischial tuberosity medially and the GT later-
ally. The sciatic nerve can be palpated in the area 
between these two. Severe tenderness can be 
illicit in patients with sciatica and/or piriformis 
syndrome.
2.7.2.4 Range of Motion
This can be assessed by asking the patient to per-
form the following:
• Flexion: ask patient to bend forward with 
extended knees and bring fingers to floor. The 
distance between the long finger and the floor 
can be documented and used to follow up 
response of treatment in cases of spondylitis.
• Extension: stabilize the pelvis and ask the patient 
to extend the back as much as possible. Figure 
2.52 demonstrates ROM of cervical spine.
Sacroiliac joint




Fig. 2.48 Some surface 
anatomy landmarks
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Fig. 2.49 Vertebral column [7]
2 Approach to Musculoskeletal Examination
58
• Lateral flexion: The patient may stand against 
the wall and bend laterally and trying to slide 
the fingers to fibula. The distance between the 
long finger and the fibula or the floor can be 
documented and used in monitoring response 
to therapy in spondylitis (Fig. 2.53).
• Thoraco-lumbar rotation: This is best exam-
ined while the patient is sitting at the edge of 
the bed. Ask the patient to turn to the side 
without moving the pelvis as much as possi-
ble; up to 70° can be achieved normally. This 
movement can be checked passively to exam-
ine for any tenderness, stiffness, limitation, 
and/or end of range stiffness (Fig. 2.53).
2.7.2.5  Special Tests
Straight Leg Raising Test (SLRT) (Fig. 2.54)
This is to test for radiculopathy of L5-S1. Keep 
the patient in supine position with extended hip 
and knee. Then flex the hip slowly until a com-
plaint of shooting radicular pain or tightness is 
a bFig. 2.50 Trendelenburg 
sign: (a) normal 
response. (b) Abnormal 
response with drop of 
the pelvis in the 
unsupported leg due to 
weakness in the opposite 
(supported leg) muscles. 
This will result in 
Trendelenburg gate
Fig. 2.51 Areas for palpitation
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reached. The test can be considered positive with 
classical radiation of the pain at 30–70° of leg 
elevation. Just lowering the examined leg few 
degrees before the pain appeared and then pas-
sive dorsiflexion of the ankle is performed as a 
confirmatory technique. Symptoms should recur 
in strongly positive test (Fig. 2.55).
Slump Test (Fig. 2.56)
This test is performed again to look for radicu-
lopathy at L5-S1. The patient should be sitting at 
the edge of the bed with both arms stabilized over 
the back. You should flex the outstretched 
extended leg to be examined by holding the toes 
or the ankle, and at the same time, ask the patient 
to flex the neck and bring the chin to the chest 
wall. A shooting radicular pain might result from 
this stretch indicating a positive test.
Sacroilliac Joints Exam
Patrick test and compression test: perform 
(FABER test (flexion abduction external rotation 
test)) Fig. 2.57. Flex the hip, abduct, and exter-
nally rotate it while the other leg in extended. 
Then compress over the iliac crest of the extended 
leg and over the knee of the flexed leg. A positive 
test produces pain in the sacroiliac joint of the leg 
being tested.
Modified Schober’s Test
This test is to assess for limited lumbar spinal 








Fig. 2.52 Range of motion of cervical spine
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drawing a line connecting both points. At the cen-
ter of this line, mark a point. Using a tape mea-
sure placed at the center point, mark 5 CM below 
this line and 10 CM above this line. Then ask the 
patient to bend forward without bending the 
knees. Now, measure the distance between the 
points. The distance between the two points 
should be more than 15 by 5 additional CM (≥ 20 
CM). Any movement that results in less than this 
is considered abnormal.
Neurological Exam
Detailed neurological exam should be conducted. 
The motor findings are reliable and should direct 
further intervention with the patient. One of the 
simple tests to perform is muscle bulk by a tape 
measure from a fixed bony prominence. More 
than 1 CM difference is considered abnormal for 
patients presenting with radicular symptoms. 
Rectal tone (S3,4,5) should be also performed in 
the right clinical settings. Fig. 2.58 represents a 
quick tool to examine in brief the roots of the 
lower limb. This quick approach includes exam-
ining the power of the following movement (note 
that it goes for simplicity from 2 to 5): hip flexion 
(L2), knee extension (L3), ankle dorsiflexion 
(L4), big toe extension (L5), and ankle plantar 
flexion (S1). This is in addition to sensory exam 
as shown in Fig. 2.59. Sensory level is an impor-
tant clinical finding to be determined in the right 
clinical setting in order to decide on further inter-
vention and follow-up. Figure 2.60 summarizes 
the steps of back examination.
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Fig. 2.53 Range of 
motion of thoraco- 
lumbar spine. (a) 
Flexion and extension. 
(b) Rotation. (c) Lateral 
extension




Fig. 2.54 Straight leg raising test
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a b
Fig. 2.55 Another approach to test for radiculopathy at L5-S1
Fig. 2.56 Slump test
Fig. 2.57 FABER test (flexion abduction external rota-
tion test) 








L5- Big toe extension
S1- Ankle toe extension
S1

























Fig. 2.59 Levels of 
principle dermatomes of 
the lower limb
2 Approach to Musculoskeletal Examination
64
Gait
• Gait: straight walking while watching for abnormal flexion (stenosis or facet
  joint), extension (disc), or Trendelenburg gait.  
• Screening: walking on toes then on heels. 
• Position: watch as patient changing position. 
Inspection
• Alignment: Kyphosis, scoliosis, or loss or exaggerated lordosis. 
• Skin: Erythema, hair patch, Café au lait spots, nodules, and or scars. 
• Inequality: watch for iliac crest and pelvic inequality => at the level of  L4-5: ask
  patient to flex his/her hip. 
• N.B: Always inspect the patient posteriorly and laterally. 
Palpation
• Examine the patient in the prone position. 
• Spinous processes: tenderness or defects. 
• Inter-spinous ligament. 
• Supraspinous ligament. 
• Paraspinal muscles. 
• Iliac crest: tenderness (Spondyloarthritis) or nodules. PSIS –Sacroilliac joint -S2 
• Ischial tuberosity -Sciatic nerve -Greater trochanter. 
Range of
Motion 
• Flexion: finger-floor 
• Extension: stabilize the pelvis and measure the distance 
• Lateral flexion: Finger-fibula (against the wall). 
• Tohoraco-lumbar rotation: 70º normally. 
Special Test
• Straight leg raising test (SLRT) 
• Slump test 
• Sacro-illiac joints exam: Patrick test and compression test
• Modified Schober's test
• Neurological exam: Muscle bulk by tape (Radiculopathy) and rectal tone (S3,4,5)
Fig. 2.60 Summary of back examination
H. Almoallim et al.
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Generally the diagnosis of rheumatic diseases is 
based on a set of clinical, serological, and radio-
logical measures. The discovery of a novel test 
that appears to be considerably more disease- 
specific and preferably sensitive would be of 
value for the early diagnosis and immediate, 
effective therapy to prevent joint deterioration, 
functional disability, and unfavorable disease 
outcome [1].
However, components of acute phase reac-
tion proteins such as erythrocyte sedimenta-
tion rate (ESR) and C-reactive protein (CRP) 
or rheumatoid factor (RF) lack specificity and 
sensitivity and could not reach the expectation 
of earlier diagnosis of specific rheumatic dis-
eases. Therefore, the discovery of immunologic 
laboratory tests has occupied a valued position 
in the practice of rheumatology and has helped 
define the pathophysiology of various rheu-
matic conditions such as the immunologic basis 
of rheumatoid arthritis (RA) [2, 3] and explain 
the contribution of genetic basis to autoimmune 
disease via the association of ankylosing spon-
dylitis (AS) with HLA-B27 and RA with certain 
HLA-DR alleles [4, 5].
Hence the salient existence of such immu-
nologic laboratory tests has assisted the more 
precise diagnosis of diverse rheumatologic condi-
tions that may share some clinical characteristics. 
In addition, these tests can provide valuable evi-
dence concerning disease manifestation, activity 
and prognosis, and therapeutic monitoring.
Essential terms concerning the laboratory tests 
are needed to be defined such as sensitivity, speci-
ficity, and positive and negative predictive values. 
Sensitivity refers to the ability of the test to detect 
the proportion of patients with a disease which 
usually have a positive test result. However, speci-
ficity refers to the ability of the test to detect the 
proportion of patients without the disease which 
usually have a negative test result. Predictive 
value refers to the likelihood of disease or non-
disease based on a positive or negative test result. 
A high positive predictive value test indicates that 
the patient with a positive test result most prob-
ably has the disease in question. Similarly, a high 
negative predictive value test indicates that the 
patient with a negative test result most likely does 
not have the disease in question.
Unlike with sensitivity and specificity of the test, 
the predictive value is markedly affected by disease 
prevalence. For instance, the predictive value of a 
positive rheumatologic test in patients with poly-
arthralgia is likely to be higher in a rheumatology 
clinic than in a family physician’s clinic [6].
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The subsequent sections will discuss the step-
wise approach to the diagnostic workup of rheu-
matic diseases and are presented as follows:
• Inflammatory markers (ESR and CRP)
• Rheumatoid factor (RF)
• Antinuclear antibody (ANA) profile, for 
instance, anti-double-stranded DNA antibod-
ies (anti-dsDNA) and anti-ribonucleic protein 
(RNP) antibodies
• Other disease-specific antinuclear antibodies 
and cytoplasmic antibodies
• Complement deficiencies and decreased com-
plement activity in certain medical conditions
• Components and classification of synovial 
fluid analysis
• Other biochemical tests: renal function tests 
and urine analysis (this section is not in the 
scope of the current chapter but it will be dis-
cussed in details in the chapter of “Renal 
System and Rheumatology”)
3.1.1  Objectives
By the end of the current chapter, the candidates 
should be able to:
• Identify the rule of acute phase reaction pro-
teins in rheumatic diseases.
• Interpret the auto-antibodies’ results based on 
clinical findings.
• Classify various types of joint effusions based on 
clinical and laboratory analysis of synovial fluid.
3.2  Acute Phase Reactants
Acute phase reactants (APRs) or proteins are 
defined as those proteins whose serum concen-
trations increase or decrease by at least 25% 
during inflammatory states. Changes in levels of 
APR largely result from the effects of cytokines, 
including interleukin (IL)-6, IL-1 beta, tumor 
necrosis factor-alpha (TNF-alpha), and inter-
feron gamma.
Serum APR level measurements are use-
ful because they frequently reflect the presence 
and intensity of an inflammatory process. The 
 assessment of APR may be most helpful in patients 
with RA, polymyalgia rheumatica, and giant cell 
arteritis.
However, APR measurements in clinical use 
are not specific to any particular disease.
The most widely used indicators of the acute 
phase response are the ESR and CRP [7].
ESR and CRP definitions, measurements, 
uses, and other important aspects are addressed 
in Table 3.1.




RF is an antibody directed against the Fc frag-
ment of immunoglobulin G (IgG). It may be of 
any isotype: IgG, IgA, IgE, and IgM. RF-IgM 
is the only one measured in clinical practice. 
The origin of RF is incompletely understood 
[7]. ACPAs are antibodies that are targeted 
against citrulline which is situated on proteins. 
Important clinical features of RF including 
measurement and common issues while dealing 
with it in clinical practice are all addressed in 
Table 3.2.
3.4  Antinuclear Antibodies 
(ANAs)
3.4.1  Definition
ANAs are serologic hallmarks of patients with 
systemic autoimmune disease. These antibod-
ies should be ordered when the clinical assess-
ment of the patient suggests the presence of 
an autoimmune or connective tissue diseases 
[7]. Clinical aspects of ANAs are discussed in 
Table 3.3.
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Table 3.1 ESR versus CRP
Definition ESR CRP
ESR is an indirect measurement of serum acute phase protein 
concentrations, defined as the rate (mm/hour) at which erythrocytes 
suspended in plasma settle when placed in a vertical tube, reflects a 
variety of factors, most notably the plasma concentration of 
fibrinogen [7]
CRP is defined as a 
pentameric protein 
comprised of five 
identical, non-covalently 
linked 23-KD subunits 
arranged in cyclic 
symmetry in a single 
plane. It is a component 
of the innate immune 
response and has both 
pro-inflammatory and 
anti-inflammatory 
actions. CRP can activate 
the complement system 
and enhance the 




Cont. ESR Cont. CRP
The Westergren method The Wintrobe method It is measured by 
immunoassay technique 
or nephelometry [7]
Uses a 200-mm tube and has a 
dilution step that correct for the effect 
of anemia.
It is the preferred method and can 
detect an ESR more than 
50–60 mm/h [7, 8]
Uses a 100-mm tube and has 
no dilution step [7, 8]
Sensitivity 
and specificity
An advanced rate does not diagnose a specific disease, but it does 
indicate that an underlying disease may exist [7, 8]
Although CRP is a 
sensitive reflector of 
inflammation, it is not 
specific for inflammation 
[9]
An elevated ESR observed together with a normal CRP is often a false-positive value for the ESR; 
this may reflect the effects of blood constituents, such as monoclonal immunoglobulins, that are 
not related to inflammation but that can influence the ESR. However, this conclusion is not always 
valid. As an example, the ESR may be markedly elevated in patients with active systemic lupus 
erythematosus (SLE), while the CRP response is muted. These variations may be explained by 
differences in the production of specific cytokines or their modulators in different diseases [10]





–  A normal value does not rule out 
the disease
–  Non-inflammatory conditions that 
can elevate ESR include aging, 
female sex, obesity, pregnancy, and 
race [7, 8]
–  The age-adjusted upper limit of 
normal for ESR is:
Male = age/2
Female = (age+10)/2
–  Normal value is less than 0.08 mg/dl
–  CRP levels vary with age, sex, and race [7]
–  The age-adjusted upper limit of normal for CRP is:
Male = age in years/50
Female = (age in years/50) + 0.6 [9]
(continued)
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3.4.2  Methods of Measurement
• Indirect immunofluorescence method using 
“fluorescence microscope” is the gold stan-
dard method to detect ANAs. Currently most 
laboratories use human epithelial cell tumor 
line (HEp2 cells) as a substrate to detect anti-
bodies that bind to various nuclear antigens 
(ANAs) instead of frozen section of rodent 
organ cells.
• Other methods that can be used for detec-
tion of specific ANA include ELISA, 





1-Causes of marked ESR elevation 
(more than 100 mm/hr):
1.  Infection (bacterial 33%)
2.  Connective tissue diseases (gain 
cell arteritis, polymyalgia 
rheumatica, SLE, vasculitides 
25%)
3.  Malignant neoplasms and renal 
disease 17%
4.  Inflammatory disorders 14% [7, 
11]





3.  Increased plasma viscosity
4.  Extreme polycythemia [7, 11]
Values between 0.3 and 1 mg/dL may indicate:
1.  Minor degrees of inflammation, e.g., periodontitis
2.  Minor degrees of metabolic malfunction (non- 
inflammatory states), e.g., obesity and insulin 
resistance [7, 9]
Values greater than 1 mg/dL can indicate:
Clinically significant inflammation [9]
Values greater than 8–10 mg/dL may indicate:
  1.  Bacterial infection
  2.  Systemic vasculitis
  3.  Metastatic cancer




1.  Inexpensive, familiar, and easy to 
perform
2.  As a patient’s condition worsens 
or improves, the ESR changes are 
relatively slow [12]
3.  A literature review was conducted 
for all clinical trials and 
observational studies of disease-
modifying medications and 
corticosteroids in RA to elaborate 
on the laboratory results of both 
ESR and CRP before treatment 
and 4 weeks to 24 weeks after 
treatment in the same patients, and 
it has been concluded that the ESR 
was more sensitive to change than 
the CRP at 12 weeks and 
24 weeks of treatment [13]
1.  It rises more quickly and falls more quickly than ESR 
[11]
2.  Measurements of CRP concentrations are of prognostic 
value in rheumatoid arthritis and can help guide 
management [11, 13–15]
3.  CRP alone may have been in favor as a simple, 
validated, reproducible, non-age-dependent test for 
disease activity assessment [12]
4.  CRP had been found to be more sensitive and specific 
marker for diagnosing bacterial infections in SLE 
compared to procalcitonin (PCT) [14, 15]. However, 
further meta-analysis report of studies describing the 
role of PCT or CRP as a biomarker of infection in 
autoimmune diseases has determined that PCT test is 
more specific than sensitive [16]. In addition, a later 
study has confirmed that PCT test is superior to CRP 
test in detecting superimposed bacterial infections in 
active SLE patients, where the PCT levels are correlated 
with the progression of bacterial infection and used to 
monitor the response to antibiotic treatment [17]
The serum protein electrophoresis is the most sensitive test for detecting inflammatory changes. 
It is the most expensive, directly quantifies the acute phase response [7]. However, there is no 
single best laboratory test to reflect inflammation
The optimal use of acute phase protein measurements may be to obtain several measurements, 
most commonly ESR and CRP, rather than a single test [9, 14, 18]
Additional tests suggest systemic inflammation: Low albumin and mild elevation of hepatic 
alkaline phosphatase [7]
A. Abdulkhaliq and M. Alotaibi
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Table 3.2 Characteristics of RF
Measurement It is measured by nephelometry, radioimmunoassay, enzyme-linked immunosorbent assay 
(ELISA), and latex agglutination techniques, although there is no single technique that has clear 
advantage over others. Automated methods, such as nephelometry and ELISA, tend to be more 
reproducible than manual methods [7]. The most commonly used technique to measure ACPA is 
the ELISA for antibodies against cyclic citrullinated peptides (CCP).
Sensitivity and 
specificity
•  The sensitivity of RF in RA has ranged from 26% to 90%
•  The reported sensitivity of the RF test in RA has been as high as 90%. However, population- 
based studies, which include patients with mild disease, have found much lower rates of 
RF-positive RA (26 to 60%) [19]
•  The sensitivity of ACPA testing is similar to RF at around 75%. However it provides much 
higher specificity rates at around 95%.
•  The specificity is 85% [19]




The common denominator for the production of RF (positive result) is chronic immune 
stimulation
Healthy individuals Non-rheumatic disorders Rheumatic disorders
  •  RF is present in some healthy 
individuals, especially the 
elderly (3–25%), male and 
female are affected equally, 
and only 20% of cases is the 
RF level significantly 
positive
  •  RF has been found in 2–4% 
of young, healthy individuals 
[7, 20]
1.  Chronic infection, e.g., 
AIDS, mononucleosis, 
parasitic infections, chronic 
viral infection (hepatitis B or 
hepatitis C (HCV) 54–76%), 
chronic bacterial infections 
(tuberculosis, subacute 
bacterial endocarditis (SBE))
2.  Cryoglobulinemia 40–100% 
especially with HCV
3.  Pulmonary disorders, such 
as sarcoidosis
4.  Malignancy, especially after 
radiation or chemotherapy 
and B-cell neoplasms
5.  Primary biliary cirrhosis 
[7, 21]
 Positive ACPA can be found in 
the following non 
rheumatological diseases:
1.  Active tuberculosis (varying 
rates)
2.  Chronic obstructive 
pulmonary disease (5%)
3.  It is important to note that 
unlike RF, ACPAs are rarely 
found in patient with 
hepatitis C virus
1.  Rheumatoid arthritis 
26–90%
2.  Sjögren’s syndrome 
75–95%
3.  Mixed connective 
tissue disease 50–60%
4.  Mixed 
cryoglobulinemia 
(types II and III) 
40–100%
5.  Systemic lupus 
erythematosus 
15–35%
6.  Polymyositis or 
dermatomyositis 
5–10%
7.  Sarcoidosis 15% [7, 
21]
 ACPAs were found to be 
positive in the following 
autoimmune diseases:
1.  SLE and primary 
Sjogrens Syndrome 
(17%)
2.  Psoriatic arthritis 
(8-16%)
Can RF be used 
as a screening 
test?
•  Measurement of RF is a poor screening test to diagnose or exclude rheumatic disease in either 
healthy populations or in those with arthralgias but have no other symptoms or signs of 
rheumatic disease [20]
•  In a population study, it has been found that the presence of both RF and anti-citrullinated 
protein antibody (ACPA) in apparently healthy people substantially increases the probability 
of having RA. So the presence of the two autoantibodies (RF and ACPA) is associated with a 
relative risk of approximately 70% [20]
•  The RF has a higher positive predictive value (PPV) if ordered more selectively in patients 
with a modest or higher chance of having an RF-associated rheumatic disease such as RA, 
Sjögren’s syndrome, or the mixed cryoglobulinemia syndrome. Included in this group are 
patients with prominent morning stiffness, with sicca symptoms, or with arthralgia or arthritis 
in a rheumatoid distribution (i.e., symmetric polyarthritis involving small joints) [19]
•  Higher titers of RF have a higher positive predictive value for RA [19].
(continued)





and ACPA in 
known RA 
cases
•  RF-positive patients with RA may experience more aggressive and erosive joint disease and 
extra-articular manifestations than those who are RF-negative. Similar findings have been 
observed in juvenile idiopathic arthritis [19]
•  RF status may be useful in combination with other indicators, including HLA-DRB1, CRP, 
the ESR, and severity of synovitis on physical exam, to predict progression of radiographic 
changes in RA patients and to guide treatment [19]
•  ACPA positivity was found to be associated with more erosive joint disease, especially 





•  The change in RF level does not reflect changes in RA disease activity
•  RF should not be used routinely to monitor RA disease activity in clinical practice
•  RF titer may fall with effective treatment of RA in patients who are originally RF-positive 
[19, 22]
•  In Sjögren’s syndrome, the disappearance of a previously positive RF may herald the onset of 
lymphoma. That is why some clinicians check RF repeatedly in patients with Sjögren’s 




•  RF and ACPA have the potential to revert and convert during the early course of disease. 
Fluctuations in RF and ACPA were not associated with clinical outcomes [23]
•  Repeated measurement of ACPA or RF during the first year after onset of arthritis does not 
offer major additional information [24]
RF and the 
mortality
Patients with RA with positive RF, especially IgA and IgM isotypes, carry a risk of dying earlier 
than patients without these serological findings [25]
Table 3.3 ANA characteristics
Positive 
result
•  It is defined as the level of ANA that exceeds the level seen in 95% of the normal population
•  In most laboratories, this level is a titer of 1:40 to 1:80 that are reported positive




Organ-specific autoimmune diseases Infections Others
  1.  SLE 93%
  2.  Scleroderma 85%





  5.  Rheumatoid arthritis 
41%
  6.  Rheumatoid 
vasculitis 33%
  7.  Sjögren’s syndrome 
48%






  9.  Discoid lupus 15%
  10.  Pauci-articular 
juvenile chronic 
arthritis 71% [7, 
26]
1.  Hashimoto’s thyroiditis 46%
2.  Graves’ disease 50%
3.  Autoimmune hepatitis 63–91%
4.  Primary biliary cirrhosis 10–40%
5.  Primary autoimmune cholangitis 
100%
6.  Idiopathic pulmonary arterial 
hypertension 40%
7.  Multiple sclerosis 25% [7, 26]










–  Malignancy (rare) 
with the exception 
of dermatomyositis 
[7, 26]
1.  Highly relatives of 
patient 15–25%
2.  Normal elderly 
20%





used as a 
screening 
test?
–  No, it cannot be used as a screening test for autoimmune disorders in the general healthy population in the absence 
of clinical findings as it may be present in very low specificity titer in normal population 5%
–  It should be used primarily as a confirmatory test when the clinicians strongly suspect SLE or autoimmune 
disorders
–  A patient with a negative ANA and strong clinical evidence of SLE or another SS-A-associated disease, antibodies 
to SS-A should be ordered [7]
(continued)
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3.5  ANA Profile
3.5.1  Definition
An ANA profile consists of many antibodies to 
measure specific ANAs for certain nuclear anti-
gens. It should be performed when the screening 
test for ANA is positive and when further infor-
mation is needed regarding the type of autoim-
mune disorder [7].
ANA profile antibodies and their specific uses 
are elaborated on Table 3.4.
3.6  Other Disease-Specific 
Antinuclear Antibodies 
and Cytoplasmic Antibodies
These antibodies have to be ordered individu-
ally according to the set-up diagnosis based on 
patient’s symptoms and clinical presentations, 
and they include:
 1. Anti-histone antibodies: sensitive (70%) for 
drug-induced lupus but nonspecific and have 
limited diagnostic utility because they may 
also be present in patients with SLE. The best 
test to conduct in patient with suspected drug- 
induced lupus is antichromatin antibody test, 
not anti-histone antibody test [7]. However, 
anti-histone antibody test might be of value in 
patients having a positive ANA test with his-
tory of exposure to medications-induced lupus, 
such as procainamide (Pronestyl) and isoniazid 
(INH) [27].
 2. Anti-Th/To antibodies: crest syndrome 
20% [7].
 3. Anti-SCL-70 antibodies (topoisomerase1): 
diffuse systemic sclerosis (scleroderma) 
22–40% [7]. They are highly specific but not 
sensitive for scleroderma [29].
 4. Anti-tRNA synthetase antibodies (anti- 
Jo- 1, other): polymyositis 20–30% [7].










The pattern type has been found to have relatively low sensitivity and specificity for different autoimmune disorders, 
and thus tests for specific antibodies have largely replaced the use of patterns
The homogeneous or 
diffuse pattern
Represents antibodies to 
the DNA-histone 
complex (anti-DNP (LE 
cell) and anti-histone)
The peripheral or 
rim pattern
It is produced by 




















It is produced by 
antibodies to RNA 
polymerase I, 





B23, PM-Scl, and 




It is produced by 
antibodies to proteins 
that are associated 





etc., are only present 
on active centromeres 
(i.e., during meiosis 
and mitosis) [7, 26]
ANA titer –  The presence of very high concentrations of antibody (titer >1:640) should arouse suspicion of an autoimmune 
disorder. However, its presence alone is not diagnostic of disease
–  If no initial diagnosis can be made, it is our practice to watch the patient carefully over time and to exclude 
ANA-associated diseases
–  An accurate ANA with titer, in combination with a full history and physical examination, can be extremely useful 
in the diagnosis and exclusion of connective tissue disease [26]
–  1–2% of patients who have active and untreated SLE will have a negative ANA, and this is because the substrate 
used in ANA test did not contain a sufficient antigen to detect SS-A antibodies
–  10–15% of SLE patients will become ANA-negative with treatment or inactive disease
–  40–50% of SLE patients with end-stage renal disease on dialysis will become an ANA-negative [7]
Table 3.2 (continued)
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• Cytoplasmic anti-neutrophil cytoplasmic 
antibodies (C-ANCA), the most common 
c-ANCA target is serine proteinase- 3: gran-
ulomatous polyangiitis (GPA) (Wegener 
granulomatosis) 90%, microscopic polyan-
giitis (MPA), eosinophilic granulomatosis 
with polyangiitis (EGPA) (rare). Its titer can 
correlate with GPA disease activity [30].
• Perinuclear anti-neutrophil cytoplasmic 
antibodies (P-ANCA), the most common 
p-ANCA target is myeloperoxidase: MPA 
70%, pauci-immune glomerulonephritis, 
and EGPA, or myeloperoxidase (−)—
ulcerative colitis, chronic infection, and 
neoplasm (rare) [30].
 6. Anti-mitochondrial antibodies (AMAs): 
primary biliary cirrhosis 80% [7].
 7. Antibodies to the gp210 and p62 proteins of 
the nuclear pore complex: primary biliary 
cirrhosis 10–40% [7].
3.7  Circulatory Complement 
Components
Complement is an important effector pathway of 
innate immunity and has a role in the pathogenesis 
of some of rheumatic conditions, namely, SLE.
Causes of Decreased Circulatory Complement 
Components
• Hereditary complement deficiencies 
(decreased production)
• Secondary complement deficiencies (acquired) 
[31]












SLE 60% –  It is very specific 
for SLE
–  It is the one that 





lupus nephritis or 














–  A very high level 







SLE 30% –  It is very specific 
for SLE
–  The sensitivity 
of anti-dsDNA 
and anti-Sm for 
the diagnosis of 
SLE is relatively 
low




when a patient 
has entered 
remission; 










































A. Abdulkhaliq and M. Alotaibi
75
3.7.1  Mechanism of Acquired 
Complement Deficiencies
 1. Increased level of circulatory immune com-





(a) SLE: Low C4 and C3 levels occur in 
about 50% of patients with SLE. Levels 
of C3 and C4 are decreased with 
increased severity of SLE, especially 
renal disease. A return to normal levels 
with treatment is a good prognostic sign. 
Serial observations reveal decreased lev-
els preceding clinical exacerbation.
(b) Cryoglobulinemia: The complement 
profile shows decreased levels of C4 and 
C2 with normal or slightly lowered C3.
(c) Systemic vasculitis especially polyar-
teritis nodosa, urticarial vasculitis: 
50% of patients with polyarteritis may 
have decreased serum complement 
levels. Its values can be helpful in 
assessing the clinical course, espe-
cially the response to therapy.
(d) RA with extra-articular manifestation 
(rare) [7, 32].
 2. Reduced hepatic synthesis (uncommon)
 3. Loss of complement components in the urine 
(rare) [30]
3.8  Synovial Fluid Analysis
The presentation of one or more hot, swollen 
joints is a common medical emergency, and 
synovial fluid aspiration, the so-called arthro-
centesis, is the single most important test 
helping in the diagnosis of different types of 
arthropathies [33].
Therefore, specialized laboratories analyze 
synovial fluid to either confirm the diagnosis 
of crystal-associated arthropathies, support the 
diagnosis of septic arthritis, or establish other 
rheumatologic diagnoses such as mono-arthritis 
or joint effusion [34].
The complete analysis of synovial fluid 
includes macroscopic (gross appearance), micro-
scopic, and specific stain tests to provide detailed 
information about the joint’s condition and helps 
in establishing the diagnosis and treatment [35]. 
Description of macroscopic analysis of synovial 
fluid includes color, clearance, volume, and vis-
cosity. However, the microscopic analysis can dif-
ferentiate between inflammatory and infectious 
processes by measuring a complete leukocyte 
count. In addition, a differential of the synovial 
WBC count should be ordered, so that if the 
results came positive for infectious process, the 
performance of Gram-stain and culture tests will 
provide guidance to diagnosis and/or antibiotic 
therapy [36].
Microscopic examination specifically can 
also allow the detection and identification of 
various types of crystal by using polarized light 
microscope. Refer to Table 3.5 for an overview 
on important issues as regards arthrocentesis 
and synovial fluid analysis. However, Table 3.6 
shows the classification of joint effusions into 
normal, inflammatory, non-inflammatory, and 
septic effusion based on clinical and labora-
tory analysis of synovial fluid with the causes 
of each type [37, 38]. Indications, contraindi-
cations, complications, and specimen analysis 
of synovial fluid are presented in Table  3.5. 
Classification and causes of joint effusions based 
on laboratory analysis of synovial fluid are pre-
sented in Table 3.6. Fig. 3.1 is the clinical diag-
nostic approach for painful peripheral joint.
3.9  Key Notes
• The likelihood diagnosis of septic arthritis is 
markedly increased with higher synovial 
WBC counts. It has been illustrated that for 
synovial WBC count the likelihood ratio (LR) 
of having septic arthritis is as follows [34]:
 – WBC count <25,000/μL, the LR is 0.32 at 
95% CI.
 – WBC count ≥25,000/μL the LR is 2.9 at 
95% CI.
 – WBC count >50,000/μL, the LR is 7.7 at 
95% CI.
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Table 3.5 Overview on arthrocentesis and synovial fluid analysis
Indications Contraindications Complications Specimen handling Synovial fluid analysis
  1.  According to the 
American College of 
Rheumatology 
(ACR), synovial 
fluid analysis should 
be performed in the 
febrile patient with 
an acute flare of 
established arthritis 
to rule out 
superimposed septic 
arthritis
  2.  Unexplained joint, 
bursa, or tendon 
sheath swelling
  3.  Suspected crystal- 
induced arthritis
  4.  Repeated aspiration 
and analysis may be 
indicated to follow 
up the response of 
septic arthritis to 
treatment and may 
also be valuable for 
diagnosis of some 
cases of gout in 
which the initial 
aspirate does not 
have detectable 
crystals [34]
1.  There is no 
absolute 
contraindication
2.  Bleeding diatheses 




could make the 
approach to the 
joint space difficult 






4.  Cartilage 
injury
5.  Vasovagal 
syncope [37]





of specimen for 
culture to the 
sterile tubes 
and plated as 
soon as 
possible













The WBC count and 
the percentage of 












1.  Gram stain and 
cultures should be 




2.  Crystal search 
using polarized 
light microscopy
3.  Chemistry 
analysis should 
not be routinely 
ordered [37]
Table 3.6 Classification and causes of joint effusions based on laboratory analysis of synovial fluid














0–200 200–2000 2000–50,000 50,000–150,000
Polymorphonuclear 
cell (PMN)%
<10% <20% 20–70% ≥75%
Causes –  Osteoarthritis
–  Joint trauma
–  Hypertrophic 
osteoarthropathy
–  Neuropathic 
arthropathy





–  Psoriatic arthritis
–  AS
–  SLE
–  Reiter syndrome
–  Sarcoidosis
–  Rheumatic fever
–  Wegener 
granulomatosis
–  Infectious arthritis
–  SBE [37, 38]
1.  It is a septic arthritis until 
proven otherwise by the fluid 
culture
2.  Pseudosepsis include reactions 
to intra-articular injections, 
gout, Reiter’s syndrome, 
leukemic infiltration, and RA 
[37, 38]
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 – WBC count >100,000/μL, the LR is 28.0 at 
95% CI.
• Polymorphonuclear (PMN) cells of 90% are 
associated with increasing likelihood of sep-
tic arthritis of 3.4, while if the percentage of 
PMN cells is less than 90%, the likelihood 
decreases down to 0.34 (95% CI) that sup-
ports the clinician’s suspicion of bacterial 
arthritis [38, 39].
• Eosinophilic cells in the synovial fluid suggest 
parasitic infection, allergy, Lyme disease, or 
neoplasm [40].
• If there is a suspicion of joint involvement by a 
neoplasm or hematologic malignancy, formal 
cytological examination should be ordered [38].
• Hemorrhagic effusions may be caused by 
hemophilia, anticoagulation or other bleeding 
diathesis, scurvy, trauma, neuropathic arthrop-
athy, and tumors [38].
3.9.1  Gram Stain
• It is used to identify common bacterial organ-
isms (Gram-positive versus Gram-negative 
coverage) for the diagnosis and treatment of 
septic arthritis.
• It may be the only evidence of infection with 
fastidious organisms that are not able to grow 
in culture [41].
• The sensitivity is not known precisely.
 – In non-gonococcal bacterial arthritis, it is 
in range from 50% to 70%.
 – In gonococcal arthritis, it is <10% [41].
• The specificity is high when performed and 
interpreted by an experienced clinician or 
technician [41].
3.9.2  Synovial Fluid Culture
• The synovial fluid samples should be rou-
tinely sent for culture for staphylococci fol-
lowed by streptococci and Gram-negative 
bacteria (non-gonococcal causes).
• Antibiotics should generally not be given 
prior to joint aspiration [42, 43].
• The specificity: Positive synovial culture 
should be indicative of septic arthritis in 100% 
of cases with exclusive of contamination and 
laboratory error [42, 43].
• The sensitivity: It is not known precisely 
because of the lack of an alternative gold stan-
dard. The joint aspirate should be cultured for 
Painful, peripheral,
swollen joint
If SEPTIC ARTHRITIS is suspected







cells % (refer to
table-6)
The higher the value the




















Fig. 3.1 Clinical 
approach for painful 
peripheral joint
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N. gonorrhoeae or unusual organisms (TB, 
Lyme disease, or fungal infections) when the 
history is suggestive [42, 43].
3.9.3  Diagnostic Approach
• It should be noted that the absence of organ-
isms on Gram stain or a negative subsequent 
synovial fluid culture does not rule out the 
diagnosis of septic arthritis especially if clini-
cal suspicion is high. In such condition, an 
empirical treatment of the case as septic arthri-
tis should be implemented [44–46].
• Moreover, it has been suggested that the “gold 
standard” for the diagnosis of septic arthritis is 
the level of clinical suspicion by an expert 
physician in the management of patients with 
musculoskeletal disease [35, 45].
• Similarly, another study had concluded that 
combining Gram stain and culture of synovial 
fluid with clinical follow-up is the best 
approach used to detect patients missed by 
Gram stain and culture alone [36].
3.9.4  Crystal Search Using Polarized 
Light Microscopy
Polarized light microscope (PLM) is a funda-
mental tool for detection and identification of 
various types of crystals present in synovial fluid 
depending on their shape (needle, rhomboid, 
cigar-shaped, etc.) birefringence, location (intra-
cellular or extracellular), and quantity (scarce or 
plentiful). The obtained results of PLM help the 
clinicians in diagnosing and managing a case of 
monoarthritis. However, the presence of artifacts 
in microscopic analysis can confuse the inexpe-
rienced observer; therefore, a suitable interpre-
tation of the synovial fluid analysis using PLM 
requires at least two experienced observers [47]. 
The microscopic features of common types of 
crystals that can differentiate between clinical 
cases of gout and pseudogout are illustrated in 
Table 3.7.
3.10  Summary
Due to the fact that musculoskeletal symptoms 
are exceedingly common compared with the 
prevalence of systemic rheumatic disease, the 
pretest probability of systemic rheumatic disease 
in the population is rather low compared with 
musculoskeletal symptoms that are nearly ubiq-
uitous. Therefore, establishing the diagnosis of a 
rheumatic disease may require exclusion of other 
differential diagnoses that present in a similar 
fashion. Even the disease established-guidelines, 
which are often used by clinicians, perform 
poorly during the assessment of a patient present-
ing with new polyarthritis [49]. As a consequence, 
widely used laboratory tests can be very specific 
and permit rapid diagnosis and appropriate man-
agement. However, clinicians should be aware of 
the false-positive tests that may result in inappro-
priate management and unnecessary concern.
Generally, serum rheumatologic tests are most 
helpful for confirming a clinically suspected diag-
nosis. For instance, testing for RF is appropriate 
when suspecting RA, Sjögren’s syndrome, or cryo-
globulinemia, whereas ANA testing is highly sen-
sitive for SLE and drug-induced lupus. Although 
an elevated ESR is a sensitive test for polymyalgia 
rheumatica and temporal arteritis, its specificity is 
quite low. In addition, ESR levels are frequently 
linked to the disease activity in rheumatoid arthritis 
and may found to be of value for monitoring thera-
peutic response. However, anti-double-stranded 
Table 3.7 Gout versus pseudo-gout
Crystal Shape Birefringence
Color of crystals parallel to axis of 
red-plate compensator
Gout Monosodium urate (MSU) Needle Negative Yellow
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DNA antibodies are usually associated with lupus 
nephritis, and their titer often correlates with dis-
ease activity in SLE. On the other hand, cytoplas-
mic anti-neutrophil cytoplasmic antibody test is 
highly sensitive and specific for GPA.
In order to increase the utility and decrease 
the cost-effectiveness of the laboratory testing 
of rheumatic disease, these tests should be used 
more selectively and avoid absolute overreliance 
on lab results. However, a logic combination of 
the clinical background and the testing results 
would provide the appropriate diagnosis of the 
rheumatic conditions. Finally, as Shmerling RH 
has stated, “the passage of time is one of most 
useful diagnostic tests as many patients with 
musculoskeletal symptoms improve over time 
without a clear diagnosis” [50].
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ANA Antinuclear antibody profile
ANCAs  Anti-neutrophil cytoplasmic 
antibodies
anti-dsDNA  Anti-double-stranded DNA 
antibodies




anti-Th/To  Antibodies to Th/To 
ribonucleoprotein
APRs Acute phase reactants or proteins
AS Ankylosing spondylitis
C4 and C3 Complements




EGPA  Eosinophilic granulomatosis with 
polyangiitis
ELISA  Enzyme-linked immunosorbent 
assay
ESR Erythrocyte sedimentation rate
GPA Granulomatous polyangiitis
HEp2 cells Human epithelial cell tumor line
HLA-B27 Human leukocyte antigen B27








P-ANCA  Perinuclear anti-neutrophil cyto-
plasmic antibodies




RNP  Anti-ribonucleic protein 
antibodies
SLE Systemic lupus erythematosus
TNF-alpha Tumor necrosis factor-alpha
WBC White blood cell count
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Over the past two decades, better understanding 
of the immunopathophysiologic basis of various 
rheumatic diseases led to the discovery of variety 
of drugs that are now approved and widely used 
in clinical practice. These drugs are categorized 
into the following categories: nonsteroidal anti- 
inflammatory drugs (NSAIDs), synthetic disease- 
modifying anti-rheumatic drugs (sDMARDs), 
biological disease-modifying anti-rheumatic 
drugs (bDMARDs), corticosteroids and drugs 
used in crystal-induced arthritis. Few other drugs 
are also used by rheumatologists. These include 
anti-resorptive drugs and symptom-specific drugs.
4.2  Learning Objectives
By the end of this chapter, you should be able to:
 – Recall the main drug categories used in the 
treatment of systemic rheumatic diseases
 – Explain the mechanism of action, dosages, 
indications, adverse effects, cautions, contra-
indications and pregnancy category of each 
drug
4.3  Nonsteroidal Anti- 
Inflammatory Drugs 
(NSAIDs)
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
are effective anti-inflammatory, antipyretic and 
analgesic drugs. Although they differ widely in 
their chemical class, they share the property of 
blocking the production of prostaglandins (PGs). 
This is achieved by inhibiting the activity of the 
enzyme prostaglandin G/H synthase (PGHS), 
also called cyclooxygenase (COX).
There are two different COX isoforms, COX-1 
and COX-2. Inhibition of COX-2 by NSAIDs 
blocks PG production at sites of inflammation, 
while inhibition of COX-1  in certain other tis-
sues, most importantly platelets and the gastro-
duodenal mucosa, can lead to common adverse 
effects of NSAIDs such as bleeding, bruising and 
gastrointestinal ulceration [1].
In addition to their use in rheumatoid arthri-
tis and osteoarthritis, NSAIDs are widely used in 
the symptomatic management of other rheumatic 
diseases characterized by chronic musculoskel-
etal pain and diverse forms of acute pain.
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NSAIDs are associated with elevated cardio-
vascular disease risk and risk for gastrointes-
tinal bleeding and ulceration [2, 3]. For that, it 
is important to identify patients with these risks, 
and if present, avoiding NSAIDs or using inter-
mittent, low-dose and short half-life drugs is 
advisable. It is also important to know that use 
of NSAIDs together with aspirin, which is an 
NSAID too, can increase gastrointestinal toxicity 
and lead to aspirin resistance [4].
Patients who take regular doses of NSAIDs 
should undergo periodic assessment of blood 
pressure, haemoglobin level, electrolytes and 
renal and liver function tests.
Complete details about different NSAIDs are 
shown in Table 4.1
4.4  Synthetic Disease-Modifying 
Anti-Rheumatic Drugs 
(sDMARDs)
This category consists of drugs that have been 
used as first-line therapies in the majority of sys-
temic rheumatic diseases. Although their precise 
mechanism of action is still incompletely under-
stood, they have both anti-inflammatory and 
immunomodulatory effects.
Generally, the choice of a sDMARD therapy 
should be decided for each patient individu-
ally. This should also give attention to patient’s 
age, fertility plans, comorbid conditions and 
other concomitant drugs. Adverse effects from 
sDMARDs may cause significant morbidity and 
mortality. So, appropriate dosing and monitoring 
for toxicity are required.
4.4.1  Methotrexate
Over the past 25 years, methotrexate has become 
the sDMARD of choice in the treatment of 
rheumatoid arthritis and is used in many other 
rheumatic diseases as well (psoriasis, psoriatic 
arthritis, polymyositis, dermatomyositis, granu-
lomatosis with polyangiitis, giant cell arteritis, 
subacute lupus erythematosus, scleroderma and 
vasculitis).
Methotrexate increases the concentration of 
adenosine, which is a potent inhibitor of inflam-
mation. It also inhibits the enzyme dihydrofolic 
acid reductase [5].
The effects of methotrexate can be enhanced 
by using the subcutaneous form instead of the 
oral form or by splitting the oral dose (within 
12-h window) when doses greater than 15  mg 
weekly are given [6]. Doses should be adjusted 
based on renal and hepatic function.
A weekly oral dose of folic acid 5–10  mg 
given 48–72  h post methotrexate dose protects 
against mucosal ulceration and keeps folic acid 
levels optimum [7].
4.4.2  Leflunomide
Leflunomide is approved for the treatment 
of rheumatoid arthritis. It has both anti- 
inflammatory and immunomodulatory effects. It 
inhibits the enzyme dihydroorotate dehydroge-
nase and pyrimidine synthesis [8].
Loading doses are not used in clinical prac-
tice due to gastrointestinal toxicity. Leflunomide 
is found to have a very long half-life because of 
its enterohepatic recirculation [9]. It is absolutely 
contraindicated in pregnancy.
4.4.3  Azathioprine
It is an imidazolyl derivative of mercaptopurine. 
It antagonizes purine metabolism and may inhibit 
the synthesis of DNA, RNA and proteins. It also 
inhibits cellular metabolism [10].
Azathioprine can be effective as a 
glucocorticoid- sparing agent in remission main-
tenance therapy, particularly in systemic lupus 
erythematosus and necrotizing vasculitis.
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Table 4.1 Nonsteroidal anti-inflammatory drugs (NSAIDs)








and release of 
inflammatory mediators
Pain: 300–800 mg PO q6hrs




Osteoarthritis: 300 mg, 400 mg, 
600 mg or 800 mg PO q6–8hrs; not 
to exceed 3.2 g/day
Rheumatoid arthritis: 300–800 mg 
PO q6–8hrs; not to exceed 3.2 g/day
May cause elevated 
creatinine or liver enzymes 
in patients with active SLE.
Gastrointestinal complaints 
like erosion, ulceration or 
bleeding
Hepatotoxicity, asthma, 
rashes, itchiness, tinnitus, 
dizziness, headache and 
aseptic meningitis 
(particularly in patients 
with systemic lupus 
erythematosus)
Fluid retention and renal 




administration with aspirin 
will antagonize the 
irreversible platelet 
inhibition induced by 
aspirin
2.  Reduce the natriuretic 
effect of furosemide and 
thiazides in some patients
3.  May also increase 
lithium plasma levels due 
to decreased renal 
clearance
4.  Use of NSAIDs with 
ACE inhibitors may 




prednisone may increase 
the risk of GIT ulceration
Pregnancy 
category: C or D 








breast milk, use 
not recommended
Naproxen Naproxen
Pain: 500 mg PO initially followed 
by 250 mg PO q6–8hrs PRN; 
alternatively, 500 mg q12hr. Not to 
exceed 1250 mg/day PO
Rheumatoid arthritis, ankylosing 
spondylitis or 
osteoarthritis:500–1000 mg PO 
divided q12hrs. Not to exceed 
1500 mg/day PO
Pregnancy 
category: B or D if 
used for prolonged 









osteoarthritis or ankylosing 
spondylitis:
7.5–15 mg PO daily; not to exceed 
15 mg/day
Pregnancy 
category: C or D 








breast milk is 




isoenzymes (does not 
affect COX-1), thus 
inhibiting synthesis of 
prostaglandin and 
release of the 
inflammatory mediators
Rheumatoid arthritis, 
osteoarthritis or ankylosing 
spondylitis:
200 mg PO once daily or divided 
Q12hr
Headache, hypertension, 
abdominal pain, nausea 
and vomiting
Fluid retention and renal 
toxicity occur less 
frequently
Increased risk of 
cardiovascular events and 
gastrointestinal toxicity
Pregnancy 
category: C or D 








breast milk, use 
should be 
carefully evaluated
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It can induce severe myelosuppression in 
patients with low or absent thiopurine methyl-
transferase (TPMT) activity that is affected by a 
polymorphism that can be identified by genetic 
screening [11]. Severe myelosuppression can 
also occur in patients with normal TPMT activity, 
and regular monitoring of white blood cell counts 
is recommended.
Azathioprine interacts with allopurinol 
and this can lead to fatal myelosuppression. 
Concomitant use of these two drugs should be 
avoided.
4.4.4  Hydroxychloroquine
It is an anti-malarial drug and a well-tolerated 
sDMARD that is now used as a cornerstone ther-
apy in patients with systemic lupus erythema-
tosus and in combination therapy regimens for 
rheumatoid arthritis [12].
Hydroxychloroquine is more commonly used 
than chloroquine. It has a very long half-life, 
attributed to its affinity for melanin-containing 
cells in the skin. Doses of hydroxychloroquine 
should not exceed 6.5 mg/kg/day in chronic ther-
apy to minimize the risk of retinal toxicity [13]. 
Although routine laboratory monitoring is not 
required, ophthalmologic screening is an essen-
tial component of toxicity monitoring.
Diabetic patients initiating hydroxychloro-
quine should be instructed to follow blood sugars 
closely because of the hypoglycaemic effects of 
the drug.
Hydroxychloroquine is considered safe in 
pregnancy; it is recommended that most pregnant 
patients with SLE remain on the drug to improve 
pregnancy outcomes.
4.4.5  Sulfasalazine
It is a sDMARD that has both antimicrobial and 
anti-inflammatory properties. The exact mecha-
nism of action is unknown. However, it is a 
5-aminocyclic acid derivative that inhibits leu-
kotriene synthesis [14].
Sulfasalazine is commonly used as part of 
combination therapy for rheumatoid arthritis. Its 
dose should be increased gradually with regular 
laboratory monitoring to minimize the risk of 
adverse effects and drug intolerance.
Gastrointestinal intolerance and rash are com-
mon side effects. Monitoring complete blood 
counts, liver transaminases and creatinine levels 
should be done periodically during therapy [15].
4.4.6  Mycophenolate Mofetil
It is a powerful inhibitor of lymphocyte prolifera-
tion that has a potential glucocorticoid-sparing 
effect. It is used for the treatment of patients with 
various rheumatic diseases. It inhibits inosine 
monophosphate dehydrogenase enzyme which 
decreases T- and B-cell proliferation and anti-
body production [16].
Mycophenolate mofetil can be used as a 
remission induction agent in lupus nephritis and 
is now increasingly used for remission mainte-
nance treatment of systemic lupus erythematosus 
and necrotizing vasculitis [17].
It is generally well tolerated, although diar-
rhoea and leucopenia may necessitate its dis-
continuation. Complete blood counts should be 
performed within the first 2 weeks of therapy and 
then once every 6–8 weeks thereafter if no cyto-
penia is noted [18].
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4.4.7  Cyclophosphamide
It is an alkylating agent and one of the most potent 
immunosuppressive therapies available. It is a pro-
drug which prevents and inhibits cell division [19].
The indications for its use include induction 
of remission in lupus nephritis. It is also used to 
treat rheumatoid vasculitis, interstitial lung dis-
ease associated with connective tissue diseases 
and many types of systemic vasculitides.
Although very effective, it has the potential 
for devastating toxicity both in the short and long 
term. Its toxicities include myelosuppression, 
infection, ovarian failure, haemorrhagic cystitis 
and malignancy including bladder cancer, espe-
cially with high cumulative doses.
The intermittent intravenous doses given 
every 3–4  weeks are associated with less blad-
der toxicity compared to oral daily doses 
[20]. To further minimize bladder toxicity, 
intravenous fluids, anti-emetics and MESNA 
(2- mercatpoethanesulfonic acid) may be used.
4.4.8  Tofacitinib
Tofacitinib is a targeted sDMARD that is now 
approved for the treatment of rheumatoid 
arthritis. It inhibits the enzymes janus kinase 
1 (JAK1) and janus kinase 3 (JAK 3) and thus 
prevents the phosphorylation and activation of 
signal transducers and activators of transcrip-
tion (STATs), which transmit extracellular 
information into the cell nucleus, influencing 
DNA transcription [21].
The most commonly reported adverse effects 
which occur in less than 5% of patients treated 
with tofacitinib are upper respiratory tract infec-
tions, headache, diarrhoea and nasopharyngitis. 
Neutropenia and lymphopenia are also reported 
in less than 1% of patients and laboratory moni-
toring is recommended.
4.4.9  Apremilast
This sDMARD is now approved for the treat-
ment of psoriatic arthritis and psoriasis. It is a 
small molecule inhibitor of phosphodiesterase-4 
(PDE4), which breaks down cyclic adenosine 
monophosphate (cAMP) in inflammatory cells. 
This results in down-regulation of the expres-
sion of a number of the pro-inflammatory fac-
tors like tumour necrosis factor alpha (TNFα), 
interleukin- 17, interleukin-23 and many oth-
ers and up- regulation of the anti-inflammatory 
interleukin-10.
Headache, back pain, nausea, diarrhoea, 
fatigue, nasopharyngitis, upper respiratory tract 
infections and weight loss are common adverse 
effects and are reported in up to 10% of patients 
taking apremilast [22].
Complete details about different sDMARDs 
are shown in Table 4.2.
4.5  Biological Disease- 
Modifying Anti-Rheumatic 
Drugs (bDMARDs)
The bDMARDs target specific components of 
the immune response that are dysregulated and 
are thought to be the cause of the disease process. 
These components are called pro-inflammatory 
cytokines. Tumour necrosis factor (TNF), inter-
leukin- 1 (IL-1), interleukin-6 (IL-6) and others 
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are the pro-inflammatory cytokines found in the 
rheumatoid synovium. Few other bDMARDs tar-
get B and T cells. These agents have considerable 
efficacy in the treatment of patients with rheu-
matoid arthritis and other systemic inflammatory 
disorders.
4.5.1  TNF-α Blockers
Five TNF-α inhibitors are approved for the treat-
ment of selected rheumatic disease by the United 
States Food and Drug Administration. These are 
adalimumab, etanercept, infliximab, golimumab 
and certolizumab.
A 2008 systematic review of synthetic and 
biologic DMARD therapy for rheumatoid arthri-
tis concluded that anti-TNF monotherapy was 
similar in efficacy to treatment with methotrex-
ate alone, while the combination of an anti-TNF 
agent with methotrexate reduced disease activity 
more and slowed radiographic progression to a 
greater extent than did anti-TNF monotherapy or 
methotrexate alone [23].
Most patients with rheumatoid arthritis 
respond to treatment with TNF inhibitors, with 
significant improvements in signs and symptoms 
of disease, significant decrease in radiographic 
damage and significant improvement in quality 
of life and functional status.
They have also proved to be highly effective 
in treating patients with ankylosing spondyli-
tis, psoriatic arthritis, psoriasis, Crohn’s disease 
and juvenile idiopathic arthritis. However, they 
were ineffective in patients with scleroderma or 
vasculitis.
4.5.2  Rituximab
Rituximab is a chimeric monoclonal antibody 
that binds to CD20 antigen and leads to B-cell 
inhibition [24]. It is an effective biologic therapy 
for rheumatoid arthritis with a greatest benefit in 
seropositive patients. If given as two infusions of 
1 gram each, it slows the radiographic progres-
sion in rheumatoid arthritis.
Rituximab is considered as a safe drug in 
rheumatoid arthritis, but infusion reactions can 
occur; most are mild to moderate. Pre-medication 
with methylprednisolone, diphenhydramine and 
acetaminophen can reduce these reactions.
Rituximab therapy carries a risk of hepatitis B 
reactivation amongst patients who have positive 
hepatitis B surface antigen (HBsAg) or hepatitis 
B core antibody (anti-HBc). All patients should 
be screened for HBsAg and anti-HBc prior to 
starting treatment [25].
4.5.3  Abatacept
It is a fully human fusion protein that inhibits co- 
stimulation (an essential step in the induction of 
adaptive immune responses) and inhibits T-cell 
activity [26].
Abatacept can be used when sDMARDs and/
or other biologic drugs have failed to control 
inflammatory arthritis. Infection risk with abata-
cept is higher compared to other biologics [26].
It is administered as a 30-min intravenous 
infusion that is usually achieved without compli-
cations. Subcutaneous administration is equally 
effective and is now approved.
Abatacept is used to treat rheumatoid arthri-
tis and polyarticular juvenile idiopathic arthri-
tis. Clinical trials on abatacept in psoriatic 
arthritis and scleroderma have shown promis-
ing results [27].
4.5.4  Tocilizumab
It is a humanized monoclonal antibody that 
antagonizes the cytokinetic effect of IL-6. It has 
been approved for treatment of rheumatoid arthri-
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tis [28] and systemic onset juvenile idiopathic 
arthritis. It was recently granted a breakthrough 
designation status by the United States Food and 
Drug Association for giant cell arteritis based on 
positive results from a phase 3 clinical trial [29].
A dose of 4 mg/kg is started initially and then 
increased to 8 mg/kg based on clinical response. 
It is administered intravenously every 4  weeks. 
Administration through the subcutaneous route 
is also available. It may cause dyslipidemia but 
is generally well tolerated. Periodic monitoring 
of lipid profile along with other routine investiga-
tion is required.
4.5.5  Ustekinumab
Ustekinumab is a humanized monoclonal anti-
body that binds to and interferes with the biologi-
cal effects of IL-12 and IL-23. It is approved for 
the treatment of psoriatic arthritis and moderate 
to severe plaque psoriasis [30].
It is administered at a dose of 45  mg sub-
cutaneously at week zero, followed by a sec-
ond dose at week 4 and then every 12  weeks. 
Nasopharyngitis, upper respiratory tract infec-
tions and nausea are common side effects.
4.5.6  Secukinumab
Secukinumab is a humanized IgG1 monoclo-
nal antibody that selectively binds to IL-17A 
and inhibits its pro-inflammatory action. It is 
approved for the treatment of active ankylosing 
spondylitis, psoriatic arthritis and moderate to 
severe plaque psoriasis [31].
Nasopharyngitis, upper respiratory tract infec-
tions and diarrhoea are common side effects. If 
administered with a loading dose, 150 mg sub-
cutaneously is given at weeks 0, 1, 2, 3 and 4 
followed by 150  mg every 4  weeks. Without a 
loading dose, 150 mg subcutaneously is adminis-
tered every 4 weeks.
Complete details about different bDMARDs 
are shown in Table 4.3.
4.6  Glucocorticoids
Glucocorticoids exert both anti-inflammatory 
and immunosuppressive effects. They inhibit 
prostaglandin and leukotriene synthesis, reduce 
macrophage phagocytosis and inhibit the release 
of collagenase and lysosomal enzymes [32].
Generally, five types of glucocorticoids are 
used in rheumatology daily practice. These are 
hydrocortisone, prednisolone, methylpredniso-
lone, triamcinolone and dexamethasone. They 
differ considerably in potency and biologic half- 
life as shown in Table 4.4. They are used in the 
majority of systemic rheumatic diseases.
The chronic use of low-dose glucocorticoids 
can cause multiple adverse events [33]. For that, 
the dose of glucocorticoids should be tapered as 
quickly as possible to the lowest effective dose 
when chronic use is anticipated. Serum glucose, 
lipid profile and bone mineral density to prevent 
glucocorticoid-induced osteoporosis should be 
performed to monitor toxicity. Patients should 
also be screened frequently for polydipsia, 
oedema and shortness of breath, visual changes, 
weight gain and changes in blood pressure during 
therapy.
Complete details about different glucocorti-
coids are shown in Table 4.4.
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Table 4.3 Biological disease-modifying anti-rheumatic drugs (bDMARDs)
Drug name
Mechanism of 










psoriatic arthritis and 
ankylosing spondylitis:
Initially: IV infusion at 
a dose of 5 mg/kg at 
weeks 0, 2 and 6
Maintenance: 5 mg/kg 
IV infusions every 
8 weeks. Dose may be 
increased to 10 mg/kg
Common:
Infusion reactions (itching, 
hives, rash, nausea, headache) 
and upper respiratory infections 
(colds, sinusitis, bronchitis, etc.)
Rare and serious:
Serious bacterial infections, 
unusual infections (tuberculosis 
and fungal), worsening of CHF, 
hepatitis B reactivation, 
hepatotoxicity, possible 
malignancies, haematologic and 

















psoriatic arthritis and 
ankylosing spondylitis:















psoriatic arthritis and 
ankylosing spondylitis:
50 mg SC once weekly 

















psoriatic arthritis and 
ankylosing spondylitis:
Initially: 400 mg SC at 
weeks 0, 2 and 4
Maintenance: 200 mg 
















psoriatic arthritis and 
ankylosing spondylitis:

















1000 mg IV infusion for 
2 doses 2 weeks apart 
(one cycle)
Repeat cycle every 








375 mg/m2 IV every 
week for 4 weeks
Common toxicity:
Infusion reactions, nausea, 
upper respiratory tract 
infections, hypertension, 






































At weeks 0, 2 and 4
Then repeated every 
4 weeks thereafter or 
may be given as 
weight-based IV 
loading dose, then 
125 mg SC once weekly
Common:
Infusion reactions, headaches, 
upper respiratory tract 




















4 mg/kg IV every 
4 weeks initially, may 
be increased to 8 mg/kg 
IV every 4 weeks based 
on clinical response
SC: 162 mg every week
Common:
Infusion reactions, dyslipidemia, 
headaches, upper respiratory 




















45 mg SC at weeks 0 
and 4, then every 
12 weeks
Common:
Infusion reactions, upper 
respiratory tract infections, 
nausea and nasopharyngitis
Rare and serious:















Psoriatic arthritis and 
ankylosing spondylitis:
With a loading dose:
150 mg SC at weeks 0, 
1, 2, 3 and 4 followed 
by 150 mg every 
4 weeks
Without a loading dose:
150 mg SC every 
4 weeks
Nasopharyngitis, upper 










4 Pharmacotherapy in Systemic Rheumatic Diseases
96
4.7  Anti-Resorptive Drugs
4.7.1  Bisphosphonates
Alendronate, risedronate, ibandronate and 
zoledronic acid are effective for the treat-
ment of osteoporosis. These drugs inhibit bone 
resorption, increase bone mass and reduce the 
incidence of fractures. They are considered 
as first-line therapy for osteoporosis in post-
menopausal women and men because of their 
efficacy, favourable cost and the availability of 
Table 4.4 Glucocorticoids
Mechanism of 








Used as a pulse dose in various 
severe systemic rheumatic 
diseases:
Severe lupus nephritis, severe 
vasculitis: 1 g IV over 1 h ×3 days
Prednisolone:
Used as a high dose (1 mg/kg/day) 
for some active severe forms of 
vasculitis and then tapered slowly. 
Or initial dose can be started and 
then increased or decreased based 
on clinical response. Dose must be 
tapered slowly
Hydrocortisone:
Used as pre-medication or during 
the perioperative period
Fat redistribution on the face 
(moon face), oedema, fluid 
retention, hypokalaemia, 
hypertension, aggravation of 
diabetes, muscular atrophies and 
weakness, fatigability, menstrual 
cycle disturbances, peptic ulcer 
and increase in the risk of 
infections
Adrenal insufficiency at rapid 
withdrawal of the treatment




depression, aggravation of 
epilepsy, increase in intracranial 
pressure in children










nursing but use 
with caution
Drug name Duration of action Anti-inflammatory potency Equivalent dose
Hydrocortisone Short acting Potency is 1 for a 20 mg dose 20 mg oral dose
Prednisolone Intermediate acting 4 times more potent than 
hydrocortisone




Methylprednisolone Intermediate acting 5 times more potent than 
hydrocortisone




Triamcinolone Intermediate acting 5 times more potent than 
hydrocortisone




Dexamethasone Long acting 30 times more potent than 
hydrocortisone
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safety data. For those who cannot tolerate oral 
bisphosphonates; who have difficulty with dos-
ing requirements, including the inability to sit 
upright for 30–60  min; or who have relative 
contraindications to bisphosphonates (achala-
sia, scleroderma oesophagus, oesophageal stric-
tures), intravenous zoledronic acid is the choice 
of therapy. Bisphosphonates should be avoided 
in renal impairment. They are also avoided in 
women of childbearing age due to foetal risk. 
Bisphosphonates cross the placenta and accu-
mulate in the foetal bones [34].
4.7.2  Raloxifene
It is a selective oestrogen receptor modula-
tor that inhibits bone resorption and reduces 
the risk of vertebral fracture. It is suggested 
for those who cannot tolerate or are not can-
didates for bisphosphonate therapy [35]. It 
is also usually chosen for osteoporosis when 
there is an independent need for breast cancer 
prophylaxis.
4.7.3  Teriparatide
It is a recombinant formulation of endogenous 
parathyroid hormone. It stimulates osteo-
blast function, increases gastrointestinal cal-
cium absorption and increases renal tubular 
reabsorption of calcium. In postmenopausal 
women, teriparatide has been shown to decrease 
osteoporosis- related fractures. This drug is also 
suggested for those who cannot tolerate or are not 
candidates for bisphosphonates therapy [36].
4.7.4  Denosumab
It is a fully human monoclonal antibody that 
specifically binds to receptor activator of nuclear 
factor kappa B ligand (RANKL). It reduces the 
formation, function and survival of osteoclasts, 
which results in decreased bone resorption and 
increased bone density. It is suggested for those 
who cannot tolerate or are not candidates for 
bisphosphonate therapy [37].
Complete details about different anti- 
resorptive drugs are shown in Table 4.5.
Table 4.5 Anti-resorptive drugs
Drug name
Mechanism of 













osteoporosis in men, 
glucocorticoid- 
induced osteoporosis:
70 mg PO once 
weekly
If CrCl is <35, not 
recommended
Reduces hip and 




abdominal pain, nausea, 
diarrhoea, acid regurgitation, 
esophagitis and bony pain
Must be taken at early morning 
with plain water on empty 
stomach. Then must stay in 
upright position for 30 min. 





























150 mg PO every 
month. Or
3 mg IV every 
3 months
If CrCl is <30, not 
recommended
No efficacy in 
non-vertebral fractures
Upper respiratory infections, 
back pain, dyspepsia, 
esophagitis and bony pain
Must be taken at early morning 
with plain water on empty 
stomach. Then must stay in 
upright position for 30 min. 



















osteoporosis in men, 
glucocorticoid- 
induced osteoporosis:
5 mg PO once daily, or 
35 mg PO once 
weekly, or 150 mg PO 
once monthly
If CrCl is <30, not 
recommended
Reduces vertebral 
fracture risk by 41% 
and non-vertebral 
fracture risk by 39% 
over 3 years
Bony pain, diarrhoea, 
headache, abdominal pain, 
esophagitis and dysphagia
Must be taken at early morning 
with plain water on empty 
stomach. Then must stay in 
upright position for 30 min




















osteoporosis in men, 
glucocorticoid- 
induced osteoporosis:
5 mg IV every year for 
treatment and every 
2 years for prevention
If CrCl is <30, not 
recommended
Reduces hip fracture 
risk by 41%, spinal 
fracture risk by 71% 
and non-vertebral 
fracture risk by 25% 
over 3 years
Bony pain, diarrhoea, 
headache, abdominal pain, 
nausea, fever, fatigue and 
anaemia






breast milk is 
unknown; avoid 
using
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4.8  Drugs Used in Crystal 
Arthropathy
4.8.1  Colchicine
It is a uricosuric agent that prevents activation, 
degranulation and migration of neutrophils asso-
ciated with mediating some gout symptoms. It 
can be used for both acute flare and prophylaxis 
against recurrent attacks of gouty arthritis [38].
Common adverse effects of colchicine may 
include diarrhoea and abdominal cramping. It is 
contraindicated in severe renal or hepatic impair-
ment. Colchicine treatment may also benefit 
patients with acute episodes of pseudogout and 
arthritis due to other crystals.
4.8.2  Allopurinol
It is a xanthine oxidase inhibitor that inhibits its 
conversion to uric acid. It is considered as the 
first-line urate-lowering agent for the treatment 
of chronic gout. The dose of allopurinol should 
Drug name
Mechanism of 















osteoporosis in men, 
glucocorticoid- 
induced osteoporosis:
20 mg SC once daily 
into thigh or 
abdominal wall
Reduces spinal 
fracture risk by 65% 
and non-spinal 
fracture risk by 54%
Hypercalcaemia, bony pain, 
flulike illness, nausea and 
orthostatic hypotension















60 mg PO once daily
Reduces spinal 
fracture risk by 
30–55%
Hot flashes, headache, flu 
syndrome, sinusitis, arthralgias 
and infection
Increased risk of thrombosis 
and embolism. Thus, 






















upper respiratory infections, 
sciatica and hypocalcaemia



















2 g/day dissolved in 
water, prior to 
bedtime, 2 h after 
eating (preferably)
If CrCl is <30, not 
recommended
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be adjusted based on the stage of renal disease. 
Febuxostat is another urate-lowering agent 
that can be used if allopurinol is to be avoided 
[39]. Allopurinol decreases the metabolism of 
azathioprine.
Complete details about different drugs used in 
crystal arthropathy are shown in Table 4.6.
4.9  Symptom-Specific Drugs
Systemic rheumatic diseases are multi-system 
diseases that can affect different body organs. 
These disease cause symptoms that can be 
either due to the immunopathologic changes or 
adverse effects from the DMARD therapy. Most 
of these rheumatic symptoms are effectively 
treated with different DMARDs. However, 
few other symptoms require additional specific 
drugs. For example, Raynaud’s phenomenon, 
fatigue, generalized aches and pains and acid 
reflux are common symptoms that patients 
describe to their rheumatologists. Table  4.7 
provides a list of common symptom-specific 
medications that rheumatologists prescribe 
during their daily clinical practice. Table  4.8 
defines the pregnancy categories for pharmaco-
logical agents.
Table 4.6 Drugs used in crystal arthropathy
Drug name Mechanism of action Indication and doses




Colchicine Uricosuric agent, 
prevents activation 
and migration of 
neutrophils
Acute gout flare:
1.2 mg PO at first sign of 
flare, then 0.6 mg PO 1 h later. 
Do not exceed 1.8 mg in 1-h 
period
Gout prophylaxis:
0.6 mg PO once or twice 
daily. Do not exceed 1.2 mg/
day
Gastrointestinal 






breast milk, use 
caution
Allopurinol Xanthine oxidase 
inhibitor, inhibits its 
conversion to uric 
acid
Chronic gout:
100 mg/day initially, increase 
weekly to reach 200–300 mg/
day. Do not exceed 600 mg/
day in severe cases
If CrCl is <40, 150 mg/day
If CrCl is <20, 100 mg/day
If CrCl is <10, 100 mg/2 days
Nausea, rash, vomiting, 







breast milk, use 
caution
Febuxostat Xanthine oxidase 
inhibitor, inhibits its 
conversion to uric 
acid
Chronic gout:
Initial: 40 mg PO once daily.
Maintenance: 40–80 mg PO 
once daily
Nausea, rash, vomiting, 






breast milk is 
unknown
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Table 4.7 Common symptom-specific drugs








Inhibit influx of extracellular 
calcium ions across myocardial 
and vascular smooth muscle cell 
membranes, resulting in 





















or refrain from 
nursing
Sildenafil Inhibits phosphodiesterase-5, 
thus increasing cyclic guanosine 
monophosphate to allow smooth 


















muscarinic action, increases 


















breast milk is 
unknown.




10–50 mg PO at 
bedtime, dose can 











or refrain from 
nursing
Duloxetine Serotonin and norepinephrine 
reuptake inhibitor
Fibromyalgia:
30 mg PO daily 
initially for 
1 week, then 
















Bind to hydrogen-potassium- 
exchanging adenosine 
triphosphatase in gastric parietal 
cells, resulting in suppression of 
acid secretion















breast milk is 
unknown, 
discontinue drug 
or refrain from 
nursing
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Abbreviations
ACEIs  Angiotensin-converting enzyme 
inhibitors
ALT Alanine amino transferase
Anti-HBc Hepatitis B core antibody
AST Aspartate aminotransferase
BID Two times a day
cAMP Cyclic adenosine monophosphate
COX  Cyclooxygenase
CrCl Creatinine clearance
DMARDs   Disease-modifying anti- rheumatic 
drugs





NSAIDs  Nonsteroidal anti-inflammatory 
drugs
PDE-4 Phosphodiesterase-4
PGHS Prostaglandin G/H synthase
PGs Prostaglandins
PO Orally (by mouth)
PRN As needed (pro re nata)
q6hrs Every 6 hours
QID Four times a day
RANKL  Receptor activator of nuclear factor 
kappa B ligand
SC Subcutaneous
SLE Systemic lupus erythematosus
STATs  Signal transducers and activators of 
transcription
TID Three times a day
TNF Tumour necrosis factor
TPMT Thiopurine methyltransferase
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5.1  Introduction
This chapter addresses different modalities of 
imaging in approaching the common musculoskel-
etal diseases (explaining the radiological part of 
diagnosis), we included: infectious arthritis (septic, 
tuberculous, and brucellosis), metabolic arthritis 
(gout and CPPD), rheumatoid arthritis, spondy-
loarthropathies (ankylosing spondylitis, psoriasis, 
and reactive arthritis), and degenerative bone dis-
eases like osteoarthritis; it also addresses the role 
of the musculoskeletal interventional radiologist in 
the management of rheumatological diseases.
5.2  Learning Objectives
By the end of this chapter, you should be able to:
 – Identify the radiological modalities used to 
diagnose different rheumatological disorders 
and their appropriate utilization.
 – Emphasize on the importance of early 
radiological detection of infectious 
arthritis.
 – Address the role of the radiologist in the pre-
vention of the long-term rheumatological 
disabilities.
 – Define the proper interpretation of the differ-
ent musculoskeletal radiological modalities.
5.3  Infectious Arthritis
5.3.1  Septic Arthritis
Septic arthritis is an emergency and a type of 
destructive infectious arthropathy; it can cause 
significant mortality and morbidity, if unrecog-
nized and left untreated. Irreversible joint destruc-
tion to a joint can be prevented by early diagnosis 
and prompt and effective treatment [1]. It is 
well-known that the definite diagnostic method is 
arthrocentesis by identification of an organism in 
the synovial fluid. The presence of painful, swol-
len joint and fever should raise clinical suspi-
cion. Radiological studies play a significant role 
especially in cases where synovial fluid cannot 
be retrieved. In these cases, ultrasound- or fluoro-
scopic-guided joint aspiration demonstrates their 
importance in reaching the diagnosis. In general, 
imaging has an adjunct role to arthrocentesis in 
diagnosing septic arthritis. Effusion and inflam-
mation in some joints like the hip and sacroiliac 
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joints are difficult to examine clinically but can 
be detected by scintigraphy, CT scan, or MRI 
for defining extent of infection. MRI is a useful 
modality, while CT-guided bone biopsy or aspi-
ration is the test of choice for defining the extent 
of bone involvement [2]. In rare cases, associated 
osteomyelitis or concurrent joint disease may be 
present, so radiographs should be obtained for 
an infected joint. In addition, it is useful to have 
a baseline radiograph to follow the response to 
therapy. In cases of failure to respond to intrave-
nous antibiotics therapy, imaging should not be 
underestimated as it may change the line of man-
agement and guide intervention.
The following demonstrates the imaging 
modalities used to diagnose septic arthritis and 
characteristic findings in each one.
5.3.1.1  Radiographs
Conventional radiography should always be the 
first imaging technique used, although results are 
usually normal at presentation and generally lack 
sensitivity and specificity. The radiological find-
ings vary according to the stage of the disease, for 
example, in the very early stage of the disease, 
X-ray may be normal, joint effusion may be seen 
Fig.  5.1, hyperemia may cause juxta- articular 
osteoporosis (Fig.  5.2), joint space may narrow 
due cartilage destruction in the acute phase, sub-
chondral bone destruction may be evident on 
both sides of a joint, reactive juxta- articular scle-
rosis may develop if left untreated, and, in severe 
cases, ankylosis may develop (Fig. 5.3). In acute 
osteomyelitis, the early finding is osteopenia and 
then cortical destruction and periosteal new bone 
formation. Subacute and chronic osteomyelitis 
have different imaging features than marginal 
sclerosis and osteopenia, which indicate areas of 
healing. In chronic osteomyelitis, the most spe-
cific finding is a sequestrum (a fragment of dead 
bone surrounded by inflammatory tissue), which 
radiographically appears as a focal area of scle-
rotic bone within an area of lucency [1].
5.3.1.2  Ultrasonography
A noninvasive and inexpensive technique, it is 
considered an improved method for the early 
diagnosis of septic arthritis, with joint effusion 
and echoes inside being the characteristic find-
ing of a septic joint. Clearly, it is superior to 
radiographs in detecting joint effusions as it can 
detect minor effusions, as small as 1–2 ml, and 
this allows ultrasound-guided arthrocentesis to 
be performed in patients with suspected septic 
arthritis. Furthermore, it is useful for examin-
ing inaccessible joints such as the hip. It can also 
show increased perisynovial vascularity using 
color Doppler. Echogenic debris may be present; 
it is very helpful in differentiating between tran-
Fig. 5.1 AP view of the right shoulder demonstrates wid-
ening of the glenohumeral joint indicative of an effusion 
with sclerotic changes present on both sides of the sacro-
iliac joint
Fig. 5.2 AP view of the right knee demonstrates sclerotic 
changes present in the distal femur with periarticular 
osteopenia present in the tibia indicative of hyperemia
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sient synovitis and fresh hemorrhagic effusions. 
Echo-free image is seen in transient synovitis and 
fresh hemorrhagic effusions, while clotted hem-
orrhagic collections and septic arthritis do not 
have an echo-free image. This means that a nega-
tive sonogram will exclude fluid collection and 
the presence of echo-free effusion will virtually 
rule out septic arthritis [3]. However, for joints 
with non-distensible capsules (e.g., sacroiliac, 
sternoclavicular, and acromioclavicular joints), 
septic arthritis cannot be excluded in the absence 
of a visible joint effusion, and, if suspected, MR 
(or CT) imaging together with guided joint aspi-
ration should be undertaken [4]. As mentioned 
earlier, on ultrasound, the hallmark of septic 
arthritis is the presence of a joint effusion in a 
patient with clinical signs and symptoms of joint 
infection. Ultrasound allows early diagnosis and 
treatment of septic arthritis, by enabling recogni-
tion and guiding the aspiration of joint fluid at 
an early stage [4]. Joint fluid in septic arthritis 
may be hypoechoic and clearly demarcated from 
joint synovium and capsule or hyperechoic and 
less clearly demarcated from joint synovium or 
capsule [4].
There are numerous advantages of clinical 
application of ultrasonography for the diagnosis 
of septic arthritis. Ultrasound is very sensitive 
in detecting the joint effusion of septic arthri-
tis. The pathological extent of septic arthritis, 
in addition to the joint effusion and the joint 
surrounding subperiosteal abscess and cortical 
erosion, can be clearly defined and may indicate 
a concurrent osteomyelitis, which will help cli-
nicians to treat by appropriate surgical debride-
ment. Ultrasound can also help the clinicians 
avoid unnecessary needle joint aspiration by dif-
ferentiating soft tissue abscess or tenosynovitis 
from septic arthritis [5].
5.3.1.3  CT Scan
CT features of septic arthritis are similar to the 
radiograph features; a fat-fluid level can be a spe-
cific sign in the absence of trauma. CT is better 
for visualizing local edema, bone erosions, oste-
itis foci, and sclerosis.
CT scan is also an imaging modality which 
may contribute to the decision of treatment, 
whether medical or surgical, not in septic arthritis 
itself but in concurrent osteomyelitis, and is able 
to detect some radiological features that indicate 
the need for surgical intervention and cannot be 
detectable by conventional imaging, for example, 
sequestra, medullary involvement, and the extent 




Fig. 5.3 Septic arthritis of the hip, (a) moderate osteoar-
thritic changes with concentric joint space narrowing 
early, (b) demonstrates sclerotic changes in the femoral 
head indicative of avascular necrosis after 4 months, (c) 
end stage after 8  months demonstrates flattening of the 
femoral head with osteolysis
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scan in planning medical and surgical treatment 
of chronic osteomyelitis is appreciated [6].
5.3.1.4  MRI
In general, MRI is the most powerful modality 
used for the evaluation of musculoskeletal joint 
infections and provides better resolution than 
radiography or CT scan for detecting joint effu-
sion and for differentiating between bone and soft 
tissue infection. When IV gadolinium contrast is 
used with MRI showing the synovial enhance-
ment, the sensitivity and specificity increase to 
100% and 77%, respectively [7].
Joint effusion, cartilage and bone destruction, 
soft tissue abscesses, bone edema, and cortical 
interruption all are MRI findings of septic arthri-
tis with or without osteomyelitis; MRI also can 
differentiate acute from chronic osteomyelitis. In 
acute infections, there is no sharp zone of transi-
tion between normal and abnormal bone marrow, 
and there is no cortical thickening or sequestrum 
(Figs. 5.4–5.6).
The presence of bone erosions is a good indi-
cator for an infected joint, but it can also be a 
finding of non-septic inflamed joint. The same 
findings can be present in both infected and 
inflamed joint, so no single sign can be consid-
ered as pathognomonic for a septic joint or help 
Fig. 5.4 AP and lateral radiographs of the left elbow demonstrate no specific abnormality
Fig. 5.5 T1-weighted images on your right demonstrate 
no effusion
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exclude its presence. Therefore, MRI is unable to 
differentiate between infective and other inflam-
matory arthritis [8].
5.3.1.5  Scintigraphy
This imaging modality can be helpful when eval-
uating suspected septic arthritis, particularly in 
the setting of prosthetic joint. Leukocyte-labeled 
111-In combined with 99-Tc sulfur colloid stud-
ies provides accuracy of 90% in this clinical situ-
ation. Uptake of the 111-In in an area that does 
not show marrow activity with sulfur colloid is 
considered positive for infection [7].
5.3.2  Tuberculous Arthritis
Tuberculous arthritis is usually monoarticu-
lar, like other infectious joint diseases; the large 
joints, such as the hip and the knee, are most 
commonly involved, but in general, any other 
joint can be affected, with lower extremity joints 
being more affected than upper extremity joints 
[9]. Tuberculous arthritis is still considered a 
major concern for clinicians and healthcare work-
ers, especially in developing countries. Advanced 
stage of the disease may be the first presentation, 
because of the delay in diagnosis.
In contrast to the old time when the diagnosis 
was made based on the clinical and basic radio-
logical presentation alone (Table 5.1) [10], nowa-
days, the radiological investigations improved 
with more new modalities and new interventional 
methods, making the diagnosis of an infected 
joint more easy at any stage. In early stages of 
the disease, when plain X-rays are negative, it 
is considered a diagnostic dilemma, so, to avoid 
missing the diagnosis, the new diagnostic modal-
ities like ultrasonography, CT, MRI, and image- 
guided aspiration of synovial fluid for PCR and 
tissue diagnosis should be used [10].
Usually, tuberculous arthritis is secondary to 
tuberculous osteomyelitis, in which a primar-
ily tuberculous metaphyseal focus crosses the 
epiphyseal plate. One of the hallmarks of tuber-
culous skeletal infection is this transphyseal 
spread, which is not found in pyogenic arthritis, 
Fig. 5.6 T1 fat-suppressed images with IV gadolinium 
on your left demonstrate enhancement of the synovial lin-
ing of the elbow joint with some fluid present
Table 5.1 Clinico-radiological classification of tuberculosis of the hip [10]
Stages Clinical findings Radiologic features
Synovitis Flexion, abduction, external 
rotation, apparent lengthening
Haziness of articular margins and 
rarefaction
Early arthritis Flexion, adduction, internal 
rotation, apparent shortening.
Rarefaction, osteopenia bony erosions in 
femoral head, acetabulum or both
No reduction in joint space
Advanced arthritis Flexion, adduction, internal 
rotation, shortening
All of the above and destruction of articular 
surface, reduction in joint space
Advanced arthritis with 
subluxation/dislocation
Flexion, adduction, internal 
rotation with gross shortening
Gross destruction and reduction of joint 
space, wandering acetabulum
Source: Tuli, Tuberculosis of Skeletal system, fourth ed., 2010. p. 72.
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so, without pre-existing osteomyelitis, arthritis 
less frequently occurs, owing to hematogenous 
spread of the tubercle bacillus to the synovial 
membrane [9].
Like any inflammatory joint, reactive 
hyperemia causing juxta-articular hyperemic 
osteoporosis, osseous erosions, and cortical 
and subcortical destruction on both sides of 
the joint space may be seen. Granulomatous 
inflammation can cause synovial thickening, 
and joint effusion may result in expansion 
of the joint; granulomatous synovial lesions 
expand inwards from the joint periphery, erod-
ing the articular surface, with patchy cartilage 
destruction, erosions, and lytic bone lesions [9]. 
In a tuberculous joint, further extension to adja-
cent para-articular soft tissue with collection of 
cold abscess and sinus tracts may occur if not 
treated and discovered early, so early diagno-
sis is essential [9]. Radiological investigations 
play an important role in the diagnosis of tuber-
culous arthritis.
The following demonstrate the imaging 
modalities used to diagnose tuberculous arthritis 
and characteristic findings in each one:
5.3.2.1  Radiograph
Plain X-rays are reliable for detecting and for 
follow-up of treatment of tubercular joint.
Features are summarized in the Phemister’s 
triad, which consists of juxta-articular osteopo-
rosis, peripheral osseous erosions, and gradual 
narrowing of the joint space.
In tight or weight-bearing joints like the hip, 
knee, and ankle, marginal erosions are character-
istic features of tuberculous arthritis.
In the early stage of tuberculous arthritis, 
lack of sclerosis or periostitis is another typical 
feature. In the end stage of tuberculous arthritis, 
severe joint destruction and eventually sclerosis 
and fibrous ankylosis may occur. Bony ankylo-
sis may also occur, but it is less common than 
in pyogenic arthritis and, when present, is more 
likely to be secondary to previous surgical inter-
vention [9].
5.3.2.2  Ultrasonography
The only finding is joint effusion, which 
is nonspecific and can occur in any joint 
inflammation.
5.3.2.3  CT Scan
CT scan is able to demonstrate bone destruction, 
sequestration, as well as extension of infection to 
the surrounding soft tissue or any sinus tract for-
mation (Fig. 5.7) [9].
5.3.2.4  MRI
To detect early changes, MRI is the study of 
choice. On T2-weighted images, joint effusion 
appears hyperintense, loose bodies, calcifications 
and hemosiderin deposits due to bleeding may 
be hypointense; therefore, tuberculous arthritis 
should be considered in the differential; when 
an articular lesion with low- or intermediate-
signal intensity on T2-weighted images is seen, 
marrow changes are of low-signal intensity on 
T1-weighted images and of high-signal intensity 
on T2-weighted images.
MRI is better than CT to detect associated 
soft tissue abnormalities, such as cellulitis, myo-
sitis, sinus tract formation, and para-articular 
collections. With IV gadolinium contrast, sinus 
Fig. 5.7 CT scan of the abdomen and the level of the T12 
demonstrate a destructive lesion of the body of T12 on the 
left side extending into the left parapelvic region with 
some calcification and enhancement peripherally
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tracts display a linear high-signal intensity 
on T2-weighted images with marginal “tram 
track enhancement” on T1-weighted images. 
Tuberculous collections may be slightly hyper-
intense on T1-weighted images, in contrast to 
collections originating from many other infec-
tions (Fig. 5.8).
Precontrast T1-weighted images show a hyperin-
tense rim around these collections, which enhances 
after administration of gadolinium contrast [9].
For differentiation of tuberculous arthritis and 
pyogenic arthritis, MR imaging of bone abnor-
malities, extra-articular lesions, and associated 
abscesses provides useful information [11].
5.3.3  Brucella Arthritis
Brucellosis is still considered a major health 
and economic issue in many parts of the world, 
and it can affect different parts of the body. 
Radiological investigations play an important 
role in the diagnosis and management of brucel-
losis [12]. Any joint in the body can be affected 
by Brucella, including sternoclavicular joints 
and sacroiliac joints, with large joints having 
more affinity to be involved. In long stand-
ing and neglected cases of Brucella, avascular 
necrosis of the femoral head can occur [12]. 
A favorite location for Brucella septic arthritis 
and osteomyelitis is the sacroiliac joint, and 
its involvement can extend to bone and muscle 
involvement in the region [8]. It also affects 
both joint spaces in the sacroiliac joint and 
causes erosive and bony destruction of the sac-
roiliac joint, with enhancement, which is one of 
the hallmarks of Brucella septic arthritis [12]. 
The radiologic features of the affected joints are 
indistinguishable from those of tuberculous or 
pyogenic arthritis; thus, differentiation depends 
on laboratory findings [13].
5.3.3.1  Radiograph
The radiographic findings in a Brucella arthritis 
are not specific and range from poorly defined 
joints, joint space narrowing or widening, anky-
losis, sclerosis, subchondral erosions, to no vis-
ible abnormalities [14].
5.3.3.2  Ultrasonography
Like any joint inflammation or infection, ultra-
sound can detect joint effusion, which is a non-
specific finding, and guide aspiration of synovial 
fluid to help in the diagnosis.
5.3.3.3  CT Scan
One of the hallmarks of Brucella septic arthritis 
is that it affects both joint spaces in the sacroiliac 
joint and causes erosive and bony destruction of 
the sacroiliac joint, with enhancement [12].
5.3.3.4  MRI
In Brucella sacroiliitis, bone marrow edema and 
intra-articular synovial fluids are important clues 
for early diagnosis. Sclerosis and ankylosis are 
observed in late phase of the disease.
Peripheral joint involvement can be diagnosed 
by the presence of bone marrow edema, joint 
derangement, enhancement of synovium, and 
periarticular soft tissues after intravenous injec-
tion of gadolinium (Figs. 5.9 and 5.10) [15].
Fig. 5.8 Sagittal MRI T1-weighted of the lumbar spine 
demonstrates kyphotic deformity of L2 with destructive 





Joints involved in a vast majority of patients show 
an increased uptake on bone scans.
5.4  Metabolic Arthritis
5.4.1  Gouty Arthritis
Gout is a common cause of arthritis; it can be 
diagnosed by expert clinician based on clinical 
picture and laboratory findings, with little or 
even no benefit from imaging, but still imaging 
is needed in cases where deep structures like the 
spine or sacroiliac joints are affected or when 
the gouty joint mimics mass lesion or infection. 
However, many patients with gout visit non- 
specialized physician, and in such cases, imaging 
may have an adjunctive role in gout diagnosis and 
management. Different radiological findings can 
be found in gout, for example, erosions, synovial 
proliferation, tophus, bone marrow edema, car-
tilage involvement, and joint effusion, all these 
findings need different imaging  modalities, with 
Fig. 5.9 (a) Plain radiograph of the left sacroiliac joint 
demonstrates sclerotic changes on the iliac side of the sac-
roiliac joint and widening of the sacroiliac joint on the left 
side. (b) demonstrates sclerotic changes of the left sacro-
iliac joint on the iliac side with widening of the sacroiliac 
joint. (c) Axial T1-weighted image demonstrates sclerotic 
changes of the sacroiliac joints with some widening. (d) 
demonstrates widening of the left sacroiliac joint with 
marked enhancement following gadolinium administra-
tion that extends into the left paraspinal muscles and sub-
cutaneous tissue
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different utilities for each, based on sensitivity 
(Table 5.2) [16].
5.4.1.1  Radiographs
It is usually a late finding, underestimating the 
degree of involvement; first MTP involvement 
is a characteristic finding of gout, juxta-articular 
erosions with sclerotic margins and overhanging 
edges, and preservation of joint spaces and peri-
articular bony density until the disease process is 
late. The gouty deposits around the joint can be 
juxta-articular, intra-articular, and subchondral 
and usually not symmetric (Fig. 5.11). The hall-
mark of chronic gout is the formation of tophus, 
which is a soft tissue nodule that represents the 
granulomatous immune reaction of the body to 
monosodium urate (MSU) crystals. Tophus cal-
cification is a late finding and may be associated 
with calcium metabolism disturbance. Erosions 
are often located next to a tophus (Figs. 5.12 and 
5.13) [16].
5.4.1.2  Ultrasonography
Without contrast agent, sonography can detect 
tophaceous deposits in the soft tissues, joints, 
cartilage, as well as synovitis, erosions, and 
Fig. 5.10 First image on your left demonstrates high sig-
nal changes in the L4 and L5 vertebral bodies on this 
T2-weighted sagittal MRI of the lumbar spine. Middle 
image is a sagittal T1-weighted image of the lumbar spine 
with extensive low-signal changes of L4 and L5 with 
involvement of the disc space. The third image on the 
right is a sagittal MRI T1-weighted image with gadolin-
ium enhancement and demonstrates marked enhancement 
of the L4 and L5 vertebral body with enhancement of the 
L4-L5 disc space
Table 5.2 Comparative utility of X-ray, US, CT, and MRI in the diagnosis of gout [16]
X-ray US CT MRI
Erosion + ++ +++ ++
Effusion + +++ ++ +++
Synovial proliferation − +++ + +++
Tophus + +++ ++ +++
Joint space narrowing +++ − +++ +++
Tendon pathology − +++ ++ +++
Bone marrow edema − − + +++
Tophus or synovial vascularity − +++ − +++
Source: Review Article, Imaging Appearances in Gout, Volume 2013 (2013), Article ID 673401, 10 pages.
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increased vascularity. It has a good role in the 
early diagnosis and monitoring the response of 
the treatment of gouty arthritis. In patients with 
an acute gout flare, or patients with history of 
prior gout attacks, or even patients with asymp-
tomatic hyperuricemia, the “double contour 
sign” is a sign that can be seen by ultrasound, an 
irregular echogenic line, caused by urate depo-
sition over the most superficial layer of hyaline 
cartilage, with a sensitivity ranging from 25% to 
95% in patients with gout [16].
The tophus on ultrasonography appears as an 
anechoic halo and hyperechoic heterogeneous 
center. Tophi by ultrasound appearance could be 
either soft or hard tophi, based on sonolucency 
(soft tophi), and difficulty to image the structure 
below them (hard tophi), which are usually long- 
standing tophi [16]. Synovitis in gout by ultra-
sound shows mixed echogenicity, predominantly 
hyperechoic with associated increased vascular-
ity. Some cases show hyperechoic foci which 
represent microtophi, resulting in “snow storm 
appearance.”
Ultrasonography is excellent for identifying 
bursitis, intratendinous deposition, enthesitis, 
and subcutaneous nodules seen with gout [16].
5.4.1.3  CT Scan
Dual-energy computed tomography (DECT) 
has a promising role in diagnosing gout. Based 
on the spectral dual-energy properties, unique 
Fig. 5.11 AP view of both hands demonstrates punched 
out erosions of the left carpal bones along with marked 
soft tissue swelling at the wrist joint indicative of tophus 
formation
Fig. 5.12 AP view of the right hand demonstrates marked 
soft tissue swelling at the first metacarpophalangeal joint, 
second PIP along with punched out erosion of the proxi-
mal second phalanx
Fig. 5.13 AP radiograph of the left first toe demonstrates 
punched out erosion of the first metatarsophalangeal joint 
and first metatarsal head. Notice that the joint space is 
preserved
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 color- coded aggregates of urate crystal can be 
seen. This distinguishes gout from other crystal 
deposition disease, such as hydroxyapatite crystal 
deposition disease. Characteristic gout erosions 
and tophi are very sensitive to be detected by con-
ventional CT, but its use is limited by cost. Gouty 
tophus can be intra-articular or extra-articular, or 
located in tendons and subcutaneous tissues, with 
pressure points preponderance. CT and MRI are 
very accurate in following up response to treat-
ment, as tophi are known to decrease in size, but 
ultrasonography is more practical for follow-up 
studies as it is more available at lower cost with 
less ionizing radiation [16].
5.4.1.4  MRI
When gout affects deep tissues like the spine or 
locations not amenable to clinical examination 
like interosseous deposits in the midfoot, MRI is 
very helpful. It is also accurate in diagnosing the 
extent of gout involvement of the bursae and ten-
dons and any associated tendon tears. On MRI, 
tophi appear as low signal on T1-weighted MRI 
and mostly intermediate signal on T2-weighted 
MRI [16].
5.4.2  Calcium Pyrophosphate 
Dehydrate (CPPD) Deposition 
Disease or Pseudogout
CPPD or pseudogout is a syndrome that mani-
fests as arthritis clinically and as chondrocalci-
nosis radiographically or as an arthropathy that 
resembles that of degenerative joint disease. 
Most likely joints to be involved are the knee, 
symphysis pubis, and triangular cartilage of the 
wrist, and they should be examined in suspected 
patients. CPPD crystals can be found in any car-
tilage and in the soft tissues where it may mimic 
calcific tendinitis [17].
5.4.2.1  Radiograph
Arthropathy of CPPD crystal deposition is char-
acterized by sclerosis, joint space narrowing, and 
osteophyte formation which is difficult to distin-
guish from degenerative joint disease except by 
the affected sites which are different than the sites 
of true degenerative joint disease. For example, 
pseudogout should be considered if radiocarpal 
joint, the elbow, or only the patellofemoral com-
partment of the knee joint is showing degenera-
tive joint disease (Figs. 5.14 and 5.15) [17].
5.4.2.2  Ultrasonography
Based on studies, ultrasonography is more use-
ful in cases of chondrocalcinosis than radiograph 
which is not sensitive nor specific [18], and it is 
better than radiograph and CT scan in diagnosing 
chondrocalcinosis in CPPD cases [19].
Fig. 5.14 AP oblique view of the right wrist demon-
strates chondrocalcinosis of the triangular fibrocartilage 
complex
Fig. 5.15 AP view of the right knee demonstrates calcifi-
cation of the articular lining of the knee. Consistent with 




5.4.2.3  CT Scan
CT scan and conventional radiography are almost 
equal in the detection of chondrocalcinosis [19]. 
The pattern of CPPD on CT scans may show a 
calcific mass with a lobulated configuration, 
typically in the ligamentum flavum or within the 
joint capsule, and within the mass are septum like 
low- density areas. In addition, pressure erosions 
may be noted with disruption of adjacent bony 
cortex. Fine granular calcifications may also be 
noted. Subchondral cysts or erosions, as well as 
fractures, may be observed [20].
5.4.2.4  MRI
In detecting the CPPD deposits presence, MRI 
is not as sensitive as radiography, but 4 T MRI 
holds better promise in detecting CPPD crys-
tals [21]. Calcifications of chondrocalcinosis are 
present on MRI as a signal void or decreased sig-
nal intensity. High-field MRI is especially effec-
tive for visualization of CPPD deposits. Because 
MRI does not visualize calcific structures well, 
CT scanning or radiographic confirmation is 
required; it has low sensitivity for visualization 
of CPPD deposits but can display massive depo-
sition [20].
Rheumatoid arthritis (RA): It is the most 
common chronic inflammatory joint disease [22]. 
It is characterized by joint swelling, joint tender-
ness, and destruction of the synovial joints, lead-
ing to severe disability and premature mortality 
[23]. The hallmark of RA is bilateral symmetric 
arthritis of more than three joints (polyarthritis) 
[3]. Over 60% of patients initially present with 
symmetric arthritis of multiple small hand joints 
[3]. Typically, the second and third metacarpo-
phalangeal (MCP) and the third proximal inter-
phalangeal (PIP) joints are involved early in the 
course of the disease; the ulnar and radial aspects 
of the radiocarpal joint and the intercarpal, carpo-
metacarpal, metacarpophalangeal, and proximal 
interphalangeal joints are other common sites 
[3]. Simultaneous synovitis of tendon sheaths of 
the wrists and hands is another distinct finding 
[3]. Bilateral and symmetric involvement of foot 
joints is another typical manifestation of RA [3]. 
The metatarsophalangeal and the interphalangeal 
(great toe) joints are favored sites [3]. All midfoot 
joints may be involved [3]. The talonavicular, 
subtalar, and tarsometatarsal joints are specific 
target areas [24].
Later in the course of the disease, large 
extremity joints and cervical spine joints could 
be insulted.
The role of radiology in RA is to either diag-
nose the disease or assess the disease status and 
progression.
5.4.2.5  Radiographs
Conventional radiography (CR) has been con-
sidered the gold standard for imaging in RA, 
its sensitivity for structural damage in RA 
diagnosis is low, and disease activity cannot be 
assessed [25]. When there is diagnostic doubt, 
CR, ultrasound, or MRI can be used to improve 
the certainty of a diagnosis of RA above clini-
cal criteria alone [25]. CR of the hands and feet 
should be used as the initial imaging technique 
to detect damage. However, ultrasound and/or 
MRI should be considered if CR do not show 
damage and may be used to detect damage at 
an earlier time point (especially in early RA) 
[25]. The periodic evaluation of joint damage, 
usually by radiographs of the hands and feet, 
should be considered [25]. Monitoring of func-
tional instability of the cervical spine by lat-
eral radiograph obtained in flexion and neutral 
should be performed in patients with clinical 
suspicion of cervical involvement. When the 
radiograph is positive or specific neurological 
symptoms and signs are present, MRI should 
be performed [25].
Erosion: It is discontinuity of the white cor-
tical line (marginal erosions) and subsequently 
become projection-like (Figs. 5.16 and 5.17).
Subcortical cysts: These are cystic changes 
in the subcortical bone which are easily identified 
as translucent lesions [24].
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Joint space narrowing: It is a late finding of 
RA and can be detected by CR (Fig. 5.18).
Periarticular osteopenia: This refers to 
non- sharp cortical end plates [3]. This finding is 
important especially radiographs are used as the 
first-line imaging tool.
Effusion: Plain radiographs demonstrate indi-
rect signs of effusion such as joint space widen-
ing and soft tissue swelling as well as shifting of 
fat pads [24].
5.4.2.6  Ultrasonography/Magnetic 
Resonance Imaging (MRI)
Over the past decade, there have been significant 
advances in the field of musculoskeletal imag-
ing, especially in the application of ultrasound 
(US) and magnetic resonance imaging (MRI) to 
the management of rheumatoid arthritis (RA). 
Both modalities offer significant advantages 
over the previous standards of clinical examina-
tion and radiography and allow direct visualiza-
tion of both joint inflammation and structural 
damage. Although measuring similar pathology, 
each of these imaging tools has its own ben-
efits and limitations, understanding of which 
can help researchers and clinicians to determine 
the appropriate role for these tools in RA joint 
assessment [22].
Ultrasound and/or MRI should be considered 
if CR do not show damage and may be used to 
detect damage at an earlier time point (especially 
in early RA) [25].
Synovitis: Cytokines mediate capillary leakage 
and edema in the acute phase. This facilitates syno-
Fig. 5.16 PA view of the forefoot shows erosive changes 
(arrow) Fig. 5.17 Flexed lateral view of the cervical spine shows 




vial swelling and leads to widening of the joint 
space, which may well be exaggerated by effusion 
[24]. Synovitis initially starts at bare areas.
Subcortical cysts: A number of more than 
three, in an eccentric location, and non-sharp 
margins increase the likelihood that the subcor-
tical cyst is the result of an inflammatory joint 
process [3]. On MRI, arthritic cysts usually do 
not contain fat or trabecular bone [3]. When 
 subcortical cysts are detected by MRI or US, they 
are considered pre-erosive changes.
Effusion: Both US and MRI can detect small 
effusion in small joints.
Periarticular osteopenia: This finding is a 
secondary indirect sign of synovitis.
Bone marrow edema (BME): MRI is the 
only modality of choice which can detect this 
finding. BME is a very useful prognostic indi-
cator in RA. Affected marrow will readily show 
significant uptake of contrast material [24]. It is 
associated with disease activity.
Erosions: Naturally, erosions arise at the bare 
areas first due to the lack of the protecting car-
tilage layer. The diagnosis of erosions is very 
important as it may well influence therapy. MR 
imaging demonstrates erosions clearly [24]. US 
can detect them too.
Computed tomography (CT): It detects all 
bony changes and pathology; however, its use is 
limited due to high radiation.
Scintigraphy: Baseline inflammatory disease 
measured by scintigraphy appears to be associ-
ated with radiographic progression. In addition, 
multiple regression analysis has demonstrated 
that progression of radiographic joint destruc-
tion was primarily predicted by 99mTc-IgG scin-
tigraphy, while joint swelling and erythrocyte 
sedimentation rate (ESR, IgM rheumatoid factor 
(RF)) are not predictive. This suggests that scin-
tigraphy may be superior to conventional clinical 
and laboratory measurements in the prediction of 
joint destruction [25].
Fig. 5.18 PA view of the hands shows joint space narrowing, erosions, and diffused osteoporosis
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5.5  Summary
The diagnosis of RA is based on history, clinical 
examination, and laboratory results. If there is a 
doubt about RA diagnosis, the radiologic modali-
ties take place to improve the diagnosis. CR is the 
gold standard modality for imaging in RA. MRI 
and/or US should be considered if the CR does 
not show any abnormality.
Assessment and follow-up periodic radio-
graphs should be obtained for follow-up. MRI 
and/or US assesses the disease progression.
Spondyloarthropathies (SpA): They are a 
group of diseases that have a strong association 
with human leukocyte antigen B27 (HLA-B27), 
are characterized by inflammation of sacroiliac 
joints (sacroiliitis), and affect axial and appen-
dicular skeleton. They include ankylosing spon-
dylitis (AS), psoriatic arthritis (PsA), reactive 
arthritis known as Reiter’s syndrome, and other 
uncommon arthritic diseases.
Ankylosing Spondylitis (AS): It is a disease 
that affects young age group, is rarely seen after 
the age of 40, and is more predominant in male 
gender. The inflammation affects the axial skel-
eton in symmetrical way and starts at sacroiliac 
joint in almost all cases. Spondylitis occurs in 
50% of patient with AS and starts at the thora-
columbar and lumbosacral spines. Cervical spine 
joints are rarely seen affected alone. AS is easy to 
diagnose as it has a unique pattern of distribution 
and clear clinical picture.
Radiography: CR is still the first imaging 
modality and should be obtained for the diagno-
sis of AS. Anteroposterior (AP) pelvic, AP, and 
lateral spine X-ray should be ordered when AS is 
suspected. Other radiologic modalities are used 
to detect the disease in earlier stage or to deter-
mine the prognosis. CR can detect many changes 
in AS but not at early stage as compared to MRI 
and CT scan.
Erosions: Small erosions resembling the ser-
rated edges of the postage stamp typically start at 
iliac side of the joint early in the disease course 
[26]. In the spine, the earliest change is enthesi-
tis at the insertion of annulus fibrosis fibers. This 
process is a result of erosions and reactive scle-
rosis which occur at vertebral corner (Romanus 
lesions) (shiny corners) and cause vertebral squar-
ing. AS is the least erosive spondyloarthropathy.
Ossification: The ossification of the ligaments 
at sacroiliac joints may appear as star shape, and 
complete joint fusion may be seen in advanced 
stage. As the disease progresses in the spines, the 
ossification starts developing at annulus fibrosis 
(syndesmophytes). When the ossification con-
tinues through the apophyseal joint, complete 
spinal fusion occurs (bamboo spine). In advance 
disease, dagger sign (Fig.  5.19) appears which 
is the ossification of supra- and interspinous 
ligaments and can be detected by radiograph 
as slim ossified streak. When the ligamentous 
ossification occurs together with ossification of 
apophyseal joint capsules, there are three vertical 
Fig. 5.19 PA view of the pelvis and spines shows bone 




radiodense lines on frontal radiography (trolley- 
track sign) [27].
Ultrasonography: It has some utility for the 
evaluation of sacroiliitis when it is very active 
by using Doppler ultrasonography to assess 
blood flow and synovitis [26]. It may be use-
ful in some cases in young children as an initial 
study but is limited to the evaluation of soft tis-
sues  surrounding the joint and not the joint itself 
[26]. Ultrasound may be used for diagnostic and 
therapeutic injections into the sacroiliac joints as 
an alternative to fluoroscopy in some cases [26].
Magnetic Resonance Imaging (MRI): MRI 
has become the gold standard imaging modal-
ity for the diagnosis of SpA of sacroiliac joints 
and spine [26]. It is very sensitive and specific to 
detect inflammatory changes in and around the 
sacroiliac joints and spine. Therefore, MRI find-
ings are divided into active and chronic inflam-
matory findings.
5.5.1  Active Inflammatory Findings
Bone Marrow Edema (BME): It can appear 
in the sacroiliac joints and spine. It is strongly 
associated with disease activity and reflects the 
response to the treatment (Fig. 5.20).
Synovitis/Capsulitis: These findings rarely 
occur without the occurrence of other findings 
in AS.
Enthesitis: This finding almost always occurs 
at muscle insertion and is considered a transient 
feature.
5.5.2  Chronic Inflammatory 
Findings
Sclerosis: This appears as low intensity on MRI 
and mainly develops at joint margins.
Fat deposition: This occurs at bone marrow 
area in the sacroiliac joint and at vertebral cor-
ners in the spine.
Bone bridging: This results from the ossifica-
tion of ligaments which further lead to the for-
mation of bone bridging and ankylosis as a final 
result.
Erosions: They are bony defects that can be 
seen as irregular shapes at joint margins.
Computed tomography (CT): CT is supe-
rior to MRI in detecting erosions. It is also used 
in case of trauma and emergency if fracture is 
suspected.
Psoriatic arthritis (PsA): PsA is a chronic 
systemic disease characterized by inflamma-
tory joint changes and is accompanied with skin 
psoriasis. PsA affects joints asymmetrically. It 
involves the hands (no sparing joint), feet, and 
axial skeleton and rarely affects large joints. 
PsA develops in 7% of patients with skin pso-
riasis [26]. Axial psoriatic arthritis occurs in 
approximately 40% of patients with peripheral 
PsA [26].
Radiography: Radiographs are the first 
radiologic modality that should be obtained. The 
radiographic hallmark of PsA is the combination 
of destructive changes and bone proliferation.
Erosion: It is discontinuity of the white cor-
tical line. Marginal erosion is an early PsA sign 
which then becomes irregular and ill-defined 
because of bone formation adjacent to ero-
sions. This sign is also called “pencil in cup” 
(Fig. 5.21).
Joint space narrowing: Dramatic joint space 
narrowing may lead to serious disability.
Fig. 5.20 MRI of the sacroiliac joints shows reduced 
bilateral sacroiliac joint space with symmetrical focal 
bone marrow edema along the iliac side of both joints
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Bone proliferation: This is a feature of PsA 
involving particularly metaphysis and diaphysis 
of the hands and feet.
Ultrasonography: Ultrasound (US) in con-
junction with power Doppler (PD) indicative of 
degree of inflammatory activity has an increasing 
important role in the evaluation of PsA. In fact, 
US is useful mainly for its ability to assess mus-
culoskeletal (joints, tendons, entheses) and cuta-
neous (skin and nails) involvement, to monitor 
efficacy of therapy and to guide steroid injections 
at the level of inflamed joints, tendon sheaths, 
and entheses [28].
Synovitis: Asymptomatic US synovitis and 
enthesopathy may indicate subclinical musculo-
skeletal involvement [28].
Erosions: These can also be detected by US.
Tenosynovitis: US findings indicative of ten-
don involvement include fusiform swelling and 
focal derangement of tendon echotexture [28]. 
Achilles tendon, plantar fascia, patellar tendon, 
and tenosynovial sheaths of the hand and ankle 
are frequently affected in patients with PsA [28].
Enthesitis: US signs of enthesitis include 
hypoechoic swelling of the tendon insertion, 
enthesophytes, and possible bursal enlarge-
ment [28].
Magnetic resonance imaging (MRI): This 
modality is mainly used when the axial skel-
eton is affected. MRI is the most sensitive imag-
ing for the detection of subtle bilateral changes, 
which can be important in distinguishing PsA 
from septic sacroiliitis. The spondylitic changes 
in PsA and reactive arthritis appear more ran-
domly than those in AS. Large chunky-appearing 
paravertebral ossification is commonly seen in 
the thoracolumbar junction. These ossifications 
do not bridge the intervertebral discs as seen in 
AS. Ankylosis, squaring of vertebral bodies, and 
spinal fusion are very rare in PsA.
Fig. 5.21 AP view of the hand shows aggressive erosions (pencil in cup) which appear in all PIP joint of both hands; 
bone proliferation appears at distal part of metacarpal bones. Pan-carpal bone involvement. MCP joints are spared
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Computed tomography (CT): CT has little 
role in the assessment of peripheral joints but 
may be useful in assessing elements of spine dis-
ease [28]. The accuracy of CT is similar to MRI 
in the assessment of erosions in sacroiliac joints; 
however, CT has radiation and is not effective in 
detecting synovial inflammation [28].
Reactive Arthritis (ReA): It is previously 
known as Reiter’s syndrome. It is usually accom-
panied by conjunctivitis and urethritis. It affects 
males between the ages of 15 and 35  years. 
Arthritis might be the only clinical manifestation 
of ReA. The radiographic features are identical to 
those in PsA, but the difference is in the pattern 
of distribution which begins in the feet and then 
hand. History and clinical examination are help-
ful in differentiating ReA from PsA.
Osteoarthritis (OA): OA is the most com-
mon arthropathy in elderly. It impacts the quality 
of life, and it has a major implication on public 
healthcare. OA asymmetrically affects joints of 
the hands (sparing MCP joints), shoulders, feet, 
knees, hip, and spine.
Radiography: CR is the gold standard radio-
logic modality in detecting OA. It detects many 
OA features. Radiographic progression appears 
specific (91%) but not sensitive (23%) for carti-
lage loss [29].
Joint space narrowing: Non-uniform nar-
rowing of the joint spaces occurs in OA.
Osteophytes: These are joint spurs that occur 
along joint margins. Osteophytes can also be 
observed on the joint line (Fig. 5.22). The defini-
tion of OA relies on the presence of osteophytes on 
anteroposterior weight-bearing radiographs [29].
Sclerosis: It is seen as an increased density on 
radiograph [30].
Cyst formation: This is seen as a loss of tra-
becular structure [30].
Ultrasonography: US is widely used in RA 
and has been accepted to be used in OA too. US 
has the advantage of assessing and visualizing 
many OA features without exposing the patient 
to radiation. One limitation of US is that it cannot 
penetrate the bony parts to visualize the structures 
beyond them. The use of US is more common for 
hand and knee OA and has very limited usage in 
the assessment of other joints.
Osteophyte: They can be seen as a disturbed 
acoustic window.
Synovitis: This appears as thickening of syno-
vial membrane.
Erosions: They can be detected in erosive 
OA.
Magnetic resonance imaging (MRI): MRI 
is widely used in knee OA and spondylolisthe-
sis as it has the ability of providing a multiplanar 
image of all compartments. MRI can assess all 
features of OA, osteophytes, synovitis, effusion, 
joint spaces, bone marrow lesions, ligaments, 
cartilage, and vertebral height, as it decreases 
with degenerative diseases.
Computed tomography (CT): This test is of 
limited use as it exposes the patient to radiation. 
It still has its main role emergencies and in cases 
of suspected fracture.
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Low-back pain (LBP) is mainly managed in pri-
mary health care. It is a symptom that is com-
monly belittled and misdiagnosed. This chapter 
aims to present a simple approach for the diag-
nosis and assessment of LBP according to the 
latest clinical recommendations. This content 
will discuss in details the definition and preva-
lence of LBP and the important stepwise 
approach to reach a diagnosis and start treat-
ment. This approach starts from history-taking, 
physical examination, and radiological studies 
and, finally, concludes with the management and 
referral guidelines. Also, inflammatory back 
pain will be explained thoroughly in an easy to 
digest way.
A major advantage of this chapter is that care-
fully designed tables, diagrammatic presenta-
tions, and illustrations were used to help 
practicing clinicians perform proper and ade-
quate work up for patients with LBP.
6.2  Learning Objectives
By the end of this chapter, you should be able to:
 1. Present a comprehensive approach for the 
diagnosis and assessment of low-back pain in 
accordance with updated clinical guidelines.
 2. Recognize the red flags of LBP and the proper 
time for referral.
 3. Prevent the delay of the diagnosis and man-
agement of inflammatory back pain (IBP) to 
avoid the long-term disabilities.
6.3  Definition
LBP is defined as pain or stiffness in the area 
between the costal margin and the inferior glu-
teal folds; this pain could also extend to the 
lower limbs [1]. LBP can also be classified as 
acute or chronic; this would be helpful for 
prognostic and management purposes. Acute 
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LBP is considered if the symptom was present 
for less than 6  weeks, while sub-acute and 
chronic would be considered if the pain lasts 
from 6 to 12  weeks and more than 12  weeks, 
respectively [2]. Table 6.1 shows some impor-
tant definitions for some terminologies used 
while dealing with patients complaining of 
LBP.
6.4  Prevalence
LBP is a worldwide problem that is more com-
monly found in females and those aged 
between 40 and 80 years [3–5]. Lifetime preva-
lence of LBP has increased significantly to 
become as high as 84%, while chronic LBP has 
reached 23%. Of this population, 11–12% will 
develop some form of impairment or 
disability.
6.5  Differential Diagnosis
Back pain is a frequently encountered symptom 
that could be caused by many specific and non-
specific underlying causes, as shown in Table 6.2. 
However, mechanical low-back pain represents 
97% of the causes [6].
6.6  Approach to Diagnosis
When assessing a patient presenting with LBP, it 
is important to rule out neurologic deficits or 
other serious inflammatory or medical conditions 
with a focused history and physical examination. 
Thorough assessments are also important to aid 
physicians in screening the patients who need 
further diagnostic investigations to rule out seri-
ous pathologies (see Fig. 6.1) [7, 8].
The history-taking elements for LBP include 
the following:
• Type of onset and character may hint at the 
underlying pathology:
 – Bones: dull and nagging.
 – Muscles: dull aching.
 – Nerves: sharp and lightning like.
Table 6.1 Important terminologies in low-back pain
Spondylosis A degenerative osteoarthritis of 
the spine. It can be seen 
radiographically as a narrowed 
disc with arthritic changes
Spondyloarthritis Also called spondyloarthropathy 
is a group of inflammatory 
rheumatic diseases that cause 
arthritis. The most common is 
ankylosing spondylitis, which 
affects mainly the spine. Others 
include reactive arthritis, psoriatic 
arthritis, and enteropathic arthritis/
spondylitis associated with 
inflammatory bowel diseases
Spondylolisthesis Anterior or posterior displacement 
of a vertebra or the vertebral 
column in relation to the vertebrae 
below. The slippage is determined 
by spinal X-ray and graded from 
grade 1 to 4
Grade 1: Less the 25% slippage
Grade 2: 25%–50% slippage
Grade 3: 50%–75%
Grade 4: More than 75%
Spondylitis Inflammation of vertebrae 
manifested by back pain and 
progressive stiffness of the spine. 
The inflamed spine can be visible 
in MRI
Discitis An inflammation of the 
intervertebral disc space often 
related to infection
Radiculopathy Impairment of a nerve root, 
usually causing radiating pain, 
numbness, tingling, or muscle 
weakness that corresponds to a 
specific nerve root
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 – Nerve root: sharp and shooting.
 – Sympathetic nerve: burning, pressure like, 
stinging, and aching.
 – Vascular: throbbing and diffuse.
• Duration: this would help guide imaging and 
treatment decisions.
• The site of pain and any radiation: this would 
help to rule out radiculopathy.
• Intensity of the pain.
• Continuous versus on and off.
• Progressive or not.
• Factors that improve or worsen the pain: day-
time vs nighttime, certain positions, activity 
vs rest, and response to treatments.
• Severity of pain.
• Associated symptoms: extra-axial joint pain, 
sciatica, paresthesias, pseudoclaudication, and 
bowel/bladder dysfunction.
• Assess for symptoms specific for certain dis-
eases like spondyloarthropathies, i.e., enthesi-
tis, dactylitis, history of psoriasis, and bowel 
symptoms.
• Assess for red flags (see “radiological 
studies”):
 – History of trauma [9].
 – Symptoms suggestive of an infection or 
malignancy, i.e., fever and unexplained 
weight loss.
 – Neurological deficits or other symptoms 
that may give a clue to serious underlying 
pathologies like cauda equine syndrome, 
compression fractures, spinal stenosis, her-
niated disc, or radiculopathy.
• Review of systems:
 – Referred pain due to underlying visceral 
pathologies.





•  Musculoligamentous strain: Experienced by up to 80% of population at some time
•  Fibromyalgia: Widespread pain in all 4 quadrants of the body, at least 3 months, 11 out of 18 
positive tender points on physical exam
•  Osteoarthritis: Affects mainly the hips, knees, spine, first CMC, DIP, and PIP
•  Rheumatoid arthritis: May affect facet joints. It presents with pain, swelling, and impaired 
function of joints with morning stiffness for ≥1 hour and has extra-articular manifestations, 
positive RF, and ACPA
•  Spondylolisthesis: Dull, aching pain in the lower lumbar or upper sacral region. Pain also extends 
into the buttocks or posterior thigh
•  Vertebral compression fracture: Symptoms could mean compression of the nerves at the 
fracture site: Numbness, tingling, weakness, and incontinence
•  Inflammatory: Spondyloarthritis (ankylosing spondylitis, reactive arthritis, psoriatic arthritis)
Spinal cord: Myelopathy
Nerve root: Radiculopathy
Degenerative or traumatic: Disc herniation, spondylosis, fracture
Metabolic: Paget’s disease, osteomalacia
Neoplastic: Lung, breast, prostate, multiple myeloma, lymphoma
Infectious: TB discitis, osteomyelitis, epidural abscess, zoster, Lyme, CMV, HIV
Referred pain:
•  Gastroenterology: PUD, cholelithiasis, pancreatitis, pancreatic cancer
•  Genitourinary: Pyelonephritis, nephrolithiasis, uterine or ovarian cancer, salpingitis
•  Vascular: Aortic dissection, leaking aortic aneurysm
Nonspecific 
causes
Poor posture, sitting and standing, lifting ergonomics, unknown causes
Risk factors Overweight, smoking, pregnancy, long-term use of medication (e.g., corticosteroids), stress, 
depression, occupation
CMC carpometacarpal joint, DIP distal interphalangeal joint, PIP proximal interphalangeal joint, RF rheumatoid factor, 






• Gait: straight walking while watching for abnormal flexion (stenosis or
  facet joint), extension (disc), or Trendelenburg gait.   
• Screening: walking on toes then on heels. 
• Position: watch as patient changing position. 
Inspection
• Alignment: Kyphosis, scoliosis, or loss of exaggerated lordosis. 
• Skin: Erythema, hair patch, Café au lait spots, nodules, and or scars. 
• Inequality: watch for iliac crest and pelvic inequality => at the level of
  L4-5: ask patient to flex his/her hip.   
• N.B: Always inspect the patient posteriorly and laterally. 
Palpation
• Examine the patient in the prone position. 
• Spinous processes: tenderness or defects. 
• Inter-spinous ligament. 
• Supraspinous ligament. 
• Paraspinal muscles. 
• Iliac crest: tenderness (Spondyloarthritis) or nodules.
  PSIS –Sacroilliac joint -S2 
• Ischial tuberosity -Sciatic nerve -Greater trochanter. 
Range of Motion
• Flexion: finger-floor 
• Extension: stabilize the pelvis and measure the distance 
• Lateral flexion: Finger-fibula (against the wall). 
• Tohoraco-lumbar rotation: 70 degree normally. 
Special Test
• Straight leg raising test (SLRT) 
• Slump test 
• Sacro-illiac joints exam: Patrick test and compression test
• Modified-modified schober's test 
• Neurological exam: Muscle bulk by tape (Radiculopathy) and
  rectal tone (S3,4,5)
Inspect for Trendelenburg gait
Inspect for Symmetry
Testing of Dermatomes
Testing of MyotomesSlump testSLRT
Fig. 6.1 Approach to back MSK examination
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• Past medical and surgical history:
 – Previous history of cancer.
 – Medications.
 – History of osteoporosis and/or pathologic 
fractures.
 – Anxiety or depression.
• Social history: history of smoking, illicit drug 
use, and type of work.
• The physical examination steps for the assess-
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Fig. 6.2 Simple approach of LBP
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 – Inspection for skin changes and gait 
abnormalities.
 – Palpation for tenderness.
 – Range of motion.
 – Special tests (Table 6.3).
6.7  Radiological Studies for LBP
Acute LBP that is free of any red flags is gener-
ally a benign and self-limiting condition that 
does not warrant any further imaging evalua-
tion. If there are any signs of complications, an 
MRI should be requested as it has replaced CTs 
and myelographies as the first-line imaging 
modality. MRIs are useful for detecting infec-
tions and neoplasia and for postoperative assess-
ments. However, CTs are more useful in patients 
with abnormalities in bone structure and for 
evaluation of surgical fusion or instrumentation 
procedures. CTs are also useful when MRIs are 
contraindicated. Other imaging modalities like 
myelography/CT, discography/CT, and radio-
isotope bone scans can be used in selected 
patients [10, 11].
Table 6.3 Special tests for LBP




•  To test for the presence of a disc 
herniation
•  In supine position, flex the patient’s 
hip while maintaining the knee in 
full extension
•  Watch for the degree of hip flexion 
where the patient reports pain
•  Positive SLRT: Radicular pain 
down the posterior portion of the 
tested leg at 40 degrees of hip 
flexion or less
•  Sensitivity 33%, specificity 87%
Slump test •  Ask the patient to hold hands behind 
his/her back while seated upright
•  Instruct to the patient to (slump) flex 
his/her spine, followed by neck 
flexion
•  With examiner’s hand on top of 
head, the patient performs knee 
extension and dorsiflexion of foot
•  Ask the patient to return the neck to 
neutral (no flexion)
•  Positive slump test: The patient’s 
symptoms are increased in the 
slumped position and released as the 
patient actively extends
•  Sensitivity 84%, specificity 83%
Patrick’s test 
(FABER)
•  To assess for the sacroiliac joint 
dysfunction or hip joint pathology
•  In supine position, bring the tested 
leg to hip flexion, abduction, and 
external rotation
•  Against the medial knee, try to bring 
the bent leg passively towards the 
table
•  Positive test: Reproduction of groin 
pain or buttock pain
•  Sensitivity 82%
Compression 
test
•  To assess for the sacroiliac joint 
dysfunction
•  While standing behind the patient, 
bring him/her to sideline position
•  Ask the patient to flex hip at 60 
degrees and knees at 90 degrees
•  Apply an inward/downward force on 
iliac crest
•  Positive test: Pain on sacroiliac 
joint
•  Sensitivity 69% and specificity 93%
Table 6.3 (continued)




•  Identify the PSISs by marking the 
inferior margins of the patient’s 
PSISs with his or her thumbs
•  Mark along the midline of the 
lumbar spines horizontal to the 
PSISs
•  Make another mark 15 cm above 
the original mark
•  With a tape pressed firmly on the 
line between the two marked 
points, instruct the patient to bend 
forward into full lumbar flexion
•  Measure the new distance between 
the superior and inferior skin 
markings
•  Distance increases less than 5 cm 




•  Measure the muscle bulk by tape
•  Assess for muscle power: Hip 
flexion (L2), knee extension (L3), 
ankle dorsiflexion (L4), big toe 
extension (L5), and ankle plantar 
flexion (S1)
•  Check knee reflex (L3 and L4) and 
ankle reflex (L5 and S1)
•  Check for skin sensory loss
•  Assess anal sphincter tone by digital 
examination (S3, 4, 5)
PSIS posterior superior iliac spine, L Lumbar vertebrae, S 
Sacral vertebrae
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Red flags that warrant further imaging [9]:
• Onset above age 70 years old.
• Pain that has persisted for more than 6 weeks.
• History of trauma, even mild trauma in 
patients aged >50.
• History of surgery in the same site of pain.
• History of malignancy.
• History of IV drug abuse.
• History of osteoporosis or long-term use of 
steroids.
• Weight loss that is unexplained.
• Fever without an obvious source of infection.
• The presence of focal neurological deficits.
• The use of immunosuppressive medication.
Imaging studies that may be considered 
include:
 1. X-ray
• It is useful in delineating degenerative 
bone disease, disc prolapse, spondylolis-
thesis, fractures, and neoplasia and to 
assess prior surgical interventions.
• Erythrocyte sedimentation rate (ESR) is a 
useful tool that can suggest the presence or 
absence of an infection or neoplasia. In 
patients with no more than 1 risk factor for 
systemic disease and an ESR less than 20, 
infections and malignancy would be con-
sidered less likely.
 2. CT
• It can help in detecting degenerative bone 
disease, spondylolisthesis, fractures, and 
malunion. It can also delineate inflamma-
tion in the sacroiliac joints.
• It can show false-positive findings follow-
ing trauma.
 3. MRI
• This is the optimal imaging modality for 
detection of soft tissue abnormalities. It 
should be offered to patients presenting 
with neurological deficits. It is a valuable 
tool for detecting conditions like disk her-
niation, spinal stenosis, osteomyelitis, dis-
citis, spinal epidural abscess, bone 
metastasis, arachnoiditis, and neural tube 
defects.
• It can reveal inflammatory changes in the 
sacroiliac joints before they start showing 
on plain X-rays.
 4. Electromyography (EMG)
• It is useful in patients complaining of 
radiculopathic pain with inconclusive find-
ings on imaging modalities who may be 
considered for surgery.
• It can be helpful in patients who were 
found to have multilevel affection on 
imaging.
 5. Radionuclide bone scans
• It is a more sensitive tool than plain X-rays, 
especially for the detection of hidden infec-
tions or malignancy.
• In patient who have normal ESR values 
and plain radiographs, however, these will 
be of limited utility.
6.8  Detection of Inflammatory 
Back Pain
Inflammatory back pain (IBP) is usually diag-
nosed late especially in primary care settings. 
Causes for this delay may include difficulties in 
differentiating between mechanical and inflam-
matory back pain. IBP can lead to significant 
functional disability. The longer the diagnosis 
is delayed, the worse the functional outcome 
[11, 12].
Seronegative spondyloarthropathies are an 
important cause of IBP.  They are a group of 
inflammatory diseases that are characterized by 
seronegative arthritis (rheumatoid factor nega-
tive) which is linked with the presence of the 
human leukocyte antigen HLA-B27.
The seronegative spondyloarthropathies 
include the following disorders:
• Undifferentiated spondyloarthritis.
• Ankylosing spondylitis: involves the spine, 
peripheral joints, and entheses. This disorder 
is a frequently underdiagnosed cause of low- 
back pain.
• Reactive arthritis or Reiter’s syndrome: pres-




• Spondyloarthritis associated with psoriasis: 
arthritis that is associated with psoriasis.
• Spondyloarthritis with inflammatory bowel 
disease: Crohn’s disease and ulcerative colitis 
are often associated with ankylosing spondyli-
tis or peripheral arthritis.
• Juvenile onset ankylosing spondylitis: affects 
children under the age of 16 years.
IBP definition criteria includes the following 
items [13, 14]:
• The pain has an insidious character.
• Pain increases at night.
• Pain that improves with activity and does not 
improve with rest.
• Onset of pain occurs in patients <40 years of 
age.
Four criteria out of five are required to make a 
diagnosis of IBP. The sensitivity and specificity of 
these criteria are at 77% and 91.7%, respectively. 
Referral to a rheumatologist should be considered 
if these criteria are fulfilled (Fig. 6.3) [15, 16].
6.9  Treatment of Low-Back Pain 
(Acute or Sub-Acute Pain) 
[17, 18]
• In patients with favorable prognosis, reassur-
ance is imperative.
• Physical activity and supervised exercise 
regimens.
• Bed rest should not be recommended.
• Nonpharmacological therapy that can be used 
in an acute setting with moderate-quality evi-
dence includes superficial heat, massage, and 
acupuncture. Low-quality evidence therapies 
include spinal manipulation.
• Second-line agents include nonsteroidal 
anti- inflammatory drugs, muscle relaxants, 
and duloxetine (as co-medications for pain 
control). Newer guidelines no longer sup-
port the use of acetaminophen and tricyclic 
antidepressants.
• Modalities such as electrotherapy should not 
be used.
• Medications and other therapies should only 
be used short term.
• There should be a multidisciplinary approach 
to treatment.
6.10  Treatment of Inflammatory 
Back Pain (IBP)
The main target for therapy is to decrease the 
severity of symptoms and inflammation and to 
halt the progression to impairment and functional 
disability. Nonpharmacological therapy includes 
exercise and patient counselling. Group exercises 
are favored over home exercises. Treatment of 
patients suffering from IBP should be tailored to 
each patient’s individual manifestations and gen-
eral condition. Factors that should be kept in 
mind include the patient’s age, sex, presence of 
comorbidities, medication interactions, socioeco-
nomic status, severity of symptoms and signs, 
and his overall prognosis. Certain clinical find-
ings should be considered while formulating a 
therapeutic plan, such as axial or peripheral 
symptom predominance and entheseal and extra- 
articular affection.
If the patient complains of persistent symp-
toms, NSAIDs are used as first-line pharmaco-
logical therapy. In cases where NSAIDs are 
contraindicated or not tolerated, paracetamol 
and/or opioids can be used. Disease-modifying 
anti-rheumatic drugs (DMARDs) such as sys-
temic steroids, sulfasalazine, and methotrexate 
were not found to be useful in axial predominant 
disease. However, intra-articular injections in 
affected sites can be beneficial.
If patients exhibit significantly active disease, 
anti-TNF agents can be considered. Surgery 
should be offered to patients suffering from pain 
that is refractory to all previously mentioned 
treatment lines. It can also be offered to patients 
with functional impairment and anatomical dam-
age found on imaging [19]. Spinal corrective 
osteotomy can be considered in patients suffering 
from severe deformities and significant func-
tional impairment. Referral to surgery should 
also be done in AS and acute vertebral fracture 
cases (Fig. 6.4).





















































Diagnostic Algorithm of Inflammatory Back Pain
In all planes
Fig. 6.3 Diagnostic algorithm of low back pain
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Patient’s complaints of LBP
Are any serious conditions strongly suspected?
Yes: perform diagnostic
study to identify the cause
No: back pain is mild with no
functional impairments
Arrive at shared decision regarding therapy & educate patient
Back pain improved or limited with no significant functional deficit
Pt. accepts benefit and risk of therapy
No-continue self-care and
re assess within 1 month
Yes: LBP on therapy No: LBP not on therapy
Specific cause identified
Yes: advise about self-care, review indications of
reassessment
No: advise about self-care & discuss noninvasive
 treatment options  
Focused Hx& PE: duration of symptoms, risk factors, symptoms of radiculopathy or
spinal stenosis, presence severity of neurologic deficit, psychological risk factors 
Yes: pt. on therapy
Follow up within 4 weeks
No: signs & symptoms of
radiculopathy or spinal stenosis
Assess response to
treatment
Initiate a limited trial
of therapy
Follow up within 4
weeks 
Yes: continue self-care and
re assess within 1 month 
Consider diagnostic imaging (MRI) if not already done consider referral
Reassess symptoms, risk factors and reevaluate
diagnosis, consider imaging 
Consider referral for surgery & invasive procedures
Consider alternative pharmacologic & non pharmacologic interventions, for significant functional
deficit consider more intensive multidisciplinary approach or referral
Fig. 6.4 How to approach a LBP patient in the clinic
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6.11  Referral
Consultations to neurosurgery or orthopedics are 
needed if any of the following symptoms and/or 
signs occur:
 1. Cauda equina syndrome: this should be sus-
pected if the patient complains of typical fea-
tures like bowel and bladder dysfunction 
(urinary retention), saddle anesthesia, and 
bilateral leg weakness and numbness.
 2. Spinal cord compression: this should be sus-
pected in cancer patients who have a risk of 
spinal metastasis. They may present with 
acute neurologic deficits and need emergent 
evaluation for surgical decompression or radi-
ation therapy.
 3. Progressive or severe neurologic deficits or if 
any neuromotor deficits that persist after 4 to 
6 weeks of conservative therapy: these patients 
should be referred to a neurologist.
 4. Sciatica, sensory deficit, or reflex loss persis-
tent for 4–6 weeks in a patient with positive 
straight leg raise test, consistent clinical find-
ings, and favorable psychosocial circum-
stances such as realistic expectations and 
absence of depression, substance abuse, or 
excessive somatization.
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Pulmonary manifestations cause a huge burden 
for patients with connective tissue diseases 
(CTD). It has been associated with higher rates of 
mortality and morbidity.
There are six CTDs which have significant 
pulmonary manifestations:
• Systemic sclerosis (SSc) or scleroderma.
• Rheumatoid arthritis (RA).
• Systemic lupus erythematosus (SLE).
• Sjogren syndrome (SS).
• Mixed connective tissue disease (MCTD).
• Polymyositis/dermatomyositis (PM/DM).
7.2  Chapter Objectives
• To develop a practical approach to chronic and 
acute dyspnea and cough for the previously 
mentioned CTDs’ patients.
• To know when and how to screen for the pul-
monary diseases related to the CTDs.
• To develop knowledge about most of the pul-
monary manifestations of CTDs and how to 
diagnose them and treat them sufficiently.
7.3  About the Chapter
In the chapter, for every CTD, the pulmonary mani-
festations will be discussed according to the anatomi-
cal structure of the respiratory system as follows:
• Airways:
 – Upper airway.
 – Lower airway.
• Parenchyma:
 – Alveolar space.
 – Interstitium.
• Vasculature:
 – Pulmonary artery.
• Pleura:




 – Chest wall muscles.
7.4  To Get the Most of the Chapter
• In general, interstitial lung diseases (ILD) and 
pulmonary arterial hypertension (PAH) are the 
most common pulmonary manifestations of 
CTDs.
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• The most common subtypes of ILD are non- 
specific interstitial pneumonia (NSIP) and 
usual interstitial pneumonia (UIP). 
Furthermore, for all CTDs except SSc, NSIP, 
which presents with ground glass opacities 
(GGO) on high resolution computed tomogra-
phy (HRCT), has better prognosis than UIP, 
which presents as reticular opacities with or 
without honeycombing on HRCT.  That’s 
because GGO represents an ongoing inflam-
matory process, while reticular opacities and 
honeycombing represent fibrosis.
Due to the rarity of some CTDs or some of the 
pulmonary manifestations, there are few or lack 
of large randomized control trials (RCTs) to relay 
on in decision making, which makes the manage-
ment not standardized.
7.5  Important Information 
about Pulmonary 
Manifestations of CTDs 
before Going through 
the Chapter
Most of the pulmonary manifestations could 
occur before, co-exist, or after the CTD itself 
being clinically manifested.
• The prevalence of each entity of pulmonary 
manifestations related to each CTD is pre-
sented in Table 7.1.
• Screening for pulmonary complications in 
CTD patients is not well established. However, 
the following model seems to be acceptable to 
be applied to all CTDs, while physicians 
should tailor it according to their patients and 
the clinical context (Fig. 7.1).
• CTD-related interstitial lung disease (CTD- 
ILD) subtypes are similar to those in idio-
pathic interstitial pneumonia (IIP). Each 
subtype has been named according to its histo-
logical and/or radiological pattern (Table 7.2).
• Classification of pulmonary hypertension 
(Fig. 7.2; Table 7.3).
• The decision of when to start treatment in 
CTD-ILD is considered a dilemma because 
some patients present with respiratory symp-
toms and others are asymptomatic but have 
physiological (i.e., pulmonary function test 
[PFT]) or radiological (i.e. HRCT) abnormali-
ties related to ILD.  Thus, a useful stepwise 
approach developed by the authors of the 
Scleroderma lung study could be used depend-
ing on the severity of the disease on HRCT. See 
text below (SSc-ILD treatment) and combine 
it with (Fig. 7.3). We think it’s appropriate to 
apply it to the rest of the CTD-ILD.
• The approach to screening for CTD-related 
pulmonary hypertension (CTD-PAH) is illus-
trated in Fig. 7.4 [1].
• The approach to acute dyspnea in CTDs is 
presented in Fig. 7.5.
• The approach to chronic dyspnea in CTDs is 
presented in Fig. 7.6.
Table 7.1 Connective tissue diseases and pulmonary manifestations
CTDs and common pulmonary manifestations
ILD Airways Pleura Vascular DAH
Systemic sclerosis +++ − − +++ −
Systemic sclerosis ++ ++ ++ + −
Primary Sjogren’s syndrome ++ ++ + + −
Mixed CTD ++ + + ++ −
Polymyositis/dermatomyositis +++ − − + −
Systemic lupus erythematosus + + +++ + ++
Adopted from Aryeh Fischer, Prof Roland du Bois. Interstitial lung disease in connective tissue disorders The Lancet, 
Volume 380, Issue 9842, Pages 689–698, 18 August 2012. The signs show prevalence of each manifestation (−, no 
prevalence; +, low prevalence; ++, medium prevalence; +++, high prevalence)
ILD interstitial lung disease, DAH diffuse alveolar hemorrhage, CTD connective tissue disease
R. Taha and M. Feteih
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• Pleural fluid analysis for CTDs (except for 
PM/DM and MCTD, due to the lack of suffi-
cient information about them) (Table 7.4).
• Although drug-induced lung injury is an 
uncommon complication (mostly reported in 
observational studies), treating physicians 
should consider it as one of the differential 
diagnoses of lung injuries. Furthermore, it’s 
important to know the common and serious 
adverse events of the medications used in 
CTD-ILD, so it would be easier to monitor 
them and follow them up with patients. Once 
drug-induced lung injury is suspected, one 
should take into consideration the duration 
between starting the drug and the develop-
ment of pulmonary manifestation in addition 
to the dose of the drug. Eventually, there is no 
single test that could help in confirming this 
diagnosis. However, withdrawal of the 
offending drug appears to be best step to diag-
nose it besides other findings, which are pre-
sented in Table  7.5. Moreover, a useful 
website established by French pulmonolo-
gists from Dijon University has been launched 
to provide  information about drugs causing 
lung toxicity (www.pneumotox.com). Of 
Approach for screening of pulmonary manifestations in
connective tissue disease
For every patient once diagnosed with one of the CTDs
Respiratory history and physical exam, PFT, HRCT, transthoracic Echo, ECG,
Serum BNP
Every 3–6 months: follow up with patient by asking
about respiratory Hx and P/E.
Screen by Hx, P/E, PFT, HRCT, Echo,
ECG and BNP
Annually: screen by Hx, P/E, PFT,










Refer to approach to
chronic dyspnea
Refer to approach to
abnormal Echo
Fig. 7.1 Screening of 
pulmonary 
complications of CTDs. 








Hx History, P/E Physical 
examination, PFT 
Pulmonary function test
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note, doing bronchoalveolar lavage (BAL) is 
a must to rule out infections (bacterial, viral, 
fungal, mycobacterial).
7.6  Pulmonary Manifestations 
According to each CTD
7.6.1  Systemic Sclerosis or 
Scleroderma (SSc)
Systemic sclerosis (SSc) is a rare multisystem 
disease that involves skin and other body organs 
causing fibrosis and vascular complications. It is 
divided into local cutaneous systemic sclerosis 
(lcSSc), which is more commonly associated 
Table 7.2 Radiological and histological patterns of idio-
pathic interstitial pneumonias







Adopted from American Thoracic Society/European 
Respiratory Society international multidisciplinary con-
sensus classification of the idiopathic interstitial pneumo-
nias. Am J Resp Crit Care Med 2002; 165:277
IPF Idiopathic pulmonary fibrosis, UIP Usual interstitial 
pneumonia, NSIP Non-specific interstitial pneumonia, OP 
Organizing pneumonia, LIP Lymphocytic interstitial 
pneumonia, RB-ILD Respiratory Bronchiolitis interstitial 
lung disease, RB Respiratory Bronchiolitis, AIP Acute 




















owing to left heart



















Fig. 7.2 World health organization (WHO) classification 
of pulmonary hypertension. (Adopted from Simonneau G, 
Galie N, Rubin L, et al. Clinical classification of pulmo-
nary hypertension. J Am Coll Cardiol. 2004;43 Suppl 
1:S5–12)
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with the CREST syndrome, and diffuses sys-
temic sclerosis (dcSSc) depending on skin 
involvement and distribution. Furthermore, lung 
involvement occurs in about 70% of SSc cases. 
Also, it is considered to be the leading cause of 
death in SSc patients [2]. Moreover, the most 
common pulmonary manifestations in SSc are 
ILD and PAH.  While less common pulmonary 
involvements are pleural effusion, aspiration 
pneumonitis, spontaneous pneumothorax, bron-
chiectasis, drug-associated pneumonitis, and 
lung cancer.
7.6.1.1  Parenchymal Lung Diseases
SSc-associated interstitial lung disease (SSc- 
ILD), it occurs in about 40–52% of all SSc 
patients. However, the dcSSc type appears to be 
associated with higher risk to develop it com-
pared with lcSSc. Risk factors are African 
American, gastroesophageal reflux disease 
(GERD), higher skin score, high level of 
C-reactive protein (CRP), hypothyroidism, car-
diac involvement, Th/To ribonucleoprotein anti-
bodies (anti-Th/To), and anti-topoisomerase I 
(Scl-70). On the other hand, anti-centromere 
antibody is considered protective against ILD in 
SSc. Of note, SSc-ILD is classified into limited 
versus extensive depending on HRCT finding 
and FVC (Fig. 7.3).
Presentation
Usually patients present with dry cough, short-
ness of breath, decreased exercise intolerance, 
fine bibasilar crackles, and, infrequently, finger 
clubbing.
Diagnosis
The diagnosis is made collectively by symptoms, 
signs, PFT (which mostly shows restrictive pat-
tern with low diffusion lung capacity of carbon 
monoxide [DLCO]) and imaging (chest radio-
graph may appear normal at the beginning but 
then progresses to irregular linear opacities and 
marked interstitial marking). However, in HRCT, 
it may show GGO without honeycombing in 
NSIP or reticular pattern with basilar honey-
combing in UIP with/without traction bronchiec-
tasis. Furthermore, the most common subtypes of 
SSc-ILD are NSIP followed by UIP.  Although 
usually the subtypes of ILD may affect the out-
come of CTD-ILD, in SSc it is not the case. For 
that, it is enough to diagnose it as SSc-ILD with-
out specifying the subtype. While BAL is helpful 
Table 7.3 World health organization functional classifi-
cation of pulmonary hypertension
WHO functional classification
I Patients with pulmonary hypertension but without 
resulting limitations of physical activity. Ordinary 
physical activity does not cause undue fatigue or 
dyspnea, chest pain, or heart syncope
II Patients with pulmonary hypertension resulting in 
slight limitation of physical activity. They are 
comfortable at rest. Ordinary physical activity 
results in undue fatigue or dyspnea, chest pain, or 
heart syncope
III Patients with pulmonary hypertension resulting in 
marked limitation of physical activity. They are 
comfortable at rest. Less than ordinary physical 
activity causes undue fatigue or dyspnea, chest 
pain, or heart syncope
IV Patients with pulmonary hypertension resulting in 
inability to carry on any physical activity without 
symptoms. These patients manifest signs of right 
heart failure. Dyspnea and/or fatigue may be 
present even at rest. Discomfort is increased by 
physical activity
Adopted from: Rich, S. Primary hypertension: executive 
summary. Evian, France. World Health Organization, 
1998
HRCT extent of disease
>20%Indeterminate<20%
PFTs
FVC <70% predFVC <70% pred
Limited disease Extensive disease
Fig. 7.3 A simple system to determine the extension of 
interstitial lung disease. FVC Forced vital capacity, PFT 
Pulmonary function test. (Adopted from Goh NS, Desai 
SR, Veeraraghavan S, et al. Interstitial lung disease in sys-
temic sclerosis: a simple staging system. Am J Respir Crit 
Care Med 2008; 177: 1248–1254)
7 Pulmonary Manifestations of Connective Tissue Diseases
144
in ruling out infection in the appropriate clinical 
context, lung biopsy is not usually required, 
unless such diagnosis is doubtful. Worth men-
tioning, the most serious complications of SSc-
ILD are respiratory failure and pulmonary 
hypertension.
Routine screening:
Annual transthoracic echocardiogram: Assess RV size, RV thickness, TAPSE and measure PAP (using PA
acceleration time and tricuspid regurgitation velocity)
Pulmonary function test every 6–12 months
ECG
Serum BNP
Reasonable to do once in all subjects; repeat if symptoms develop or in those at high risk: lcSSc, anticentromere
antibodies, falling DLCO
Decreased DLCO or DLCO/alveolar volume Increased serum BNP Dilated
RV or right atrium on echocardiogram RVH on ECG
Assessment of symptoms:
Unexplained dyspnoea, 
exercise intolerance, or syncope
Transthoracic echocardiogram, measure PO2, exercise
testing, and/or 6-min walk test
TR jet >3 m.s-1 and unexplained symptoms or poor
exercise capacity:
CT scan (spiral and thin slice): exclude PE and PF
V/Q scan: exclude PE
Consider oximetry or sleep study to exclude sleep apnoea
TR jet <3 m.s-1 Normal RV size
and function Well-preserved
exercise function Normal ECG
Right and left heart catheterisation: If mPAP " 25 mmHg
and PVR " 3 Wood units and wedge #15 mmHg and no
other cause for PH (acute vasodilator testing: this
determines safety of use of CCBs and predicts survival),
refer to PH clinic for treatment with:
WHO class IIIb–IV: intravenous or inhaled prostaglandin
WHO class II–II: s.c. prostaglandin or oral ETRA or PDE5
inhibitor
WHO class I: no evidence for therapy, consider CCB, PDE5
inhibitor, or observation
Reassure and reassess or look
for other aetiologies (e.g.
deconditioning, ILD)
Fig. 7.4 The approach to screening for CTD-related pul-
monary hypertension (CTD-PAH). BNP B-type natri-
uretic peptide, CCBs Calcium channel blockers, DCLO 
Diffusing capacity carbon monoxide, ECG 
Electrocardiogram, ETRA Endothelin receptor antagonist, 
FVC Forced expiratory vital capacity, LcSSc Limited 
cutaneous systemic sclerosis, mPAP mean pulmonary 
artery, PDE-5 inhibitor phosphodiesterase type 5 inhibi-
tor, PE pulmonary embolism, PF pulmonary fibrosis, RV 
right ventricular, RVH right ventricular hypertrophy, 
TAPSE Tricuspid annular plane systolic excursion, TR 
Tricuspid regurgitation, V/Q Ventilation/perfusion, WHO 
World health organization, WU Wood Units. (Adopted 
from Sweiss NJ, Hushaw L, Thenappan T, et al. Diagnosis 
and management of pulmonary hypertension in systemic 
sclerosis. Curr Rheumatolo Rep)
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Prognosis
ILD in SSc has poor outcome despite treatment. 
It’s associated with higher mortality. The median 
survival for patients is 5–8 years.
Treatment
Many issues are involved in treating SSc-ILD, 
which are the decision of initiation of treatment, 
treatment modalities, the follow-up of treatment, 
duration of treatment, and assessment of success 
of treatment and promising drugs.
It is difficult to decide whether to initiate treat-
ment or not since treatment has a minor effect on 
the outcome of SSc-ILD. Physicians should bal-
ance between the benefit of treatment and the 
adverse drug reactions.   Factos that favor starting 
treatment are the presence of respiratory symp-
toms, abnormal or declining lung functions (spe-
cially DLCO and forced vital capacity [FVC]), 
progressive disease, early intervention (within 
12–24  months of the diagnosis of SSc-ILD), 
young age, GGO on HRCT, and no contraindica-
tions (such as active or suspected infection, neu-
tropenia, history of cyclophosphamide 
hemorrhagic cystitis, pregnancy, and lactation) 
[3, 4].
When physician and patient agree to start 
treatment, there are three modalities available, 
which are drug therapy, lung transplantation, and 




































Fig. 7.5 Approach for 












(Book), published by 
opentech. ALP Acute 
lupus pneumonitis, BAL 
bronchoalveolar lavage, 




angiogram, DAH diffuse 
alveolar hemorrhage, 
GGO’s ground-glass 
opacities, V/Q Scan 
ventilation/perfusion 
lung scan
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Fig. 7.6 The approach to chronic dyspnea in CTDs. CXR 
Chest X-ray, CTD Connective tissue disease, C-P Costo- 
phrenic angle, Dx Diagnostic, Rx Therapeutic, Bx Biopsy, 
GGO Ground glass opacity, HRCT High resolution com-
puted tomography, PFT Pulmonary function test, ILD 
Interstitial lung disease, NSIP Non-specific interstitial 
pneumonia, OP Organizing pneumonia, UIP Usual inter-
stitial pneumonia, OB Obliterative bronchiolitis, DLco 
Diffusion Lung capacity for carbon monoxide, DL/VA 
Diffusion per unit area of alveolar volume, MIP Maximum 
inspiratory pressure, MEP Maximum expiratory pressure, 
VC Vital capacity, FVC Forced vital capacity, EMG 
Electromyogram, SLS Shrinking lung syndrome, PASP 
Pulmonary artery systolic pressure, TR Tricuspid regurge, 
RHC Right heart catheterization, PAP Pulmonary artery 
pressure, PCWP Pulmonary capillary wedge pressure, R/o 
Role out, PH Pulmonary hypertension, PCP Pneumocystis 
pneumonia, CMV Cytomegalovirus, HSV Herpes simplex 
virus, TB Tuberculosis, LDH Lactate dehydrogenase, RF 
Rheumatoid factor, RBC Red blood cell, Anti-nuclear 
antibody
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with, there is no drug, up to date, considered as 
the gold standard treatment for SSc-ILD because 
of lacking of strong evidence to relay on. 
However, commonly used regimen is cyclophos-
phamide (CYC) (oral or intravenous) combined 
with low dose glucocorticoids (equal to or less 
than 10  mg/day equivalent to prednisone) for 
12  months duration [5–10].Then, physicians 
could stop the CYC and the steroids and start a 
maintenance therapy with azathioprine (AZA) 
for18 months [11]. Although oral cyclophospha-
mide is superior to IV route, some clinicians pre-
fer the IV route due to possible less side effects as 
a result of lower cumulative dose. An alternative 
regimen to CYC and steroids is AZA plus low- 
dose prednisone [12, 13]. This regimen is inferior 
to CYC and steroids but could be used if patient 
could not tolerate CYC. Steroids are used mostly 
as an adjuvant therapy to cyclophosphamide with 
low doses (equal to or less than 10 mg/day equiv-
alent to prednisone). That’s because moderate to 
high doses (>15  mg/day equivalent to predni-
sone) could expose patients to the risk of devel-
oping scleroderma renal crisis (SRC), which 
presents with acute kidney injury (AKI), hyper-
tension (including hypertensive crisis), and mild 
proteinuria. Of note, there are some other prom-
ising drugs such as mycophenolate mofetil [14–
20], rituximab [21, 22], and imatinib [23, 24], but 
more trials are needed to compare their efficacy 
to cyclophosphamide.
Monitoring usually consists of monthly follow-
up to make sure there are no drug adverse events 
and, then, a visit every 6 months to check for respi-
ratory symptoms, PFT, and HRCT.  Clinicians 
should monitor patients for CYC drug toxicity by 
monitoring white blood cell (WBC) count, renal 
function, and urine analysis (specially for red 
blood cells [RBCs]) in urine to predict hemor-
rhagic cystitis and/or proteinuria [25].
Afterward, the treatment is considered suc-
cessful if stabilization (no improvement nor dete-
rioration) of respiratory symptoms and PFT is 
achieved. However, mild to moderate improve-
ment could occur.
Cyclophosphamide is associated with high tox-
icity profile, which is a concern for both patients 
and physicians. The new preferred regimen is 
mycophenolate mofetil (MMF) (oral or intrave-
nous) along with glucocorticoids. Both regimens 
showed significant reduction in loss of pulmonary 
function, but mycophenolate mofetil has safer pro-
file with less side effects, better  toleration, and the 
improvement last longer with (MMF) than (CYC). 
Table 7.4 Pleural fluid analysis for rheumatic diseases
RA SLE Sjogren
Appearance Variable Clear N/A
WBC <5000 cells/mm3 <5000 High 
lymphocytes
Glucose Low (<1.6 mmol/L) Normal/low Normal
Protein High (>30 g/L) Low High
Cholesterol >5.18 mmol/L N/A N/A
RBC 0 0 N/A
pH Low (< 7.3) N/A Normal
Cytology Positive tadpole cells N/A N/A
Complement Low Low Low
RF >240 IU/mL (titer 
>1:320)
None N/A
ANA +/− Positive (titer >1:160 is more sensitive than 
specific)
N/A




Immune complex High High N/A
ANA Anti-nuclear anti-body, LDH Lactate dehydrogenase, RBC red blood cell, RF rheumatoid factor, N/A not 
applicable
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Although the MMF duration in the last study was 
for 2 years, most of expertise recommend to con-
tinue the treatment for several years [26].
The second modality of treatment is lung 
transplantation. It is considered when drug ther-
apy fails. The 1-year survival is 68–93% [27, 28]. 
Absence of GERD may play a great role in 
improving survival [27].
Last treatment modality is hematopoietic stem 
cell transplantation. It is still an experimental 
therapy. However, great improvement in FVC 
within 2 years occurred when using this method. 
Furthermore, it shows superiority to IV cyclo-
phosphamide [29].
Aspiration Pneumonitis
A strong association between the degree of gas-
troesophageal reflux (GER) and the severity of 
ILD, which may raise the flag of micro- 
aspirations. However, it is still not clear whether 
the treatment of GER will improve or even pre-
vent ILD [30, 31].
7.6.1.2  Vascular Diseases
SSc-associated pulmonary arterial hypertension 
(SSc-PAH).
Introduction
Pulmonary hypertension (PH) defined as mean 
pulmonary artery pressure (PAP) equals to 
or > 25 mmHg at rest. It can occur as a complica-
tion of SSc itself, which is SSc-PAH, or as a com-
plication of ILD caused by SSc. Here, SSc-PAH 
is discussed.
It presents in 12–38% of SSc patients. Risk 
factors are increased number of telangiectases, 
lcSSc with anti-centromere antibody, dcSSc with 
ANA (dcSSc alone is less commonly associated 
with PAH), progressive decline in DLCO, and 
exercise-induced PAH on right heart 
catheterization.
Presentation
Patients usually present with exertional dyspnea, 
lethargy, and fatigue, which are the most common 
symptoms, and, less frequently, could be exer-
tional angina, exertional syncope, symptoms of 
right ventricular failure (RVF) (due to Cor pulmo-
nale), cough, hemoptysis, and Ortner’s syndrome 
(horsiness due left recurrent laryngeal nerve palsy 
caused by pulmonary artery compression or other 
cardiac cause). On physical examination, if there 
is no right ventricular hypertrophy (RVH), loud 
pulmonary component of second heart sound is 
heard. However, If right ventricular hypertrophy 
present, then, parasternal heave, forth heart sound, 
prominent A wave in jugular venous pressure 
(JVP) could be noticed. Moreover, ascites and 
lower limb edema may be present. Recent studies 
showed that combination therapy with phosphodi-
esterase type 5 inhibitors or combination between 
(ERA/PDE5I) is superior than endothelin receptor 
antagonist alone by decreasing deterioration time, 
recent European guidelines recommend combina-
tion initial therapy, But it still has not established yet 
in American guidelines [32]. 
Screening
In regard to screening for SSc-PAH, physicians 
could use the same screening method as any 
patient newly diagnosed with SSc (Fig.  7.1). 
Also, other indications for earlier echocardiogra-
phy screening are when symptoms, signs, and 
PFT findings are suggestive of PAH are present, 
such as DLCO <70% predicted or FVC/DLCO 
>1.6 and echocardiography with Doppler study 
findings are suggestive of PAH such as RVH, 
right ventricular enlargement (the chamber 
itself), right atrial enlargement, tricuspid regurge 
(TR), mid-systolic notch on the pulmonary artery 
Doppler flow tracing and shifting of the interven-
tricular septum toward the left ventricle, pulmo-
nary artery systolic pressure (PASP) >50 and the 
maximum tricuspid regurgitant jet velocity 
(TVR) >3.4.
Diagnosis
The SSc-PAH diagnosis is confirmed by right 
heart catheterization when mean pulmonary arte-
rial pressure equals to or > 25 mmHg at rest and 
mean pulmonary capillary wedge pressure 
(PCWP) <15 mmHg after excluding other causes 
of PH such as having normal ventilation/perfu-
sion scan (V/Q scan) (to rule out chronic 
 thromboembolic disease), negative HIV and hep-
atitis serology, normal or mild ILD findings on 
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HRCT (to rule out significant ILD), and normal 
sleep study in the appropriate clinical context.
Prognosis
Although the advancement of treatment during 
the past decade has improved the survival, it’s 
still worse than that in idiopathic PAH (IPAH) 
[33]. The 3-year survival is estimated to be 64% 
[33]. Moreover, early detection has a good impact 
in survival [34]. On the other hand, SSc-PAH 
associated with ILD has worse prognosis than 
that of SSc-PAH alone. The 3-year survival for 
SSc-PAH with ILD is 47% [35].
Treatment
In general, therapy is usually directed to the 
underlying cause of PAH and to the PAH itself if 
it persisted. However, since there is no specific 
treatment for SSc, the therapy will be directed to 
PAH itself. Nevertheless, many issues are 
involved in the treatment of SSc-PAH such as the 
decision of initiation of treatment, treatment 
modalities, duration of treatment, and follow-up 
of therapy.
The decision of initiation of treatment is all 
symptomatic patients defined by the World 
Health Organization (WHO) functional classes 
of II or more (i.e., at minimum to have dyspnea 
when doing ordinary activity). This category 
should receive treatment.
Treatment modalities are PAH specific drug 
therapy, supportive therapy, and lung transplanta-
tion. To start with, for the PAH specific drug ther-
apy, there is no single drug that has shown 
superiority for treatment in SSc or other CTDs in 
general.
However, the drug classes that have shown effect 
in CTD-PAH are endothelin-1 receptor antagonists 
(ERA), phosphodiesterase type 5 (PDE5) inhibi-
tors, and prostanoids (PGI-2). All of them improved 
the 6-min walk test (6MWT) [36]. Clinicians 
should, most of the time, start with monotherapy 
then step up for a combination if no improvement is 
observed. Furthermore, the choice for PAH-specific 
drug therapy depends on physician expertise, 
patient preference, and cost-effectiveness.
Also, supportive therapy should be consid-
ered for most patients. It consists of supple-
mental oxygen for patients with hypoxemia, to 
keep oxygen saturation  >  90%. In addition, 
diuretics could be given for patients with fluid 
overload. Moreover, anticoagulation might be 
considered for all patients based on non-ran-
domized trials, especially those who receive IV 
prostaglandins (due to the risk of catheter 
related thrombosis) but also one should weigh 
risk of bleeding against benefits [37]. 
Furthermore, warfarin is the drug of choice to 
reach a therapeutic INR of 1.5–2.5 [37]. On top 
of that, exercise, with a special training pro-
gram (bicycle ergometer at lower and higher 
workload for 15–30  min/day, dumbbell train-
ing [0.5–1 kg], and respiratory training) could 
be advised. However, heart rate should be 
monitored not to reach above 120 beat/min and 
the oxygen saturation not to fall <90% (if a 
supplemental oxygen is given). These exer-
cises has been tested and showed improvement 
in 6-min walk test (6MWT) [38, 39]. Lastly, 
digoxin is not usually used in PAH because 
there are no enough data to support its effec-
tiveness [37]. Nevertheless, it is usually used 
in patients with COPD and biventricular fail-
ure [40].
As a last resort, when drug therapy fails, lung 
transplantation should be considered, specially, 
in patients with severe symptoms. The 2-year 
survival reaches 71% [27].
7.6.1.3  Airway Disease
Bronchiectasis
It is a common finding on HRCT, but usually not 
clinically manifested, reaching 59% of SSc 
patients, and this may be attributed to the high 
number of GERD and aspirations [41]. Clinicians 
should pay attention to bronchiectasis when 
intended to start immunosuppressive therapy due 




Occurs in about 7% of SSc patients. Usually 
asymptomatic and occasionally associated with 
pericardial effusion. It resolves spontaneously.
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Spontaneous Pneumothorax
It’s a rare complication of SSc. Patients present 
with shortness of breath and/or pleuritic chest 
pain. The management depends on cardiopulmo-
nary status and pneumothorax size on 
CXR. Supplemental oxygen and air drainage by 
needle aspiration or chest tube insertion should 
be considered depending on the clinical context.
Respiratory Muscle Weakness
This could lead to respiratory failure with or 
without hypercapnia [43, 44].
7.6.1.4  Systemic Lupus Erythematosus 
(SLE)
Background
SLE is a multisystem autoimmune disease and 
affects mostly women in childbearing age. 
Pulmonary involvement, manifested clinically or 
radiologically, occurs in around 25% of all SLE 
patients. They usually happen later in the course 
of the disease. Furthermore, most common pul-
monary diseases are pleuritis (78%) followed by 
bacterial infections (58%), alveolar hemorrhage 
(26%), distal airway alterations (21%), opportu-
nistic infections (14%), and, lastly, acute or 




• Presents as pleuritic chest pain, shortness of 
breath, and fever. On physical examination, 
pleuritic friction rub may be heard. It is a clin-
ical diagnosis. However, pleural biopsy could 
be done but rarely needed. If so, it shows 
peculiar immunofluorescent pattern character-
ized by staining of nuclei with anti-IgG, anti- 
IgM, and anti-C3 [45]. Treatment usually 




It tends to be bilateral and small to moderate in 
size; however, large effusion may occur. It usu-
ally presents with shortness of breath, cough, 
and/or chest pain. Nevertheless, sometimes, it 
could be asymptomatic. Physical examination 
may show dullness on percussion, decrease tac-
tile fremitus, decrease intensity of breath sound, 
and decrease vocal resonance.
Diagnosis
Although the following investigations could lead 
to the diagnosis of pleural effusion to be second-
ary to SLE, physicians should always rule out 
other common/serious causes of pleural effusion 
such as heart failure, parapneumonic effusion, 
and pulmonary embolism if suspected.
Chest radiograph shows blunting of costo-
phrenic angle. Furthermore, pleural fluid analysis 
is shown in Table 7.4.
Treatment
Small asymptomatic pleural effusion needs no 
treatment. It resolves spontaneously. On the other 
hand, mild symptomatic effusion usually responds 
to NSAIDs [46], while severe symptomatic effusion 
is treated with steroids. Also, if patient is currently 
on steroids, increasing the dose may be required 
[46]. In refractory cases, tetracycline or talc 
pleurodesis might be an alternative option [47–49].
7.6.1.5  Parenchymal Lung Disease
Acute Lupus Pneumonitis (ALP)
Introduction
It’s an uncommon but serious complication of 
SLE, which occurs in 2–8% of patients. It affects 
younger and newly diagnosed SLE patients and 
also could manifest as a fulminant pattern in 
pregnant women.
Presentation
Acute-onset fever, cough, shortness of breath, 
pleuritic chest pain, and, occasionally, hemopty-
sis. Physical examination shows signs of hypoxia 
and bibasilar crackles.
Diagnosis
It’s a diagnosis of exclusion (Fig.  7.5). 
However, BAL, with or without transbron-
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chial biopsy, must be done to rule out infec-
tion. Blood tests may show high levels of 
anti-Ro (anti-SS-A), which are associated 
with more likelihood of ALP.  Chest radio-
graph may show bilateral alveolar infiltrates 
with predominance in lower lung fields. Also, 
pleural effusion may occur in half of the 
cases. Rarely, chest radiograph could be nor-
mal or showing nodules. Chest CT may show 
diffuse ground glass opacities. BAL, when 
done, the sample should be sent for cell count 
and differential, bacterial, fungal, and viral 
cultures, cytology, pneumocystis pneumonia 
(PCP) stain, and acid-fast bacilli (AFB) 
smear, and culture in the appropriate clinical 
context. Transbronchial biopsy, when done, 
shows non-specific diffuse alveolar damage 
(DAD) with or without alveolar hemorrhage 
and capillaritis. Less common pathologic fea-
tures are alveolar edema, hyaline membrane 
formation, and immunoglobulin and comple-
ment deposition.
Treatment
Usually starts with empiric broad-spectrum anti-
biotics for 3 days. If no response, then, pulse ste-
roids (1 g methylprednisolone daily for 3 days) 
should be started. Furthermore, adding another 
immunosuppressive agents like cyclophospha-
mide (CYC) could be considered [50]. In refrac-
tory cases, intravenous immunoglobulin (IVIG), 
plasma exchange, or rituximab may help 
[51–53].
Prognosis
It has poor prognosis with mortality reaching 
50% [54]. BAL showing eosinophilia and neutro-
philia have worse prognosis than lymphocytosis.
7.6.1.6  Diffuse Alveolar Hemorrhage 
(DAH)
Introduction
The prevalence ranges from <2% to 5.4% and it 
tends to recur. Furthermore, it occurs more fre-
quently in lupus nephritis patients and with high 
levels of serum anti-DNA antibody.
Presentation
Usually presents with acute shortness of breath, 
cough, fever, and hemoptysis, although absence 
of hemoptysis dose not rule out DAH. The mean 
duration from onset of DAH to resolution of 
radiographic finding is 7.8 days. Physical exami-
nation reveals signs of respiratory distress and 
hypoxia.
Diagnosis
Blood tests may show acute drop in hemoglobin 
and low complement level. Chest radiograph may 
show bilateral alveolar infiltrates. But also could 
happen unilaterally in 18% of patients. Chest CT 
scan could show new bilateral ground glass opac-
ities and consolidation. Moreover, magnetic reso-
nance imaging (MRI) can suggest presence of 
blood. PFT show elevated DLCO (>130% pre-
dicted) due to excess hemoglobin in alveolar 
space. BAL is essential to rule out infection. 
Furthermore, bloody sample under microscope 
suggests DAH if hemosiderin-laden macro-
phages are present. Transbronchial biopsy could 
be done in stable patients. This may reveal bland 
hemorrhage (72%) or capillaritis (14%). Both of 
them are associated with intra-alveolar hemor-
rhage and hemosiderin-laden macrophages. Also, 
immunoglobulin G (IgG), complement 3 (C3), or 
immune complex deposition occurs in 50% of the 
cases. Thoracoscopic lung biopsy is rarely 
needed.
Treatment
Supportive therapy (i.e., mechanical ventila-
tion) plays a major rule since most patients are 
admitted to the intensive care unit (ICU) [55, 
56]. However, if infection is ruled out or BAL 
suggest hemorrhage, physician should start 
pulse intravenous steroids (methylpredniso-
lone 1 g/day for 3  days) followed by 60 mg/
day of oral prednisone plus intravenous CYC 
every 4 weeks (the CYC could be started after 
discharge from hospital) [55, 56]. In refrac-
tory cases, plasmapheresis is an effective 
alternative, which improves survival. Also, 
rituximab has shown promising results 
[56–58].
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Prognosis
DAH has a very poor outcome with mortality 
ranges between 50% and 90% [55, 58].
7.6.1.7  Chronic ILD
Introduction
Occurs in around 9% of SLE patients [59, 60]. 
Moreover, the most common ILD patterns are 
NSIP, UIP, and lymphocytic interstitial pneumo-
nia (LIP).
Presentation
The initial presentation could be a dry cough. 
Other symptoms are shortness of breath and 
decreased exercise intolerance. Physical exami-
nation could reveal fine bibasilar crackles; how-
ever finger clubbing is rare.
Diagnosis
It is made by symptoms, signs, PFT, and HRCT 
collectively. Lung biopsy is not usually required 
unless such diagnosis is doubted. Chest radio-
graph may be normal at the beginning but then 
progresses to irregular linear opacities and 
marked interstitial markings. HRCT may show 
GGO without honeycombing in NSIP.  On the 
other hand, reticular pattern with basilar honey-
combing occurs in UIP with/without traction 
bronchiectasis. Moreover, 30% of asymptom-
atic patients could have abnormal HRCT find-
ings. PFT may show restrictive pattern with low 
DLCO.  Also, it does not correlate with the 
severity of ILD in HRCT.  BAL is helpful in 
rolling out infection. While biopsy needed to 
confirm the subtype of ILD when HRCT is 
controversial.
Treatment
In mild cases, systemic corticosteroid (predni-
sone 60  mg/day for at least 4  weeks) could be 
used [56]. However, for moderate to severe cases, 
a combination therapy of oral glucocorticoids 
and AZA is a choice [60]. Furthermore, in severe 
cases, a combination of oral glucocorticoids and 
CYC could be considered [60].
Prognosis
ILD associated with SLE has better prognosis 
compared to the idiopathic forms [61].
7.6.1.8  Pulmonary Vascular Diseases
Thromboembolic Disease
Introduction
Venous thromboembolic (VTE) events are well- 
known manifestations of SLE specially when 
antiphospholipid (aPL) antibodies are present. 
This, in turn, will establish the diagnosis of 
antiphospholipid syndrome. Patients diagnosed 
with antiphospholipid syndrome  are at risk of 
recurrent DVT, PE, chronic thromboembolic pul-
monary hypertension (CTEPH), abortions, DAH, 
and acute respiratory distress syndrome (ARDS). 
Furthermore, when small vessel occlusion occurs 
in three or more organs, the condition is known as 
catastrophic antiphospholipid syndrome (CAPS). 
SLE patients are at risk of VTE events with a prev-
alence of 9%. This percent would become as high 
as 42% if SLE patients had aPL. Moreover, aPL 
present in up to two thirds of SLE patients [62].
Presentation
Patients could present with deep vein thrombosis 
(DVT) or pulmonary embolism (PE). DVT pres-
ents with calf pain (usually unilateral), swelling, 
and redness. On the other hand, pulmonary 
embolism (PE) presents with shortness of breath, 
pleuritic chest pain, cough, and/or hemoptysis. 
Furthermore, CTEPH manifested as progressive 
shortness of breath and exercise intolerance.
Diagnosis
DVT is diagnosed by Doppler ultrasound (US). 
PE is confirmed by chest CT angiogram. 
Moreover, CTEPH needs all diagnostic proce-
dures needed to diagnose PAH.
Treatment
Long-term anticoagulation with warfarin is 
highly recommended with targeting INR of 2.0–
3.0. High-intensity warfarin (targeting INR 3.0–
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4.0) showed no superiority to moderate intensity 
[63]. Some clinicians use long-term low-dose 
aspirin as a primary prevention [64].
CAPS is usually treated by systemic glucocor-
ticoids, immunosuppressants, plasmapheresis, 
and/or IVIg in addition to anticoagulation [56].
Prognosis
For CAPS, the mortality reaches 50% [65].




For definition of PAH, please see SSc-PAH.
The duration of SLE, since diagnosis, does not 
correlate with the risk of development SLE- 
PAH.  Its prevalence varies between 0.5% and 
15% in SLE patients. Risk factors are Raynaud’s 
phenomenon, which occurs in 75% of SLE-PAH 
[54]; antiphospholipid antibodies (aPL), which 
present in 83% of SLE-PAH; and anti-U1 ribo-





Due to the rarity of PAH in SLE, annual echocar-
diogram screening should be directed to women 
in childbearing age, pregnant ladies, patients 
with Reynaud’s phenomenon, anticardiolipin 
antibody, and anti-U1 RNP antibody [66].
Treatment
All patients should receive supportive therapy as 
needed (See SSc-PAH). On the other hand, mild 
PAH patients should receive immunosuppressive 
therapy alone, while moderate to severe PAH 
patients should receive PAH-specific therapy 
with or without immunosuppressive therapy [56].
PAH-specific therapies are effective in SLE- 
associated PAH specially epoprostenol, bosen-
tan, sildenafil, ambrisentan, and tadalafil. They 
improved the 6MWT and functional class [67–
70]. Adding immunosuppressive therapy (e.g., 
IV CYC with or without oral glucocorticoids) 
showed improvement in 6MWT and lowered 
PAP [71–74].
Acute Reversible Hypoxia
It’s a rare complication of lupus, and patients 
usually present with acute and unexplained 
hypoxia and hypercapnia. Blood investigation 
may show high C3 levels. Chest radiograph could 
be normal. V/Q scan should show no evidence of 
PE.  Lastly, arterial blood gases (ABG) shows 
increase alveolar-arterial (A-a) PO2 gradient. 
Furthermore, it responds quickly to high-dose 
systemic corticosteroids [75, 76].
7.6.1.10  Airway Disease
Upper Airway Involvement
Introduction
It occurs in around 30% of SLE patients. Also, it 
involves laryngeal mucosal inflammation or 
ulceration, cricoarytenoiditis, vocal cord paraly-
sis, necrotizing vasculitis, and angioedema.
Presentation
Patients usually present with hoarseness and/or 
dyspnea. Moreover, they could develop angio-
edema symptoms such as lip and mouth swelling, 
dysphagia, odynophagia, and breathing 
difficulty.
Diagnosis
Chest radiograph and CT scan are usually nor-
mal. PFT may show flattening of the inspiratory 
or expiratory loop or both depending on the 
 location of the obstruction. Furthermore, 3-D 
reconstructive images are needed to locate the 
site of obstruction. Fibro-optic laryngoscopy or 
bronchoscopy is needed for direct visualization 
of the vocal cord.
Treatment
Corticosteroids are of benefit in laryngeal muco-
sal inflammation or ulceration and vocal cord 
paralysis [77, 78]. However, in refractory cases, 
infectious causes should be considered (e.g., 
Haemophilus influenzae and Streptococcus. 
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Other rare pathogens are Histoplasma, 




HRCT findings suggestive of bronchiectasis 
occur in around 21% of SLE patients. However, 
patients usually are asymptomatic [79].
Bronchiolitis Obliterans (BO)/Obliterative 
Bronchiolitis (OB)
It’s a rare complication of SLE, which is charac-
terized by severe airflow obstruction which is 
mostly irreversible. Patients usually present with 
progressive shortness of breath. Moreover, chest 
HRCT Shows mosaic attenuation pattern that 
gets accentuated in the expiratory images. PFT 
shows obstructive pattern. Biopsy is rarely 
required. Furthermore, anticholinergics were 
reported to have favorable outcome when com-
pared to systemic steroids and immunosuppres-
sive therapy [80, 81].
7.6.1.11  Muscle Involvement
Shrinking Lung Syndrome (SLS)
Introduction
It’s an uncommon disorder, with a prevalence of 
0.6–0.9% of SLE patients [80–82], characterized 
by unexplained dyspnea, decreased lung vol-
umes, elevated diaphragm, and restrictive PFT 
pattern in the absence of parenchymal lung 
disease.
Presentation
Patients usually present with shortness of breath 
aggravated by being in supine position. Pleuritic 
chest pain is also reported. Physical examination 
reveals diminished breath sounds at the lung 
bases with or without crackles.
Diagnosis
Chest radiograph and HRCT show elevation of 
both diaphragms and basal atelectasis without 
evidence of parenchymal lung disease. PFT 
shows restrictive pattern with preservation of 
DLCO when corrected for alveolar volume (DL/
VA). Also, respiratory muscle assessment could 
show reduced maximal inspiratory pressure 
(MIP) and stable maximal expiratory pressure 
(MEP).
Treatment
Oral glucocorticoids with or without other immu-
nosuppressive therapy showed to be effective 
[83, 84]. Other options are AZA, methotrexate 
(MTX), CYC, and rituximab [82–87].
Prognosis
SLS has good prognosis when treated. Moreover, 
respiratory failure rarely occurs [64, 88].
7.6.1.12  Associated Lung Disorders
Adult Respiratory Distress Syndrome 
(ARDS)
It occurs in 4–15% of SLE patients. The most 
common cause of ARDS in SLE is sepsis. Other 
causes are ALP, DAH, and CAPS. Furthermore, 
it occurs more frequently in younger age group 
and is more progressive than in non-SLE patients. 
ARDS-related mortality contributes to 30% off 
all lupus deaths. Furthermore, mortality could 
reach up to 70%. The treatment is mainly sup-
portive care.
Infectious Complications
Most of the SLE infectious complications happen 
in patients who are on immunosuppressive ther-
apy. It accounts for 30–50% of all SLE deaths. 
Furthermore, bacterial infections are the most 
common (75%) followed by mycobacterial 
(12%) then fungal infections (7%) and lastly 
viruses (5%). It could mimic ALP or DAH, so, 
careful diagnostic approach is recommended. 
The diagnosis is usually conducted by chest 
radiograph and HRCT and also BAL to differen-
tiate infectious from non-infectious causes 
(Fig. 7.5).
Pneumocystis Pneumonia (PCP) 
Prophylaxis
Since the incidence of PCP in SLE patients is 
very low (0.6%), it is not clear if all SLE patients 
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on immunosuppressants should receive prophy-
laxis. But, at least patients at highest-risk of PCP 
infection (e.g., who receive biologic agents or 
immunosuppressants in addition to high dose 
daily steroid) should do so. The prophylactic 
drug of choice is trimethoprim-sulfamethoxazole 
(TMP-SMX) [89].
Lung Cancer
SLE patients are at increased risk of developing 
lung cancer. Furthermore, histologically, adeno-
carcinoma is the most common type (similar to 
the general population). However, there is a ten-
dency for uncommon thoracic malignancies like 
carcinoids and bronchoalveolar carcinoma.
Drug Reactions
Please refer to Table 7.5.
7.7  Rheumatoid Arthritis (RA)
7.7.1  Introduction
RA is an autoimmune disorder characterized by 
joint involvement in a chronic and symmetrical 
fashion. Pulmonary involvement considered one 
of the most frequent extraarticular manifestations 
together with the cutaneous involvement. 
Furthermore, around 10–20% of RA deaths are 
attributed to pulmonary causes. The most com-
mon pulmonary involvements are ILD, airway 
disease, rheumatoid nodule, and pleural 
effusion.
 1. Pulmonary manifestations.
 2. Parenchymal involvement.
 3. Interstitial lung disease (ILD).
7.7.1.1  Introduction
It’s the most common pulmonary manifesta-
tion of RA with a prevalence of 20–63% radio-
graphically by HRCT. And up to 9.4% of the 
patients have clinically significant symptoms. 
Usually happens in a well-established RA dis-
ease. However, in around 20%, it could pre-
cede it. The most common patterns are UIP 
followed by NSIP then desquamative intersti-
tial pneumonia (DIP) and organizing pneumo-
nia (OP). Also, risk factors for that are older 
age group, male gender, history of cigarette 
smoking, high titer of rheumatoid factor (RF), 
and anti-cyclic citrullinated peptides (anti-
CCP) [90].
7.7.1.2  Presentation
Symptoms start to appear when lung function is 
greatly impaired. Moreover, pleuritic chest pain 
occasionally accompanied ILD symptoms. 
Please see SSc-ILD for more information.
7.7.1.3  Diagnosis
Chest radiograph might be normal in affected 
patients especially in early disease [91]. However, 
chest HRCT is the most important tool to diag-
nose early RA-ILD. UIP manifests as reticulation 
and honeycombing, while NSIP presents with 
GGO with/without bronchiectasis. The correla-
tion between the radiographic and the histopatho-
logic pattern is poor in NSIP [86]. Also, OP 
appears as diffuses patchy alveolar opacity and 
GGO.  It’s common to see different patterns 
simultaneously [90]. PFT may show restrictive 
pattern with declining of DLCO to be the earliest 
PFT sign [92, 93]. BAL might be utilized to rule 
out opportunistic infections, DAH, and/or drug 
reactions [86, 94, 95]. Biopsy is not recom-
mended as a regular investigation unless the 
radiologic pattern is unclear and another treat-
ment could make a difference [90].
7.7.1.4  Treatment
Patients with mildly progressive disease should 
receive high dose prednisone [96]. However, 
there are anecdotal reports of using daily oral 
CYC and corticosteroids in rapidly progressive 
extensive disease [97]. There is also another regi-
men  of monthly IV CYC combined with cortico-
steroids. In refractory cases, physician could use 
rituximab, infliximab, or tocilizumab. The rou-
tine use of these agents has not been established 
yet due to the lack of strong evidence and the 
questionable safety, which is under investigation 
[98]. Of note, PCP prophylaxis should be given.
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7.7.1.5  Prognosis
In general, RA-ILD has mild and slowly progres-
sive nature. However, spontaneous resolution 
could happen [99].
When DLCO is <54%, it is suggestive of 
worse prognosis [99]. On the other hand, NSIP 
has better prognosis than UIP [100, 101].
7.7.2  Pleural Diseases
7.7.2.1  Pleural Effusion
Introduction
It’s the second most common pulmonary involve-
ment in RA (after ILD) with a prevalence ranges 
between 5% and 22%. It usually occurs unilater-
ally and small to moderate in size; however, large 
effusions may occur. Moreover, it is associated 
with RA flares. Risk factors are smoking, previ-
ous pleurisy, rupture of subpleural nodule, and 
high effusion protein levels (prevents 
resorption).
Presentation
Mostly asymptomatic, but if not, dyspnea, fever, 
and chest pain (if pleurisy) are the main manifes-
tations [102].
Diagnosis
Chest radiograph shows blunting of costophrenic 
angles. Chest CT scan is more sensitive than 
chest radiograph. Furthermore, thoracentesis, if 
done, pleural fluid analysis could be diagnostic as 
following (Table  7.4). Pleural biopsy may be 
considered when TB or malignancy is suspected 
or when thoracentesis is not diagnostic. Also, the 
parietal pleura are the mainly involved part rather 
than the visceral one. When biopsy is done, it 
shows absence of the normal mesothelial cells 
covering the pleura, and they are replaced by 
pseudostratified layer of epithelioid cells with 
giant cells [103].
Treatment
If asymptomatic, mostly it will resolve spontane-
ously in up to 36 months. However, if symptom-
atic, for acute relief, a therapeutic thoracentesis 
could be done. If no need for acute treatment, 
then start with NSAIDs. After that, if failed, 
moderate dose of oral glucocorticoids (10–20 mg 
prednisolone daily), intrapleural corticosteroids, 
fibrinolytics, or immunosuppressive could be 
given. In refractory cases, pleurodesis (mechani-
cal or chemical) is an option.
Complications
The following complications may develop if pleu-
ral effusion is not treated. First of all, pleural 
fibrosis and lung entrapment, which could be 
treated by decortications. Moreover, broncho-
pleural fistula could develop, which intervention 
with video-assisted thoracoscopy (VATS) did not 
show effectiveness in RA. An open approach with 
thoracotomy and direct closure may be helpful. 
Lastly, empyema which can be treated with anti-
biotics (Usually it’s polymicrobial infection) and 
drainage through chest tube. Worth mentioning, 
that bronchopleural fistula has been reported in 
the vast majority of the empyema cases in RA.
7.7.3  Pulmonary Vascular Diseases
7.7.3.1  PAH
It has lower prevalence than in other CTDs [104]. 
For presentation, diagnosis and treatment (see 
PAH in SSc).
7.7.3.2 DAH
It’s a very rare complication of RA [105]. “Risk 
factors are treatment with infliximab, lefluno-
mide, and rituximab [106–108]. For presentation, 
diagnosis, and treatment, please see DAH in 
SLE.
7.7.4  Airway Diseases: Upper 
Airway Diseases
7.7.4.1  Cricoarytenoid Arthritis
Introduction
The cricoarytenoid joint function is to abduct and 
adduct the vocal cord when a person speaks. 
Good history taking could reveal upper airway 
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symptoms in around two thirds of RA patients. 
The prevalence ranges between 26% and 55% 
with female predominance. Furthermore, joint 
abnormalities such as prominence, erosions, 
abnormal positioning of the vocal cord, and sub-
luxation may occur [109].
Presentation
Patients usually presents with hoarseness of the 
voice (reaching 30%), dyspnea, sore throat, full-
ness sensation in the throat, shocking, stridor, 
dysphagia, and odynophagia.
Diagnosis
PFT shows fixed or variable upper airway 
obstruction. CT scan shows the abnormalities 
such as prominence, erosions, abnormal position-
ing of the vocal cord, and subluxation. 
Laryngoscopy may show vocal cord 
dysfunction.
Treatment
When patients presented with chronic symptoms, 
clinicians should start with medical treatment 
such as systemic or intra-articular steroid, which 
both have shown benefit. However, surgical 
options (e.g., tracheostomy, arytenoidectomy, 
arytenoidopexy) should be considered only if 
medical treatment failed [110].
On the other hand, patients may present with 
acute manifestations such as severe stridor and 
should get emergent tracheostomy [111].
Prognosis
Excellent results occur with aggressive therapy 
[112].
7.7.4.2  Vocal Cord Rheumatoid Nodule
Could mimic squamous cell carcinoma [111].
7.7.5  Airway Diseases: Lower 
Airway Diseases
7.7.5.1  Bronchiectasis
Prevalence ranges between 30% and 58% when 
elected by HRCT.  However, only 1–5% of RA 
patients are symptomatic. Bronchiectasis usually 
is a late manifestation of RA, but it can precede 
the articular involvement. Furthermore, presenta-
tion and management is like any other bronchiec-
tasis without rheumatoid arthritis.
7.7.6  Airway Obstruction 
and Bronchial Hyperreactivity
It occurs in about 60% of RA patients when doc-
umented by spirometry. Recurrent airway infec-
tions and smoking could precipitate airway 
disease in RA.  Patients usually present with 
wheeze and productive cough. Furthermore, PFT 
may shows obstructive pattern. However, HRCT 
is more sensitive than PFT in detecting the 
obstruction. It shows air trapping, attenuation in 
lung heterogeneity, and bronchiectasis. The treat-
ments are mainly inhaled corticosteroids and 
bronchodilators.
7.7.6.1  Bronchiolitis Obliterans (BO)
Introduction
It’s a clinically progressive small airway dis-
ease, which is characterized by narrowing, 
ulceration, and scarring of the respiratory and 
terminal bronchioles. The prevalence varies 
between 8% and 65%. Also, risk factors are 
female gender, long- standing RA, 
D-penicillamine, gold salt, and methotrexate 
use [113, 114].
Presentation
Progressive dyspnea and dry cough are the most 
common presentations, while physical examina-
tion reveals inspiratory crackles and squeaks.
Diagnosis
PFT shows progressive irreversible airflow 
obstruction. However, HRCT is more sensitive 
than PFT in detecting the disease. It may show air 
trapping (mosaic pattern of regions of low attenu-
ation which get accentuated on expiratory 
images). BAL is done to rule out infections if 
suspected, while biopsy shows airway narrowing, 
ulceration, scarring, and lymphoplasmacytic 
infiltrate.
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Treatment
Physicians should stop offending agent and may 
start oral prednisone, some studies suggested the 
use of IV CYC  as well [115, 116] or stop offend-
ing agent and start low dose oral macrolide 
(erythromycin 400–600 mg/day, clarithromycin 
200–400 mg/day or azithromycin) for 6 months 
may be used as improvement was shown in the 
treatment of diffuse panbronchiolitis [117, 118].
Prognosis
Usually carries poor prognosis specially when 
using corticosteroids only. Thus, adding CYC or 
trying macrolides may be beneficial.
7.7.6.2  Follicular Bronchiolitis
Introduction
The bronchioles are invaded by lymphocytic, 
plasmacytic, and hyperplasic lymphoid follicles, 
and reactive germinal cells infiltrates. It has some 
overlap with COP and BO [114].
Presentation
Patients usually present with dyspnea and also 
may present with fever and cough.
Diagnosis
Chest radiograph may show reticular or reticulo-
nodular opacities. Furthermore, HRCT shows 
bilateral centrilobular and peribronchial nodules 
associated with areas of GGO.
Also, PFT may show obstructive, restrictive, 
or both patterns. DLCO is usually decreased. 
BAL is done to rule out infections. Biopsy shows 
bronchioles, which are invaded by lymphocytic, 
plasmacytic, hyperplasic lymphoid follicles, and 
reactive germinal cells infiltrates.
Treatment
May start with corticosteroid then after taper-
ing starts oral macrolides (erythromycin, clar-
ithromycin, or azithromycin) for up to 1 year 
[119].
Prognosis
Follicular bronchiolitis has relatively good prog-
nosis when treated.
7.7.7  Rheumatoid Nodule and its 
Complications: (Necrobiotic 
Nodule)
7.7.7.1  Rheumatoid Nodule
Introduction
Up to 32% of rheumatoid nodule occurs in the 
lungs. Also, because the most common site in the 
respiratory system is subpleural or interlobular, it 
could present by many different ways such as 
pneumothorax, cavities, pleural effusion, empy-
ema, and bronchopleural fistula. Furthermore, it 
could be solitary or multiple nodules. On the 
other hand, radiologically, it could mimic non- 
small cell lung cancer. So, physicians should be 
meticulous when approaching such patients spe-
cially when there is history of smoking. Also, his-
tologically, it has a great overlap with 
granulomatous diseases. For that, biopsy should 
be interpreted very carefully [120]. Risk factors 
for rheumatoid nodule are with male gender, pos-
itive rheumatoid factor (RF), long-standing dis-
ease (but may precede the diagnosis of RA), and 
smoking.
Presentation
Mostly asymptomatic. However, if symptomatic, 
it depends on the complication, e.g., cavities 
present with hemoptysis, pneumothorax presents 
with dyspnea and chest pain, pleural effusion 
presents with dyspnea, empyema presents with 
dyspnea and fever, and bronchopleural fistula 
presents with productive cough, dyspnea, and 
fever occasionally.
Diagnosis
Chest radiograph may show nodule but always 
should compare with previous chest radiographs 
to notice any changes in size or shape. Also, 
HRCT will give better details and physician 
should look for size, shape, lymph nodes, and 
effusions. It could be solid or as a cavity.
Treatment
If no complications, spontaneous resolution is 
the usual natural history. Moreover, rituximab 
has shown effectiveness in its resolution. 
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However, if complicated, treat accordingly (e.g., 
if secondary pneumothorax happened, it’s better 
to perform surgical intervention to prevent 
recurrence).
Rheumatoid Nodulosis
It is multiple rheumatoid nodules in different 
places. Risk factors are methotrexate, etanercept, 
and leflunomide use. Actually, it could lead to the 
same presentations the rheumatoid nodule does. 
Furthermore, the treatment is usually to stop the 
offending drug and start hydroxychloroquine, 
D-penicillamine, colchicine, or sulfasalazine.
7.7.7.2  Caplan Syndrome (Rheumatoid 
Pneumoconiosis)
Introduction
It occurs in RA patients who get exposed to coal, 
silica, asbestos, and ceramics industry and roof 
tiles products. Furthermore, it characterized by 
rapid-onset lung nodules and could mimic TB or 
neoplasm. It occurs more commonly in Europe 
than in the United States. Also, it’s more common 
in positive RF patients and in male.
Presentation
Most of the time patients are asymptomatic 
unless complicated by pneumothorax, pleural 
effusion, or progressive massive fibrosis, which 
is uncommon; they would present with dyspnea 
and/or chest pain. Also, rarely, patients may pres-
ent with hemoptysis or Aspergillus colonization.
Diagnosis
Chest radiograph shows well-defined nodules 
starting from 0.5 cm in diameter and larger. Also, 
it could cavitate or calcify. Usually present in 
lung periphery [121]. HRCT may have a role in 
following up and detection of changes. Biopsy, 
since it could mimic TB or neoplasm, it is often 
done specially when there is high index of 
suspicion.
Treatment
There is no specific treatment, although some 
studies showed improvement when using cortico-
steroids when the lesions are compressive or rap-
idly progressive [122]. However, if complicated, 
treat accordingly.
Prognosis
It takes few weeks or months until nodules reach 
the final size. Usually, they remain at the final 
size for many years or may heal but leave behind 




It’s clear that lung infections is increased in RA 
patients since pneumonia is twice more common 
than in general population. However, it’s very 
difficult to make sure if the risk of infection is 
due to RA itself or the immunosuppressive agents 
used to treat RA.
Immunosuppressive agents and risk of 
infection:
• Corticosteroids: It increases the risk of pneu-
monia by dose-depending mechanism. For 
most of patients, a dose of more than 10 mg/
day is sufficient to cause it [123–126].
• MTX: With or without corticosteroids, it 
makes patients at risk of developing opportu-
nistic infections, e.g., PCP and disseminated 
histoplasmosis [124, 127]. Usually occurs in 
the first 2 years of initiation the MTX [124].
• Anti-tumor necrosis factor-alpha (TNF-a): 
Exposes patients to risk of many opportunistic 
infections, most importantly Mycobacterium 
tuberculosis (TB). Others like coccidioidomy-
cosis, histoplasmosis, listeria, aspergillus, and 
norcodia have been reported [128].
7.7.8.2  Latent Tuberculosis Infection 
(LTBI) Screening [129]
Before initiating the treatment with any of the 
following biologic agents (adalimumab, certoli-
zumab pegol, etanercept, infliximab, golimumab, 
abatacept, rituximab, or tocilizumab) a TB skin 
testing or interferon gamma release assay (IGRA) 
should be done to screen for latent TB infection 
(LTBI) regardless of the presence or absence of 
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TB risk factors. If negative results without pres-
ence of risk factors, then starting the treatment 
with the biologic agent is permissible. If negative 
results with the presence of TB risk factors, the 
physician should repeat the test in 1–3 weeks. If 
results are positive, CXR should be done. If nega-
tive CXR for TB signs, this is latent TB infection 
(LTBI), and referral to an infectious disease (ID) 
specialist should be undertaken. In this situation, 
the physician can initiate the treatment with the 
biologic agent after 1 month of starting the treat-
ment of the LTBI. If positive CXR, then do spu-
tum stain and culture for TB.  If negative, it is 
LTBI. But if the sputum tested positive for TB, 
refer the patient to an ID specialist to start the 
treatment for active TB infection [129]. Of note, 
if patient is already on glucocorticoids, indura-
tion of 5 mm is considered positive [90].
For further reading, please see Infectious 
Disease Chap. 11.
7.7.8.3  Cancer
RA patients are at increased risk for developing 
lung cancer and lymphoma. The reason is not 
clear. But, a proposed theory could be due to RA 
itself, smoking, immunosuppressive therapy, or 
because RA is a middle age disease, which equals 
to the age at which cancers usually detected. 
Once mediastinal lymph node is detected, biopsy 
has to be undertaken as soon as possible.
7.7.8.4  Myopathy and Muscle 
Weakness
Introduction
Usually happens due to medication toxicity, 
rheumatoid vasculitis, and rheumatoid myositis. 
Physicians should suspect it when patients have 
progressive dyspnea with unclear cause and no 
improvement with treatment. Risk factors are the 
use of D-penicillamine and hydroxychloroquine.
Diagnosis
Blood tests show creatine-kinase (CK) within the 
normal limits. PFT show restrictive pattern. Also, 
FVC and VC in supine position is reduced by 
more than 10% than in upright. Furthermore, 
maximal inspiratory pressure (MIP) and maximal 
expiratory pressure (MEP) are reduced. DLCO is 
normal unless another pathology present. Biopsy 
may be needed to confirm the diagnosis.
7.7.8.5  Fibrobullous Disease
It’s a rare complication of rheumatoid arthritis and 
usually occurs in the apical part of the lung. It 
could be a complication of a rheumatoid nodule 
even in the absence of a radiological evidence.
7.7.8.6  Amyloidosis
Secondary amyloidosis, which involves lungs, 
has been reported. It could present as nodules, 
ILD, or tracheobronchomalacia.
7.8  Sjogren Syndrome (SS)
7.8.1  Background
It’s an autoimmune disease characterized by 
involvement of exocrine glands through infiltra-
tion of lymphocytes. A clinically significant pul-
monary manifestation occurs in around 9–24% of 
SS patients. Also, pulmonary involvements in 
asymptomatic SS patients who were detected by 
PFT, CT scan, or BAL reach 75% of patients. 
Also, pulmonary manifestations usually occur 
late in the disease course. Furthermore, if they 
were clinically significant, it could increase the 
risk of mortality by fourfold [130]. Risk factors 
for pulmonary involvement are positive rheuma-
toid factor, hypergammaglobulinemia, positive 
anti-Ro and anti-La, and decreased FVC and 
FVC1, smoking, elderly patients, and male sex. 
Overall, rituximab is a promising drug to treat SS 
and its extra-glandular manifestations (because it 





Around 18.5% of SS patients complain of 
nasal crusting. It is found in 50% during phys-
ical exam. The treatment usually consists of 
the use of room humidifiers and saline nasal 
spray as needed.
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7.8.2  Epistaxis
It occurs in around 31.8% of patients with 
SS. The treatment is the same as for any patient 
with epistaxis.
7.8.3  Hoarseness of the Voice
This occurs in about 1/3 of SS patients. The diag-
nosis is done by laryngoscopy, which shows most 
commonly dryness or thick mucus covering the 
vocal cords. However, rarely, the presence of 
Bamboo node, which is a transverse yellow or 
white submucosal lesion, occurs in the vocal 
folds. Also, granulomatous and non- 
granulomatous nodules have been reported.
7.8.4  Xerotrachea 
and Xerobronchitis
Usually developed due to structural of functional 
disability of the mucociliary cells to clear the 
thickened secretions. It occurs in around 17% of 
SS patients. Those usually presents almost always 
with dry cough. Chest radiograph, HRCT, and 
PFT are normal. On the other hand, recurrent 
bronchitis, bronchopneumonia, atelectasis, and 
peribronchial and peribronchiolar scarring and 
narrowing might occur as complications.
7.8.5  Lower Airway Disease
7.8.5.1  Follicular Bronchiolitis (FB)
Introduction
It’s a benign lymphoproliferative disorder, char-
acterized by hyperplasic lymphoid follicles dis-
tributed along the bronchioles and the 
peribronchiolar interstituim unlike the LIP, which 
involves the whole parenchyma. It is a histopath-
ological diagnosis; however, it could be sus-
pected by history, CT scan, and PFT results. It’s a 
common manifestation of SS.  Usually, patients 
present with cough, dyspnea, and sometimes 
fever.
Investigation
CT scan shows bilateral peribronchial and centri-
lobular nodules with size range between 1 and 
3 mm but could reach up to 12 mm. Other find-
ings are reticular opacities, GGO, and intratho-
racic lymphadenopathy. Furthermore, PFT 
usually shows restrictive pattern but also could be 
obstructive pattern or both. Biopsy shows hyper-
plasic lymphoid follicles distributed along the 
bronchioles and the peribronchiolar interstitium.
Treatment
Primary treatment of SS could be enough. 
However, systemic corticosteroid is shown to be 
effective [131].
Prognosis
Has good prognosis when treated with 
corticosteroid.
7.8.6  Chronic Obstructive 
Pulmonary Disease (COPD)
It is found to be more prevalent in SS patients 
through their disease course, especially smokers, 
who have 5 times higher chance compared to 
non- smokers to develop COPD [132].
7.8.7  Lung Parenchyma
7.8.7.1  ILD
Introduction
It’s the most common pulmonary manifestations 
of SS.  Furthermore, the most common subtype 
are NSIP followed by lymphcytic interstitial 
pneumonia (LIP) then UIP and lastly OP.  It is 




It occurs in about 28–61%. Presentation is usu-
ally chronic dyspnea. Chest radiograph may 
show bilateral interstitial infiltrates. PFT shows 
restrictive pattern with decreased DLCO. HRCT 
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shows GGO (with subpleural and basilar pre-
dominance). Furthermore, reticular abnormali-
ties with or without traction bronchiectasis could 
be found. Honeycombing happened with 
advanced disease. BAL is done to rule out infec-
tion when suspected. Biopsy shows uniform or 
homogenous pattern of cellular inflammation 
and/or fibrosis of the alveolar walls. Moreover, 
no need for treatment if patients are asymptom-
atic. However, if symptomatic with worsening 
symptoms, physician could give steroids (predni-
sone 1  mg/kg/day) [133]. Also, if refractory, 
immunosuppressive therapy (commonly 
AZA.  Rarely CYC or cyclosporines) could be 
used [134–137]. The prognosis depends on the 
extent of fibrosis. The less fibrosis, the better 
prognosis [132].
Lymphocytic interstitial pneumonia (LIP)
It’s one of the most common pulmonary manifes-
tations of SS.  It has potentials to progress into 
lymphoma. Thus, biopsy should always be con-
sidered if there is no response to standard ther-
apy. The prevalence is 17% among SS patients 
who develop ILD [133] with female predomi-
nance [138]. Patients usually present with dys-
pnea and cough and, also, less commonly fever, 
weight loss and night sweat. Blood tests show 
polyclonal hypergammaglobulinemia (80% of 
cases). Chest radiograph may show bilateral 
reticular or reticulonodular opacities, more com-
monly in the lower zones. HRCT shows diffuse 
GGO and walled cysts (in 50% of cases). Also, 
interlobular septal thickening, centrilobular nod-
ules, and bronchovascular bundle could be seen. 
PFT show restrictive pattern with low 
DLCO. BAL is done to rule out infection if sus-
pected. Again, since it could progress to lym-
phoma, biopsy should always be considered if 
there is no response to standard therapy. 
Histopathology reveals infiltration of the intersti-
tial septa and, sometimes, filling of the alveolar 
space by lymphocyte (B&T cells), plasma cells, 
and histiocytes. Patients usually treated with cor-
ticosteroids (start with prednisone 0.75–1.0 mg/
kg/day then taper slowly for the following 
3–6 months) [139–141]. Furthermore, initially, it 
responds well to corticosteroids. However, up to 
1/3 of patients die due to progression of disease 
or due to the infectious complications resulted 
from the intensive immunosuppression therapy 
[142]. Rarely it could resolve spontaneously.
7.8.8  Pleural Involvement
7.8.8.1  Pleural Effusion
It’s a very rare manifestation of SS.  Therefore, 
when present, one should think of a secondary 
cause (i.e., in the setting of secondary SS), e.g., 
RA or SLE. Usually occurs bilaterally, but a uni-
lateral presentation could happen. Pleural fluid 
analysis should be done for diagnosis (Table 7.4).
7.8.9  Pulmonary Vascular Disease
7.8.9.1  PAH
Introduction
It’s a rare complication and usually occurs due to 
pulmonary artery vasculitis. Also, occasionally, it 
co-exists with Raynaud’s phenomenon. Risk fac-
tors are Raynaud’s phenomenon, ILD, skin vas-
culitis, hypergammaglobulinemia, positive 
anti-Ro, positive RF, and positive antiribonucleo-
protein (anti-RNP) antibodies. Moreover, for 
 presentation and diagnosis (see PAH in SSc). The 
mainstay of treatment is the use of PAH specific 
treatment (endothelin receptor antagonists, phos-
phodiesterase type 5 inhibitors, or prostanoids) 




The risk of SS patients to develop lymphoma in 
general, not only pulmonary lymphoma, is 44 
times compared with healthy population [144], 
while pulmonary lymphoma prevalence is 1–2% 
among SS patients [145]. Furthermore, SS 
patients could develop benign lymphocytic infil-
tration, like in LIP, and this in turn could progress 
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to lymphoma [145]. This benign lymphocytic 
infiltration is characterized by polyclonal B and T 
lymphocytes proliferation. Moreover, the most 
common type of lymphoma in SS patients is non- 
Hodgkin’s lymphoma with a subtype of mucosa- 
associated lymphoid tissue (MALT) [145], while 
the most common pulmonary lymphoma is the 
low-grade extranodal marginal B-cell lymphoma 
of MALT type [145]. Risk factors are hypocom-
plementemia, cryoglobulinemia, vasculitis (pal-
pable purpura), and severe exocrine involvement 
at time of diagnosis of SS [145].
Presentation
80% are asymptomatic at time of lymphoma 
diagnosis due to the incidental finding in radio-
logical studies. If symptomatic: dyspnea, cough, 
weight loss, fatigue and sweat.
Diagnosis
Chest CT scan manifests as nodules (solitary or 
multiple), bilateral diffuse infiltrate, interstitial 
infiltration with slight lower zone predominance, 
mediastinal lymphadenopathy, and pleural effu-
sion (usually do not occur alone rather happen 
with the parenchymal involvement). Furthermore, 
biopsy shows most commonly a non-Hodgkin’s 
low-grade extranodal marginal B-cell lymphoma 
of MALT type [145]. Also, it has good prognosis 
with 5-year survival of more than 80% [146]. Of 
note, progression to high-grade lymphoma occa-
sionally happens [145].
Pseudolymphoma
It’s a rare and benign entity, also called pulmo-
nary nodular lymphoid hyperplasia or bronchus- 
associated lymphoid tissue (BALT). It is 
characterized by infiltration of polyclonal lym-
phocyte and plasma cells. Usually it’s asymptom-
atic but could present with dyspnea and cough. 
CT scan typically shows solitary nodule. 
However, less frequently, multiple nodules, 
which involve blood vessels, consolidation, 
mediastinal lymph node and/or pleural effusion, 
could be seen. Biopsy usually reveals bronchus- 
associated lymphoid tissue (BALT). Furthermore, 
corticosteroids or immunosuppressive therapy 
could be given [147]. It has good prognosis when 
treated [147]. However, rarely transforms into 
lymphoma.
Amyloidosis
Its prevalence is around 0.6%, and patients’ pre-
sentation depends on the location such as larynx, 
trachea, bronchi, interstitium, and/or mediasti-
num. CT scan shows micronodular lesions (could 
be calcified or cavitary) predominantly in the 
subpleural area and in the lower lobes, while 
biopsy shows positive amyloid staining. The 
prognosis is usually good [148, 149].
7.9  Mixed Connective Tissue 
Disease (MCTD)
7.9.1  Introduction
It was first described in 1972 and defined as a 
combination of SSc, SLE, and polymyositis/der-
matomyositis (PM/DM) with positive anti- 
ribonucleoprotein (Anti-RNP). Yet, it’s not clear 
if it’s a separate entity of disease or not. 
Furthermore, pulmonary manifestations occur in 
up to 65% of MCTD patients. Worth mentioning, 
that patients with MCTD could present with any 
pulmonary manifestations related to SLE, SSc, or 
PM/DM [150].
7.9.2  Pulmonary Manifestations
7.9.2.1  Lung Parenchyma
Interstitial Lung Disease (ILD)
Introduction
It occurs in around 50–65% of MCTD patients 
[150]. Also, esophageal dilatation is a risk factor 
for developing ILD [151].
Presentations
Please see ILD in SSc.
Diagnosis
In early stages, PFT shows reduction in DLCO 
only. Then, in late stages, it shows restrictive pat-
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tern with low DLCO. HRCT shows septal thick-
ening, GGO, and non-septal linear opacities with 
predominance in the periphery or within the 
lower lobe. Also, in fact, no study encountered 
pathological findings, but thought to be NSIP and 
UIP.
Treatment
Physician should start corticosteroid (methyl-
prednisolone 2  mg/kg/day) for 4–6  weeks then 
assess, if no improvement add CYC oral or IV to 
complete 6 months [152].
Prognosis
Good prognosis (in terms of preventing further 
progression of the disease) if treated during the 
acute inflammatory phase (GGO). Once signs of 
fibrosis on HRCT present, the response will be 
poor.
Alveolar Hemorrhage
It’s an uncommon manifestation. Also, for pre-




Prevalence ranges between 3.4% and 27%. 
Furthermore, for presentation, diagnosis, screen-
ing and treatment, see SSc-PAH.
Pleural Diseases
Pleural Effusion
It’s a common manifestation of MCTD with 
prevalence about 50% [153]. Pleural fluid analy-
sis is usually exudative and with lymphocytic 
predominance. Moreover, it usually resolves 
spontaneously. However, if it persists, then a trial 
of corticosteroid could be effective.
7.10  Polymyositis (PM)/
Dermatomyositis (DM)
7.10.1  Introduction
Pulmonary manifestations play big role in the 
mortality and morbidity of PM/DM patients. 
Moreover, the main pulmonary complications are 
ILD, aspiration pneumonia, and hypoventilation 
due to muscle weakness.
7.10.2  Pulmonary Manifestations
7.10.2.1  Parenchymal Lung Disease
Interstitial Lung Disease (ILD)
Introduction
It’s the most common pulmonary complication, 
which reaches up to 65% when screened by CXR, 
HRCT, or PFT. Furthermore, it can present as an 
acute, chronic, or asymptomatic with radiologi-
cal findings only. When it is symptomatic, more 
than 60% of patients present with cough and dys-
pnea and normal radiograph, HRCT, or PFT. Also, 
it is more common in DM than in PM. However, 
recently, a new subtype of DM has been reported, 
the clinically amyopathic dermatomyositis 
(CADM), which is DM without muscle involve-
ment. This subset, when associated with anti- 
CADM- 140 antibodies, associated with higher 
prevalence of rapidly progressive ILD. Risk fac-
tors are positive antihistidyl tRNA synthetase 
antibody (anti-Jo-1), Krebs Von den Lungen-6 
(KL-6), serum surfactant protein D, serum cyto-
keratin 19 fragment (CK-19), and 
 anti- CADM- 140 antibody (which associated 
with rapidly progressive ILD). All of them aren’t 
present in every center as a routine test.
Presentations
Patients usually present with dyspnea and cough.
Diagnosis
PFT shows restrictive pattern with low 
DLCO.  While HRCT could shows NSIP, UIP, 
OP, or DAD pattern. BAL to rule out infection or 
drug-induced pneumonitis. Biopsy is rarely 
needed because the HRCT findings correlate well 
with histopathology. Although transbronchial 
lung biopsy is inferior to open lung biopsy, it is a 
good choice if opportunistic infection or neo-
plasms are suspected because open lung biopsy 
associated with high mortality rate.
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Treatment
Most commonly, corticosteroids with (CYC, 
AZA, cyclosporines) are given [154–161]. 
However, IVIG alone or with corticosteroids has 
shown good results in progressive disease [162, 
163]. Also, tacrolimus and rituximab, individu-
ally, are promising drugs [164–166]. Anti-tumor 
necrosis factor-alpha (Anti-TNF-a) and MTX are 
less likely to be effective. In fact, they may induce 
irreversible lung fibrosis [167].
Prognosis
ILD in PM/DM increases mortality. A 5-year sur-
vival ranges between 60% and 86% [168, 169]. 
Also, worse prognosis is expected with DM com-
pared to PM. Furthermore, when corticosteroids 
combined with other immunosuppressive ther-
apy, approximately 1/3 of the patients will 
improve, 1/3 will remain the same, and 1/3 will 
deteriorate [154]. Moreover, rapidly progressive 
ILD has fatal outcome with 3-year survival of 
around 24% [170].
7.10.2.2  Aspiration Pneumonia
It occurs in around 17% [171] of PM/DM patients 
and is related to the dysfunction happens to the 
pharynx and esophagus muscles which lead to 
abnormal swallowing and frequent regurgitation. 
Risk factors are severe muscle disease [172]. 
Furthermore, investigations and treatment are 
like any other case of aspiration pneumonia.
7.10.2.3  Pulmonary Vascular Disease
PAH
Occasionally happens. For, presentation, diagno-
sis, and treatment, see SSc-PAH.





They occur in two different clinical scenarios. 
The first one is vasculopathy with or without 
mild ILD (vasculopathy such as skin ulcers or 
bronchial wall necrosis). The second one is 
severe ILD with or without vasculopathy. 
Whenever one of these complications (PNX, 
pneumomediastinum, or subcutaneous emphy-
sema) happens, one should suspect pulmonary 
vasculitis. Diagnosis is made by chest radiograph 
and chest CT scan. Moreover, physicians should 
start corticosteroid and immunosuppressive ther-
apy together at the beginning then taper the ste-
roid gradually [173].
7.10.4  Respiratory Failure 
and Hypoventilation
7.10.4.1  Introduction
This happens due to severe respiratory muscle 
weakness with prevalence around 21.8% [171].
7.10.4.2  Diagnosis
PFT shows restrictive pattern. Furthermore, FVC 
and VC in supine position are reduced by more 
than 10% than in upright. Also, maximal inspira-
tory pressure (MIP) and maximal expiratory 
pressure (MEP) are reduced. DLCO is normal 
unless another pathology is present. Chest radio-
graph may show decreased lung volumes, ele-
vated diaphragms, and basal atelectasis.
7.10.4.3  Complications
Atelectasis and recurrent pneumonia may 
develop due to mucus plugging because of 
reduced cough reflex secondary to respiratory 
muscle weakness.
7.10.4.4  Treatment
Physicians should start immunosuppressive ther-
apy. However, if failed, home mechanical venti-
lation could be used which could saves life and 
improves the quality of life.
7.10.4.5  Lung Cancer
There may be an association between lung cancer 
and myositis, especially DM.
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The nervous system can be affected by many rheu-
matologic disorders. The involvements are differ-
ent in various diseases. Some rheumatologic 
diseases have prominent nervous system features, 
e.g. SLE, while in others these are minor (Table 8.1).
Patients with rheumatologic disorders can 
have nervous system involvement secondary to 
medications including immunosuppressive  ther-
apy or related to associated comorbidities. It also 
can be related or a sequel of the disease process 
itself.
The objective of this chapter is to provide a 
systemic approach to patients with various rheu-
matic conditions presenting with neurological 
syndromes.
8.1.1  Specific Objectives
By the end of the chapter, the reader should be 
able to:
 1. Recognize different neurological manifesta-
tions associated with SLE.
 2. Compose a diagnostic approach to SLE 
patients presenting with acute headache.
 3. Compose a diagnostic approach to SLE 
patients presenting with chronic headache.
 4. Manage SLE patients presenting with acute 
stroke.
 5. Recall the different causes of stroke in SLE 
patients.
 6. Recall the differential diagnosis of general-
ized seizure in SLE patients.
 7. Recall the differential diagnosis of focal sei-
zure in SLE patients.
 8. Use appropriate investigation for SLE 
patients presenting with seizure.
 9. Recognize SLE patients with seizure who 
will require long-term antiepileptic 
medications.
 10. Compose a diagnostic approach and manage 
SLE patients presenting with spinal cord 
dysfunction.
 11. Recognize neurological manifestations of 
rheumatoid arthritis (RA).
 12. Recognize RA patients at high risk of cervi-
cal spine disease.
 13. Manage RA patients with suspected cervical 
spine disease.
 14. Recognize causes of neuropathy in RA 
patients.
 15. Compose a diagnostic approach to RA 
patients presenting with neuropathy.
 16. Compose a diagnostic approach to patients 
with neuropathy and skin rash.
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8.2  Systemic Lupus 
Erythematosus (SLE)
In 1999, the American College of Rheumatology 
(ACR) established 19 different neuropsychiatric 
SLE syndromes (NPSLE) (Table 8.2).
In this chapter, the diagnostic approach to 
patients with SLE presenting with different neu-
rological complaints will be presented. In gen-
eral, obtaining good and detailed history and 
examination will assist to narrow the differential 
diagnosis and help with obtaining specific diag-
nostic tests (Table 8.3).
8.2.1  Headache
The prevalence of headache in patients with SLE 
is reported around 47.1–57% [1–3]. The differen-
tial diagnosis and approach to headache in SLE 
patients is different for acute versus chronic 
headache (Figs. 8.1 and 8.2). Patients with SLE 
can present with headache as primary disorders 
or can be secondary to other causes. The objec-
tive is to rule out serious causes before attributing 
it to primary headache disorder.










giant cell arteritis 
and Takayasu’s 
arteritis
Headache, visual loss, 
papilloedema, amaurosis 
fugax, stroke
















Rheumatoid arthritis Rheumatoid vasculitis causing 













plexopathy; cranial and/or 
peripheral neuropathy, 
myasthenia gravis, 
autonomic disorder, stroke, 
migraine, headache
Behçet’s disease Meningitis, encephalitis, 
seizure, stroke, headache









Peripheral or cranial 
neuropathy, mononeuritis 
multiplex, ocular disorders
Sjogren’s syndrome Myelopathy, polyneuropathy, 
motor neurone syndromes, 
cognitive
Dysfunction
Table 8.2 Neuropsychiatric syndromes associated with 
systemic lupus erythematosus
NPSLE associated with 
the central nervous 
system
NPSLE associated with the 
peripheral nervous system
  –  Aseptic meningitis
  –  Cerebrovascular 
disease
  –  Demyelinating 
syndromes
  –  Headaches
  –  Movement disorders 
(chorea)
  –  Myelopathy
  –  Seizure disorders
  –  Acute confusional 
state
  –  Anxiety disorders
  –  Cognitive 
dysfunction
  –  Mood disorders
  –  Psychosis




–  Autonomic neuropathy
–  Mononeuropathy, single 
or multiplex
–  Myasthenia gravis
–  Cranial neuropathy
–  Plexopathy
–  polyneuropathy
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8.2.1.1  Approach
Obtain a careful history of the headache: onset, 
duration, types, and precipitating, aggravating, 
and relieving factors. Headache that increases 
with coughing or sneezing and also that is worse 
with lying down raises the possibility of raised 
intracranial pressure. The presence of history of 
visual obscuration is also suggestive of increased 
intracranial pressure. Ask about any associated 
neurological symptoms that will make primary 
headache unlikely and necessitate neuroimaging. 
In female patients, ask about the relation of head-
ache to the menstrual cycle. Headaches that 
worsen in relation to menstrual cycle likely will 
be migraine related.
In addition, a comprehensive evaluation of SLE 
itself (current active symptoms like joint pains, 
skin rashes, and urinary symptoms, duration, organ 
involvements, and prior NPSLE attacks).
Detailed drug history should be obtained as 
some may precipitate or worsen headaches, e.g. 
some nonsteroidal anti-inflammatory drugs 
(NSAIDs) like ibuprofen can cause aseptic 
meningitis.
On examination, look carefully for signs of 
meningitis and focal neurological deficits, and do 
not forget to look for papilledema.
Workup depends on your initial findings 
(Figs. 8.1 and 8.2).
Indications for neuroimaging:
 1. New-onset headache or worsening of pre- 
existing headache.
 2. Features suggestive of increased intracranial 
pressure from history or examination, e.g. 
papilledema.
 3. Altered level of consciousness.
 4. Focal neurological signs and symptoms.
 5. Associated seizure.
Treatment depends on the cause of the head-
ache. Patients with venous sinus thrombosis 
will require treatment with anticoagulants. 
Meningitis should be treated with antibiotic 
therapy. If the headache is attributed to pri-
mary headache disorders, use abortive therapy 
as indicated. If primary headache is frequent, 
preventive therapy should be considered 
according to the headache type.
Table 8.3 Summary of NPSLE syndromes and differential diagnosis
NPSLE 
manifestations Diseases to exclude Notes
Headache Aseptic meningitis, CNS infections, venous 
sinus thrombosis
1.  Diagnosis of NPSLE is by exclusion of 
other important causes by ordering routine 
tests:
a.  Laboratory: CBC, electrolyte, renal, and 
liver function tests
b.  CSF: WBC, protein, glucose, gram stain 
and culture, viral PCR
c.  Imaging: Either CT brain or MRI brain 
and spinal cord according to the case
d.  EEG, EMG, NCV
2.  Treatment is by glucocorticoids and 
immunosuppressive drugs and 
anticoagulant in certain conditions
–  In refractory cases, you can add one or all 
of the following:
a.  Plasmapharesis




Drug side effects, depression, endocrine 
disorders like adrenal disease, stroke
Stroke Thromboembolic causes, cerebral vasculitis
Seizure Infection, electrolyte abnormalities, uraemia, 





Metabolic causes like renal or liver failure, CNS 
infections, medication side effects, seizure, 
structural lesion, e.g. tumour
Myelopathy Infectious myelitis, neuromyelitis optica
Movement 
disorders
Hereditary causes like Huntington’s, Wilson, 
metabolic causes, structural like brain tumour
Peripheral 
neuropathy
Metabolic causes like diabetes, infectious 
causes, vitamin deficiency, etc.
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8.2.2  Stroke
Cerebrovascular diseases account for around 
2–17% [2–4] of all NPSLE events.
Approach to SLE patients with acute stroke is 
the same as in non-SLE patients (Fig. 8.3).
Keep in mind that in SLE patients, further con-
sideration of the aetiology of the events should be 
considered. When patients with SLE present with 
acute neurological deficit within a 4.5-h window, 
immediate evaluation with brain CT scan is war-
ranted to rule out presence of intracerebral haemor-
rhage. In absence of contraindication, thrombolytic 
therapy should be administered. Patient who arrived 
outside the thrombolytic window should have 
CT brain before starting antiplatelet therapy. The 








Bacterial Fungal Viral, NSAIDS related, SLE
related Aseptic meningitis 
Antibiotics antifungal
ICH or SAH Negative
CSF examination (Cell
count, Chemistry, Gram
Stain ang Culture, Fungal 









offending drugs  





Abbreviations: -CT (computed tomography), ICH (intracerebral hemorrhage), SAH (subarachnoid
hemorrhage), NSAIDS (nonsteroidal anti-inflammatory drugs), PRES (posterior reversible
leukoencephalopathy)
Fig. 8.1 Diagnostic approach to SLE patients with acute headache
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initial workup for any SLE patient with stroke 
should include:
 1. Fasting blood glucose.
 2. Fasting lipid profile.
 3. Carotid Doppler.
 4. Holter monitoring.
 5. Echocardiogram.
 6. Antiphospholipid antibodies.
Disease activity should be determined (anti- 
dsDNA level, urinalysis, complement level (C3 
and C4), creatinine). Specific treatment for active 
disease with immunosuppressive therapy should 
be considered. All patients should get 
 cardiovascular risk factor modifications. In 
patients with negative antiphospholipid antibodies 
and with no indication for anticoagulation such as 
atrial fibrillation, antiplatelet therapy is the corner-
stone for the prevention of further events. Patient 
with antiphospholipid antibodies should be antico-
agulated with warfarin at an INR >3.0 or com-
bined antiplatelet-anticoagulant (INR 2.0–3.0). 
There is no consensus agreement on this [5].
8.2.3  Seizure
Seizure is a transient neurological dysfunction 
that results from excessive abnormal discharges 
of cortical neurons. Seizure can be generalized or 
focal in onset. The differential diagnosis of 
generalized- onset seizure is different than focal- 
onset seizure (Table 8.4).
















Brain MRI Primary Headache Disorders
Vasculitis
Space occupying lesions
Fig. 8.2 Approach to SLE patient with chronic headache
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Different aetiological factors can cause 
seizure in SLE patients (Tables 8.5 and 8.6). 
The prognosis and the need for further treat-
ment of seizure are dependent on the cause of 
seizure [6, 7].
8.2.3.1  Tips in History
 1. Disease activities.
 2. Seizure onset, duration, and postictal events.
 3. Determine the seizure type by asking if there 
was a preceding aura and by taking exact 
description of seizure from a witness.
 4. History of fever.
 5. Any associated other neurological symptoms 
or signs.
 6. Medication history.
 7. History of comorbidities, e.g. hypertension 
or renal failure.
A patient with a unilateral  motor
weakness  and  sensory symptom
and loss of one of the higher cerebral
functions like: aphasia 
Brain imaging to diagnose the cause of deficit
Measure the blood sugar, HgA1c, lipid profile to
assess cardiovascular risk factors.
ECG, Holter moniter, Echocardiogram and carotid
Doppler
Antiphospholipid antibodies
Rule other causes of stroke in young:-
1- Inherited hypercoagulable state
2- Drug abuse
3- Mitochondrial disaeses
1. Use thrombolytics within the
    appropriate time frame  unless
    contraindicated.
2. Antiplatltes therapy
3. Risk factor modification
4. Anticoagulation for antiphospholipid




Fig. 8.3 Approach to SLE patients with acute stroke
Table 8.4 Cause of generalized versus partial onset 
seizure




















NPSLE (single unprovoked seizure)






Brain MRI and MRV
EEG
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 8. Similar events in the past.
 9. History of prior CNS insults, e.g. stroke.
 10. Family history of epilepsy.
Treatment with an antiepileptic is not indicated 
for a single unprovoked seizure and for seizure 
secondary to metabolic causes. Use an antiepilep-
tic in the presence of recurrent events, abnormal 
EEG, and abnormal neuroimaging which carry a 
higher risk of recurrence without treatment.
If seizure happens in a setting of high disease 
activities, treatment with immunosuppressive 
therapy is indicated.
8.2.4  Myelopathy
It is a condition that results from inflammation of 
the spinal cord. Although it is considered rarer 
than other NPSLE syndromes, its development 
carries poor functional outcome. The classical 
presentation is with symptoms of spinal cord 
dysfunction including motor weakness, sensory 
loss with sensory level, and loss of sphincter con-
trol. The presentation differs according to the 
specific localization of the cord inflammation 
(Table 8.7).
Patients with SLE can present with transverse 
myelitis and rarely can also present with longitu-
dinal myelitis where more four segments of the 
cord are involved. The development of longitudi-
nal myelitis carries a worse prognosis and man-
dates aggressive immunosuppressive therapy. In 
the presence of longitudinal myelitis, brain MRI 
should be done to rule out brain demyelination. 
Anti-NMO antibodies (neuromyelitis optica) 
should be sent for those patients.
When dealing with patients with symptoms of 
acute cord dysfunction, one should rule out surgi-
cal causes first as an early intervention will affect 
the outcome (Fig. 8.4). When surgical causes are 
excluded, patients should have CSF examination 
to rule out infectious causes of myelitis. 
Treatment with immunosuppressive therapy 
should be delayed. Combine it with antiviral 
therapy until negative culture is obtained.
Different immunosuppressive regimens have 
been used in patients with myelopathy including 
pulse steroid therapy with or without intravenous 
cyclophosphamide or plasmapheresis. Aggressive 
therapy with combined three modalities can be 
used for patients with more severe disease espe-
cially with longitudinal myelitis, although one 
case series did not show superior outcome with 
the combined three modalities [8]. That observa-
tion may be explained by the fact that patients 
who had combined therapy had severe disease at 
their presentation. In a subgroup of patients with 
antiphospholipid antibodies, the use of anticoag-
ulation is recommended.
8.3  Rheumatoid Arthritis
Rheumatoid arthritis (RA) is the most common 
inflammatory destructive joint disease. Besides its 
articular manifestations, patients with RA exhibit 
multiple extra-articular manifestations. The ner-
vous system can be involved at varying degrees in 
patients with RA [9]. Both central and peripheral 
nervous system can be involved (Fig. 8.5). Central 
nervous system involvements can happen in the 
form of necrotizing vasculitis or as a result from 
cervical spine involvements and the development 
of atlantoaxial subluxation. Peripheral nervous sys-
tem involvement can be primary due vasculitis or 
secondary to the joint deformities or compression 
from rheumatoid nodules. Also the nervous system 
can be involved secondary to drug side effect.
The approach to patients with rheumatoid 
arthritis and atlantoaxial subluxation as well to 
patients presenting with neuropathy will be dis-
cussed (Fig. 8.6).
Table 8.7 Symptoms and signs of myelopathy according 
to the spinal level
Cervical 
cord
Motor weakness affecting four limbs 
(lower motor neuron signs at the level 
with upper motor neuron signs below the 
level of the lesion in chronic stage)
Sensory loss below the level with cervical 
sensory level
Loss of sphincter control




Motor weakness below the lesion (usually 
upper limb preserved unless T1 involved)
Sensory loss below the lesion with truncal 
sensory level
Loss of sphincter control
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Patient with feature of acute spinal cord dysfunction
Determine the exact level of the cord involved from
history and examination 
MRI of the cord
Surgical cause is identified Feature of myelitis
Neurosurgical referral
Check disease activity CSF examination
including viral serology and cultures 
Start immunosuppressive therapy
Plus antiviral pending the CSF results



















Fig. 8.5 Causes of 
neurological 
manifestations of RA
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RA with. 
• High Rheumatoid factor titres.
• Other extra -articular manifestations of RA beside the neurological ones.




• History of neck pain radiaitng to the occipt.
• History  of motor weakness and parasthesia of the hands and the feet.
• Ask about history of trauma.
 • Think of possible medications side effects.
• Do a complete neurological examination to confirm the presence of
atlantoaxial sublaxation.
Investigations.
• Order RF, CRP, ESR, WBC.
• Order x-ray of the peripheral joint looking for erosion.
• Order MRI of the spine to confirm the diagnosis  after stablizing the patient
if the compression is acute.
Treatment.
• Glucocorticoid in the case of acute compression.
• Surgical treatment is the definitive treatment of this condition
  (decompression and fusion).
• Get RA under control 
Fig. 8.6 Approach to RA patient with suspected atlantoaxial subluxation
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8.3.1  Atlantoaxial Subluxation
 1. RA is the most common inflammatory disor-
der affecting the cervical spine. The involve-
ment of cervical spine is related to active 
erosive RA and early age of onset [10].
 2. Craniocervical complications arise in 
30–50% of patients with RA more than 
7  years; however, the atlantoaxial sublux-
ation with myelopathy develops in 2.5% of 
RA more than 14 years [11].
 3. Cervical spine involvements by RA include 
atlantoaxial subluxation, cranial settling, 
subaxial subluxation, or combinations of the 
above.
 4. Atlantoaxial subluxation is the most com-
mon type of cervical spine affection.
 5. The subluxation can be anterior, posterior, or 
lateral, and the anterior subluxation is the 
most common type that results from laxity of 
the primary and secondary ligamentous 
structures.
 6. It is very important to recognize this particu-
lar complication especially in neurologically 
normal patients, as early recognition and 
treatment will improve outcome.
 7. Patients with atlantoaxial subluxation can be 
asymptomatic, or more commonly involve 
complaints of neck pain. Patients may pres-
ent with occipital neuralgia, facial pain, ear 
pain, or pain in the suboccipital region.
 8. In cases where cord compression already 
developed, patients would present with 
weakness, sensory symptoms related to the 
cord compression, as well as loss of sphinc-
ter control. (When you deal with any RA 
patients presenting with any of the above 
symptoms, consider atlantoaxial 
subluxation).
 9. Detailed neurological examination is manda-
tory with careful evaluation for signs of 
myelopathy.
 10. In order to prevent the development of neu-
rological sequels, an evaluation for possible 
atlantoaxial subluxation radiologically is 
mandatory for any patient with RA at presen-
tation and periodically thereafter and prior to 
any surgical procedures.
 11. If atlantoaxial subluxation is suspected, 
besides assessing the disease activity with 
DAS-28 score, for example (see Chap. 1), 
and peripheral joint X-ray, the status of the 
cervical spine should be assessed. Plain 
X-ray that includes lateral, anteroposterior, 
open mouth odontoid views and lateral 
flexion- extension dynamics is necessary to 
assess joint stability.
More advanced imaging is required for patients 
with neurological symptoms to assess multilevel 
disease. MRI is better than CT scan to evaluate the 
neurological structures as well as to provide better 
look at the ligamentous structures.
The mainstay of treatment is early surgical 
intervention before the onset of severe neurologi-
cal dysfunction, appropriate and aggressive 
disease- modifying therapy to control the disease 
activity, and adequate rehabilitation services to 
optimize neurological outcome.
8.3.2  Neuropathy
Neuropathy in patients with RA can result from 
nerve compression or secondary to vasculitis. 
When RA patients present with symptoms of 
mononeuropathy, it is essential to differentiate 
between neuropathy related to nerve compression 
and vasculitis as the treatment will be different.
Take appropriate history related to neurologi-
cal complaints. The onset of symptoms, progres-
sion, and whether there is sensory and/or motor 
deficits should be checked. Check if the symp-
toms are all related to one nerve or multiple 
nerves (mononeuritis multiplex). Assess RA 
activity, severity with the presence of erosions on 
X-rays, functional decline, duration, and medica-
tions used for RA. On examination, try to iden-
tify the deficit and if you can which nerve is 
involved (Table  8.8). Examine all other periph-
eral nerves to assess whether it is a single or mul-
tiple processes. Examine the activity of RA and 
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assess deformity. Look for rheumatoid nodules. 
Nerve conduction studies (NCS) and electromyo-
gram (EMG) will help to establish the diagnosis 
of nerve involvements. If it develops in a site of 
entrapment, e.g. carpal tunnel for median nerve 
and tarsal tunnel for posterior tibial nerve, the 
condition is most likely to be related to nerve 
compression rather than vasculitis and requires 
supportive care and may require surgical inter-
vention. Neuropathy that develops in a non- 
compression site is related to vasculitis. Those 
patients may exhibit mononeuropathy or features 
of multiple nerve involvement (mononeuritis 
multiplex). Usually it happens in the setting of 
active erosive disease and with seropositive dis-
ease. Treatment with steroid should be initiated 
together with the use of disease-modifying ther-
apy to achieve disease control. Patients with RA 
can also present with features of peripheral neu-
ropathy that can be sensory, sensory-motor, or 
motor neuropathy. The approach to such patients 
will be discussed in the next part.
8.4  Neuropathy with Skin Rash
When neuropathy either mononeuropathy, mono-
neuritis multiplex, or peripheral neuropathy 
occurs in a setting of skin rash, vasculitis should 
be considered as an etiological factor. Vasculitis 
is a condition that results from inflammation of 
the blood vessels. It can be primary or secondary 
to other conditions, e.g. connective tissue dis-
ease, infection (hepatitis C), hypersensitivity 
reaction, and paraneoplastic condition. (See 
Chap. 19 for full details about vasculitis.)
Figure 8.7 shows  the diagnostic approach to 
patient with neuropathy and rash.
8.4.1  Tips in History and Physical 
Examinations
 1. Identify the nature of neuropathy (sensory, 
sensory-motor, motor, mono, multiple versus 
peripheral).
Table 8.8 Things to look for in common nerve involvements
Nerve Motor symptoms Sensory symptoms Notes
Radial 
nerve
Wrist drop due to 
weakness of extensors of 
the wrist and the fingers.
Loss of elbow extension 
if the upper third of the 
nerve is affected
Loss of sensation over the anatomical 
snuff box
Flex the elbow, pronate the 
forearm, and extend the 
wrist and the fingers to 




Loss or weakness of the 
thumb abduction mainly
Loss of wrist flexors
Loss of sensation over the palmer aspect 
of the thumb, index, middle, and lateral 
half of the little finger and the 
corresponding part of the palm if it is 
affected above the wrist
Pen touching test for lesion 
at the wrist.
Ochsner clasping for lesion 
in the cubital fossa
Ulnar 
nerve
Weakness of most of the 
small muscles of the hand 
which will lead clawing 
of the hand
Loss of sensation over the little finger 
the medial half of the ring finger
Froment’s test can be used to 
demonstrate loss of thumb 




Weakness in knee 
extension
Loss of sensation over the medial aspect 
of the thigh and the leg
Sciatic 
nerve
Weakness of all the 
muscles below the knee 
that results mainly in foot 
drop and weakness of the 
hip flexion
Loss of sensation over the posterior 
aspect of the thigh, all the aspects of the 
lower limb below the knee except for the 
medial aspect of the leg
It divides into the common 
peroneal nerve and the 
posterior tibial nerve at the 




Foot drop Usually minimal sensory loss over the 
lateral aspect of the dorsum of the foot
Loss of eversion is another 
feature
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 2. Symptoms of asthma like shortness of breath 
may suggest Churg-Strauss syndrome, eosin-
ophilic granulomatosis with polyangiitis 
[EGPA], or allergic granulomatosis.
 3. Symptoms of renal involvement like perior-
bital oedema and hypertension may suggest 
ANCA-associated vasculitis including 
microscopic polyangiitis and Henoch- 
Schonlein purpura (HSP).
 4. The age of the patient may give a clue since 
HSP is rare in a patient who is older than 18.
 5. Associated gastrointestinal symptoms are 
important findings in HSP.
 6. Symptoms of liver involvement are essential 
to be established as hepatitis C is associated 
with cryoglobulinaemic vasculitis and hepa-
titis B is strong risk factor for polyarteritis 
nodosa.
Palpable purpura  which might be painful, motor weakness and
sensory symptoms suggestive of neuropathy 
Take full history and do appropriate  and complete physical examination
and order CBC, ESR, CRP, Rheumatology panel, biopsy, NCV, and EMG,
renal and liver function tests, drugs screen, porphoria, vitamin assays
and imaging modalities for suspected cancer.     
History of liver disease and
positive serology  for Hepatitis
B or C.
Think of polyartritis nodosa,
and cryoglobulinemia.
History of  asthma,
esinophilia with positive p




and site related symptoms
with positive imaging think
of para-neoplastic
phenomenon. 
History of periorbital edema, urine changes, hypertension
(renal involvement).
- positive ANA, anti smith, anti DNA think of SLE.
- Positive C ANCA  think of microscopic poly angitis.
- Gastrointestinal symptoms in patient less than 18 years
  old and history of preceding  viral infection think of HSP 
History of either drug intake, or
systemic viral infection think of
hypersensitivity reactions
(serum sickness).
In the case of primary vassculitis use glucocorticoids and cyclophosphamide.
Control the precipitating condition in the case of secondary vassculitis in addition
to same agents used for primary vassculitis e.g: DMARDS  for connective tissue
diseases antimicrobial for certain infection, discontinuation of the culprit drugs.
Fig. 8.7 Approach to patient with rash and neuropathy
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 7. History of recent use of drugs or recent sys-
temic viral infection that can be associated 
with hypersensitivity reactions.
 8. Symptoms of connective tissue diseases like 
SLE, RA, and Sjogren disease are suggestive 
for a secondary cause of vasculitis.
 9. Constitutional symptoms can be associated 
with rheumatologic diseases or solid tumours 
like lung cancer or lymphoma in what is 
known as paraneoplastic phenomenon.
 10. Family history of similar presentation as 
some genetically determined disease, e.g. 
porphyria can present with skin rash and 
neuropathy.
 11. High risk factors, e.g. multiple sexual partner 
and IV drug abusers, may suggest infections 
like HIV and/or syphilis.
 12. The patient’s job is important to exclude 
exposure to certain toxins.
 13. Pay attention to the patient’s nutritional sta-
tus as vitamin deficiencies can lead to neu-
ropathy and rash that might be mistaken for 
vasculitis.
 14. Thorough systemic examination is mandatory 
to help narrow your differential diagnosis.
8.4.2  Laboratory Investigations 
and Imaging Modalities
 1. CBC, C-reactive protein, and ESR to assess 
the presence of inflammatory condition in 
the body like vasculitis and connective tissue 
disease.
 2. NCS and EMG help to categorize the type of 
neuropathy [12].
 3. Nerve biopsy is the ultimate gold standard to 
diagnose vasculitis as a cause of neuropathy 
[12].
 4. Rheumatologic autoantibody profile like 
ANA, ANCA, RF, anti-DNA, anti-RO, anti-
 Jo, and anti-CCP will help identify if vascu-
litis were secondary to connective tissue 
disease (see for details in Chap. 4).
 5. Assess the patient’s liver, renal, thyroid, as 
well as glucose levels to help narrow the dif-
ferential diagnosis.
 6. Serology for hepatitis B and C, HIV, and 
cryoglobulin level and VDRL to exclude sec-
ondary syphilis.
 7. Vitamin assays like B12, folate, and E to 
exclude vitamin deficiency as the cause of 
patient presentation.
 8. Toxicology screen looking for drug 
toxicities.
 9. Look for porphyrins according to which sub-
type you suspect in the patient.
 10. Use the different imaging modalities to look 
for solid tumour or lymphoma if you think 
they are the culprit.
8.4.3  Treatment
 1. Immunosuppressive therapy with glucocorti-
coids is the mainstay of treatment. Depending 
on disease severity, the addition of cyclophos-
phamide should be considered to minimize the 
risk of relapse, morbidity, and mortality [13].
 2. Control the precipitating condition in the case 
of secondary vasculitis in addition to same 
agents used for primary vasculitis, e.g. 
DMARDs for connective tissue diseases, anti-
microbial for certain infection, discontinua-
tion of the culprit drugs, etc.
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Patients with muscle disorders are a diagnostic 
challenge to physicians, because of the various 
ways of presentation. A comprehensive approach 
should be followed systematically in order to 
reach the correct diagnosis. Weakness is a com-
mon symptom among patients including those 
with central or peripheral nervous systems dis-
eases and those with muscular and/or neuromus-
cular diseases. Muscle weakness is not only a 
regular finding in rheumatologic diseases, but in 
inflammatory myopathies as well. This chapter 
focuses on skills needed to approach any patient 
that presents with weakness, specifically proxi-
mal myopathy.
In addition to IIM and CTD, proximal myopa-
thy has a wide range of differential diagnosis 
including drugs, alcohol, thyroid disease, heredi-
tary myopathies, malignancy, and infections. 
Clinical assessment should aim to distinguish 
proximal myopathy from other conditions that 
present with weakness. Patients with proximal 
myopathy who need prompt attention, like those 
with cardiac, respiratory, or pharyngeal muscle 
involvement, should be identified early and 
quickly.
In this chapter, the aim is to provide a system-
atic diagnostic approach to adult patients present-
ing with proximal myopathy. This is an essential 
step to establish the correct diagnosis in order to 
conduct the appropriate management.
9.1.1  Objectives
By the end of this chapter, you will be able to:
 1. Identify true muscular weakness by history 
and physical examination.
 2. Construct diagnostic approach to proximal 
myopathy.
 3. Manage a case of inflammatory myopathy.
9.2  Clinical Presentation 
of Proximal Myopathy
Myopathies are diseases that primarily affect the 
muscles and are usually characterized clinically 
by weakness, fatigue, or stiffness. Symmetrical 
proximal muscle weakness, wasting, normal sen-
sation, and normal stretch reflexes are classical 
findings in patients with myopathies particularly 
in IIM and myopathies associated with 
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CTD.  Aching muscle cramps can also occur. 
Clinical presentations sometimes can be com-
plex, hence the need to follow a comprehensive 
approach to weakness.
9.2.1  History
Weakness is a common complaint with different 
interpretations by patients. The aim of history 
taking is to try to define what the patient means 
by “weakness.” The generalized feeling of tired-
ness and/or fatigability is usually associated with 
systemic diseases like congestive heart failure, 
cirrhosis, and anemia. In these patients there is 
usually a long-standing history of a chronic dis-
ease like ischemic heart disease and/or chronic 
liver disease. The activity in these patients is usu-
ally limited by dyspnea, chest pain, joint pain, 
fever, and/or depressed mood. Long-standing 
chronic diseases can lead to cachexia with severe 
muscle atrophy, wasting, and consequent gener-
alized weakness. The sense of generalized tired-
ness and/or fatigability should be differentiated 
from the complaints of generalized body aches 
and pains in patients with fibromyalgia. The gen-
eralized body aches and pains have their own 
approach that is beyond the scope of this 
chapter.
Once it is established that the weakness is not 
a consequence of a non-muscular, generalized, 
systemic disease and there are no generalized 
body aches and pains, then it is essential to find 
out whether this weakness is localized to certain 
areas. Hemiparesis (weakness affecting upper 
and lower limbs on the same side of the body) 
should direct the history towards central ner-
vous system diseases like stroke. Paraparesis 
(weakness of both lower limbs) and/or quadri-
paresis (weakness of the four body limbs) 
should limit the differential diagnosis to spinal 
cord and/or cerebral cortex and/or brain stem 
diseases. Monoparesis (weakness of one limb) 
is usually a disease of a peripheral nervous sys-
tem including disc prolapse causing radiculopa-
thy by compressing on a spinal nerve to 
peripheral nerve involvement in vasculitis. 
Figure  9.1 is a schematic that should be fol-
Motor root
Sensory root
Mixed nerve (contains motor
and sensory fibers) (Guillain-













Fig. 9.1 The four 
anatomic stations 
underlying lower motor 
neuron weakness
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lowed while obtaining history and examining 
patients with weakness.
Symmetrical weakness occurs in large number 
of diseases including inflammatory myositis, inher-
ited muscle dystrophy, endocrine disorders, and 
neuromuscular junction diseases. In symmetrical 
and diffuse weakness, it is important to know if the 
weakness is proximal or distal. There are several 
clues in the history that point towards proximal 
myopathy (muscles of the trunk, shoulders, and 
thighs). The patient will have difficulty combing 
hair, difficulty climbing up the stairs, difficulty 
standing from a sitting position, and/or difficulty in 
getting up from bed. In distal myopathy, the patient 
will complain about difficulties while performing 
fine work like handling the objects by hands and 
driving. These patients may also present with wrist 
drop or foot drop. It must be noted that there are 
diseases affecting proximal muscles in an asym-
metrical fashion like diabetic amyotrophy as well 
as diseases with both proximal and distal muscle 
weakness in symmetrical and/or asymmetrical 
fashion like in systemic lupus erythematosus (SLE) 
with myopathy and vasculitis, respectively. 
Inclusion body myositis, a rare IIM in elderly 
patients, presents with both proximal and distal 
myopathies simultaneously. The focus should be 
simply to identify the localization of the weakness, 
and then with comprehensive approach to history 
taking like what is described in Chap. 1, the differ-
ential diagnosis should be easier to obtain.
There are special characters for weakness that 
signify certain alerts to specific diagnoses. 
Ascending pattern of weakness should direct the 
attention towards demyelinating diseases like 
acute inflammatory demyelinating polyneuropa-
thy (Guillain-Barre syndrome). Descending pat-
terns that start centrally and proceed progressively 
to distal areas should direct the attention to infec-
tions like botulism. The weakness that is wors-
ened by repetitive movement at the end of the day 
with double vision and drooping eyelids should 
direct the attention towards neuromuscular disor-
ders like myasthenia gravis.
An extensive review of rheumatologic symp-
toms should follow; this was outlined thoroughly 
in Chap. 1. Detailed history of joint pain, skin 
rashes, fever, recent infections, bleeding tenden-
cies, history suggestive of malignancies, and/or 
drug history (particularly statins and glucocorti-
coids) should all be obtained. Endocrine disor-
ders should also be ruled out by reviewing 
common symptoms like neck swelling, diarrhea/
constipation, and heat/cold intolerance. Further 
details are found below. Detailed family history 
should be obtained as there are several rare 
hereditary myopathies that run in families (see 
below). A family history may also be present in 
other causes of weakness including dermatomyo-
sitis, polymyositis, and potassium-related paraly-
ses. A thorough neurological history is important. 
Sensory deficits, impaired level of conscious-
ness, speech or visual defect, seizure, and sphinc-
ter control should be obtained from patients with 
weakness. In addition, social history will further 
help narrow the diagnosis; thus, history of smok-
ing, alcohol, illicit drug use, and exposure to tox-
ins like organic phosphorus should be obtained.
There are life-threatening symptoms associated 
with IIM like dysphagia and nasal regurgitation 
resulting from skeletal muscle involvement of the 
pharynx and upper third of the esophagus and/or 
chest pain and heart failure from cardiac muscle 
involvement. These should be identified promptly 
as they need urgent medical intervention. 
Breathlessness might suggest respiratory muscle 
involvement. Respiratory failure can occur in 
some diseases like Guillain-Barre syndrome, 
myasthenia gravis, and amyotrophic lateral sclero-
sis. Table  9.1 summarizes some of the common 
symptoms of diseases presenting with weakness.
9.2.2  Physical Examination
The physical examination is an objective confir-
mation of the distribution and the severity of the 
muscle weakness. The first step is to observe the 
patient doing certain activities like raising arms, 
standing up from a chair, or writing. This will 
determine if the weakness is proximal, distal, or 
combined. A comprehensive neurological exami-
nation should follow with higher function exami-
nation and examination of cranial nerves. You 
may find ptosis, ophthalmoplegia, and/or poor 
gag reflex in myasthenia gravis patients. The next 
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step is performing detailed motor examination. 
This starts with inspection of the muscle bulk and 
determining whether if it is normal, atrophied, or 
hypertrophied. In addition to observation for any 
fasciculation that might suggest LMND, tone, 
power, reflexes, and gait should also be exam-
ined. Clear distinctions between signs of upper 
motor neuron disease (UMND) (hypertonia, 
hyperreflexia, and upgoing plantar response) and 
signs of LMND (for lesions from the anterior 
horn cell until muscles) (hypotonia, normal or 
low or absent reflexes, and equivocal or downgo-
ing plantar response) should be made. Usually 
with signs of UMND, patients may present with 
hemiparesis, paraparesis, and quadriparesis or 
with variable locations in the central nervous sys-
tem as in multiple sclerosis. Since weakness is a 
prominent sign present in both UMND and 
LMND, it is essential to assess the power and 
document the degree of weakness, as well as for 






































































































Fig. 9.2 Clinical approach to weakness
Table 9.1 Associated symptoms presented with muscle 
weakness
Disease Symptoms
Dermatomyositis Skin rash, e.g., upper eyelids 
(heliotrope rash), erythema of 
the knuckles (Gottron rash), 
anterior chest (v sign), or 
back (shawl sign)
Weight loss, anorexia, 
bleeding tendency, abnormal 





Myasthenia gravis Squint, dysphagia




Autonomic symptoms, e.g., 
dry mouth, impotence
History of lung cancer
Mixed connective 
tissue disease and 
overlap syndrome
Other connective tissue 
disease’s symptoms; arthritis, 
skin rash
Rhabdomyolysis History of trauma, seizure, 
dark urine
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treatment. Clinical approach to weakness is illus-
trated in Fig. 9.2. Grades of power are shown in 
Table 9.2.
Reflexes are usually intact in proximal myop-
athy, and any signs of abnormal reflexes suggest 
neurological cause. The last step in the neuro-
logical examination is examining sensory level. 
For example, in peripheral neuropathy loss of 
sensation is parallel to the weakness. After com-
prehensive neurological examination, a search 
for extra-muscular signs should follow. The 
examination of the face, hands, lower limbs, 
chest, and abdomen is important, since any 
abnormality can help in the differential diagno-
sis. Few signs of common diseases presenting 
with myopathy are shown in Table 9.3.
There are certain associations essential to be 
recognized while performing the physical exami-
nation. These associations may easily reveal the 
diagnosis without spending efforts on unneces-
sary investigations. Changes in the mental status, 
for example, with muscle weakness may indicate 
electrolyte imbalance. Cardiovascular assess-
ment may reveal signs of cardiomyopathy, which 
is associated with some inflammatory and heredi-
tary myopathies. Pulmonary assessment may 
reveal crackles of interstitial lung disease associ-
ated with some inflammatory myopathies. Lymph 
node examination is essential as malignancies are 
associated with a significant number of IID 
including lymphoma. Small joint examination is 
essential as well to detect any tenderness and/or 
swelling suggestive of rheumatoid arthritis (RA) 
and/or systemic lupus erythematosus (SLE)-
associated myopathies. Skin examination is help-
ful: signs like Gottron’s papules in 
dermatomyositis, erythema nodosum in sarcoid-
osis, and skin bronzing in adrenal insufficiency 
(see Dermatology chapter). Also a search for any 
signs possibly related to underlying malignancy 
like finger clubbing, fecal occult blood, and hepa-
tosplenomegaly should be made. Table 9.4 lists 
findings with their most likely definitive diagno-
sis. The vital signs should be measured to exclude 
any life-threatening problems. Postural hypoten-
sion can be seen in autonomic neuropathy, e.g., in 
diabetes mellitus and Lambert-Eaton syndrome. 
Also, body mass index (BMI) should be mea-
sured to assess if the patient is underweight sug-
gestive of a malignant disease process.
9.3  Differential Diagnosis 
of Proximal Myopathy
Several conditions cause proximal myopathy. 
Myopathies can be classified into idiopathic or 
acquired. The clinical history and physical exam-
Table 9.2 Grades of power
5 Normal muscle strength, full resistance
4 Reduced, but still against resistance
3 Further reduced, only against gravity
2 Only moves with gravity
1 Flicker of movement
0 No movement
Table 9.3 Common signs with specific myopathies
Head and neck Hands Chest and abdomen








–  Erythema of anterior chest (v 
sign), or back (shawl sign)
–  Axillary lymphadenopathy, breast 
lump or abdominal mass
Overlap syndrome 
and MCTD
–  Fish mouth, pinched 
nose (in scleroderma)






Signs of lung fibrosis and serositis
Lambert-Eaton 
syndrome




–  Chest finding if there are 
complications for lung cancer e.g. 
pleural effusion, lymphadenopathy
Myasthenia gravis SVC syndrome 
(thymoma)
– –
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ination are essential in identifying the presence 
of a myopathy and narrowing down the differen-
tial diagnosis. In adults a major cause of myopa-
thy is medication like statins [1]. Myopathy due 
to endocrine causes, for example, thyroid dis-
ease, Cushing disease, and adrenal diseases, 
should be diagnosed promptly because treating 
the primary condition will result in resolution of 
the myopathy [2]. Inflammatory diseases typi-
cally affect older adults including both proximal 
and steroid responsive disorders like polymyosi-
tis and dermatomyositis and distal and proximal 
myopathies with less response to steroid like 
inclusion body myositis. Rheumatologic disor-
ders causing weakness, such as SLE and RA, can 
occur in young and elderly persons. Figure  9.3 
summarizes the differential diagnosis of proxi-
mal myopathy. Further details about these disor-
ders will be mentioned briefly in this section.
9.3.1  Toxins- and Drug-Induced 
Myopathy
Considering toxin and drug exposure in the dif-
ferential diagnosis of every single patient pre-
senting with proximal myopathy is essential. The 
timely diagnosis allows for optimum recovery. 
There are many drugs that cause proximal myop-
athy, such as lipid-lowering drugs, glucocorti-
coids, antimalarial drugs, antiretroviral drugs, 
alcohol, and cocaine [1]. There is an acute pre-
sentation in drug-induced myopathy. Statin ther-
apy associated with muscle problems is seen in 
approximately 10–25% of patients treated in 
clinical practice. Statin-induced myopathy can 
present as myalgia and myositis or sometimes is 
severe enough to cause rhabdomyolysis. The 
average onset of statin-induced myopathy is 
weeks to months. The only treatment is discon-
tinuation of statin which results in resolution of 
muscle symptoms [3]. Glucocorticoids are a 
common cause of muscle weakness. Long-term 
use of glucocorticoids results in an insidious 
onset of proximal myopathy. Muscle enzymes 
are usually normal. Relief of the weakness occurs 
with lowering the dose of glucocorticoids [4]. 
Alcohol-induced myopathy generally follows a 
history of long-standing alcohol intake and/or 
consumption of large amount of alcohol. 
Table  9.5 summarizes pertinent features of the 
common causes of toxin- and drugs-induced 
myopathy.
9.3.2  Endocrine Myopathy
Hormones play an essential role in body metabo-
lism. Deficiency or excess in most hormones will 
affect muscle metabolism. In endocrine-related 
muscle diseases, the presentation is more likely 
to be fatigue than true muscle weakness. The 
Table 9.4 Correlation between findings and suggestive 
diagnoses of weakness
Findings Suggestive diagnosis
Acute focal weakness decreased 
muscle power, hyperreflexia, 
hypertonia, positive Babinski 
sign, ± sensory deficit, ± loss of 
bladder/bowel control
Stroke, or spinal 
cord injury
Diffuse or localized peripheral 
weakness, muscle atrophy, 




Asymmetrical distal weakness, 
muscle atrophy, hypotonia, loss 
of reflexes, sensory deficit






Acute onset of combined 
weakness (ascending), 
fasciculations, loss of deep 
tendon reflexes, sensory deficit
Guillain-Barre 
syndrome
Facial weakness, fatigability, 
ptosis
Myasthenia gravis
Symmetrical weakness of 
proximal muscles, muscle 
wasting, with some types, 
muscle tenderness, normal 
reflexes, no sensory level
Proximal 
myopathies

























































and progress very slowly
Acutely or subacutely and
progress rapidly
Thyroid (hypo or hyper)
Hypokalemic periodic paralysis → Episodic weakness
Sarcoidosis
Osteomalecia
Adult males 50 ys
Fig. 9.3 Differential diagnosis of proximal myopathy
Table 9.5 Features of toxin- and drug-induced myopathy
Toxin/drug Effect on muscle Characteristics Management
Alcohol Large consumption of alcohol 
will cause direct muscle necrosis







Resolution with cessation of alcohol
Glucocorticoid Direct catabolic effect
Chronic use of prednisone at a 
daily dose of ≥30 mg/day








Improved muscle strength within 
3–4 weeks after lowering the dose
Statin Varying degrees of muscle 
necrosis
Severe complications such as 
rhabdomyolysis and 
myglobinuria




Muscle pain may be 
related to exercise
Muscle weakness will resolve with 
decreasing the dose or cessation of 
the statin
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serum CK level is often normal (except in hypo-
thyroidism). Nearly all endocrine myopathies 
respond to treatment [5].
Abnormalities in thyroid hormone can lead to 
a wide range of muscle diseases. For example, 
hypothyroid patients have frequent muscle com-
plaints such as cramps, pain, and weakness. 
Almost one third of hypothyroid patients present 
with proximal myopathy. They present mainly 
with shoulder and hip muscle weakness. 
Treatment by thyroid replacement usually leads to 
resolution of symptoms and laboratory abnormal-
ities [6]. Proximal myopathy is a very common 
presentation in hyperthyroid patients and may be 
the only symptom of the disease. Bulbar, respira-
tory, and even esophageal muscles may be 
affected, causing dysphagia and aspiration. Other 
neuromuscular disorders may occur in association 
with hyperthyroidism including  hypokalemic 
periodic paralysis, myasthenia gravis, and a pro-
gressive ocular myopathy. Because proximal 
weakness is a presenting sign of  hyperthyroidism 
and hypothyroidism, checking thyroid-stimulat-
ing hormone (TSH) is essential. Adrenal insuffi-
ciency causes muscle fatigue rather than true 
muscle weakness. Conn’s syndrome can lead to 
proximal myopathy which is related to hypokale-
mia [7]. Pituitary disorders like acromegaly if 
long-standing can cause myopathy [8]. 
Neuromuscular complications of diabetes melli-
tus (DM) are mainly due to neuropathy which can 
be presented as asymmetrical proximal weakness. 
Ischemic infarction of the thigh muscles can pres-
ent with severely uncontrolled diabetes [9] (see 
Chap. 21 (Diabetes and Rheumatology)). 
Table 9.6 summarizes pertinent findings of myop-
athies caused by endocrine disorders.
9.3.3  Dystrophic Myopathies
Dystrophic myopathies are a distinct group of 
inherited muscle disorders that generally present 
chronically. They are slowly progressive in nature 
resulting in muscle atrophy with exception of 
metabolic myopathies, where symptoms on occa-
sion can be precipitated acutely. Each type of 
dystrophic myopathy has some characteristic 
structural abnormalities on muscle immunohisto-
chemistry. Congenital myopathies present pre-
dominantly in the perinatal period. Some can 
present later in childhood, and these children 
may have a milder course of the disease. Multiple 
gene defects can give rise to similar clinical and 
ultrastructural phenotypes; thus, muscle immu-
nohistochemistry should be tested to reach a final 
diagnosis. Table 9.7 shows the features of dystro-
phic myopathy [10].
9.3.4  Inflammatory Myopathies
Inflammatory myopathies are a group of complex 
diseases of unknown etiology. The most common 
types are dermatomyositis, polymyositis, and 
inclusion body myositis. Table 9.8 represents the 
current classification for IIM.  The incidence of 
inflammatory myopathies is 5–10/million cases 
per year [11]. These diseases are characterized by 
progressive muscle weakness with extra- 
muscular organ involvement and high serum 
muscle enzymes. Generally there is a female pre-
dominance 2:1, but in inclusion body myositis, 
the opposite is seen as it is three times more com-
mon in males [12]. The main pathophysiology is 
related to autoimmunity, though recent studies 
show that the mechanism of muscle damage is 
multiple and complex [13].
The clinical features of inflammatory myopa-
thy in general are muscle weakness occurring 
within weeks to months. The distribution of 
weakness is mainly proximal in dermatomyositis 
and polymyositis, but as the disease progresses, 
distal muscles may become affected. On the other 
hand, distal muscle weakness is the initial pre-
sentation of inclusion body myositis. The onset 
of polymyositis is usually after the second decade 
of life. Dermatomyositis has two peaks, the first 
peak at around 10–15 years of age and the second 
peak between 40 and 70  years. Inclusion body 
myositis occurs after the age of 50. Table  9.9 
summarizes the pathological and clinical features 
of the most common IID.
Dermatomyositis is known for its cutaneous 
manifestations. The rashes can precede, follow, 
or occur simultaneously with the myopathy. 
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Gottron’s papules and heliotrope rash are pathog-
nomonic features of dermatomyositis [14]. 
Dermatomyositis and polymyositis are also 
known to cause manifestations related to the car-
diovascular system, respiratory system, and gas-
trointestinal system.
Patients diagnosed with IID tend to have a 
higher risk of developing malignancies. Patients 
with dermatomyositis or polymyositis have an 
increased risk of developing malignancy. Those 
with dermatomyositis are three to six times more 
likely and those with polymyositis are two to four 
times more likely than the normal population to 
develop ovarian, gastric, pancreatic, and lung 
cancer and non-Hodgkin lymphoma. Thus 
screening for malignancies is highly recom-
mended in this population [15].
9.3.5  Myopathy Due to Infectious 
Disease
Infectious diseases may cause an acute presenta-
tion of weakness with muscle cramps, myoglo-
binuria, and rhabdomyolysis. Among the 
infectious causes, viral infections are the most 
Table 9.6 Pathophysiology and characteristics of endocrine myopathies
Endocrine disease Pathophysiology Characteristics
Hypothyroidism Exact mechanism is unknown
T4 is essential for metabolism
Decrease in T4 leads to decrease in glycogenolysis 
which leads to impaired muscle function
Proximal myopathy occurs in one 
third (shoulder and hip girdle 
muscles)
Muscle cramps, stiffness, pain are 
common complaints
More common in women
Muscle hypertrophy is a rare sign 
(Hoffman’s sign)
Delayed deep tendon reflexes
Hyperthyroidism Exact mechanism is unknown
Impaired muscle function may be due to increased 
cellular metabolism and energy utilization, 
increased catabolism and protein degradation, and 
inefficient energy utilization
Muscle weakness ± tenderness and 
atrophy in 60–80% of patients
Presentation may be acute or 
chronic
Two-thirds of patients with 
hyperthyroid myopathy report 
proximal weakness, mainly hip 
flexors and quadriceps
Cramps are less common
Atrophy is usually absent
Bulbar symptoms may be present





Hyperparathyroidism 25% of patients will have insidious 
onset of proximal myopathy, legs 
more than arms
Atrophy is a common feature
Fatigue, muscle pain, and 
hyperreflexia are common
Adrenal insufficiency 100% of patients present with 




Weakness is a common complaint
Weakness and paralysis are usually 
due to the hypokalemia
Cushing syndrome (see Glucocorticoid myopathy)
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common. Myalgia is the most common symp-
toms, but can last up to 2–3  weeks. Usually 
myopathy due to viral infections is self-limiting, 
but severe cases may cause myoglobinuria and 
renal impairment.
Human immunodeficiency virus (HIV) is an 
important differential when approaching myopa-
thy; the condition is often referred to as HIV 
polymyositis. HIV polymyositis can be a pre-
senting manifestation of HIV infection or can 
occur in later stages. Patients with HIV polymyo-
sitis may present with asymptomatic elevation of 
CK levels, or as severe muscle tenderness and 
muscle weakness. HIV-related myopathy appears 
to have a better prognosis than idiopathic inflam-
matory myopathies. See the treatment section for 
how to manage HIV polymyositis.
Table 9.7 Features of dystrophic myopathy
Type of myopathy Distribution Characteristic
Mode of 
inheritance
Duchenne Proximal Age of onset 3–5 years
Weakness starts in the trunk
Spreads to arms and legs
Gower’s sign
Calf hypertrophy





Becker’s Proximal Age of onset 3–20 years
Less severe than Duchenne
X-linked
Limb-girdle Proximal Age of onset 3–20 years
Shoulder and hip muscles
Low back pain







Proximal Age of onset is variable (average 
10–20 years)
Infant form wheelchair by 9 years
Severe facial weakness
Inability to close eyes
Inability to smile
Weakness can involve shoulder and hips
Early onset: Hearing loss, seizures, cognitive 
impairment
AD
Myotonic dystrophy Distal Age of onset is variable
Most common adult-onset muscular 
dystrophy
Type 1, type 2
Affects facial muscle, arms, legs




Table 9.8 Classification of idiopathic inflammatory 
myopathies
  1.  Primary idiopathic dermatomyositis
  2.  Polymyositis or dermatomyositis with malignancy
  3.  Juvenile dermatomyositis (or polymyositis)
  4.  Inclusion body myositis
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9.4  Diagnostic Approach
A thorough history and physical examination is 
the cornerstone to reach the diagnosis. 
Investigations should be tailored to screen for 
reversible causes of a myopathy (Fig. 9.4).
When the cause of muscle weakness is unclear, 
appropriate testing should be performed, and it is 
recommended to start with blood tests including 
electrolytes (potassium, calcium, phosphate, and 
magnesium), thyroid-stimulating hormone (TSH) 
level, alkaline phosphatase and 25 (OH) vitamin 
D level, and HIV [16].
9.4.1  Muscle Enzyme
The measurement of serum levels of muscle 
enzymes is of critical value for the evaluation and 
monitoring of muscular disorders. Creatine 
kinase (CK), lactate dehydrogenase (LD), ala-
nine aminotransferase (ALT), aspartate amino-
transferase (AST), and aldolase are the serum 
muscle enzymes that are measured in clinical 
practice. In patients with suspected myopathy 
who do not demonstrate CK elevation, testing for 
aldolase can be helpful, but it is less sensitive and 
less specific [17].
Approach to high level of CK is demonstrated 
thoroughly in Table 9.10. It must be noted that 
CK elevation is, however, not specific to myopa-
thy and further testing should be performed in a 
comprehensive approach. Table  9.11 shows the 
differential diagnosis to high CK level.
While diagnosing myocardial infarction, 
besides symptoms and abnormal ECG findings, 
there will be rise in CK-MB, the isoenzyme of 
CK, electrophoretically distinguished and high in 
concentration in the cardiac tissue. However, it is 
neither specific nor sensitive as troponins [18].
Table 9.9 The pathogenetic mechanisms and clinical features of the most common IID
Condition Pathogenesis Age/sex Clinical features
Dermatomyositis Humeral mediated process
CD4 cells and B 
lymphocytes attack the 
vascular endothelium; 
result in necrosis of 




















disease (may lead to 
respiratory failure 
and death)







involvement in the 





Polymyositis Cellular mediated process
CD8 cytotoxic cells 
recognize MHC-1 on the 
muscle fiber, and this is the 










considered the most 
effective way to establish 
the diagnosis of PM
Inclusion body 
myositis




surrounding myofibers and 
rimmed vacuoles, and 
some myofibers are 






Insidious onset and 
progressive asymmetric 
distal weakness with wrist 
and index finger flexors 
weaker than extensors. 
Associated with early 
atrophy and poor response 
to steroid
9 Diagnostic Approach to Proximal Myopathy
202
CK might be falsely elevated secondary to 
ethnicity (can be high in Afro-Caribbean men), 
exercise (can remain elevated for up to 72  h), 
intramuscular injections, needle electromyogra-
phy (EMG), medications, hypothyroidism, and 
motor neuron disease [16].
9.4.2  Rhabdomyolysis
Muscle injury due to vigorous exercise, medica-
tion, infection, and metabolic derangements can 
cause rhabdomyolysis. Severe myalgia, weak-
ness, and red to brown urine due to  myoglobinuria 
are classical initial presenting features. Rise of 
CK levels is typically seen after 2–12 h of injury 
and reaches its maximum within 24–72  h. A 
decline is usually seen within 3–5 days of cessa-
tion of muscle injury. Myoglobinuria is present 
in 50–75% of patients at the time of initial eval-
uation. Thus it is recommended to perform rou-
tine dipstick urine analysis in any patient with 
extremely elevated CK level and myopathy. 
There are serious metabolic derangements that 
complicate this massive muscle destruction in 
the body. Electrolyte imbalance and acute renal 
failure are serious examples.
9.4.3  Other Tests
In addition to CK, to diagnose rheumatologic 
myopathy, erythrocyte sedimentation rate (ESR) 
C-reactive protein (CRP), antinuclear antibody 
assay (ANA), rheumatoid factor, anti-double-
stranded DNA,  antiphospholipid antibodies, 
and anti-centromere antibodies should be 
ordered. In case of inflammatory myopathy, 
check for anti-Jo1 antibody, directed against 
histidyl-tRNA synthetase. Recognition of anti-
Jo1 syndrome is important because such patients 
can develop extra-muscular features, such as 
interstitial lung disease, Raynaud’s phenome-

















Check for reversible causes
Drug interactions, hypothyroidism, AKI,
CKD, CLD and Vitamin D deficiency 
Assess risk and benefit for
cardiovascular risk  
If CK <4 ULN with symptoms
Discontinue statin 
CK >10 ULN even without symptoms 
Persistent symptoms despite
adjustment of doses and switching to
pravastatin, lovastatin,
with CK >4 ULN
Fig. 9.4 Approach to statin-induced myopathy
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9.4.4  Electromyography (EMG)
Electromyography (EMG) is a test that is used to 
record muscle electrical activity and assess the 
nerves that control the muscles. An abnormal 
electromyogram can indicate a neuropathy or 
neuromuscular disease. Characteristic EMG find-
ings of myopathy include short duration and 
decreased amplitude of action potential unlike 
neuropathies that are characterized by increased 
duration and amplitude of action potential. 
Table 9.10 Approach to high CK level
Episodic













Antimalarial, cholesterol-lowering drugs (statins), 
cocaine, alcohol, colchicine → 10- to 20-fold
Rhabdomyolysis
Acute, massive muscle 
injury due to: Trauma, 
seizures, electrolyte 
imbalances, infections
The degree of 
myoglobinuria might
Correlate with the risk of 
acute renal failure
CK levels decrease rapidly 
to normal after managing 
the cause
Metabolic myopathies
















Specific autoantibodies anti-U1 RNP and anti-PM/Scl
Infectious myopathies







80 percent of patients
Polymyositis & 
dermatomyositis
Abnormal EMG and 
muscle biopsy findings 
correlation between the 
height of CK elevation at 




Facioscapulohumeral dystrophy, myotonic dystrophy
CK levels peak by age 2 and then progressively fall, 
often to the normal range, as more and more muscle 
is replaced by fat and fibrosis
Motor neuron disease (amyotrophic lateral sclerosis)
Table 9.11 Differential diagnosis to high CK level
  •   Differential diagnosis 














–   Metabolic and 
congenital myopathy
–  Medications
–   Race (African 
Americans)
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Although there are no pathognomonic features 
that distinguish different forms of myopathy, 
EMG can help distinguish inflammatory from 
non-inflammatory forms of myopathy. Normal 
EMG examination, however, would not exclude 
myopathy [18]. In case of polymyositis, the site 
of muscle biopsy should be opposite to where the 
EMG was conducted [16].
9.4.5  Muscle Magnetic Resonance 
Imaging (MRI)
MRI evaluates deep muscles not readily accessi-
ble by EMG and plays a role in the diagnostic 
process by identifying subclinical signs of mus-
cle involvement. Fat-suppressed and short tau 
inversion recovery techniques differentiate 
between active myositis, pictured as edema, and 
chronic inactive myositis in patients with inflam-
matory myopathy, presented as fat [20]. A sec-
ondary role for muscle MRI is to provide 
information about the best site for muscle biopsy 
by showing which muscles are involved in the 
myopathic process.
9.4.6  Muscle Biopsy
Establishing the diagnosis of IID is essentially 
based on histopathological grounds. There are 
currently advanced therapies that can be used 
effectively in these patients. The justification of 
using these drugs or even steroids should be 
based on muscle biopsy. Open surgical biopsy is 
preferable to closed needle biopsy because of the 
patchy nature of inflammation in PM and so that 
adequate tissue could be obtained. However, in 
some circumstances, the biopsy is performed by 
expert radiologists. Muscle biopsy is a reliable 
instrument in the diagnosis of PM in 85% of the 
patients [18]. It is an outpatient procedure that 
may cause pain, bleeding, infection, or sensory 
loss. No special preparation is required other than 
that patients should discontinue using anticoagu-
lants before the procedure [21].
The best muscles to biopsy are those moder-
ately affected by the disease process but not atro-
phied. Previous sites of injections, EMG 
examination, or trauma should be avoided. The 
most common biopsy sites are the deltoid, quad-
riceps for proximal myopathy, and gastrocnemius 
for distal myopathies.
Technology using genetic markers is advanc-
ing rapidly. In inflammatory myopathies, immune 
staining for major histocompatibility classes I 
and II (MHC-I/II) is upregulated in myofibrils, 
whereas MHC-I immune staining alone is non- 
specific [22].
9.4.7  Screening for Malignancy
Idiopathic inflammatory myopathies PM and 
DM have positive relation to malignancy; retro-
spective studies’ results justify CT of the chest, 
abdomen, and pelvis in addition to age-appro-
priate screening tests such as colonoscopy and 
mammography for any patient newly diag-
nosed. This is shown in Southeast Asia where 
input of otolaryngologists is invaluable due to 
the higher incidence of nasopharyngeal carci-
noma for DM patients. Recent advances in 
understanding of pathogenesis of idiopathic 
inflammatory myopathies have led to discovery 
of biomarkers like type 1 interferon and myeloid 
cell signatures to distinguish active disease 
from chronic injury [17].
9.4.8  Genetic Testing
Genetic testing is becoming increasingly useful 
in confirmation of patient with muscular dystro-
phies and heritable myopathies. These mutations 
can be identified through peripheral blood DNA 
analysis. Molecular testing often eliminates the 
need for muscle biopsy.
9.5  The Management 
of Myopathy
9.5.1  Inherited Myopathy
For most patients with congenital myopathy or 
muscular dystrophy, the treatment is mainly sup-
portive. Physical therapy, occupational therapy, 
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management of contractures, nutrition, and 
genetic counseling together play a role in manag-
ing congenital myopathies. In patients with 
Duchenne muscular dystrophy, treatment with 
prednisone has been shown to improve strength 
and muscle bulk and slow the rate of natural pro-
gression of the disease. Patients should also be 
monitored over time for complications related to 
kyphoscoliosis or involvement of cardiac, respi-
ratory, or bulbar muscles. Finally, genetic coun-
seling should be offered to all patients with 
inherited myopathy and their family members.
9.5.2  Acquired Myopathy
Management of proximal myopathy depends on 
underlying etiology. Treatable causes should be 
sought and treated accordingly. Discontinuation 
of offending drug is likely to improve symptoms 
in patients with drug-induced myopathy, e.g., 
statins [5]. Dose reduction should be considered 
for those patients in whom abrupt discontinua-
tion of drug may not be possible, e.g., steroid 
myopathy [6]. In HIV-related myositis, treatment 
with the combination of highly active antiretrovi-
ral therapy (HAART) and steroids may be 
beneficial.
Treatment of IIM is largely empirical because 
of paucity of well-controlled trials. Current evi-
dence is mostly based on retrospective or open 
prospective trials involving small numbers of 
patients. Corticosteroids are the cornerstone in 
the treatment of PM and DM [19, 20]. In the 
absence of placebo-controlled trials, the optimal 
initial dose and duration of therapy are uncertain, 
but patients are generally started on 0.75–1 mg/
kg body weight/day of prednisolone. Intravenous 
pulse methylprednisolone is initially considered 
for those with cardiac, respiratory, or pharyngeal 
muscle involvement to obtain quicker response. 
Because maximal improvement may not be seen 
for several weeks, the usual practice is to start 
tapering the dose of prednisolone only after about 
4–12  weeks, guided by clinical improvement. 
Many patients relapse when corticosteroids are 
discontinued, and therefore, a maintenance dose 
of 5–10  mg/day is often required for several 
years. About a third of patients with PM or DM, 
and those with IIM, might fail to show any 
response to prednisolone. Second-line immuno-
suppressive drugs are tried in patients who do not 
respond to corticosteroids alone and in those with 
progressive disease and internal organ involve-
ment. Choice of drug is largely empirical and 
depends on disease severity, extra- muscular 
manifestations, and personal experience of treat-
ing physician, again because of paucity of well- 
conducted trials.
Azathioprine [23] or methotrexate is usually 
preferred. Intravenous immunoglobulin (Ig), the 
only agent for which there is positive evidence 
from randomized placebo-controlled trial [21, 
24], is especially useful for patients with dyspha-
gia and treatment-resistant DM.  Intravenous Ig 
is, however, expensive and limited in availability. 
Cyclophosphamide, given as monthly intrave-
nous pulses for 3–6 months, is also an option for 
patients with respiratory muscle weakness, inter-
stitial lung disease, or cardiac involvement [25]. 
Plasmapheresis has also been studied, but was 
not found to be helpful in a double-blind placebo- 
controlled trial [26]. Rituximab, a CD20 mono-
clonal antibody that depletes B cells, has been 
reported to have a favorable effect in small open- 
label uncontrolled trials [27, 28]. A new double- 
blind, placebo-phase trial in refractory adult and 
pediatric myositis using rituximab revealed good 
results [29]. Tumor necrosis factor inhibitors 
such as infliximab, adalimumab, and etanercept 
are ineffective in treating IID and may cause 
deterioration or trigger the disease [30]. Other 
biological agents that may be considered as 
experimental treatments include alemtuzumab, 
which is reportedly effective in polymyositis 
[31], and anti-complement C3 (eculizumab), 
which may be effective for the treatment of der-
matomyositis. Overall, the long-term outcome of 
inflammatory myopathies has substantially 
improved, with a 10-year survival rate of more 
than 90% . Table  9.12 shows a step-by-step 
approach in the management of IID [32].
Input of physiotherapist is also valuable 
because randomized controlled trials among 
patients with IIM have demonstrated that exer-
cise therapy, adapted to the patient’s condition, is 
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beneficial and safe [33]. Benefits of exercise not 
only include improved muscle endurance, 
strength, and functional abilities but also prevent 
muscle wasting and fibrotic contractures.
Acknowledgments The authors would like to thank 
Haytham Abbas, MD, for his contributions to this chapter 
in the previous edition.
References
 1. Dalakas MC. Toxic and drug-induced myopathies. J 
Neurol Neurosurg Psychiatry. 2009;80:832–8.
 2. Horak HA, Pourmand R.  Neurol Clin. 
2000;18(1):203–13.
 3. Thompson PD, Clarkson P, Karas RH.  Statin- 
associated myopathy. JAMA. 2003;289:1681.
 4. Afifi AK, Bergman RA, Harvey JC. Steroid myopa-
thy. Clinical, histologic and cytologic observations. 
Johns Hopkins Med J. 1968;123:158.
 5. Horak HA, Pourmand R.  Endocrine myopa-
thies. Neurol Clin. 2000;18:203–13. https://doi.
org/10.1016/S0733-8619(05)70186-9.
 6. McKeran RO, Slavin G, Ward P, et  al. Hypothyroid 
myopathy. A clinical and pathological study. J Pathol. 
1980;132:35.
 7. Cicala MV, Mantero F. Primary aldosteronism: what 
consensus for the diagnosis. Best Pract Res Clin 
Endocrinol Metab. 2010;24:915–21. https://doi.
org/10.1016/j.beem.2010.10.007.
 8. Del Porto LA, Liubinas SV, Kaye AH.  Treatment 
of persistent and recurrent acromegaly. J Clin 
Neurosci. 2011;18:181–90. https://doi.org/10.1016/j.
jocn.2010.10.003.
 9. Yildirim Donmez F, Feldman F. Muscle compromise 
in diabetes. Acta Radiol. 2008;49:673–9. https://doi.
org/10.1080/02841850802105269.
 10. Emery AE.  The muscular dystrophies. Lancet. 
2002;359:687.
 11. Briani C, Doria A, Sarzi-Puttini P, Dalakas 
MC. Update on idiopathic inflammatory myopathies. 
Autoimmunity. 2006;39:161e70.
 12. Yazici Y, Kagen LJ. Clinical presentation of the idio-
pathic inflammatory myopathies. Rheum Dis Clin 
North Am. 2002;28:823–32.
 13. Targoff IN.  Immune manifestations of inflam-
matory muscle disease. Rheum Dis Clin N Am. 
1994;20:857–80.
 14. Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad 
Dermatol. 998(39):899–920.
 15. Sigurgeirsson B, Lindelof B, Edna O, Allander 
E. Risk of cancer in patients with dermatomyositis or 
polymyositis. N Engl J Med. 1992;326:363–7.
 16. Ghaoui R, Clarke N, Hollingworth P, Needham 
M. Muscle disorders: the latest investigations. Intern 
Med J. 2013;43(9):970–8.
 17. Suresh E, Wimalaratna S. Proximal myopathy: diag-
nostic approach and initial management. Postgrad 
Med J. 2013;89(1054):470–7.
 18. Weisberg LA, Strub RL, Garcia CA, Strub 
AC. Diseases of muscle and neuromuscular junction. 
In:  Essentials of clinical neurology: University Park 
Press; 1983.
 19. Inflammatory myopathies. Postgrad Med J. 
2006;82:417–24. 59
 20. Greenberg SA. Inflammatory myopathies: evaluation 
and management. Semin Neurol. 2008;28:241–9.
 21. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled 
trial of high-dose intravenous immune globulin infu-
sions as treatment for dermatomyositis. N Engl J 
Med. 1993;329:1993–2000.
 22. Chawla J. Stepwise approach to myopathy in systemic 
disease. Front Neurol. 2011;2:49.
 23. Bunch TW.  Article first published online: 23 Nov 
2005. https://doi.org/10.1002/art.1780240107.
 24. Wang DX, Shu XM, Tian XL, et  al. Intravenous 
immunoglobulin therapy in adult patients with poly-
myositis/dermatomyositis: a systematic literature 
review. Clin Rheumatol. 2012;31:801–6.
 25. Al-Janadi M, Smith CD, Karsh J. Cyclophosphamide 
treatment of interstitial pulmonary fibrosis in polymy-
ositis/dermatomyositis. The Journal of Rheumatology, 
1989;16(12):1592—6. http://europepmc.org/abstract/
MED/2625692.
Table 9.12 Approach to treatment of inflammatory 
myopathies
Clinical situation Treatment for IID
New-onset disease Prednisone (0.75–1 mg /
kg) for 4–12 weeks






3–5 days and then switch 
to oral
If patient responds to 
glucocorticoids








globulin (2 g/kg in 
divided doses over 
2–5 days)







Dalakas, Marinos C. “Inflammatory muscle diseases.” 
New England Journal of Medicine 372.18 (2015): 
1734–1747
H. Almoallim et al.
207
 26. Miller FW, Leitman SF, Cronin ME, et al. Controlled 
trial of plasma exchange and leukapheresis in poly-
myositis and dermatomyositis. N Engl J Med. 
1992;326:1380–4.
 27. Levine TD.  Rituximab in the treatment of dermato-
myositis: an open-label pilot study. Arthritis Rheum. 
2005;52:601–7.
 28. Chung L, Genovese MC, Florentino DF. A pilot trial 
of rituximab in the treatment of patients with derma-
tomyositis. Arch Dermatol. 2007;143:763–7.
 29. Rituximab in the treatment of refractory adult and 
juvenile dermatomyositis and adult polymyositis. 
Arthritis Rheum. 2013;65(2):314–24. https://doi.
org/10.1002/art.37754.
 30. Brunasso AMG, Aberer W, Massone C. New onset 
of dermatomyositis/polymyositis during anti-
TNF-α therapies: A systematic literature review. 
The Scientific World Journal; 2014. https://doi.
org/10.1155/2014/179180.
 31. Thompson BEN, Corris P, Miller JAL, Cooper 
RG, Halsey JP, Isaacs JD, Rheumatologist C. 
Alemtuzumab (Campath-1H) for Treatment 
of Refractory Polymyositis. The Journal of 
Rheumatology. 2008;35(10):2080–2. http://www.
jrheum.org/content/35/10/2080.abstract.
 32. Yin G, Liang Y, Deng R, Wang Y, Xie QB, Zuo C. 
[Survival analysis and risk factors for survival in 
idiopathic inflammatory myopathies: a retrospective 
cohort study]. Sichuan Da Xue Xue Bao Yi Xue Ban. 
2013;44(5):818–22. Chinese. PMID: 24325120.
 33. Habers GE, Takken T.  Safety and exercise training 
in patients with an idiopathic inflammatory myopa-
thy: a systematic review. Rheumatology (Oxford). 
2011;50:2113–24.
Open Access  This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in 
any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to 
the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, 
unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons 
license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to 
obtain permission directly from the copyright holder.
9 Diagnostic Approach to Proximal Myopathy
209© The Author(s) 2021 





Bone is a target tissue in many inflammatory dis-
eases including rheumatic diseases such as rheu-
matoid arthritis (RA), ankylosing spondylitis 
(AS), systemic lupus erythematosus (SLE), and 
psoriatic arthritis.
A relationship between inflammation and 
bone disease has been established in a variety of 
clinical settings and animal models of inflamma-
tory disease [1–4]. It has been established that the 
nature of the inflammatory disease can influence 
on the extent and type of bone disease and that 
even a small rise in the level of systemic inflam-
mation can impact on bone remodeling and 
increase fracture risk [5].
The inflammatory joint disorders, namely, 
rheumatic diseases, are usually accompanied 
with extra-articular side effects, mainly bone 
loss, or osteoporosis that would result in an 
increased risk of fractures and deformities, which 
are in turn associated with increased morbidity 
and mortality [6]. Therefore, such types of mus-
culoskeletal diseases are considered as one of the 
major causes of disability around the world and 
can explain the enormous cost of the musculo-
skeletal conditions to the community.
In order to easily understand the underlying 
pathology and mediators that affect bones in 
rheumatic conditions, a brief overview on bone 
structure, biology, physiology, and essential 
molecular mechanism and signaling pathways 
needs to be explained clearly.
10.2  Objectives
 1. To explain the underlying bones pathology 
among patients with rheumatic diseases.
 2. To identify the common bone lesions occur 
with rheumatic diseases.
 3. To recognize the serious impact of developing 
secondary osteoporosis among patients with 
rheumatic diseases.
 4. To provide an updated approach for preven-
tion and treatment of glucocorticoid-induced 
osteoporosis (GIOP) and bone fractures 
among patients with rheumatic diseases 
receiving glucocorticoids.
10.3  Bone Structures
Bone is a dynamic and highly specialized form 
of connective tissue, in which the extracellu-
lar components are mineralized, thus giving the 
property of marked rigidity and strength while 
retaining some degree of elasticity. Bone repre-
sents a store of calcium and other inorganic ions 
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and actively contributes to the maintenance of 
calcium homeostasis.
Two types of bone can be identified macro-
scopically: compact or cortical bone and cancel-
lous or trabecular bone. Microscopically both 
types of bone have the same histological structure. 
Like other supporting connective tissues, bone is 
composed of cells and extracellular matrix that is 
made up of 35% of organic component and 65% 
inorganic component [7]. The inorganic part con-
sists of calcium and phosphorus in hydroxyapa-
tite crystal form, while the organic component 
consists of type 1 collagen and ground substance 
containing proteoglycan aggregates and several 
specific structural glycoproteins [8] (Fig. 10.1).
10.4  Bone Remodeling and Bone 
Cells
Bone remodeling is the lifelong process whereby 
old bone is removed by bone resorbing cells and 
subsequently replaced by new bone via the action 
of bone-forming cells to maintain the bone struc-
ture. Bone remodeling occurs normally in all 
individuals, and in adults about 25% of trabecular 
and 3% of cortical bone is replaced by such pro-
cess each year [9]. Bone remodeling also helps 
to maintain mineral homeostasis via the libera-
tion of calcium and phosphorus into the circula-
tion. The remodeling process occurs at discrete 
sites on cortical and cancellous bone surfaces and 
involves the integrated and sequential actions of 
osteoclasts (bone resorbing cells) and osteoblasts 
(bone-forming cells), comprising anatomic struc-
tures known as basic multicellular units (BMUs).
10.4.1  Bone Cells
Mesenchymal stem cells have the potential to dif-
ferentiate into various cell types including osteo-
blasts, chondrocytes, adipocytes, myoblasts, and 
fibroblasts. Determination of the final fate of the dif-
ferentiation process is determined by and depend-
ing on the signaling transcription pathways that are 
activated during the initial phase of differentiation 
of mesenchymal progenitor cells [10, 11].
Among the important signaling pathways 
that are responsible to direct the differentia-
tion into osteoblast lineage are the mitogen-
activated protein kinase (MAPK) and protein 
kinase A  (PKA)-dependent pathway [12] and 
Wnt-signaling pathway with its related β-catenin 
protein [13, 14]. Moreover, of the transcriptional 
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essential for osteoblast differentiation from mes-
enchymal precursors including Runx2 [15–17].
The plasma membrane of activated osteo-
blast is rich in alkaline phosphatase and exhibits 
receptors for parathyroid hormone (PTH) [18], 
whereas the nuclei have receptors for estrogens 
[19], vitamin D3 [20], and glucocorticoids [21], 
which all are involved in the regulation of osteo-
blast differentiation and activity.
Osteoblasts contribute in the synthesis and 
secretion of new organic part of bone matrix (but 
not yet mineralized), called osteoid, between the 
secreting osteoblast layer and in contact with 
older bone matrix of previously formed bone. 
This process is referred to as bone apposition 
and is completed by further mineralization of the 
newly formed bone matrix (deposition of cal-
cium salts into matrix), a process regulated by 
osteoblast too. At the end of the secreting period 
of osteoblasts, those osteoblasts are embedded 
within the bone and differentiated into osteocytes.
Osteoclasts originate from hematopoietic 
stem cells (HSCs), precisely from cells of the 
colony-forming unit of macrophage (CFU-M) 
that differentiate to multinucleated, giant, motile 
cells on stimulation with macrophage colony- 
stimulating factor (M-CSF) and receptor acti-
vator of nuclear factor-kappa B “NFkB” ligand 
(RANKL) (Fig. 10.2).
Firstly, the osteoclast progenitors proliferate 
and differentiate into mononuclear preosteoclasts 
and then fuse with each other to form multinu-
cleated cells. The terminal differentiation in this 
lineage is characterized by acquisition of mature 
phenotypic markers, such as the calcitonin recep-
tor, tartrate resistant acid phosphatase (TRAP), 
and integrin αvβ3 [22]. The mature and active 













































Fig. 10.2 Pathways regulating the development of (a) 
osteoblasts and (b) osteoclasts. Hormones, cytokines, and 
growth factors that control cell proliferation and differen-
tiation are shown above the arrows. Transcription factors 
and other markers specific for various stages of develop-
ment are depicted below the arrows. BMPs, bone morpho-
genetic proteins; Wnts, wingless-type mouse mammary 
tumor virus integration site; PTH, parathyroid hormone; 
Vit D, vitamin D; IGFs, insulin-like growth factors; 
Runx2, Runt-related transcription factor 2; M-CSF, mac-
rophage colony-stimulating factor; PU-1, a monocyte- 
and B lymphocyte-specific ets family transcription factor; 
NFB, nuclear factor B; TRAF, tumor necrosis factor 
receptor-associated factors; RANK ligand, receptor acti-




rough endoplasmic reticulum, a well-developed 
Golgi apparatus, and abundant mitochondria, 
while the surface of their plasma membrane fac-
ing bone matrix is having ruffled border (clear 
or sealing zone), which is devoid of organelles 
but rich in actin microfilaments that form a ring 
of contractile protein serving to attach the cell to 
the bone surface via integrin receptors during the 
resorptive process [8]. The clear zone is a site of 
adhesion of the osteoclast to the bone matrix and 
creates a microenvironment where bone resorp-
tion takes place. From the ruffled border, osteo-
clasts secrete collagenase (and other proteolytic 
enzymes) and pump protons (low pH) into micro-
environment and thus promoting the localized 
digestion of matrix and the dissolving of bone 
mineral (calcium salt crystal), respectively.
Several systemic and local factors have influ-
enced osteoclasts and their bone resorption 
ability. In normal physiological conditions, the 
osteoclast activity is highly balanced by those 
factors. However, in pathological conditions, this 
balance becomes disturbed such as during exces-
sive activation of the immune system, due to the 
secretion of additional pro-inflammatory cyto-
kines, produced mainly by activated T cells [23].
10.4.2  The Remodeling Cycle
The remodeling cycle is comprised of four dis-
tinct phases including activation, resorption, 
reversal, and formation phase (Fig. 10.3). Bone 
remodeling starts with activation of the lining 
cells via increasing the surface expression of 
RANKL.
In the activation phase, RANKL interacts with 
its receptor RANK, thus triggering the recruit-
ment of osteoclast progenitors to bone where 
they proliferate and differentiate into osteoclasts 
and attach tightly to the bone matrix.
Next is the resorption phase, when the acti-
vated osteoclasts possess ruffled borders under 
which the proteolytic enzymes are secreted and 
the hydrogen ions are pumped resulting in diges-
tion of collagens and dissolving the mineralized 
Activation phase
preOCLs










Fig. 10.3 Process and phases of normal bone remodeling [26]
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matrix with the formation of a resorption cavity 
and allowing the release of several growth factors 
usually stored in the bone matrix. In addition, 
there is an accumulation of high concentration of 
calcium that directly controls osteoclasts activity 
resulting in cell retraction [25] and movement of 
osteoclasts across the bone surface to resorb a new 
area. At the end of this stage, osteoclasts undergo 
apoptosis after a life span of about 3 weeks, and 
thus the process of remodeling requires the con-
tinual production of osteoclast precursors.
In the reversal phase, the remnant debris of 
matrix degradation will be removed, while the 
released growth factors including bone morpho-
genetic proteins (BMPs), fibroblast growth fac-
tors (FGFs), and transforming growth factor-β 
(TGFβ) are likely to be responsible for recruit-
ment of osteoblasts to cover the bottom of the 
resorption cavity, forming osteoid tissue until the 
cavity is filled.
In the final formation phase of bone remod-
eling, osteoblasts initially synthesize the organic 
matrix and then preside over its mineralization, 
thus completing the bone remodeling process. 
Toward the end of this process, some osteoblasts 
start to flatten and become quiescent lining cells; 
others become embedded in the matrix and dif-
ferentiate into osteocytes, while the remaining of 
osteoblasts will undergo programmed cell death.
10.4.3  Factors Influencing 
Remodeling
The rate at which new osteoblasts and osteoclasts 
are supplied and the timing of apoptosis of these 
cells are crucial determinants of bone remodeling. 
The development of osteoclasts and osteoblasts is 
controlled by growth factors and cytokines pro-
duced in the bone marrow microenvironment and 
is modulated by systemic hormones and immu-
nological mechanisms [27–30]. Certain signaling 
pathways, systemic hormones, pro-inflammatory 
cytokines, and growth factors are considered as 
fundamental regulators of bone remodeling.
Taken together, positive stimulator of osteo-
blast activity includes PTH, vitamin D3, IGFs, 
BMPs, and Wnt signaling, while those that 
promote osteoclast activation are monocyte- 
macrophage colony-stimulating factor M-CSF, 
RANKL, IL-1, and IL-6.
Eventually, the recent discovery of osteopro-
tegerin (OPG) and the subsequent identification 
of its cognate ligand, OPG ligand (OPGL or 
RANKL), have illuminated our understanding of 
the molecular basis that links between osteoblas-
togenesis and osteoclastogenesis and thereby the 
rate of bone remodeling upon which other inputs 
(hormonal, biomechanical, etc.) operate.
10.4.4  RANK/RANKL/OPG System
Despite that the principal function of the osteo-
blasts is to synthesize bone matrix proteins and 
to enhance bone mineralization, osteoblasts also 
play a crucial role in osteoclast biology that has 
been clearly demonstrated by the release of key 
molecules, which regulate osteoclastogenesis and 
bone resorption. Of these regulators are RANKL 
which is expressed on the surface of the osteo-
blast and interact with its receptor RANK [22] to 
mediate signals for osteoclast proliferation, dif-
ferentiation, activation, and function [31] (Fig. 
10.4), while OPG is acting as a decoy receptor 
for RANKL [32], noting that the OPG/RANK/
RANKL system accounts only for signaling of 
osteoblasts to osteoclasts.
The human RANK is a polypeptide of 616 
amino acids, related to the type 1 transmembrane 
protein class [33], and is expressed in various 
tissues such as the skeletal muscle, liver, and 
small and large intestines. Among bone cells 
RANK- mRNA is exclusively expressed in osteo-
clast precursor cells [22, 32]. On the other hand, 
RANKL is a TNF-related cytokine that exists in 
both transmembrane, the predominant form, and 
soluble (cleaved) forms [22]. The gene expres-
sion of RANKL can be found abundantly in the 
skeleton and lymphoid tissues and is produced by 
osteoblasts, bone marrow stromal cells, and other 
cells under the control of various pro-resorp-
tive growth factors, hormones, and cytokines. 
Moreover, osteoblasts and stromal cells produce 




Collectively, RANKL is of great importance 
for the development and function of osteoclasts 
through binding to its transmembrane-signaling 
receptor RANK [35]. RANK-RANKL interac-
tions lead to pre-osteoclast recruitment, fusion 
into multinucleated osteoclasts, osteoclast acti-
vation, and osteoclast survival. These effects are 
very selective to bone and can be inhibited by the 
natural, soluble, decoy receptor OPG [32].
OPG is considered as a humoral regulator of 
bone resorption. It blocks osteoclast maturation 
and differentiation, and subsequently it can pro-
tect the bone from both normal osteoclast remod-
eling and ovariectomy-associated bone loss [36].
Certain human adult tissues showed a high 
level of OPG mRNA expression, namely, the 
heart, the bone, the placenta, and the thyroid 
gland [37]. It has been demonstrated that OPG 
expression is upregulated in various human 
osteoblastic cell systems by 1,25-dihydroxyvita-
min D3, bone morphogenetic protein-2 (BMP-2), 
pro- inflammatory cytokines such as interleukin-1 
(IL-1) [38], estrogen [39], as well as transform-
ing growth factor-β (TGF-β) [40]. However, 
some discrepancies were noticed in the effect of 
these modulators on the expression of the OPG 
mRNA and OPG protein levels depending on 
the species of the cells used and on the stage of 
osteoblastic differentiation. In contrast, it has 
been established that glucocorticoids downregu-
late the OPG transcript in human osteoblast and 
in human marrow stromal cells [41, 42], and they 
can suppress OPG production resulting in accel-
eration of osteoclastic bone resorption [43].
10.5  Mediators of Bone Loss 
in Rheumatic Diseases
Systemic bone loss in rheumatic diseases occurs 
as a result of several factors including direct 
effects of inflammation, poor nutrition, reduced 
lean body mass, immobility, and the effects of 
therapeutic agents, specifically glucocorticoids. 
These mechanisms are complex and interrelated 
but are eventually mediated through influencing 
on the bone remodeling cycle and may result in 
increasing bone resorption, decreasing bone for-
mation, but most commonly affecting both of 
these processes.
Adding to the referred mechanisms that cause 





















Fig. 10.4 Mechanisms of action for OPG, RANKL, and RANK [34]
A. Abdulkhaliq
215
ing factors, which increase the risk of fractures 
due to bone loss, and they include age, gender, 
family history of osteoporosis, low body mass 
index (BMI), falling risk, and sedentary lifestyle 
(Fig. 10.5) [44].
The following sections will discuss the 
main underlying mechanisms that cause bone 
destruction in different rheumatic conditions, 
namely, the disease activity (inflammation), 
immobility, and treatment with glucocorticoids 
are considered. Noting that each rheumatic dis-
ease has a unique effect on articular bone or on 
other site on skeleton whether local or general-
ized bone loss, however, they remarkably share 
common pathways of skeletal remodeling (the 
RANKL/OPG pathway), which is involved in 
the regulation of bone resorption. In addition, 
most human and animal studies in the field of 
rheumatic arthritis have referred to the osteo-
clast as the principal cell type mediating bone 
loss in arthritis [45].
10.5.1  Effects of Systemic 
Inflammation
Inflammatory process in rheumatic diseases is 
usually associated with skeletal destruction. 
The effects of inflammation in induction bone 
loss involve two mechanisms, the role of pro- 
inflammatory cytokines and/or the role of inflam-
matory cells.
10.5.1.1  Role of pro-Inflammatory 
Cytokines
• Many of the pro-inflammatory cytokines and 
growth factors (Fig. 10.6) [46] involved in the 
inflammatory processes in rheumatic diseases 
have been found to have a great impact on 
osteoclast differentiation and activation either 
directly, by acting on cells of the osteoclast 
lineage, or indirectly, by modulating the 
expression of the key osteoclastogenic factor 
(RANKL) and/or its inhibitor, OPG [47].
• Because a wide range of cytokines have posi-
tive and negative impact on OPG/RANKL 
system or directly on osteoclastogenesis, they 
are usually kept in balance in healthy subjects. 
However, imbalance of these cytokines occurs 
during inflammation but varies between dis-
ease states, and this variation would account 
for differences in predisposition to bone loss.
• The cytokines that have positive (stimulatory) 
effects on osteoclastogenesis include TNF-α, 
IL-1b, IL-6, IL-11, and IL-17, whereas those 
that have negative (inhibitory) effects include 
interferon (IFN)-γ, IL-4, and transforming 
growth factor-β (TGF-β) [48].
• For instance, tumor necrosis factor-alpha 
(TNF-α) can increase the expression of 
RANKL by osteoblasts and hence induce 
osteoclastogenesis and the bone-resorbing 
activity. However, TNF-α and interleukin-1 
(IL-1) can synergize with RANKL to directly 
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10.5.1.2  Role of Inflammatory Cells
• Under normal conditions, RANKL is derived 
from osteoblasts; however, during inflamma-
tion, a variety of inflammatory cells can also 
produce RANKL including lymphocytes and 
fibroblasts, which have been found in the 
inflamed synovium in various studies [49–51]. 
The expression or production of RANKL on/
from non-osteoblastic cells causes a direct 
osteoclastogenic effect independent of 
osteoblasts.
• An example of these cells is T lymphocytes 
that are derived from Th17 subset, which has 
been called so after the ability of these lym-
phocytes to secrete IL-17, and hence they are 
considered to have an osteoclastogenic cyto-
kine profile [52]. The presence of this lympho-
cyte subset prominently in inflammatory 
arthritis could explain the tendency to local 
osteoclastogenesis and thus bone destruction 
in this condition [53].
• A subsequent to the increased bone resorp-
tion, there should be also a stimulation of bone 
formation because the processes of bone 
resorption and formation are normally tightly 
coupled. However, during chronic inflamma-
tion, “uncoupling” of bone formation from 
resorption occurs with a suppressed or 



























Fig. 10.6 Illustration of the impacts of chronic inflammatory disease on bone formation and resorption. A stimulatory 
effect is indicated by C and an inhibitory effect by K [46]
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10.5.1.3  Causes of Uncoupling 
Process
The Wnt Signaling and its 
Antagonist, DKK1
Studying animal models of inflammatory arthri-
tis could explain the uncoupling process via the 
implication of the Wnt-signaling pathway and 
precisely the Wnt antagonist dickkopf-1 (DKK1), 
in this process [54].
The canonical Wnt-signaling pathway is 
essential for bone development, directing dif-
ferentiation of mesenchymal precursor cells into 
mature osteoblasts, as well as having a major 
role in the normal development of the skeleton 
in the embryo [55, 56]. The naturally occurring 
soluble Wnt antagonists such as DKK1, which 
suppress this process, are important during nor-
mal bone remodeling. This finding has been sup-
ported by that the DKK1 knockout mice develop 
an increased bone mass [57] and conversely 
myeloma cells with aberrant DKK1 expression 
are associated with purely lytic lesions with little 
evidence of bone formation [58].
The synovial fibroblast can secrete DKK1; 
however, in rheumatoid arthritis, the secretion 
is enhanced by TNF-α, and thus the circulating 
levels of DKK1 have been found much elevated 
in those patients [54]. Thus, the secreted DKK1 
from the synovium would have a suppressive 
effect on osteoblast maturation and on OPG 
function leading to inhibition of local bone for-
mation and increased bone resorption, respec-
tively. Understanding the mechanism of Wnt 
signaling and its antagonist, DKK1 (Fig.  10.7), 




















Fig. 10.7 Schematic illustration of the possible role of 
DKK1 in the bone remodeling imbalance in inflammatory 
joint disease. Production of DKK1 in response to TNF-α 
production by inflammatory cells is proposed to inhibit 
bone formation but increase bone resorption by osteo-




antibody would be able to prevent bone erosions 
and reverse this block on osteoblast formation 
which resulted in a paradoxical excess of bone 
formation during inflammation as proved by the 
development of new osteophytes [54].
Alteration of Glucocorticoid Signaling
The effects of glucocorticoids will be explained 
later in the following sections, but the current 
paragraph will discuss the influence of inflam-
mation on glucocorticoid action in bone cells. 
Because of the intracellular metabolism of 
glucocorticoids by 11b-hydroxysteroid dehy-
drogenases (11β-HSDs) [59], it has become 
known that the levels of active glucocorti-
coids present within the circulation differ from 
that in the tissues. Specifically, 11β-HSD1 
enzyme is expressed on osteoblast and can 
increase local glucocorticoid action in these 
cells by converting the inactive glucocorti-
coids such as cortisone and prednisone to their 
active counterparts’ cortisol and prednisolone, 
respectively.
Overexpression of the enzyme in osteoblasts 
reduces proliferation and the synthesis of bone- 
specific proteins such as osteocalcin when cells 
are exposed to inactive glucocorticoids [60, 
61]. It was reported previously by [62] that pro- 
inflammatory cytokines such as TNF-α or IL-1b 
can effectively induce the expression and activ-
ity of this enzyme in osteoblasts. Thus, during 
inflammation, osteoblasts at the site of bone 
exposed to pro-inflammatory cytokines are 
likely to also be exposed to high doses of locally 
active glucocorticoid [62, 63]. This is potentially 
a major mechanism by which the uncoupling 
process of osteoblasts and osteoclasts occurs. 
Overall, a high glucocorticoid level in osteo-
blasts will decrease bone formation through 
direct effects on osteoblasts [64], but it can also 
induce osteoclastogenesis due to upregulation of 
RANKL and downregulation of OPG in osteo-
blast precursors [42].
Studying the correlation of locally generated 
glucocorticoids with other proposed mechanisms 
of uncoupling such as DKK1 induction is essen-
tially needed for therapeutic purposes of rheu-
matic diseases.
10.5.2  Effects of Immobility
Immobility has consequences on all inflamma-
tory diseases specifically neuromuscular and 
joint disease. The major impact on bone occurs 
due to uncoupling process that results in reduced 
bone formation and increased bone resorption 
[65] with overall bone loss. It has been found 
that osteocytes mediates mechanosensing, which 
means they can response to mechanical strain and 
maintain bony matrix via modulation of the major 
pathways such as the Wnt pathway that couple 
bone formation and resorption [66]. This effect 
may partly be dependent on estrogen receptor 
signaling, and thus hypogonadism would reduce 
the mechanosensing [67].
Regular exercises can maintain force on bone 
and thus control bone loss through mechani-
cal stimulation. However, a more advanced 
approach is the administration of a vibration 
signal that could stimulate mechanosensing 
effects, which in turn will induce an anabolic 
response to bone [46].
10.5.3  Effects of Glucocorticoids
Glucocorticoids (GCs) are frequently prescribed 
for patients with variety of chronic inflammatory 
diseases such as rheumatic diseases. An excess 
of circulating GCs has a major negative effects 
on bone [64, 68, 69]. These adverse effects on 
bone are owing to reduced bone formation, char-
acterized by a low mineral apposition rate that 
is explained by decreased numbers of osteo-
blasts, while bone resorption is unchanged or 
even elevated [70], leading to the development of 
glucocorticoid- induced osteoporosis (GIOP).
Overall negative effects of GCs on bone are 
either directly on bone cells or indirectly by 
affecting the bone metabolism. The underly-
ing molecular mechanisms of GIOP include the 
increased apoptosis of osteoblasts and osteocytes 
and increased half-life time of osteoclasts, i.e., 
the direct effects on bone cells (Fig. 10.8) [71]. 
It has been reported that the increased osteoblast 
apoptosis results in a significant reduction in 
bone formation, while decreased osteocyte num-
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bers result in a disturbed osteocyte-canalicular 
network and thus failure to respond to bone dam-
age [72].
The process of apoptosis is induced by activat-
ing caspase-3 [73] and glycogen synthases kinase 
3β (GSK3β), which suppresses the Wnt-signaling 
pathway by increasing the production of DKK-1, 
the Wnt pathway inhibitor [74, 75].
In addition to the increased apoptosis of 
osteoblasts, GCs impair osteoblast function by 
suppressing osteoblast differentiation [76] via 
interfering with both the bone morphogenetic 
protein (BMP) pathway and the Wnt-signaling 
pathway.
Moreover, recent studies proposed that high 
doses of GCs cause a shift of bone marrow stro-
mal cells, the precursor cells of osteoblasts, to 
differentiate toward adipocytes instead of osteo-
blasts. This is mainly achieved either through 
an increased expression of the peroxisome 
proliferator- activated receptor-γ2 (PPR- γ2) and 
repression of the osteogenic transcription fac-
tor Runt-related protein 2 [77] or via suppres-
sion of AP-1, a process that not only mediates 
anti- inflammatory actions but also reduces bone 
strength [78].
In contrast to increased apoptosis of osteo-
blasts and osteocytes, GCs therapy would reduce 
the apoptosis of osteoclasts by extending their 
life span through upregulation of RANKL and 
suppression of OPG [42].
Likewise direct effects on osteoblasts, osteo-
cytes, and osteoclasts, GCs have indirect effects 
on bone (Fig.  10.9). Previous studies asserted 
that GCs impair bone metabolism by inhibit-
ing both the gastrointestinal absorption and the 
renal tubular reabsorption of calcium, leading 
to hypocalcaemia and the subsequent hyper-
parathyroidism [71]. Recent reports referred 
that GCs have influenced the bone mineraliza-
tion by decreasing the production of important 
proteins for matrix formation, namely, osteocal-
cin and type 1 collagen [69]. Furthermore, GCs 
can cause steroid myopathy [79] [4] that may 
increase the risk of falling and thus indirectly 
increase the fracture risk.
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Fig. 10.8 The direct effects of glucocorticoids on bone [71]
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10.6  Common Bone Diseases 
Associated with Rheumatic 
Disease
Osteoporosis-related fragility fractures repre-
sent one of the most important complications that 
may occur in patients with rheumatic diseases; 
obviously, these fractures may contribute to an 
important decrease in quality of life, and hence 
osteoporosis becomes increasingly recognized as 
an eminent public health problem.
Osteoporosis is a metabolic bone disease 
characterized by both low bone density (mass) 
and low bone quality, which includes not only 
microarchitecture deterioration of bone tissue 
but also alterations in bone remodeling, damage 
accumulation (e.g., microfractures), and min-
eralization. These changes in bone density and 
quality enhance bone fragility with a consequent 
increase in fracture risk after minimal trauma. 
Osteoporosis is caused by an imbalance between 
bone formation and resorption with in favor of 
bone resorption over bone formation, leading to 
altered bone remodeling.
The reduction in bone mass can be quantified 
by measurement of bone mineral density (BMD) 
using dual-energy x-ray absorptiometry (DXA), 
which is the diagnostic method of osteoporosis 
[80]. Therefore, osteoporosis can be defined by 
DXA result when T score is ≤2.5 (i.e., bone den-
sity is 2.5 standard deviation below estimated 
peak BMD for the population), whereas osteo-
penia is defined when a T score is between −1 
and −2.5.
10.6.1  Rheumatoid Arthritis 
and Bone Loss
Rheumatoid arthritis (RA) is characterized 
by three types of bone lesions: periarticular 
osteopenia, bone erosions, and osteoporosis:
Effects of Corticosteroid on Bones
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Fig. 10.9 The indirect effects of glucocorticoids on bone [71]
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• Periarticular osteopenia is one of the first 
radiographic signs of RA. It appears markedly 
in early disease and is mainly associated with 
disease activity.
• Bone erosions develop within the first months 
of the disease onset and account as the radio-
graphic sign of RA and reflect undesirable 
prognosis of RA. Hence, the extent and sever-
ity of the erosions reflect the increasing dis-
ease activity and indicate the disability of the 
disease.
Within 6  months of disease onset, less than 
50% of patients showed radiographic erosions, 
while almost 70% of the patients have erosions 
detected by MRI [81–83] and may be accom-
panied by bone edema, where CD34+ cells and 
potential osteoclast precursors [84] can be found 
during joint aspiration.
• Osteoporosis in RA is mainly characterized 
by marked loss of bone in the hip and the 
radius, while the axial bone is scarce, a pattern 
not similar to that of postmenopausal osteopo-
rosis. In addition, several cross-sectional stud-
ies reported a lower bone mineral density 
(BMD) in patients with RA, with a twofold 
increase in osteoporosis compared to age- and 
sex-matched controls.
10.6.1.1  Predisposing Factor 
of Osteoporosis in RA
In addition to the risk factors of osteoporosis 
(Fig.  10.5), other factors may also contribute 
in RA, such as muscle wasting, glucocorticoids 
therapy, and disease duration. Interaction between 
several factors should be considered, for exam-
ple, additional muscle wasting contributes to 
increased immobilization [85].
10.6.1.2  Pathological Process
• Several evidences suggested the presence of 
osteoclasts at the site of bone erosions, indicat-
ing the increased of bone resorption [86, 87].
• In RA, the local and generalized bone loss 
share common pathways: the RANKL/OPG 
pathway. The main inflammatory cytokines 
that have been found in RA and involve in 
upregulating RANKL, with subsequent acti-
vation of osteoclastogenesis, include TNF-α, 
IL-1, IL-6, and IL-17 [88, 89].
• The Wnt-signaling pathway is another path-
way that regulates osteoblast activity, and thus 
the activation of the Wnt/β-catenin pathway is 
crucial for osteoblastic differentiation [90, 
91]. There are two blockers of the Wnt- 
signaling pathway, dickkopf-1 (Dkk-1) and 
sclerostin, both of which play an important 
role in the pathogenesis of RA.  TNF-α can 
induce both sclerostin and Dkk-1 [89], leading 
to inhibition of osteoblastic differentiation.
• Further studies in RA patients confirmed these 
pathological processes and revealed that OPG/
RANKL ratio was lower than in healthy con-
trols, while Dkk-1 and sclerostin were higher. 
After treatment with anti-IL-6, OPG/RANKL 
increased, Dkk-1 decreased, and sclerostin 
increased [92].
10.6.1.3  Management of Bone Loss 
in RA
• Recent treatments with biological agents were 
introduced in patients with rheumatoid arthri-
tis. All available TNF-alpha blocking agents 
are quite successful in the prevention of ero-
sion formation.
• However, progression of structural damage 
in RA patients treated with methotrexate can 
be avoided by denosumab, a fully human 
monoclonal IgG2 antibody that binds 
RANKL [93].
• It has also been found that in patients with RA 
treated with infliximab, the bone loss was 
abolished in the spine and hip, but not in the 
metacarpal cortical hand [94].
• Moreover, preventing the loss of vertebral 
strength in patients with RA can be principally 
achieved by treatment with alendronate [95].
• After this extensive review, here comes the 
value of early diagnosis of RA and early and 
aggressive intervention with disease- 
modifying anti-rheumatic drugs (DMARDs) 




10.6.2  Systemic Lupus 
Erythematosus and Bone Loss
10.6.2.1  Predisposing Factors of Bone 
Loss in SLE
• In addition to the traditional background fac-
tors, there are also disease-related factors 
(Fig.  10.5) such as inflammation, metabolic 
factors, hormonal factors, serologic factors, 
and medication-induced adverse effects [96].
• Another factor that may contribute in 
decreased BMD in SLE is the associated high 
frequency of vitamin D deficiency [97–99], a 
metabolic condition that induces bone loss. 
Vitamin D deficiency might induce bone loss 
in SLE via several factors including (a) photo-
sensitivity (so patients avoid exposure to the 
sun and use sunscreens), (b) dark skin pig-
ment, (c) renal failure, and (d) treatment with 
GC (has a dual action, it can induce bone loss, 
but also it has a beneficial effect on bone mass 
by suppressing inflammation) and possibly 
hydroxychloroquine (HCQ) (via inhibiting 
hydroxylase α1 that form active vitamin D), 
which showed a controversial results [98, 
100]. Due to these inconsistent results of 
HCQ, further studies in large groups of SLE 
patients and patients with other diseases 
treated with HCQ are needed to clarify the 
relationship between HCQ uses and bone 
metabolism.
• Changes in hormonal pattern may also nega-
tively influence the BMD in patients with 
SLE, where a relatively high estrogenic and 
low androgenic state and a decrease in dehy-
droepiandrosterone (DHEA) have been dem-
onstrated and associated with low BMD [101].
• Collectively, the factors that may adversely 
affect bone mass, resulting in osteoporosis 
and possible fracture risk in SLE, have been 
summarized in Table 10.1.
10.6.2.2  Pathological Process
• Chronic systemic inflammation is a cause of 
bone loss in SLE, where the activated inflam-
matory cells at sites of inflammation produce 
a wide spectrum of cytokines that stimulate 
local and generalized bone resorption.
• Researchers have revealed increased serum 
levels of tumor necrosis factor (TNF) [103] 
and oxidized low-density lipoprotein (LDL) 
[104] in patients with active lupus. Oxidized 
LDL stimulates the activation of T cells, 
which in turn can increase the production of 
RANKL and TNF.  Consequently, TNF and 
RANKL will induce the maturation and acti-
vation of osteoclasts [103]. In addition, oxi-
dized LDL has the ability to inhibit osteoblast 
maturation, and hence it can negatively influ-
ence bone formation [105].
• Moreover, high levels of homocysteine 
(caused by inflammation) have been reported 
in patients with SLE, and this might be attrib-
uted to the accelerated bone loss [106, 107] 
via enhancing the bone resorption and reduc-
tion of bone formation.
• Until recently, the previous clinical studies 
have not been able to demonstrate the associa-
tion between bone loss in SLE and the disease 
activity score [108–110]. However, several 
Table 10.1 Summary of risk factors for osteoporosis in 
patients with SLE [101]
Risk factors for osteoporosis in patients with SLE
Non-modifiable risk factors
  •  Caucasian or Asian ethnicity.
  •  Female sex.
  •  Advanced age.
  •  Personal or family history of osteoporotic 
fractures.
  •  High risk of falls.
  •  Premature menopause.
Modifiable risk factors
  •  Weight < 127 lb. (58 kg).
  •  Inadequate calcium and vitamin D intake.
  •  Lifestyle habits: Smoking, alcohol use, high 
number of sedentary hours daily.
Risk factors specific for systemic lupus 
erythematosus
  •  Medication use [glucocorticoids, gonadotropin- 
releasing hormone agonists, cytotoxic drugs, 
antimalarial agent (HCQ)].
  •  Metabolic causes.
  –  High frequency of vitamin D deficiency.
  –  High homocysteine level.
  –  Hormonal changes in SLE, a relatively high 
estrogen and low dehydroepiandrosterone 
(DHEA) [100]
  •  Prolonged active SLE.
  •  Systemic and localized inflammation.
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studies showed an association between organ 
damage and reduced BMD [111], and because 
prolonged active SLE usually causes organ 
damage in the patients, this finding suggests 
that disease activity contributes to reduced 
BMD in SLE. Moreover, the Hopkins Lupus 
Cohort study [112] has established that low 
complement C4 levels (a measure of active 
disease) were a predictor of low spine BMD 
among patients with SLE.
10.6.2.3  Management of Bone Loss 
in SLE
• To approach bone health in SLE patients, the 
underlying risk factors for bone loss should be 
evaluated. For instance, evaluation of calcium 
and vitamin D levels and homocysteine status 
is recommended. Although there is not enough 
data relating the low levels of vitamin D and 
SLE activity, the possible association would 
suggest that replacement of vitamin D may 
have benefits beyond bone health for those 
patients [113].
• Supplementation with vitamin D should aim 
to keep the serum 25-hydroxyvitamin D 
[25(OH)D] level above 25  ng/mL, and cal-
cium supplementation should be at the recom-
mended daily allowance for the age of the 
patient (Table 10.2).
• Bear in mind that it takes approximately 
3  months to achieve a steady state of 
25(OH)D level once vitamin D supplemen-
tation is started, so rechecking a 25(OH)D 
should not be done earlier than 3  months 
[114, 115].
• Moreover, if homocysteine levels are ele-
vated, folic acid should be initiated at 1 mg 
daily [116].
• Patients with SLE are at increased risk of 
bone loss due to the synergistic effect of the 
inflammatory process and its treatment with 
corticosteroids; therefore adequate manage-
ment is essential to prevent osteoporotic 
fractures and maintain BMD.  However, all 
preventative measures and pharmacological 
therapy will be mentioned later on under the 
section of “Glucocorticoid- Induced 
Osteoporosis” according to ACR 2010 
recommendations.
10.6.3  Ankylosing Spondylitis 
and Bone Loss
Inflammation in ankylosing spondylitis (AS) 
is characterized by subchondral bone marrow 
edema with subchondral bone erosive lesions 
and eventually to subchondral new bone forma-
tion through the articular cartilage and ossifica-
tion of the periarticular ligaments [85].
Bone edema is accounted as a sign of inflam-
matory activity and may affect limited or exten-
sive parts of vertebrae (Fig.  10.10). Recent 
studies suggested a possible sequence of events 
of new bone formation in AS, as follows: first 
erosions at the site of inflammation, followed by 
repair reaction, and subsequently ended by new 
bone formation (10).
• For instance, at the corners of the vertebral 
bodies, there might be marginal erosive 
lesions with adjacent subchondral edema and 
sclerosis (Romanus lesion). Also, a new peri-
osteal intraosseous bone formation was found 
and provided the typical picture of squaring of 
the vertebrae [85].
Table 10.2 ACR 2010 Recommendations on counseling 
for lifestyle modification and assessment of patients start-
ing glucocorticoids at any dose of >3 months duration
ACR 2010 recommendations on counseling for lifestyle 
modification
  •  Weight-bearing activities
  •  Smoking cessation
  •  Avoidance of excessive alcohol intake (>2 drinks 
per day).
  •  Nutritional counseling on calcium and vitamin D 
intake.
  •  Fall risk assessment .
  •  Baseline dual x-ray absorptiometry .
  •  Serum 25-hydroxyvitamin D level .
  •  Baseline height .
  •  Assessment of prevalent fragility fractures .
  •  Consider radiographic imaging of the spine or 
vertebral fracture assessment for those initiating 
or currently receiving prednisone 5 mg/day or its 
equivalent.
  •  Calcium intake (supplement plus oral intake) 
1200–1500 mg/daya.
  •  Vitamin D supplementationa.
aRecommendations for calcium and vitamin D supple-
mentation are for any dose or duration of glucocorticoids, 
rather than a duration of 3 months
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10.6.3.1  Fracture Risk in AS
Subsequent results to bone changes in AS lead 
to an increase in bone loss (osteoporosis) and 
bone fragility and therefore increased the risk 
of bone fractures.
• AS is associated with an elevated risk of verte-
bral fractures, which are six to seven times 
higher than in healthy population [117, 118], 
and these fractures are often accompanied by 
neurological signs and symptoms [119]. 
However, the increased in morphometric and 
clinical vertebral fractures [120] but not in 
peripheral (forearm or hip) fractures indicates 
a more local effect of AS on bone, unlike RA, 
where the inflammatory effects are more sys-
temic. Furthermore, despite sharing similar 
pathogenesis of osteoporosis but with differ-
ent clinical phenotypes, bone loss in AS is 
accompanied by new bone formation contrast-
ing to RA and postmenopausal conditions,
• Of most important types of spinal fractures in 
AS includes wedging fracture, which contrib-
utes to spine rigidity and hyperkyphosis of 
upper part of the spine and impaired physical 
function [119, 121, 122]. In addition to wedg-
ing fracture, structural damage of the spine 
and the disease activity are other significant 
contributors to hyperkyphosis [123].
10.6.3.2  Management of Bone Loss 
in AS
• Because of the concomitant bone loss and the 
new abnormal bone formation and the pres-
ence of syndesmophytes, the reliability of 
BMD measurement is affected, and there 
would be a large variation in the prevalence of 
osteoporosis in patients with AS [124, 125].
• Taken together, AS is characterized by bone 
and cartilage degradation. The bone destruc-
tion reflects the systemic inflammatory effects 
on bone density and can be inhibited by 
TNF-α blocking agent. However, the cartilage 
damage might be related to syndesmophyte 
formation, which is not influenced by anti- 
inflammatory therapy [120]. This highlights 
the suggestion that bone degradation and new 
bone formation are uncoupled mechanisms in 
AS, the reason that might make their therapeu-
tic intervention basically different.
• A remarkable but yet not confirmed finding 








Fig. 10.10 Sites of bone 
edema, bone loss, and 
bone erosion in AS [85]
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decreased in AS patients taking NSAIDs, 
which could relieve the inflammatory back 
pain and stiffness and thus improving the 
physical activity that helped in maintaining 
bone mass and reducing the risk of falling and 
subsequent fracture [126, 127]. In addition, it 
has recently been suggested that NSAIDs may 
also inhibit the formation and growth of syn-
desmophytes of AS in the spine via interfering 
with the prostaglandin metabolism. Therefore, 
if the divergent inhibitory effects of NSAIDs 
on osteoporotic fractures (bone loss) and pro-
gression of syndesmophytes (bone formation) 
can be confirmed, this would be an important 
clue in further explaining pathophysiological 
mechanisms in AS.
• In contrast to the treatment of osteoporosis in 
patients with RA, treatment of osteoporosis 
in patients with AS is not yet common. Data 
supporting the efficacy of this treatment in 
AS are rare. Of all bisphosphonates, alendro-
nate and risedronate are found to be effective 
in increasing BMD in men. Alendronate and 
risedronate significantly increase BMD in 
both vertebrae and femur, with a significant 
reduction of vertebral fractures [128, 129]. 
More recently teriparatide was tested with 
the same aims, but only a positive effect on 
BMD could be shown [130]. It is clear that 
there is a need for evidence- based knowledge 
in these fields in the near future. Our studies 
highlight the need to develop strategies to 
identify high-risk patients with AS. Research 
on the treatment of osteoporosis to prevent 
vertebral fractures in these patients is 
urgently needed.
10.6.4  Glucocorticoid-Induced 
Osteoporosis (GIOP)
Steroids are widely used in the medical practice 
to treat various diseases such as asthma, systemic 
connective tissue diseases, and other autoim-
mune diseases and in addition to rheumatic dis-
eases. Treatment with GCs results in bone loss 
within 1 month after initiation of the therapy but 
primarily occurs in the trabecular bone, so that 
it mainly increases the risk of vertebral fracture 
rather than non-vertebral fractures [79]. Fractures 
are considered the most clinically relevant risk of 
prolonged steroid therapy.
GIOP is a common type of secondary osteo-
porosis which occurs at any age and in both men 
and women. It has been known that one loss in 
GIOP is biphasic, with a rapid reduction in BMD 
of 6–12%* which occurs followed by a slower 
annual loss of about 3%* for as long as the glu-
cocorticoids are administered [131, 132].
10.6.4.1  Impact of GIOP
• As a consequent to the bone loss during GCs 
therapy, it has been reported that the relative 
fracture risk within the first 3 months after ini-
tiation of the therapy increases by 75% even 
before any BMD changes occur [133].
• Although the increase of fracture risk has 
appeared to be dose dependent [134], it was 
found to be partially reversible so that the 
fracture risk would gradually return to base-
line [135].
10.6.4.2  Approaching Managements 
of Patients with GIOP
• American College of Rheumatology (ACR) 
have developed and updated recommenda-
tions to provide guidance for prevention and 
treatment of GIOP in order to be applied by 
the physicians in light of each patient’s 
circumstances.
• ACR recommendation 2001 [136] has been 
updated and replaced by ACR recommenda-
tion 2010 [137], which had expanded the rec-
ommendations for counseling (Table  10.2) 
and monitoring updated pharmacological 
guidelines and used patient’s overall clinical 
risk instead of T score alone.
 – Afterward, ACR 2017 recommendations 
have been released for GIOP prevention 
and treatment, based on the balance of rel-
ative benefits and harms of the treatment 
options and highly considering the quality 
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of the evidence and patients’ values and 
preferences [138]. Therefore, due to lim-
ited evidence on the benefits and harms of 
interventions in GC users, most recom-
mendations in ACR 2017 guidelines are 
conditional or of good clinical practice. 
The strength of the recommendations is 
based on the fracture risk categories in 
GC-treated patients [138].
 – The ACR 2017 recommendations for GIOP 
prevention and treatment have addressed, in 
addition to all adults’ categories (< 40 years 
and > 40 years of age), special populations 
categories, namely children, people with 
organ transplants, women of childbearing 
potential, and people receiving very high-
dose GC treatment.
 – The initial approach of patients with GIOP 
begins with clinical assessment of fracture 
risk by interpreting detailed clinical and 
biochemical data, together with identifying 
the diagnostic criteria for assessment of 
bone mineral density (BMD) results, as 
follows:
 1. Clinical Assessment: This is concerned with 
having detailed medical history to identify the 
cumulative risk factors for bone loss 
(Fig.  10.11) and performing proper physical 
examination to detect any underlying medical 
conditions or evidence of osteoporosis such as 
fracture, kyphosis, and loss of height or deter-
mine muscle strength and size.
 2. Biochemical Assessment: The baseline levels 
of the following parameters are needed to be 
obtained in order to rule out any underlying 
medical diseases that may affect the outcome 
of GIOP such as low levels of calcium or vita-
min D; those would affect the bone formation 
and metabolism [137, 138]. These parameters 
include:
• Complete blood cell count.
• Serum calcium and phosphorus.
• Serum 25-hydroxyvitamin D.
• Serum-free testosterone in males.
• Estradiol in premenopausal women.
• Renal Function Tests specifically 24-hour 
urinary calcium and sodium.
• Liver function test, because healthy liver is 
important for synthesis of sex hormones.
 3. Assessment of Bone Mineral Density 
(BMD): Measuring the BMD is one of the 
salient determinants of bone strength. It can 
be measured at different sites in the body by 
distinct methods. For instance, dual-energy 
x-ray absorptiometry (DXA) measures BMD 
mainly at lumbar spine and proximal femur, 
while quantitative computed tomography 
(QCT) is used mostly to estimate bone den-
sity at the forearm, tibia, or lumbar spine. 
The World Health Organization (WHO) has 
defined the diagnostic criteria for assessment 
of BMD results (Table 10.3) [139].
 4. Assessment and Classification of Fracture 
Risk: Identifying patients with increased frac-
ture risk solely using BMD assessment has 
some limitations due to its age dependency and 
its inaccuracy in measuring bone quality. 
Therefore, it has been recommended that frac-
ture risk should be assessed using tools that cal-
culate the absolute fracture risk for a given 
patient. One of the available tools proposed by 
the World Health Organization (WHO) is called 
Fracture Risk Assessment (FRAX) tool [140].
FRAX is a unique model that is considered 
in calculating the risk of the following factors, 
age, sex, race, family history, the BMD, and 
the usage of BMD, but excludes the dosage 
and the evaluation of the risk factors of falls 
and the presence or absence of prevalent ver-
tebral deformities, although they are known as 
risk factors for fractures. The output of FRAX 
calculation is a 10-year probability of hip 
fracture and the 10-year probability of a major 
osteoporotic fracture (clinical spine, forearm, 
hip, or shoulder fracture) [140].
• Based on the risk factors shown in 
Fig.  10.11 as well as the FRAX results, 
adult patients receiving GC can be classi-
fied into low-, moderate-, and high-risk 
categories accordingly (Fig.  10.12). The 
ACR 2017 recommendations for GIOP 
prevention and treatment have addressed, 
in addition to all adults’ categories (< 40 
years and > 40 years of age), special popu-
lations, namely children, people with organ 
transplants, women of childbearing poten-




• Therefore, the primary implication of ACR 
2017 recommendation is to clarify that all 
clinicians treating patients with GCs have 
to be aware of the GIOP risk, identify 
patients at high fracture risk (Fig. 10.12), 
and be able to provide the appropriate treat-
ment [138].
• Moreover, the assessment of fracture risk 
may not only be useful in treatment deci-
sions, but also in improving patients’ treat-
Fig. 10.11 Risk factors that may shift an individual to a greater risk category for GIOP (ACR 2010) [137]
Table 10.3 WHO criteria 




ment compliance that would provide the 
patients a better insight into their future 
fracture risk.
10.6.4.3 Recommendations 
for Fracture Risk Assessment 
and Reassessment of Patient 
with GIOP
These recommendations are considered as good 
practice recommendations.
• Initial fracture risk assessment:
For all adults and children, an initial 
clinical fracture assessment should be per-
formed as soon within six months of the ini-
tiation of long-term GC treatment. This 
clinical assessment should include the 
following:
 – A detailed clinical history of GC use (dose, 
duration, mode, and pattern of use),
 – An evaluation of underlying risk factors 
for fracture including history of falls, frac-
tures, frailty, others such as (malnutrition, 
significant weight loss or low body weight, 
hypogonadism, secondary hyperparathy-
roidism, thyroid disease, family history of 
hip fracture, history of alcohol use [at > 3 
units/day] or smoking), and other clinical 
comorbidities.
 – A physical examination including mea-
surement of weight and height, detailed 
examination of musculoskeletal system, 
and other clinical findings of undiagnosed 
fracture (e.g., spinal tenderness, deformity, 
and reduced space between lower ribs and 
upper pelvis).
For adults >40 years old, the initial abso-
lute fracture risk should be evaluated using 
FRAX with correction of GC dose and BMD 
(if available) as prompt as possible but within 
at least six months of starting the GC therapy 
(Fig. 10.13) [138].
For adults <40 years old, BMD testing 
should be done as promptly as possible but at 
least within 6 months of starting the GC treat-
ment if the patient has a history of previous 
OP fracture(s) (high risk) or if the patient has 
Fig. 10.12 Fracture risk categories in GC-treated patients [138]
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other significant OP risk factors (Fig. 10.13) 
[138].
• Reassessment of fracture risk:
For all adults and children, if GC therapy 
is used continuously, a clinical fracture risk 
reassessment (as referred earlier) should be 
performed every 12 months. For detailed 
pathways of reassessment of clinical fracture 
risk in adults <40 and ≥40 years of age, refer 
to Fig. 10.14 [138].
10.6.4.4 Recommendations for Initial 
Treatment and Prevention 
of GIOP
• In addition to adjusting the pharmacologic 
treatment of GIOP, optimizing the dose of cal-
cium and vitamin D uptake and counseling 
lifestyle modification are included within both 
the ACR 2010 and the ACR 2017 recommen-
dations for treating patients with GIOP.
• A conditional recommendation is reported, 
generally for all adults on GC at a dose of 
≥2.5 mg/day for ≥3 months, to optimize cal-
cium intake (1000–1200 mg/day) and vitamin 
D intake (600–800  IU/day; serum level 
≥20  ng/mL) [138, 141] alongside lifestyle 
modification with regard to weight, nutrition, 
smoking, and alcohol intake (Table 10.2).
• For children 4–17 years of age receiving GC 
therapy, a calcium intake of 1000  mg/day 
and vitamin D of 600  IU/day is 
recommended.
Fig. 10.13 Initial fracture risk assessment [138]
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• The ACR 2017 recommendations of initial 
pharmacologic treatment are categorized 
according to the following groups and are 
highlighted in Fig. 10.15 and Table 10.4.
 – All adults >40 years of age, they are 
divided into women >40 years old but not 
of childbearing potential, and men >40 
years old, who are at moderate to high risk 
of fracture (Fig. 10.15).
 – Adults <40 years of age, includes (women 
not of childbearing potential and men) 
with a history of OP fracture, or those con-
tinuing GC treatment (>6 months at a dose 
of >7.5 mg/day), who have either a hip or 
spine BMD with Z score <−3 or DXA 
result reveals bone loss of >10%/year at 
the hip or spine (Fig. 10.15).
 – Special populations that have further sub-
groups including (Table 10.4):
Women who meet criteria for moderate-
to-high risk of fracture and are of child-
bearing potential but do not plan to become 
pregnant within the period of OP treatment 
and are using effective birth control or are 
not sexually active.
Adults >30 years of age who are receiv-
ing very high-dose GC treatment (initial 
prednisone dose of >30 mg/day [or equiva-
lent GC exposure] and a cumulative annual 
dose of >5  gm) (Table 3 of main 
reference).
Adults who have received an organ 
transplant and who are continuing treat-
ment with GCs.
GC-treated children at 4–17 years of 




• GIOP can be partially prevented by using 
bisphosphonates (alendronate and zoledronic 
acid) [142]. However, oral bisphosphonates 
are limited by low adherence rates, and there-
fore zoledronic acid provides the intravenous 
form of this medication and can be prescribed 
rather than the patient receiving no additional 
therapy beyond calcium and vitamin D.
• On the other hand, PTH 1-34 (teriparatide) 
therapy seems to be superior to oral bisphos-
Fig. 10.14 Reassessment of fracture risk [138]
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Fig. 10.15 Initial pharmacologic treatment for adults 
[138]. Recommended doses of calcium and vitamin D are 
1000–1200  mg/day and 600–800  IU/day (serum level 
≥20 ng/mL), respectively. Lifestyle modifications include 
a balanced diet, maintaining weight in the recommended 
range, smoking cessation, regular weight-bearing and 
resistance training exercise, and limiting alcohol intake to 
1–2 alcoholic beverages/day. Very high-dose glucocorti-
coid (GC) treatment was defined as treatment with predni-
sone ≥30 mg/day and a cumulative dose of >5 gm in the 
past year. The risk of major osteoporotic (OP) fracture 
calculated with the FRAX tool should be increased by 
1.15, and the risk of hip fracture by 1.2, if the prednisone 
dose is .7.5 mg/day (e.g., if the calculated hip fracture risk 
is 2.0%, increase to 2.4%)
phonates but is more expensive [143] and can 
be used if bisphosphonate is not appropriate.
• If neither oral nor IV bisphosphonates nor 
teriparatide treatment is appropriate, deno-
sumab should be used rather than the patient 
receiving no additional treatment beyond cal-
cium and vitamin D. Denosumab is a human-
ized monoclonal antibody to RANKL and is 
useful for GC-treated patients with renal insult 
but with stable serum Ca+2 levels and are not 
candidates for bisphosphonates or teripara-
tide. Denosumab has been approved for the 
prevention of vertebral and non-vertebral frac-
tures, in women with postmenopausal osteo-
porosis [144]. Moreover, it was revealed that 
denosumab therapy increased spine and hip 
BMD and reduced bone turnover markers for 
12  months in patients received GC [145]. A 
recent randomized, doubleblind, comparative 
study of denosumab and risedronate in patients 
≥19 years of age taking prednisolone ≥7.5 mg/
day for ≥3 months reported that denosumab 
significantly increased spine and femoral 
BMD compared to risedronate [146].
• If none of these medications is appropriate for 
postmenopausal women, raloxifene [selective 
estrogen receptor modulator (SERM)] should 
be used rather than the patient receiving no 
additional treatment beyond calcium and vita-
min D. The order of the preferred treatments 
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Table 10.4 Recommendations for initial treatment for prevention of GIOP in special populations of patients beginning 
long-term GC therapy [138]
Recommendations for initial treatment for prevention of GIOP in special populations
Women of childbearing potential at moderate-to-high risk of fracture who do not plan to become pregnant within 
the period of OP treatment and are using effective birth control or are not sexually active
     Treat with an oral bisphosphonate over calcium and vitamin D alone, teriparatide, IV bisphosphonates, or 
denosumab.
     Oral bisphosphonates preferred for safety, cost, and because of lack of evidence of superior antifracture benefits 
from other OP medications.
    Other therapies if oral bisphosphonates are not appropriate, in order of preference:
      Teriparatide
        Safety, cost, and burden of therapy with daily injections
     Consider the following therapies only for high-risk patients due to lack of safety data on use of these agents 
during pregnancy:
      IV bisphosphonates
        Potential fetal risks of IV infusion during pregnancy
      Denosumab
        Potential fetal risks during pregnancy
     Conditional recommendations because of indirect and very low-quality evidence on benefits and harms of these 
treatments to the fetus during pregnancy
Adults age ≥30 years receiving very high-dose GCs (initial dose of prednisone ≥30 mg/day and cumulative dose 
>5 gm in 1 year)
    Treat with an oral bisphosphonate over calcium and vitamin D alone.
    Treat with an oral bisphosphonate over IV bisphosphonates, teriparatide, or denosumab.
     Oral bisphosphonates preferred for safety, cost, and because of lack of evidence of additional anti-fracture 
benefits from other OP medications.
     If bisphosphonate treatment is not appropriate, alternative treatments are listed by age (≥40 years and <40 years) 
in Fig. 10.15
     Conditional recommendations because of low-quality evidence on absolute fracture risk and harms in this 
population
Adults with organ transplant, glomerular filtration rate ≥30 mL/min, and no evidence of metabolic bone disease 
who continue treatment with GCs
     Treat according to the age-related guidelines for adults without transplants with these additional 
recommendations:
    An evaluation by an expert in metabolic bone disease is recommended for all patients with a renal transplant.
     Recommendation against treatment with denosumab due to lack of adequate safety data on infections in adults 
treated with multiple immunosuppressive agents.
     Conditional recommendations because of low-quality evidence on antifracture efficacy in transplant recipients 
and on relative benefits and harms of the alternative treatments in this population
Children ages 4–17 years treated with GCs for ≥3 months
     Optimize calcium intake (1000 mg/day) and vitamin D intake (600 IU/day) and lifestyle modifications over not 
optimizing calcium and vitamin D intake and lifestyle modifications.
     Conditional recommendation because of lack of antifracture efficacy of calcium and vitamin D in children but 
limited harms
Children ages 4–17 years with an osteoporotic fracture who are continuing treatment with GCs at a dose of 
≥0.1 mg/kg/day for ≥3 months
     Treat with an oral bisphosphonate (IV bisphosphonate if oral treatment contraindicated) plus calcium and 
vitamin D over treatment with calcium and vitamin D alone.
     Conditional recommendation because of very low-quality antifracture data in children but moderate-quality 
evidence of low harms of oral bisphosphonates in children and less potential harm of oral over IV 
bisphosphonates
GIOP glucocorticoid (GC)-induced osteoporosis, IV intravenous
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was established according to a comparison of 
efficacy (fracture reduction), toxicity, and 
cost.
10.6.4.6 Follow-up Treatment 
Recommendations
Initial treatment failure is defined if the osteopo-
rotic fracture occurs after 18 months of treatment 
initiation with oral bisphosphonate or if there is 
significant BMD reduction (≥10%/year) at fol-
low-up. Various categories of treatment failure of 
GIOP are explained in Table 10.5 with appropri-
ate recommendations according to the reassess-
ment of fracture risk status.
10.7  Summary
Chronic inflammatory diseases, namely, rheu-
matic diseases such as rheumatoid arthritis, 
systemic lupus erythematosus, and ankylosing 
spondylitis, are commonly associated with extra- 
articular side effects, including bone loss and 
fractures. Osteoporosis-related fragility fractures 
represent one of the most important adverse out-
comes that may occur in patients with rheumatic 
diseases. These fractures may contribute to a sig-
nificant decrease in quality of life and thus would 
have a great impact on the economic status of the 
society.
Table 10.5 Recommendations for follow up treatment for prevention of GIOP [138]
Recommendations for follow-up treatment for prevention of GIOP according to reassessment of fracture risk
Adults age ≥40 years continuing GC treatment who have had a fracture that occurred after ≥18 months of treatment 
with an oral bisphosphonate or who have had a significant loss of bone mineral density (≥10%/year) [Definition of 
Treatment Failure]
     Treat with another class of OP medication (teriparatide or denosumab; or, consider IV bisphosphonate if 
treatment failure is judged to be due to poor absorption or poor medication adherence) with calcium and vitamin 
D over calcium and vitamin D alone or over calcium and vitamin D and continued oral bisphosphonate.
     Conditional recommendation because of very low-quality evidence comparing benefits and harms of the 
compared treatment options in this clinical situation.
Adults age ≥40 years who have completed 5 years of oral bisphosphonate treatment and who continue GC 
treatment and are assessed to be at moderate-to-high risk of fracture:
     Continue active treatment, without drug holiday, (with an oral bisphosphonate beyond 5 years or switch to IV 
bisphosphonate [if concern with regard to adherence or absorption] or switch to an OP treatment in another 
class) over calcium and vitamin D alone.
     Conditional recommendation because of very low-quality data on benefits and harms in GC-treated patients, but 
moderate-quality data in the general OP literature on benefits and harms of continuing treatment with oral 
bisphosphonates past 5 years for people at high risk of fracture.
Adults age ≥40 years taking an OP medication in addition to calcium and vitamin D who discontinue GC treatment 
and are assessed to be at low risk of fracture:
    Discontinue the OP medication but continue calcium and vitamin D over continuing the OP medication.
     Conditional recommendation made by expert consensus; evidence informing it too indirect for the population 
and very low-quality.
Adults age ≥40 years taking an OP medication in addition to calcium and vitamin D who discontinue GC treatment 
and are assessed to be at moderate-to-high risk of fracture:
    Complete the treatment with the OP medication over discontinuing the OP medication.
     Strong recommendation for high-risk patients based on expert consensus that patients who are at high risk 
should continue an OP treatment in addition to calcium and vitamin D.




The concept of osteoimmunology elucidates in 
depth the links between the immune system and 
bone physiology. The predisposing factors that 
cause the underlying pathology of bone loss in 
rheumatic patients are multifactorial. In addition 
to the traditional background fracture risks, such 
as age, BMI, and gender, there are potential bone 
loss mediators that substantially increase fracture 
risk in these patients. Of these common mediators 
are inflammation (high disease activity), immo-
bility, and treatment with glucocorticoids. Other 
mediators would contribute in bone loss in rheu-
matic patients and may include poor nutrition, the 
increase of catabolic state, and the decrease in 
reproductive hormones (hypogonadism) in both 
men and women.
These effector mediators appear to interact 
in a complex and synergistic way to reinforce 
each other through various mechanisms that act 
on a shared common pathway, the bone remod-
eling cycle. The net result of these mediators is 
the production of a wide spectrum of cytokines 
that stimulate local and/or generalized bone 
resorption and that inhibit (as in RA) or stimu-
late (as in AS) bone formation. For instance, dur-
ing the inflammatory process, the Wnt-signaling 
antagonist (DKK-1) is secreted from the syno-
vial fibroblast and inhibits osteoblast matura-
tion and OPG function leading to suppression of 
local bone formation. Therefore, administration 
of anti DKK-1 would be useful to prevent bone 
erosions and reverse the inhibition on bone for-
mation. However, immobility will suppress the 
mechanosensing process of osteocytes leading to 
uncoupling of bone formation and bone resorp-
tion through the Wnt-signaling pathway.
Although GCs are frequently prescribed for 
the rheumatic patients, they have a great adverse 
impact on bone quality leading to GIOP.  The 
overall effects of GCs on bone are either directly 
on bone cells or indirectly by affecting the bone 
metabolism, both of which result in enhancing 
bone resorption and decreasing bone formation. 
Inhibition of bone formation by GCs occurs by 
increasing the osteoblast and osteocyte apop-
tosis and/or impairing osteoblast function via 
suppressing the BMP pathway and the Wnt-
signaling pathway. On the other hand, GCs can 
stimulate bone resorption by reducing osteoclast 
apoptosis via upregulation of RANKL and inhi-
bition of OPG.
GIOP is a significant clinical complication 
that occurs as a result of adverse effects of the 
prescribed GCs for patients with rheumatic dis-
ease. ACR 2010 had set several recommenda-
tions updated that of ACR 2001 for evaluating 
and monitoring patients, who has just initiated 
or received GCs for/or more than 3 months dura-
tion. However later, ACR 2017 recommendations 
have been released and aimed to standardize the 
classification of patients at risk of GC induced 
fracture (Fig.  10.12). So that the appropriate 
recommendations can be applied on each cat-
egory, while reducing the risk and burden of 
radiological testing and the anti-fracture therapy. 
Therefore, all clinicians treating patients with 
GCs should be aware of these fracture risks and 
identify the patient’s level of fracture risk accord-
ing to the ACR 2017 guidelines for assessment 
and reassessment of fracture risks. The recom-
mendations of anti-fracture pharmacotherapy in 
order of preference, for prevention and treatment 
of GIOP, were based on their efficacy, potential 
harms, and cost. Hence, oral bisphosphonates 
were recommended as preferred first-line therapy 
over other recommended anti-fracture therapies.
Taking together, the salient approach for 
early diagnosis of rheumatic diseases would be 
very crucial and of great help in diminishing the 
magnitude of bone destruction that occur during 
the pathogenesis of these diseases and therefore 
preventing further bone erosion and osteoporosis. 
Finally, GIOP is a medical problem that patients 
should be aware of its fracture risk and clinicians 
should consider evaluating the fracture risks 
for all GC-treated patients and actively prevent 
reduction of bone mass.
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In all the patients with rheumatic diseases, fever 
should prompt an immediate and thorough evalu-
ation. There are different disorders that can cause 
fever and arthritis. Fever that is thought to be 
due to active rheumatic disease is seen in over 
50% of patients with SLE30. However, it can be 
also related to or a sequel of an infectious pro-
cess. There are many infectious diseases with 
rheumatological manifestations. The aim of this 
chapter therefore is to address variable relation-
ships of fever with patients with arthritis. Fever 
of unknown origin will be addressed as some 
systemic rheumatic disease may present with 
fever. It is always a dilemma when an established 
patient with arthritis presents with fever. What 
should you do? This issue is addressed with a 
suggested diagnostic approach that guides you in 
a stepwise manner until you reach to the defini-
tive diagnosis.
A quick review of rheumatological manifesta-
tions of some infections is presented. This is to 
widen your knowledge about this area in medi-
cine and not to ignore common viruses, for exam-
ple, in your differential diagnosis of fever and 
arthritis. Vaccination is quite an ignored aspect 
of clinical practice among patients with arthritis.
The objective of this chapter is to provide 
a systemic approach to patient with fever and 
arthritis.
Specific objectives:
By the end of the chapter the reader should 
be able to:
• Approach a patient with fever of unknown 
origin.
• Approach a patient with known rheumatologi-
cal disease presenting with fever and  recognize 
the common infections that affect immuno-
compromised patients.
• Recognize the rheumatological manifesta-
tions of common infectious diseases.
• Provide a safe and proper method of vaccina-
tions to patients with rheumatological 
disease.
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11.2  Fever of Unknown Origin 
(FUO)
11.2.1  Definition [28]
• Temp >38.3 on several occasions.
• Duration ≥3 weeks.
• No clear diagnosis after 1 week of in-hospital 
investigation.
11.2.2  Epidemiology
The epidemiology of FUO has changed over time 
due to scientific and technologic advances (better 
imaging, more advanced organism isolation, and 
more understanding of connective tissue disease). A 
prospective multicenter study on fever of unknown 
origin showed the following distribution: connec-
tive tissue diseases 22%, infection 16%, malig-
nancy 7%, miscellaneous 4%, no diagnosis 51%.
Epidemiology: Table  11.1 shows the etiologies 
of FUO.
11.2.3  General Principles 
in the Treatment of FUO 
(Table 11.2)
Physician should explain to the patient that FUO 
is a well-known entity, and it needs time for 
investigation to decrease anxiety of the patient. 
Empiric therapy with antimicrobial or glucocor-
ticoids should not be given to stable patients with 
FUO because it often obscure or delay the diag-
nosis [29]:
• The diagnostic yield of some investigation 
like cultures will be reduced after starting 
antimicrobial.
• Empiric treatment of a certain infection can 
affect other infection (e.g., therapeutic trial for 
tuberculosis with rifampicin may suppress 
staphylococcal osteomyelitis or diminish the 
ability to detect difficult to isolate organisms 
causing endocarditis.
• The duration of a therapeutic trial is also 
unclear.
• Initiation of glucocorticoid without rolling out 
infection can lead to severe life-threatening 
infections.
There are some exceptions where patient with 
FUO should be treated empirically. The excep-
tions are:
 1. Septic or hemodynamically unstable patient 
→ empirical treatment.
 2. Immunocompromised or neutropenic 
patient→ empirical treatment.
 3. Query giant cell arteritis → treat with cortico-
steroids until biopsy result → risk of visual 
loss.
Figure 11.1 shows a suggested algorithm to 
approach a patient with FUO.
Box 11.1 Initial evaluation for FUO
• Comprehensive History (Table 11.2)
• Detailed Physical examination 
(Table 11.2)
• CBC with differential & Blood film
• U&E–LFTs–LDH–ESR - CRP
• hepatitis A, B, and C serologies if LFTs 
are abnormal
• Blood cultures (X3  - different sites  - 
several hours between each set  - off 
antibiotics)
• HIV antibody assay and HIV viral load 
for patients at high risk
• Urinalysis + microscopic examination + 
urine culture
• CXR
M. Cheikh and N. Bahabri
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Table 11.2 Initial evaluation for FUO
History Physical examination
Carefl and through history including:
  •  Any localizing symptoms.
  •  Travel Hx (TB, malaria, hepatitis, typhoid 
fever, parasitic infections, Rocky Mountain 
spotted fever, or Lyme disease).
  •  Exposure to TB patient.
  •  Unpasteurized milk and cheese,
  •  Animal and insect exposure.
  •  Immunosuppression (medication or 
diseases).
  •  Sexual contacts.
  •  New unusual activity.
  •  Drug and toxin history including alcohol, 
illicit drug use, over-the-counter medications 
and recent antimicrobial.
  •  Ethnic background.
Complete physical examination including:
  •  Skin, mucous membranes, and lymphatic system.
  •  Abdominal palpation for masses or organomegaly.
  •  Joint examination and the back → Pott’s disease.
  •  Heart auscultation → new murmur (infective 
endocarditis).
  • Sinuses.
  •  Prostate examination.
Table 11.1 Etiologies of FUO [1–27]
Infection •  Tuberculosis: require high clinical suspicion as patient can have normal PPD or interferon 
gamma release assay and may require biopsy to yield diagnosis.
•  Abscesses: Intra-abdominal, pelvic, dental, or paraspinal.
•  Osteomyelitis: some sites can have no localized symptoms like vertebral and mandibular 
osteomyelitis.
•  Endocarditis: consider culture negative organism→ HACK, Coxiella, Bartonella, T. whipplei, 
Brucella, Mycoplasma, Chlamydia, Histoplasma, and Legionella.
•  Other causes: Brucellosis, HIV, sinusitis, CMV, EBV, secondary syphilis, Lyme disease, 
prostatitis, visceral leishmaniasis, Q fever, leptospirosis, psittacosis, tularemia, melioidosis, 
disseminated gonococcemia, chronic meningococcemia, Whipple’s disease, and yersiniosis.
Connective 
tissue disease
•  Adult Still’s disease: evanescent rash, arthritis, lymphadenopathy, and high ferritin.
•  Giant cell arteritis: >50y, headache, scalp pain, visual disturbances, myalgias, arthralgias, 
high ESR.
•  Other: polyarteritis nodosa, granulomatosis with polyangiitis, RA, SLE, psoriatic or reactive 
arthritis, PMR, Takayasu’s arteritis, mixed cryoglobulinemia.
Malignancy •  Lymphoma (especially non-Hodgkin’s).
•  Leukemia.
•  Myelodysplasia.
•  Renal cell carcinoma (increase HCT, microscopic hematuria).
•  Hepatocellular carcinoma or other tumors metastatic to the liver.
•  Multiple myeloma.
•  Pancreatic and colon cancers, sarcomas, mastocytosis.
•  Atrial myxomas (arthralgias, emboli, and hypergammaglobulinemia).
Miscellaneous •  Drug-induced fever.
•  DVT/PE.
•  Hematoma.
•  Thyroid storm, thyroiditis, adrenal insufficiency, pheochromocytoma.
•  Sarcoidosis.
•  Alcohol or granulomatous hepatitis.
•  Hereditary periodic fever syndromes: FMF, TRAPS, hyper-IgD syndrome, muckle-Wells 
syndrome, and familial cold autoinflammatory syndrome.
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CT Abdomen & Pelvis with













 Other appropriate 
diagnostic test 
MALIGNANCY
 Stool occult blood      
 Tumor markers  
 CT Chest\Mammogram
 EGD\Colonoscopy
 Serum protein 
electrophoresis
 Nuclear imaging 
 PET scan            
 Biopsy                                                         
Infection
 Evaluate for IE (Modified Duke
Criteria +/- TTE or TEE)
 AFB stain & culture (x3)




 CMV IgM antibodies 
 Heterophile Antibody
 Brucella titer






Establish the diagnosis of FUO
1- Temp   > 38.3 → Use fever chart to document fever 
2- Duration ≥ 3 weeks




Fig. 11.1 Suggested algorithm to approach patient with FUO
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11.2.4  Tips in FUO
• Think of uncommon presentations of common 
diseases rather than thinking of uncommon 
diseases.
• <40 Y → infection > rheumatological > 
malignancy.
• >40 Y → Infection > Malignancy > 
Rheumatological.
• Rheumatological disease usually present in 
stable condition.
• Empirical treatment not recommended unless 
there is an indication.
• If empiric treatment is a must avoid quinolone 
(TB resistance).
• Chills, rigors, night sweat (infection > 
rheumatological).
• Most of undiagnosed cases of FUO are related 
to viruses that we don’t usually investigate.
• Viral infections can give a temperature up to 
40–41 °C and can persist up to 3 weeks (aver-
age 9 days).
11.3  Fever and Rheumatology
11.3.1  Introduction
Approach to fever is a very challenging in a 
patient with rheumatic disease as it could be an 
infection, disease activity, or medication side 
effect. Fever that is thought to be due to active 
disease is seen in over 50% of patients with SLE 
[30]. On the other hand, fever is a rare presenta-
tion of RA disease activity. Infections are often 
difficult to diagnose and treat in this group of 
patient because of the following reasons:
 1. Clinical manifestations of infections are often 
indistinguishable from the underlying disease 
and vice versa [52–55].
 2. The typical signs and symptoms of infection 
may be absent because of concomitant immu-
nosuppressive therapies [56–58].
 3. The anti-inflammatory and antipyretic 
effects of glucocorticoids may diminish the 
usual systemic and localizing signs of 
infection.
 4. With the immunosuppressive impact of the 
medication and the disease itself, the spec-
trum of potential pathogens is large, making 
empiric treatment difficult.
In patient with rheumatoid arthritis, bone and 
joints, skin, soft tissues, and the respiratory tract 
are the most frequently involved sites in infec-
tious processes [33]. In patients with chronic 
inflammatory rheumatic or autoimmune diseases 
without arthritis, infections of the respiratory 
tract are the most common site. Finally, ascrib-
ing fever to the underlying rheumatological 
disease itself in an immunosuppressed patient 
should be done only after reasonable and 
good efforts have been made to exclude infec-
tion. Figure 11.2 shows suggested algorithm to 
approach a patient with rheumatic disorder pre-
senting with fever.
Risk factors for infection in a patient with 
rheumatic disease include:
• Active disease.













Fever in Rheumatology patient
Infection Disease activity Drug
Initial Work up
•  Complete history & physical exam
•  CXR
•  Basic work up 
•  Blood culture and other cultures as clinically indicated 
•  CRP, ESR, Procalcitonin, complement level 
•  See Table 11.3.
Any positive findings pursue
aggressively some examples:
History 
•  Unexplained Headache
   personality
   changes Confusion   
•  Acute joint pain, swelling 
Arthrocentesis and send for:
Synovial fluid for cell count Gram
stain & cultures 
CT/MRI  especially hip and 
sacroiliac joints
Physical Examination
•  Focal Neurologic
   finding 
•  Inflamed Joint 
•  Cutaneous lesion 
Biopsy  Send for histology &














Sputum induction for TB & PCP




Total protien, LDH, 
glucose,  PH
cell count & diff 
gramstain & culture 




LP and send for:
Cell count & differential 
Gram stain & culture
AFB stain & culture 
Total protein, glucose, 
LDH
Complement level   
SEE (table 3 CNS)
Fig. 11.2 Suggested algorithm to approach a patient with rheumatic disorder presenting with fever
Points to consider in the approach to this 
group of patients:
• Respiratory viral infections are the most com-
mon cause of fever in rheumatological patient 
as non-rheumatological patient.
• There is no single clinical or laboratory finding 
that can differentiate between infection, disease 
activity, or drug-induced insult as a cause of 
fever. It is rather a collective clinical and labo-
ratory finding with good clinical judgment.
• One of the crucial points in determining the 
cause of fever is to know the patient’s dis-
ease activity statues prior to presentation 
and if he is on immunosuppressive therapy 
or no.
• Both the patient’s underlying rheumatic dis-
ease and its therapy need to be taken into con-
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sideration when evaluating the white blood 
cell count in a febrile immunosuppressed 
patient because:
 – Glucocorticoids therapy can cause a neu-
trophilic leukocytosis.
 – Cytotoxic drug therapy can impair a 
patient’s ability to mount a neutrophilic 
leukocytosis in response to infection.
 – Neutrophilic leukocytosis may be a mani-
festation of certain rheumatic diseases, 
such as active granulomatosis with polyan-
giitis [101].
• Recent systemic review and meta-analysis for 
the utility of procalcitonin as a diagnostic 
marker for bacterial infection in patients with 
autoimmune disease showed that:
 – Procalcitonin has higher diagnostic value 
than CRP for the detection of bacterial sep-
sis in patients with autoimmune disease, 
and the test for procalcitonin is more spe-
cific than sensitive 32.
 – Procalcitonin test is not recommended to 
be used in isolation as a rule-out tool 32.
11.4  Fever in Rheumatology 
Patient
11.4.1  History
Careful and through history including:
• Medication history → immunosuppressed 
(type and for how long)→ suspect new 
 infection, particular if other signs of active 
disease have begun to remit.
• Onset of symptoms → few days → infection.
• Days to weeks → disease activity/opportunis-
tic infection
• Fever pattern → episodic → disease activity/
infection.
• Sustained → drug/CNS involvement
• Shaking chills occurred in significantly more 
patients with proven infections (68% versus 
27% non-infectious).
• Contact with children (viral infection).
• Recent travel and exposure to TB.
• Vaccination history.
11.4.2  Physical Examination 
(Table 11.3)
Complete physical examination includes:
• Oral mucosal candidiasis →significant immu-
nodeficiency → increased risk of opportunis-
tic infections, such as PCP [36].
• Erythematous necrotic cutaneous lesions→? 
Gram-negative sepsis, in particular P. 
aeruginosa.
• Cutaneous vesicular rash → varicella.
• Pulmonary infiltrates + cutaneous lesions→? 
Disseminated histoplasmosis, Cryptococcus, 
and nocardiosis (Table 11.4).
• Pulmonary infiltrates + focal neu-
rologic deficits→? Disseminated 
infection with  mycobacteria, fungi (C. neo-
formans, Aspergillus spp.), or Nocardia spp. 
(Table 11.5).
• A detailed neurologic examination should be 
performed and repeated frequently to monitor 
the patient’s progress.
• Each patient should undergo a careful oph-
thalmologic examination looking for papill-
edema, signs of retinal and choroid infection 
(e.g., cryptococcosis, toxoplasmosis), and 
proptosis (suggestive of orbital infection or 
cavernous sinus involvement).








Rheumatologic manifestations of infectious dis-
eases are well-recognized and relatively com-
mon. This topic will review the most common 
infectious diseases associated with rheumato-
logic manifestations. An overview of each infec-
tious agent is presented separately.
11.5.1.1  Hepatitis B Virus Arthritis 
[104]
Evidences have shown that four rheumatologic 
syndromes are linked with hepatitis B virus 
infection.
Clinical and laboratory features of each syn-
drome will be described below.
11.5.1.2  Acute Hepatitis B 
and Arthritis
The symptoms are abrupt in onset, and they are 
composed of low-grade fever, a symmetrical 
polyarthritis which might be additive or migra-
tory in pattern, morning stiffness, and other con-
stitutional symptoms. The most common joints 
involved are the knees and small joints of the 
hands, but any peripheral joint might be involved 
with either arthralgia or frank arthritis. It may last 
from several days to several months.
11.5.1.3  Chronic Active Hepatitis B
Chronic active hepatitis is linked with joint 
discomfort and occasional rash. The joints 
Table 11.3 Possible pathogens by the predominant immune system defect caused by pharmacological agent used in 
the treatment of rheumatic disease [37–38]
Abnormality Agent Infection








Coag (−) staph, Staphylococcus aureus, 
Streptococcal spp., Corynebacterium spp., 
Bacillus spp., Nocardia spp.
Gram negative
Escherichia coli, Klebsiella pneumoniae, 
Pseudomonas aeruginosa
Viral VZV, HSV1&2, CMV









Bacterial Salmonella spp., Campylobacter, Listeria, 
Yersinia, Legionella, Rhodococcus, Nocardia, 
TB, non-TB Mycobacterium spp.
Viral CMV, EPV, VZV, HSV, JC virus, BK virus
Fungal Candida, Histo, crypto, Coccidio, Aspergillus, 
pneumocystis, Zygomycetes spp., and other 
mold













Other bacteria: E. coli And GNRs
Viral VZV, Echovirus, Enterovirus
Parasites Babesia, Giardia
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Table 11.4 Causes of CXR abnormalities in patient with rheumatic diseasea
Radiographic pattern Infectious causes Noninfectious causes










Eosinophilic granulomatosis with 
polyangiitis
Pulmonary embolus
Diffuse infiltrates Pneumocystis jiroveci
Bacterial pneumonia (haematogenous spread)
Mycoplasma pneumoniae
Chlamydia spp.

































aThe appearance or progression of pulmonary disease following the initiation or intensification of immunosuppressive 
therapy should always prompt a thorough evaluation for a possible infectious cause
Table 11.5 Infections in rheumatological patient and most common causes [34, 35, 100, 102, 103, 133–136]
Disease Causes Comments
Pneumonia   •  Immunocompromised patient are prone to the same 
pathogens acquired in the community by 
immunocompetent hosts.
  •  (S. pneumoniae, S. aureus, and enteric GNRs) are the 
most common isolated pathogens
  •  Less common organism.
Fungi (Pneumocystis jirovecii→most common OI, Aspergillus 
spp., C. neoformans, C. immitis, and H. capsulatum)




  •  Pneumonia is one of the most 
frequent life-threatening 
infections in patients with 
rheumatic diseases.
  •  Pneumonia in 
immunosuppressed 
rheumatic patient is a 
challenging diagnosis 
because of:
  1.  Pulmonary manifestations 
of certain rheumatic 
diseases and medications 
used to treat rheumatic 
diseases may produce 




  2.  The usual radiographic 
appearance of pulmonary 
infections can be 










Clinical syndrome Infectious causes Non- infectious 
causes
  •  CNS involvement occurs in 




Behcet’s disease, and most 
frequently SLE.
  •  Immunosuppressive therapy 
increases the risk of CNS 
infections which may be 
indistinguishable from CNS 
manifestation of underlying 
rheumatic disease.
  •  The usual signs and 
symptoms of life- 
threatening CNS infection 
may be greatly diminished 
or absent because of the 
effect of 
immunosuppressive therapy.
  •  In lupus cerebritis, clinical 
and LP findings are almost 
similar to bacterial 
meningitis with the 
exception of:
  –  Less nick stiffness in 
lupus cerebritis.
  –  Normal lactic acid level 
(↑ bacterial).









































UTI   •  Usually caused by gram negative organisms and may be 
accompanied by septicemia.
  •  Candida albicans→ immunosuppressed .
  •  The incidence of UTI in 
immunosuppressed patients 
other than diabetics or renal 
transplant recipients is not 
higher than the incidence in 
immunocompetent 
individuals.
  •  Neutropenia blunts the 
clinical manifestations of 
UTI and predisposes to 
bacteremia.




Skin infection   •  Staphylococcus aureus, group A streptococci, and GNR.
Neutropenic Initial infection:





Bacterial Nocardia spp., 
atypical 
mycobacteria








  •  Staphylococcus aureus (most common), other species 
Streptococcus pneumoniae, groups B, C, and G Strep, 
Haemophilus, and gram-negative bacilli.
  •  Consider →OI such as atypical mycobacteria and 
Pneumocystis jirovecii immunocompromised host.
  •  The risk of septic arthritis in 
RA patient, irrespective of 
therapy, is increased by 
4–15-fold.
  •  Diagnosis of septic arthritis 
in the rheumatoid patient is 
often delayed.
  •  Use of anti-TNF therapy in 
RA is associated with a 
doubling in the risk of 
septic arthritis.
  •  DMARDS can predispose 
some patients with 
rheumatoid arthritis to 
septic arthritis.
Osteomyelitis Haematogenous Usually monomicrobial →
S. aureus (most common), 
Mycobacteria
Contiguous Polymicrobial or monomicrobial → 
Staphylococcus aureus, coagulase-
negative staphylococci, and (aerobic 
gram
+ anaerobic GPC and GNR)
In immunocompromised patients consider →Aspergillus spp., 









  •  The presentation and etiology of bacteremia or fungemia 
is similar to that in other patients.
  •  Disseminated Neisseria and non-typhoid Salmonella 
infections are more common in SLE patients.
Salmonella:
  •  Can cause serious infections 
in SLE patients.
  •  Most cases occur during 
periods of active SLE and 
may be the presenting 
illness of SLE.
  •  Although fever at 
presentation is the rule but 
15% to 20% of patients may 
be afebrile. And most 
patients are not toxic or 
septic on admission.
  •  Clinical syndromes include 
gastroenteritis, arthritis, and 
pneumonia. Less commonly 
diagnoses included 
cellulitis, osteomyelitis, 
urinary tract infection, or 
meningitis.
Neisseria:
  •  Patients are often young 
sexually active women with 
renal disease and low C3 
and C4 levels.
  •  Arthritis is a common 
presentation of disseminated 
Neisseria infection and less 




  •  Viruses can cause both systemic and organ-specific 
disease.
  •  The most common viral infections in patients with SLE 
are parvovirus B19 and CMV. Other herpesviruses are 
common in immunosuppressed SLE patients.
  •  Viral infection can be easily confused with a lupus flare 
due to significant overlap in the features induced by acute 
viral infections (fever, arthralgia, malaise, cutaneous rash, 
lymphadenopathy, and cytopenia) and those observed in 
active SLE.
  •  Acute viral infections are not adequately investigated in 
SLE patients and are only suspected after rolling out other 
causes of fever.
  •  The differential diagnosis of SLE patients presenting with 
fever suspected to be of infectious origin should consider 
not only common bacterial infections but also 
opportunistic viral infections, especially in patients with 
severe SLE involvement or those who are on 
immunosuppressive therapy. This group of patient should 
have a detailed physical examination, serologic studies, 
and invasive organ-specific diagnostic procedures to rule 
out an underlying viral infection.
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abnormality usually manifest as arthralgias 
which have a fleeting nature which have a fleet-
ing nature (Table 11.6).
11.5.1.4  Polyarteritis Nodosa
• The incidence of HBs antigenemia in polyar-
teritis nodosa is varied based on the criteria used 
for diagnosis and the sensitivity of the technique 
used for detection of the HBs antigen.
• Clinically, these patients might present with 
multisystem involvement of the skin, muscles, 
nervous system, lungs, and polyarthritis as 
well as liver disease.
11.5.1.5  Essential Mixed 
Cryoglobulinemia
It has the following clinical features: non- 
thrombocytopenic purpura upon exposure to 
cold, diffuse arthralgia, and generalized weak-
ness and hepatosplenomegaly; rarely it is associ-
ated with neuropathy and gangrene.
11.5.2  Hepatitis C Virus Arthritis
Hepatitis C virus (HCV) is associated with many 
rheumatologic manifestations including those 
related to joints, muscles, and connective tissue 
resulting from the body’s immune system inter-
action with the infectious agent antigens with the 
subsequent immune complex formation that will 
be deposited in various parts of the body elicit-
ing an inflammatory reaction that damage the 
involved organs. Patients who are infected with 
HCV often have no symptoms. Anyone newly 
diagnosed with arthritis or cryoglobulinemia 
should be tested for HCV infection. Also, there 
are certain drugs used in the treatment of HCV 
infection, e.g., interferon can worsen a related 
rheumatologic disease.
Arthritis is noted in 2 to 20% of HCV patients 
[107, 108]. The arthritis takes the form of eva-
nescent rheumatoid-like picture in two-thirds of 
the cases and an oligoarthritis pattern in the rest. 
Rheumatologic manifestations include painful 
joints and muscle and fatigue, “the first and most 
common complain,” and less commonly patients 
might have joint swelling and vasculitis.
Cryoglobulinemia happens when cryoglobu-
lins (which are abnormal immunoglobulin) 
precipitate in cold temperature. It may affect 
the blood vessels specially during cold weather 
leading to “‘Raynaud’s phenomenon.” [105, 
106] The diagnosis of HCV can be made by find-
ing HCV Immunoglobulins or by detecting the 
virus RNA.
Table 11.6 Rheumatic manifestations of hepatitis B virus
Acute hepatitis B
Chronic active 
























CNS, muscle, liver, 









Variable Up to 40% Rarely present
Serum free 




Not present Rarely present Present in 48%
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11.5.3  Parvovirus B19 Arthropathy
Parvovirus B19 is the cause of fifth disease 
“slapped cheeks” or erythema infectiosum. The 
disease manifests by rash, arthritis/arthralgia, 
laboratory abnormalities, and other connective 
tissue diseases like syndrome. It may mimic sys-
temic lupus (SLE) both in children and adults 
(Table 11.7) [109, 110].
Arthritis/arthralgia may accompany or follow 
the skin eruption. The rheumatologic symptoms 
may persist for weeks to rarely months with reso-
lution, but recurrences are reported [111, 112].
The diagnosis of acute parvovirus infection 
is made by finding IgM antibody, while IgG 
antibody is evidence of preexisting exposure. 
Acute phase reactant, i.e., erythrocyte sedimenta-
tion rate and C-reactive protein are occasionally 
elevated. The leukocyte remains normal, but in 
some cases, rheumatoid factor and antinuclear 
antibody may be present in the acute period.
11.5.4  Dengue Virus
• The classical features of dengue virus (DV) 
are acute febrile illness, headache, and muscle 
and joint pain. It is also referred to as “break- 
bone fever.” [114] Arthralgia occurs in 60 to 
80% of the patients infected with DV.
Investigations may reveal leucopenia, throm-
bocytopenia, and elevated liver enzymes. A small 
percentage of patients may have potentially lethal 
forms known as hemorrhagic fever and dengue 
shock syndrome [115].
11.5.5  Septic Arthritis
It is a bacterial infection of the joint that is usually 
curable with treatment, but morbidity and mortal-
ity are still significant specially in patients who 
have underlying rheumatoid arthritis, patients 
who have prosthetic joints, elderly patients, and 
patients who have severe and multiple comor-
bidities. Incidence of septic arthritis 10 cases 
per 100,000 patient-years in general population 
in Europe [116]. Incidence of septic arthritis in 
patients with rheumatoid arthritis.
(Based on prospective British Society for 
Rheumatology Biologics Register)
1.8 cases per 1,000 patient-years in 3,673 
patients taking non-biologic disease-modifying 
antirheumatic drugs, where 4.2 cases per 1,000 
patient-years in 11,881 patients taking anti-tumor 
necrosis factor therapy.
Usually it is monoarthritis, but up to 20% of 
patients have infection in >1 joint “polyarticular.” 
[116] The joints mostly affected are knee (which 
is the most common affected joint approximately 
50%) followed by the hip, shoulder, and then elbow 
[120]. In IV drug users, axial skeletal joints are 
mainly involved often with Staphylococcus aureus.
The most common causes of septic arthritis in 
adults are: [116]






Children [113] Adults [112]
  •  Occur in about 8%.
  •  Pattern:
Asymmetrical or pauciarticular
  •  Joint involved.It affects the knee 
most often
  •  At times children may meet criteria 
of juvenile idiopathic arthritis.
  •  Occur in about 60%.
  •  Many adult have arthritis alone without 
other symptoms.
  •  Typical pattern.
Acute onset symmetrical polyarticular 
arthritis
  •  Joints involved.
Proximal interphalangeal with 
metacarpophalangeal most commonly
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• Staphylococcus aureus most frequent caus-
ative agent, followed by Streptococcus.
• Neisseria gonorrhoeae, but it is considered 
separately as disseminated gonococcal 
infection.
• Gram negatives, Haemophilus, are usually 
seen in older patients.
In IV drug users, septic arthritis is frequently 
duo to methicillin-resistant Staphylococcus 
(MRSA), mixed infections, fungal infections, 
or unusual organisms [116]. Patients may 
have 1–2  weeks history of joint pain, tender-
ness, warmth, redness, restricted motion, loss 
of function, and fever. Joint-related risk factors 
for infection are joint prosthesis, intra-articular 
injection, and joint trauma [119]. Fever occurs in 
about one-third of patients [116]. “Large joints 
in legs (hips and knees) are the typical sites 
of infection.” [116–118] Septic arthritis is diag-
nosed by clinical signs (hot, red, tender, swollen, 
restricted) with any of the following:
• Pathogenic organism in synovial fluid detected 
by culture and gram stain.
• Pathogenic organism isolated in blood or other 
site.
• Turbid synovial fluid in patient with recent 
antibiotic treatment.
• Synovial WBC count more than 30,000.
• Leukocytosis.
11.5.6  Poncet’s Disease (Reactive 
Arthritis Associated 
with Tuberculosis) [121]
There is a new pattern of reactive arthritis associ-
ated with tuberculosis (TB), identified as Poncet’s 
disease (PD) or tuberculous rheumatism, which 
is a sterile reactive arthritis that can emerge dur-
ing any stage of acute TB infection. In a retro-
spective case series study, seven cases of Poncet’s 
disease were identified:
• The most common presentation was extrapul-
monary with involvement.
 – of multiple sites.
• Six out of seven patients developed arthritis 
after initiation of anti-TB drugs.
• One patient developed polyarthritis after com-
pletion of anti-TB medication.
• Asymmetrical polyarthritis was the most com-
mon pattern of joints involvement.
The resolution of the arthritis was with symptom-
atic treatment and continuation of anti-TB drugs. 
PD may manifest in a variable pattern during the 
course of active tuberculous infection. Physicians 
should be aware of this rare complication associated 
with a common disease to prevent delay in diagno-
sis and initiation of appropriate treatment.





It is well known that vaccination is one of the 
most effective measures to prevent infections 
and as discussed earlier in this chapter patient 
with autoimmune inflammatory rheumatic dis-
eases is at increased risk of infection compared 
to the normal population with the respiratory 
tract being the most affected organ [122, 123]. 
However, vaccination of immunocompromised 
patients is challenging both regarding efficacy 
and safety. The efficacy of vaccinations in 
patients with AIIRD may be reduced, and there 
is a potential risk of flares of the underlying 
AIIRD following vaccination. The two major 
issues to consider in vaccine administration of 
this group of patients are what is the expected 
immune response following vaccination and 




11.6.2  General Rules
All inactivated vaccines can be administered 
safely to persons with AIIRD whether the vac-
cine is a killed whole organism or a recombinant, 
subunit, toxoid, polysaccharide, or polysaccha-
ride protein-conjugate vaccine. Live viral and 
bacterial vaccines should be avoided whenever 
possible in immunosuppressed patients with 
AIIRD because it might lead to severe infection 
in immunocompromised patients (Table  11.8). 
Table 11.9 shows vaccinations recommendations 
in adult patient with autoimmune inflammatory 
rheumatic diseases (AIIRD).
Table 11.8 Vaccinations by type













Typhoid (IM) Typhoid (oral)
Inactivated polio Live polio (oral)





Table 11.9 Vaccination recommendation in AIIRD * [124–127]
Inactivated influenza 




  •  Age 19 to 64 y.
(one dose + revaccination 
dose)
  •  All adults ≥65 y of age.





  •  Age 19 to 64 y.
  •  No revaccination.
Tetanus toxoid 
vaccine
Like general population In case of major and/or contaminated wounds in patients 
who received rituximab within the last 24 W ⇨ tetanus 




Hepatitis A vaccine Only recommended in 
patient at increased risk
Protective antibodies against hepatitis A should be absent
Hepatitis B vaccine EULAR/ACIP ⇨ only for 
patient at increased risk
ACR:
  •  Should be given before 
starting DMARD or 
biologic drug.
  •  If not ⇨ give to patients 
already on DMARD or 
biologic drug.
Protective antibodies against hepatitis B should be absent
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Venous thromboembolism (VTE) is a disease of 
blood coagulation that occurs in the veins, most 
often in the calf veins first, from where it may 
extend and cause deep vein thrombosis (DVT) 
or pulmonary embolism (PE). The first described 
case of venous thrombosis that we know of dates 
back to the thirteenth century, when deep vein 
thrombosis was reported in the right leg of a 
20-year-old man [1].
The risk of thrombosis is influenced by both 
genetic and environmental factors. The risk fac-
tors for venous thrombosis are immobility, major 
surgery, underlying medical conditions like 
malignancies, medication use such as hormonal 
therapies, obesity, and genetic predisposition. In 
contrast to that, the major risk factor for arterial 
thrombosis is atherosclerosis [2].
In 1859, a German scientist, Rudolf Virchow, 
elucidated the mechanism of pulmonary embo-
lism and hence deduced the major patho-
genic determinants for DVT and PE, named as 
Virchow’s triad that comprised (1) blood stasis, 
(2) changes in the vessel wall, and (3) hypercoag-
ulability. This triad still applies, with essentially 
all prothrombotic factors, whether systemic or 
molecular, influencing one of these three mecha-
nisms [3] (Fig. 12.1).
DVT and PE are extremely common medical 
problems, and they are among the major cause of 
morbidity and death worldwide [3].
About 1–2 per 1000 individuals are affected 
by VTE per year with PE being the lethal com-
plication and is associated with a high mortality 
rate that exceeds 15% in the first 3 months after 
diagnosis [4].
Although disturbance of the coagulation and 
anticoagulation mechanisms is a very important 
risk factor for VTE, several studies suggest the 
role of innate immunity in the development of 
VTE [4].
Venous thrombosis results from multiple 
interactions between acquired and inherited risk 
factors [4].
In this chapter, we discuss the association 
of thrombosis with autoimmune rheumatologic 
disorders. The pathophysiology of thrombosis, 
effects of inflammation, endothelial dysfunc-
tion, some novel factors on promoting thrombo-
sis in different rheumatic disorders, diagnostic 
strategies for thromboembolic disease, and its 
treatment, management, as well as preventive 
measures will be addressed in detail. This chap-
ter is useful for students, residents, fellows, and 
physicians interested in learning about rheumatic 
disease and thrombosis. The main objective of 
this chapter is to make the readers able to achieve 
the following goals:
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 1. Explain and discuss the pathophysiology of 
thrombosis in rheumatic diseases.
 2. Recognize the multifactorial role of inflam-
mation in inducing the hypercoagulable state 
which promote thrombosis in autoimmune 
rheumatic disorders.
 3. Classify thrombosis in patients with rheuma-
tologic diseases (arterial or venous) accord-
ing to the presence of different risk factors 
and type of the disorders.
 4. Identify the role of different autoantibod-
ies in specific rheumatic diseases such 
as systemic lupus erythematosus and 
antiphospholipid syndrome that contrib-
ute to the high risk of thrombosis in these 
conditions.
 5. Describe the effects of different therapies 
commonly used in patients with rheumatic 
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Fig. 12.1 Virchow’s triad and some inflammatory changes and their association with venous and arterial thrombosis
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 6. Recognize the clinical features of thrombo-
embolic diseases, as well as formulate a 
comprehensive history of thrombosis from 
patients with rheumatic diseases.
 7. Judge when to select specific assays for 
thrombophilia screening, clotting factors, 
autoantibodies, and other tests for throm-
botic episodes in rheumatic diseases and 
choose the appropriate investigations neces-
sary for the diagnosis of thrombosis in these 
patients.
 8. Construct an approach to the diagnosis of 
thrombosis in rheumatic diseases based on 
patient’s clinical presentation, pretest proba-
bility scores, and investigations.
 9. Describe therapeutic regimens for thrombo-
sis in rheumatic diseases.
 10. Discuss the role of adjunctive and preven-
tive therapy in thrombosis in rheumatic 
disease.
 11. Identify conditions that mandate prophylaxis 
with antithrombotic medications in patients 
with rheumatic diseases.
To achieve these purposes, this chapter is writ-
ten in three sections.
In Sect. 2 of this chapter, we will discuss the 
mechanism and pathophysiology of thrombosis 
in individual rheumatic disorders, i.e., systemic 
lupus erythematosus (SLE), antiphospholipid 
syndrome (APS), rheumatoid arthritis (RA), vas-
culitis, and Behçet’s disease; this includes the 
effects and role of different medications used 
specifically in rheumatic disorders in promoting 
or preventing thrombosis.
In Sect. 3, we discussed in general the 
approach and the strategies for diagnosing VTE 
(DVT and PE) and arterial thrombi in different 
autoimmune rheumatic disorders.
In Sect. 4, we will discuss updates about the 
management of thrombosis in rheumatic dis-
eases and recommendations for prophylaxis and 
secondary thrombosis prevention in rheumatic 
disorders.
12.2  Pathophysiology 
of Thrombosis in Rheumatic 
Disorders
Arterial and venous thrombosis and systemic 
inflammatory diseases are highly linked, and 
the systemic inflammation promotes an exten-
sive cross-link to exist between inflammation 
and hemostasis [5]. Systemic inflammation dis-
turbs the natural tight balance between the pro-
coagulants and the anticoagulants in the blood 
by release of certain inflammatory markers and 
cytokines like tumor necrosis factor alpha (TNF- 
α) and interleukin-1 (IL-1) and interleukin-6 (IL- 
6) that finally promote a prothrombotic state [5] 
(Fig. 12.2).
Inflammation is a common feature of many 
rheumatic and immune-mediated disorders; 
systemic inflammation modulates thrombotic 
responses by suppressing fibrinolysis, upregulat-
ing procoagulants, and downregulating anticoagu-
lants. Several studies indicate the role of innate 
immunity in promoting thrombosis as it was 
shown that coagulation and innate immunity have 
a common evolutionary origin; this leads to the 
concept that the immune system and coagulations 
system are linked [4]. These findings conclude 
that autoimmune disorders such as SLE, APS, 
Behçet’s disease, RA, and vasculitis syndromes 
like Wegener’s granulomatosis have been linked 
to an increased risk of venous thrombosis [4].
RA, as well as other types of arthritides and 
connective tissue diseases, are associated with 
accelerated atherosclerosis and increased cardio-
vascular morbidity and mortality [6].
Chronic systemic inflammation predisposes 
to accelerated atherosclerosis, a risk that is well- 
known in systemic lupus erythematosus (SLE) 
and in rheumatoid arthritis (RA) patients [7].
The mechanisms for an enhanced and prema-
ture atherosclerosis in autoimmune rheumatic 
disorders such as RA, SLE, and systemic scle-
rosis (SS) include chronic inflammatory process, 
immune dysregulation, and the classical risk fac-
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tors; this explains the very high risk of cardiovas-
cular disease in patients with SLE and RA and 
some other autoimmune diseases [8].
The coagulation factor XII (FXII, Hageman 
factor) activity correlates with fibrinolysis [9]. 
Some studies had found the association between 
pulmonary embolism and decreased levels of 
FXII; one study was done on large cohort of 
patients in Japan with different rheumatic disor-
der reports that FXII reduction coexisted with the 
presence of antiphospholipid antibodies (a PL) 
in most thrombotic patients with rheumatic dis-
orders; they conclude the presence of anti-FXII 
autoantibodies as a cause of FXII deficiency in 
the presence of aPL antibodies [9].
12.2.1  SLE and Thrombosis
Thrombosis in SLE is multifactorial, and hence 
SLE patients are at significantly increased risk 
of thrombosis and atherosclerosis. Arterial and/
or venous thrombosis is a well-known clinical 
entity in SLE, with a prevalence >10%. This 
prevalence may even exceed 50% in high-risk 
patients [10]. The incidence of thrombosis in 
SLE patients according to two studies was 26.8 
and up to 51.9 per 1000 patient-years, according 
to the disease duration [10]. Other study reported 
that the incidence of thrombosis was 36.3 per 
1000 patient years [10]. In a 10-year prospective 
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Fig. 12.2 Close relationship between mechanisms of inflammation and thrombosis in Rheumatic diseases
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quent causes of death were active SLE (26.5%), 
thrombosis (26.5%), and infection (25%), with 
thrombosis dominating the second 5-year period 
of follow- up [11]. Patients with SLE have throm-
bosis at an early age than the age of thrombosis 
occurrence in the general population, with the 
incidence being increased in the first year, which 
may be explained by high disease activity, circu-
lating immune complexes, cytotoxic antibodies, 
or a higher inflammatory state at first year of SLE 
diagnosis [10].
Thrombosis is the most frequent cause of 
death in SLE. With its frequent manifestation in 
patients with SLE, thrombosis contributes sig-
nificantly to high morbidity and mortality [11].
Several studies showed that atherosclerotic 
cardiovascular and cerebrovascular diseases are 
more common causes of late deaths than active 
SLE itself. Some studies revealed that subclini-
cal coronary heart disease and carotid plaque 
were present in a significantly higher propor-
tion of SLE patients than in control subjects of 
similar age and sex with similar risk factors. 
Compared with individuals without SLE, the risk 
of myocardial infarction in SLE patients is 2–50 
times higher, and the risk of stroke is 2–10 times 
higher. The prevalence of symptomatic coronary 
heart disease in SLE patients has been reported 
to be 6–20%, depending on the characteristics of 
the cohort, disease duration, study design, preva-
lence of antiphospholipid antibodies (aPL), and 
ethnic composition. 3–15% of SLE patients have 
a nonfatal stroke [12].
12.2.1.1  Risk Factor and Etiology 
of Thrombosis in SLE
Inflammation and Disease Activity
Inflammation promotes thrombosis through its 
several effects on blood coagulation [10, 13].
Inflammation induces the expression of tis-
sue factor (TF), which is an important factor in 
coagulation initiation [10, 13]. The production of 
plasminogen activator inhibitor (PAI) is upregu-
lated in inflammation which leads to decreased 
fibrinolysis activity and increases the risk of 
thrombosis [10]; high levels of C-reactive pro-
tein (CRP) released in inflammatory conditions 
facilitate the interaction between the monocyte 
and the endothelial and promote plasminogen 
activator inhibitor-1 (PAI-1) and TF [13]. In 
inflammation, fibrinogen, an acute phase reac-
tant, is secreted in higher concentrations which 
further increase the risk of thrombosis in patients 
with SLE [13]. Inflammation impairs protein C 
pathway and decreases protein S level, thus wors-
ening the risk of thrombosis in SLE patients who 
might have thrombotic events early in the disease 
as compared to patients without SLE [10, 13]. It 
was found that SLE patients with lupus nephritis 
have a high disease activity and inflammation, 
and this is associated with increase risk of DVT 
and renal vein thrombosis; they also frequently 
have systemic hypertension and hyperlipidemia 
which further worsen thrombotic risk [10].
Antiphospholipid (aPL) Antibodies
aPL antibodies are type of autoantibodies that 
directed towards phospholipid binding proteins, 
anionic phospholipids, or a combination of the 
two [9]; they include anticardiolipin antibod-
ies (ACA), lupus anticoagulant (LA), and anti 
ß2-glycoprotein I (anti-ß2-GPI) [14]. aPL anti-
bodies induce platelet activation, interfere with 
coagulation inhibitors such as protein C, inhibit 
antithrombin and fibrinolysis, and then initiate 
the formation of a thrombus [10]; they are associ-
ated with an increased risk of arterial and venous 
thrombosis in addition to recurrent pregnancy 
loss in which they comprise an antiphospholipid 
syndrome (APS) which could occur as a pri-
mary disease (primary APS) or associated with 
several autoimmune disorders, most frequently 
in SLE patients, where it is named as secondary 
APS [15]. Lupus anticoagulant is considered as 
significant risk factor for stroke and myocardial 
infarction [10] as well as a strongest predictor of 
thrombosis [15].
There is a significant occurrence of aPL anti-
bodies among SLE patients [16]; about one-third 
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of patients with SLE show aPL positivity, but 
not all of them have the clinical presentation of 
thrombosis or APS [14].
In one retrospective study of 42 SLE patients, 
60% were positive for one or two aPL antibodies, 
but only 27% of them (10 patients) had a history 
of APS. The most common clinical presentation 
was DVT/PE in eight patients. Less common 
was arterial thrombosis and pregnancy loss. One 
patient with a history of PE developed autoim-
mune hemolytic anemia. Another patient without 
history of DVT/PE presented with thrombocyto-
penia [16].
The risk of thrombosis in LA and ACA positive 
patients has been addressed by many research-
ers. In patients with SLE, 42% of LA-positive 
and 40% of ACA-positive individuals had a his-
tory of thrombosis; in contrast, the prevalence of 
thrombosis in LA-negative or ACA-negative SLE 
patients was only10–18% [10].
APS is the main cause of thrombosis and a 
major predictor of irreversible organ damage and 
death in SLE patients [15].
ACA might be transiently positive, or persis-
tently positive, and considered significant when it 
tests positive on at least two occasions, 12 weeks 
apart. The risk of thrombosis was significantly 
higher in persistently positive ACA antibodies 
(33% risk) versus 3% risk in those with transiently 
positive ACA as shown in the prospective, obser-
vational cohort study by A Martinez- Berriotxoa 
et al. (2007) [15].
• Persistently positive ACA: patients are posi-
tive for IgG and/or IgM ACA at medium-high 
levels (titers ≥20 GPL and/or MPL) in whom 
more than two-thirds of the ACA determina-
tions were positive; ACA were measured four 
or more times in all patients [15].
• Transiently positive ACA: patients are posi-
tive for IgG and/or IgM aCL in which less 
than two-thirds of the ACA determinations 
were positive; ACA were measured four or 
more times in all patients [15].
In all patients with SLE, even if there are no 
clinical manifestations, aPL antibodies should 
be done as they are considered part of American 
College of Rheumatology (ACR) classification 
criteria for SLE, and they have been associated 
with increased risk of thrombosis [10], as the 
first presentation can be fatal presenting with a 
CVA.  Diagnosis allows prophylactic measures 
to be instituted in high-risk situations, e.g., 
prolonged immobility and postoperative states; 
increased awareness of APS should lead to ear-
lier recognition of associated episodes and labo-
ratory screening for all SLE patients to allow for 
prophylactic anticoagulation in high-risk situa-
tions [16].
Protein C and S and Antithrombin 
Deficiencies
They are rare but carry a higher risk for venous 
thrombosis [10].
Factor V Leiden
Activation of factor V leads to the formation of a 
cross-linked fibrin clot. Factor V Leiden (FVL) 
is the most common inherited risk factor for 
venous thrombosis in the general population and 
is an important factor for thrombosis in patients 
with SLE.  FVL polymorphism is considered to 
be risk variant for thrombosis and confers resis-
tance to activated protein C, thus shifting the bal-
ance towards thrombosis in the clotting cascade. 
FVL variant is found in 20–60% of patients with 
idiopathic DVT but without SLE.  Patients with 
SLE and/or aPL positivity who have the FVL 
polymorphism have at least two times the odds 
of thrombosis compared to patients without this 
polymorphism. This observation places FVL to 
be an independent risk factor for thrombosis in 
SLE [11].
Hyperhomocysteinemia
Hyperhomocysteinemia is a strong and indepen-
dent factor for increased risk of atherosclerosis, 
mainly of the carotid and coronary arteries, as 
well as venous thrombosis to some extent [10, 
17]. 27.3% of SLE patients with thrombosis have 
hyperhomocysteinemia, which is significantly 
higher than those without thrombosis in whom it 
is detected at 16.9% [10]. Patients with shortened 
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APTT have a hypercoagulable state and were 
found to have high levels of homocysteine that 
place them at a higher risk of thrombotic events, 
as shown in a study done by T. M. K. Refai et al. 
(2002) [17]. In this study, the researchers found 
that 21% of SLE patients had elevated levels of 
homocysteine; interestingly, the level was higher 
in male patients more than in female ones and 
also those on prednisolone; they observed that 
lupus patients with hyperhomocysteinemia had 
a threefold increase in odds ratio of thrombotic 
episodes. This is partly because of the direct toxic 
effect of homocysteine on endothelium and partly 
indirect effects, such as induction of a vascular- 
endothelial- cell activator, promotion of vascular 
smooth muscle proliferation, and an inhibitory 
effect on endothelial cell growth; these findings 
support the hypothesis that hyperhomocystein-
emia is an independent risk factor for thrombosis 
in young patients with SLE [17].
Traditional Risk Factors
Smoking is associated with worse outcome and 
mainly venous thrombosis by inducing endothe-
lial damage; patients with SLE may have hyper-
tension (HTN), diabetes mellitus (DM), and 
dyslipidemia which predispose them to throm-
botic events. Older patients have more endothe-
lial damage and vascular morbidity, and hence 
age is considered to be a risk factor for thrombo-
sis in SLE [10].
12.2.1.2  Medication and Thrombosis 
in SLE
• Glucocorticoids have been used frequently in 
SLE; they mediate endothelial damage and 
hence lead to accelerated atherosclerosis; high 
doses of glucocorticoids are associated with 
abnormalities of the coagulation system [10]. 
Chronic glucocorticoid consumption has been 
reported to increase plasma von Willebrand 
factor (VWF) levels, endothelial dysfunction, 
increased oxidative stress, and insulin resis-
tance. Glucocorticoids use also increases 
(PAI-1); it was found that secretion of t-PA 
levels is limited in patients receiving gluco-
corticoids, which further worsen the coagula-
tion system and cause hypercoagulable state 
which further enhances thrombosis risk in 
SLE patients [18].
• Hydroxychloroquine (HCQ) is an antimalarial 
agent used in patients with SLE; it has anti-
thrombotic effect by inhibiting platelet aggre-
gation and adhesion and arachidonic acid 
release from stimulated platelets; it also 
decreases the thrombus size and the time of 
thrombus development which is dose depen-
dent. HCQ inhibits GPIIb/IIIa receptor expres-
sion that is induced by aPL antibodies. Its role 
is more extended in the protection from throm-
bosis by lowering cholesterol level and lower-
ing LDL; it also reduces interleukin-6 levels 
and decreases SLE flare episodes [10, 19].
• Aspirin (ASA) inhibits platelet aggregation 
through inhibition of cyclooxygenase enzyme 
and hence the synthesis of thromboxane A2 [10].
Table 12.1 summarizes the risk factors of 
thrombosis and accelerated atherosclerosis in 
SLE patients.
12.2.2  RA and Thrombosis
RA is a common chronic systemic inflammatory 
disease with worldwide distribution. There is 
Table 12.1 Risk factors of thrombosis and accelerated 
atherosclerosis in SLE patients




smoking, obesity, old 
age.
2 Inflammation and high 
disease activity
↑ expression of TF, ↑ 
PAI, ↓ fibrinolysis, 
↑CRP, lupus 
nephritis




LA in moderate to 
high titers
4 Hyperhomocysteinemia
5 Genetic hypercoagulable 
states
Deficiency of 
proteins C and S, 
antithrombin and 
FVL
6 Drugs Glucocorticoids 
(chronic use)
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increased incidence of premature cardiovascular 
disease (CVD) and venous thrombosis in patients 
with rheumatoid arthritis and hence increased 
premature mortality and death on average 
2.5 years earlier in community-based studies and 
approximately 18 years earlier in hospital-based 
studies than non-RA patients [20, 21]. The risk 
of VTE in patients with RA is increased to more 
than threefold than non-RA, as shown by Bacani 
A et al. (2012); they found that RA patients had 
a higher VTE cumulative incidence at 10 years 
than non-RA patients (6.7  in RA versus 2.8  in 
non-RA), and the risk of VTE was significantly 
higher within 90 days following hospitalization 
[20]. RA patients showed a higher age- and sex- 
adjusted increased risk of mortality (60%) and 
thromboembolic events (30%–50%) during a 
5-year follow-up compared to non-RA patients. 
Similarly significant elevated risks (70% for 
death and 30%–40% for thromboembolic events) 
were seen when compared to OA patients. 
Several studies have shown that RA patients are 
30%–60% more likely to suffer a cardiovascular 
event [19].
12.2.2.1  Risk Factor and Etiology 
of Thrombosis in RA
Lifestyle in RA
Patients with RA are physically less active due 
to their disease, and they may suffer from obe-
sity, diabetes mellitus (DM), and hypertension 
that may result from medication use like steroids; 
some of RA patients are smokers as well; all 
these factors contribute to the accelerated ath-
erosclerosis in RA subjects. Obesity is a time- 
dependent risk factor for development of VTE in 
RA patients, as shown by Bacani et  al. in their 
study [20].
Inflammation
RA is characterized by a chronic inflammation 
that results in impaired immune system as well 
as persistent endothelial dysfunction, which pre-
disposes to vascular wall damage and accelerated 
atherosclerosis. Such damage can be detectable 
by ultrasound measurement of carotid intima- 
media thickness (IMT) in a preclinical stage of 
the disease. Carotid IMT in RA patients is associ-
ated with markers of systemic inflammation and 
disease duration [22]. CD4+ are subsets of T cells 
that lack surface CD28 molecule (CD4 + CD28-) 
and expand when stimulated by endothelial auto-
antigens, in a subgroup of RA patients. Moreover, 
they infiltrate the atherosclerotic plaques and 
pose high pro-inflammatory and tissue-damaging 
properties which promote vascular injury. The 
role of these cells in contributing to early devel-
opment of atherosclerosis in RA has been con-
firmed by recent studies which showed that RA 
patients with CD4 + CD28- cell expansion have 
a higher degree of endothelial dysfunction and a 
higher carotid IMT than patients without expan-
sion of these cells [22].
High Disease Activity and High Levels 
of Inflammatory Markers
RA patients with high ESR and/or high CRP 
were found to have increased carotid artery IMT 
as well as increased probability of vessel plaque, 
which supports hypotheses of the relationship 
between systemic inflammation and atheroscle-
rosis. ESR primarily reflects increased fibrinogen 
levels in response to systemic inflammation. The 
association between fibrinogen, as measured by 
the ESR, and increased carotid IMT suggests that 
inflammation-coagulation interactions may also 
have a role in atherogenesis. CRP is produced by 
the liver in response to interleukin-6, an earlier 
inflammation mediator, and can be found in the 
atheromatous lesions, suggesting its pathogenic 
role in atherothrombosis [23]; CRP is an indepen-
dent risk factor for atherothrombotic disease [19].
Hospitalization
The relative risk factor for VTE is increased 
within 90 days post-hospitalization in RA patients. 
Orthopedic surgeries are reported to be a time-
dependent cofactor risks for VTE development in 
RA patients that may develop within 90 days fol-
lowing lower extremity arthroplasty [20].
aPL Antibodies
RA patients may develop APL antibodies in 





It causes endothelium damage and promotes 
blood coagulation through monocyte activation 
by increasing the TF levels [19].
Fibrinogen, VWF, Tissue Plasminogen 
Activator (t-PA) Antigen, and D-Dimer
Levels of these thrombotic variables are signifi-
cantly higher in patients with RA [21].
Leukocytosis, Thrombocytosis, Increasing 
Platelet Activity, and Low Serum Albumin
These inflammatory markers are associated with 
increased cardiovascular risk and accelerated 
atherosclerosis in RA patients [19, 21].
High Systolic Blood Pressure (SBP) 
and Low Levels of High Density 
Lipoprotein (HDL)
High SBP in RA patients is mostly a result of 
a widespread use of NSAIDs and rarely can be 
caused by renal vasculitis and amyloidosis; HDL 
has a cardioprotective role against ischemia; low 
levels of HDL are found in RA. So, it is consid-
ered that both high SBP and low HDL are car-
diovascular risk factors in patients with RA [21].
Rheumatoid Factor (RF)
RF positivity is associated with vascular injury 
and vasculitis, which increases plasma levels of 
VWF and t-PA that further enhance the throm-
botic risks in RA patients [21].
Prothrombotic Condition in RA
Homocysteine (Hcy), in patients with RA the 
degree of inflammation is found to be correlated 
with Hcy levels. A positive relationship was 
found between the Hcy concentration and some 
parameters of inflammation, such as adhesion 
molecules and CPR [19].
Microparticles (MP) are membrane-bound 
vesicles that circulate in the blood and mediate 
inflammation and thrombosis. The most abun-
dant MP in the blood come from platelets, and 
high levels of platelets MP were found in RA 
patients and correlated to high disease activity as 
measured by disease activity score (DAS 28). MP 
derived from granulocytes and monocytes have 
been found in the synovial fluid of RA patients as 
well; they stimulate TF and factor VII-dependent 
thrombin generation and lead to intra-articu-
lar inflammation and formation of fibrin clots, 
known as rice bodies [19].
12.2.2.2  Medications and Thrombosis 
in RA
• Nonsteroidal anti-inflammatory drugs 
(NSAIDs) are widely used for pain manage-
ment in RA, associated with enhance cardio-
vascular events risk through rising the blood 
pressure, especially indomethacin and piroxi-
cam, which rise the mean arterial BP by 
approximately 5 mm Hg [21].
• Glucocorticoids, through their effects on 
blood pressure, insulin resistance, lipid pro-
file, body weight, coagulation, and endothelial 
dysfunction, might significantly increase the 
risk of CVD in RA patients [19].
• Disease-modifying anti-rheumatic drugs 
(DMARDs), methotrexate (MTX), the most 
common DMARDs used in RA, inhibit the 
homocysteine-methionine pathway which 
leads to hyperhomocysteinemia, but the con-
comitant use of folic acid reduces homocyste-
ine level, thus decreasing the risk of CVD in 
AR patients; a long-term follow-up of RA 
patients has shown that the use of MTX is 
related to reduced cardiovascular mortality, 
probably related to a reduction of disease 
activity. Leflunomide and cyclosporine can 
cause hypertension which increases the risk of 
cardiovascular disease in RA patients; the 
suboptimal control of inflammation by both 
these drugs also increases the risk of thrombo-
sis. Antimalarials, such as HCQ, have a bene-
ficial effect in decreasing the serum cholesterol 
and low-density proteins [19].
• Biologic Therapy with TNF-α Blockers.
A recent study suggested that the risk of 
developing any CV event in RA is lower in 
patients who receive TNF-α blockers. One 
study reported that TNF-α blockade using inf-
liximab improves endothelial function after 
12  weeks of therapy. This improvement 
depends on the clinical improvement of the 
joint manifestations and on a decrease in the 
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CRP and ESR levels. Other studies have 
shown the potential effect of short-term adali-
mumab therapy on endothelial function in RA 
patients with long-standing disease [19].
12.2.3  Vasculitis and Thrombosis
Vasculitides are a heterogeneous group of dis-
eases characterized by the presence of vascular 
inflammation, which can lead to either a vessel 
wall destruction (leading to aneurysm or rupture) 
or a vessel stenosis (leads to tissue ischemia and 
necrosis) [24].
12.2.3.1  Large Vessel Vasculitis
They include Takayasu’s (TAK) and giant cell 
arteritis (GCA). Chronic vascular inflammation 
leads to endothelial dysfunction that results in 
a premature atherosclerosis. The risk of arterial 
thrombosis is increased; strokes and transient 
ischemic attacks (TIA) have a similar rate of 
occurrence in this form of vasculitis, but there 
has been no clear increased risk of venous throm-
bosis [5].
12.2.3.2  Medium Vessel Vasculitis
Polyarteritis nodosa (PAN) is associated with 
increased risk of both arterial thrombi and 
VTE. This risk is high during active disease (3.27 
events/person/year versus 0.58  in patients with 
inactive disease) and independent of hepatitis B 
status. The coronary arteries are affected mainly 
by arterial thrombosis, but there is no clear asso-
ciation between ischemic strokes and PAN [5].
12.2.3.3  Small Vessel Vasculitis
They include granulomatosis with polyangiitis 
(GPA), microscopic polyangiitis (MPA), and 
Churg-Strauss syndrome. This type of vascu-
litis is associated with high risk of arterial as 
well as venous thrombosis. The risk of a first-
time symptomatic VTE has been considered by 
some researcher to be as seven times first symp-
tomatic VTE risk in SLE [5]. The prevalence of 
cardiovascular disease is high and biphasic; the 
highest risk of cardiac ischemia appears either 
within 4 years of diagnosis or after 10 years of 
diagnosis. Prospective data from four European 
Vasculitis Study Group trials found that 14% of 
patients with GPA and MPA will have a cardio-
vascular event within 5  years of diagnosis [5]. 
The age-standardized annual cardiovascular 
mortality rate was found to be 3.7 times higher 
than expected in the general population. The 
presence of proteinase 3 (PR3) antineutrophil 
cytoplasmic antibodies (ANCA) was found to be 
protective, whereas a positive myeloperoxidase 
ANCA test was associated with an increased risk 
of cardiovascular events. There is no evidence of 
increased risk of ischemic stroke in small vessel 
vasculitis [5].
12.2.3.4  Risk Factors for Thrombosis 
in Vasculitis
Changes in Endothelial Function 
and Hypercoagulability
The endothelium loses its anti-thrombogenic 
activity which results from its damage and 
 activation during inflammation. During inflam-
mation, several cytokines are released; these 
cytokines along with vessel ischemia cause 
endothelial damage. Circulating ANCAs also 
cause endothelial damage, and circulating endo-
thelial cells as a marker for endothelial damage 
have been detected in ANCA-associated vas-
culitis (AAV) patients, especially when AAV is 
active [25].
Hypercoagulability
Hypercoagulable state is present in patients 
with active AAV, and it is triggered by pro- 
inflammatory cytokines, such as TNF-α and 
IL-1. It is manifested by the presence of high 
levels of D-dimers and thrombin-antithrombin 
III complexes which reflects activated clotting 
system, increased expression of tissue factor, 
which activates factor VIII factor which in turn 
increases VTE risk in these patients. Increased 
platelet aggregation and reduced fibrinolytic 
capacity during active disease are among the 





Eosinophils contain preformed protein- 
containing granules which are released when 
activated. Some of these proteins have prothrom-
botic effects through releasing tissue factor and 
several other proteins and enzymes which result 
in decrease fibrinolysis and block the anticoagu-
lant effects of endothelial bound and exogenous 
heparin, stimulate the production of platelet fac-
tor 4 from platelets, and inhibit protein C activa-
tion [5].
aPL Autoantibodies
They are well-known cause of VTE, and they 
are detectable in some patients with vasculitis 
(especially AAV); aPL antibodies were detected 
in 19% in patients with GPA (formerly known 
as Wegener’s granulomatosis) according to one 
study [25].
12.2.3.5  Medications and Thrombosis 
in Vasculitis
• Cyclophosphamide, the most commonly 
drug used in the treatment of vasculitis, is 
associated with an increased risk of VTE in 
patients with AAV, through induction of vas-
cular endothelial damage, endothelial cells 
apoptosis, platelet activation, and cytokines 
release [5].
• Corticosteroids, particularly in high doses, 
can be thrombogenic through induction of 
high levels of factor VIII and lower fibrino-
lytic activity [25].
• Low-dose ASA is proven to be beneficial in 
the prevention of cerebrovascular insults and 
visual loss in GCA and thus is recommended 
to use for same purpose in TAK [5].
12.2.4  Behçet’s Disease (BD)
BD is a chronic inflammatory disorder of 
unknown cause; its manifestations are considered 
to be caused by an underlying vasculitis [26], 
characterized by recurrent oral aphthous ulcers, 
genital ulcers, and uveitis, followed by involve-
ment of other systems causing thrombophlebitis, 
arthritis, pulmonary and neurological involve-
ment, erythema nodosum, and gastrointestinal 
disease [27]. Vascular involvement is common 
in BD; it affects up to 40% of patients resulting 
in arterial and venous thrombosis and aneurysms 
particularly of pulmonary arteries [5, 27]; vessels 
of all sizes are involved, both in the arterial and 
venous systems [28]. Venous thrombi are more 
common with involvement of DVT and superfi-
cial thrombophlebitis [27]. Asymptomatic DVT 
of the extremities in patients with BD with no 
history of vascular thrombosis is reported to be 
6% which is higher than that seen in a healthy 
population [5]. BD is associated with low rate of 
pulmonary thrombosis (between 4 and 10%); this 
is because of tight adhesions of the peripheral 
thrombosis to the venous walls [5]. Other sites 
of venous thrombi in BD are vena cava throm-
bosis, Budd-Chiari syndrome (which coexists 
with inferior vena cava and portal vein throm-
bosis), and cerebral venous sinus thrombosis. 
BD  complicated with Budd-Chiari syndrome 
is associated with poor and mean survival of 
10 months compared with 16 months in patients 
affected with Budd-Chiari syndrome without 
BD. Cerebral venous sinus thrombosis (CVT) is 
estimated to occur in 8% of BD patients and in 
about 13% of BD with neurologic involvement. 
CVT most commonly manifests as intracranial 
hypertension. CVT in BD more likely affects 
male gender, presents at a younger age, and less 
likely develops venous infarcts [5]. The mortal-
ity rate is higher in patients with BD who had 
venous thrombosis, especially if large vessel is 
involved (mortality rate reached 12.1%) than in 
those without VTE [28].
12.2.4.1  Risk Factors for Thrombosis 
in BD
Endothelial Cell Dysfunction
Inflammation and resultant endothelial dysfunc-
tion suppresses nitric oxide (NO) secretion in 
patients with active BD, thereby impairing its 
normal function of vasodilation and inhibition of 
platelet aggregation, which in turn increases the 
risk of thrombosis in BD [5].
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Low Protein C
BD is associated with a significant reduction in 
activated protein C, lower endothelial protein C 
receptor levels, and increased resistance to acti-
vated protein C, leading to significant impairment 
of anticoagulation as well as anti-inflammatory 
properties of protein C. Lower levels of activated 
protein C is found in patients with a history of 
VTE as compared to those without VTE history, 




MP are small membrane particles derived from 
platelets, monocytes, and leukocytes; they are 
secreted in higher levels during active inflam-
mation and lead to the expression of TF tissue 
factor and anionic phospholipids which trigger 
the coagulation cascade and increase the risk of 
thrombosis in patients with BD [5].
Vascular Endothelial Growth Factor (VEGF)
VEGF levels in BD patients with acute throm-
bosis were higher than those of BD patients in 
chronic stage. Also, higher levels of MCP-1 were 
found in BD patients with acute thrombosis as 
compared with healthy controls. The positive cor-
relation of the elevated levels of various factors 
with venous thrombosis can be a useful marker to 
predict the likelihood of thrombosis in BD [29].
HLA-B51 and HLA-B35 Positivity
BD patient positive for HLA-B51 are at increased 
risk of VTE, while those with HLA-B35 are pro-
tective from VTE [55].
12.2.4.2  Medications and Thrombosis 
in BD
• Azathioprine, immunosuppression with aza-
thioprine 2.5  mg/kg per day, decreased the 
rate of DVT according to one control trial [5].
• Glucocorticoids, cyclophosphamide, one 
large study had found that immunosup-
pressives and glucocorticoids significantly 
decreased the risk of recurrent DVT in 807 
patients with BD [5]. The European League 
Against Rheumatism (EULAR) in 2008 rec-
ommended the use of immunosuppressants 
(glucocorticoids, azathioprine, cyclophospha-
mide, and cyclosporine A) in the management 
of acute DVT in patients with BD disease [5]. 
Immunosuppressive agents improve prog-
nosis in patients with BD by decreasing the 
odds of venous thrombosis relapse in BD by 
fourfold; immunosuppression in Budd-Chiari 
syndrome is associated with a significant 
improvement in prognosis as shown in a study 
done by Desbois et  al. [28]. A retrospective 
study of 37 patients with venous thrombosis 
in BD compared immunosuppressive agents, 
anticoagulation treatment, and the combina-
tion of immunosuppressive agents and anti-
coagulation treatment; 3 of the 4 patients in 
the anticoagulant-treated group (75%) devel-
oped new thromboses, compared to 2 of 16 
patients in the immunosuppressive agent-
treated group (12.5%) and 1 of 17 patients in 
the combination- treated group (5.9%) [28].
12.2.5  Antiphospholipid Syndrome 
(APS) and Thrombosis
APS is characterized by recurrent venous and 
arterial thrombosis and/or fetal loss in combina-
tion with the persistent presence of circulating 
aPL antibodies, which comprise LA, ACA, and/
or anti β2GPI antibodies [30].
DVT is the most frequent clinical manifesta-
tion of APS.  Larger veins like subclavian, ilio-
femoral, upper abdomen, portal, and axillary 
veins may be affected as well. Thrombosis of 
almost every organ has been described in APS, 
which result in different clinical conditions and 
syndromes, such as superficial thrombophlebitis; 
superior vena cava syndrome; renal vein throm-
bosis; adrenal infarction; Addison’s syndrome; 
Budd-Chiari syndrome; pulmonary hyperten-
sion, due to recurrent pulmonary embolism; and 
diffuse pulmonary hemorrhage, due to micro-
thromboses [31].
Arterial thrombosis consists a main clini-
cal feature of APS, but appears less frequently 
than Venous, the most common site of arterial 
thrombosis is the cerebral circulation, leading to 
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stroke or transient ischemic attack (TIA), CVT, 
coronary, renal and mesenteric arteries throm-
bosis has been observed also. In women under 
50 years, LA is considered to be a major risk fac-
tor for arterial thrombosis as shown in RATIO 
study (Risk of Arterial Thrombosis In Relation to 
Oral Contraceptives). CNS involvement in APS 
mainly strokes and TIAs is associated with high 
morbidity and mortality [31].
Other manifestations of hypercoagulopathy 
and thrombosis in APS include thrombocytope-
nia, hemolytic anemia, pregnancy loss, eclampsia, 
livedo reticularis, purpura, Libman-Sacks valvu-
lopathy, amaurosis fugax, retinal vessels thrombo-
sis, and avascular necrosis of the bones [32].
12.2.5.1  Risk Factors for Thrombosis 
in APS
aPL Autoantibodies
aPL antibodies are a heterogeneous group of dif-
ferent autoantibodies with distinct specificity for 
cardiolipin or for plasma proteins with affinity 
for anionic phospholipids such as β2 GPI, pro-
thrombin, or annexin A5 [33]. Oxidized β2 GPI is 
able to bind to and activate dendritic cells which 
results in autoantibodies production [32]. aPL 
antibodies are highly thrombotic. The ACA are 
directed against cardiolipin and b2GPI, the anti- 
β2GPI antibody is directed against β2GPI, while 
the LA measures functional anti-β2GPI antibod-
ies and antiprothrombin antibodies. β2GPI anti-
bodies are responsible for the increased risk of 
thromboembolic complications; patients positive 
for all three aPL antibodies have a significant 
increased risk of recurrence of thromboembolic 
disease, while patients positive for only one of 
the three aPL antibodies hardly have a significant 
increase in recurrence compared to patients with 
thrombosis but without aPL antibodies as shown 
by Pengo et al. (2011) [34].
The presence of LA, triple positivity (combina-
tion of LA, aCL and β2GPI antibodies), isolated, 
but, persistently positive aCL at medium–high 
levels are conditions considered as a high risk 
serological aPL profile for thrombosis. Patients 
with triple positivity have aPL levels much higher 
than others, thus making thrombosis highest risk 
of thrombosis in this group. Patients with isolated 
aCL or β2GPI at low-medium titers, particularly 
if intermittently positive, are considered to have a 
low-risk profile for thrombosis [30] (Table 12.2).
LA positivity increased the risk of stroke 
48-fold and the risk of myocardial infarction 
11-fold, while β2GPI antibodies are associated 
with double risk for stroke as shown by Urbanus 
RT et al. in the RATIO study [30].
The Effects of aPL Antibodies 
on Endothelial Cells
Anti-β2GPI antibodies result in increased expres-
sion of adhesion molecules (ICAM-1, VCAM-
1, E-selectin); aPL autoantibodies increase the 
 synthesis and secretion of pro-inflammatory 
cytokines IL-1, IL-6, and IL-8 and increase TF 
expression and upregulation of tissue factor mes-
senger RNA (mRNA) as well as enhancement of 
endothelin-1 levels [32]. aPL antibodies cause 
defective apoptosis of endothelial cells, which 
exposes membrane phospholipids to the binding 
of various plasma proteins [31, 32].
Hypercoagulable Effect of aPL Antibodies
Production of antibodies against coagulation fac-
tors, including prothrombin, protein C, protein 
S, and annexins, platelets activation to enhance 
endothelial adherence, activation of vascular 
endothelium, which, facilitates the binding of 
platelets and monocytes that result in a hyper-
coagulable state. aPL antibodies react with oxi-
Table 12.2 Determinants of high- and low-risk factors 




1 Isolated (LA) positivity High
2 Triple positivity 
(LA + aCL + anti-β2GPI)
High
3 Isolated persistent positivity of aCL 
(medium-high titers)
High
4 Isolated, intermittent positivity of 
aCL or anti-β2GPI (low and 
medium titers)
Low
5 Concomitant SLE High
6 Presence of hypertension, 
hypercholesterolemia
High
7 Smoking, use of oral contraceptive 
pills
High
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dized LDL and predispose to atherosclerosis. 
Moreover, complement activation by aPL has 
been recognized as a possible significant cause 
in APS pathogenesis. Emerging evidence from 
murine models suggests that APL-mediated 
complement activation may be a primary event in 
pregnancy loss [32].
Platelet Activation and Aggregation 
by aPL
β2GPI antibodies activate platelets aggregation 
and release of platelets factor 4 (PF4) and throm-
boxane B2; aPL cannot bind to the surface of 
“intact” platelets, while they have the ability to 
bind to platelets with exposed negatively charged 
phospholipids in their membranes [31]. Bleeding 
time is prolonged in about 40% of patients with 
APS, without accompanying bleeding tendency, 
which indicates impaired platelet function in 
APS as a result of platelet activation by aPL. The 
expression of platelet membrane glycoproteins, 
particularly GPIIb-IIIa (fibrinogen receptor, criti-
cal in platelet aggregation) and GPIIIa, is also 
increased that enhance platelets aggregation fur-
ther [31]. Another mechanism of platelets activa-
tion is the production of high plasma levels of 
active VWF in patients with β2GPI antibodies. 
In the normal conditions, binding of β2GPI to 
VWF results in inhibiting its ability to promote 
adhesion and platelet aggregation, but in the pres-
ence of anti-β2GPI antibodies, this anticoagulant 
effect is blocked [31]. β2GPI antibodies and LA 
induce the formation of stable thrombi and large 
aggregates, as shown by Jankowski et al. in ani-
mal model [31].
β2GPI Binding with Platelet Factor 4 (PF4)
PF4 is recognized recently as the dominant 
β2GPI-binding protein. PF4 binds in vitro, with 
high-affinity, recombinant β2GPI; PF4 tetra-
mers can bind two β2GPI molecules simultane-
ously. Anti-β2GPI antibodies selectively interact 
with complexes composed of (β2GPI)2-(PF4)4. 
This reaction is higher against PF4-β2GPI com-
plex than against β2GPI alone. Anti-β2GPI- 
β2GPI-PF4 complex significantly induced 
platelet p38 MAPK phosphorylation and 
thromboxane A2 production [37]. p38 MAPK 
is mitogen- activated protein (MAP) kinase that 
controls many cellular responses, such as prolif-
eration, migration, differentiation, and apoptosis. 
In platelets, p38 MAPK regulates platelet adhe-
sion to collagen and aggregation [37]. β2GPI 
antibodies form stable complexes with PF4, 
leading to the stabilization of β2GPI, which 
facilitates antibody recognition. This interaction 
is found to be involved in the procoagulant ten-
dency of APS [36].
Activation of Monocytes by aPL 
Antibodies
This will result in increased TF expression and 
activity as well as increased production of pro- 
inflammatory cytokines, which increases the risk 
of thrombosis in APS patients; many research-
ers had found high levels of soluble TF (sTF) in 
the peripheral blood of patients with a history of 
thrombosis and aPL [31, 35].
Other Risk Factors for Thrombosis in APS
Hypertension, smoking, hypercholestrolemia or 
estrogen use: the coexistent presence of these 
factors is associated with thrombosis. The inter-
action between aPL, smoking, and oral contracep-
tive pills (OCP) has been identified and clarified 
in the case-control study; the risk for suffering 
a stroke doubled among smoking LA-positive 
women, as compared with non- smokers; the risk 
of stroke among OCP users is increased to seven-
fold. One study showed that all smoker women 
who had LA suffered a myocardial infarction 
[29]. Concomitant SLE in APS (SAPS) increases 
the risk of thrombosis further in these patients 
(see SLE and thrombosis in this chapter) [29].
12.3  Approach and Diagnosis 
of Thrombosis in Rheumatic 
Diseases
The clinical features of thrombosis in patients 
with rheumatic diseases are similar to that in 
patients with other diseases and the general pop-
ulation; therefore it is very important for the phy-
sician who attends such patients to take a careful 
detailed history, perform a thorough physical 
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examination, and do an appropriate workup (lab-
oratory and imaging).
Unprovoked (idiopathic) venous thrombotic 
events are defined as venous thrombosis that 
occurs in the absence of any of the known risk 
factors; about 50% of patients presenting with a 
first idiopathic venous thrombosis have an under-
lying thrombophilia [38]; therefore special atten-
tion is needed to consider thrombophilia in the 
history and the workup of thrombosis.
12.3.1  History Taking
Symptoms of PE and DVT are not specific, so 
it is important to ask about the risk factors such 
as the age, previous history of VTE, recent long- 
distance travelling for active malignancy, coagu-
lation disorders, hormone replacement therapy 
(HRT) in postmenopausal women, use of an oral 
contraceptive pills (OCP) in a female of child-
bearing age, abdominal/pelvic surgery/knee joint 
replacement, and diseases or conditions that lead 
to limited mobility [39–42], as well as a com-
prehensive history of rheumatic disorders that 
associated with increased risk of thrombosis, 
especially if VTE is recurrent, or unusual presen-
tation in the absence of the known risk factors, or 
if the patient is a young one with no known pre-
disposing factors for thrombosis, or if the patient 
presents with multiple thrombi at different sites 
or had both arterial and venous thrombosis.
Detailed history of medications must be taken 
in patients with rheumatic disorders, as some of 
them have thrombotic risks, while others have 
a protective role (see details of thrombosis and 
medications in individual disorder in Sect. 1).
Inquire about the constitutional symptoms in 
rheumatic disorders, this includes fever, sweats, 
loss of appetite and weight.
History of skin rashes, such as malar rash, 
photosensitivity, raynaud’s phenomenon if SLE 
is considered in the differential diagnosis of 
VTE. Mouth and genital ulcers and visual com-
plaints may provide a clue to the presence of BD 
or other rheumatic diseases.
A careful obstetrical history is mandatory if 
APS (either primary or secondary) is suspected 
to be the cause of thrombosis in a young female 
in the absence of the traditional risk factors.
Inquiries about the renal complications must 
be included in the history in patients with SLE 
who presents with thrombotic episodes.
Patients with PE present to the emergency 
room (ER) and may complain of sudden dyspnea, 
pleuritic and non-pleuritic chest pain, cough or 
hemoptysis, fever, and diaphoresis; they may 
have cyanosis or syncope especially if massive 
PE [41, 43, 44]. Patients may have DVT at the 
same time which can be asymptomatic, since less 
than 25% of PE patients presented with symp-
toms and signs of DVT [41].
Patients suffering from DVT may complain 
of sudden ipsilateral leg swelling, redness, 
intermittent cramps, and pain in the calf or leg 
[45–47]. Presence of risk factors will increase 
suspicious of DVT which include prior history 
of DVT or PE, recent surgery, active cancer, 
trauma, hospitalization, immobility, co mor-
bidities, family history of VTE, advanced age, 
current pregnancy, hormonal contraceptives and 
hormonal replacement therapy, and obesity [42, 
45, 47, 48].
DVT and PE are considered combined emer-
gency problem; 70% of patients diagnosed with 
PE have DVT in their leg and 50% of DVT 
patients established asymptomatic PE [47]. For 
that, we must diagnose DVT to prevent PE by 
history, physical examination, and investiga-
tions [48].
12.3.2  Physical Examination
The physical examination of patients with PE 
reveals some signs, of which tachypnea is the 
most common [43, 49]; other signs such as 
hypotension and cardiogenic shock may present 
in massive PE.  Signs of right ventricular fail-
ure (RVF) such as tachycardia, distended neck 
veins, and tricuspid regurgitation may be there; 
wheezes, loud pulmonary component of second 
heart sound (loud P2), and pleural rub may also 
be heard sometimes [44]. Signs of DVT must be 
looked for [43]; they include leg redness, edema, 
warmth, tenderness, superficial dilation of veins, 
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and fever; tachycardia and sign of pulmonary 
embolism should be looked for as well even in 
the absence of symptoms [47, 50].
Rheumatic disorders should be considered as 
the top most differential diagnosis in unusual pre-
sentation of different forms of thromboembolic 
diseases such as young patients with no known 
risk factors, or thrombosis in unusual sites, or 
in case of multiple or mixed arterial and venous 
thrombi; thus, a careful examination should be 
done.
Many diseases mimic the sign and symptoms 
of DVT and PE, rendering the physical examina-
tion to be not enough for diagnosis, although very 
essential to perform [47, 50]. Therefore, another 
methods need to be used before going further to 
work up these patients.
12.3.3  Clinical Pretest Probability 
(CPTP) for VTE
CPTP includes Wells and modified Wells criteria 
[44, 51]; it is a useful and important method to 
determine the probability of DVT and PE, respec-
tively, and to classify the risk as low, medium, 
and high and is helpful in selecting the proper test 
for workup [41].
Wells criteria is based on history and physi-
cal examination and classifies the patient as high 
risk if score is between 3 and 8 points, moderate 
risk if 1–2 points, and low risk if 0 to −2 points 
[44, 45, 48, 50, 52]. For details see Fig. 12.3 and 
Table 12.3.
In modified Wells criteria, the total point is 
12, based on symptoms and signs and risk to 
get the disease. Patients are considered low risk 
if less than 2 points, intermediate risk if 2 to 6 
points, and high risk if more than 6 points [8, 
16]; the probability of PE is also categorized 
as likely and less likely; if it was more than 4 
points, the patients are likely to have PE [44]. 
Clinical sign and symptoms of DVT (3points), 
other diagnosis less likely than pulmonary 
embolism (3 points), heart rate (HR) > 100/min 
(1.5 points), immobilization >3 days or surgery 
in previous 4  weeks (1.5 points), previous PE 
or DVT (1.5 point), hemoptysis (1 point) and 





probability   
Patient who had recent
casting of lower limb or
history of paralysis or paresis  
Patients who have history of
active malignant disease or
treated in within 6 month.  
Patients who need general
or regional anesthesia
within 12 weaks for major
surgery or history of
bedridden more than three
days
Asymmetrical calf
swelling more than 3 cm 
1 point
for each 
Other diagnosis less likely
- 2 point for each
Non varicose superficial
vein
Deep vein tenderness 
Pitting edema by
examination 
Past history of deep





Fig. 12.3 Wells Criteria for DVT Probability
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12.3.4  Laboratory and Radiology 
Workup
Duplex ultrasound (DUS) is recommended as 
an initial imaging test for patients with high and 
moderate clinical probability of DVT, if DUS 
is positive then DVT is established, but if nega-
tive then D-dimer should be obtained, positive 
D-dimer and negative DUS after that follow up 
the patient and repeat the ultrasound, but if both 
DUS and D dimer are negative, DVT is ruled out, 
while a low clinical probability of DVT require 
D-dimer as initial test, if negative, DVT is ruled 
out, but if positive, DUS should be done [44]. 
Venography is indicated in patients with high 
clinical probability and negative DUS or if DUS 
cannot be done [48] (Fig. 12.5).
D-dimer is recommended for patients with 
low or intermediate risk for PE, and, if negative, 
PE is ruled out, but if positive, then CT pulmo-
Table 12.3 Wells criteria for DVT probability
1 Active cancer or cancer treated 
within 6 month
1 point
2 Calf swelling 3 cm greater than the 
other leg (measured 10 cm below the 
tibial tuberosity)
1 point
3 Prominent superficial veins 
(non-varicose)
1 point
4 Pitting edema in symptomatic leg 1 point
5 Paralysis, paresis, or recent 
orthopedic casting of a lower 
extremity
1 point
6 Localized tenderness in the deep vein 
system
1 point
7 Recent bed rest for >3 days or major 
surgery requiring regional or general 
anesthetic within past 12 weeks
1 point
8 Previous history of DVT or PE 1 point
9 Swelling of entire leg 1 point





Other diagnosis less likely than pulmonary embolism
History of cancer 
3 points
for each     
1.5 point








If Patient has symptoms or signs of deep venous thrombosis
e.g. (swelling, redness, cramps, calf or leg pain, leg edema,
warmth, tenderness, superficial dilation of veins).
Patients who are Immobile more than 3 days or did surgery 
in last 4 weeks
If patient had past medical history of pulmonary embolism
and deep venous throm bosis 
Fig. 12.4 Modified Wells Criteria for PE Probability
Table 12.4 Modified Wells criteria for PE probability
1 Clinical sign and symptoms of DVT 3 points
2 Alternative diagnosis less likely than 
PE
3 points
3 Heart rate > 100/min. 1.5 
points




5 Previous PE or DVT 1.5 
points
6 Hemoptysis 1 points
7 Malignancy 1 points
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nary angiography (the gold standard) [39] is 
required. If patient’s risk for PE is high, CT pul-
monary angiography should be done, but in situ-
ation where contraindication for contrast is used 
in CT angiogram such as in patients with renal 
failure, ventilation/perfusion (V/Q) scan can be 
done [43, 51, 53] (Fig. 12.6).
Pulmonary embolism rule out criteria (PERC) 
is used in patients who are less likely to have 
PE (4 points or less); factors of PERC are 
age < 50 years, HR < 100/min, oxygen saturation 
>94%, no unilateral leg swelling, no hemoptysis, 
no surgery or trauma within 4  weeks, no prior 
DVT or PE, and no estrogens or progestin use. 
If patients met these criteria, they are regarded 
as negative for PE, and no further investigations 
are needed, but if PERC is not met, they are con-
sidered positive for PE, and D-dimer should be 
tested; if it is negative, PE is ruled out [44, 54] 
(Fig. 12.7).
Other imaging such as chest X-ray may be 
required to confirm the diagnosis; chest X-ray 
is usually normal in PE, but it is important to 
exclude other diseases. Signs of PE on chest 
radiograph are atelectasis, pleural-based infil-
trates, or effusions, there may be a wedge shaped 
opacity and oligemia  - cut off  - of arteries, and 
right descending enlargement of the pulmonary 
artery) [39, 43, 44].
In PE, ECG may show supraventricular 
arrhythmia, signs of right ventricular (RV) 







































Fig. 12.6 Clinical probability of PE
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V1–V4, right bundle branch block, S1Q3T3, and 
QR in V1 or P pulmonale [39, 43, 44].
Arterial blood gases can show hypoxemia, 
hypocapnia, and widened (A-a) O2 gradient [44].
In patients with PE, check troponin and brain 
natriuretic peptide (BNP) levels, since their high 
levels are associated with RV strain and linked to 
increased mortality in PE [44].
Laboratory investigations include general 
and specific workup. Generally, for all patients 
with thrombosis, full blood count, renal and liver 
function, and coagulation profile need to be done. 
Specific workup for thrombophilia and hereditary 
hypercoagulable disorders, this includes: Factor 
V Leiden, Prothrombin 20210A, Protein C and 
S, Antithrombin III [38], as they also can pres-
ent in autoimmune rheumatic disorders such as 
SLE.  Acquired hypercoagulable states includes 
anti- aPL antibodies (LA, ACA, β2GP1) should 
be done in idiopathic thrombosis or if there mul-
tiple thrombi, HLA-B51 test for BD if thrombo-
sis is at an usual site (Bud Chairi syndrome) or 
both arterial and venous thrombi or idiopathic 
CVT should be considered [55].
Other blood workup includes acute phase 
reactants that measure disease activity (CRP, 
ESR), since their high levels correlate with high 
risk of thrombosis and atherosclerosis in certain 
diseases such as RA [19].




12.4.1  Management of Thrombosis 
in Rheumatic Diseases
There are no specific recommendations for the 
management of thrombosis in patients with rheu-
matic disorders, the same plan of treatment as of 
patients with other diseases and general popula-
tion. Anticoagulation with intravenous unfrac-
tionated heparin (UFH) or subcutaneous low 
molecular weight heparin (LMWH), followed by 
warfarin, is the initial treatment strategy for cases 
with acute thrombosis [57].
If score > 6, add
anticoagulation
Pulmonary Embolism
role out criteria (PERC)












1- Age < 50 years     
2- Heart rate <100 bpm  
3- Oxygen saturation
    >945  
4- No Hemoptysis           
5- No unilateral leg
    swelling
6- No trauma or surgery
    within past 4 weeks         
7- No prior DVT or PE 
8- No use of estrogen or
    progesterone hormones
Fig. 12.7 Probability of Pulmonary Embolism algorithm
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Treatment of patients with PE depends on 
clinical probability of pulmonary embolism 
and hemodynamic stability of patients, ini-
tial treatment with anticoagulant if clinical 
probability is high or intermediate and cannot 
get the investigation within 4 h and in case of 
low probability and investigation deferred for 
24 hours, anticoagulant therapy include LMWH, 
or fondaparinux, both are administered subcu-
taneously, do not require monitoring of PT and 
APTT, and not to be used in renal failure, UFH is 
administered intravenously and it is preferred in 
massive PE. If there is contraindication to anti-
coagulant, then inferior vena cava filter should 
be considered. Thrombolytic therapy is used in 
patients who have hemodynamic instability [40, 
41] (Fig. 12.8).
In patients with DVT, LMWH is recom-
mended, as it is superior to UFH especially in 
pregnant and patient with cancer, but it should 
not be used in patient with renal failure; they 
should be treated with unfractionated heparin 
(Fig.  12.9); warfarin should be started together 
with LMWH until targeted INR is reached; infe-
rior vena cava filter is indicated in patient with 
contraindication to anticoagulation therapy [45, 
48, 56] (Fig. 12.10).
Compression stocking is used within 1 month 
of DVT diagnosis to prevent post-thrombotic 
syndrome and for at least 1 year after diagnosis 
[45, 56].
Anticoagulation with warfarin had been asso-
ciated with several disadvantages related to the 
drug itself such as slow onset of action, variable 
pharmacologic effects, food-drug interactions, 
prolonged half-life, and the need for close moni-
toring of INR [65]. However, several large stud-
ies have been done in this field, and researchers 
had found that the NOACs are now emerging as 
the alternative anticoagulation therapy to conven-
tional therapy for patients with acute VTE; the 
advantages of these novel anticoagulant therapy 
are many and overcome the troubles of warfa-
rin therapy, such as the fixed therapeutic dose, 
without the need of dose adjustment; they do 
not require routine laboratory monitoring of PT 
and INR. They reach their peak efficacy within 
1 to 4 h after ingestion; thus a prolonged period 
of bridging therapy is not required when switch-
ing from initial treatment with UFH or LMWH to 
Treatment of Pulmonary embolism 
Step one  1-Anticoagulantion with
subcutaneous (SC) LMWH, fondaparinux, or 




deferred  for 4 hrs
low and
investigation
deferred for 24 hrs
{1 PLUS 2}
1- Anticoagulation as in step 1for at least 5 days, until
    targeted INR, continue overlap for 24-48 hrs, then discontinue 
2- Oral warfarin (monitor INR)                                                 
3- If new oral anticoagulants are considered, can be given










stroke, active bleeding) 
Confirmed PE
diagnosis 











tics of special population 
and types of heparin
Treatment of Acute DVT 
Anticoagulation Inferior vena cava filter
Contraindication to anticoagulantion
(recent surgery, hemorrhagic stroke, active bleeding)
OR, New oral anticoagulants (NOAC)
1- Rivaroxaban
2- Apixaban
(factor Xa  inhibitors)
3- Dabigatran
(direct thrombin inhibitor)





UFH (SC or IV)
(for at least five days until
targeted INR, continue overlap
for 24-48 hrs, then discontinue 
YESNO
Fig. 12.10 Management of DVT algorithm.
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these novel agents and less risks of major bleed-
ing. Unfortunately, the antidote for bleeding 
events is not available yet [64,65,66]. No data is 
available regarding the safety of NOACs in preg-
nancy, for which it should be avoided in a preg-
nant patient and also in some other conditions 
such as patients with mechanical heart valves and 
in severe renal insufficiency [65].
Two groups of NOACs are available, factor 
Xa inhibitors (rivaroxaban, apixaban) and direct 
thrombin inhibitors (dabigatran). The safety and 
efficacy of these agents for the treatment and pre-
vention of recurrent VTE have been studied by 
large randomized prospective trials [64].
Apixaban has a rapid onset of action and is 
approved for use in the prevention of stroke and 
systemic embolism in adult patients with nonval-
vular atrial fibrillation (AF) and in the primary 
prevention of VTE in adult patients who have 
undergone elective total hip or total knee arthro-
plasty [65].
Apixaban is effective for the prevention of 
recurrent VTE if patients complete 6 to 12 months 
of anticoagulant therapy for acute VTE, with 
major bleeding risk similar to those for placebo.
Therapy with apixaban was compared with 
conventional anticoagulant therapy in patients 
with acute symptomatic VTE in the AMPLIFY 
trial (Apixaban for the Initial Management 
of Pulmonary Embolism and Deep-Vein 
Thrombosis as First-Line Therapy) [66]. The 
AMPLIFY study has very impressive results 
and concluded that a fixed-dose oral apixaban 
alone was as effective as conventional treat-
ment which consists of enoxaparin followed by 
warfarin and was associated with a clinically 
relevant reduction of 69% in major bleeding, 
and its efficacy in patients with PE was simi-
lar to that in the patients with DVT. Moreover, 
the efficacy and the reduction in major bleeding 
with apixaban were consistent with that of war-
farin, but clinically relevant  non- major bleeding 
were less. Interestingly, The efficacy and safety 
of apixaban were consistent in all patients par-
ticipated in the trial including patients older 
than 75  years, obese patients of more than 
100  kg, use of parenteral anticoagulant treat-
ment before randomization, and treatment dura-
tion. AMPLIFY trial results are very promising 
and encouraging to consider apixaban a safe and 
effective regimen for the initial and long-term 
VTE treatment [66].
12.4.1.1  Special Consideration 
for Thrombosis in Rheumatic 
Disorders
• Patients with rheumatic diseases and throm-
bosis need a long-term management (indefi-
nite) for thrombosis especially those with aPL 
autoantibodies to prevent recurrent thrombo-
sis, that is, secondary thrombosis prevention; 
they require the optimal intensity of anticoag-
ulation with warfarin [30, 57].
• Several studies had proven that high-intensity 
treatment with warfarin to maintain INR = 3.0 
with or without low-dose aspirin was more 
effective than moderate-intensity warfarin or 
low-dose aspirin for the prevention of recur-
rent thrombosis in aPL-positive patients, but, 
recently, some trials demonstrated that high- 
intensity anticoagulation (INR 3.1–4.0) was 
no better than moderate intensity (INR 2.0–
3.0). So, moderate-intensity anticoagulation is 
the current standard of treatment of first 
venous thrombosis [57–60] (Fig. 12.9).
• For the management of acute DVT in BD 
immunosuppressive agents such as corticoste-
roids, azathioprine, cyclophosphamide, and 
cyclosporine A are recommended, but there is 
no evidence of benefit from, and uncontrolled 
experience with anticoagulation, use of anti-
platelet or antifibrinolytic agents in the man-
agement of DVT or for the use of 
anticoagulation in arterial thrombosis in 
patients with BD, in patients with CVT (dural 
sinus thrombosis) treatment with is corticoste-
roids is recommended (modified EULAR 2008 
recommendation) [59]. Anticoagulant therapy 
must be used cautiously and only after sys-
temic immunosuppressant, and if thrombi are 
not extensive, antiplatelet treatment with low-
dose aspirin is probably sufficient [61].
• • In patients with a low-risk aPL profile, who 
had first venous thrombosis in the presence of 
a known transient risk factor, anticoagulation 
could be limited to 3–6 months [30].
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12.4.2  Prophylaxis and Secondary 
Thrombosis Prevention 
in Rheumatic Disorders
• Daily ASA in doses of 75–325 mg are suitable 
for inhibition of platelet aggregation for pro-
phylaxis against cardiovascular events in RA 
patients [19].
• Prophylaxis use of LMWH to prevent venous 
thrombosis during periods of immobilization, 
as immobilization in RA patients is related to 
disease activity and inflammation [19].
• ASA (75–150  mg/day) is recommended for 
the prevention of cerebrovascular events and 
vision loss in GCA, and it should be also con-
sidered for the primary prevention of cardio-
vascular events in TAK [5].
12.4.2.1  Primary Prophylaxis in SLE 
Patients
• HCQ reduces thrombotic risk and disease- 
related morbidity and mortality in SLE and is 
recommended for all patients unless it is con-
traindicated [10].
• HCQ plus low-dose ASA is recommended for 
SLE patients with positive LA or ACA 
(medium-high titers) [30].
12.4.2.2  Primary Prophylaxis in APS 
Patients
• In asymptomatic individuals, aPL antibodies 
positivity is an incidental finding; thus, pri-
mary prophylaxis can be considered with ASA 
81 mg per day [59, 60].
• Healthy individuals, with positive aPL anti-
bodies in high titers and with no thrombotic 
manifestations, should be advised for a pri-
mary prophylaxis with ASA 325  mg orally 
daily [60].
• HCQ 400 mg orally daily decreases aPL anti-
body titers and thus protects from further 
thrombotic episode; that is based on trials in 
animal models and an indirect evidence from 
human studies, so more studies are needed to 
prove this effect of HCQ for standard recom-
mendation in healthy aPL-positive patients 
[60] (Fig. 12.11).
12.4.2.3  Primary Prophylaxis in High- 
Risk Situations
All patients with aPL positivity should receive 
usual doses of LMWH in high-risk situations, 
such as surgery, prolonged immobilization, and 
puerperium [30]; the same is applied for all 
patients with other rheumatic disorders.
12.4.2.4  Secondary Prophylaxis 
in Patients with Positive aPL 
Antibodies
• Patient who suffered from either arterial or 
venous thrombosis and aPL who do not fulfill 
criteria for APS should be managed in the 
same manner as aPL-negative patients with 
similar thrombotic events [30].
• Recurrent venous thrombosis has been reported 
in patients with APS at 3% to 24%. Secondary 
prophylaxis with high-intensity warfarin 
(INR  =  3–4), or moderate-intensity warfarin 
(INR = 2–3) plus ASA is recommended [60].
• Treatment of APS patients with arterial 
thrombosis is controversial, and only ASA 
325 mg/day can be given or moderate-inten-
sity warfarin (INR = 2–3) alone or combined 
low-dose ASA or high-intensity warfarin 
(INR > 3) [30, 60].
• In pregnant women, with recurrent fetal loss, a 
combination of ASA and heparin is recom-
mended. ASA 81  mg/day should be started 
when attempting conception, and when the 
pregnancy is confirmed, heparin subcutane-
ously should be started as LMW (enoxaparin 
1  mg/kg/day, dalteparin 5000  units/day, or 
nadroparin 3800  units/day) or as unfraction-
ated (5000–10,000 units 12 hourly) [60].
• In catastrophic APS, a combination therapy is 
required with (1) anticoagulation with intrave-
nous (IV) heparin for 7–10 days, (2) steroids 
in high doses with (IV) methylprednisolone 
1 g daily for 3 or more days, (3) IV immune 
globulin (IVIG) 0.4  mg/kg/body weight/day 
for 4–5  days, and/or (4) plasmapheresis for 
3–5  days at least with fresh frozen plasma 
replacement [60].
(See Fig. 12.11 for treatment and second-
ary prophylaxis of thrombosis in APS)
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• In patients with a low-risk aPL profile without 
SLE, who have first non-cardioembolic cere-
bral arterial event due to one of the reversible 
risk factors, antiplatelet agents are considered 
for the secondary prophylaxis [30].
12.4.2.5  Refractory and Difficult 
Situations in aPL-Positive 
Patients
In patients with difficult management due to 
recurrent thrombosis, fluctuating INR levels, 
major bleeding, or a high risk for major alter-
native therapies with a long-term low LMWH, 
HCQ or statins are needed for the management 
of acute thrombosis as well as the secondary pro-
phylaxis [30].




Statins have pleiotropic effect (anti- inflammatory, 
antioxidant, and potent antithrombotic) in addi-
tion to a lipid-lowering effect. Thus, by inhibition 
of atherosclerosis progression, statin decreases 
the cardiovascular risk for arterial thrombosis 
in rheumatic and other diseases [62]. Several 
studies revealed that the use of statins is associ-
ated with decrease levels of inflammatory mark-
ers such as IL-6, IL-8, MCP-1, and CRP which 
cause endothelial dysfunction. In addition to that, 
statins were found to exert an antioxidant func-

































































Treatment recommendations in APS, for persistently positive aPL
antibodies with heparin, warfarin and ASA
Fig. 12.11 Recommendation for treatment and prevention of thrombosis in patients with APS
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the JUPITER trial, use of rosuvastatin in patients 
with elevated CRP levels results in a significant 
reduction of DVT [63]. Knowing these advanta-
geous effects of statin, it is advised to consider 
it for prophylaxis of venous thrombosis in rheu-
matic diseases, but further trials are needed in 
this field [63].
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Hematologic disorders including anemia, white 
blood cells abnormalities, platelet abnormalities, 
coagulopathy, and hematologic malignancies can 
be manifested in many autoimmune rheumatic 
diseases [1].
This chapter discusses the most common 
hematological abnormalities in rheumatoid 
arthritis (RA) and systemic lupus erythematosus 
(SLE). It also provides a simple approach to eval-
uate hematological abnormalities in patients with 
RA or SLE.  This approach includes the most 
common causes, differential diagnosis, treat-
ment, and prevention, with a special emphasis on 
ruling out life-threatening and urgent conditions.
13.2  Objectives
• Describe hematological manifestations of 
rheumatic diseases including different types 
of anemia, white blood cells, and platelets 
abnormalities, with brief about malignancies 
in rheumatoid arthritis.
• Construct a diagnostic approach to anemia in 
rheumatoid arthritis.
• Describe hematological manifestations of sys-
temic lupus erythematosus including different 
types of anemia, white blood cells, and plate-
lets abnormalities, with brief about lymphade-
nopathy, splenomegaly, and antibodies to 
clotting factors and antiphospholipids.
• Construct a diagnostic approach to anemia in 
systemic lupus erythematosus.
• Describe macrophage activation syndrome 
(MAS), and construct a diagnostic approach 
to it.




A review of hematologic involvement in RA is 
presented here, with an algorithm constructing a 
simple approach to RA patients with hematologi-
cal manifestations (causes, diagnosis, and treat-
ment) which is shown in Fig. 13.1.
13.3.1.1  Anemia
Anemia of chronic disease (ACD) and iron defi-
ciency anemia (IDA) are considered the most 
common hematologic manifestations in patients 
with rheumatic diseases [2], with an estimated 
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prevalence in RA (30%–70%) in different stud-
ies [3, 4].
Anemia of Chronic Disease (ACD)
The ACD is associated with the following labora-
tory abnormalities:
• Mean corpuscular volume (MCV) and mean 
corpuscular hemoglobin concentration 
(MCHC) are usually normal (normocytic and 
normochromic) but may decrease due to con-
current iron deficiency, often to values charac-
teristic of microcytic hypochromic anemia.
• The ferritin level is usually high with low 
serum levels of transferrin and iron [5].
• Bone marrow biopsy usually shows the pres-
ence of hemosiderin and normal cellularity, 
with increased numbers (in most cases) of 
plasma cells that are associated with lymphoid 
aggregates. However, these findings are unpre-
dictable and usually represent the various eti-
ologies of cytopenias in RA patients.
The pathogenesis of the ACD is not entirely 
known. There are two major reasons seem to be 
of significant: defect in hemoglobin synthesis 
due to the diminished available iron secondary 
to iron trapping in macrophages and difficulty in 
bone marrow to produce more red blood cells in 
response to the anemia [6]. Immune mediators, 
such as tumor necrosis factor-alpha (TNF-alpha), 
interleukin-1, interleukin-6, interleukin-10, and 
interferon gamma, have great impact on these 
changes [6, 7]. Hepcidin, that is produced by the 
liver in response to inflammation, may have a 
great role in ACD, as it decreases iron absorp-
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Fig. 13.1 Algorithmic approach for hematological mani-
festations of rheumatoid arthritis (RA). Classified by the 
affected component of the blood (platelets, HB, or WBC), 
in this approach; the authors suggest to broaden the 
differential diagnosis and to rule out non-rheumatological 
causes of mentioned abnormalities, including systemic 
diseases, infections, and drug-induced and primary hema-
tological diseases. The evidence to support this approach 
is based on cumulative literature, current guidelines, and 
the author’s experience (Abbreviations: RA rheumatoid 
arthritis, R/O rule out, HCV hepatitis C virus, HIV human 
immunodeficiency virus, TSH thyroid stimulating hor-
mone, PT prothrombin time, PTT partial thromboplastin 
time, INR international normalization ratio, DIC dissemi-
nated intravascular coagulation, HIT heparin-induced 
thrombocytopenia, ITP immune thrombocytopenic pur-
pura, TTP thrombotic thrombocytopenic purpura, H. 
pylori Helicobacter pylori, WBC white blood cell, HB 
hemoglobin, 2ry secondary, -ve negative, +ve positive)
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Low levels of erythropoietin and decreased 
response to erythropoietin may lead to the ane-
mia in RA; these findings led to using erythro-
poietin in such patients which resulted in some 
increase in hemoglobin levels in few patients 
with improvement in arthritis symptoms [2, 8, 
9].
Since the anemia may correlate with RA activ-
ity, patients may need higher doses of erythropoi-
etin, which a medication with a high cost [10]. 
Hence, it should be considered only for patients 
with severe symptomatic anemia [11].
In the algorithm provided, if RA patient pres-
ents with normocytic normochromic anemia 
without hemolytic manifestations (normal levels 
of LDH and reticulocyte and negative Coombs’ 
test) and no other obvious inflammatory causes, 
patient should be treated with iron supplement 
and disease modifying anti- rheumatic drugs 
(DMARDs), and consider erythropoietin for 
symptomatic anemia (Fig. 13.2).
Iron Deficiency Anemia (IDA)
Iron deficiency anemia can be seen in up to 50% 
to 75% of RA patients who have chronic active 
disease [12].
It is mostly caused by chronic blood loss from 
gastritis (induced by prednisone [13] and/or non- 
steroidal anti-inflammatory drugs), peptic ulcer, 
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Fig. 13.2 Algorithmic approach for anemia in RA 
patients. In this approach the authors classified the anemia 
according to MCV and MCH, aiming to widen the differ-
ential diagnosis and to include non-rheumatological 
causes and co-factors. The evidence to support this 
approach is based on cumulative literature, current guide-
lines, and the author’s experience (Abbreviations: HB 
hemoglobin, MCV mean corpuscular volume, MCH mean 
corpuscular hemoglobin, LDH lactate dehydrogenate, −ve 
negative, +ve positive, DMARD disease-modifying anti- 
rheumatic drugs, AIHA autoimmune hemolytic anemia, 
2ry secondary)
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As with all patients, occult blood in stool 
should not be neglected. All RA patients with 
IDA, epigastric pain, and/or occult blood in the 
stool should undergo upper gastrointestinal endo-
scopic examination.
Making the diagnosis of IDA among RA 
patients could be challenging, since the rou-
tine laboratory indices with mild to moder-
ate iron deficiency may overlap with the ACD 
[14.15]. Thus, if iron deficiency is suspected, it 
may be most reliably verified by the absence of 
iron stores on bone marrow examination [14]. 
However, pursuing for bone marrow biopsy may 
be unnecessary if clear signs of iron deficiency 
such as a mean cell volume below 85, serum fer-
ritin concentration below 40 mcg/L, and transfer-
rin saturation ≤ 7% are present [15].
RA patients frequently may have both IDA 
and ACD.  In such case, the hemoglobin level 
usually decreases to below 9.5 g/dL, and the 
mean corpuscular volume is usually less than 80.
Measurement of serum soluble transferrin 
receptor (TfR) may be useful in differentiating 
IDA from anemia of chronic disease. [16].
Macrocytic Anemia
Less frequently, a megaloblastic anemia second-
ary to deficiency of folic acid or vitamin B12, 
methotrexate, or azathioprine is found in RA 
patients [2].
One study of 25 patients with RA noted vita-
min B12 and folic acid deficiency in 29% and 
21% of patients, respectively [2]. It was found that 
more than one type of anemia can present simul-
taneously in RA patients with anemia. Identifying 
each type could be masked by another.
Folic acid deficiency anemia in RA is usually 
due to the combination of increased requirements 
and reduced intake (e.g., pregnancy in a patient on 
a restricted diet) or to concurrent iron deficiency. 
On the other hand, there may be a genetic predis-
position to develop macrocytosis and bone mar-
row toxicity with azathioprine. Approximately 
0.3% of normal subjects have very low levels of 
thiopurine methyltransferase, one of the enzymes 
responsible for azathioprine metabolism. This 
abnormality is genetically determined and is 
linked to a higher risk of myelosuppression and 
macrocytic anemia [5].
The diagnosis is established by demonstrat-
ing a reduced folate level or vitamin B12 level, ; 
however, blood film is recommended to suggest 
the diagnosis and to rule out malignancies.
Hemolytic Anemia
Hemolytic anemia is not a typical feature of RA, 
although antibody-mediated, Coombs’ positive 
hemolytic anemia has been described, primarily 
in Felty’s syndrome [17].
Drug-induced hemolysis may also occur and 
is usually reversible when the offending drug is 
withdrawn, but most patients require corticoste-
roid therapy.
Bone Marrow Hypoplasia with Anemia
One of the serious hematologic complication of 
RA is bone marrow hypoplasia, ; luckily it is not 
frequently seen in RA patients. When present, 
it is mostly observed in association with Felty’s 
syndrome, renal failure, and the administration of 
gold, penicillamine, azathioprine, cyclophospha-
mide, or other immunosuppressive agents.
Pure Red Cell Aplasia
This uncommon hematologic abnormality among 
RA patient should be suspected if the patient has 
severe normocytic normochromic anemia with 
very low absolute reticulocyte count without evi-
dences of blood loss or hemolysis. Autoimmune 
suppression of erythroid stem cells, DMARDs, 
and parvovirus infection have been implicated 
in this complication [18], although single case 
report suggests that pure red cell aplasia could 
be an extraarticular manifestation of RA [19]. 
Isolated case reports have noted improvement in 
patients treated with corticosteroids, cyclophos-
phamide, azathioprine, or cyclosporine [20].
Treatment of Anemia in RA
Effective therapy of patient with RA and anemia 
is based upon an accurate determination of the 
cause of the anemia. As a result:
• Vitamin deficiencies leading to anemia should 
be corrected by the administration of folic 
acid or vitamin B12.
• Iron should not be given unless iron deficiency 
has been documented. It is recommended to 
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start with a combination of oral ferrous sul-
fate, which is usually given with 250 to 
325  mg of ascorbic acid and on an empty 
stomach to enhance iron absorption. 
Alternatively, ferrous gluconate 300 mg three 
times daily may be used.
• Patients with persistent gastric intolerance to 
iron tablets may tolerate elixir of ferosol.
• If oral therapy fails, it is switched to intramus-
cular iron, and only very rarely parenteral iron 
as a slow IV infusion can be used.
• Hemolysis can be managed with corticoste-
roids (prednisone 60 mg/day).
• If no response is observed after 1 to 2 weeks, 
an immunosuppressive agent may be adminis-
tered, such as azathioprine (50 to 150 mg/
day).
• DMARD-induced bone marrow suppres-
sion should be treated by dose alteration or 
complete withdrawal of the suspected drug.
• The ACD often responds to therapy directed 
against RA, including DMARDs, and/or corti-
costeroids (prednisone at a dose of 0.5 to 1.0 
mg/kg per day) [2].
• Several interventional studies have demon-
strated the efficacy of erythropoietin in treat-
ing the anemia of RA [11]; however, only a 
limited number of patients with RA and ACD 
may require this treatment. High doses (300 to 
800 units/kg/week given subcutaneously once 
or twice a week) are required, making this an 
expensive form of therapy. One specific role 
for erythropoietin among patients with RA is 
in the peri-operative management of anemia. 
Treating anemia in this setting may prevent 
the need for transfusion [2].
13.3.1.2  White Blood Cell (WBC) 
Count Abnormalities
Neutropenia and Felty’s Syndrome
The principal leukopenic disorder among 
patients with RA is Felty’s syndrome, which 
is defined as a triad of RA, splenomegaly, and 
neutropenia.
• Splenomegaly is not necessarily present [21].
• This disorder occurs in about 1% of patients 
with RA.  Patients with this syndrome often 
has an advanced form of nodular RA, with 
high levels of rheumatoid factor.
• This disorder may be accompanied by severe 
infections, vasculitis, ulcers, neuropathic 
symptoms, interstitial lung disease, secondary 
Sjögren’s syndrome, hepatomegaly, and lower 
extremity hyperpigmentation. These manifes-
tations are rare in the current era of early 
aggressive therapy with DMARDs.
Although leukopenia is a common conse-
quence of many rheumatic diseases, it is most 
frequently caused by the administration of 
DMARDs, including azathioprine, methotrex-
ate, gold salts, sulfasalazine, and penicillamine 
[22, 23]. In addition, viral infections are another 
important differential diagnosis and should be 
excluded before considering the diagnosis of 
Felty’s syndrome.
Management of Felty’s syndrome is aimed at 
suppressing the inflammatory rheumatoid disease. 
There are several reports on the good outcome 
with use of gold salts, methotrexate, and biologi-
cal therapy in these patients. In one retrospective 
review of all Felty’s syndrome cases (1979 to 
2003), it was concluded that Felty’s syndrome is 
considered a mild disease and is not commonly 
linked to infectious complications. Gold is an 
effective treatment of Felty’s syndrome [21].
Leukocytosis
Leukocytosis can occur during an inflamma-
tory flare of RA.  However, an associated bac-
terial infection must be considered and should 
excluded in such patients.
Eosinophilia
Significant eosinophilia occurs in some patients 
with RA. It usually correlates with the presence 
of vasculitis, pleuropericarditis, pulmonary fibro-
sis, subcutaneous nodules, or gold-induced skin 
rashes [23].
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13.3.1.3  Platelet Abnormalities
Thrombocytosis is common in RA, and a posi-
tive correlation has been found between the 
platelet count and disease activity. Extreme 
thrombocytosis has been noticed with extraar-
ticular manifestations of the disease, particularly 
pulmonary involvement, peripheral neuropathy, 
and vasculitis [24]. The mechanism of thrombo-
cytosis is unclear yet.
Thrombocytopenia is rare in RA, mostly 
induced by drug treatment such as gold, peni-
cillamine, methotrexate, azathioprine, and 
TNF antagonists [25, 26]. Felty’s syndrome, 
is another cause of thrombocytopenia in RA 
patients.
13.3.1.4  Hematological Malignancies 
in RA
Several studies have noted a higher risk of 
hematologic malignancy among RA patients 
contributing significantly to a higher morbidity 
and mortality of the disease [27–30]. Most large 
registries noted a higher risk for the develop-
ment of lymphoproliferative diseases, particu-
larly non- Hodgkin lymphoma (NHL). A study 
of nearly 18, 000 RA patients noted a higher risk 
of lymphoma in patients with RA in comparison 
to the general population (the standardized inci-
dence ratio or SIR) (SIR of1.9) [31]. Although 
the risk in those treated with anti-tumor necro-
sis factor- alpha agents was greater than that for 
patients treated with methotrexate (SIRs of 2.9 
and 1.7, respectively), the authors of the study 
noted that this difference could result if patients 
with active RA, who have a higher increased 
risk of developing lymphoma, were more often 
managed with anti-TNF therapy than those with 
less active RA.
The results of studies that have addressed the 
question of whether TNF inhibitor use is asso-
ciated with increased cancer risk are mixed, and 
large observational studies were unable to dem-
onstrate a significant increase in either hemato-
logic malignancies or solid tumors for patients 
taking biologic DMARDs compared with those 
taking methotrexate [32, 33].




Hematological involvement is commonly seen in 
(SLE) and could be the presenting manifestations 
of SLE in many patients. Also, it could mimic 
many primary hematological disorders.
The most common forms of hematologic 
manifestations in patients with SLE are anemia, 
leukopenia, thrombocytopenia, and the antiphos-
pholipid syndrome (APS). Further details about 
APS and thrombosis are found in Chap. 12 
(Thrombosis in Rheumatological diseases).
In this chapter; an overview of the hemato-
logic manifestations of SLE will be discussed, 
with an algorithm at the end constructing a sim-
ple approach to hematological manifestations in 
SLE patients (Fig. 13.3).
13.4.1.1  Anemia
Many patients with SLE may have anemia at 
some point of time; the most common types of 
anemia in such patients are anemia of chronic 
disease, IDA, autoimmune hemolytic anemia 
(AIHA), drug-induced myelosuppression, and 
anemia associated with chronic renal failure 
which is uncommon [34]. There are different 
mechanisms which may explain the development 
of anemia in patients with SLE; at the end of this 
chapter, you will find a simple approach regard-
ing common differential diagnosis, causes, and 
investigations. Figure 13.4 shows an algorithmic 
approach for Anemia in SLE patients.
Anemia of Chronic Disease
In a single-center prospective study of 132 SLE 
patients with anemia, ACD found as the most 
common type, representing 37% of all patients 
[34]. ACD is classified as normocytic and nor-
mochromic anemia and may be associated with 
a low reticulocyte count and a low serum iron, ; 
however bone marrow iron stores are adequate, 
and ferritin concentration is usually high.
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13.4.2  Treatment
Usually the treatment is not indicated unless 
the patient has symptomatic anemia or renal 
impairment.
Patients with symptomatic anemia second-
ary to ACD and with no indication for cortico-
steroid or other immunosuppressant agents may 
be offered a therapy to enhance erythropoiesis, 
e.g., epoetin alfa (recombinant human erythro-
poietin). It should be started at 80 to 120 units/kg 
per week (usually as 2 to 3 injections per week). 
The patient should be reassessed after one month, 
and the dose should be increased monthly until 
the hemoglobin level is maintained at ≥11 g/dL.
Darbepoetin alfa; a unique molecule that stim-
ulates erythropoiesis with a longer half-life than 
recombinant human erythropoietin. A typical 
dose of darbepoetin alfa for adults is 0.45 mcg/
kg once a week.
Erythropoietin was evaluated in patients with 
SLE and ACD; it was found that 58% of patients 
in one study had an adequate response to erythro-
poietin supplementation [35].
Patients with symptomatic anemia secondary 
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Fig. 13.3 Algorithmic approach for anemia in SLE 
patients. In this approach the authors classified the anemia 
according to MCV and MCH, aiming to widen the differ-
ential diagnosis and to include non-rheumatological 
causes, life-threatening causes, and co-factors. The evi-
dence to support this approach is based on cumulative lit-
erature, current guidelines, and the author’s experience 
(Abbreviations: HB hemoglobin, MCV mean corpuscular 
volume, MCH mean corpuscular hemoglobin, LDH lactate 
dehydrogenate, −ve negative, +ve positive, IDA iron defi-
ciency anemia, AIHA autoimmune hemolytic anemia, TTP 
thrombotic thrombocytopenic purpura, 2ry secondary)
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poietin supplementation, often improve on gluco-
corticoids at high doses (1 mg/kg/day) which is 
usually the next step in their management.
After 1 month of being on steroid, if the 
response is insufficient (e.g., hemoglobin still 
<11 g/dL), glucocorticoids dose should be 
tapered down rapidly and stopped.
If there is a response, the dose should be 
tapered as rapidly as to possible to the lowest 
dose that maintains the improvement.
13.4.2.1  Iron Deficiency Anemia (IDA)
IDA is the second most prevalent type of ane-
mia in patients with SLE [36]; in female, it 
could be secondary to menorrhagia, or it may 
represent an acute or chronic blood loss from 
gastrointestinal tract usually as a result of 
chronic administration of NSAIDs and cortico-
steroids. It can exacerbate and/or coexist with 
ACD.
Long-standing anemia of chronic inflamma-
tion can also result in to IDA.
Diffused pulmonary hemorrhage is an uncom-
mon cause of anemia in patients with SLE.
13.4.2.2  Autoimmune Hemolytic 
Anemia (AIHA)
AIHA is an antibody-mediated erythrocyte 
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Approach to Hematological manifestations of SLE
SLE
Fig. 13.4 Algorithmic approach for hematological mani-
festations of systemic lupus erythematosus (SLE). 
Classified by the affected component of the blood (plate-
lets, HB, or WBC), in this approach, the authors suggest 
to broaden the differential diagnosis and to rule out non- 
rheumatological causes of mentioned abnormalities, 
including systemic diseases, infections, and drug-induced 
and primary hematological diseases. The evidence to sup-
port this approach is based on cumulative literature, cur-
rent guidelines, and the author’s experience 
(Abbreviations: RA rheumatoid arthritis, R/O rule out, 
HCV hepatitis C virus, HIV human immunodeficiency 
virus, TSH thyroid stimulating hormone, PT prothrombin 
time, PTT partial thromboplastin time, INR international 
normalization ratio, DIC disseminated intravascular coag-
ulation, HIT heparin-induced thrombocytopenia, ITP 
immune thrombocytopenic purpura, TTP thrombotic 
thrombocytopenic purpura, MAHA microangiopathic 
hemolytic anemia, H. pylori Helicobacter pylori, WBC 
white blood cell, HB hemoglobin, Plt platelets, 2ry sec-
ondary, -ve negative, +ve positive, BM bone marrow, 
MDS myelodysplastic syndrome)
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(AIHA) is characterized by:
• High reticulocyte count,
• Reduced haptoglobin levels,
• High indirect bilirubin concentration,
• Positive direct Coombs’ test,
• Found in up to 10% of SLE patients [37, 38].
Approximately 2/3 of patients with SLE- 
associated AIHA have symptoms at the onset 
of SLE [26]. The presence of hemolytic anemia 
could be associated with other sever SLE fea-
tures including lupus nephritis, neuropsychiatric 
manifestations, and serositis. Some patients may 
have a positive Coombs’ test without evidence of 
hemolysis. [36, 37]. The antibodies are divided 
into IgG-mediated “warm, ”, and IgM-mediated 
“cold” agglutinin.
Treatment: AIHA usually improves on corti-
costeroids (1 mg/kg/day of prednisone) in 75 to 
96% of patients [39].
Once the hematocrit starts to increase and the 
reticulocyte count decreases, prednisone can be 
quickly tapered down.
If the patient didn’t achieve response, pulse 
steroid can be considered (e.g., 1 g methylpred-
nisolone intravenously daily for 3 days) [39], 
azathioprine (up to 2 mg/kg per day) [40], cyclo-
phosphamide (up to 2 mg/kg) [40], or splenec-
tomy [41, 42].
Response rates for splenectomy in AIHA can 
reach up to 60% [41], ; however, other study has 
contradictory result [30]. In case of refractory 
AIHA, one can consider intravenous immune 
globulin [30], danazol (in doses of 600 to 800 
mg/day) [42], mycophenolate mofetil [44], and 
rituximab [45].
Anemia due to chronic kidney disease:
An inappropriately low level of erythropoietin 
is the major feature of anemia due to chronic kid-
ney disease. In this setting, typically decreased 
production of erythropoietin by the impaired 
kidneys plays a major role in the pathogenesis 
of this type of anemia. In such patients, specially 
patients with no other evidence of inflammation, 
prescribing erythropoiesis-stimulating agents 
could be indicated in symptomatic anemia or if 
the hemoglobin is less than 11 g/dL.
13.4.2.3  Red Cell Aplasia
In SLE, red cell aplasia may occur secondary 
to antibody-mediated injury to erythropoietin 
or erythroblast in the bone marrow, although it 
is uncommon, but it has been reported [46, 47]. 
This type of anemia usually improves on cortico-
steroid, ; in refractory cases cyclophosphamide 
and cyclosporine have been successfully used.
13.4.2.4  Microangiopathic Hemolytic 
Anemia (MAHA)
SLE is one of many causes of thrombotic micro-
angiopathic hemolytic anemia [48]. It usually 
presents with schistocytes in peripheral blood 
smear and high serum lactate dehydrogenase 
(LDH) levels as well as high indirect bilirubin 
concentration.
As you will see in the algorithm at the end of 
this chapter, it is essential to consider MAHA in 
any SLE patient who present with normocytic 
normochromic anemia, MAHA is manifested by 
schistocytes in peripheral film which necessitate 
urgent treatment with plasmapheresis and corti-
costeroid .
Thrombotic thrombocytopenic purpura 
(TTP), which is life-threatening condition, is 
typically manifested by a pentad of thrombocyto-
penia, fever, microangiopathic hemolytic anemia 
(MAHA), neurologic manifestations, and renal 
impairment.
Other patients with MAHA may not mani-
fest with fever or neurologic abnormalities, 
presenting a condition called hemolytic-uremic 
syndrome (HUS). The pathogenesis of this syn-
drome isn’t entirely known [49].
Treatment: In MAHA and TTP, plasmapher-
esis is considered the most important acute inter-
vention. Because of the adverse outcome which 
associated with delay in its initiation, it should be 
started immediately in all patients with suspected 
TTP [50, 51].
In a review study, 28 patients with TTP man-
aged with plasmapheresis, glucocorticoids alone, 
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or no therapy. The mortality rate was 25% in 
those treated with plasmapheresis, 50% in glu-
cocorticoids alone group, and 100% in those who 
received no therapy [53].
The current recommendations suggest that 
plasma exchange should be immediately in the 
patients diagnosed to have TTP; it should be 
carried on at least for 5 days, along with pulse 
steroid (methylprednisolone 1 g intravenously 
daily for 3 days) with the first dose usually given 
immediately after the first plasmapheresis  session 
[50]. Recently, in some cases of TTP anti- CD20 
antibody, rituximab has been used, however more 
data are needed [52].
TTP-HUS is often associated with reduced 
activity of ADAMTS13 (<10%), usually due to 
an inhibitor of ADAMTS13 activity. However, 
results of ADAMTS13 activity measurement 
should not influence the decision to initiate 
plasma exchange, and plasmapheresis shouldn’t 
be delayed while awaiting its result [50, 53].
13.4.3  WBC Abnormalities
At the end of this chapter, the reader will find an 
algorithm which constructing an approach to SLE 
patients who present with WBC abnormalities; 
including leukocytosis, leucopenia, neutropenia, 
lymphocytopenia, and other abnormalities. This 
approach emphasizes rolling out serious conditions 
as well as considering SLE related WBC disorders.
13.4.3.1  Leucopenia and Neutropenia
Leucopenia is a characteristic feature of SLE and 
can include lymphopenia, neutropenia, or both. 
It defined as less than 4000 cells/mL of white 
blood cell (WBC) count, and it usually represents 
an active disease. According to the American 
College of Rheumatology (ACR, leucopenia is 
considered as one of the criteria to diagnose SLE 
[54]. It can be seen in up to 50% to 60% of SLE 
patients [55, 56].
Other comparative retrospective study which 
was done in Saudi Arabia showed that the most 
common hematologic presentation among SLE 
patients was leukopenia which was found in 
58.7% of the patients [57].
In some cases, leukopenia becomes challeng-
ing specially if the patients require a medication 
that can cause bone marrow suppression, e.g., 
cyclophosphamide, azathioprine, methotrex-
ate, and, rarely, cyclosporine, mycophenolate 
mofetil, or HCQ.  If a patient developed a rapid 
leucopenia, hemophagocytic syndrome should 
be considered, and proper workup should be 
perused [55].
Neutropenia may reflect primary hematologi-
cal disease, infection, or treatment side effects 
(e.g., cyclophosphamide or azathioprine); how-
ever, all those causes should be considered in cor-
relation with history and clinical finding. In SLE, 
neutropenia which attributed to an active disease 
usually respond to steroids.
13.4.3.2  Lymphocytopenia
Lymphopenia is considered one of the most 
prevalent hematological features of SLE, and 
although it was noted to be contributory to leu-
copenia, yet it can be independent to total white 
blood cell count. Reduced absolute lymphocytic 
count can correlate with SLE activity, and those 
with absolute lymphocytic count less than 1500/
μL at diagnosis may have a higher frequency of 
fever, musculoskeletal manifestations, and neu-
ropsychiatric manifestations [55].
13.4.3.3  Decreased Eosinophils 
and Basophils
Generally, corticosteroids may contribute to a 
low absolute eosinophil and monocyte counts.
Basophil count can be reduced as well in 
SLE, especially during lupus flare, basophil 
degranulation usually occurs which result in 
the release of platelet activating factor and as 
well as other mediators which can play a role 
in vascular permeability and immune complex 
deposition [31].
13.4.3.4  Treatment of Leukopenia
Not all SLE patients with leucopenia need to be 
treated, unless the patient has neutropenia with 
recurrent infections. On other hand, side effects 
of the treatment may complicate the situations, 
; prednisone (10 to 60 mg/day) may increase the 
leucocyte count but may result in high risk of 
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infections as well; immunosuppressive therapies 
like azathioprine or cyclophosphamide may con-
tribute toward the worsening of the leukopenia 
through their effect on bone marrow suppression 
[31]. In such cases, these medications should be 
used with caution and frequent monitoring of 
white blood cell count and for signs of infections.
Treating leukopenia in SLE in other set-
tings may result in unfavorable outcomes. As an 
 example, recombinant granulocyte colony-stim-
ulating factor (G-CSF) studied in the treatment 
of sever neutropenia associated with refractory 
infections, although it was effective in increasing 
neutrophilic count, yet it was associated SLE flare 
in three out of the nine patients in this study [32].
13.4.3.5  Leukocytosis
Leukocytosis can be found in patients with 
SLE.  Two contributing factors include underly-
ing infectious process or leukocytosis associated 
with high dose of steroids [31]. It also can be 
found during SLE flare. In case of leukocytosis 
secondary to infections, shifting of granulocytes 
to more immature forms (a left shift) is usually 
seen.
13.4.4  Platelet Abnormalities
Both qualitative and quantitative disorders of 
platelets are not uncommon in SLE patients; at 
the end of this chapter, you will find a simple 
approach to platelets disorders, considering the 
life-threatening conditions, disease activity, and 
other associated diseases. It has been found that 
almost in 25% to 50% of SLE patients may have 
a mild thrombocytopenia with platelet counts 
ranging between 100, 000 and 150, 000/microL, 
and 10% of SLE patients may have more severe 
form in which the counts become less than 50, 
000/microL [1].
In a cohort study of 632 patients with SLE, 
the percentage of patients with platelet counts 
ranging between 50, 000 to 100, 000/μL was 
54%, while those with counts between 20, 000 
and 50, 000/μL represent 18%, and patients with 
counts less than 20, 000/μL represent 28% of 
the cohort [58].
There are many potential causes of thrombocy-
topenia in SLE patients. Among them, immune-
mediated platelet destruction is considered the 
most common cause, but platelet consumption 
is another factor specially in association with 
MAHA or may be due to reduced platelet pro-
duction secondary to cytotoxic medications.
Pathogenesis—the main mechanism is bind-
ing of immunoglobulin to the surface of the plate-
lets which later get involved in the phagocytosis 
inside the spleen, similar to idiopathic thrombo-
cytopenic purpura (ITP) [51]. Another mecha-
nism in some patients involves bone marrow 
suppression by cytotoxic medications, increased 
consumption due to a thrombotic microangiopa-
thy (e.g., TTP), the antiphospholipid syndrome, 
or antibodies against the thrombopoietin receptor 
on megakaryocytes or their precursors.
Patients with SLE can present initially with 
ITP followed by other manifestations later on.
In patients with isolated ITP, it has been found 
that 3–15% may develop SLE [59]. Evans syn-
drome, which is defined as the presence of both 
autoimmune thrombocytopenia and autoimmune 
hemolytic anemia, can also precede the onset of 
SLE.
Thrombocytopenia is uncommonly severe, 
and complications related to bleeding are gen-
erally low as a minority of patients only experi-
ences severe bleeding. However, it is well-known 
that thrombocytopenia in patients with SLE con-
sidered poor prognostic factor and put the patient 
at risk of other organ involvement such as cardiac 
involvement, nephritis, or neuropsychiatric mani-
festation [38, 48].
Our algorithm at the end of this chapter sim-
plified the approach to thrombocytopenia in SLE 
patients;, we suggest to do peripheral blood smear 
to rule out serious conditions such as MAHA, 
TTP, and malignancies; to order lupus antic-
ouagulant and anticardiolipin to rule out APS; to 
do hemolysis workup and direct Coombs’ test to 
rule out AIHA and Evans syndrome;, and to con-
sider disease activity as well as secondary throm-
bocytopenia causes in your differential diagnosis.
Treatment: In patients with thrombocytope-
nia with counts ranging between 20, 000/microL 
and 50, 000/microL, usually they have prolonged 
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bleeding time; however bleeding is rarely seen 
with this range, while counts of less than 20, 000/
microL can be associated with petechiae, purpura, 
ecchymoses, epistaxis, gingival, and other clini-
cal bleeding. Treatment is usually indicated for 
patients with symptoms and counts of less than 
50, 000/microL and for those with counts of less 
than 20, 000/microL.  Glucocorticoid therapy is 
the main treatment, prednisone (1 mg/kg per day 
in divided doses) [47]. Dexamethasone also can 
be used as 40 mg/day dose for 4 days, with repeat-
ing the doses every 2–4 weeks, an intervals of 2–4 
weeks may have similar remission rates and better 
long-term responses than those treated with daily 
prednisone [39]. The majority of patients improve 
on glucocorticoid within 1–8 weeks; in case of no 
response within 1–3 weeks or intolerance to ste-
roids, other lines of therapy should be considered. 
The choice of second medication depends on the 
severity of the thrombocytopenia and the pres-
ence of other SLE manifestations.
• Azathioprine (0.5 to 2 mg/kg per day) [60].
• Cyclophosphamide, given as daily oral doses 
or intravenous pulse therapy. Intravenous 
pulse cyclophosphamide is usually preferred 
in patients with concurrent active lupus 
nephritis [40].
• Intravenous immune globulin, which is an 
effective and usually considered a first choice 
in conditions when a quick increase in plate-
lets is needed, e.g., active bleeding or in case 
of emergency surgery [43].
• Mycophenolate mofetil, usually considered 
in patients who failed other medications [41].
• Rituximab—It is a chimeric monoclonal anti-
body which has been used as well to treat pri-
mary ITP (without SLE) refractory to 
previously mentioned therapies. It is given as 
once weekly dose for 4 consecutive weeks at 
doses of 375 mg/m2 [42].
• Splenectomy—Splenectomy may increase 
the platelet count, but it does not reliably make 
a consistent remission of thrombocytopenia. 
After splenectomy, relapse may happen and 
has been reported at varying times from 1 to 
54 months following surgery.
• Thrombocytopenia following splenec-
tomy—Some patients may have persistent 
thrombocytopenia following splenectomy;, 
those patients may respond to azathioprine, 
cyclophosphamide, rituximab, intravenous 
immunoglobulin, or danazol [44]. Patient who 
underwent splenectomy is at high risk of 
pneumococcal infections;, that’s why it is 
highly recommended for patients to receive 
immunization with pneumococcal vaccine 
before splenectomy if possible.
• Danazol (400 to 800 mg/day) [45]—May be 
considered for patients who failed other thera-
pies. In a series of 34 patients, excellent long- 
term results were achieved with danazol [46].
• Vincristine—Successful use of vincristine 
has been reported [46].
13.4.4.1  Thrombocytosis
Thrombocytosis is unfrequently seen in patients 
with SLE.
We suggest to ruling out secondary causes 
such as infection or other inflammatory process, 
or APS.
As an example, among 465 patients with 
SLE, 17 (3.7%) were found to have thrombocy-
tosis (platelet ≥400, 000/mm3). Three of these 
patients had one or more of the following fea-
tures on peripheral blood film: Howell-Jolly bod-
ies, spherocytes, and target cells.
Ultrasound, CT, and liver-spleen scintigraphy 
failed to demonstrate a spleen. All three patients 
had aPL [69]. These observations suggest that 
autosplenectomy may occur in patients with 
SLE, perhaps mediated by aPL.
13.4.5  Pancytopenia
Destruction of all three cell line (red blood cells, 
white blood cells, and platelets) may occur 
peripherally;, it also may suggest bone marrow 
failure, as in the case in aplastic anemia. Hence, 
bone marrow biopsy is the most significant diag-
nostic test to do. In a study published in 2012, 
concluded that among SLE patients with periph-
eral cytopenia, the incidence of bone marrow 
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abnormalities is high. Bone marrow may be one 
of the common affected organs by immune dys-
regulation in active SLE.  Peripheral cytopenia 
can be consequently improved after treatment 
of disease activity; hence, bone marrow biopsy 
should be recommended in patients with refrac-
tory cytopenia to conventional treatment [61].
There are many causes of bone marrow fail-
ure which include drugs and coexisting diseases 
such as acute leukemias, myelodysplastic syn-
dromes, severe megaloblastic anemia, parox-
ysmal nocturnal hemoglobinuria (PNH), and 
infections. Furthermore, unexplained cytopenia 
can be associated with bone marrow necrosis, 
dysplasia, and distortion of the bone marrow 
architecture [62, 63].
13.4.6  Lymphadenopathy 
and Splenomegaly
Patients with SLE may present with lymphade-
nopathy, which could be regional or peripheral 
lymphadenopathy. The common sites involved 
in SLE lymphadenopathy are cervical and axil-
lary nodes. In a cohort of 698 patients with SLE, 
lymphadenopathy was found in 59% of the study 
group. Patients who presented with lymphade-
nopathy as initial presentation represented 1% of 
the cohort. Furthermore, the lymph nodes’ size 
ranged from 3 to 4 centimeter in diameter, most 
of them were not tender and soft. [64].
The typical histological finding in SLE lymph-
adenopathy includes reactive lymphoid follicu-
lar hyperplasia with variable levels of coagulative 
necrosis. A usual finding, yet highly associated with 
SLE, is the presence of hematoxylin bodies [1].
SLE lymphadenopathy is present usually ini-
tially at the diagnosis and during SLE flares in 
most of the cases. When SLE patient presents 
with an enlarged lymph node, other etiologies 
should be considered such as infection and lym-
phoproliferative disorders (e.g., angioimmuno-
blastic T-cell lymphoma); both of these diseases 
are relatively common in SLE compared to nor-
mal population. In case of infectious lymphade-
nopathy, lymph nodes are usually tender.
Splenomegaly may present in 10–46% of 
SLE patients, especially during SLE flares, and 
it should not necessarily be linked to cytopenia.
Based on the fact that splenomegaly and 
lymphadenopathy are common among SLE 
patients, physicians should consider lymphopro-
liferative disorders in those patients, especially 
because patients with SLE have up to fivefold 
higher risk of non-Hodgkin lymphoma [65].
Kikuchi-Fujimoto disease (KFD), also known 
as histiocytic necrotizing lymphadenitis, is a 
disease characterized by the presence of fever, 
lymphadenopathy commonly in cervical nodes, 
and constitutional symptoms [67].
KFD is usually self-limited, and sometimes 
confused with SLE or lymphoma. Typically, it is 
present in young women, and preceded by flu- like 
illness. The etiology of KFD remains unknown. 
No specific laboratory tests are associated with 
this disease, ; however, 50% of the patients may 
develop mild leucopenia. Histological finding 
of hematoxylin bodies and plasma cells and the 
DNA deposition in the blood vessels are highly 
associated with SLE lymphadenitis and help dif-
ferentiating between the two diseases. It is always 
recommended to exclude SLE with proper sero-
logical testing before making the diagnosis of 
KFD. There have been few reports of SLE with 
coexisting KFD [55, 64, 66].
Castleman disease, also known as angiofol-
licular lymph node hyperplasia, is one of the rare 
lymphoproliferative diseases which manifested 
as enlarged lymph node that may or may not 
be associated with constitutional symptoms and 
could be confused with SLE or lymphoma. Its 
etiology remains unknown.
13.4.7  Antibodies to Clotting Factor 
and Phospholipids
Hematologic manifestations of SLE may involve 
coagulation system in some patients. SLE 
patients may have antibodies directed against the 
following factors VIII, IX, XI, XII, and XIII [1].
These antibodies can cause a biochemi-
cal abnormality (in vitro), but it also can cause 
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some clinical abnormalities manifested as overt 
bleeding.
Antiphospholipid antibodies (aPL) are com-
monly seen in SLE patients. They can cause a pro-
longed partial thromboplastin time through lupus 
anticoagulant activity. Clinically, these antibod-
ies have well-recognized risks of arterial as well 
as venous thrombosis and  thrombocytopenia. 
Additionally, female in childbearing age with 
aPL is at high risk fetal loss [68].
Moderate to high titers of aPL and other anti-
bodies to binding proteins such anticardiolipin 
antibodies can be associated with certain clini-
cal features. If aPL is present with certain clinical 
features, it may suggest the presence of antiphos-
pholipid syndrome (APS) (see Chap.   12, , 
Thrombosis in Rheumatological diseases).
High prevalence of aPL in SLE patients follow-
ing treatment with cyclophosphamide was noted 
in a single retrospective study that compared 177 
cyclophosphamide-treated SLE patients to 203 
patients with SLE never treated with this alkyl-
ating agent [52]. Sero-conversion occurred at 
a higher rate in the cyclophosphamide- treated 
patients (19 versus 1%, respectively).
13.5  Macrophage Activation 
Syndrome (MAS)
13.5.1  Introduction
The macrophage activation syndrome (MAS), 
also known as hemophagocytic lymphohistiocy-
tosis (HLH), is a condition that requires urgent 
attention and treatment. It is classically associ-
ated with systemic juvenile idiopathic arthritis 
in children and adult onset Still’s disease [69], 
but can occur in any rheumatic disease including 
SLE, RA, vasculitis, Sjögren’s syndrome, mixed 
connective tissue disease, systemic sclerosis, and 
inflammatory myopathies [70]. MAS can develop 
anytime during rheumatologic disease. It can be 
the first manifestation of the rheumatologic dis-
ease or may occur while patient is on treatment. 
It may also be associated with infection.
Hematological manifestation of MAS includes 
pancytopenia, hepatosplenomegaly, hyperferri-
tinemia, and coagulopathy.
An overview of MAS is presented here, with 
an algorithm at the end constructing a simple 
approach to diagnose MAS/HLH in a patient 
with rheumatologic disorder.
13.5.1.1  Pancytopenia
Together, anemia and thrombocytopenia are pres-
ent in more than 80% of patients [71–73]. The 
median hemoglobin level is 7.2 g/dl, and plate-
let count is 69, 000/microL [71]. Neutropenia 
with absolute counts below 1000/microL is not 
uncommon.
Patients with juvenile idiopathic arthritis and 
adult onset Still’s disease may develop cytopenia 
later in the course of disease as they tend to have 
elevated blood counts prior developing MAS.
13.5.1.2  Hepatosplenomegaly
Reticuloendothelial system is commonly 
affected in MAS/HLH.  In retrospective study 
including 249 patients of HLH, hepatomegaly 
was observed in 95% and lymphadenopathy in 
33% of the patients. Another European registry 
includes 122 patients, 97% of them were found 
to have splenomegaly [74].
13.5.1.3  Hyperferritinemia
Severe hyperferritinemia is associated with 
MAS/HLH;, a level above 10, 000 ng/mL is 90% 
sensitive and 96% specific for MAS/HLH [75].
In HLH-94 study, it was found that ferritin 
greater than 10,000, 5000, and 500 ng/mL were 
seen in 25, 42, and 93%, respectively [72]. It is 
very rare to have MAS/HLH with ferritin levels 
below 500, ; however, low ferritin does not totally 
exclude MAS.
13.5.1.4  Coagulopathy
High partial thrombin time and high prothrom-
bin time due to liver involvement and impaired 
liver synthetic function in association with dis-
seminated intravascular coagulopathy are seen in 
MAS/HLH [70].
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The HLH-2004 revised diagnostic criteria 
are used to diagnose MAS/HLH. Five out of the 
eight criteria as shown in Fig. 13.5 are required 
for the diagnosis.
13.5.2  Treatment
Salvage treatment for adults with refractory/
relapsing HLH usually requires intensification 
using combined chemotherapy and consolidation 
with allogenic stem cell transplantation. Novel 
agents are providing promising therapeutic alter-
natives including those incorporating ruxolitinib 
(JAK1/2 inhibitor), anakinra (IL-1 blockade), 
alemtuzumab, and emapalumab [76].
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Renal System and Rheumatology
Sami Alobaidi, Manal Alotaibi, Noura Al-Zahrani, 
and Fahmi Al-Dhaheri
14.1  Introduction
Many rheumatic diseases can be associated with 
different complications in kidneys and urinary 
tract. The goal of this chapter is to provide a 
summary of renal manifestations in rheumatic 
diseases that is easily accessible by students, resi-
dents, and practitioners.
The material presented provides a simple 
approach to patients presenting with renal and 
rheumatic manifestations. It is not meant to be an 
exhaustive review.
It presents a stepwise approach to the evalua-
tion of proteinuria and hematuria in patients with 
rheumatic diseases. It also provides a summary on 
the renal complications of rheumatic diseases. The 
chapter also discusses lupus nephritis (LN) in more 
detail as it is common and severe manifestation of 
systemic lupus erythematosus with increased risk 
of death and end-stage renal disease.
14.2  Objectives
By the end of this chapter, you should be able to:
 1. Construct a diagnostic approach to patients 
with proteinuria or hematuria.
 2. Diagnose and manage lupus nephritis (LN).
 3. Discuss renal involvement in different rheu-
matic diseases.
 4. Review the common side effects of antirheu-
matic medications on kidney function.
14.3  Proteinuria
Proteinuria screening among populations is based 
on measurement of albumin in random urine dip-
stick test. Most adolescents who have proteinuria 
through dipstick test do not have renal disease, 
and this proteinuria usually resolves on repeat 
testing. However, prolonged proteinuria is sug-
gestive of kidney disease in patients with diabe-
tes mellitus, hypertension, primary renal disease, 
SLE, or other systemic illnesses [1].
Proteinuria greater than 200 mg/24 h is con-
sidered abnormal. Urine protein excretion rang-
ing between 200 and 3000  mg/24  h is termed 
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sub-nephrotic range proteinuria. Nephrotic range 
proteinuria is typically more than 3000 mg/24 h.
Proteinuria is an important indicator of renal dis-
ease activity and progression. It reflects an underly-
ing pathology causing a change in the permeability 
properties of the glomerular filtration barrier [1].
A stepwise approach that may help physi-
cians detect and evaluate benign and pathological 
causes of proteinuria is illustrated in Fig. 14.1.
14.4  Hematuria
Microscopic hematuria refers to the presence 
of erythrocytes in urine that can be exclusively 
detected by microscopic exam or dipstick 
analysis. It is a frequent reason for referral to 
urology or nephrology. It is often asymptom-
atic and found incidentally on routine urine 
examination.
PR3-ANCA (c-ANCA): Granulomatosis with polyangiitis GPA (Wegener’s)
MPO-ANCA (P-ANCA): Eosinophilic granulomatosis with polyangiitis EGPA (Churg-Strauss)
Anti-GBM: Goodpasture syndrome
Antistreptolysin O titers: Postinfectious glomerulonephritis (PSGN)
ANA and anti-dsDNA: SLE
Hepatitis serologies, RF, Cryoglobulinemia, polyarteritis nodosa (PAN)
Decreased C3 and C4: PSGN, SLE, cryoglobulinemia, endocarditis, and membranoproliferative glomerulonephritis
Lipid profile, HbA1c, HIV serology, phospholipase A2 receptor antibodies and ESR
Renal Biopsy
Testing to make a diagnosis of Glomerular proteinuria
Types according to the amaount of proteinuria
Glomerular proteinuria:
It can be nephrotic or subnephrotic
proteinuria
(Nephrotic syndrome: proteinuria
more than 3000 mg/24 hr)
The more the proteinuria, the worse
the renal disease 
Tubular proteinuria:
It is caused by acute tubular
necrosis (ATN)
or other defects in kidney’s tubules.
Proteinuria range: 500 -3500 mg/24 hr 
Transient proteinuria:
It is usually seen in a small
percentage of healthy individuals
If it persists, and is not related to
prolonged standing, stress, or fever,
then a kidney biopsy should be done
Urine Exam 
1- Urine dipstick test: Detects albumin only 
2- Microscopic analysis: To assess for urine sediments, cells
   and other substances. Results are interpreted as follows:
-  Dysmorphic red cells: Glomerulonephritis.
-  Red cell casts: Glomerulonephritis
-  WBC casts: Glomerulonephritis or interstial nephritis
1- 24-hour urine protein collection: The gold
    standard test 
2- The urine protein-to-creatinine ratio (UPCR): It
    correlates well with 24-hour urine protein
    collection 
Clincal findings
History of chronic diseases: Diabetes mellitus or
hypertension
History of chronic Infections: HIV, TB, hepatitis B or C
History of autoimmune diseases: Sjogren's, sarcoidosis,
SLE
Vasculitis: Non-specific symptoms (fatigue, myalgias,
muscle weakness, fever and unexplained weight loss)
wheezing, painful or painless oral ulcers or purulent or
bloody nasal discharge
Physical Examination: Orthostatic hypotension,
increase in blood pressure, edema and SLE findings
Signs of vasculitis: Palpable purpura, paranasal sinus
abnormality, mononeuritis multiplex, livedo reticularis,
finding of diffuse high pitched wheezes on expiration,
ENT manifestations, evidence of hepatitis B virus
infection, signs of pulmonary involvement and
gastrointestinal involvement   
Fig. 14.1 Approach to a patient with proteinuria [1]
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Macroscopic (grossly visible) hematuria is 
more commonly associated with malignancy 
than microscopic hematuria. For this reason, a 
full investigation, including upper tract imag-
ing and cystoscopy for the lower tract, for all 
patients with macroscopic hematuria is usually 
required.
Opinions regarding which patients with micro-
scopic hematuria should be evaluated and need to 
be investigated remain controversial [2, 3].
Figures 14.2 and 14.3 provide simplified 
approaches to detect and evaluate significant 
microscopic hematuria according the recent 
guidelines [2, 3].
History:
A detailed history  is essential  to rule out serious conditions such as urinary tract malignancy
Urinary tract malignancy risk factors: Age > 40 years, tobacco use, previous radiation exposure, certain
occupational exposures (dyes, benzenes, aromatic amines) and medications such as cyclophosphamide
Transient causes: recent exercis, sexual activity and menstruation
The upper urinary tract causes (glomerular or non-glomerular): smoking history, fever, weight loss, flank pain,
trauma history, history of chronic diseases or cancers such as DM, HTN, SLE, TB, HIV, Sickle cell anemia, or Lymphoma
The lower urinary tract causes: Usually present with dysuria, suprapubic pain, frequency and urgency.
UTI: fever, dysuria and suprapubic pain
Clincal Findings
Another classification according to the frequency
Transient hematuria:
It may occur in young patients following exercise or sexual
intercourse
It can represent underlying malignancy in patients over the
age of 50 years 
It can also represent UTI with the presence of other UTI signs
(eg, pyuria and bacteriuria)
Persistent hematuria:
It should always be evaluated. The more common pathologic
causes are kidney stones, malignancy and glomerular disease 





























without documented stones 
Renal cell carcinoma 
Papillary necrosis
Renal infarction
Renal vein thrombosis 



































The presence of two or more RBCs per high-power field (RBC/HPF) in 2 of 3 urine specimens
without recent exercise, menses, sexual activity or instrumentation. 
Fig. 14.2 approach to a patient with hematuria.
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14.5  Renal Involvement 
in Different Rheumatic 
Diseases
Rheumatic diseases are frequently associated 
with renal complications. These complications 
include vascular, glomerular, and tubulointersti-
tial changes.
Drug-induced renal impairment should be 
included in the differential diagnosis of renal 
complications in a rheumatic patient.
Renal involvement clinically manifests in 
many different ways. The spectrum ranges from 
slight functional disorders such as slight eryth-
rocyturia/proteinuria with normal renal function 
to rapidly progressive renal failure. Table  14.3 
provides a summary of renal involvement in dif-
ferent rheumatic diseases.
14.6  Lupus Nephritis (LN)
Renal involvement is common in SLE.  It is the 
leading cause of morbidity and mortality in 
patients with lupus, characterized by the loss of 
self-tolerance, production of autoantibody, and 
development of immune complexes that deposit 
in the kidney to induce nephritis. Proteinuria 
is one of the most commonly observed abnor-
































































Fig. 14.3 Classification of hematuria
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Figure  14.4 provides an overview of pathogen-
esis, clinical manifestations, and complications 
of lupus nephritis.
14.6.1  Diagnostic Criteria
Criteria for lupus nephritis in patients with 
SLE include any of the following conditions 
(Table 14.1):
 1. Persistent proteinuria.
• 500 mg/24 h protein
• 3+ protein on urine dipstick
• Spot urine protein/creatinine ratio  >  0.5 
mg/mg.
 2. Cellular casts.
 3. Active urinary sediment (> 5 red blood cells/
high power field [RBC/hpf], > 5 white blood 
cells[WBC]/hpf in the absence of infection, or 
cellular casts limited to RBC or WBC casts).
 4. Renal biopsy: Immune complex-mediated 
glomerulonephritis compatible with lupus 
nephritis.
 5. Opinion of rheumatologist or nephrologist 
[11].
14.6.2  Treatment
The American College of Rheumatology 
(ACR) recommends treatment according to 
the International Society of Nephrology/Renal 
Pathology Society (ISN/ RPS) classification of 
lupus nephritis. (Check sect. 3 for full presen-
tation of the recommendation for management 
guidelines). Response to treatment is based on 
several factors including age, gender, location, 
and race/ethnicity (Table 14.2) [14].
14.6.3  Adjunctive Treatments
 1. Hydroxychloroquine for all patients with SLE 
unless contraindicated.
 2. Angiotensin-converting enzyme inhibitors or 
angiotensin receptor blockers if proteinuria 
≥500 mg/24 h [15]
 3. Statin therapy if LDL cholesterol >100 mg/dL 
(2.6 mmol/L).
 4. Control hypertension at a target of 
≤130/80 mm Hg [11]
Note: Patients with lupus should remain on 
antimalarial therapy even during disease qui-
escence as it was shown to be associated with 
 associated with reduced risk of renal damage, 
improved survival, and decreased incidence of 
lupus flares [16].
14.7  Sjögren’s Syndrome
Sjögren’s syndrome is a chronic inflammatory 
disorder characterized by lymphocytic infiltra-
tion of the lacrimal and salivary glands which 
result in dryness of the eyes and mouth [17]. 
Systemic features may include arthritis, renal, 
hematopoietic, pulmonary involvement, and 
vasculitis (Fig.  14.5). These manifestations are 
secondary to vasculitis, autoantibody-mediated 
mechanisms, or lymphocytic infiltration of the 
target organs. The prevalence of renal involve-
ment ranges from 2 to 67% [22].
14.8  Cryoglobulinemic 
Syndrome (CG)
Cryoglobulinemic vasculitis is an immune- 
complex-mediated disease caused by the 
deposition of cryoglobulins in the small- and 
medium-sized arteries and veins. Renal involve-
ment is noted in around 20% of patients with 
mixed cryoglobulinemic vasculitis and usu-
ally diagnosed 2.5  years after the disease 
onset. Membranoproliferative glomerulone-
phritis is reported in around 80% of patients 
[23]. Figure 14.6 provides an overview of renal 
involvements in CG.












A, complement components)    
Histologic classification based on
signs of activity and chronicity





chronicity index: sclerotic glomeruli,





History of presenting illness:
1- Foamy urine or nocturia (early
    signs of glomerular or tubular
    dysfunction) 
2- Microscopic hematuria,








worse outcome  
Elevated serum creatinine, total
cholesterol levels and proteinuria 
Complications:
1- Chronic kidney disease, nephritic
    syndrome, rapidly progressive renal
    failure (ISN/RPS Class  IV) 
2- Severe extra-renal manifestations
    such as lupus cerebritis, lupus
    pneumonitis 
Fig. 14.4 Overview of pathogenesis, clinical manifestations, and complications of lupus nephritis [7–9]
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Table 14.1 Recommended workup for suspected lupus nephritis
Tests Findings Analysis
Serum creatinine To evaluate renal functions [6]
Antinuclear antibodies (ANA) Frequently positive in patient with connective tissue 




High in patient with LN, it plays an important role in 




To evaluate autoimmune disease especially SLE, its 
presence means increase risk of thrombosis [6]
Anti-C1q antibodies It is sensitive and specific to diagnosis of lupus nephritis 
and evaluating the disease activity [10]
Complement 3 (C3) and 
complement 4 (C4)
Lack of C3 and C4 may indicate lupus nephritis because 
the presences of these complement components exert a 
protective effect against disease onset, although it may be 
normal [6]
Urine studies Persistent proteinuria -  Increases incrementally within severity classes
-  >500 mg/24 h protein
-  >3+ protein on urine dipstick
-  Spot urine protein/creatinine ratio > 0.5 [6, 11]
Dysmorphic erythrocytes -  Indicate inflammatory glomerular disease [6, 11]
RBC or WBC cells -  (> 5 red blood cells/high power field [RBC/hpf], > 5 
white blood cells[WBC]/hpf in the absence of infection
-  Indicate glomerulonephritis or tubulointerstitial disease 
[6, 11]
Cellular casts -  RBC or WBC casts which indicate inflammatory 
glomerular disease [6, 11]
Lipiduria -  May result from abnormal glomerular permeability [6, 
11]
Renal biopsy Indications American College of Rheumatology (ACR) 
recommendations
  1 to confirm suspected 
nephritis
  2 to evaluate disease 
activity and damage
  3 to determine appropriate 
therapy
  4 to make sure that the type, 
duration, and intensity of 
treatment matches the 
severity of disease
  5 to predict outcome and 
identify the alternative 
causes of renal disease
-  Biopsy is highly recommended in patients with systemic 
lupus erythematosus with the following:
   Increasing serum creatinine without alternative cause 
(such as sepsis, hypovolemia, or medication induced).
   Confirmed proteinuria ≥1000 mg/24 h (either 24-hr 
urine specimens or spot protein/creatinine ratios).
   Combinations of following (confirmed in ≥2 tests 
done within short period and in the absence of 
alternative causes).
   Proteinuria ≥500 mg/24 h plus hematuria (≥ 5 red 
blood cells per high power field).
   Proteinuria ≥500 mg/24 h plus cellular casts.
   All patients with clinical evidence of active lupus 
nephritis, previously untreated, should have renal 
biopsy to classify glomerular disease by current 
International Society of Nephrology/Renal Pathology 
Society (ISN/ RPS) classification (unless biopsy is 
strongly contraindicated) [11]
Second biopsy: To detect disease progression
Indications:
  1. When the patient does not respond to therapy
  2. In case of worsening of renal function [12]
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14.9  Scleroderma
Scleroderma is manifested by widespread pro-
gressive fibrosis of the skin and internal organs 
due to accumulation of collagen. Renal involve-
ment occurs in around half of the patients and is 
manifested as mild proteinuria, worsening kid-
ney function, and/or hypertension (Fig.  14.7) 
[26]. Scleroderma renal crisis is the most seri-
ous renal manifestation which occurs in 5 to 
10% of patients with systemic sclerosis, more 
commonly in diffuse cutaneous systemic scle-
rosis [27].
14.9.1  Rheumatoid Arthritis (RA)
Rheumatoid arthritis is a systemic inflamma-
tory disorder of unknown etiology that primar-
ily involves the joints. It has been reported that 
the annual incidence of rheumatoid arthritis is 
around 40 per 100,000. Females are affected two 
to three times more often than males, and the peak 
onset is between 50 and 75 years of age [28]. An 
observational study has shown that the incidence 
of impaired kidney function is higher in patients 
with rheumatoid arthritis; these changes were 
anticipated by many factors like cardiovascular 
disease, dyslipidemia, elevated sedimentation 
rate in the first year of rheumatoid arthritis, and 
NSAIDs use [29]. Figure 14.8 provides an over-
view of renal involvement in RA.
14.9.2  Renal Involvement 
in Vasculitis
14.9.2.1  Polyarteritis Nodosa (PAN)
It is a systemic necrotizing vasculitis of medium- 
sized and occasionally small vessels [34]. It is a 
rare disease and characterized by the absence of 
antineutrophil cytoplasmic antibodies (ANCA) 
[34]. Any organ can be affected including the 
kidneys (renal artery involvement is common 
and leads to stenosis, hypertension, and even-
tually chronic kidney disease) (Fig.  14.9). This 
disease spares the lungs [34]. Most cases are 
idiopathic; however, 33% of cases are associated 
with chronic HBV infection [34]. Renal disease 
is the most common cause of death. It is fatal if 
left untreated, but has favorable response to treat-
ment [34].
Table 14.2 Summary of the classification and treatment of lupus nephritis [11, 13]
Classifications of lupus nephritis Treatment
Class I (minimal mesangial LN) 
and class II (mesangial 
proliferative LN)
Treated as dictated by the extra-renal clinical manifestations of lupus
Class III LN (focal LN) and class 
IV LN (diffuse LN)
Initial therapy: Corticosteroids (1 mg/kg, to be tapered according to clinical 
response) combined with either cyclophosphamide (500 mg IV every 2 weeks 
for 6 doses) or mycophenolate mofetil (up to 3 g per day as tolerated)
Maintenance therapy: Mycophenolate mofetil (1–2 g/d in divided doses) or 
azathioprine (1.5–2.5 mg/kg/d) and low-dose oral corticosteroids (≤10 mg/d 
prednisone equivalent)
Class V LN (membranous LN) Non-nephrotic-range proteinuria: Angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers. Corticosteroids and 
immunosuppressive therapy use is dictated by the presence of extrarenal 
manifestations of lupus
Persistent nephrotic-range proteinuria: Corticosteroids plus an additional 
immunosuppressive agent—(Cyclophosphamide, tacrolimus, cyclosporine), 
mycophenolate mofetil or azathioprine
Class VI LN (advanced sclerosis 
LN)
Treated with corticosteroids and immunosuppressive therapy only as dictated 
by the extra-renal manifestations of lupus. Discussion of renal replacement 
therapy (dialysis vs kidney transplant)




It is a chronic inflammatory
disease characterised by 
lymphocytes-mediated
infiltration of exocrine
glands [14]  
Renal complications 1- Tubulointerstitial
nephritis





can damage the tubules
A- Distal renal tubular
acidosis (RTA): Non-anion
gap metabolic acidosis and
hypokalemia due to defect in
distal acidification
B- Nephrogenic diabetes
insipidus (NDI): Polyuria and
hypernatremia due to













NDI: Low sodium and
protein diet, thiazide
diuretics and NSAIDs 
Glomerular disease
Immunosuppressant [17]
Fig. 14.5 Renal involvement in Sjögren’s syndrome: [18–21]






It is a form of immune-complex
mediated systemic vasculitis involving
small and medium sized arteries and
veins 
- Types II and III CG (mixed
  cryoglobulinemic)  are the most common
  forms of cryoglobulinemia, typically
  characterized by a triad of purpuric
  lesions, glomerulonephritis (nephritic),
  generalized weakness
Pathogenesis
- Chronic Hepatitis C virus stimulates B-
  cell polyclonal proliferation with
  subsequent polyclonal IgM production 
- Vessel wall damage may be the result of
  immune-complex mediated complement




type 1 membranoproliferative) 
Blood tests &
urinalysis 
- Serologic testing for the presence of 
  cryoglobulins
- Serologic testing for hepatitis B and C
- Very low levels of ‘early’
  complements, especially C4
- Normal or slightly decreased levels of C3
- Blood urea nitrogen (BUN) and
  creatinine
- Urinalysis (looking for active GN)
Renal biopsy
Leukocytoclastic arteritis characterized
by predominant neutrophilic infiltration
with fibrinoid necrosis 
Treatment of
renal involvment Requires combined treatment with
corticosteroids and cytotoxic drugs such
as cyclophosphamide
Fig. 14.6 Overview of renal involvements in CG [23]




it is a chronic connective tissue disease.
It can be subdivided into three groups:
systemic sclerosis, localized
scleroderma, and scleroderm-like a
conditions, comprising a heterogeneous
group of diseases linked by the
presence of thickened, sclerotic skin     
Renal complications
Scleroderma Renal Crisis (SRC):
Occurs in 5–10% of SSc patients. It is
characterized by an abrupt onset of a
moderate-to-marked hypertension
that is accelerated and often




The pathogenesis may involve intimal
thickening of the renal interlobular and
arcuate arteries, which lead to
decreased renal perfusion, and
subsequently hyperplasia of the
juxtaglomerular apparatus and




management with ACEI is the
mainstay of therapy. Other
agents such as calcium channel
blocking agents can be added in
patients with inadequate blood
pressure reduction. Blood
pressure should be reduced
gradually to prevent further
decrease in renal perfusion and
increase the risk of acute tubular
necrosis [19]
It can progress to ESRD and death
if left untreated [20]        
Risk factors of SRC:
1- Rapid and progressive skin
disease
2- Corticosteroid therapy
3- Other risk factors: anaemia,
HRT, pericardial effusion, cardiac
insufficiency, high skin score and
large joint contractures, the
presence of antibodies to RNA
polymerases and new cardiac
events [19]        
Fig. 14.7 Renal involvement in scleroderma [24, 25]




It is a systemic inflammatory disorder
of unknown etiology that primarily
involves joint. Extra articular
manifestation indicates the severity of
the disease and is associated with
increased morbidity and mortality. The
kidneys are much less likely to be








Membranous nephropathy: Occurs in




glomerulonephritis is the most
frequent histopathological finding in RA   
Rheumatoid vacuities: Blood vessels
inflammation may occur in patients
with long standing RA. The renal
findings are similar to those in other
systemic vasculitis
Analgesic nephropathy:
Characterized by renal necrosis and
chronic interstitial nephritis. It is
caused by chronic analgesic use
particularly phenacetin in




by discontinuation of the drug 
Secondary amyloidosis: Treated by
controling the underlying
inflammatory process with medical therapy   
Glomerulonephritis: Treated by
immunosuppressive therapy 
Rheumatoid vacuities: Treated with
regimens similar to those used in
primary systemic vaseculitis  
Analgesic nephropathy: Treated by
discontinuation of the drug 
Fig. 14.8 Overview of renal involvement in RA [30–33]
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14.9.3  Eosinophilic Granulomatosis 
with Polyangiitis EGPA 
(Churg-Strauss)
It is a systemic necrotizing vasculitis that affects 
small-sized muscular arteries [35]. It is a rare 
disease and characterized by the presence of 
antineutrophil cytoplasmic antibodies (ANCA) 
[35]. Asthma, peripheral eosinophilia, and gran-
ulomas on histology are common associations 
with this disease [35]. Renal involvement can 





It is a systemic necrotizing vasculitis that
typically affects the medium-sized arteries.
Antineutophil cytoplasmic anatibodies (ANCA)
are negative. 
Renal complications
The kidneys are the most commonly involved
organs.
Renal involvement frequently leads to:
hypertension (common)
variable degrees of renal insufficiency
rupture of renal arterial aneurysms can lead 
to perirenal hematomas
Multiple renal infarctions (in severe vasculitis)
Renal biopsy and
urinalysis  
Renal biopsy in classic PAN may
reveal pathognomonic inflammation
of the medium-sized arteries.
Renal arteriography is an alternative
to biopsy for the diagnosis of PNA.
On urinalysis: minimal
proteinuria and modest
hematuria (indicative of sub-
nephrotic abnormality), but red
blood cell casts (indicative of a
glomerular focus of 
inflammation) are usually absent
Treatment of renal involvment
Treat patients with more serious
disease manifestations (i.e., renal
insufficiency, mesenteric artery
ischemia, mononeuritis multiplex)




(ACE) inhibitors are effective in 
treatment of hypertension
Fig. 14.9 Medium vessel vasculitis: polyarteritis nodosa (PAN) [34]
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These are systemic vasculitides of the medium- and 
small-sized arteries, as well as the venules and arte-
rioles [29]. They are known to cause many renal 
complications, e.g., glomerulonephritis, acute kid-
ney injury, and proteinuria (Fig. 14.11) [29, 30].
Rapidly progressive glomerulonephritis is a 
common and severe feature with Wegener’s gran-
ulomatosis or proteinase-3 (PR3)-ANCA vascu-
litis, and it might lead to end-stage renal diseases 
[29, 30]. In addition, necrotizing granulomatous 
inflammation is the histopathologic hallmark 
of GPA [29, 30]. Microscopic polyangiitis or 
myeloperoxidase (MPO)-ANCA vasculitis are 
associated with chronic renal injury more than 
glomerulonephritis [29, 30].
14.9.5  Henoch-Schönlein Purpura 
(HSP) (IgA Vasculitis)
It is a systemic vasculitis of the small-sized blood 
vessels (the post-capillary venules), character-
ized by the deposition of IgA-containing immune 
complexes [40].
IgA vasculitis is considered the most common 
systemic vasculitis in children [40]. Renal involve-
ment occurs in 20% to 100% of patients. HSP 
nephritis is common and generally mild in chil-
dren (particularly young children) (Fig. 14.12). It 
is mainly presented with microscopic hematuria 








It is a vasculitis of the small-sized muscular
arteries and is often assocaited with vascular
and extravascular granulomatosis.  
Renal complications
Rapidly progressive or acute renal
insufficiency
Glomerulonephritis mainly with positive ANCA
Hypertension
Isolated proteinuria  
Renal biopsy and
urinalysis 
The diagnosis of EGPA is confirmed by
lung biopsy or biopsy of other clinically
affected tissues.
Renal biopsy in classic EGPA may reveal
necrotizing glomerulonephritis 
On urinalysis: proteinuria,
hematuria or isolated proteinuria
or microscopic hematuria  
Treatment of renal involvment Treat patients with systemic
glucocorticoids
Cyclophosphamide is typically used
in combination with glucocorticoids
for patients with severe, multiorgan
disease 
Fig. 14.10 Eosinophilic granulomatosis with polyangiitis EGPA (Churg-Strauss) [35]













These are systemic vasculitides of the medium
and small-sized arteries, as well as the venules
and arterioles. A migratory oligoarthritis is often
among the initial disease manifestations of these
conditions
Both are associated with ANCA, have similar
features on renal histology, and have similar
outcomes. There are, however, several
differences between these disorders
The absence of ANCA does not exclude the
diagnosis of GPA. The sensitivity of PR3-ANCA for
GPA is related to the extent, severity, and activity




Acute kidney injury with hematuria and
cellular casts
A variable degree of proteinuria that is
usually subnephrotic
Rapidly progressive glomerulonephritis is
common in this group of diseases
[27, 28, 29]. 
Renal biopsy and
urinalysis  
Necrotizing granulomatous inflammation is
the histopathologic hallmark of GPA
Renal biopsy findings in GPA and MPA
generally parallel the severity of the clinical
presentation, ranging from mild focal and
segmental glomerulonephritis in patients
with asymptomatic hematuria and normal
or near-normal renal function to a diffuse
necrotizing and crescentic
glomerulonephritis in patients with acute
kidney injury[ 27, 28, 29].  
On urine analysis:
Initial manifestation: asymptomatic
hematuria, with normal renal function.
According to European Medicines 
Agency (EMA): patients with GPA
Glomerulonephritis can have: hematuria
associated with red cell casts, >10
dysmorphic red cells, 2+ hematuria or 2+









methotrexate [30].    
Fig. 14.11 Granulomatosis with polyangiitis GPA (Wegener’s) and Microscopic Polyangiitis (MPA) [36–39]







It  is a systemic vasculitis of the small-sized
blood vessels (most prominent in the
postcapillary venules), characterized by the
deposition of IgA-containing immune complexes
Renal complications
Renal involvement ranges from 21 to 54%
and is typically noted within a few days to one
month after the onset of systemic symptoms, but
is not predictably related to the severity of
extrarenal involvement
HSP (IgAV) nephritis is generally mild in children
(particularly young children), while adults are
more likely to develop moderate to severe
disease
Renal biopsy and urinalysis  
There is a general correlation between the
severity of the renal manifestations and the
findings on renal biopsy
A kidney biopsy is generally reserved for
patients in whom the diagnosis is uncertain
or who have more severe renal involvement.
Light microscopy can show a wide spectrum
of glomerular changes, ranging from isolated
mesangial proliferation, focal and segmental
proliferation, to severe crescentic
glomerulonephritis. 
On urine analysis: microscopic or
macroscopic hematuria with or
without red cell and other cellular
casts or proteinuria 
Treatment of renal
involvment
Specific treatment of HSP (IgAV) nephritis should be
considered only in patients with severe renal
dysfunctions
The  regimen consisting of pulse intravenous
methylprednisolone (250 to 1000 mg per day for three
days) followed by oral prednisone (1 mg/kg per day for
three months) may be beneficial
Other regimens that have been evaluated in children
with crescentic nephritis include glucocorticoids and
azathioprine
Renal transplantation can be performed in patients
who progress to end-stage renal disease 
Fig. 14.12 Henoch-Schönlein purpura (HSP) (IgA vasculitis) [40]
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Table 14.3 Summary of renal involvement in different rheumatic diseases
Rheumatic disease Renal complications
Systemic lupus 
erythematosus
  • Interstitial nephritis.
  • Necrotizing vasculitis.
  • Glomerulosclerosis.
  • Chronic kidney disease.
  • Nephritic syndrome.
  • Rapidly progressive renal failure .
Sjögren’s syndrome   • Interstitial nephritis (may precede onset of sicca symptoms).
  • Renal tubular acidosis (types I and II) (in 11%).
  • Interstitial cystitis (rare).
  • Glomerulonephritis (rare).
  • Nephrolithiasis (rare).
Cryoglobulinemia   • Membranoproliferative glomerulonephritis (60 to 80%).
Henoch-Schönlein 
purpura (HSP) (IgA 
vasculitis)
  • Hematuria with or without proteinuria.
  • Isolated hematuria.
  • Nephritic syndrome.
  • Renal insufficiency.
  • Hypertension.
  • End-stage renal failure.
Polyarteritis
Nodosa
  • Hypertension (common).
  • Variable degrees of renal insufficiency.
  • Rupture of renal arterial aneurysms can lead to perirenal hematomas.






  • Glomerulonephritis.
  • Acute kidney injury with hematuria and cellular casts.
  • Subnephrotic proteinuria.





  • Focal segmental glomerulonephritis common but renal failure rare.
  • Rapidly progressive or acute renal insufficiency.
  • Glomerulonephritis mainly with positive ANCA.
  • Hypertension.
  • Isolated proteinuria .
Rheumatoid arthritis 
(RA)
  • Acute tubular necrosis related to nonsteroidal anti-inflammatory drug (NSAID) 
use.
  • Secondary amyloidosis due to the chronic inflammation; it is now relatively rare in 
RA.
  • Nephrotic syndrome secondary to membranous nephropathy.
  • Necrotizing glomerulonephritis.
  • Destructive inflammation within the walls of renal arteries.
Mixed connective tissue 
disease (MCTD)
  • Glomerulonephritis.
  • Renal vasculopathy.
  • Malignant hypertension.
  • Immune complex- mediated nephritis.
  • Interstitial nephropathy.
  • Severe renal disease (rare) [4]
Scleroderma   • Renal impairment usually mild.
  • Scleroderma renal crisis rare (occurs in 1%–10%).
Ankylosing spondylitis   • Secondary renal amyloidosis.
  • Immunoglobulin A (IgA) nephropathy.
  • Membranoproliferative glomerulonephritis.
  • Treatment-associated nephrotoxicity.
  • Membranous glomerulonephritis (rare).
  • Focal glomerulosclerosis (rare).
  • Proliferative glomerulonephritis (rare) [5]
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14.9.6  Renal Side Effects of DMARDs 
and NSAIDs
Renal toxicity of disease-modifying antirheu-
matic drugs (DMARDs) and nonsteroidal anti- 
inflammatory drugs (NSAIDs) varies depending 
on the age and the kidney function of the 
patient. Side effects are commonly observed 
in elderly patients with compromised kidney 
function. Therefore, the use of NSAID should 
be avoided in patients with chronic kidney dis-
ease. Cyclosporine, gold, and penicillamine are 
associated with more serious renal side effects. 
Fortunately, gold and penicillamine are now 
very rarely used for the treatment of rheumatic 
diseases. Others like methotrexate, azathioprine, 
antimalarials, sulfasalazine, and leflunomide are 
safer with relatively less renal toxicity [35, 36]. 
Table14.4 summarized the renal side effects of 
commonly used drugs in rheumatic diseases.
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There are many rheumatic diseases presenting 
with skin manifestations. This could be the 
first presenting feature of a systemic rheumatic 
disease. In addition, some of these skin mani-
festations could be an indication of an active 
disease or a sign of a serious medical emer-
gency. In this chapter the skin manifestations 
of common rheumatic diseases will be 
described. Particular focus will be placed on 
rheumatic diseases with polyarthritis. The dif-
ferential diagnosis of erythema nodosum will 
be discussed as this condition is observed in 
several disorders with arthritis. There are many 
drugs used in rheumatology, some of them like 
allopurinol can lead to life-threatening derma-
tological conditions. A quick review on some 
of these conditions will be outlined. At the end 
of this chapter, the reader should be able to rec-
ognize different dermatological signs associ-
ated with patients with arthritis, discuss the 
differential diagnosis of erythema nodosum, 
and recognize life-threatening dermatological 
conditions.
15.2  Objectives
• To identify the dermatological signs in patients 
presenting with polyarthritis.
• To construct a diagnostic approach to patients 
presenting with erythema nodosum.
• To recognize life-threatening dermatological 
conditions.
15.3  Polyarthritis with Skin: 
(Diagram 15.1)
15.3.1  Rheumatoid Arthritis (RA)
RA is a chronic inflammatory disorder that 
affects the joints and causes symmetrical arthri-
tis. It usually involves extra-articular structures 
like the skin, eye, lung, heart, kidney, blood ves-
sels, and bone marrow. The skin manifestations 
of RA will be discussed here.
15.3.2  Pyoderma Gangrenosum
It presents as an inflammatory and ulcerative dis-
order of the skin. It’s an uncommon neutrophilic 
dermatosis. It presents commonly as an inflamma-
tory papule or pustule that progresses to a painful 
ulcer; it may also present with bullous, vegetative, 
peristomal, and extracutaneous lesions.
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15.3.3  Rheumatoid Vasculitis
Inflammation of blood vessel is a central feature 
of RA, and it is considered as one of the primary 
events in the formation of rheumatoid nodule. 
Histologically it is characterized by mononuclear 
cell cuffing of postcapillary venule. It occurs in 
patients with long-standing joint-destructive 
RA.  It affects vessels from medium vessel to 
small arterioles; it leads to ischemia and necrosis 
to blood vessel “occlusion.”
15.3.4  Rheumatoid Nodule
It is one of the most common cutaneous manifes-
tations in RA.  The nodule is seen on pressure 
area such as olecranon process and many other 
areas in the body. It is firm, with size varies 
between 2 mm and 5 cm; non-tender and move-
able in subcutaneous tissue; it could be painful, 
interfere with function, and may cause neuropa-
thy [1]. Around 75% of patients with Felty’s syn-
drome have a nodule [1], and a vast majority of 
patient with nodule have positive RF [2]. Patients 
with nodule are more likely to have vasculitis [3] 
(Figs. 15.1 and 15.2).
15.3.5  Skin Ulceration
It may result from venous stasis, vasculitis, arterial 
insufficiency, and neutrophilic infiltration [4].
There are many cutaneous changes that occur 
in patients with RA such as granulomatous der-
matitis and medication-induced skin changes, 
and also there are rare manifestations as linear 
bands or annular lesions, urticarial eruption, 
erythema elevatum diutinum, and dermal 
papule.
15.3.6  Systemic Lupus 
Erythematosus (SLE)
The dermatological manifestations are the most 
common presentation of SLE in general. They 
involve the skin, mucous membranes, and hair. 
Polyarthritis + Skin
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Fig. 15.1 The dermatological signs of patient presenting with polyarthritis. Source: Kelley’s textbook of rheumatology 
. available on:- www.medscape.com
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The new classification criteria of SLE contains 
acute cutaneous lupus erythematosus (ACLE) 
lesions, subacute cutaneous lupus erythematosus 
(SCLE), and chronic cutaneous lupus erythema-
tosus as follows.
15.3.7  ACLE (Localized)
15.3.7.1  Malar Rash
Characterized by erythematous butterfly-shaped 
rash over the cheeks and nasal bridge sparing the 
nasolabial folds, it can be flat or raised, painful, 
and lasting for days to weeks [5].
15.3.7.2  Disseminated (Generalized) 
ACLE
This lesion is characterized by erythematous to 
violaceous, scaly maculo-papular widespread 
exanthum symmetrically involves trunk and 
extremities. Other nonspecific lesions can be 
seen, for example; subungual erythema, ulcers, 
pitting scars stubby hair cheilitis, periorbital 
edema, and diffuse telogen effluvium [5].
15.3.7.3  SCLE
The clinical fissures of this type are characterized 
by circulating anti-Ro and anti-La antibodies and 
the HLA-B8 and HLA-DR3 haplotype. There are 
two variants that have been identified: annular 
variant and papulosquamous variant. The annular 
variant contains slightly raised erythemas with 
central clearing, while the papulosquamous vari-
ant consists of psoriasis-like or eczematous-like 
lesions. These two variants usually involve 
UV-exposed skin, including the lateral aspects of 
the face, the “V” of the neck, the upper ventral 
and dorsal part of the trunk, and the dorsolateral 
aspects of the forearms [5]. SCLE lesions com-
monly lead to hypopigmentation or depigmenta-
a b
Fig. 15.2 Periarticular skin-colored rheumatoid nodule
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tion and never lead to scarring. The systemic 
symptoms are mild like arthralgias and musculo-
skeletal complaints [5].
15.3.7.4  CCLE
This is also called discoid CLE characterized by 
erythematous discoid plaque that becomes hyper-
keratotic and finally leads to atrophy and scarring 
and can lead to dyspigmentation; it mainly involves 
the face, ears, and neck but may be widespread, and 
there are no relation of sun exposure. This lesion 
can affect the mucosal membranes including the 
lips, mucosal surfaces of the mouth, nasal mem-
branes, conjunctivae, and genital mucosa. CCLE 
has several types like hypertrophic/verrucous lupus 
erythematosus, lupus erythematosus tumidus, lupus 
panniculitis/profundus, chilblain lupus erythemato-
sus, and DLE–lichen planus overlap [5].
15.3.8  Others
15.3.8.1  Photosensitivity
Macular rash present only after sun exposure 
may appear on the face, arms, or hands and per-
sist for more than 1 day [6].
15.3.8.2  Discoid Rash
Erythematous patches with keratotic scaling over 
sun-exposed areas, plaque-like in character with 
follicular plugging and scarring [6] (Fig. 15.3).
15.3.8.3  Alopecia
Mainly affects the temporal regions or creates a 
patchy pattern of hair loss [7] (Fig. 15.4).
15.3.8.4  Oral Ulcer
It is an important manifestation of SLE; it occurs 
more than three times per year and is usually 
painless [7].
15.3.8.5  Systemic Sclerosis 
“Scleroderma”
Scleroderma is a term used to describe a thick-
ened skin. It may affect the skin and subjacent 
tissues, or it may be associated with systemic 
involvement [8].
15.3.8.6  Raynaud Phenomenon
Changes of the color of the digits due to abnor-
mal vasoconstriction of digital arteries and cuta-
neous arterioles due to a local defect in normal 
vascular responses, (pallor , cyanosis and then 
redness). It is exaggerated by cold temperatures 
or emotional stress [9] (Fig. 15.5)
15.3.9  Telangiectasia
It may develop anywhere within the body but 
mostly seen in perioral area, hands, and ante-
rior chest. It’s small dilated blood vessels that 
locate beneath the dermis on skin (venule) 
(Fig. 15.6).
Fig. 15.3 Discoid lesions of lupus erythematosus. Show 
dyspigmentation, atrophy, and scarring
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Fig. 15.4 Diffuse non-scarring alopecia
Fig. 15.5 Raynaud's phenomenon. Note the demarcation of color difference (pallor and cyanosis)
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15.3.10  Sclerodactyly
It is a localized thickening and tightness of the 
skin of the fingers or toes. Sclerodactyly is com-
monly associated with atrophy of the underlying 
soft tissues. It is considered as a characteristic 
feature of scleroderma (Fig. 15.7).
15.3.11  Cutaneous Sclerosis
It is the formation of scar tissue in the skin or in 
tissues around joints (Fig. 15.8).
Note the tight and shiny appearance of skin.
15.3.12  Digital Ulcers
With scleroderma, repeated episodes of spasm of 
the fingers (Raynaud’s) can cause pitted fingertip 
scars, and in some people this results in fingertip 
ulcers [10].
15.3.13  Calcinosis Cutis
It is mostly asymptomatic and developed grad-
ually, in which amorphous, insoluble calcium 
salt deposits in the skin and subcutaneous tis-
sue [11]. It’s usually firm, multiple, whitish 
dermal papules, plaques, nodules, or subcuta-
neous nodules. The lesion spontaneously ulcer-
ated, and it may be tender and may restrict joint 
mobility. In severe cases it may cause cutane-
ous gangrene due to vascular calcification 
which diminishes the pulse.
Hyperpigmentation and finger swelling are 
also considered as skin manifestations which 
occur in systemic sclerosis.
Fig. 15.6 Telangiectasia
Fig. 15.7 Sclerodactyly
Fig. 15.8 Cutaneous sclerosis
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15.4  Psoriasis
15.4.1  Scales (Fig. 15.9)
15.4.1.1  Nail Involvement
Nail disease is more common in patients with 
psoriatic arthritis [12]. There is usually involve-
ment of the nail matrix or nail bed. Nail abnor-
malities may include: beau lines, leukonychia, 
onycholysis, oil spots, subungual hyperkeratosis, 
splinter hemorrhages, spotted lunulae, transverse 
ridging, cracking of the free edge of the nail, and 
uniform nail pitting.
15.4.1.2  Erythroderma
Patients commonly present with generalized 
erythema, then after the onset of erythema 2–6 
weeks, scaling appears usually from flexural 
area. Pruritus commonly results in excoria-
tions. If it persist for weeks, hair may shed, 
nails may become ridged, thickened and it may 
shed. Inflammation and edema in periorbital 
skin may occur resulting in ectropion 
(Fig. 15.10).
15.4.1.3  Guttate Lesion
It is a clinical presentation that is characterized 
by a distinctive, acute eruption of small, droplike, 
1–10 mm in diameter, salmon-pink papules, usu-
ally with a fine scale. It occurs primarily on the 
trunk and the proximal extremities; also it may 
have general distribution on the body [13] 
(Fig. 15.11).
15.4.1.4  Psoriatic Arthritis
Psoriatic arthritis is one of the seronegative spon-
dyloarthropathies which include ankylosing 
spondylitis and reactive arthritis. The prevalence 
of psoriatic arthritis among individuals with pso-
riasis is ranging from 7 to 48% [14–18]. There 
are several patterns of joint involvement in psori-
atic arthritis patients [19]:
Fig. 15.9 Psoriatic plaques. Note the white to silvery scales over an erythematous base
Fig. 15.10 Generalized erythroderma with scaly skin 
appearance
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• Arthritis mutilans, characterized by deform-
ing and destructive arthritis.
• Spondyloarthropathy which includes sacroili-
itis and spondylitis.
15.4.2  Dermatomyositis (DM)
15.4.2.1  Gottron’s Papules
They are symmetrical erythematous eruptions 
which involve the extensor aspects of the meta-
carpophalangeal (MCP) and interphalangeal (IP) 
joints and may involve the skin between them; 
they may be associated with scale and ulcer if the 
eruption was prominent [20] (Fig. 15.12).
Fig. 15.11 Guttate psoriasis. Small discrete papules and plaques with fine scales
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15.4.2.2  Heliotrope Eruption
Erythematous lesion occurs on the upper eyelids 
and may be associated with eyelid edema 
(Fig. 15.13).
15.4.3  Facial Erythema
This lesion can mimic the malar rash seen in 
SLE.  To easily differentiate between both of 
them, look at the nasolabial fold; if it is involved, 
then the rash is mainly due to DM; however, if it 
is not involved, then the rash is mainly due to 
SLE (Fig. 15.14).
15.4.4  Photodistributed 
Poikiloderma
Poikiloderma consists of both hyperpigmentation 
and hypopigmentation; it always occurs in upper 
chest, the V of the neck, and upper back (shawl 
sign); it may come as macular (nonpalpable) or 
papular erythema if it happens in early stages of 
cutaneous disease. It is usually associated with 
pruritus, and this is the difference between DM 
and photo-exacerbated eruption of lupus erythe-
matosus. If the patient presents with poikiloderma 
on the lateral aspects of the thighs, this is now 
called Holster sign (Fig. 15.15).
15.4.5  Periungual Abnormalities
These are characterized by erythematous lesion 
with vascular changes in the capillary nail beds 
which also may be associated with areas of dila-
tation and dropout and with periungual ery-
thema [21].
15.4.6  Psoriasiform Changes 
in Scalp
The scalp lesion in DM is diffuse, associated with 
prominent scaling and poikilodermatous changes. 
Fig. 15.12 Gottron’s papules. Flat-topped papules over 
the proximal interphalangeal and metacarpophalangeal 
joints
Fig. 15.13 Heliotrope sign. Note the pink to violaceous 
discoloration over eyelids and forehead
Fig. 15.14 Facial erythema
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It may be difficult to distinguish from seborrheic 
dermatitis and psoriasis. It happens usually as a 
result of severe burning, pruritus, or sleep 
disturbance.
15.4.7  Calcinosis Cutis
It is more common in juvenile DM than adult 
DM.  It means deposition of calcium within the 
skin. It is associated with a delay in treatment 
with glucocorticoids and immunosuppressive 
therapy; this lesion can be seen in other diseases 
like systemic sclerosis and SLE but more com-
mon with DM [22, 23].
15.4.8  Reactive Arthritis
15.4.8.1  Circinate Balanitis
It is an asymptomatic genital lesion characterized 
by shallow ulcers in the penis [24].
Fig. 15.15 Photodistributed poikiloderma. Note the hyperpigmentation, hypopigmentation, telangiectasia, and 
atrophy
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15.4.8.2  Keratoderma
Hyperkeratotic skin rashes involve soles and 
palms [24] (Fig. 15.16).
15.4.9  Hepatitis C Virus (HCV)
15.4.9.1  Porphyria Cutanea Tarda
It is a skin lesion strongly associated with HCV 
and characterized by photosensitivity, bruising 
skin, fragility, facial hirsutism, and vesicles or 
bullae that can become hemorrhagic. It is a skin 
disease caused by a reduction of hepatic uropor-
phyrinogen decarboxylase activity [25].
15.4.9.2  Leukocytoclastic Vasculitis
This lesion is usually associated with palpable 
purpura and petechiae that usually involve the 
lower extremities and may happen in conjunction 
with essential mixed cryoglobulinemia; in skin 
biopsy, there is dermal blood vessel destruction 
associated with a neutrophilic infiltration in and 
around the vessel wall (Fig. 15.17) [26].
15.4.10  Lichen Planus
It involves mucus membranes, hair, and nails 
characterized by flat-topped, violaceous, pruritic 
papules with a generalized distribution. In skin 
biopsy, there is a dense lymphocytic infiltration 
in the upper dermis [27, 28] (Fig. 15.18).
15.4.11  Necrolytic Acral Erythema
This lesion is pruritic and characterized by sharply 
marginated, erythematous to hyperpigmented 
plaques with variable scale and erosion which 
involves the lower extremities (Fig. 15.19) [29].
15.4.12  Polyarteritis Nodosa
15.4.12.1  Livedo Reticularis
It is characterized by tenderness and it does not 
blanch with active pressure [30–32].
15.4.12.2  Ulcerations
It usually involves the lower extremities 
[30–32].
15.4.13  Digital Ischemia
It may be associated with splinter hemorrhages 
and gangrene [30–32].
15.5  Sarcoidosis
It is a granulomatous disease and defined as pres-
ence of non-caseating granulomas in different tis-
sues and organs such as lymph nodes, eyes, 
joints, brain, kidneys, lung, and skin. The signs 
that appear with sarcoidosis are as follows.
Fig. 15.16 Keratoderma blennorrhagicum. Note the 
thick yellow scales on the soles
Fig. 15.17 Leukocytoclastic vasculitis. Note the scat-
tered palpable purpura and hemorrhagic macules
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15.5.1  Erythema Nodosum
It is the most common nonspecific lesion of sar-
coidosis and characterized by inflammatory, ten-
der, erythematous, subcutaneous plaques and 
nodules in the anterior tibial areas. The patient 
can present with low-grade fever, arthritis, and 
lower extremity edema (Fig. 15.20) [32].
15.5.2  Papular Sarcoidosis
It is the most common specific lesion charac-
terized by numerous non-scaly, skin-colored, 
yellow- brown, red-brown, violaceous, or 
hypopigmented 1 to 10  mm papules, and the 
 papules can demonstrate a slight central 
depression. The most common site is the face, 
a
b
Fig. 15.18 Flat-topped, polygonal, and violaceous papules of lichen planus
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with a predilection for the eyelids and nasola-
bial folds [33].
15.5.3  Nodular Sarcoidosis
Subcutaneous sarcoidosis or nodular sarcoidosis, 
all these terms describe the nodule arising from 
subcutaneous tissue [32]; it is one of the most 
common lesions in sarcoidosis, and it results 
from large collections of sarcoidal granulomas in 
the dermis or subcutaneous tissue characterized 





































Fig. 15.20 Erythema 
nodosum
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as asymptomatic or mildly tender, flesh-colored, 
erythematous, violaceous, and hyperpigmented. 
The upper extremities are the most common site 
of nodular sarcoidosis [34]. It can be single or 
multiple, and its size could be about 1 and 2 cm 
in diameter. The differential diagnosis of subcu-
taneous sarcoidosis includes lipomas, cysts, cuta-
neous manifestations of lymphoproliferative 
malignancies, subcutaneous granuloma annulare, 
foreign body, or granulomas [35, 36].
15.5.4  Maculopapular Sarcoidosis
This lesion is characterized by raised papules that 
are often around 1 mm in diameter, slightly ten-
der, pruritic, slightly hyperpigmented patches, 
red, brown, or violaceous in color [37]; the most 
common sites are facial and eyelid areas, and it 
may involve mucous membranes, neck, trunk, or 
extremities [32].
15.5.5  Plaque Sarcoidosis
This lesion is characterized by oval or annular 
shaped, indurated, different color such as flesh- 
colored, erythematous or brown rash that may 
have scale at the end stage. The most common 
sites involved are the arms, shoulders, back, and 
buttocks; it has common features with psoriasis, 
lichen planus, discoid lupus, granuloma annu-
lare, cutaneous T cell lymphoma, secondary 
syphilis, and Kaposi’s sarcoma [36].
15.5.6  Lupus Pernio
This lesion is characterized by erythematous, 
indurated papules, plaques, or nodules [38]; the 
most common sites involved are the face, nasal 
tip, alar rim, and cheeks, and it may involve ears 
and lips [39]. If this lesion is not treated, it will 
progress rapidly and increase in thickness, size, 
and induration. After the lesion is resolved, it will 
leave scar [37]. This lesion is associated more 
with extracutaneous manifestations such as respi-
ratory tract involvement and lytic and cystic bone 
lesions [40].
15.5.7  Hypopigmented Sarcoidosis
It affects mostly dark-skinned persons of African 
descent, and the lesion is characterized by round 
to oval, hypopigmented, well-demarcated patches 
and may have raised plaques [33, 41].
15.5.8  Atrophic and Ulcerative 
Sarcoidosis
This lesion is a combined lesion meaning it is 
involved with atrophic and ulcerated lesions, 
which are characterized by depressed plaques not 
elevated [42]; this lesion is associated with other 
mucocutaneous manifestations of sarcoidosis. 
The ulcerative lesion is more common in women 
and black patients [43].
15.6  Rheumatic Fever
Acute rheumatic fever is a non-suppurative 
sequela that occurs after 2–3 weeks of group A 
streptococcus and pharyngitis. It mostly affects 
children aged 5 to 15 years. This disease is char-
acterized by arthritis, carditis, chorea, erythema 
marginatum, and subcutaneous nodules. The 
damage to the cardiac valve is chronic and it may 
progress [44].
To make a diagnosis of rheumatic fever, there 
is a special criterion called Jones Criteria, which 













• Elevated acute phase reactants (erythrocyte 
sedimentation rate [ESR], C-reactive protein 
[CRP]).
• Prolonged PR interval.
In this chapter we will talk only about the 
rheumatological and dermatological manifesta-
tions, which are as follows.
15.6.1  Arthritis
It is the early symptom of rheumatic fever. The 
classical history of arthritis involves migratory 
polyarthritis within days to a week. The meaning 
of migratory is “it affects the joint then migrates to 
the other joint”; the most common joints involved 
are knees, elbows, and wrists [36]; the patient will 
complain of limitation in his movement because of 
the severity of the joint pain. The inflammation of 
each joint lasts no more than 1 week and the signs 
of inflammation are usually present [45].
15.6.2  Erythema Marginatum
This lesion appears early in the course of the rheu-
matic fever characterized by an evanescent, pink or 
faintly red, non-pruritic rash; the outer edge is sharp 
and the inner is diffuse; it has continuous margins 
and sometimes has a ring shape. It usually affects 
the trunk and may affect the limbs, but it is unlikely 
to affect the face [46]. The course of this lesion is 
intermittent meaning that it appears, disappears, and 
then reappears in a matter of hours [47].
15.6.3  Subcutaneous Nodules
This lesion is characterized by symmetrical, 
firm, painless lesions ranging from a few milli-
meters to 2 cm in size, and the average number 
of nodules is about three to four, and it has non-
inflamed skin above it. The nodules present 
over the bony surface or prominence or near 
tendons. This lesion appears 1 week after the 
disease and is associated with sever carditis 
lasting no more than 1 month. We can distin-
guish rheumatic fever nodules from rheumatic 
arthritis nodules as the rheumatic fever nodules 
are smaller and more short-lived than the nod-
ules of rheumatoid arthritis and almost involve 
the olecranon, while rheumatoid nodules are 
usually found 3 to 4 cm distally; finally all of 
them involve the elbows [48].
15.7  Behçet’s Disease
Behçet’s disease is a complex, multi-systemic 
disease that involves the mucocutaneous, ocular, 
cardiovascular, renal, gastrointestinal, pulmo-
nary, urologic, and central nervous systems, the 
joints, blood vessels, and lungs. Men are more 
commonly affected by this disease than women, 
and it is more common in the third decade of life, 
but it can occur at any age. Signs and symptoms 
of this disease may precede the onset of the 
mucosal membrane ulcerations by 6 months to 5 
years, and prior to the onset of the disease, the 
patient experiences generalized and various 
symptoms.
In patients with Behçet’s disease, a variety of 
cutaneous changes appear on them [49].
15.7.1  Erythema Nodosum-like 
Lesion
It is red to violet and painful subcutaneous nod-
ule. It occurs on the extremities especially the 
lower extremities; also it can present on the face, 
neck, and buttocks. It resolves spontaneously or 
it may ulcerate leaving a scar and hyperpigmen-
tation area.
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15.7.2  Acneiform Lesion
It may be more common in those with associated 
arthritis [50]. It consists of papules and pustules that 
are difficult to distinguish from ordinary acne [51].
15.7.3  Folliculitis-like Rash
It distributes on the back, face, neck, chest, and 
hairline of patients. It resembles acne vulgaris.
15.7.4  Papulopustular Eruptions
Pustular skin lesions are often not sterile and may 
contain Staphylococcus aureus and Prevotella 
spp. [52].
15.7.5  Erythema Multiforme-like 
Lesions
15.7.6  Superficial Thrombophlebitis
It is a migratory superficial thrombophlebitis of 
the skin. It may be associated with deep vein 
thrombosis that causes lower extremities edema.
15.7.7  Ulcers (Oral, Genital)
During physical exam:
 – Oral ulcer: difficult to distinguish from com-
mon aphthae (Table 15.1).
 – The most common sites are the tongue, lips, 
buccal mucosa, and gingiva; the tonsils, palate, 
and pharynx are less common sites. The inter-
val between recurrences ranges from weeks to 
months.
 – Genital ulcers: recurrent and painful, and it 
may cause scarring.
15.7.8  Pyoderma Gangrenosum
It is an ulcerative cutaneous condition starting 
from a small, red papule or pustule and then 
changing into an ulcerative lesion.
15.7.9  Positive Pathergy Reaction 
at Injection Site
Nonspecific inflammatory reaction to scratches 
and intradermal saline injection is a common and 
specific manifestation to these lesions.
15.7.10  Arthritis
During an exacerbation of disease, a non-erosive, 
asymmetrical arthritis occurs in about 50% of 
patients with this disease. It involves large and 
medium joints (wrist, knee, and ankle). Also for 
the patient with Behçet’s disease, experiencing 
myalgias and migratory arthralgias without 
overt arthritis is common. On the other hand, 
arthritis occurs in about 50% of patients with 
Behçet’s disease [53].
There are also genital, ocular, gastrointestinal, 
joint, and neurologic manifestations.
Table 15.1 Oral ulcer description on physical 
examination
Oral ulcer description on physical exam
More 
extensive
More painful More 
frequent
Appear 























in the oral 
cavity
Subside without leaving 
scars
Persist for 1–2 weeks
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15.8  Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) includes two 
major disorders, which are ulcerative colitis and 
Crohn’s disease. This group of diseases cause 
many extraintestinal manifestations including 
eye, skin, joint, renal, and urologic conditions. In 
this chapter we will talk about skin and the mus-
culoskeletal manifestations of IBD.  The most 
common skin lesions presenting with IBD are 
erythema nodosum and pyoderma gangrenosum 
and other less common lesions such as Sweet 
syndrome, necrotizing cutaneous vasculitis, and 
psoriasis.
15.8.1  Erythema Nodosum (EN)
This lesion is equally present in ulcerative colitis 
and Crohn’s disease, and it is characterized by 
raised, tender, red or violet subcutaneous nodules, 
which are around 1 to 5 cm in diameter. The most 
common sites involved are the extensor surfaces of 
the extremities, specifically over the anterior tibial 
area. The presence of erythema nodosum reflects 
the activity of the intestinal disease and usually 
disappears by management of intestinal manifes-
tations. Also this lesion is diagnosed clinically, and 
if we take a biopsy, it will show focal panniculitis, 
which is rarely done [54].
15.8.2  Pyoderma Gangrenosum
This lesion is less common than EN, and it has 
a severe course because of its persistence, and 
it is an uncomfortable lesion preceded by 
trauma to the skin and initially appears as sin-
gle or multiple erythematous papules or pus-
tules [55]. The most common site involved is 
the legs, but it can appear at any site including 
abdomen and at the site of surgical scars or at 
the stoma after colectomy. It may form deep 
ulceration that contains purulent material by 
subsequent necrosis of the dermis, and usually 
the culture of the purulent material is sterile. 
Pyoderma gangrenosum reflects the activity of 
IBD disease, and it needs a course of high-dose 
glucocorticoids over several weeks of treat-
ment [56].
15.8.3  Oral Ulcer
It is a common manifestation in patients with 
IBD, especially patients with Crohn’s disease.
15.8.4  Musculoskeletal 
Manifestations
The musculoskeletal manifestations of IBD are 
considered the most common extra-intestinal 
manifestation, and they include; non-destructive 
peripheral arthritis and axial arthritis, other less 
common musculoskeletal manifestations are 
osteoporosis, osteopenia, and osteonecrosis.
15.8.5  Arthritis
The joints that are involved are the spine, sacro-
iliac joints, and appendicular joints; there are two 
types of peripheral arthritis: type 1 is acute and 
remitting and type 2 is a chronic problem and 
causes frequent relapses; other joint pain can 
result from complications of IBD such as bacte-
rial infection of the sacroiliac or peripheral joints 
or as adverse effects from chronic use of gluco-
corticoid such as osteonecrosis, and those com-
plications must be distinguished from sterile 
inflammation [57].
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15.9  Severe and Life-Threatening 
Conditions (Fig. 15.21)
15.10  Stevens-Johnson Syndrome 
(SJS) and Toxic Epidermal 
Necrolysis (TEN)
They are rare, acute immune complex medited 
hypersensitive and life that are nearly always 
drug-related. Allopurinol is the most common 
cause [58]. They are a consequence of exten-
sive keratinocyte cell death that results in the 
separation of significant areas of skin at the 
dermal- epidermal junction, producing the 
appearance of scalded skin [59]. We can clas-
sify this disease simply into as follows:
 – Stevens-Johnson syndrome (a minor form 
of toxic epidermal necrolysis): less than 10% 
body surface area (BSA) detachment.
 – Overlapping Stevens-Johnson syndrome/
toxic epidermal necrolysis: detachment of 
10–30% of the BSA.
Toxic epidermal necrolysis: detachment of 











































Severe and life threatening conditions
Fig. 15.21 Severe and 
life-threatening 
conditions
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The initial symptoms of Stevens-Johnson syn-
drome and toxic epidermal necrolysis that precede 
cutaneous manifestations by 1 to 3 days are fever, 
productive cough with thick purulent sputum, pain 
on swallowing, headache, arthralgia, and malaise.
A patient with SJS and TEN may complain of 
a rash, which appears first on the trunk, spreading 
to the neck, face, and proximal upper extremities. 
The following points are characteristic of cutane-
ous lesions:
15.10.1  Rash
It first appears as macules and then develops into 
papules, vesicles, bullae, urticarial plaques, or 
confluent erythema (erythroderma) (Fig. 15.22).
15.10.2  Bullous Lesions
It appears as flaccid blisters and may rupture 
leaving denuded skin (Fig. 15.23).
15.10.3  Urticarial Lesions (Not 
Pruritic)
It may be edematous, erythematous to pale area 
involving the dermis and epidermis (Fig. 15.24).
15.10.4  Erythema
Erythema and erosions of the buccal, ocular, and 
genital mucosae are present in more than 90% of 
patients.
15.10.5  Palpable Purpura
15.10.6  Edema (Face, Tongue)
15.10.6.1  Sloughing of Skin
 – Skin looks like wet cigarette paper.
 – Skin ulceration.
 – Skin necrosis.
 – Nikolsky sign: it should be sought by exerting 
tangential mechanical pressure with a finger 
on several erythematous zones and considered 
positive if dermal-epidermal cleavage is 
induced (Fig. 15.25).
15.11  Erythroderma Exfoliation
More than 90% of body surface areas are involved 
by generalized redness and scaling of the skin 
due to generalization of pre-existing dermatoses 
(such as psoriasis or atopic dermatitis), drug 
reactions, or cutaneous T-cell lymphoma (CTCL) 
[60]. The clinical features are as follows:
15.11.1  Erythema
15.11.1.1  Exfoliation and Scales (2–6 
Days after Erythema)
There is variation in the size and the color of the 
scales. In acute phases, scales are usually large 
and crusted while in chronic states are smaller 
and drier. Occasionally, the cause of the erythro-
derma is suggested by the character of the scale:
• Fine scale in atopic dermatitis or 
dermatophytosis.
• Bran-like in seborrheic dermatitis.
• Crusted in pemphigus foliaceus.
• Exfoliative in drug reactions.
Fig. 15.22 Dusky to violaceous rash of toxic epidermal 
necrolysis
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Fig. 15.23 Flaccid bullae with detachment of necrolytic epidermis
Fig. 15.24 Urticarial plaques (wheals) Fig. 15.25 Nikolsky sign
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15.11.2  Pruritus
Approximately 90% of patients complain from it, 
so it is the most frequent complaint. Thickness of 
the skin and areas of lichenification are seen in 
one-third of cases due to itching.
15.11.3  Pain
Most patients complain of severe skin pain.
15.11.4  Dyspigmentation
Hyperpigmentation area (45%) observed more 
frequently than hypo- or depigmentation (20%).
15.11.5  Palmoplantar Keratoderma
Hyperkeratosis of the palms and soles. Approxi-
mately 30% of erythrodermic patients present with it.
15.11.6  Nail Changes
They are related to the underlying cause of eryth-
roderma, for example, pit in psoriasis or horizontal 
ridging in dermatitis. Most often “shiny” nails are 
observed, but discoloration, brittleness, dullness, 
subungual hyperkeratosis, Beau’s lines, paro-
nychia, and splinter hemorrhages can be seen.
15.11.7  Diffuse Non-scarring 
Alopecia
It appears in 20% of patients with chronic 
erythroderma.
15.11.8  Systemic Manifestation
• Generalized peripheral lymphadenopathy.
• Pedal or pretibial edema.
• Facial edema.
• Tachycardia.
• Splenomegaly is rarely seen and occurs most 
often in association with lymphoma.
15.11.9  Complications
• Multiple seborrheic keratosis.




• Risk of cardiac failure.
• Anemia.
15.12  Gonococcal Arthritis
Considered as the most common form of septic 
arthritis in the United States and caused by gram- 
negative diplococcus Neisseria gonorrhoeae. It 
is composed of two forms:
 – Bacteremic form (arthritis-dermatitis syndrome).
 – Septic arthritis form (localized to the joint) 
[58]
Bacteremic form (arthritis-dermatitis syndrome)




 – Upper extremities involvement more than 
lower extremities.
 – The most commonly affected joints are 
wrists, elbows, knees, and ankles.
 – It may evolve into a septic arthritis.
• Tenosynovitis:
An inflammation that involves the tendon 
and its sheath; it is almost always asymmetri-
cal and commonly over the dorsum of the 
wrist and hands. Also, it can affect the ankle, 
knee, and metacarpophalangeal joints [60].
• Dermatitis:
Around 40–70% of patients with bactere-
mic form are affected.
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It presents as:
 – Tiny maculopapular, pustular, or vesicular 
lesions on an erythematous base.
 – Painless and non-pruritic lesions.
 – The lesion’s center may become necrotic or 
hemorrhagic.
 – The lesions may rarely resemble erythema 
nodosum or erythema multiforme [60].
Other presentations may include:
• Fever, rarely higher than 39 °C.
• Fitz-Hugh-Curtis syndrome (gonococcal 
perihepatitis).
• Sepsis with Waterhouse-Friderichsen syndrome.
• Gonococcal endocarditis (rare in the antibiotic 
era).
• Gonococcal meningitis (very rare in the anti-
biotic era).
Septic arthritis form:
It presents as an acute inflammation to the 




• Reduced range of motion.
• Marked erythema.
One form of complication is permanent joint 
damage. Other complications are pericarditis, 
perihepatitis, pyomyositis, glomerulonephritis, 
meningitis, endocarditis, and osteomyelitis [58].
Abbreviations
RA Rheumatoid arthritis
PND Paraneoplastic neurological disorders
HCV Hepatitis C virus
SLE Systemic lupus erythematosus
ACLE Acute cutaneous lupus erythematosus
SCLE Subacute cutaneous lupus 
erythematosus
CCLE Chronic cutaneous lupus 
erythematosus
DLE Discoid lupus erythematosus
DIP Distal interphalangeal joint
DM Dermatomyositis
CTCL Cutaneous T-cell lymphoma
ESR Erythrocyte sedimentation rate
CRP C-reactive protein
IBD Inflammatory bowel disease
EN Erythema nodosum
SJS Stevens-Johnson syndrome
TEN Toxic epidermal necrolysis
BSA Body surface area
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The prevalence of various cardiovascular dis-
eases (CVD) in the different rheumatologic dis-
orders is a very important topic. Each disease has 
a number of unique manifestations despite the 
fact that an overlap is present due to shared com-
mon risk factors, which may be related to the lon-
ger life expectancy of the recent therapeutic 
advances. A growing understanding of the role of 
inflammation and immune system in the initia-
tion and progression of atherosclerosis as well as 
the early detection of cardiovascular manifesta-
tions is due to the availability and use of sophisti-
cated noninvasive cardiac and vascular diagnostic 
technology. Such discipline results in the detec-
tion of cardiac manifestation unique to each 
rheumatologic disorder. This was not possible 
previously due to short life expectancy, limited 
therapeutic interventions, vague understanding 
of pathological process for each disease, and the 
limited diagnostic resources.
Cardiovascular diseases (CVD), including 
coronary artery diseases (CAD), can be present at 
the time of or after the diagnosis of rheumato-
logic disease. Cardiovascular association can be 
the principal introduction of the rheumatologic 
diseases in case of late diagnosis. The manifesta-
tions of CVD in rheumatologic diseases vary 
from subclinical to severe manifestations [4, 5], 
and they involve different structures of the heart. 
They can lead to significant morbidity and mor-
tality. Therefore, we need to draw attention to 
their symptoms, to the risk factors that contribute 
to CVD development, as well as adaption of pre-
ventive measures that may control them. We will 
also consider the coronary artery disease (CAD), 
which maybe a crucial contributor to morbidity 
and mortality in numerous rheumatological dis-
eases [6–9].
The prevalence of atherosclerotic CAD is 
increased in patients with chronic inflammatory 
rheumatic diseases, particularly in those with sys-
temic lupus erythematous (SLE) and rheumatoid 
arthritis (RA) [10, 11]. The increased risk of CAD 
results from both traditional risk factors and fac-
tors unique to these rheumatic diseases [12, 13]. 
For example, accelerated atherosclerosis is one of 
the important risk factors for the development of 
CAD, and it can be attributed to the prolonged 
inflammatory process in these diseases, vascular 
endothelial dysfunction, and a specific form of 
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low-density lipoprotein (LDL). The importance 
of metabolic syndrome in various rheumatic dis-
eases and its implications on morbidity and mor-
tality will be discussed as metabolic syndrome, 
which is commonly diagnosed among those 
patients and also plays an important role in the 
CVD development [14–16].
Several medications are now used in the man-
agement of various rheumatologic diseases, 
which can affect the development of CAD—
either by decreasing or increasing the CAD 
severity or by decreasing or increasing its risk 
factors. In fact, many discussions are held nowa-
days with focus on how and when to use them. 
For example, the use of aspirin and statins in 
rheumatology and their effect on CAD. We will 
discuss the latest guidelines for their use here.
In this chapter, we address the various cardio-
vascular events that patients are exposed to, with 
CAD as one of the major factors that increase 
their mortality [10]. We will also discuss the 
important areas in regard to the identification of 
high-risk groups that need interventions, how to 
decrease the risk of CAD in these groups, and the 
way to better understand the effects of common 
medications on the risk of CAD in these patients.
16.2  Cardiovascular 
Manifestations 
in the Rheumatic Diseases
In this section, we look at CVD involvements in 
the different rheumatologic diseases and address 
the important issues in regard to their develop-
ment (Tables 16.1 and 16.2 give a summary of 
the points given below).
The coronary artery disease (CAD) contrib-
utes significantly to the morbidity and mortality 
in various rheumatic diseases, whereas the occur-
rence of atherosclerotic CAD is increased in 
patients with chronic inflammatory rheumatic 
Table 16.1 Type of CVD diseases
Disease CVD
RA Atherosclerotic   • Myocardial infarction.
  • Congestive heart failure.
  • Peripheral arterial disease.
Non-atherosclerotic   • Pericarditis.
It is possible to occur as an inflammatory manifestation of RA.
  • Myocarditis and endocarditis.
They are also possible to occur as a complication in RA.
  • Vasculitis.
(e.g., aortitis, coronary arteritis)
It can cause neurovascular disease (e.g., mononeuritis multiplex), 
cutaneous ulceration, or organ infarction based on the affected artery.
  • Other less common complications.
Conduction abnormalities
  • Amyloidosis.
  • Pulmonary hypertension.
SLE Pericardium   • Pericarditis.
  • Pericardial effusion.
Myocardium   • ECG findings: Prolonged PR intervals.
  • MRI to help in diagnosis.
Endocardium and valves   •  Systolic murmur: Possibly from hyperdynamic state because of 
anemia.
  • Libman-sacks endocarditis .
Systemic 
sclerosis
Histology of CVD in 
SSc
  • Hemosiderin deposits.
  • Involvement of subendocardial layers.
Myocardium   •  Fibrosis affects the myocardium in both ventricles and the 
conducting system.
  • Tricuspid regurgitation.
Pulmonary arteries   •  Pulmonary hypertension with irreversible fibrosis at the arterial walls, 
which will cause resistance against right ventricular contraction.
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diseases, particularly those with SLE and RA. 
This again is emphasizing the importance of 
those conditions to the development of CAD. This 
increased risk is mediated by the presence of both 
traditional risk factors and factors unique to those 
with systemic inflammatory disorders. It is a mat-
ter of higher risk as well as the presentation.
A larger proportion of patients with RA has a 
clinical silent CAD in comparison to demograph-
ically similar individuals in the general popula-
tion. Patients with RA are also less likely to 
report chest pain during an acute coronary event 
than those without RA.  It is still uncertain why 
this is happening, but acceptable explanations 
include the following: many patients with active 
disease and joint damage are less physically 





CAD   • MI and cardiac death with APL positive.
  • Unstable angina.
Valvular disease   • Mitral, aortic, and less common in tricuspid valves.
  • It can progress to heart failure.
Pseudo-endocarditis   • Vegetation commonly at the mitral and aortic valves.
  • High APL.
  • Blood culture is negative for infection.
Peripheral artery disease   • At lower extremities.
DVT   • Most common venous manifestation.
  • Pulmonary embolism is a common eventual complication.
Intracardiac thrombus   • Not common and usually misdiagnosed.
Ankylosing 
spondylitis
Conduction defects Inflammation and fibrosis of interventricular septum will cause damage 
of atrioventricular node, which can lead to first, second, and third-degree 
heart block and bundle branch block
Aortic incompetence Aortic wall inflammation (aortitis) above and behind sinuses of valsalva, 
and may extend below to the aortic roots and the wall of the mitral valve
Left ventricular 
dysfunction
A possible increased connective tissue involvement in the myocardium
Less common   • Pericarditis.
  • Cardiomyopathy.
  • Mitral valve disease.
  • Endocarditis .
Psoriatic 
arthritis
  • CAD
  • Cerebral vascular disease.
  • Peripheral vascular disease.
Inflammatory 
myopathies
  • Myocarditis.
  • CAD.
  • Affected myocardial small vessels .
Systemic 
vasculitis
  • CAD
  • Myocardium, pericardium, endocardium, and conduction system involvements.
  • Peripheral vascular disease.
Table 16.1 (continued)
Table 16.2 Summarized types of CVD in rheumatologic 
diseases
Disease RA SLE APS SSc AS PsA
MI ✓ ✓ ✓ ✓ ✓ ✓
CHF ✓ ✓ ✓ ✓
PAD ✓ ✓ ✓ ✓
PH ✓
Myocardial diseases ✓ ✓ ✓ ✓ ✓
Endocardial diseases ✓ ✓ ✓ ✓
Valvular disease ± ✓ ✓ ✓
Pericarditis ✓ ✓ ✓ ✓
Arteritis (coronary, 
aorta)
Conduction defects ± ✓ ✓ ✓
Symbol definitions, MI: Myocardial infarction, CHF: 
Congestive heart failure, PAD: Peripheral arterial disease, 
PH: Pulmonary hypertension, SSc: Systemic sclerosis, 
AS: Ankylosing spondylitis, PsA: Psoriatic arthritis. ±: in 
case of rheumatoid nodule
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ficient demand on the heart to elicit angina, which 
may attribute to RA pain. Patients with CAD tend 
to use nonsteroidal anti-inflammatory drugs 
(NSAID), glucocorticoids, or disease-modifying 
antirheumatic drugs (DMARDs), which can 
change their pain perception. Patients with rheu-
matoid arthritis (RA) have a reduced life expec-
tancy when compared with the general population. 
Cardiovascular death is considered the leading 
cause of mortality in patients with RA; it is 
responsible for approximately half the deaths 
observed in RA [8]. Epidemiologic studies have 
shown that this increased mortality is largely 
attributed to cardiovascular diseases, primarily 
CAD.  Considerable evidence suggests that 
inflammation plays a role in the pathogenesis of 
atherosclerosis [10]. The prevalence of cardio-
vascular comorbidity is difficult to assess accu-
rately since CAD has a tendency to remain silent 
in the rheumatoid patients, but deaths from CVD 
occur earlier than in the general population. It has 
also been suggested that the increased risk of 
CAD in RA precedes the onset of clinical rheu-
matoid disease [17].
The lowering of CAD morbidity and mortality 
by recognizing patients at risk, and revealing 
their nontraditional1 risk factors as well as their 
 contribution in developing cardiovascular 
 complications are important. Many rheumatic 
diseases have their share of these complications, 
e.g., RA, SLE, and vasculitis. The studies showed 
the importance of prevention strategies. 
Furthermore, many studies have been discussing 
various reasons of the increased in cardiac mani-
festations and the risk of mortality due to 
CAD.  One could be the increase of traditional 
risk factors and its explanation. The second could 
be the special nontraditional risk factors, which 
are related to the pathophysiology of rheumatic 
diseases (See Tables 16.1 and 16.2).
Traditional risk factors include smoking,2 
hypertension, diabetes mellitus (DM), hyperlip-
idemia, and obesity [12].
1 Patients are exposed to both the traditional risk factors of 
CAD and the nontraditional risk factors related to their 
disease.
2 Apart from the known effects of smoking on CAD, it 
The nontraditional risk factors are associ-
ated with elevation of CAD occurrences, which 
include severity of the disease, more extra- 
articular manifestation at presentation, cortico-
steroids, NSAIDs, and the low socioeconomic 
status. The presence of the accelerated athero-
sclerosis in those patients is associated with CAD 
development and subsequently the increased 
mortality from CAD in them (Tables  16.3 and 
16.4).
16.2.1  Rheumatoid Arthritis (RA)
Rheumatoid arthritis is a chronic systemic 
inflammatory disease, which affects approxi-
mately 1% of the adult general population [18]. It 
has many extra-articular manifestations (e.g., 
heart and lung) in about 40% of patients with RA 
over their life time [19]. The mortality gap in 
comparison to the general population widened 
with the dramatic improvement in the overall 
mortality rate in the latter group [20]. For exam-
ple, if we compare the general population to the 
patients with RA, there is an increased incidence 
of cardiovascular events, including myocardial 
infarction, stroke, and cardiac death among the 
patients with RA.
Cardiovascular disease is recognized as the 
leading cause of death in RA patients, accounting 
for nearly 40% of mortality [18]. Patients with 
RA are at twofold increased risk for myocardial 
infarction and stroke, with risk increasing to 
nearly threefold in patients who have had the dis-
ease for 10 years or more [18]. Congestive heart 
failure appears to be a greater contributor to 
excess mortality than ischemia. This increased 
cardiovascular disease risk in RA patients seems 
to be independent of traditional cardiovascular 
risk factors. Pathogenic mechanisms include pro- 
oxidative dyslipidemia, insulin resistance, pro-
thrombotic state, hyperhomocysteinemia, and 
immune mechanisms, such as T-cell activation 
increases the severity of the rheumatoid arthritis, which 
can lead to atypical manifestation of the CAD and increas-
ing the difficulty of the early detection (Tables 16.3 and 
16.4).
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that subsequently lead to endothelial dysfunc-
tion, a decrease in endothelial progenitor cells, 
and arterial stiffness, which are the constitutes of 
accelerated atherosclerosis observed in RA 
patients [18]. These patients are greatly suscep-
tible to CAD (myocardial infarction and angina), 
heart failure, pericarditis, myocarditis, atrial 
fibrillation, valvular heart disease, and cardiac 
amyloidosis.
16.2.1.1  Pericarditis
Pericarditis is the most common cardiac manifes-
tation in RA, which is usually an asymptomatic 
disease. Clinical pericarditis is observed in 
around 4% of the patients [21], which is lower 
than the autopsy proven one that occurs in around 
30%–50% of patients with RA [22]. Patients with 
RA are more likely to develop pericardial effu-
sion than the ones without RA by ten times [23]. 
Most of the patients develop the pericardial effu-
sion after the onset of the arthritis; however, RA 
was diagnosed after pericardial effusion in a 
minority of patients [3]. The variables associated 
with the development of extra-articular manifes-
tations including pericarditis are as follows: male 
gender, presence of increased serum concentra-
tions of rheumatoid factor, joint erosions, subcu-
taneous nodules, number of disease-modifying 
antirheumatic drugs (DMARD), presence of nail 
fold lesions, and any other extra-articular feature 
1 year before the time of the diagnosis, or treat-
ment with corticosteroids at the time of the diag-
nosis [21].
Patients with findings of edema, shortness of 
breath, chest pain, raised jugular venous pressure, 
pericardial rub, and paradoxical pulse were found 
to have 100% mortality rate within 2 years [4]. In 
patients with pericardial effusion, the diagnosis of 
RA was mainly clinical without the need for inva-
sive procedure [3]. Biologic agents are now con-
sidered one of the cornerstones of RA therapy 
associated with the development of pericardial 
effusion mostly within 4 months of the start of the 
infliximab and etanercept [24]. Purulent pericar-
dial effusion was reported in patients receiving 
infliximab and etanercept [25, 26].
Treatment: Although most of the evidence 
came from patients with immune-mediated peri-
carditis, it can be extrapolated to the 
RA-associated pericarditis as follows:
 1. Asymptomatic disease usually diagnosed 
accidently will resolve spontaneously.
 2. Symptomatic disease therapy includes the 
following:
• Nonsteroidal anti-inflammatory drug 
(NSAID) is the mainstay therapy for idio-
Table 16.3 Prevalence of traditional risk factors
Prevalence Smoking Hypertension DM Dyslipidemia Obesity
RA ↑↑ ↑ ↑↑ ↑↑ ↑
SLE ↑ ↑↑ ↑ ↑ ↑
General population ↑ ↑ ↑ – ↑
Table 16.4 Effects of traditional risk factors on RA
Effects of RA
Smoking ↑RA development
↑ RF and ACPA-positive RA
↑worse prognosis
Hypertension ↑more than the general population, 
it is unclear whether it is from 
under diagnosis or from under 
treatment
↑BP from NSAIDs, chronic 
corticosteroids, leflunomide, and 
cyclosporine
DM Possible association between RA 
and insulin resistance
Can predict a new cardiovascular 
event
Dyslipidemia ↓ or ↑ Total lipid
↓ or ↑ LDL
↓↓HDL
Can predate the diagnosis of RA
BMI ↑BMI and obesity = ↑other 
traditional risk factors = ↑worse 
prognosis = CVD
↓BMI and cachexia = acute 
inflammation
16 Cardiovascular Diseases and Rheumatology
358
pathic pericarditis, and the two agents that 
proved their efficacy are ibuprofen and 
indomethacin [27].
 – Corticosteroids: low- to moderate-dosage 
prednisone (0.2–0.5  mg/kg per day) for 
4  weeks and then slowly tapered, if the 
patient is intolerant to aspirin or NDSAID 
or with pericardial effusion [27].
 – Colchicine: in patients with acute and 
recurrent pericarditis in addition to aspi-
rin or NSAID in the dose of 0.5 mg twice 
daily in patients >70 kg and 0.5 mg once 
daily in patients ≤70 kg [27].
 – If previous medical treatment fails, 
there is growing evidence for oral aza-
thioprine, intravenous human immuno-
globulins, and anakinra [27].
 – Tocilizumab was reported to be success-
ful too [28, 29].
 – Surgical management includes pericar-
diocentesis, pericardiectomy, or pericar-
diotomy in the cases of hemodynamic 
compromise, cardiac tamponade, or 
constrictive pericarditis.
 – Biologic-agents-associated pericarditis 
should be stopped and treated accord-
ingly [24].
 – Purulent pericarditis with biologic 
agents should be stopped and antibiotic 
therapy to be used accordingly [25, 26].
16.2.1.2  Myocardial Involvement
Myocarditis is less common than RA-associated 
pericarditis. It was found in 19% of patients with 
RA based on post-mortem study where the 
majority were females with active arthritis; how-
ever, most of the patients with myocarditis were 
clinically asymptomatic [30].
Cardiomyopathy with finding of left ventri-
cle hypertrophy (LVH) was found in around 
37% of asymptomatic RA patients by echocar-
diography [31]. The pathohistological finding 
was either diffuse or focal inflammation of the 
myocardium [32].
Diagnosis: The left ventricle function is usu-
ally evaluated with echocardiography, but it has a 
limited role in the evaluation of myocardium 
involvement. Cardiac magnetic resonance imag-
ing (CMR) is helpful as noninvasive evaluation 
tool for myocarditis as it shows increased 
T2-weighted edema ratio (ER) score suggesting 
myocardial tissue edema. It has a role too in iden-
tifying the chronicity of myocarditis [33].
Treatment: Conventional therapy to support 
the left ventricle function is generally used. High- 
dose prednisolone (60  mg) daily for 2  months, 
tapered over 4 months followed by maintenance 
dose, normalizes the left ventricle ejection frac-
tion and the gallium uptake [34].
Antimalarials-Induced Cardiotoxicity
Hydroxychloroquine and chloroquine are medi-
cations initially used as antimalarial treatment. 
They found to be effective as disease-modifying 
antirheumatic drugs. Hydroxychloroquine- 
induced cardiotoxicity has been reported in 
patients with RA [35].
Risk factors: Old age, female sex, long dura-
tion of therapy, high daily dose, preexisting car-
diac disease, or renal impairment [35].
Presentation: Features of systolic dysfunction 
and prolonged QT interval were reported too [35].
Diagnosis:
 (a) Echocardiography shows diffuse thickening 
ventricular walls [35].
 (b) CMR: Shows areas of patchy gadolinium 
enhancement. It is important to differentiate 
it from other causes of cardiomyopathy [35].
 (c) Endomyocardial biopsy: Shows enlarged and 
vacuolated cells, and the presence of myeloid 
and curvilinear bodies within the cardiac 
myocytes [35].
Treatment: Mainly withdrawal of the antima-
larial agents and conventional heart failure treat-
ment if needed [35].
16.2.1.3  Heart Failure
It is a clinical syndrome that is two times higher 
in RA patients than the general population [36].
Associations: Rheumatoid factor positivity 
was associated with higher risk of congestive 
heart failure [36].
Causes: Patients with RA develop heart fail-
ure mostly due to ischemic cardiomyopathy, 
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drug-induced myopathy (e.g., antimalarial 
drugs), rheumatoid nodule, NSAID use, or 
amyloidosis.
Treatment: Treat the underlying cause and 
conventional heart failure treatment. Avoid the 
use of tumor necrosis factor-alpha (TNF alpha) 
inhibitors especially the high doses (10 mg/kg) in 
NYHA classes 3 and 4 heart failure [37]. In 
patients with congestive heart failure and RA, the 
combined use of synthetic DMARDs, non-TNF 
biologic, or tofacitinib over TNF inhibitors is rec-
ommended [38].
16.2.1.4  Coronary Artery Disease 
(CAD)
Patients with rheumatoid arthritis (RA) have a 
reduced life expectancy when compared with the 
general population, where cardiovascular death is 
considered the leading cause of mortality in 
patients with RA; it is responsible for approxi-
mately half the deaths observed in RA [8]. 
Epidemiologic studies have shown that this 
increased mortality is largely attributable to car-
diovascular diseases, primarily CAD. Considerable 
evidence suggests that inflammation plays a role in 
the pathogenesis of atherosclerosis [10]. The prev-
alence of cardiovascular comorbidity is difficult to 
assess accurately because CAD has a tendency to 
remain silent in the rheumatoid patient, but deaths 
from CVD occur earlier than in the general popu-
lation. It has also been suggested that the increased 
risk of CAD in RA precedes the onset of clinical 
rheumatoid disease [17].
Traditional risk factors for atherosclerosis, 
such as smoking, hypercholesterolemia, hyper-
tension, DM, and sedentary lifestyle, may be 
more common in RA than in the population as a 
whole but do not account for all of the increase in 
the disease. Currently, there is a large body of 
evidence that a chronic inflammatory state can 
enhance the harmful effects of some traditional 
risk factors, such as the association between sys-
temic inflammation and arterial wall stiffness in 
hypertension or the proatherogenic lipid profile 
(high LDL and lipoprotein (a) low HDL) seen 
with increasing rheumatoid disease activity. The 
burden of addressing CAD in RA is therefore 
divided between rigorous control of traditional 
risk factors and effective disease control through 
immunosuppression [39]. The more extended the 
span of the RA and the utilization of TNF alpha 
inhibitors are, there is a chance for improvement 
of atherosclerosis [40]. The two are a surrogate 
for the seriousness of the illness and a presence 
of coronary calcification [41]. Male gender and 
severe inflammatory state (high inflammatory 
markers and disease activity score) are usually 
associated with atherosclerosis [42].
Factors influencing cardiovascular disease 
in rheumatoid arthritis:
• Oxidized LDL (oxLDL) and antibodies to 
oxidized LDL are both established as signifi-
cant risk factors for CVD in RA. It has been 
consistently observed that the levels of oxLDL 
are higher in patients with active disease [39].
• C-reactive protein: Higher levels of CRP are 
associated with CVD in non-RA patients [39]. 
Treatment of CAD with statins or angiotensin- 
converting enzyme (ACE) inhibitors has been 
demonstrated to lower CRP levels [39]. 
Attention was specifically focused on high- 
sensitivity CRP (hsCRP). Raised hsCRP is 
found in hypertension, smoking, and DM, as 
well as CAD.
In RA baseline, CRP predicts cardiovascu-
lar mortality [43], and the molecule acts 
directly in a pro-inflammatory manner at a 
range of sites. For example, CRP activates 
vascular endothelial cells to express adhesion 
molecules in a dose-dependent manner, and 
CRP activates monocyte chemotactic pro-
tein-1 (MCP-1), which can be inhibited by 
statins and fenofibrates [39].
• Homocysteine: Homocysteine is increasingly 
regarded as an epiphenomenon of CAD rather 
than a causative factor [39].
Elevated levels of homocysteine have been 
associated with CAD in the general population as 
well as in reduced levels of various vitamins 
including folate and B6 [39]. It has also been 
shown that homocysteine is present in higher 
concentrations in the joints of RA patients, where 
it may enhance production of pro-inflammatory 
cytokines such as IL-1 and thus act as a driver for 
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joint damage; it may also accelerate atherosclero-
sis in a similar manner [44].
• Physical disability due to rheumatoid 
arthritis: Poor functional status, especially in 
the lower limbs, is a powerful predictor of 
mortality in RA, while regular exercise is 
known to have beneficial effects on the cardio-
vascular system. Exercise capacity is also 
inversely related to the presence of metabolic 
syndrome [45]. Patients with chronic RA have 
physical disabilities, which prevent them from 
taking regular exercise. This influences CAD 
in several ways; the presence of CAD usually 
causes delay in the individual’s presentation to 
clinician since reduced physical activity may 
not exacerbate symptoms. The delay in pre-
sentation would also prevent treatment at an 
earlier stage of CAD, even with the lack of 
CVD, physical disability would still stop ade-
quate exercise.
• Leptin and the adipocytokines: Leptin is an 
adipokine that functions both as a hormone 
and a cytokine. It is produced by the adipose 
tissue, and its main role appears to be to reduce 
food intake and to stimulate the sympathetic 
nervous system. It is known to stimulate 
inflammatory cytokine production, and to 
have direct deleterious effects on articular car-
tilage. It is also known to cause endothelial 
dysfunction, oxidative stress, and platelet 
aggregation and to be elevated in RA; while 
fasting has been implicated as a means of 
reducing leptin levels and improving RA dis-
ease activity [39]. Leptin has the potential to 
play a key role linking obesity, inflammation, 
and cardiovascular damage.
Prevention of CAD in RA.
Since it is generally similar to prevention in 
patients without RA [46], here are some impor-
tant points to prevent CAD in RA patients.
One needs to:
• Stop smoking.
• Measure fasting blood glucose annually or in 
the event of significant weight gain especially 
in patients taking steroids. In already diabetic 
patients, the steroids should be kept in the 
lowest dose.
• Monitor blood pressure for RA patients before 
beginning medications and then at regular 
intervals for patients using NSAID, cyclospo-
rine, and corticosteroids. NSAIDs reduce the 
antihypertensive effects of diuretics, 
β-blockers, and angiotensin-converting 
enzyme inhibitors, but it is less likely to inter-
fere with calcium channel blockers [47]. In 
those group of patients either to increase the 
dose of the antihypertensive medications or to 
use a calcium channel blocker.
• Manage hypercholesterolaemia according to 
recommendation for the general population.
• Manage obesity as well as weight loss.
• Supplement the diet with fish oil that is rich in 
omega-3 fats, because this has demonstrated 
efficacy in the treatment of RA, facilitated 
reduction of NSAIDs use and reduced cardio-
vascular mortality risk [48].
• Diagnose and treat RA early:
 – Methotrexate: shown to decrease cardio-
vascular mortality among RA patients [49].
 – TNF inhibitors: shown to decrease the risk 
of MI among patients who have controlled 
synovitis within 6 months of treatment [50].
16.2.1.5  Rheumatoid Nodule
Valvular nodule is 10 times higher in RA patients 
than the general population [23].
Incidence: Echocardiographic evidence of 
aortic valve nodule was observed less than mitral 
valve nodule in the rate 0.3% vs. 0.6% among 
RA patients [31], respectively.
Presentation: Differs according to the site of 
the nodule, as it causes functional impairment, 
such as arrhythmias and valve disease [51]. It 
was associated with complete atrioventricular 
(AV) block necessitating pacemaker as it involves 
the AV node [52, 53].
Treatment: According to the presentation.
16.2.2  SLE
It is a multisystem autoimmune disease with a 
strong female predilection.
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Cardiovascular morbidity and mortality is a fre-
quent complication, particularly in females aged 
35–44 years, where the risk of myocardial infarc-
tion is raised 50-fold [54]. The cardiac morbidity 
is the most common cause of death in SLE patients, 
which is around 25% of deaths in SLE [55].
The heart is one of the most frequently affected 
organs in systemic lupus erythematosus (SLE), 
where any part can be affected, including the 
pericardium, myocardium, coronary arteries, 
valves, and the conduction system. In addition to 
pericarditis and myocarditis, high incidence of 
CAD has become increasingly recognized as 
cause of mortality, especially in older adult 
patients and those with long-standing SLE [56].
Pericarditis is the most common cardiac 
abnormality in SLE patients, but lesions of the 
valves, as well as myocardium and coronary ves-
sels, may all occur. In the past, cardiac manifesta-
tions were severe and life threatening, often 
leading to death. Therefore, they were frequently 
found in postmortem examinations. Nowadays, 
cardiac manifestations are often mild and asymp-
tomatic. However, they can be frequently recog-
nized by echocardiography and other noninvasive 
tests (Echocardiography is a sensitive and spe-
cific technique in detecting cardiac abnormali-
ties, particularly mild pericarditis, valvular 
lesions, and myocardial dysfunction). Therefore, 
echocardiography should be performed periodi-
cally on SLE patients [57].
16.2.2.1  Pericarditis
The most common clinical cardiovascular mani-
festation of SLE.
Prevalence: Echocardiographic evidence of 
pericardial effusion was detected in 27% of SLE 
patients, where most of them had asymptomatic 
disease [58]. Lupus pericarditis occurs predomi-
nantly in females in around 92% [59] which is 
mostly due to main predominance of SLE in 
females.
Associations: Mostly associated with active 
SLE in 93% and involvement of other organs 
with SLE in 72% [59]. In the absence of renal 
failure, constrictive pericarditis or pericardial 
effusion is rarely reported [60]. Patients with 
tamponade had lower serum level of C4 in com-
parison to the ones who did not develop tam-
ponade [61].
Clinical presentation: Ranges from asymp-
tomatic to pericardial effusion [58] to cardiac 
tamponade in 16% [59].
Diagnosis: Either by the presence of pericar-
dial effusion by echocardiography only or the 
presence of 2 out of 4 of the following 
(Retrosternal pain, pericardial friction rub, 
 widespread ST-segment elevation, and new/
worsening pericardial effusion) among SLE 
patients [59].
Treatment: The treatment of lupus pericardi-
tis is mainly derived from immune-mediated 
pericarditis, as previously mentioned in the RA 
section, where it responded well to NSAID and 
corticosteroids [59]. High-dose corticosteroids, 
complete drainage, and pericardial window were 
used for treating patients with large pericardial 
effusion/tamponade [61, 62].
16.2.2.2  Myocarditis
Effects: SLE is associated with the increase in the 
left ventricle mass, and this would be even more if 
SLE was associated with hypertension (HTN) [63].
Associations: The association is strong 
between lupus myocarditis with the presence of 
myositis but weak with the presence of the anti-
bodies to nuclear ribonucleoprotein (RNP) [64]. 
High SLE Disease Activity Index is an indepen-
dent risk factor in the development of lupus myo-
carditis [5], where anticardiolipin IgG and lupus 
anticoagulant were positive in patients with 
severe symptoms [65].
Clinical features: It ranges from asymptom-
atic disease discovered accidently to symptom-
atic heart failure and sudden death [5].
Diagnosis: Echocardiography: Most patients 
suffered from wall motion abnormalities (WMA), 
whereas less than 50% of lupus myocarditis 
patients showed decrease in the left ventricle 
ejection fraction after the exclusion of other 
causes of myocarditis [5].
Treatment: Conventional treatment of heart 
failure [5]. Immunosuppressive therapy (high- 
dose systemic corticosteroids with subsequent 
dose tapering, intravenous immunoglobulin, 
plasmapheresis, or cyclophosphamide) showed 
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improvement in heart failure symptoms, EF, and 
the WMA of the heart [5]. After corticosteroids 
therapy, the EF improved up to a mean of 49.5% 
after around 7 months of follow-up from a mean 
of 33.8% [66]; one article reported normal EF 
after follow-up [67]. Refractory lupus myocar-
ditis can be treated with rituximab [68]. 
Intravenous “pulse” cyclophosphamide was 
used in patient with lupus myocarditis refrac-
tory to corticosteroids, and it showed improve-
ment in heart failure symptoms and EF from 
19% to 63% [69]. Mycophenolate mofetil was 
effective in a case series [70]. Intravenous 
immunoglobulin was effective in the treatment 
of patients with severe lupus myocarditis in con-
junction with corticosteroids and cyclophospha-
mide [65]. One rare case report showed that 
plasmapheresis and extracorporeal membrane 
oxygenation (ECMO) were effective in lupus 
myocarditis [71].
16.2.2.3  Coronary Artery Disease 
(CAD)
Prevalence: The prevalence of the angina, myo-
cardial infarction, and sudden cardiac death was 
found to be 8.3% as per a Johns Hopkins SLE 
cohort study [9]. Another study found more than 
50-fold risks of MI in young women 35–44 years 
old when compared to the control group [11].
Risk Factors
 (a) Traditional risk factors for atherosclerosis.
It has an increased prevalence in patients 
with SLE as hypertension, DM, premature 
menopause, sedentary lifestyle, and high 
homocysteine level [12].
 (b) Inflammation-related risk factors.
• High disease activity and elevated level of 
CRP [13].
• In lupus nephritis, it was found that 
patients with long-term lupus nephritis 
had frequent episodes of cardiac lesions, 
mainly cardiac infarctions [72].
• Low serum levels of C3, antiphospho-
lipid antibodies (APL), and elevated lev-
els of antibodies to anti-ds DNA were 
found to be independent predictors of 
thrombosis. Hydroxychloroquine is pro-
tective against future thrombosis in those 
patients [73].
• Several autoantibodies such as anti-DNA, 
APL, anti-SSA (Ro antibodies), and anti- 
endothelial cell antibodies present in 
patients with SLE can mediate cardiac 
damage [74].
• Old age at diagnosis of SLE [9, 11].
• Longer duration of SLE [9, 11].
• Longer duration of steroid therapy [9].
• High levels of oxidized low-density lipo-
protein cholesterol and homocysteine [9].
Preventions of CAD in SLE.
To prevent CAD, one has to:
• Control the traditional risk factors, to use the 
statins according to the guidelines for the gen-
eral population, and to control blood pressure 
aggressively.
• Improve the lipid profile by using hydroxy-
chloroquine as it lowers the level of the cho-
lesterol in the blood, especially in patients 
taking steroids [75], and it is associated with a 
reduced risk of DM [76].
• Minimize the use of steroids.
16.2.2.4  Endocarditis (Libman–Sacks 
Endocarditis)
It was first described by Libman and Sacks in 
1942 after they discovered valvular lesions in 
four patients with SLE.
Prevalence: Echocardiographic evidence was 
detected in around 11% of patients with SLE [77].
Associations: It was found to be associated 
with longer SLE duration and activity, thrombo-
sis, stroke, thrombocytopenia, and antiphospho-
lipid syndrome [77]. Its coexistence with 
antiphospholipid antibodies (APLs) increases the 
risk of thromboembolic complications, espe-
cially stroke [78].
Pathology: Since the main involved valve is 
the mitral followed by the aortic [78], the left side 
is mainly more involved than the right. Therefore, 
the main dysfunction is regurgitation; stenosis is 
rarely found [78].
Diagnosis: Echocardiography: It is mani-
fested as valve vegetations, thickening, and/or 
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regurgitation [79]. Transesophageal echocardiog-
raphy (TEE) was found to be more sensitive than 
transthoracic echocardiography (TTE) for the 
detection of echocardiographic findings [79]; for 
example, valvular thickening was found higher 
with TEE at 70% vs. 52% with TTE [79].
How to differentiate it from infective endo-
carditis? Infective endocarditis is an uncommon 
complication of SLE, yet at the same time, it 
should be in the differential diagnosis as both dis-
eases can be presented with fever and valvular 
vegetation. Three laboratory tests can help differ-
entiate between them to a degree, and these are the 
white blood cell count (WBC), the CRP level, and 
the antiphospholipid antibody (APL) level [80]. 
The test results show that the WBC is expected to 
be low during lupus flare and high during infec-
tion, CRP is high with infection and suppressed 
during lupus flare, and the aPL is high in SLE and 
unlikely to be positive in infection [80].
Treatment
The control of the SLE disease activity is 
important with the use of the corticosteroids. 
Although the use of corticosteroid is not benefi-
cial for the valve lesion, it is important to control 
underlying diseases [78]. The corticosteroids, on 
the other hand, were noted to be associated with 
fibrosis and severe dysfunction (e.g., mitral valve 
insufficiency) after high doses of corticosteroid 
are used [81, 82]. Patients with Libman–Sacks 
Endocarditis, who suffered from a thromboem-
bolic event, are recommended to be on life-long 
anticoagulation to prevent further episodes [78]. 
Accordingly, conventional treatment of heart 
failure and valvular lesion as needed is crucial.
16.2.3  Systemic Sclerosis (SSc)
Widespread vascular lesions, fibrosis of the skin, 
and internal organs characterize a connective tis-
sue disease. More than half of the patients with 
SSc, who underwent autopsy, were found to have 
significant cardiac abnormalities [37]. Cardiac 
involvement is recognized as a poor prognostic 
factor when clinically evident, with a 5-year mor-
tality rate is around 75% [83]. Primary myocar-
dial involvement is common in SSc; increasingly, 
evidence strongly suggests that myocardial 
involvement is related to repeated focal ischemia 
leading to myocardial fibrosis with irreversible 
lesions. Reproducible data have shown that this 
relates to microcirculation impairment with 
abnormal vasoreactivity, with or without associ-
ated structural vascular abnormalities. 
Consistently, atherosclerosis and macrovascular 
coronary lesions do not seem to be increased in 
SSc. Myocardial involvement leads to abnormal 
systolic, diastolic left ventricular dysfunction, 
and right ventricular dysfunction. Sensitive and 
quantitative methods have demonstrated the abil-
ity of vasodilators—including calcium channel 
blockers and angiotensin-converting enzyme 
inhibitors—to improve both perfusion and func-
tion abnormalities. By that, they emphasize the 
critical role of microcirculation impairment [84].
Asymmetric hypertrophy of the interventricu-
lar septum with signs of sub-aortic obstruction 
consistent with hypertrophic obstructive cardio-
myopathy was evident in echocardiogram in 
patients with diffuse SSc. Hypertrophic cardio-
myopathy is associated with the human lympho-
cyte antigen HLA DR3 [85], and this may provide 
a possible link with SSc as this HLA phenotype 
is common in the latter condition [85].
16.2.3.1  Myocardial Fibrosis
Prevalence: Around 66% of patients with SSc 
based on MRI [86]. The presence of the left ven-
tricle (LV) dysfunction (ejection fraction (EF) 
<55%) was reported in around 5.4% among SSC 
patients [1].
Pathology: Patchy distribution of myocardial 
fibrosis is pathognomonic [87]; Foci of contraction 
band necrosis (mostly due to the recurrent vaso-
spasm of the small vessels of the heart) is found in 
all parts of the myocardium mainly in the subendo-
cardial area [88]. Asymptomatic patients with 
impaired coronary flow reserve did not show ste-
notic lesions of the major epicardial coronary arter-
ies [89]. Contrarily, symptomatic patients (e.g., 
angina) with SSc had evidence of CAD in similar 
rate to the symptomatic ones without SSc [90].
Associations: There is association between 
the high volume of fibrosis and Raynaud’s phe-
nomenon duration of 15  years or more and 
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abnormal Holter study results [86]. Male sex, 
old age, presence of digital ulcerations, and 
myositis were associated with higher prevalence 
of LV dysfunction [1].
Diagnosis
 (a) Echocardiography: Most patients had LV 
hypertrophy in around 22.6%, followed by 
LV diastolic dysfunction in around 17.7%, 
and a rare percent of LV systolic dysfunction 
in around 1.4%, in the absence of the pulmo-
nary arterial hypertension [91].
 (b) Heart MRI: Delay enhancement MRI can 
identify areas of fibrosis in a significant num-
ber of patients [86].
Treatment
Vasodilators (e.g., calcium channel blockers 
and angiotensin-converting enzyme (ACE) inhib-
itors) showed improvement of the myocardial 
perfusion and halting of the disease progression 
[92]. Patients showed radiological improvement 
in myocardial perfusion and function after the 
administration of nifedipine (60  mg daily) for 
14 days [93]. Among SSc patients, it was found 
that the ones treated with calcium channel block-
ers (CCB) have less reduced LVEF [1]; the car-
diac protective effect of CCB still needs to be 
established.
16.2.3.2  Myocardial Ischemia
SSc is an independent risk factor for acute myo-
cardial infarction with no protective effect was 
noted with the immunosuppressive therapy [6].
16.2.3.3  Pericarditis
Prevalence: Symptomatic pericardial disease is 
observed in around (5–16%) of the patients, which 
is lower than the autopsy proven one and was dem-
onstrated in around (33–72%) of SSc patients [94]. 
Symptomatic pericarditis in patients with limited 
scleroderma is more than the patients with diffuse 
scleroderma, which was observed at the rate of 
30% vs. 16%, respectively [2].
Associations: Symptomatic pericarditis is 
associated with pulmonary hypertension [95], 
while cardiac tamponade and heart failure are 
associated with poor prognosis [87].
Presentation: It is usually asymptomatic [2], 
yet it can rarely be present with large symptomatic 
pericardial effusion [2]. The large pericardial effu-
sion usually occurs after the clinical and labora-
tory manifestations of the scleroderma [2], but still 
it can happen before, so it is part of the differential 
diagnosis of pericardial effusion [96]. Renal fail-
ure can be presented in the setting of large pericar-
dial effusion and constrictive pericarditis [87].
Laboratory: exudative pericardial effusion pat-
tern with predominance of mononuclear cells [97].
Treatment: In the setting of pericarditis, 
NSAID and corticosteroids were effective [94], 
and with the presence of active inflammation, 
immunosuppressive therapy may have a role [94].
Conventional heart failure treatment is helpful 
[94]. Cardiac tamponade is to be treated accord-
ingly, e.g., pericardiocentesis [87]. Constrictive 
pericarditis is to be treated accordingly, e.g., 
diuretics, sodium and fluid restriction, and/or 
pericardial stripping [87].
16.2.4  Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is a systemic 
autoimmune disease associated with arterial and 
venous thrombotic events and recurrent fetal loss. 
The heart is a target organ in APS.
Endocardial disease, intracardiac thrombo-
sis, myocardial involvement including CAD 
and microvascular thrombosis, as well as pul-
monary hypertension, have all been described 
in APS patients. Valvular involvement is the 
most common manifestation with a prevalence 
of 82% detected by transesophageal echocar-
diography. Symmetrical—nodular thickening 
of the mitral and/or aortic valves—is character-
istic. Anticoagulant/antiplatelet treatment is 
ineffective in terms of valvular lesion regres-
sion [98]. Some patients require cardiac valve 
replacement. However, patients with APS have 
shown an increased perioperative morbidity 
and mortality. Intracardiac thrombosis, 
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although a rare complication, can cause pulmo-
nary and systemic emboli [98].
16.2.4.1  Aspirin and APS
The primary prophylaxis of thrombosis with low 
dose aspirin (81  mg) in asymptomatic, persis-
tently antiphospholipid antibody (APL)-positive 
individuals was not beneficial when compared to 
placebo [99]. SLE patients with persistent posi-
tive lupus anticoagulant (LA) antibody are at 
high risk of thrombosis, and primary prophylaxis 
with low-dose aspirin and hydroxychloroquine is 
recommended [100].
16.2.5  Ankylosing Spondylitis (AS)
It is a chronic inflammatory condition that usu-
ally affects young men, mainly affecting the 
spine and the sacroiliac joints and, to lesser 
extent, the peripheral joints. Cardiac dysfunction 
and pulmonary disease are well known and com-
monly reported extra-articular manifestation 
associated with ankylosing spondylitis (AS). The 
cardiac manifestations were reported in around 
2–10% [101], and it may reach up to 30% [102] 
of patients with AS—mostly conduction defects 
and aortic insufficiency [101]. The cardiac mani-
festation is mostly observed in patients with 
long-term AS and peripheral joint involvement 
[103]. AS has also been reported to be specifi-
cally associated with aortitis, aortic valve dis-
eases, conduction disturbances, cardiomyopathy, 
and CAD.  There is no difference between the 
type of rheumatic therapy and its use among 
patients with AS, who have myocardial infarction 
versus who does not [101].
16.2.5.1  Aortic Involvement
It was first described in 1973 AD by Bulkley and 
Roberts during autopsy examination of patients 
with AS that had congestive heart failure due to 
severe aortic regurgitation [104]. It is an impor-
tant topic, because if patients with AS developed 
chest pain, you should rule out aortic dissection.
Prevalence: Echocardiographic evidence of 
aortic regurgitation was mostly mild and was 
observed in around 3–13% of patients with AS 
[60]. Positive HLA-B27 patients with aortic 
regurgitation around half of them do not have 
clinical features of rheumatic disease [105].
Pathology: Arteritis around the aortic root 
and valve due to inflammatory process with 
platelets aggregation lead to tissue thickening 
[104]. There is fibrous growth of the intimal 
layer that leads to aortic root dilatation [104]. 
Increase in stiffness of the aorta and decreased 
global myocardial performance are features of 
AS and correlate with the disease activity and 
its duration [106].
Diagnosis: Echocardiography: TEE showed 
aortic root thickening, increased stiffness, dilata-
tion, and nodularities of the aortic cusps. The first 
two were the most common findings [107]. Valve 
regurgitation was seen in around half of the 
patients [107].
16.2.5.2  Myocardial Involvement
Prevalence: Diastolic dysfunction was found at 
the rate of 20% [108] ranging to 50% [109], 
while systolic dysfunction was affected less than 
that in around 18% of AS patients [110].
Pathology: It was found to have an increase in 
myocardial inflammation and the connective tis-
sue/myocyte rate, which will give the picture of 
the increase in diffuse interstitial connective tis-
sue [110].
Presentation: Diastolic dysfunction in AS is 
usually not severe enough to cause diastolic heart 
failure [111]. Rarely, were LV systolic dysfunc-
tion and hypertrophy reported in the absence of 
significant aortic regurgitation [48].
16.2.5.3  Conduction Abnormalities
It is the most common finding in AS patients, 
and it usually precedes the other cardiac find-
ings [102].
Prevalence: Conduction abnormalities were 
observed in around 2–20% of AS patients [60]. 
Around half of the positive HLA-B27 patients 
with conduction abnormalities do not have clini-
cal features of rheumatic disease [105].
Pathology: Inflammatory process leads to 
damage of the interventricular septum wall, and 
AV node dysfunction is secondary to the compro-
mise of the arterial supply to the AV node [112]. 
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Another factor is the autonomic nervous system 
abnormalities that can lead to conduction defects 
and arrhythmias at the end [113].
Associations: Disease duration is associated 
with the prolongation of the PR and the QRS 
intervals [112]. Conduction abnormalities occur 
more frequently in patients with positive HLA- 
B27 [105].
Types:
 1. Supraventricular extrasystoles and ventricular 
extrasystoles are very common findings 
among AS patients [102].
 2. Prolonged QRS interval in about 29.2% of AS 
patients [112].
 3. First-degree atrioventricular (AV) block in 
around 4.6% of AS patients [112].
 4. Complete right bundle branch block (RBBB) 
in around 0.8% of AS patients [112].
 5. Left anterior hemiblock 0.8% of AS patients 
[112].
16.2.6  Psoriatic Arthritis
The increased risk of clinical and subclinical 
CVD is mostly due to accelerating atherosclero-
sis, and the incidence of mortality in CAD was 
similar to that of RA [114]. Patients with psori-
atic arthritis have higher occurrences of CVD 
risk factors and CAD, peripheral vascular dis-
ease, and congestive heart failure [115].
16.2.6.1  Arrhythmias
Incidence: Patients with psoriasis were found to 
have higher risk of developing arrhythmia than 
the normal population at the rate of 15.41 per 
1000 person-years, and this was even higher 
among patients with psoriatic arthritis [116].
16.2.6.2  CAD:
Incidence: The incidences of myocardial infarc-
tion is 5.13 per 1000 person-years, while it is 
5.13 for severe psoriasis, which is higher than the 
general population [7]. The new events of heart 
failure were higher among psoriasis patients, 
especially among the severe psoriasis group than 
the general population [117].
Associations: Severe psoriasis is associated 
rationally with a higher risk of death, specifically 
cardiovascular being the most common cause 
[118]. CAD is associated with young patients [7, 
119], psoriatic arthritis [119], and/or severe pso-
riasis [7, 119]. Severe psoriasis has higher risk of 
CAD and stroke [119].
Pathology: Metabolic diseases, such as obe-
sity and diabetes mellitus, are more among pso-
riasis patients, which may play a role in the 
development of atherosclerosis in addition to the 
inflammatory process [120].
Prevention: Treatment with methotrexate and 
TNF alpha inhibitors therapy appears to lower the 
rates of CAD among patients with psoriasis [120].
16.2.7  Systemic Vasculitis
CVD is significantly involved in different types 
of systemic vasculitis, ranging from large to 
small vessel vasculitis (see Chap. 20 on 
“Vasculitis and Rheumatology”).




This can be called an immune system-mediated 
inflammatory process as the immune cells can be 
found within atherosclerotic plaques, and inflam-
mation activates this process.
(Table 16.5 shows the major contributing fac-
tors for atherosclerosis in different rheumato-
logic diseases).
16.4  Metabolic Syndrome 
and Rheumatological 
Diseases
The concept of metabolic syndrome was first rec-
ognized by Raven when he discussed that insulin 
resistance has a central role in type 2 DM, hyper-
tension, and CAD [121]. Later, it became known 
as metabolic syndrome. The major components 
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Table 16.5 : Atherosclerosis in rheumatologic diseases
Disease Contributed factors
All   • Active prolonged inflammatory process.
  • Vascular endothelial dysfunction and injury.
  • ↑ Oxidized LDL (oxLDL) engulfed by macrophages to form foam cells
  •  Immune dysregulation by ↑ CD4+ T cells that lack surface CD28 molecule (CD4 + CD28−), 
which infiltrate the atherosclerotic plaques and display a high pro-inflammatory and tissue-
damaging potential; this promotes vascular injury.
  •  ↑Beta 2 glycoprotein I (Β2GPI) is present along with CD4 lymphocytes in the plaque cells which 
increase the lesion area.
  •  The plague secretes interleukins, tumor necrosis factor-α (TNF), and platelet-derived growth 
factor for more expansion of the lesion.
  • ↑Anti-oxLDL, (aCL) antibodies, anti-β2GPI antibodies when there is extensive atherosclerosis.
Disease Contributed factors Subclinical detection
RA   • Endothelial dysfunction.
  • Traditional risk factors.
  • Depletion of endothelial progenitor cells.
Preclinical atherosclerosis can be 
detected by:
  1. B mode-carotid ultrasound:
  •  IMT (intimal medial 
thickness).
  •  See atherosclerotic plague by 
echolucency and calcific 
acoustic shadowing.
  2. CT scan of coronary arteries:
  • Presence of calcification.
  • Extent of calcification.
  3. Arterial stiffness:
  • Pulse wave velocity (PWV).
  • Pulse wave analysis (PWA).
  4. Elevated CRP.
SLE   • Traditional risk factors.
  • Depletion of endothelial progenitor cells.
  • Inflammation.
  •  Metabolic changes in SLE: Renal dysfunction and early 
menopause.
  • Antiphospholipid antibodies.
APS   •  Possible involvement of antiphospholipid antibodies 
(APL) in the pathogenesis of atherosclerosis.
  •  Positive APL is associated with arterial atherosclerosis 
which will develop into thrombosis at coronary, carotid, 
and lower peripheral arteries.




  •  Endothelial injury and its activation can lead to loss of 
vasomotor function and vasoconstriction.
  •  Myofibroblasts develop from activated vascular muscles 
and cause thickening of the intima, lumen narrowing, and 
irreversible fibrosis.
  • It may also induce formation of intravascular thrombosis.
Ankylosing 
spondylitis
  • There are very limited studies.
  • Inflammation is a possible contributed risk.
  • Endothelial dysfunction.
  •  No difference in IMT compared 
with the general population.
  •  Impaired flow-mediated 
dilatation and coronary flow 
reserve.
Vasculitis   • There is inflammatory cells infiltration in the layers of 
arterial wall.
  • Variable.
of metabolic syndrome include dyslipidemia, 
central obesity, insulin resistance, and hyperten-
sion [122]. The major components are not occur-
ring concurrently; as it was found that insulin 
sensitivity will predict the increase in waist cir-
cumference (obesity), and the latter will predict 
the remaining components, e.g., dyslipidemia 
and hypertension [123]. The adipose tissue is act-
ing as endocrine organ by the secretion of the 
pro-inflammatory factors called adipokines. 
Insulin resistance has a role in the development 
of CVD (probably due to the adipokines from the 
adipose tissue) [124] as it has a role in the 
enhancement of vascular inflammation and endo-
thelial dysfunction [125]. Different adipokines 
have been recognized in metabolic syndrome 
with rheumatic diseases, and their effects were 
emphasized (see Table 16.6).
Patients with rheumatic diseases are under the 
pressure of chronic inflammation mainly with 
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RA and SLE. Many patients with rheumatic dis-
eases—mainly RA, SLE, and AS—have been 
diagnosed with metabolic syndrome [14–16].
Here, we will discuss the rheumatic diseases 
and its relationship with metabolic syndrome.
16.4.1  RA
It was initial to associate insulin sensitivity to be 
lower in RA patients compared to osteoarthritis 
patients [126]. Later, it was found that the main 
factors of insulin resistance in RA are obesity and 
disease activity [127]. The prevalence of meta-
bolic syndrome among RA patients ranges from 
44% to 53% [15, 128]. Such patients were found 
to have higher disease activity than those without 
metabolic syndrome with low level of high- 
density lipoprotein cholesterol [15]. Its presence 
is associated with higher systemic inflammatory 
marker and glucocorticoids use [129]. Patients 
with RA, who were diagnosed with metabolic 
syndrome, were found to have higher risk of cor-
onary artery calcification [128].
16.4.2  SLE
Non-diabetic patients with SLE were found to have 
significant decrease in sensitivity to insulin, and 
around 18% of them were diagnosed with meta-
bolic syndrome [130]. The prevalence of metabolic 
syndrome among SLE patients ranges from 16% to 
32.4% [14, 131, 132]. SLE patients have higher 
fasting insulin level, and cardiovascular risk factors 
were also elevated among the last group [133]. 
Metabolic syndrome was associated with higher 
level of C-reactive protein, homocysteine, lipopro-
tein, and cholesterol [14] . Metabolic syndrome and 
CVD among SLE patients were associated with 
prolonged SLE duration and increased cumulative 
organ damage [131]. Lupus nephritis, high cortico-
steroid doses, Korean and Hispanic ethnicity were 
associated with metabolic syndrome in SLE patients 
[132]. The use of hydroxychloroquine was associ-
ated with protective effect of CVD [131].
16.4.3  AS
The prevalence of metabolic syndrome among 
AS is around 45.8% [16], whereas low AS dis-
ease activity is not associated with accelerated 
atherosclerosis [134].
16.4.4  Psoriasis
Psoriasis is associated with DM. The prevalence of 
DM was higher with severe psoriasis than mild 
psoriasis in the rate of 7.1% vs. 4.4%, respectively 
[135]. The prevalence of metabolic syndrome 
among psoriatic patient ranges from 15% to 35.5% 
[136–138]. Psoriatic patients are prone to the 
development of the main components of metabolic 
syndrome (e.g., DM and hypertension) [139]. 
Treating psoriasis was found to be associated with 
improvement in the metabolic risk biomarkers, 
such as high-sensitivity CRP, adiponectin, and the 
oral glucose tolerance test [140].
Table 16.6 The effects of different adipokines on rheumatologic diseases [154]
Rheumatic disease
Adipokines
Leptin Adiponectin Visfatin Resistin
RA ↑, pro-inflammatory ↑, Synovitis ↑, Radiographic joint 
damage
↑, Disease activity 
and joint 
destruction
PsA Controversial Controversial Controversial –
PsA – – –
AS Marker of disease 
activity??
– Controversial –
Gout – – – –
OA ↑, cartilage 
destruction
Controversial ↑, degradation of 
collagen
–
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16.4.5  Gout
The initial association of gout with metabolic syn-
drome was with the close association of hyperure-
cemia and the components of metabolic syndrome 
(e.g., hypertension, insulin resistance, and obesity) 
was noted [141]. Elevated uric acid levels among 
gout patients can be associated with insulin resis-
tance since renal clearance is inversely related 
with insulin resistance [142]. The prevalence of 
metabolic syndrome among gout patients ranges 
from 44% to 88% [143–145].
16.5  The Various Medications that 
Are Being Used 
in the Management 
of Rheumatologic Disease 
that Have Variable Effects 
on CAD
It is important to mention these factors because 
managing clinicians may not pay attention to 
these effects as they focus mainly on the activity 
of the rheumatologic disease.
16.5.1  NSAIDs3
• The risks of major cardiovascular events—
such as myocardial infarction, stroke, and 
death—appear to increase to a similar degree 
by the use of most nonselective NSAIDs at 
high doses. The exception is naproxen, which 
does not increase such risk [146].
• All of the COX-2 selective inhibitors (coxibs) 
appear to increase the risk of ischemic cardio-
vascular disease in a dose-dependent fashion. 
Recent data showed that naproxen, celecoxib, 
and ibuprofen did not differ in the risk of the 
cardiovascular mortality, but naproxen was 
less than the last two for the risk of the gastro-
intestinal bleeding [147]. Certain COX-2 
3 The association of nonsteroidal anti-inflammatory drugs 
(NSAIDs) with  cardiovascular morbidity and  mortality 
in patients with RA is still controversial.
inhibitors are associated with twofold increase 
in CAD risk.
• COX inhibition leads to CAD with two possi-
ble mechanisms:
 – It can interfere with normal platelet and 
endothelial vasodilator functions.
 – It can cause hypertension.
• All (NSAIDs) can increase blood pressure in 
both normotensive and hypertensive individu-
als. Its use may reduce the effect of all antihy-
pertensive drugs except calcium channel 
blockers.
(Figure 16.1 summarizes the effects of 
NSAIDs on the cardiovascular system)
16.5.2  Glucocorticoids (GC)
This medication is known to have serious nox-
ious effects by increasing blood pressure, insulin 
resistance, body weight, and fat distribution. 
There is an excess risk of cardiovascular morbid-
ity and mortality when the drug is used in high 
cumulative doses and for a long duration. There 
is 68% of increased risk of myocardial infarction 
among RA patients treated with GCs [148]. 
Cushing disease is associated with accelerated 
atherosclerotic vascular disease [149].
16.5.3  Methotrexate
Many studies have demonstrated that its use has 
been associated with a beneficial reduction in 
CVD events among patients with systemic 
inflammation diseases primarily from RA [49]. It 
is known to decrease homocysteine level. RA 
patients who used methotrexate have lower LDL 
levels, significant increase in mean HDL, and 
decrease in carotid artery intima-media thick-
ness, compared with baseline values.
16.5.4  TNF Biologic DMARDs
• A large study showed significant reduction in 
fatal and nonfatal CVD outcomes associated 
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with TNF inhibitors, but this remains 
controversial.
• The cardiovascular benefit of TNF inhibi-
tors may be limited to patients with RA 
whose synovitis responds to these agents. 
Patients whose disease activity was reduced 
by TNF inhibitor therapy within the first 
6  months of treatment had markedly 
decreased risk of myocardial infarction 
compared with those who continued to have 
active disease.
• It was associated with a significant increase in 
both total cholesterol and HDL with no change 
in regard to the atherogenic index [150].
16.5.5  Non-TNF Biologic DMARDs
• Rituximab has no significant effect on CVD, 
with no positive outcome on lipid profile or 
endothelial dysfunction.
• Tocilizumab is associated with beneficial low 
CRP after early introduction, but it has unclear 
worse effect regarding elevation of total cho-
lesterol, LDL [151, 152] when used for years, 
even though it does not increase CVD events. 
Tofacitinib is also associated with increased 
level of LDL [153].
In summary, for the prevention of CAD in rheu-
matologic diseases, we should do the following:
• Traditional CAD risk factors control.
• Early diagnosis and management of CAD.
• Long follow-up for CAD complications.
• Early diagnosis and management of rheuma-
tologic disease with strict control of the dis-
ease activity.
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 Appendix 1
Note about tables and figures
* Diagnostic markers of CVD in rheumato-
logic disease (including CAD): we have a table 
that summarizes the workup needed for the detec-
tion of CVD in each group of patients with rheu-
matologic disease (Table 16.A.1).
* Management and control of CVD risk 
factors (Including CAD): The control and the 
prevention of the risk factors for CVD and what 
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 NSAIDs and risk of CVD
Fig. 16.1 NSAIDs and risk of CVD
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RA MI   • ECG and cardiac enzymes: Mainly troponins and CK MB.
  • Echocardiogram.
Congestive 
heart failure
  • Echocardiogram.
  • Chest X-rays.
  •  CBC, serum electrolytes, BUN, creatinine, liver function test, and fasting 
blood sugar.
  •  Elevated B-type natriuretic peptide (BNP) levels are not specific for left 
ventricular systolic dysfunction, and may be reduced by concomitant diuretic 
and angiotensin-converting enzyme inhibitor therapy, limiting sensitivity 
[155]
  • Exercise stress tests.
Peripheral 
arterial disease
  •  Clinical investigation of arterial stiffness to look for incompressibility and 
obstruction and performing:
  – PWV: Pulse wave velocity.
  – PWA: Pulse wave analysis.
  • Ankle-brachial systolic pressure index (ABI),
  • Exercise testing (ABI) if rest (ABI) is normal.
  • Contrast arteriography is the gold standard.





  • ECG findings: Diffuse ST-elevation and T-wave abnormalities.
  •  Pericardiocentesis if significant pericardial effusion, fever (to rule out 
concomitant infections) or failed medical treatment.
  •  Low antinuclear antibodies (ANA), phagocytic cells containing nuclei (LE 




  • ECG findings: Prolonged PR intervals, ST and T-wave abnormalities.
  • Echocardiography.
  • MRI.
  • Myocardial biopsy.
Endocardium 
and valves
  • Echocardiography if a new murmur is detected or changing in cardiac 
function.
  • Blood culture and echocardiography if fever or new heart murmur.
  •  Transesophageal Doppler echocardiography produces high- resolution images 
of the cardiac valves and is superior to transthoracic echocardiography in the 
detection of valve abnormalities.
  •  Libman-sacks endocarditis is typically asymptomatic. However, the verrucae 
can fragment and produce systemic emboli, and infective endocarditis can 
develop on already damaged valves [156]..
Conduction 
defects
  •  Preconception or early prenatal testing for anti-Ro/SSA and anti-La/SSB 







  • ECG: Look for tachyarrhythmia.
  • Chest X-ray.
  • Doppler echocardiogram:
  – Rhythm.
  – Conduction disturbance.
  – Cardiac chambers and valves (morphology and function).
  – Pulmonary arterial pressure.
  • Cardiac pulmonary stress test.
  • Cardiac catheterization for better diagnosis of pulmonary hypertension.
  • MRI.
  • Nuclear studies of myocardial function and perfusion .
Myocardium
AS & PsA Different 
CVDs
  • Clinical assessment.
  • ECG.
  • Cardiac enzymes.
  • Echocardiogram.
(continued)






APS IHD   • Clinical assessment.
  • ECG.
  • Cardiac enzymes.
Valvular 
disease
  • Clinical: Asymptomatic regurgitation.
  • Echocardiogram: Vegetation and marked thickening.
Pseudo-
endocarditis
  • Clinical: Fever, murmur, and splinter hemorrhage.
  • Echocardiogram with the presence of mitral valve nodules and mitral 
regurgitation.
  • High APL titer.
  • Blood culture is negative for infection.
Peripheral 
artery disease
  • Ankle-brachial index at lower extremities is abnormal.
DVT   • Clinical assessment.
  • Duplex ultrasound.
  • D-dimer for exclusion in low probability cases..
Intracardiac 
thrombus
  • Not common and misdiagnosed.
  • Clinical: Angina-like pain.
  • Exercise test: Positive.
  • Angiogram: Normal coronary arteries.
Inflammatory 
myopathies
CVDs are rare   • ECG: Conduction defects and arrhythmia.
  • Specific marker is the level of cardiac isoform troponin-I.
  • Creatine kinase (CK)-MB is not a specific cardiac marker, so it is not helpful.
Vasculitis According to 
the type
  • ECG and echocardiogram.
  • Contrast-enhanced cardiac MRI.
  • BNP.
  • ANCA.
Table 16.A.2 Management and control of CVD risk factors [157]
Health 
parameters Maintenance
Dyslipidemia   • Annual lipid profile screening is recommended.
  •  Statin use decreases TC and LDL levels, which lower the risk of cardiovascular events; give if 
it is indicated.
  • In high-risk patients who use statins, the goal of LDL-C level: < 70 mg/dL. .
DM   • Monitoring of blood glucose (fasting and random).
  •  Annual screening of hemoglobin A1c in patients with active disease and chronic corticosteroid use.
  • Treatment of DM as guidelines.
Hypertension   • Early blood pressure monitoring when there is a risk from medication.
  • Regular monitoring of blood pressure and start treatment as guidelines.
  • Control level of blood pressure, the goal: <140/90 mmHg.
Smoking   •  Cessation is strongly recommended to improve disease activity and therapy effectiveness of 
RA, and its benefit on lowering CVD events is probable.
Obesity   • Regular monitoring of BMI.
  • Waist to hip ratio.
  • Encouragement of healthy diet.
  • Body mass index goal: 18.5–24.9 kg/m2.
  •  Waist circumference goal: Women 35 inches (89 cm), men 40 inches (102 cm).
Physical 
activity
Goal: At least 30 min per day, minimum 3–4 times a week
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* Preventive tips for using common medica-
tions in rheumatologic disease: As we recognize 
the numerous and various medications that are being 
used in the management of rheumatologic diseases 
that are being associated with adverse effects on the 
CV system and CAD so here we tried to have a sum-
mary of preventive tips to use while using them in 
those patients as shown in Table 16.A.3.
* The use of aspirin: there are no specific 
rules for its use in rheumatologic disease as the 
rules applied in those patients are the same as the 
general population. Figure 16.2 is a simple dia-
gram showing the approach to use it.
* The use of statins: There are no specific 
rules for its use in rheumatologic disease as the 
rules applied in those patients are the same as the 
general population. We have here a simple dia-
gram based on the latest guidelines from the 
American Heart Association (AHA) that was 
released in 2013 (Fig. 16.3).
Table 16.A.3 Medications of rheumatologic disease and the preventative measures
Medication Disease Effects on CVD
Glucocorticoids RA
SLE
  • Reduced doses will lower the risk of CAD.
  • Calcium and vitamin D should be given.
  • Since the risk is dose-dependent, it is a must to keep the duration of using 
steroids as short as possible and the dose as minimal as possible.
  • A close surveillance of blood pressure and modification of antihypertensive 
regimens is recommended when the patient is hypertensive and is receiving 
moderate to high doses of GCs.
  • Increased cardiovascular disease was associated with glucocorticoid use at doses 
≥7.5 mg/day of prednisone or its equivalent [158].
Methotrexate RA   • Folic acid supplementation to correct homocysteine level.
  • It is advisable to continue using it as indicated as a DMARD.
  • Its CVD benefit is not fully approved, but a definitive result will come out from 
further studies which may prove the hypothesis of CVD as an inflammatory 
mechanism, and it can be beneficial in chronic CVD management.
TNF blockers RA
AS
  • Annual lipid screening is recommended when the risk of lipid disturbance is 
there.
  • Inpatients with RA, it is recommended to continue using TNF inhibitors as 
biologic DMARD therapy.
  • Anti-TNF biologic (infliximab) is not recommended in patient with NYHA class 
3 or 4 cardiac failure with an ejection fraction of ≤50% due to a worsening effect 
of infliximab on the cardiac function.
  • Check pulse wave velocity and analysis for possible transient improvement of 
vascular morbidity.
  • TNF blockers may decrease CVD involvement and atherosclerosis in ankylosing 
spondylitis, but no strong evidence.
Non-TNF RA   • More, larger studies are needed to clear the risky-beneficial nature of these 
medications and their effects over the CVD.
NSAIDS RA
AS
  • Effective for pain management, but it is wise to be cautious about the 
cardiovascular side effects of NSAIDs especially in patients with high CVD risk 
factors.
  • Extra caution regarding the dose, risk factors, and comorbidity status.
Statins SLE For primary and secondary prevention (as evident by the last AHA guidelines 2013) 
[159]
  • Anti-inflammatory effect.
  • Lowering LDL-C and CRP.
  • Antithrombotic effect.
  • Immuno-modulating effect.
Aspirin SLE
APS
Should be indicated in SLE if no contraindication:
  • History of CAD.
  • Ongoing risk factors like HTN, DM, high cholesterol, and smoking.
  • Prophylactic low-dose aspirin in patients with thrombosis-free and -positive 
APL.
(continued)
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Table 16.A.3 (continued)
Medication Disease Effects on CVD
Anticoagulation 
therapy
APS   • In patients with first event of venous thrombosis (INR: 2.0–3.0).
  • In patients with recurrent venous or arterial thrombosis, give intensive therapy 
(INR: 3.0–4.0).






  • Anti-inflammatory effect.
  • Anticoagulant effect.
  • For lipid profile improvement.
  • Prophylactic dose in patients with thrombosis-free positive APL in APS.
Cyclophosphamide SLE   • It is the standard treatment of severe SLE with organ involvement, e.g., 
myocarditis.
  • It is recommended to give pulse steroids and pulse cyclophosphamide.
Calcium channel 
blockers
SSc   • Nifedipine and Diltiazem use with caution as they are contraindicated in MI and 








SSc   • Iloprost for widening narrow blood vessels and better blood circulation.
  • Ventavis inhaled solution for stage 3 or 4 pulmonary hypertension.
Sidenafil SSc   • For improvement of hemodynamics .
Aspirin





↑ Risk of MI
Age 45–59 and 10-year risk ≥ 4%
Age 60–69 and 10-year risk ≥ 9%
Age 70–79 and 10-year risk ≥ 12%
Age 80 aor older: no sufficient data
Age 55–59 and 10-year risk ≥ 3%
Age 60–69 and 10-year risk ≥ 8%
Age 70–79 and 10-year risk ≥ 11%
Benefits > GI bleeding risk
Aspirin 75 mg daily
10-year risk at least 10% but not <5%
Women: Age > 60
Men: Age > 50
Aspirin 75–162 mg daily
Aspirin 75–162 mg daily
A dose >162 mg offersno additional
benefit in preventing CVD
Aspirin 81 mg daily or 100 mg
every other day is recommended
Women
↑ Risk of Ischemic
History of CAD, MI or storke
Fig. 16.2 The use of aspirin for primary and secondary prevention of CAD [161]
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Use of Statins
age (40 to 75)












High Intensity Statins Therapy
•  Atorvastatin 40–80 mg
•  Rosuvastatin 20–40 mg
Moderate Intensity Statin Therapy
•  Atorvastatin 10–20 mg
•  Rosuvastatin 5–10 mg
•  Simvastatin 20–40 mg
•  Pravastatin 40–80 mg
•  Lovastatin 40 mg
•  Fluyastatin XL 80 mg
•  Fluyastatin 40 mg








Age > 75 Age < 75 High intensity statins
LDL-C >190 mg/dl
Fig. 16.3 The use of the statins for management of CAD [159]
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There are changes that occur in the maternal 
organ systems due to increased demands of preg-
nancy. Most of the rheumatic disorders occur in 
the reproductive age group. The hormonal 
changes that occur during pregnancy may mimic 
the signs and symptoms of rheumatic disorders 
thereby making the diagnosis difficult. 
Rheumatological disorders need to be diagnosed 
and treated at least 6 months before the onset of 
pregnancy; otherwise they may have consider-
able effect on the prognosis of the disease. This is 
particularly evident in cases of SLE and anti- 
phospholipid antibody syndrome. Therefore, 
pregnancy is a crucial issue that needs to be 
clearly addressed in details in all female patients 
in the reproductive age group having some of the 
rheumatological disorders.
There are two concerns in these patients. The 
first one is the effect of the disease activity on 
pregnancy, and the second is the influence of 
pregnancy on the disease. That explains why 
pregnancy should be planned carefully at least 
6  months of remission before attempting preg-
nancy. This is supported with close follow-up for 
the disease activity during pregnancy. Therefore, 
managing pregnant patients with rheumatic dis-
ease can be very challenging. The simple expla-
nation is the combination of aggravation of 
disease by pregnancy, the aggravation of preg-
nancy by disease, and the use of special medica-
tions in pregnancy. A successful pregnancy 
requires achievement of multiple biological steps 
from “conception, embryogenesis, placental and 
fetal development, maternal-fetal communica-
tion to labor and delivery” [1].
17.2 Objectives
By the end of this chapter, you should be able to:
1. To discuss the physiology of pregnancy.
2. To discuss systemic lupus erythematosus flare 
manifestations and management during 
pregnancy.
3. To diagnose and manage antiphospholipid 
syndrome during pregnancy.
4. To discuss neonatal lupus erythematosus 
pathophysiology and management.
5. Review management of other common rheu-
matologic diseases during pregnancy.
17.3  Physiology of Pregnancy
There are added burden by the mother, the fetus, 
and the placenta during pregnancy. All of these 
should be met by the mother’s organ systems. 
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Thus, there are certain cardiovascular, hemato-
logical, immunological, endocrinal, and meta-
bolic changes that happen in the mother in normal 
pregnancy.
17.3.1  Changes in Cardiovascular 
System
The most important physiological changes that 
happen in pregnancy are the increase in cardiac 
output and retention of sodium and water. These 
changes result in significant increase in blood 
volume and reduction in systemic vascular 
 resistance and blood pressure. Such changes start 
as early as fourth week of pregnancy, reaching 
their highest level during the second trimester, 
and then remain relatively constant until delivery. 
As the increase in the red cell volume is propor-
tionately much less than the increase in plasma 
volume, there is hemodilution (physiological 
anemia) by the end of second trimester [2].
The increased level of plasma erythropoietin is 
responsible for balanced increase in the red cell 
mass. The physiological anemia that happens in 
pregnancy reduces the cardiac work load and 
helps for enhanced placental perfusion by decreas-
ing the blood viscosity. It also decreases the risk 
of thrombosis in uteroplacental circulation. The 
increased blood volume also defends against the 
usual blood loss in the peripartum period.
Cardiac output increases by 30–50% during 
normal pregnancy. This is as a result of increase 
in the preload owing to rise in blood volume, 
decrease in afterload due to decrease in systemic 
vascular resistance, and increase in the maternal 
heart rate. The cardiac output and systemic vas-
cular resistance steadily return to non-pregnant 
levels over a period of 3 months postpartum [3].
17.3.2  Hematological Changes
The total white cell count is increased up to 40%, 
and the platelet count gradually declines till the 
term, while they do not fall below 100,000/cu 
mm. This is expected as a result of dilutional 
effect, increased destruction, and turnover [4].
17.3.3  Changes in Coagulation 
System
Pregnancy is linked with changes in several coag-
ulation factors that result in a 20% reduction of 
prothrombin and the partial thromboplastin times 
creating a hypercoagulable state. This acts as a 
double-edged sword, both for protection (e.g., 
hemostasis contributing to reduced blood loss at 
delivery) and increased risk (e.g., thromboem-
bolic phenomenon). Venous thrombosis in preg-
nancy happens in approximately 0.7 per 1000 
women and is three- to fourfold higher in the 
puerperium than during pregnancy. The risk is 
amplified in women with underlying inherited 
thrombophilia (e.g., factor V Leiden or the pro-
thrombin gene mutation) [5].
17.3.4  Changes in the Maternal 
Immune System
The local modification of the maternal immune 
system is accountable for the successful coexis-
tence between the mother and the fetus/placenta 
expressing both maternal (self) and paternal anti-
gens. The cell-mediated adaptive immune 
responses are reduced, bypassed, or even elimi-
nated. However, the antibody-mediated immu-
nity is reformed, while the natural immunity 
(innate immunity) remains intact which contin-
ues to offer the host defense against infection. 
During insemination, the transforming growth 
factor β1 (TGF-β1), found in the seminal fluid, 
excites the production of granulocyte- 
macrophage colony-stimulating factor (GM-CSF) 
and enrolment of inflammatory cell infiltrates in 
the uterus [6].
During implantation of the fertilized ovum, 
the majority of the lymphocytes infiltrating the 
decidua are typical uterine natural killer (NK) 
cells which are CD56++, CD16-, and CD3- and 
express various receptors. Uterine decidua and 
the fetoplacental unit produce large number of 
cytokines which contribute to shift of the immune 
response from T helper 1 (Th1) to T helper 2 
(Th2) response. While there are many specific 
mechanisms for immunological protection 
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against the fetus, the most essential one is altered 
HLA expression [7].
17.3.5  Changes in the Endocrine 
Glands
Maternal changes in pregnancy involve the hypo-
thalamus, pituitary, parathyroid, adrenal glands, 
and ovaries to adapt the needs of the fetal- 
placental- maternal unit. The hypothalamus still 
controls much of the endocrine system through 
hypothalamic-pituitary axis, directly affecting 
the function of the abovementioned endocrine 
organs.
 (a) Hypothalamus: These hormones released 
from hypothalamus are available in high con-
centrations in portal circulation where they 
are biologically active. The circulating con-
centrations of many of these hormones are 
also raised in pregnancy due to placental pro-
duction of identical or variant hormones [8].
The most important changes are seen in 
the following hormones:
Gonadotropin-releasing hormone 
(GnRH) level increases during pregnancy. 
The main source is the placenta and exerts a 
main role in placental growth and function. 
Corticotropin-releasing hormone (CRH) 
from hypothalamus is engaged in stress 
response in pregnancy and delivery. It is also 
released by the placenta, chorionic tropho-
blasts, amnion, and decidual cells. The pla-
cental CRH do not stimulate 
adrenocorticotropic hormone (ACTH) secre-
tion but helps in induction of labor. Besides 
CRH the gestational tissues also secrete uro-
cortin which shares the same function as that 
of placental CRH. The urocortin-2 also con-
trols the tone of vascular endothelium which 
also plays a major role in parturition [9].
 (b) Pituitary Gland: Anterior lobe of pituitary 
gland expands threefold during gestation 
because of hypertrophy and hyperplasia of 
lactotrophs. It needs minimum 6  months 
after delivery to return to normal size. 
Follicle- stimulating hormone (FSH), lutein-
izing hormone (LH), and thyroid-stimulating 
hormone (TSH) levels are decreased, while 
growth hormone (GH), ACTH, and prolactin 
(PRL) levels are increased mainly due to the 
synthesis by the placenta.
The serum PRL concentration increases due 
to increase estradiol during pregnancy, reaching 
the maximum at delivery to prepare the breast for 
lactation. The plasma sodium concentration 
drops by 5 meq/L due to resetting of osmorecep-
tors as a result of increased levels of human cho-
rionic gonadotropin (HCG). Oxytocin level 
increases steadily during gestation and is involved 
in parturition and lactation. There is increase in 
thyroxin-binding globulin (TBG) but TSH (along 
with triiodothyronine (T3) and thyroxin (T4)) is 
in the normal range [10].
The renin-angiotensin-aldosterone system is 
stimulated during pregnancy due to reduction in 
peripheral vascular resistance and blood pres-
sure, but there is a gradual decline in vascular 
responsiveness to angiotensin II. The aldosterone 
level increases by four- to sixfold, and the blood 
pressure usually reduces by 10 mmHg. Relaxin, a 
vasodilator factor produced by the placenta and 
aldosterone, is critical in sustaining sodium bal-
ance in the setting of peripheral vasodilatation. 
During pregnancy there is an increase in the lev-
els of maternal and placental ACTH, cortisol- 
binding protein, atrial natriuretic peptide (ANP), 
plasma rennin activity (PRA), sex hormone- 
binding protein, and testosterone levels [11].
17.4  Systemic Lupus 
Erythematosus
17.4.1  Introduction
Systemic lupus erythematosus (SLE) is a chronic 
multisystem autoimmune disease occurring in 
young women in their childbearing age. It is one 
of the most common rheumatological conditions 
encountered in pregnancy with considerable 
influence on its outcome. It mainly affects the 
skin, joints, blood, kidney, and other organs. 
Pregnancy can have influence on the disease, and 
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the disease also has considerable influence on 
pregnancy.
The annual incidence of SLE is 3 cases per 
100,000 population out of which 90% belong to 
the female gender. Asians and African Americans 
found to have more severe disease with renal 
involvement. The thrombotic complications are 
seen in 10% of these cases [12]. SLE is a hyper-
coagulable state due to antiphospholipid antibod-
ies and increase in certain procoagulants due to 
inflammation and platelet hyperfunction. This 
further leads to thrombogenesis by multiple-hit 
theory. The factors which increase thrombosis 
risk also encourage pregnancy loss in lupus.
17.4.2  Influence of Pregnancy on SLE
SLE patients experience different kinds of preg-
nancy related complications more than non-SLE 
women. One of the common pregnancy-related 
complications are pregnancy-induced hyperten-
sion (PIH); preeclampsia (blood pres-
sure ≥ 140/90 mmHg after 20 weeks of gestation 
and proteinuria ≥300 mg/24 hrs), eclampsia (pre-
eclampsia plus seizures), HELLP syndrome 
(hemolysis, elevated liver enzymes, and low 
platelets), and gestational diabetes [13].
17.4.3  Lupus Flares
The risk of lupus flare is enlarged if the woman 
has had active lupus in the last 6 months of preg-
nancy. Therefore, quiescent disease at the onset 
of pregnancy offers optimum protection against 
the occurrence of flare during pregnancy [14]. 
Lupus may flare through any trimester of preg-
nancy or postpartum period. The flares are usu-
ally mild mainly involving the joints, skin, and 
blood. Some of the physiological changes of 
pregnancy can simulate the symptoms of the 
active disease such as palmar erythema, arthral-
gia, myalgia, and lower limb edema.
The laboratory data specific for lupus flare as 
compared to pregnancy data include rising titer 
of anti-double strand DNA antibodies, presence 
of red blood cell casts in the urine, positive direct 
Coombs test, and presence of antiplatelet anti-
body with thrombocytopenia. Complement levels 
can be in natural range as complement levels 
increase during pregnancy due to estrogen- 
induced hepatic synthesis of complements. 
Hence, it is important to differentiate lupus flare 
from pregnancy-related complications and physi-
ological changes of pregnancy [15].
Previous studies have suggested that several 
factors may increase the risk of preeclampsia in 
pregnancies complicated by SLE. These factors 
include preexisting hypertension, renal insuffi-
ciency, presence of APS, as well as active SLE 
[16]. The differentiating features of preeclampsia 
from lupus nephritis are mentioned in Table 17.1.
17.4.4  Lupus Nephritis (LN)
Lupus pregnancies with long-standing LN are at 
high risk of spontaneous abortions and increased 
perinatal and maternal mortality. However, the out-
come of pregnancy in patients with stable LN at 
conception is relatively favorable. Remission in 
lupus nephritis has been defined as stable renal 
function, a serum creatinine within the normal 
range, urinary red cells below 5/high power field, 
proteinuria below 0.5  g/day, and ideally normal 





High BP Present or absent Diastolic 
BP > 90 mmHg
Proteinuria •  >500 mg/24 h 
if normal 
baseline
•  Doubling if 
>500 mg/24 h 
at baseline.
•  Occur before 
third trimester.
•  >300 mg/24 h 
if normal 
baseline






Uric acid Normal or elevated Elevated






serum complement component 3 (C3) levels for the 
last 12–18 months [17]. LN flare can be associated 
with other findings of active lupus such as serositis, 
arthritis, and high titers of anti-DNA antibodies. 
The proteinuria of preeclampsia decreases after 
delivery but not that of active lupus patient.
17.4.5  Influence of SLE on Pregnancy
SLE patients are as fertile as the overall female 
population [18]. Reduced fertility rate is seen in 
patients with active disease on high-dose steroids, 
patients with proven renal disease, and patients 
with moderate to severe renal failure. End-stage 
renal disease resulting from LN can lead to amen-
orrhea. However, amenorrhea in renal patients 
may also be because of ovarian failure from cyclo-
phosphamide use or of autoimmune origin [19].
Lupus flares can occur at any time during 
pregnancy with potential adverse effects on the 
conception. Lupus flares happen more commonly 
throughout pregnancy and postpartum period 
more than in non-pregnant SLE patients. Increase 
in lupus activity is seen at least in 1/3 cases in 
pregnancy. Therefore, for a better outcome of 
lupus pregnancy, it is important to control disease 
activity and to achieve clinical remission for at 
least 6 months before pregnancy [20].
Adverse live-birth outcome was significantly 
correlated with low pre-gestational serum albu-
min level, elevated gestational anti-dsDNA anti-
body, and diabetes mellitus. Spontaneous abortion 
was directly correlated with low levels of pre-ges-
tational serum albumin, positive anticardiolipin 
IgA, anti-B2-glycoprotein IgM, and anti-La anti-
bodies. The risk of obstetric complications and 
maternal mortality is high in patients with active 
LN associated with preexisting hypertension [21].
17.4.6  Hypercoagulability in SLE
Pregnancy itself is a hypercoagulable state with 
fetal demise, thrombosis, and preeclampsia being 
associated with factor V Leiden mutation, pro-
thrombin gene mutation 20210A, and deficien-
cies of anti-thrombin III, protein C, and protein S 
[22]. Pregnancy complications in SLE are rather 
common with maternal hypertensive complica-
tions occurring in 10–20%, preterm births in 
20%, fetal growth restriction occurring in about 
28%, and an average drop in fetal growth weight 
to around 16%. The increased stillbirth rate in 
SLE is fourfold greater than the general popula-
tion [23]. Hence, SLE-specific thrombophilic 
factors are additive to the background of 
pregnancy- related hypercoagulability (multiple 
hits). Collectively, this encourages the occur-
rence of worse fetal outcomes in lupus.
Hypercoagulability in SLE is due to multiple 
factors (multiple-hit theory)
 (a) Lupus-specific procoagulant factors-APLA 
(antiphospholipid antibodies).
 (b) Other lupus-specific factors include antibod-
ies to factor XII, prothrombin, and annexin V 
[24].
 (c) Lupus nonspecific factors.
 (d) Non-lupus-related procoagulant factors.
Chronic inflammation happening in SLE 
patients contributes to the occurrence of throm-
bosis. The factors responsible for this state can be 
summarized into:
 1. Elevated or activated procoagulant factors—
factors 2, 7, 8, 9, and 10, VWF, and 
fibrinogen.
 2. Reduced anticoagulant factors—protein C, S, 
antithrombin III.
 3. Inhibition of fibrinolysis  – PAI-1 elevation, 
hyperhomocysteinemia.
 4. Elevated ESR, CRP, high-sensitivity CRP 
(HsCRP), complement activation, fibrinogen.
 5. Increase in proinflammatory cytokines: IL-1, 
IL-6, tumor necrosis factor (TNF), and vascu-
lar endothelial growth factor (VEGF) [24].
17.4.6.1  Platelet Activation
The prothrombotic effects of antiphospholipid 
antibodies occur through different mechanisms. 
They include platelet activation, endothelial cell 
activation with resultant upregulation of adhesion 
molecules and production of thromboxane A2, and 
stimulation of monocytes to make tissue factor. 
17 Gestational Rheumatology
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Ultimately, all this will enhance clotting and vaso-
constriction. Tissue factor activates the extrinsic 
coagulation system, while tissue plasminogen 
activator (tPA) activates fibrinolysis. Tissue factor 
pathway inhibitor activity is diminished in SLE, 
and this is correlated with elevated levels of tissue 
factor and subsequent hypercoagulability [25].
17.4.6.2  Lupus Platelets
Inflammatory process in SLE leads to release of 
tissue factor which further leads to platelet acti-
vation. The antiphospholipid antibodies bind to 
activated platelet membrane ultimately leading to 
hyperfunction of platelets similar to sticky plate-
let syndrome. Hyperfunction of platelets in SLE 
is one of the important factors in causation of 
thrombosis [26].
17.4.6.3  Laboratory Workup
In general, more than basic tests are needed to eval-
uate the full range of possibly disrupted clotting 
mechanisms. This involves testing for lupus- specific 
antiphospholipid antibodies and other hemostatic 
markers of coagulation. The lupus- specific antibod-
ies include lupus anticoagulant, anticardiolipin anti-
bodies, and anti-β-2 glycoprotein- 1 antibodies. 
These antiphospholipid antibodies are a heteroge-
neous group of antibodies identified by various 
laboratory techniques; each of them has some prob-
lems with standardization, specificity, interpreta-
tion, and quality control [27]. The target antigens 
for these different antibodies involve prothrombin 
and negatively charged phospholipids [28].
Apart from antiphospholipid antibodies, a 
coagulation risk laboratory profile also necessi-
tates to be checked in lupus patients with throm-
bosis and fetal loss. Such profile includes testing 
for fibrinogen, factor VII, factor VIII, tPA, PAI-1, 
plasminogen activity, von Willebrand factor 
activity and antigen, protein C activity, protein S 
activity, homocysteine, and high-sensitivity 
C-reactive protein (Hs-CRP) [29].
17.4.6.4  High-Risk Clinical Scenarios
Selecting SLE patients for a coagulation assess-
ment is well recognized for those with a throm-
bosis or fetal loss but is not well outlined for 
those who are at risk but have not yet had an 
event. Therefore, patients who have had an event 
should obviously be selected for a coagulation 
workup. The high-risk scenarios which needed 
workup are given in Table 17.2.
17.4.6.5  Management of Lupus 
Pregnancy
Ideally, management of lupus pregnancy should 
begin before the onset of pregnancy. Thus, at pre-
conception counseling, the physician not only 
estimates the risk profile of the patients but also 
reviews their drugs. The aim is to avoid known 
teratogenic drugs, to discontinue certain medica-
tions, and to initiate other drugs. This had been 
the golden goal to protect the mother and fetus 
from adverse effects of these medications. Hence, 
it is important to monitor the mother for at least 
6 months before attempting conception. This is to 
assure a better outcome in lupus pregnancy.
There is a need for different subspecialists like 
rheumatologist, obstetrician, nephrologist, and 
neonatologist, to come together in managing 
such high-risk lupus pregnancy with close 
monitoring.
A) Management Issues
Once results are positive for pregnancy, we 
should have a baseline assessment of the disease 
activity, severity of the disease, and major organ 
involvement.
• Prenatal care visits: Every 4  weeks up to 
20 weeks, then every 2 weeks until 28 weeks, 
and then weekly until delivery [Table 17.3].
Table 17.2 High-risk lupus pregnancy
High-risk lupus pregnancy
Renal involvement High-dose steroid therapy




Interstitial lung disease Pre-organ transplantation














Owing to the advancement of treatment inter-
ventions, more and more women with SLE are 
able to become pregnant. Pregnancy outcomes 
have improved noticeably over the last 40 years, 
with a decrease in pregnancy loss rate from a 
mean of 43% in 1960–1965 to 17% in 2000–
2003 [30].
Pregnant patients with SLE on immunosup-
pressive therapy should receive prophylaxis for 
infection (including antibiotics for invasive pro-
cedures) and immunization with influenza and 
pneumococcal vaccine.
Other goals to achieve in managing a lupus 
pregnancy are:
 1. Checking for high-risk clinical settings.
 2. Performing coagulation risk lab profile in 
high-risk cases.
 3. Assessment of the number and degree of pro-
coagulant hits.
 4. Prevention of thrombosis and adverse fetal 
outcomes.
 5. Treatment of active lupus disease.
 6. Treatment of hypercoagulable state.
 7. Ensuring safety of medications used in treat-
ment of the disease.
Treatment of hypercoagulable state:
 1. Thromboprophylaxis for acute high-risk 
conditions.
 2. Chronic prophylaxis for thrombosis 
prevention.
 3. Full treatment dose anticoagulation therapy 
for thrombosis.
Thromboprophylaxis is controversial for 
patients with positive antiphospholipid antibodies 
(aPLs) but without any clinical history of throm-
bosis. However, evaluating risk of thrombosis by 
evaluating the multiple hits with a full thrombo-
philia profile would provide good support for 
deciding on intensity and type of thromboprophy-
lactic treatment. For example, in pregnant SLE 
patients who are positive for lupus anticoagulant, 
it is recommended to use low-dose molecular 
weight or unfractionated heparin during preg-
nancy because neither can cross the placenta [31].
Treatment for acute arterial or venous throm-
bosis consists of an initial course of unfraction-
ated or low molecular weight heparin followed 
by long-term treatment with warfarin to keep the 
international normalized ratio (INR) between 2.0 
and 3.0. Heparin-type drugs or, more recently, 




•  Baseline CBC, electrolytes, serum 
creatinine, liver enzymes, uric acid.
•  Fasting blood glucose, fasting lipid 
profile if at high risk, for example, if 
patient is nephritic or on steroids.
•  Normal antenatal checkup.
•  ANA, anti-dsDNA, anti-Ro and 
anti-La, antibody titers.
•  Complements levels (C3,C4,CH50).
•  Anticardiolipin antibodies, lupus 
anticoagulant, and β2 glycoprotein.
•  Urinalysis, 24-hour urine collection 




•  Baseline laboratory studies.
•  Anti-dsDNA.
•  Complement levels (C3, C4, CH50), 
urinalysis.
•  Obstetric ultrasound: Every 4 weeks 
from 20 weeks of gestation until 
delivery “to monitor fetal growth”.
•  Mother with positive anti-Ro and/or 
anti-La antibodies, serial fetal 




•  Repeated laboratory studies.
•  Urinalysis, 24-hour urine protein 
collection if proteinuria is present.
•  Weekly fetal non-stress test (NST) 
and/or biophysical profile (BPP) 
scoring from 28 weeks gestation.
•  Fetal Doppler ultrasonography to be 
done in presence of intrauterine 
growth restriction.
Each visit •  Careful blood pressure measurement.
•  Urine dipstick for proteinuria.
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one of the newer thrombin or factor Xa inhibitors 
can be used. For arterial thrombosis (stroke, 
myocardial infarction), addition of antiplatelet 
agents (low-dose aspirin, clopidogrel 75  mg) 
may be helpful, particularly if platelet hyperfunc-
tion is present [32]. Treatment for antiphospho-
lipid syndrome (APS) is detailed in the section of 
antiphospholipid syndrome.
B) Treatment of Active Lupus Activity
SLE is common in women in the childbearing 
age. Physicians should be competent in the safe 
use of medications at preconception, conception, 
and during lactation. They should also be compe-
tent in addressing the effects of certain drugs on 
infants. The Food and Drug Administration 
(FDA) has a classification system for pregnancy 
risk. The pharmacological management of SLE 
could be puzzling as it has an unpredictable clini-
cal course, with different organ system involve-
ment and the absence of clear understanding of 
disease pathogenesis [33].
As hypertensive disorders of pregnancy are 
the leading cause of maternal mortality and 
morbidity, the target blood pressure of less than 
140/90 is to be achieved. The safer antihyper-
tensive drugs in pregnancy based on the evi-
dence relate to parenteral hydralazine or 
labetalol and oral labetalol, nifedipine, or meth-
yldopa [34]. Treatment with low doses of aspi-
rin during pregnancy would be indicated in 
women with SLE, APS, hypertension, history 
of preeclampsia, and renal disease. Low dose of 
aspirin is safe throughout pregnancy. Women 
who took aspirin had a significantly lower risk 
of preterm delivery than those treated with pla-
cebo, but there is no significant difference in 
perinatal mortality [35].
NSAID should be used in the lowest effective 
dose and should be withdrawn before 8 weeks of 
expected date of delivery [36]. Nevertheless, 
because of the shared character of inhibition of 
prostaglandin synthesis, adverse effects like con-
striction of the ductus arteriosus in utero, renal 
dysfunction in the neonate, persistent pulmonary 
hypertension, increased maternal blood loss, and 
prolongation of pregnancy and labor are all pos-
sible when administered to pregnant patients.
Hydroxychloroquine (HCQ) is now consid-
ered an extremely essential therapeutic choice in 
the treatment of lupus. These drugs are highly 
effective for discoid lupus erythematosus (DLE) 
cutaneous lesions. HCQ improves photosensitive 
skin lesions and prevents lupus flares [37]. 
Studies have confirmed that HCQ can preclude 
renal and central nervous system lupus. It also 
exerts the role of a prophylactic agent against 
some of the major comorbidities of SLE and its 
treatment, namely, hyperlipidemia, diabetes mel-
litus, and thrombosis [38]. More recently, chloro-
quine and HCQ have been shown to improve 
survival in a cohort of 232 SLE patients after 
adjusting for patient characteristics and disease 
activity [39]. It has been recently suggested that 
HCQ may affect TLR9 (toll-like receptor 9) acti-
vation and IFN-alpha production. From all of 
these perspectives, this drug is now considered an 
extremely essential therapeutic choice in the 
management of lupus.
Steroids are used in pregnant SLE, and safety 
is not a major concern for their use in pregnancy 
based on the clinical indication. But one needs 
to look into the maternal morbidity it causes like 
maternal hypertension, gestational diabetes, 
infection, weight gain, acne, and proximal mus-
cle weakness. Consequently, close monitoring is 
essential with the use of the lowest possible 
dose of corticosteroid needed to control disease 
flare along with vitamin D and calcium supple-
ment [40].
There are few immunomodulator drugs that 
are used in SLE patients such as cyclophospha-
mide, methotrexate, mycophenolate mofetil, 
cyclosporine, azathioprine, and rituximab. The 
use of these drugs needs a thorough discussion 
with the pregnant lupus patient before starting 
them. As most of these drugs are classified by 
FDA as pregnancy risk category B and few as 
category X or D, they need to be shifted to aza-
thioprine which is found to be safe in pregnancy 
[41]. Plasmapheresis and intravenous immuno-
globulin (IVIG), the other two modalities of 
treatments used in lupus patients, are safe in 





SLE is not an indication for delivery by cesarean 
section, and one should allow for vaginal delivery 
as much as possible [42]. There should be a team 
approach to the pregnant women with SLE. This 
is to guarantee a safe vaginal delivery and allow 
performing a cesarean section for obstetric indi-
cations only. The indications for cesarean section 
are the same as in other conditions.
D) Puerperium
The optimum management does not stop with 
the birth of a healthy baby. Actually, postpar-
tum period should be addressed as high risk for 
pregnant lupus patients with several possible 
complications. The mother can suffer a lupus 
flare. Several studies have confirmed the post-
partum period is specifically high risk for 
increased lupus activity. A close surveillance in 
the first 4  weeks after delivery is thus war-
ranted, especially in patients with recent activ-
ity or with a previous history of severe disease. 
However, no specific prophylactic therapy, such 
as increasing the dose of steroid, is recom-
mended. Thromboembolic risk is also high dur-
ing the puerperium [43].
SLE is a chronic multisystem disease occur-
ring in young women in their childbearing age. 
Therefore, the collaboration of rheumatologists 
and obstetricians who are experienced in high- 
risk pregnancies management is essential for 
managing pregnant patients with SLE. The aim is 
to have successful outcomes for both the disease 
and the pregnancy. Some manifestations of nor-
mal pregnancy can be misinterpreted as signs of 
lupus activity. Thus, understanding of pregnancy 
and lupus interaction has resulted in better 
approaches of monitoring and treating this par-
ticular clinical condition.
17.5  Antiphospholipid Syndrome 
in Pregnancy
17.5.1  Introduction
APS or Hughes’ syndrome is a multisystem auto-
immune disorder with hypercoagulable state 
characterized by thrombosis (arterial, venous, or 
small blood vessels) or some obstetric complica-
tions (recurrent spontaneous abortions, stillbirth, 
preterm delivery, or severe preeclampsia) in the 
presence of antiphospholipid antibodies [44]. In 
50% of the cases, it is primary (PAPS), and in the 
rest, it is secondary (SAPS) to any autoimmune 
disease particularly SLE.
APS is the most common cause of acquired 
thrombophilia and is a known risk factor for 
the development of deep vein thrombosis 
(DVT) with or without pulmonary embolism, 
new strokes in individuals below the age of 50, 
and recurrent fetal loss [45]. APS is seen in 
0.5% in the general population and 1–5% in 
healthy women of childbearing age. The 
antiphospholipid antibodies are present in 
30–40% of SLE patients, and up to a third of 
these patients develop clinical manifestations 
of APS, especially venous or arterial thrombo-
ses. Majority of these patients (85–90% of the 
cases) are seen in the females in the reproduc-
tive age group [46].
17.5.2  Diagnostic Criteria
The 1999 Sapporo criteria is replaced by revised 
Sydney criteria in 2006. Since then many research 
work was done, but the criteria remain the same 
as in 2006 [47].
The clinical criteria include any of the 
followings:
 1. Vascular (arterial, venous, or small vessel) 
thrombosis excluding superficial thrombosis.
 2. Pregnancy morbidity.
 (a) ≥1 unexplained deaths of a morphologi-
cally normal fetus at or beyond ≥10 ges-
tational weeks (GW)
 (b) ≥1 premature births of a morphologically 
normal neonate ≤34 GW due to severe 
preeclampsia, eclampsia, or severe pla-
cental insufficiency
 (c) ≥3 unexplained consecutive spontaneous 
abortions ≤tenth GW (Excluding ana-




The laboratory criteria include the presence of 
any one of the three antibodies on two occasions 
at least 12 weeks apart. They are lupus anticoagu-
lant (LA), anticardiolipin antibodies (aCL-IgG or 
IgM), or anti-β2-glycoprotein 1 antibody 
(aβ2GP1-IgG or IgM). LA is to be tested 
2–3 weeks after discontinuation of warfarin.
One clinical criteria and one antibody test are 
required for diagnosis of APS.
The aPL should be in medium or high titers at 
least tested twice >12  weeks apart. The strict 
objective criteria laid down for each clinical cri-
terion should be fulfilled for the diagnosis of 
APS. aPLs are not only seen in APS (primary or 
secondary) but also in other diseases (syphilis, 
Lyme disease, CMV, EBV, HIV, HCV, and vari-
cella) or patients on phenothiazines or even in 
normal general population. Therefore, the tests 
for aPL need to be repeated and established that 
these aPLs are persistently elevated and in 
medium or high titers to separate the APS patients 
from other causes of elevated aPL [47].
17.5.3  Pathogenesis of APS
Thrombotic and non-thrombotic mechanisms 
(inflammatory complement mediated) were pro-
posed to explain the clinical manifestations in 
obstetric APS.  In the last decade, the non- 
thrombotic mechanism proved to be the most 
important one causing cellular activation of 
endothelial cells, neutrophils, monocytes, and 
platelets leading to upregulation of tissue factor 
(TF) ultimately activating the coagulation path-
way [48].
Obstetric APS complications are explained by 
three mechanisms:
17.5.3.1  Thrombosis (Thrombosis 
of Vessels and Placenta)
The main target antigens described in patients 
with APS include anti-β2GP1/cardiolipin, pro-
thrombin, and annexin V which accounts for 
more than 90% of antibody-binding activity. The 
other targeted antigens are thrombin, protein C, 
protein S, thrombomodulin, tissue plasminogen 
activator, kininogens, prekallikrein, factor VII/
VIIa, factor XI, factor XII, complement compo-
nent C4, heparan sulfate proteoglycan, heparin, 
and oxidized low-density lipoproteins [49].
Negatively charged phospholipids exposed on 
the outer side of cell membranes attract the main 
autoantigens. This is happening excessively 
under special circumstances such as injury, apop-
tosis (e.g., endothelial cell), or after activation 
(e.g., platelets) [49]. The aPL acts on the clotting 
regulatory proteins like annexin A5, prothrom-
bin, factor X, protein C, and plasmin, thereby 
promoting thrombosis [50]. Anti-β2GP1 disrupts 
the anticoagulant annexin A5 shield on tropho-
blast and endothelial cell monolayers causing a 
procoagulant state which subsequently leads to 
infarction and thrombosis of the placenta [49]. 
The activated platelets by aPL lead to increased 
expression of GPIIb/IIIa followed by synthesis of 
thromboxane A2 thereby causing a procoagulant 
state [51].
17.5.3.2  Defective Placentation
Defective placentation is either due to impair-
ment of invasion of trophoblast or inhibition of 
endometrial angiogenesis. Anti-β2GP1 is the 
most important antibody responsible for this 
mechanism. This antibody directly binds to the 
maternal decidua causing exposure of the cell 
membrane of the syncytiotrophoblast followed 
by injury, apoptosis, inhibition of proliferation, 
and formation of syncytia [52]. This results in 
defective secretion of growth factors and 
decreased production of human chorionic gonad-
otropin (HCG), thereby causing impaired inva-
sion of trophoblast [52]. The aPL binds to human 
endometrial epithelial cells (HEEC) on maternal 
side inhibiting angiogenesis [53]. Endometrial 
angiogenesis and decidualization are fundamen-
tal prerequisites for successful implantation and 
placental development.
17.5.3.3  Inflammation
A physiological development of pregnancy 
requires a fine regulation of the maternal immune 
response during implantation of embryo. Acute 
inflammatory events are recognizable causes of 
adverse pregnancy outcomes through proinflam-
matory mediators, such as complement, tumor 
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necrosis factor-alpha (TNF-alpha), and chemo-
kines [54].
The aPLs induce an inflammatory response 
leading to compliment activation (both classical 
and alternate pathways with excessive generation 
of C3a and C5a), activation of endothelial cells 
and monocytes, upgrading of TF and release of 
inflammatory mediators like intracellular adhe-
sion molecule (ICAM), vascular cell adhesion 
molecule (VCAM), selectins, TNF-alpha, and 
interleukins (ILs) resulting in poor pregnancy 
outcome [55]. A new probable mechanism of 
aPL-mediated fetal loss linking TF and comple-
ment activation has been recently explained. TF, 
best known as the primary cellular initiator of 
blood coagulation, also contributes to different 
biological processes. Although APS is a throm-
bophilic disorder, it needs a triggering factor 
popularly known as “second hit” (inflammation, 
tobacco, estrogens, etc.) to complete the cascade 
of thrombosis [56].
PAPS is a hereditary condition without a 
known cause and more often seen in patients 
with genetic marker HLA-DR7. SAPS is sec-
ondary to a known autoimmune disease, out of 
which the commonest is SLE.  Other diseases 
where it could also be seen are rheumatoid 
arthritis, scleroderma, Sjogren’s syndrome, 
Behcet’s disease, psoriatic arthritis, and tempo-
ral arteritis. It is also common in individuals 
with genetic markers: HLA-B8, HLA-DR2, and 
HLA-DR3, and it is also seen more in blacks, 
Hispanics, and Asians [57].
17.5.4  Treatment
17.5.4.1  Low-Dose ASA (LDA): Either 
Alone or Combined 
with Heparin
Pregnant women with aPL positivity should be 
stratified in order to administer the optimal treat-
ment. The recommended treatment of established 
APS in pregnancy generally consists of aspirin 
combined with heparin. LMWHs are at least as 
effective as unfractionated heparin and are safer 
[58]. The rationale of this combination is that 
aspirin may inhibit aPL-mediated hypercoagu-
lopathy in the intervillous space of the placenta. 
Heparin on the other hand may prevent aPLs 
from interfering with cytotrophoblast migration 
and promote blastocyst implantation in addition 
to prevention of venous thrombosis [59].
Prophylaxis and treatment of pregnancy with 
positive aPLs are shown in the flow chart 
(Fig. 17.1).
17.5.4.2  Aspirin/Heparin-Resistant 
APS (AHR-APS)
At least 20% of the patients do not respond to the 
recommended treatment, and there is no approved 
treatment for this group of patients. Nevertheless, 
since recurrence of thrombotic events occurs 
despite the therapy and thrombosis cannot 
account for all of the histopathological findings 
in placenta from women with APS, other sug-
gested mechanisms of reproductive impairment 
were expected to be involved [60] in obstetrical 
APS. The most essential mechanism for heparin 
to protect placenta in APS emerges to be its abil-
ity to prevent the binding of aPL antibodies to 
trophoblast cells. Recent studies showed that 
heparin also acts by inhibiting the endometrial 
angiogenesis and now several trials go on to dem-
onstrate the beneficial effects of neutralizing anti-
bodies by using synthetic peptides using β2GPI 
epitopes [61].
The AHR cases, which are approximately 
20%, need to be approached differently. If they 
are resistant to conventional treatment of aspirin 
and heparin (unfractionated), it is better to give 
LMWH, particularly tinzaparin, which is found 
to be more effective or switch to fondaparinux 
with vitamin D supplements. If still not effective, 
the next step is to add high-dose HCQ (400–
800  mg/day) or low-dose prednisolone (10–
15 mg/day). Further resistance is counteracted by 
adding prednisolone to HCQ. If it is found still to 
be ineffective, then add pentoxifylline or IVIG in 
order for the treatment to be more effective.
Apart from these drugs, there are others which 
are being tried in resistant cases of APS. These 
include the combination of antiplatelet agents 
like aspirin and dipyridamole (adenosine uptake 
inhibitor), rituximab, homocysteine, direct 
thrombin inhibitors (dabigatran), oral direct fac-
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tor Xa inhibitors (rivaroxaban or apixaban), dila-
cept (an adenosine uptake inhibitor, similar to 
dipyridamole) [62], defibrotide (a single-stranded 
DNA derivate), and histone deacetylase inhibi-
tors which act to inhibit endothelial or monocyte 
TF expression [63].
17.5.5  Conclusion
APS is a preventable and treatable thrombophilic 
multisystem autoimmune disorder causing two 
clinically important manifestations, namely, 
thrombosis and obstetric complications like 
recurrent consecutive spontaneous abortions, 
stillbirths, premature deliveries, and pregnancy- 
induced hypertension. It is a commonly prevalent 
disorder which needs high index of suspicion to 
diagnose early and offer prophylactic and thera-
peutic management. The cornerstone of manage-
ment is low-dose aspirin with or without heparin 
based on the popular theory of thrombosis. 
Recently inflammatory theory is gaining more 
importance, and accordingly management by 
drugs other than aspirin with heparin seems to 
play a prominent role in the future. However, this 
requires well-designed double-blind placebo- 
controlled randomized trials.
17.6  Neonatal Lupus 
Erythematosus
17.6.1  Introduction
Neonatal lupus erythematosus (NLE) or neonatal 
lupus syndrome is a rare syndrome seen in 1–2% 
of neonates with autoantibodies to SSA/Ro, SSB/
La, and/or U1 RNP passively transferred trans-
placentally from the mother. Such a mother is 
either asymptomatic or having manifestations of 
SS, SLE, or other systemic rheumatic disease. 
NLE is distinguished by cutaneous, cardiac, or 
rarely both clinical manifestations.
Pregnant lupus patient
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Fig. 17.1 Flow Chart 
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17.6.2  Pathogenesis and Clinical 
Features
The skin manifestation is appreciated at least in 
30% of these patients. This may present in the 
form of periorbital annular erythematous plaques 
later spreading to other areas of the face, scalp, 
trunk, and extremities. It is non-scarring and non- 
atrophic and usually transient lasting for days to 
months. The cardiac manifestation is seen in up 
to 60% of the patients. It is mainly in the form of 
complete congenital heart block (CHB). This is 
irreversible and associated with cardiomyopathy 
in at least 10% of the cases. CHB is also associ-
ated with higher morbidity and mortality. Almost 
all the patients with cardiac lupus require perma-
nent pacemaker. The recurrence rate of NLE is as 
much as 25% in the following pregnancies. There 
has been better understanding of etiopathogene-
sis of the disease in the recent past due to rapid 
development in field of medicine [64].
NLE is presumed to result from transplacental 
passage of maternal anti-SSA/Ro and/or anti- 
SSB/La autoantibodies. These autoantibodies 
enter the myocardial cell resulting in exaggerated 
apoptosis. This leads to expression of these anti-
bodies on the surface of the cardiocyte. It is pos-
tulated that resident cardiocyte participates in 
physiologic clearance of apoptotic cells. 
However, clearance is now inhibited by opso-
nization through these maternal autoantibodies. 
This results in accumulation of these apoptotic 
cells promoting inflammation and stimulating 
macrophages. Consequently, these macrophages 
secrete cytokines mainly transforming growth 
factor-beta (TGF-β) that stimulate fibroblast pro-
liferation. Ultimately, this leads to fibrosis of the 
conduction system (causing CHB) or myocar-
dium (leading to cardiomyopathy or endocardial 
fibroelastosis) or both [65, 66].
Presentation in the neonate could be in the 
form of bradycardia, intermittent cannon waves 
in the neck, varying intensity of first heart sound, 
intermittent gallops, and murmurs. The newborn 
is at greatest risk with a rapid atrial rate, often 
150 beats/min or faster, and a ventricular rate less 
than 50 beats/min with junctional or atrioventric-
ular (AV) nodal escape or ectopic rhythm. First- 
or second-degree heart block found in infants at 
birth can progress to CHB [67]. It may take just 
1 week for a neonate to develop CHB from a nor-
mal PR interval. Therefore, weekly fetal echocar-
diography is essential between 16 and 24 weeks. 
The diagnosis of NLE is made when a fetus or 
newborn of a mother with anti-SSA/Ro and/or 
anti-SSB/La or anti-RNP antibodies develops 
heart block and/or the typical rash or hepatic or 
hematologic manifestations in the absence of 
other causes.
Women who test positive for SSA/Ro and 
SSB/La autoantibodies may benefit from more 
intense evaluation for fetal heart block. This 
requires frequent fetal echocardiographic testing 
weekly from the 16th through the 26th week of 
pregnancy and then every other week until 
32  weeks. The most vulnerable period for the 
fetus is during the period from 18 to 24 weeks 
gestation. Normal sinus rhythm can progress to 
complete block in 7  days during this high-risk 
period. New onset heart block is less likely from 
26 to 30  weeks, and it rarely develops after 
30 weeks of pregnancy. Fetoscope auscultation to 
detect heart blocks by detecting bradycardia, bio-
physical profile scoring, and non-stress testing 
can also be used to diagnose CHB [68].
17.6.3  Treatment of Congenital 
Heart Block
The ultimate treatment for CHB is prevention as 
once it is diagnosed, medical treatment seems to 
be less favorable. Testing for culprit antibodies is 
essential prior to initiating therapy for a pre-
sumed case of neonatal cardiac lupus (NCL) as 
there are cases of heart block not associated with 
anti-SSA/Ro and SSB/La antibodies. The inci-
dence of CHB is only 2% in the offspring of 
unselected anti-Ro antibody positive mothers. 
Therefore, the preventative therapy cannot be 
recommended for this group. Yet, in women with 
a previous child with CHB, the risk is greater, in 
the range of 17–19%. Graham Hughes has sug-
gested that in this group of patients, maternal 
administration of intravenous immunoglobulins 
(IVIG) may cut the risk of recurrences. Another 
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possible strategy to avoid recurrence in subse-
quent pregnancies is immune suppression with 
fluorinated steroids, which cross the placenta. 
However, the toxicity of these agents prevents 
their use as a preventative therapy [69]. A case- 
control study proposed that using HCQ, a  toll- like 
receptor (TLR) inhibitor may decrease the risk of 
NCL related to anti-SSA/SSB antibodies [67].
Treatment of different degrees of heart blocks 
is variable. Complete heart block is permanent, 
and nothing could reverse it even with glucocor-
ticoid therapy [70]. On the other hand, second- 
degree heart block may be reversible. 
Unfortunately, it may progress to complete heart 
block despite therapy [71]. The clinical conse-
quence of first-degree heart block is uncertain, 
since development from first-degree block to 
more advanced heart block in untreated fetuses 
has not been reported.
Fluorinated glucocorticoids such as dexameth-
asone and betamethasone, which are not inacti-
vated by placental 11-beta hydroxysteroid 
dehydrogenase, may suppress the associated pleu-
ropericardial effusion or hydrops and may improve 
outcomes. Fluorinated glucocorticoids are also 
considered for signs of a more global cardiomy-
opathy. Maternal dexamethasone in conjunction 
with transplacental β-adrenergic stimulation for 
bradycardia in fetus with HR of <55 beats/mt was 
reported to be effective in CHB [67].
Many children with CHB (33–53%) require 
pacing as newborns. There is a long-term risk of 
sudden death. From this perspective, the majority 
of patients are paced by the time they reach adult 
life [72]. Neonatal cutaneous lupus requires 
mainly avoidance of sun exposure and use of sun-
block and hydrocortisone cream. There is usually 
no need for systemic steroids in these patients. 
Systemic antimalarials, on the other hand, are not 
recommended due to slow onset of action in a 
transient illness and due to its potential toxicity in 
infants [73].
17.6.4  Conclusion
NLE is due to passive transplacental transfer of 
maternal IgG autoantibodies (SSA/Ro, SSB/La 
or U1RNP) to the fetus. It is seen in 1–2% of 
these neonates. It can cause transient and self- 
limiting cutaneous lupus that usually does not 
require treatment. It can also manifest as CHB 
which is usually permanent requiring pacemaker 
in most of the patients. They are susceptible for 
cardiomyopathy either as a direct effect of the 
disease or due to right ventricular pacing which 
also adds to mortality at least by 10%. The diag-
nosis is made by identifying autoantibodies to 
SSA or SSB or U1 RNP in the mother. The diag-
nosis of CHB is made mainly in utero by periodic 
fetal echocardiography from 16 weeks onwards.
The outcome of heart blocks in general is not 
a favorable one. The mortality is considered high 
among children with CHB detected in utero than 
those detected after birth. The mortality is high 
mainly in the first year and particularly more in 
the first 3  months of life. Many aspects of the 
pathogenic mechanisms are discovered, but more 
research is needed. This is to help prevent this 
disease and provide better therapies for these 
patients.
17.7  Rheumatoid Arthritis (RA) 
and Pregnancy
17.7.1  Introduction
Rheumatoid arthritis (RA) is an autoimmune dis-
ease that is favorably influenced by pregnancy 
but classically flares after delivery [74]. The 
restructuring effect of pregnancy on RA has been 
well-known since 1938. Improvement of RA 
symptoms usually occurs in the first trimester 
and probably increases as pregnancy advances.
17.7.2  Effect of Pregnancy on RA
Pregnancy and postpartum period associated 
with changes in sex hormone levels, glycosyl-
ation of immunoglobulins, and cortisol level. 
One of the important immunological modifica-
tions during pregnancy is the Th1/Th2 shift. This 
is happening because of the progressive increase 
of progesterone and estrogens during pregnancy. 
H. Al-Osaimi and A. Althubiti
397
They reach their peak level in the third trimester 
of gestation. At high levels, estrogens seem 
mainly to suppress Th1 cytokine and stimulate 
Th2-mediated immunological responses as well 
as antibody production. For this reason, 
 Th1- mediated diseases, like RA, tend to improve 
[75]. Also changes in the percentage of IgG 
molecules lacking the terminal galactose units 
in the oligosaccharide chains attached to H2 
regions have been tested as a probable explana-
tion for ameliorating of RA during pregnancy. 
The percentage of agalactosyl IgG (Gal-o) var-
ies with the age in normal healthy individuals. 
However, in patients with RA, Gal-o levels 
exceed normal values [76]. The levels of the 
glucocorticoids closely follow with the clinical 
improvement of RA in pregnancy. There is a 
progressive rise in total plasma cortisol levels 
with advancing gestation. The plasma concen-
tration of free/active form of cortisol almost 
doubles in pregnant females as compared to the 
non-pregnant ones [77].
17.7.3  Effects of RA on Pregnancy
Women with well-controlled RA have a preg-
nancy outcome that is equivalent to the general 
obstetric population. Furthermore, disease 
activity and prednisone use during pregnancy 
were both adversely associated with birth 
weight. Only higher disease activity was associ-
ated with a lower birth weight, whereas the 
effect of prednisone on birth weight was medi-
ated by shortening of the gestational age at 
delivery [1, 78]. The short- and long-term desir-
ability of pregnancy needs to be always consid-
ered in women with RA in their reproductive 
age. This is extremely vital while choosing dis-
ease-modifying antirheumatic drugs 
(DMARDs). Educating both women and men 
about appropriate contraception is a key to 
avoiding unplanned pregnancies while taking a 
DMARD that is teratogenic and/or has unknown 
safety profile during pregnancy. A strategy for 
RA management during pregnancy is necessary 
as well for the health of the mother to reduce 
possible toxicity to the fetus [79].
The safe strategy to be used in managing RA 
in those planning pregnancy is as follows:
 (a) Patients in remission—Review and adjust the 
medications compatible with pregnancy.
 (b) Patients with active disease—Delay preg-
nancy till improvement is achieved with ade-
quate treatment.
In RA, antepartum evaluation should include 
in addition to detailed history and musculoskele-
tal examination a careful examination of upper 
airway and cervical spine. A lateral cervical spine 
radiograph should be obtained in case a pregnant 
patient is affected by severe erosive disease or 
presence of neck symptoms or duration of the 
disease for more than 10 years. This film should 
be with flexed neck to exclude atlanto-axial ante-
rior subluxation [80]. Extreme caution should be 
taken while managing the airway of these patients 
for any surgical intervention.
17.8  Sjogren’s Syndrome (SS) 
and Pregnancy
Sjogren’s syndrome (SS) is a chronic autoim-
mune inflammatory disease that can present 
either alone, primary Sjogren’s syndrome (PSS), 
or in the context of an underlying connective tis-
sue disease (secondary SS). It may occur at any 
age but mainly affects women in the fourth 
decade of life with a female-to-male ratio of 9:1 
[32]. It is important to notice that the systemic 
form may be associated with other autoimmune 
disease, for example, RA in 30% of cases, SLE in 
10%, and scleroderma in 1% autoimmune thy-
roid disease, chronic hepatitis, or lymphatic sys-
tem disorders. Furthermore, systemic SS is 
characterized by anti-Ro/SSA 70–80%, and 
afflicted pregnancies may be exposed to high risk 
of CHB, cardiomyopathy, and neonatal lupus. 
These risks in some reports have been higher 
than in patients with SLE [81].
PSS can occur in all age groups, including 
children. Pregnancy complications due to the 
presence of anti-Ro/SSA and anti-La/SSB auto-
antibodies in the maternal serum are well recog-
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nized as NLE and CHB. Reports on pregnancy 
outcomes beyond these two disorders are rare in 
PSS in contrast to the situation in SLE and 
APS.  Pregnancy outcome in PSS has not been 
thoroughly studied but has in overall not been 
considered to be associated with adverse fetal 
outcome [82]. Data on pregnancy outcome in 
PSS are few and conflicting. In the past decades, 
the paucity of reports maybe related to the fact 
that PSS doesn’t usually become clinically appar-
ent until the fourth decade of life. However, the 
advanced maternal age of the first pregnancy has 
been discovered recently to explain the increased 
impact on pregnancies complicated by PSS [83].
17.9  Systemic Sclerosis (SSc) 
and Pregnancy
Systemic sclerosis (SSc) is a chronic autoim-
mune disorder with approximate female-to-male 
ratio of 5:1. Reports of pregnancies in SSc are 
rare owing to the low prevalence of the disease. 
The onset of the disease is usually after the fourth 
decade of life [84]. Most physicians concur that 
SSc women have a high probability of successful 
pregnancy if careful planning, close monitoring, 
and appropriate therapy are implemented. 
Moreover, retrospective case-control studies 
showed less ominous outcomes [85]. Still, an 
increased occurrence of preterm births and small 
full-term infants, compared to the controls, was 
noticed. Symptoms related to SSc particularly 
Raynaud’s phenomenon improves during preg-
nancy, but esophageal reflux worsens. After preg-
nancy, some women with diffuse SSc had 
increased skin thickening [85].
The exertional dyspnea is particularly worse 
in the third trimester as the uterus increases in 
size. It is essential to rule out pulmonary hyper-
tension during preconception counseling [86]. 
The extreme danger in pregnant SSc women is 
the occurrence of renal crisis, secondary to acute 
onset severe hypertension that can be fatal for 
both mother and child. It can be puzzled with pre-
eclampsia and HELLP syndrome. However, in 
contrast to preeclampsia, delivery of the fetus 
does not affect the hypertension or renal dysfunc-
tion. Elevation of blood pressure in these patients, 
even mild, should be considered possibly serious, 
yet pregnancy itself does not appear to increase 
the risk of renal crisis.
Renal crisis is more prevalent in patients with 
early diffuse SSc (within 5 years from symptom 
onset). Risk factors include the presence of anti- 
topoisomerase, anti-RNA polymerase III anti-
bodies, and exposure to high doses of 
corticosteroids. Preeclampsia rate does not seem 
to be increased in SSc patients [85]. Angiotensin- 
converting enzyme inhibitors (ACEI) are a life- 
saving treatment in hypertensive renal crisis in 
patients with SSc despite their association with 
congenital malformations and kidney dysfunc-
tion in the infant [86].
History of a renal crisis during a previous 
pregnancy should delay the following pregnancy 
until the disease has been stabilized. This usually 
takes around 3–5 years from the onset of symp-
toms. These women are usually treated with nife-
dipine to maintain good control of blood pressure. 
Delivery is usually recommended if appropriate 
antihypertensives fail. ACEI may be initiated 
during pregnancy in severe cases after appropri-
ate counseling about the risk of congenital abnor-
malities [86]. High rate of complications during 
pregnancy is seen in women with history of sig-
nificant interstitial lung disease, scleroderma 
renal crisis, early diffuse SSc with rapid onset, or 
moderate-severe pulmonary arterial hypertension 
(PAH).
If a patient with SSc wishes to continue 
with pregnancy after applicable counseling of 
risks, aggressive monitoring and co-manage-
ment with experts in renal and pulmonary dis-
ease are mandatory. Medications such as ACEI 
and prostaglandins which conduct high risk for 
congenital malformations with higher inci-
dence of other fetal toxicities need to be con-
sidered. The benefits to both mother and fetus 
may overshadow known risks of antenatal 
exposure [87]. Previous events of renal crisis 
are not a complete contraindication for future 
pregnancy. It is recommended that a woman 
postpone several years until her disease is sta-
ble before trying to conceive. A trial without 
ACEI prior to pregnancy is suggested to deter-
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mine if blood pressure can be effectively con-
trolled with substitute antihypertensive 
medications [88].
Labor and delivery are susceptible period in 
these cases. Some patients may need prolonged 
observation in the hospital following delivery to 
monitor for acute cardiovascular collapse in 
case of PAH [87]. In SSc, a thorough search 
should be conducted for systemic dysfunction, 
namely, renal disease, systemic hypertension, 
PAH, cardiac dysfunction, and fetal distress. 
Close surveillance should be performed for arte-
rial pulses, peripheral venous access, extent of 
Raynaud’s involvement, and special positioning 
needs [80].
17.10  Vasculitis and Pregnancy
17.10.1  Introduction
There are profound immune and endocrine 
changes which happen during pregnancy. The 
physiological increase of cortisol, progesterone, 
estradiol, and testosterone during the third tri-
mester of pregnancy seems to lead to Th2 cyto-
kine polarization both at systemic level and at the 
feto-maternal interface.
The following issues should be taken into con-
sideration while counseling the patient with vas-
culitis for pregnancy:
 (a) Patients should receive a mode of contracep-
tion at least while receiving high dose of 
cytotoxic medications.
 (b) Pregnancies should be planned when the dis-
ease is in remission.
 (c) Strict monitoring is recommended for 
patients during gestation and postpartum 
periods by multidisciplinary team.
 (d) In case of disease relapse on adequate treat-
ment, aggressive management should be 
recommended.
 (e) Pregnancy complicated by the onset of vas-
culitis particularly has worse prognosis.
In patients with systemic vasculitis, the risk of 
thromboembolic events is increased [24].
17.10.2  Large Vessel Vasculitis
17.10.2.1  Behcet’s Disease (BD)
Systemic vasculitides are infrequent diseases 
characterized by an abundant variety of symp-
toms, ranging from mild to life-threatening mani-
festations. Pregnancy is more frequent in 
vasculitis that have onset at younger age and 
affect the female gender such as Takayasu’s arte-
ritis (TA) and Behcet’s disease (BD) [89, 90]. BD 
is an inflammatory disorder of unknown etiology 
that affects mostly young adults. It involves the 
oral and genital mucosae as well as the eyes, 
joints, and central nervous system (CNS). 
Furthermore, arterial and/or venous thrombosis 
also may occur during the course of BD. This has 
been connected with considerably increased mor-
bidity. Limited data are available concerning the 
impact of pregnancy on the course of BD 
(Table 17.4) [90].
Although BD appears to improve during 
pregnancy, disease flare consists mainly of oral 
and genital ulcerations. Mucocutaneous ulcer-
ations seem to predominate during the second 
Table 17.4 Effect of pregnancy on the course of sys-
temic vasculitis [90]









PAN Frequent flares Rare flares 
(25%)
MPA Risk of maternal death Frequent 
flares 
(50%)





TA High risk of maternal 
morbidity and fatality in 
patients with severe aortic 




BD Frequent improvement (50%) Rare flares 
(25%)
(GPA granulomatous polyangiitis, PAN polyarteritis 
nodosa, MPA microscopic polyangiitis, EGPA eosino-
philic granulomatous with polyangiitis, TA Takayasu’s 
arteritis, BD Behcet’s disease)
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and third trimesters of pregnancy. Life-
threatening complications such as thrombosis or 
CNS lesions can happen as well. The postpar-
tum period is still a vulnerable period. The 
global risk of obstetric complications in patients 
with BD is similar to that in the overall popula-
tion. However, the risk of miscarriage seems to 
be increased in patients with a history of vascu-
lar involvement. The use of colchicine is safe in 
pregnant women with BD and could even reduce 
the risk of disease flares. Other medications like 
azathioprine and glucocorticoids can also be 
used during pregnancy, seemingly without an 
increased risk of complications. Pregnancy is 
consequently a viable option for women who 
have BD [91].
BD activity may vary between pregnancies in 
the same patient. It has to be noted that remission 
and exacerbation both have been reported during 
pregnancy. Relapses occur most frequently in the 
first trimester. They represent primarily mucocu-
taneous findings with ocular and thrombotic 
complications being rare. Active disease does not 
seem to worsen maternal or fetal outcome. 
Maternal BD has not been linked to an increased 
rate of miscarriage, pre-maturity, fetal anomalies, 
or neonatal BD.  Pregnant patients who suffer 
from genital ulcers at the time of delivery may 
benefit from cesarean section. Patients should 
continue to be monitored postpartum as the dis-
ease might flare according to several reports [92]. 
Pregnancy is a hypercoagulable state; therefore 
anticoagulation is recommended in women with 
prior history of thrombosis.
Most infants born to mothers with BD are 
generally healthy. Reports of neonatal BD have 
appeared infrequently in the literature. While 
some have proposed that the mechanism of dis-
ease of neonatal BD is similar to that of NLE, 
there is no evidence of any transplacental transfer 
or maternal antibodies [93]. Most of the reports 
of neonatal BD have portrayed a transient disease 
with spontaneous resolution [93].
17.10.2.2  Takayasu’s Arteritis
TA is a granulomatous vasculitis that affects large 
vessels such as the aorta, its major branches, and 
pulmonary arteries. TA manifests at a younger 
age, typically affecting the women of childbear-
ing age. Fertility appears not to be affected. 
Neither the fetal mortality nor spontaneous abor-
tion rates are increased in TA, but the incidence 
of low birth weight is increased. Maternal com-
plications include accelerated hypertension, heart 
failure, and stroke [94].
It is obligatory to tightly control blood pres-
sure (BP) using both noninvasive (BP measure-
ment at upper and lower limbs and Doppler flow 
if pulses are not palpable) and invasive proce-
dures (intra-arterial monitoring through arterial 
cannulation). This is mandated particularly when 
BP values cannot be accurately measured due to 
multiple vascular stenosis. In order to prevent BP 
increase during vaginal pushing, spinal analgesia 
should be given, and BP monitoring should be 
continued at least 24–48 h after delivery. This is 
due to the hemodynamic changes that occur in 
the postpartum period which might promote aor-
tic dissection.
Aortic valvular disease has been reported as a 
risk factor for maternal morbidity in patient with 
TA.  The baseline cardiac function should be 
assessed at the onset of pregnancy and monitored 
through pregnancy [95]. In postpartum period, 
antibiotics should be given to prevent bacterial 
endocarditis in patients with aortic insufficiency 
and/or luminal narrowing of the aorta and its 
branches [89].
The indications for cesarean section in TA are 
mainly for [19]:
 1. Obstetrical reasons.
 2. Mild disease but with elevated systolic BP 
despite adequate medical treatment at the time 
of labor.
 3. Presence of one or more complications like 
retinopathy, secondary hypertension, aortic 
insufficiency, aortic/arterial aneurysm, and 
non-recordable BP in both arms.
 4. Severe complications of TA like heart failure 
or dysrhythmias.
Disease relapse during pregnancy are generally 
treated with prednisone 1 mg/kg/day until the dis-
ease control is obtained. Then prednisone can be 
tapered to the lowest possible effective dose. In 
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refractory cases, the use of azathioprine is recom-
mended. Hypertension has to be managed very 
aggressively with ∝  −  methyldopa, Ca-channel 
blocker, or hydralazine. ACEIs are contraindicated 
because of their high incidence of fetal toxicity [92].
17.10.3  Medium Vessels Vasculitis
17.10.3.1  Polyarteritis Nodosa (PAN)
PAN is a disorder characterized by necrotizing 
inflammation of medium size or small arteries. In 
patients with PAN, prevalent manifestations are 
general symptoms like malaise, fever and fatigue, 
musculoskeletal pain and arthralgias, mucocuta-
neous findings, and gastrointestinal manifesta-
tions [95]. Peripheral neuropathy especially 
mononeuritis multiplex is common as well [95]. 
Approximately 30% cases of PAN are associated 
with co-infection with hepatitis B.  Like other 
forms of vasculitis, PAN can be associated with 
hypertension, abdominal pain, and proteinuria 
simulating some of the more common complica-
tions of pregnancy [90].
Some patients have a medium vessel vasculitis 
that is restricted to the skin. This form of vasculi-
tis, known as cutaneous PAN, generally does not 
evolve to the systemic form [90]. Worsening of a 
mild form of vasculitis in a pregnant patient may 
be treated effectively with glucocorticoids alone. 
Use of cyclophosphamide is required in the pres-
ence of life-threatening manifestations particu-
larly bowel infarction, CNS, and/or cardiac 
involvement [95].
17.10.4  Small Vessels Vasculitis
17.10.4.1  Granulomatosis 
with Polyangiitis (GPA) 
(Wegner’s Granulomatosis)
Pregnancies in women with GPA are uncom-
monly observed. The disease peaks after the 
age of 40, and it affects mainly the upper respi-
ratory tract, the lungs, and the kidneys. The 
relapse or worsening of renal involvement in 
the late pregnancy can be difficult to differenti-
ate from preeclampsia. There are few useful 
parameters in this regard with active urine sedi-
ment indicating GPA nephritis [96]. Premature 
delivery is a common complication of preg-
nancy in patients with GPA, particularly in 
those with active disease during gestation. In 
case of insufficient response to corticosteroids, 
azathioprine can be used. Cyclophosphamide 
may be considered for life- threatening manifes-
tations occurring during the second or third tri-
mester of pregnancy [96].




Eosinophilic granulomatosis with polyangiitis 
(EGPA) formerly known as Churg-Strauss syn-
drome is a disorder characterized by pulmonary 
and systemic small vessel vasculitis, extravascu-
lar granulomas, and hypereosinophilia occurring 
in patients with asthma and allergic rhinitis [96]. 
Pregnancy is not a common event in EGPA due to 
various reasons such as the rarity of the disease, 
the peak incidence of the disease around the fifth 
decade, and male preponderance [97].
EGPA relapse was reported in 50% of women 
who conceived, while the disease was in remis-
sion. The commonly observed manifestations 
during the relapse were worsening of asthma, 
mononeuritis multiplex, and skin rash. Patients 
with disease onset during pregnancy are consid-
ered as unfortunate as they had a very poor prog-
nosis. Cases of fulminant EGPA associated with 
pregnancy may be caused by decrease or discon-
tinuation of the medications in use. This is in 
addition to the loss of lung capacity associated 
with pregnancy, which may further exacerbate 
the existing bronchospasm [90]. Treatment of 
EGPA relapses during pregnancy consists of the 
use of prednisone with adjusted doses according 
to the severity of disease manifestations. In 
EGPA patients, special care should be given to 




17.11  Polymyositis (PM)/
Dermatomyositis (DM) 
and Pregnancy
Women in reproductive age group are rarely 
affected by PM/DM as the onset of the disease is 
over the age of 45 years. Data for such diseases 
are extremely limited. Patients are encouraged to 
achieve and maintain stable disease prior to con-
ception. It is recommended obviously to have the 
disease totally quiescent as active muscle weak-
ness adversely affects both pregnancy and labor. 
The typical guidelines applied while using medi-
cations during pregnancy in other rheumatic dis-
eases should be applied again in these diseases. 
Medications that are contraindicated in preg-
nancy would need to be substituted prior to con-
ception [1].
The fetal prognosis matches activity of the 
maternal disease. In patients with preexisting 
quiescent disease, little clear risk to the mother 
or fetus is observed. This is in contrast to new 
onset of disease or exacerbation during preg-
nancy for which a significantly worse outcome 
is noted [98]. Treatment with corticosteroids, 
azathioprine, and intravenous immunoglobulin 
may be suitable for active myositis during preg-
nancy. It is observed that patients with PM are 
sensitive to non-depolarizing muscle relaxants 
and the use for their antagonist drugs may cause 
muscle weakness and severe arrhythmias. 
Steroid- induced myopathy may lead to an 
increased sensitivity to neuromuscular blocking 
drugs and an unpredictable response. All these 
are important clinical vignettes that should be 
taken care of while dealing with these patients 
particularly during anesthesia. Other important 
aspects to be considered in the anesthetic man-
agement are respiratory insufficiency, risk of 
aspiration, arrhythmias, cardiac failure, and 
hyperkalemia [99].
Disease activity and underlying cardiopulmo-
nary involvement should be thoroughly evaluated 
in affected patients with PM/DM. In the presence 
of muscle weakness, spirometry should be done 
to evaluate respiratory muscles involvement. 
Chronic aspiration due to pharyngeal weakness 
may lead to pulmonary diffusion deficits. An 
ECG should be done to exclude conduction 
abnormalities and arrhythmias [80]. 
Echocardiogram and full cardiac evaluation may 
be required accordingly.
17.12  Spondyloarthritis 
and Pregnancy
Ankylosing spondylitis (AS) is a chronic, pro-
gressive autoimmune disease, mainly involving 
sacroiliac joint, vertebral column, and peripheral 
joints. It is also complicated with some other 
manifestations including uveitis and the aortic 
valve lesions in the heart [100, 101]. Pregnancy 
may occur in patients with this disease as the 
peak incidence of AS is in the 25–34 years of age 
group [102]. Pregnancy has been observed to sig-
nificantly improve peripheral arthritis and uveitis 
in most patients, but there is deterioration in 25% 
of patients with predominantly axial disease in 
pregnancy [100]. As with other rheumatic dis-
ease, there is an increased risk of flares in post-
partum period [100].
Clinicians who are taking care of a pregnant 
patient with this disease need to be concerned for 
few issues. These include the method of delivery, 
the optimal choice of labor analgesia, and the 
type of anesthesia to be provided in the event of 
cesarean section. Possible pelvic joint ankylosis 
associated with AS can interfere with a normal 
spontaneous vaginal delivery. The potential car-
diac involvement in AS may also have an influ-
ence on the mode of delivery. Although aortic 
regurgitation correlated with AS is often asymp-
tomatic, even trivial valvular disease may cause 
decompensation in the pregnant patient. Other 
cardiac involvements in AS which have been 
reported include proximal aortitis, mitral 
 regurgitation, and conduction defects. 
Preanesthetic evaluation should include a careful 
physical examination of the chest and cardiovas-
cular systems as well as a baseline electrocardio-
gram. Transthoracic echocardiography may be 
used to evaluate the abnormal findings of the 
heart in the clinical examination [90]. However, it 
might be considered as a baseline for patients 
with long- lasting disease.
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Pulmonary involvement in AS have also been 
described. A restrictive pattern of lung function is 
seen due to costochondral rigidity and flexion 
deformity of the thoracic spine.
Placement of epidural anesthesia in these 
patients may be technically difficult. This could 
be related to calcification of interspinous liga-
ments, formation of bony bridges between the 
vertebrae, or ankylosis of the vertebral column 
with restriction in lumbar flexion. General anes-
thesia is sporadically necessary in patients with 
AS.  Involvement of the cervical and temporo-
mandibular joint or cricoarytenoid arthritis may 
cause obstacles with tracheal intubation. 
Moreover, loss of normal neck flexibility with 
increasing osteoporosis predisposes the spine to 
fracture, even with minor trauma. An awake 
fiberoptic intubation should be considered when-
ever a difficult intubation is anticipated or anky-
losis of the spine is expected [102].
17.13  Conclusion
As rheumatic diseases affect women during the 
childbearing age, every pregnancy for those 
patients should be considered as high risk and 
should be strictly monitored by meticulous ante-
natal evaluation. It is essential to know the effect 
of each disease on pregnancy and vice versa. 
Therefore, the physician should focus on the pre- 
pregnancy planning, fertility, medications use, 
and fetal complications and need to continue the 
care through the postpartum and lactation 
periods.
Most of the complications of these diseases 
during pregnancy can be prevented. This can be 
achieved by carefully planning the pregnancy 
during the inactive phase of the disease and 
timely discontinuation of harmful medications 
used in these disorders. However, pregnancy can 
still be threatened by active disease, presence of 
autoantibodies, and severe affection of major 
organ involvement by the disease. Therefore, the 
management of these rheumatic diseases in preg-
nancy needs a multidisciplinary approach by the 
rheumatologist, obstetrician, neonatologist, and 
at times other specialists (nephrologist, hematol-
ogist, etc.). This is to support these unfortunate 
patients from all dimensions to have a healthy 
child [103].
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18.1  Introduction
The aim of this chapter is to present a simple 
approach to the assessment of patients with dif-
ferent rheumatologic diseases, especially rheu-
matoid arthritis (RA), before undergoing 
orthopedic surgery. Perioperative assessment 
confirms an early diagnosis of the patient’s medi-
cal condition and comorbidities, overall health, 
and the assessment of the risk factors associated 
with the proposed interventions. Perioperative 
assessment allows for proper postoperative man-
agement of complications. It can also aid in the 
management of high-risk drugs used by rheuma-
tologic patients such as disease-modifying anti-
rheumatic drugs (DMARD), antiplatelets, and 
corticosteroids. The assessment also supports 
postoperative plans and patient education [1–3].
18.1.1  Objectives
 1. To present a comprehensive preoperative 
medical evaluation for patients with rheuma-
tologic disorders before undergoing orthope-
dic surgery.
 2. To clarify the assessment of specific clinical 
issues in patients with RA and systemic lupus 
erythematosus (SLE).
 3. To present the perioperative management of 
medications for patients with rheumatologic 
disorders before undergoing orthopedic 
surgery.
 4. To clarify how to follow-up and educate the 
patient postoperatively.
18.2  The Preoperative Medical 
Evaluation
18.2.1  History Taking
Detailed information should be obtained. There 
are several components of the history that should 
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be outlined. These include the patient’s age, dura-
tion of rheumatologic disorder, current functional 
level, specific joint involvement with arthritis, 
any extra-articular manifestations of the disease, 
current medications including DMARDs and 
previous use of steroids, previous complications 
associated with surgery, and any comorbidities 
like hypertension and/or diabetes mellitus.
18.2.2  Physical Examination
Obviously, for any rheumatic disease patients, 
there should be specific focus on the musculo-
skeletal system during the physical examination. 
This should include posture, location and pattern 
of joint involvement, gait, and range of motion 
(ROM) of the examined joints. Furthermore, 
underlying disorder must be identified. The skin 
should also be assessed for any manifestations 
suggestive of an underlying rheumatologic dis-
eases that may impact skin integrity.
18.2.3  Investigations
The following tests may be considered along 
with routine tests:
• A complete blood count for an examination of 
possible drug related hematologic side effects. 
This may include anemia due to gastric or 
duodenal irritation, leukopenia, and/or pancy-
topenia from massive bone marrow suppres-
sion. This is essential in situations where 
significant blood loss is expected, such as total 
hip replacements.
• A complete renal profile, liver enzymes, and 
liver function tests to screen for DMARDs 
side effects.
• A urinalysis and urine culture should be 
obtained. It is important to rule out urinary 
tract infections in patients undergoing total 
joint arthroplasty [4, 5].
• A 12-lead electrocardiogram (ECG) is neces-
sary as a baseline cardiovascular evaluation 
for patients undergoing surgeries. ECG is rec-
ommended in men over the age 40 and women 
over 50 having major surgery. This is essential 
even in the absence of history or physical 
exam findings.
• Chest x-ray is necessary as a baseline for pul-
monary evaluation. It is indicated for patients 
over the age 50 undergoing major joint or 
spine surgery. This is even in the absence of 
symptoms and/or signs suggestive of active 
pulmonary disease [6, 27].
18.2.4  Assessment of Specific Clinical 
Problems in Patients with RA
18.2.4.1  Cardiovascular
Special focus should be made to risk stratify RA 
patients for coronary artery disease. Many con-
tributing factors including accelerated athero-
sclerosis put RA patients at high risk for cardiac 
morbidity and mortality. RA patients presenting 
for orthopedic surgery for any kind of procedure 
and/or intervention should receive careful pre-
operative cardiac risk stratification. There are 
several measures to be taken. Dipyridamole 
thallium scintigraphy (DTS) conducted preop-
eratively is found to be most useful to stratify 
selected nonvascular surgery patients at inter-
mediate or high risk by clinical assessment [6–
9, 28].
18.2.4.2  Pulmonary
Multiple pulmonary complications including 
fibrosis, bronchiolitis, and pleuritis can have sig-
nificant impact on RA patients. Serial pulmonary 
function test (PFT) among patients with RA is 
recommended. This can help in early detection of 
defected ventilation. [10]
18.2.4.3  Cricoarytenoid Arthritis
This is a common involvement in RA patients. It 
places concerns of complicated intubation or 
obstructed airway after surgery. Most patients are 
asymptomatic, but despite that they may present 
with symptoms such as hoarseness, sore throat, 
and/or difficult inspiration. Therefore, it is 
extremely essential to avoid intraoperative mus-
culoskeletal trauma in patients with RA by apply-
ing generous padding during joint positioning 
and by avoiding sudden movements of the neck 
and torso [11, 23–26].
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18.3  Perioperative Drug 
Management
18.3.1  Perioperative Management if 
Antirheumatic Drugs [12–16]
(See Table 18.1)
18.3.2  Perioperative Management 
of Other Systemic Medications 
[12–14, 16, 17]
(See Table 18.2)




  •  There is no increased risk of infection or other postoperative complications in patients 
with RA who continued MTX.
  •  Continue the current dose of methotrexate for patients undergoing elective total hip 
arthroplasty (THA) or total knee arthroplasty (TKA).
  •  Withheld the week before and the week after surgery if there are additional concerns 
regarding the perioperative safety of MTX such as renal insufficiency or if a more 
complex surgical intervention is required.
  •  MTX should be reinstated as soon as the patient is stable postoperatively.
  •  MTX treatment should be discontinued until full recovery if prolonged surgery or 
artificial respiration is anticipated or in case of pulmonary complications, to reduce the 
risk of pneumonia [30, 31].
TNF blockers   •  It is recommend stopping TNF blockers use 1 to 4 weeks before surgery, proportional to 
the drugs half-lives.
  •  Withhold TNF blockers and other biologic agents prior to surgery in patients undergoing 
elective THA or TKA, and schedule the surgery at the end of the dosing cycle.
  •  Treatment may be restarted at minimum 14 days postoperatively if there is no evidence of 
infection and once wound healing is satisfactory [32].
Tocilizumab   •  Infection rates attributed to tocilizumab are comparable to those associated with other 
biologic DMARDs.
  •  Discontinuing tocilizumab 11 to 13 days before surgery, based on the drug half-life, is a 








  •  Withhold their current doses 1 week prior to surgery in all patients with stable SLE 
undergoing THA or TKA.
  •  Continue their current doses through the surgical period in all patients with severe SLE 
undergoing THA or TKA.
Rituximab   • Rituximab has been shown to be safe in patients with prior recurrent bacterial infections.
  •  Compared with TNF blockers, rituximab is associated with a lower risk for bacterial 
infections, which are the primary concern in perioperative management, although the 
presence of low immunoglobulin levels in a small proportion of patients raises the 
infection risk.
  • Elective surgery can be arranged in the 7th month from the last given dose [31].
Abatacept   •  The risk of infection in patients treated with abatacept is not significantly increased over 
baseline non-biologic-treated RA patients.
  •  Abatacept is administered either as a monthly infusion or a weekly subcutaneous 
injection, and conservative timing of surgery should be at the end of the dose cycle [31].
Steroid   •  In general, limiting minimal doses of steroids preoperatively should be considered to 
prevent impairment of wound healing and surgical site infections.
  •  Chronic use of steroid also increases the potential risk of subversive consequences of an 
inadequate adrenal response [31].
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18.3.3  DVT Prophylaxis
• Meta-analysis showed that extended-duration 
prophylaxis against deep vein thrombosis 
(DVT) with low-molecular-weight heparin 
(LMWH) or unfractionated heparin (UFH) in 
patients with major hip or knee replacement 
surgery can reduce the risk of symptomatic 
venous thromboembolism significantly [18].
• There are many options for the prevention of 
venous thromboembolism in patients under-
going elective hip or knee arthroplasty and 
who are not at increased risk beyond that of 
the surgery itself for venous thromboembo-
lism or bleeding. Prophylaxis should be 
started after surgery (specific timing given 
separately for each drug) and continued for 
28–35 days for hip patients and 10–14 days 
for knee patients: dabigatran, fondaparinux, 
LMWH, rivaroxaban, and UFH (for patients 
with renal failure) are all options [18, 19, 35].
• It has to be considered that the benefit here is 
associated with increased risk of minor bleed-
ing but with no excess major bleeding [18].
• In patients undergoing hip fracture surgery 
(HFS), it is recommended to use one of the 
following rather than no antithrombotic pro-
phylaxis for a minimum of 10 to 14  days: 
LMWH, fondaparinux, LDUH, adjusted-dose 
VKA, or aspirin.
• There are specific considerations for patients 
undergoing major orthopedic surgery, total 
hip arthroplasty (THA), total knee arthro-
plasty (TKA), hip fracture surgery (HFS), and 
receiving LMWH as thromboprophylaxis; it is 
recommended to start either 12 h or more pre-
operatively or 12  h or more postoperatively, 
rather than within 4 h or less preoperatively or 
4 h or less postoperatively [19, 36].
• It has to be noted that in patients undergoing 
THA or TKA, irrespective of the concomitant 
use of an intermittent pneumatic compression 
device (IPCD) or length of treatment, it is sug-
gested to use LMWH in preference to the 
other agents recommended as alternatives: 
fondaparinux, apixaban, dabigatran, rivaroxa-
ban, low-dose UFH, adjusted-dose vitamin K 
antagonist (VKA), or aspirin.
18.3.4  Prophylactic Antibiotics 
[20, 29]
• Prophylactic antibiotics are needed for RA 
patients who will be undergoing long proce-
dures especially patients with TKA, joint 
replacement, and prosthetic joints. This is to 
prevent surgical site infections.
• Obviously, antibiotics must be administered to 
patients undergoing surgery in an infected 
area with a high bacteremia risk.
• Cefazolin or cefuroxime antibiotics are the 
antibiotic of choice and should be given 30 to 
60 min before skin incision.
• In case of a confirmed ß-lactam allergy, van-
comycin may be used. It should be started 
within 2 h prior to incision.
• The dose of antibiotic varies according to 
patient’s weight; for patients >80 kg, the doses 
of cefazolin should be doubled.
• It has to be noted that additional intraoperative 
doses of antibiotic might be needed. It should 
be given for prolonged procedures and if there 
is significant blood loss during the procedure.
• Prevention of wound infection is essential. 
This can be prevented after surgical repair of 
closed fractures by a single dose of 
cephalosporin.
• Prophylactic antibiotics should be stopped 
within 24 h of the end of surgery.
18.4  Assessment of Specific 
Clinical Problems in Patients 
with SLE
Specific perioperative concerns must be consid-
ered for patients with SLE undergoing orthope-
dic surgery. This should include assessing risk 
factors for worse outcomes including smoking or 
use of oral contraceptive pills (OCP), adequate 
blood pressure (BP), and lipid control. It has to 
be noted that SLE patients undergoing both non-
elective and elective hip and knee surgery have a 
high mortality and morbidity rate compared to 
RA patients [21].
It is also necessary to assess medication man-
agement around the operation time. SLE patients 
18 Perioperative Management of Patients with Rheumatic Diseases
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have multiple organ involvement. This should be 
assessed as well including hematologic abnormal-
ities, renal disease, and immune dysfunction, and 
thromboembolic disease. Moreover, a careful bal-
ance should be addressed in the risk assessment in 
patients with antiphospholipid antibody syndrome 
(APS). The aim is to evaluate these patients pre-
operatively to decrease the risk of major bleeding 
and the risk of a thromboembolic event.
18.5  Postoperative Follow-Up
There has to be a thorough postoperative risk 
assessment for the following patients:
• Carful follow-up for patients with RA and 
SLE assessing the risk of prosthetic joint 
infections, DVT, and pulmonary embolism. 
These patients have greater risk for the devel-
opment of these complications 
postoperatively.
• Hospitalized patients with autoimmune dis-
ease have a high risk of postoperative venous 
thrombosis. These patients can be offered a 
regional anesthesia, as it reduces the postop-
erative DVT significantly.
• Patients with gout should be assessed for the 
risk of flare of gout postoperatively.
• There are special precautions for patients with 
Raynaud’s phenomenon. Hypothermia must 
be avoided postoperatively and pressure ulcers 
must also be prevented [22].
18.6  Patient Education
To assure patients’ safety, it is recommended to 
inform the patient of the following:
• Patients should be aware about the expected 
duration of movement limitations and options 
for pain control. This is immediately after the 
surgery and in the following weeks to months.
• They should also be aware about the impor-
tance of a comprehensive physical activity 
program following surgery.
• Each patient should be aware of the pain con-
trol plan. The associated fluctuation of pain 
with different medication withdrawal or insti-
tution must be explained.
• More details should be delivered to patients 
according to their needs, issues like possible 
drug-drug and/or drug-food interactions of 
new medication regimens. The classical and 
common examples are the potential risk of 
anticoagulant drugs and foods affecting 
potency of warfarin. Patients should be aware 
about any follow-up instructions including 
monitoring of laboratory investigations.
• Obviously, patients should be aware about the 
importance of early immobilization [22].
18.7  Physical Activity 
and Rehabilitation
Patients should undertake physical therapy 
since physical activities are essential for 
patients with rheumatologic disease. The major 
benefits are to prevent disabilities, restore func-
tion, and relieve pain. These activities should 
be evaluated preoperatively to verify consis-
tency with treatment goals. These are greatly 
augmented by prescribed therapeutic exercises 
and functional activities. Special precautions 
should be given for patients with active inflam-
matory joint or soft tissue diseases. The thera-
peutic exercises should be balanced with 
essential rest periods for a successful treatment. 
The aim is usually dedicated at preserving or 
increasing functional level, decreasing pain and 
joint inflammation, and increasing range of 
motion and strength [22].
Figure 18.1 illustrates a summary of periop-
erative management of patients with rheumatic 
diseases.
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Comprehensive history and 
physical examination:
Patient’s age, duration of 
rheumatologic disease, 
current functional status, 
specific joint involvement, any 
extra-articular manifestations 
of disease, current 
medications including 
previous use of steroids,  
previous complications 
associated with surgery, and 
any co-morbidities. Also, ask
about a history of malignant 
hyperthermia or, for patients 
never exposed to anesthesia, 
about severe fever or 
perioperative death in family.
MSK examination
posture, location of joint 





Discontinue: If prolonged 
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week before and the week 
after surgery.
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18 Perioperative Management of Patients with Rheumatic Diseases
416
 4. Koulouvaris P, Sculco P, Finerty E, Sculco T, Sharrock 
NE. Relationship between perioperative urinary tract 
infection and deep infection after joint arthroplasty. 
Clin Orthop Relat Res. 2009;467(7):1859–67.
 5. Sousa R, et  al. Is asymptomatic bacteriuria a risk 
factor for prosthetic joint infection? Clin Infect Dis. 
2014:ciu235.
 6. Silvestri L, Maffessanti M, Gregori D, Berlot G, 
Gullo A.  Usefulness of routine pre-operative chest 
radiography for anaesthetic management: a pro-
spective multicentre pilot study. Eur J Anaesthesiol. 
1999;16(11):749–60.
 7. Kannel WB, Abbott RD.  Incidence and progno-
sis of unrecognized myocardial infarction. An 
update on the Framingham study. N Engl J Med. 
1984;311(18):1144–7.
 8. Lee TH, Marcantonio ER, Mangione CM, et  al. 
Derivation and prospective validation of a simple 
index for prediction of cardiac risk of major noncar-
diac surgery. Circulation. 1999;100(10):1043–9.
 9. Fleisher LA, et  al. 2014 ACC/AHA guideline on 
perioperative cardiovascular evaluation and man-
agement of patients undergoing noncardiac surgery. 
Circulation. 2014:CIR-0000000000000106.
 10. Wong C.  The medicine consult handbook. 4th ed; 
2011.
 11. Jackson MB, et  al. The perioperative medi-
cine 1 consult handbook: Springer International 
Publishing Switzerland; 2015. https://doi.
org/10.1007/978-3-319-09366-6_1.
 12. Lee MA, Mason LW, Dodds AL.  The perioperative 
use of disease modifying and biologic therapies in 
patients with rheumatoid arthritis undergoing elective 
orthopedic surgery. Orthopedics. 2010;33(4):257–62.
 13. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate 
and early postoperative complications in patients with 
rheumatoid arthritis undergoing elective orthopaedic 
surgery. Ann Rheum Dis. 2001;60(3):214–7.
 14. Harle P, Straub RH, Fleck M. Perioperative manage-
ment of immunosuppression in rheumatic diseases 
what to do? Rheumatol Int. 2010;30(8):999–1004.
 15. del Olmo BH L, Galindo-Izquierdo M, Tébar 
D, Balsa A, Carmona L.  Perioperative manage-
ment of disease modifying antirheumatic drugs: 
Recommendations based on a meta-analysis 
pubmed Revista Española de Cirugía Ortopédica y 
Traumatología (English Edition). Rev Esp Cir Ortop 
Traumatol. 2012;56(5):393–412.
 16. Goodman SM, Springer B, Guyatt G, et  al. 2017 
American College of Rheumatology/American 
Association of hip and Knee Surgeons Guideline 
for the perioperative Management of Antirheumatic 
Medication in patients with rheumatic diseases 
undergoing elective Total hip or Total knee arthro-
plasty. Arthritis Care Res. 69:1111–24. https://doi.
org/10.1002/acr.23274.
 17. Carmona L, Galindo M.  Perioperative manage-
ment of immunosuppression. Oxford Textbook of 
Rheumatology. Oxford, UK: Oxford University 
Press, 201310. Oxford Medicine Online. 20161027. 
Date Accessed 26 Feb. 2017 <http://oxfordmedicine.
com/view/10.1093/med/9780199642489.001.0001/
med-9780199642489-chapter-93>.
 18. Eikelboom JW, Quinlan DJ, Douketis JD. Extended- 
duration prophylaxis against venous thrombo-
embolism after total hip or knee replacement: a 
meta-analysis of the randomised trials. Lancet. 
2001;358(9275):9–15.
 19. Sun Y, Chen D, Xu Z, Shi D, Dai J, Qin J, et al. Deep 
venous thrombosis after knee arthroscopy: a system-
atic review and meta-analysis. Arthroscopy. 2014 
Mar;30(3):406–12.
 20. American Academy of Orthopaedic Surgeons. 
Recommendations for the use of intravenous antibi-
otic prophylaxis in primary total joint arthroplasty. 
2004. (Revised 2014).
 21. Domsic RT, Lingala B, Krishnan E. Systemic lupus 
erythematosus, rheumatoid arthritis, and postar-
throplasty mortality: a cross-sectional analysis 
from the nationwide inpatient sample. J Rheumatol. 
2010;37(7):1467–72.
 22. Cohn SL. Preoperative evaluation for noncardiac sur-
gery. Ann Intern Med. 2016;165(11):ITC81–96.
 23. Crosby ET, Lui A.  The adult cervical spine: impli-
cations for airway management. Can J Anaesth. 
1990;37(1):77–93.
 24. Kwek TK, Lew TW, Thoo FL.  The role of preop-
erative cervical spine X-rays in rheumatoid arthritis. 
Anaesth Intensive Care. 1998;26(6):636–41.
 25. Jin F, Chung F.  Minimizing perioperative adverse 
events in the elderly. Br J Anaesth. 2001;87(4):608–24.
 26. Lopez-Olivo MA, et al. Cervical spine radiographs in 
patients with rheumatoid arthritis undergoing anes-
thesia. JCR. 2012;18.2:61–6.
 27. Cheng S-P, et  al. Perioperative care of the elderly. 
International Journal of Gerontology. 2007;1.2:89–97.
 28. Patel AY, Eagle KA, Vaishnava P.  Cardiac risk 
of noncardiac surgery. J Am Coll Cardiol. 
2015;66(19):2140–8.
 29. Coblyn JS.  Infections, drugs, and rheumatoid 
arthritis. What have we learned? J Rheumatol. 
2008;35(3):375–6.
 30. Loza E, Martinez-Lopez JA, Carmona L. A system-
atic review on the optimum management of the use 
of methotrexate in rheumatoid arthritis patients in 
the perioperative period to minimize perioperative 
morbidity and maintain disease control. Clin Exp 
Rheumatol. 2009;27(5):856–62.
 31. Goodman SM, Paget S. Perioperative drug safety in 
patients with rheumatoid arthritis. Rheum Dis Clin N 
Am. 2012;38(4):747–59.
 32. Goh L, Jewell T, Laversuch C, Samanta A.  Should 
anti-TNF therapy be discontinued in rheumatoid 
arthritis patients undergoing elective orthopaedic sur-
gery? A systematic review of the evidence. Rheumatol 
Int. 2012;32(1):5–13.
 33. Krause ML, Matteson EL.  Perioperative manage-
ment of the patient with rheumatoid arthritis. World 
J Orthop. 2014;5(3):283–91. https://doi.org/10.5312/
wjo.v5.i3.283.
M. Alotaibi et al.
417
 34. Marathe PH, Gao HX, Close KL. American Diabetes 
Association standards of medical Care in Diabetes 
2017. J Diabetes. 2017;9:320.
 35. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, 
Dahl OE, Schulman S, et  al. Prevention of VTE in 
orthopedic surgery patients: antithrombotic therapy 
and prevention of thrombosis, 9th ed: American 
College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines. Chest. 2012;141(2 
Suppl):e278S–325S.
 36. Nieto JA, Espada NG, Merino RG, Gonzalez 
TC.  Dabigatran, rivaroxaban and apixaban versus 
enoxaparin for thomboprophylaxis after total knee or 
hip arthroplasty: pool-analysis of phase III randomized 
clinical trials. Thromb Res. 2012 Aug;130(2):183–91.
Open Access  This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in 
any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to 
the Creative Commons license and indicate if changes were made.
The images or other third party material in this chapter are included in the chapter's Creative Commons license, 
unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons 
license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to 
obtain permission directly from the copyright holder.
18 Perioperative Management of Patients with Rheumatic Diseases
419© The Author(s) 2021 





The ocular involvement in rheumatology can be in 
a wide variety; it ranges from simple episcleritis to 
significant visual loss. Early detection followed by 
appropriate management can reserve vision. 
Ophthalmic involvement may occur in all of the 
rheumatic disorders. Ocular manifestation may be 
a presenting sign in some disorders, as in juvenile 
idiopathic arthritis (JIA), ankylosing spondylitis 
(AS), and Sjogren’s syndrome (SjS), or can be a 
presenting sign with the systemic involvement as in 
systemic lupus erythematosus (SLE), polyarteritis 
nodosa (PAN), granulomatosis with polyangiitis 
(GPA), and systemic sclerosis. Thus ocular mani-
festations in rheumatologic diseases (Table  19.1) 
can be the link in approaching the diagnosis.
Detection of the ocular manifestations can be 
simple, yet the cooperation with ophthalmolo-
gists is crucial in some conditions. The major 
manifestations of ocular involvement in rheu-
matic disease include uveitis, scleritis, retinal 
vascular disease, neuro-ophthalmic lesions, 
orbital disease, keratitis, and SjS.(*).
Approximately 16% of patients with RA have 
ophthalmic manifestations including scleritis and 
peripheral ulcerative keratitis PUK, a condition 
characterized by inflammation and thinning of 
the peripheral cornea, which may lead to perfora-
tion and blindness. While in patients with 
Adamantiades-Behçet’s disease (ABD) ocular 
involvement occurs in approximately 70%, and 
characterized by recurrent, explosive exacerba-
tions of intraocular inflammation most com-
monly presenting as a posterior uveitis or 
panuveitis accompanied by a destructive retinal 
vasculitis, ocular or orbital involvement of 
Wegener’s granulomatosis is seen in approxi-
mately 29–52% of the patients with PUK, cor-
neal granuloma, episcleritis, necrotizing scleritis, 
or uveitis [1].
Concerning the ocular manifestations of rheu-
matic conditions, another aspect to shed light on 
is the side effects of medications used in the treat-
ment of rheumatic diseases, for instance, one of 
the most serious side effects of hydroxychloro-
quine is toxicity in the eye.
In this chapter ocular manifestations of rheu-
matic diseases will be discussed along with his-
torical points, basic ophthalmological 
examination, investigation, and management.
19.1.1  Objectives
By the end of this chapter, the reader is expected 
to construct an approach to the most common 
ocular presentations of rheumatic diseases, which 
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include uveitis, eye dryness, corneal ulcer, 
 scleritis, episcleritis, and ocular side effects of 
rheumatic medications.
19.2  Uveitis
Uveitis is the inflammation of the middle layer of 
the eye, which includes choroid posteriorly, cili-
ary body, and iris anteriorly. Uveitis is a common 
manifestation of rheumatic and immune- 
mediated disorders. The most common systemic 
immune disorders causing uveitis are spondylo-
arthritis (SpA). Those with HLA-B27-positive 
disease are likely to have earlier onset with more 
severe manifestations [2].
19.2.1  Approach to Uveitis
19.2.1.1  History
The main symptoms of anterior uveitis are eye 
pain and redness. These symptoms must be dis-
tinguished from other causes. Asking about con-
stitutional symptoms and making systemic 
review in history aid you to target a specific diag-
nosis. Table  19.2 demonstrates the differential 
diagnosis of uveitis in terms of rheumatic 
diseases.
Sudden mood of onset, unilateral affection, 
and resolution of symptoms within few months 
with recurrence to the other eye are features sug-
gestive for SpA (such as AS), reactive arthritis 
(ReA). Keep in mind that males are more com-
mon to be affected with SpA than females.
Insidious mood of onset, bilateral affection, 
and chronic duration are features suggestive for 
Table 19.1 Ocular involvement in rheumatic diseases
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psoriatic arthritis which is more common in 
females than males.
Bilateral affection with episodic attacks that 
do not resolve completely is a feature suggestive 
for Behçet’s disease.
Insidious mood of onset, bilateral affection, 
and chronic duration in young children are 
 features suggestive for JIA.  Keep in mind that 
uveitis in JIA is commonly accompanied with 
other complications like band keratopathy (cal-
cium deposition in corneal epithelium), posterior 
synechiae (which is iris adhesion to the lens), 
cataract, and glaucoma. Rule out other causes by 
asking about HIV infection and its risk factors 
and about the status of immune system to rule out 
CMV infection and tuberculosis.
19.2.1.2  Eye Examination
Presence of leukocytes in the anterior chamber 
by slit lamp examination is characteristic of ante-
rior uveitis. A haze or flare may also be seen 
which represents protein accumulation in the 
anterior part of the eye. Direct visualization of 
active chorioretinal inflammation and the pres-
ence of leukocytes in the vitreous humor behind 
the eye lens can also be a sign for posterior uve-
itis. Inflammation in the anterior chamber, vitre-
ous, and choroid or retina is termed panuveitis.
19.2.1.3  Treatment
In patients with systemic disease associated with 
uveitis, the treatment for the systemic disease 
may or may not be enough to control the uveitis 
[3]. Treatment for uveitis can be given systemi-
cally or delivered directly to the eyes.
The main use of local therapy is for the treat-
ment of unilateral or asymmetric disease [3]. 
Topical glucocorticoids are for anterior uveitis. 
Periocular or intraocular injections of glucocorti-
coids (e.g., Kenacort injection) in posterior uve-
itis or panuveitis. A dilating drop such as 
scopolamine or cyclopentolate can relieve pain 
due to papillary muscle spasm.
Systemic treatment is generally reserved for 
resistant uveitis and in glaucoma patients, who 
cannot be treated with local injection. In addi-
tion, patients with bilateral disease are often 
treated with systemic therapy. A small percent-
age of patients with uveitis may require immu-
nosuppressive medications. Absolute indications 
for their use include Behçet’s syndrome, Vogt- 
Koyanagi- Harada syndrome, sympathetic oph-
thalmia, and rheumatoid sclerouveitis, while 
relative indications include intermediate uveitis, 
retinal vasculitis with central vascular leakage, 
chronic severe iridocyclitis or panuveitis, JRA- 
related iridocyclitis, and children with interme-
diate uveitis [4]. Additionally, patients who 
require a daily dose of 10 mg or more of predni-
sone to control their ocular inflammation may 
benefit from a glucocorticoid-sparing agent, 
such as an antimetabolite, as a safer long-term 
alternative [5]. Infliximab and adalimumab are 
antitumor necrosis factor-alpha (TNF-a) drugs. 
It can be very useful in patients refractory to 
conventional therapy. [6] Interferon-alpha 
appears capable of inducing disease remission 
in patients with Behçet’s disease [3]. Rituximab, 
an anti-CD20 (i.e., anti-B-cell) monoclonal 
antibody has been reported to be effective in 
patients with refractory scleritis due to 
Wegener’s disease [3].
19.3  Eye Dryness
Also known as keratoconjunctivitis sicca, it is a 
multifactorial disease of the tears and ocular sur-
face that results in symptoms of discomfort, 
visual disturbance, and tear film instability with 
potential damage to the ocular surface, accompa-
nied by increased osmolarity of the tear film and 
inflammation of the ocular surface [7, 8]. Dry eye 
is the most recognized ocular manifestations of 
SLE together with lupus retinopathy [1].
19.3.1  Approach to Dry Eye
19.3.1.1  History
A good history probably guides you to the possi-
ble underlying cause of the dry eye like 
 medications, weather conditions, or systemic dis-
eases. Symptoms of dry eye can be burning or 
foreign body sensation, eye irritation, redness or 
dryness, and/or blurred vision.
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Contact lenses use, previous eye surgeries, 
chemical insult, Parkinson’s disease, and familial 
history might give a hint about the possible cause 
of the dry eye.
Ocular dryness associated with mouth dryness 
increases the susceptibility of SjS, which can be 
a primary disorder or a secondary disorder of 
other systemic immune-mediated diseases. 
Table 19.3 shows the differential diagnosis of dry 
eye in terms of rheumatic diseases.
19.3.1.2  Eye Examination
Use the slit lamp to examine the lacrimal glands, 
the conjunctiva, and the eyelids to assess meibo-
mian gland function. Examine ocular surface by 
fluorescein stain to look for corneal abrasions 
and assess corneal sensation.
Assessment of tear film is also an important 
step using tear break-up time, in which fluores-
cein stain is used to assess the stability of tear 
film or Schirmer’s test, quantitative measurement 
of tear production by each eye.
19.3.1.3  Treatment
The treatment of dry eye deepened on the sever-
ity of the condition; it includes artificial tear sub-
stitutes, gels/ointments, topical cyclosporine and 
corticosteroids, systemic omega-3 fatty acids 
supplements, systemic cholinergic agonists, sys-
temic anti-inflammatory agents, mucolytic 
agents, autologous serum tears, punctal plugs, 
and tarsorrhaphy [9].
19.4  Corneal Ulcer
Ulcers are primarily divided into infectious and 
noninfectious categories. Noninfectious ulcers 
include autoimmune, neurotrophic, toxic, and 
allergic keratitis, as well as chemical burns and 
keratitis secondary to entropion, blepharitis, and 
a host of other conditions.
19.4.1  Approach to Corneal Ulcer
19.4.1.1  History
Some patients are asymptomatic, while others 
present with mild symptoms of conjunctival 
swelling, hyperemia, and ocular irritation. There 
is a history of a systemic immune disorder such 
as RA, SLE, and GPA. It’s essential that the treat-
ing rheumatologist manages the underlying 
immune condition. Examples of these immune 
conditions are listed in Table 19.4.
Moderate to severe ulcers can progress rapidly 
to melting and perforation.
19.4.1.2  Eye Examination
The appearance of noninfectious ulcers is often 
quite different from infectious lesions. Most 
notably, the underlying cornea is relatively clear 
without diffuse haziness or white blood cells. 
Sterile infiltrates smaller than 1 mm can be seen, 
as well as gray-white circumlimbal lesions.
19.4.1.3  Treatment
Sterile infiltrates are usually self-limiting and 
resolve within a week or two. If an ulcer does 
develop but is less than 2 mm, fairly round, and 
peripheral, without much stromal involvement or 
inflammation, it is most likely a sterile ulcer 
which is very responsive to topical steroids.
Although systemic immunomodulation is 
required, some topical measures, such as 
 lubricating the surface, may be helpful. The clini-
cian may also consider using topical cyclospo-
rine to help heal the eye and immunosuppressant 
drops such as ascorbate to reduce the risk of stro-
mal melting [10–14].
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Around 50% of patients present with scleritis 
have underlying systemic diseases. GPA is the 
most common vasculitic disorder to manifest 
with scleritis.
19.5.1  Approach to Scleritis
19.5.1.1  History
Ask about pain; scleritis presents with severe pierc-
ing eye pain that may worsen at night and awaken 
patients from sleep with ipsilateral referral to head 
or face. Other symptoms include photophobia and 
redness. Severe eye and periorbital pain that is pro-
gressive and worsen in the early morning are fea-
tures suggestive for necrotizing anterior scleritis. 
Severe pain and difficult to localize, diplopia, ocu-
lar pain upon eye movement, and reduced vision 
are features suggestive for posterior scleritis. In 
your history cover constitutional symptoms and 
systemic review to target rheumatic diseases and 
also previous ocular surgery are important. A list of 
rheumatic causes of scleritis is in Table 19.5.
19.5.1.2  Eye Examination
Signs of scleritis include tender globe, sclera, and 
episcleral edema. Slit lamp examination in 
advanced disease shows blood vessel closure 
with scleral thinning and a bluish discoloration. 
Diffuse ocular erythema and scleral edema with 
no nodules or necrosis are features suggestive for 
diffuse anterior scleritis. Areas of localized ten-
der edema with deep episcleral vessel dilatation 
are features suggestive for nodular anterior scle-
ritis. Keep in mind that the eye in anterior scleri-
tis appears red while in isolated posterior scleritis 
the eye appears white but there are other impor-
tant signs in posterior scleritis which are detected 
by fundoscopic examination like choroidal folds, 
annular choroidal detachment, retinal folds, exu-
dative retinal detachment, retinal vasculitis, optic 
disc edema, and posterior uveitis. Posterior scle-
ritis can also cause glaucoma.
19.5.1.3  Treatment
Pain relief should be the goal of treatment. It 
could be achieved by topical lubricants, topical 
glucocorticoids, and oral NSAIDs. Treat the 
underlying disease. Azathioprine has been shown 
to be effective in the management of scleritis sec-
ondary to relapsing polychondritis. In necrotiz-
ing scleritis, cyclophosphamide is considered the 
treatment of choice. Infliximab has been used 
effectively in scleritis secondary to JIA, ankylos-
ing spondylitis, Wegener granulomatosis, sar-
coidosis, and Crohn disease [15].
19.6  Episcleritis
19.6.1  Approach to Episcleritis
19.6.1.1  History
Ask in your history about the mood of onset, eye 
redness and whether it is diffused or localized, 
and eye irritation because episcleritis usually 
manifests as an acute onset, localized or diffused 
eye redness, and/or irritation. Bilateral eye 
involvement may suggest an immune-mediated 
disease. Examples of these immune-mediated 
episcleritis are listed in Table 19.6.
19.6.1.2  Eye Examination
Shows vasodilatation of superficial episcleral 
vessels and episcleral edema.
19.6.1.3  Treatment
Treat the underlying disease. Pain relief should 
be the goal of treatment. It could be achieved by 
Table 19.5 Differential diagnosis of scleritis in respect 
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topical lubricants, topical NSAIDs [16], topical 
glucocorticoids, and oral NSAIDs.
19.7  Cataract
Cataract is defined as an opacity in the lens of the 
eye. In rheumatology practice, cataract results 
from the use of topical or systemic glucocorti-
coids for treatment of immune-mediated dis-
eases. The lens of the eye is composed of layers 
like an onion. The outermost is the capsule, the 
layer inside the capsule which is the cortex, and 
the innermost layer which is the nucleus. A cata-
ract may develop in any of these areas and is 
described based on its location in the lens shown 
in Fig. 19.1. Risk factors and symptoms can be 
reviewed in Tables 19.7 and 19.8.
19.7.1  Approach to Cataract
19.7.1.1  History
Ask about vision difficulties experienced by the 
patient that may limit their daily activities and 
other general health concerns affecting vision.
19.7.1.2  Eye Examination
It includes visual acuity measurement to deter-
mine to what extent a cataract may be limiting 
clear vision at distance and near, refraction to 
determine the need for changes in an eyeglass or 
contact lens prescription, as well as slit lamp 
examination to determine the extent and loca-
tion of any cataracts. It would be better to evalu-
ate the retina of the eye through a dilated pupil 
to exclude any retinal disease. It is also advis-
able to measure the intraocular pressure. 
Supplemental testing for color vision and glare 
sensitivity could be done.
19.7.1.3  Treatment
The treatment of cataracts is based on the level of 
visual impairment they cause. If a cataract affects 
vision only minimally, or not at all, no treatment 
may be needed. Patients may be advised to moni-
tor for increased visual symptoms and follow a 
regular check-up schedule. In some cases, a 
change in eyeglass prescription may provide tem-







Fig. 19.1 Types of 
cataract
Table 19.7 Risk factors for cataract
Old age
Diabetes mellitus





Table 19.8 Signs and symptoms of cataract
Blurred or hazy vision
Reduced intensity of colors
Increased sensitivity to glare from lights, particularly 
when driving at night
Increased difficulty seeing at night




Glaucoma is a group of eye disorders leading 
to progressive damage to the optic nerve. Like 
in cataract, glaucoma in rheumatology practice 
results from the use of topical or systemic glu-
cocorticoids for treatment of immune-medi-
ated diseases. It is usually associated with 
increased pressure inside the eye and is charac-
terized by loss of optic nerve tissue resulting in 
loss of vision. Advanced glaucoma may even 
cause blindness. Figure  19.2 shows the types 
of glaucoma.
19.8.1  Approach to Glaucoma
19.8.1.1  History
Ask about any symptoms the patient is experi-
encing and the presence of any risk factors for 
glaucoma which are listed in Table 19.9.
19.8.1.2  Eye Examination
Measure visual acuity to determine the extent to 
which vision may be affected. Measurement of 
the pressure inside the eye is an essential step and 
can be done by tonometry or more preferably by 
applanation. Pachymetry to measure corneal 
thickness could be done for more accurate intra-
ocular pressure estimation. Visual field testing, 
also called perimetry, is often done for glaucoma 
patients to check if the field of vision has been 
affected by glaucoma. Evaluation of the retina 
can be done to monitor any changes that might 
occur over time. Supplemental testing may 
include gonioscopy, a procedure to give clearer 
views of the angle anatomy.
19.8.1.3  Treatment
The treatment of glaucoma is aimed at reducing 
intraocular pressure. The most common first-line 
treatment of glaucoma is usually prescription eye 
drops that must be taken regularly. In some cases, 
systemic medications, laser treatment, or other 
surgery may be required. While there is no cure 
as yet for glaucoma, early diagnosis and continu-
ing treatment can preserve eyesight. Patients 
need to continue treatment for the rest of their 
lives. Because the disease can progress or change 
silently, compliance with eye medications and 
eye examinations are essential, as treatment may 
need to be adjusted periodically. Early detection, 
prompt treatment, and regular monitoring can 
help to control glaucoma and therefore reduce 
the chances of progression vision loss.
Types of glaucoma
Normal tension glaucomaCongenital glaucoma
Angel closure Open angle
Secondary Primary
Fig. 19.2 Types of 
glaucoma
Table 19.9 Risk factors for glaucoma
Age Increased risk after 60 years, after 
40 years in people of African 
descent
Race Increased risk in African race (open 
angle) and Asians (closed angle)
Family history Increased risk in people who have 
siblings or parents with glaucoma
Medical 
conditions
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19.9  Ophthalmologic Side Effects 
of Rheumatic Medications [17]
There are several ocular side effects of rheumatic 
medications (Table 19.10). It is well documented 
that corticosteroid use induces cataract and 
increases intraocular pressure causing glaucoma. 
Most common type of cataract induced by corti-
costeroids is posterior subcapsular cataract. The 
incidence of posterior subcapsular cataract is 
associated with dosage of steroids use and dura-
tion of treatment. In a number of randomized, 
controlled trials, the incidence of corticosteroid- 
induced cataracts reported to be ranging from 
6.4% to 38.7% after oral corticosteroid use [18, 
19]. Glaucoma incidence has been reported in 
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patients using oral, intravenous, eye drops, intra-
nasal, or inhalational steroids.
Indomethacin is one of the most potent 
NSAIDs that has been associated with cases of 
corneal opacities and blurred vision, especially 
when used long term. Reports on ocular side 
effects from the usage of sulfasalazine are rela-
tively few, including peripheral facial nerve palsy 
and blurred near vision in association with sul-
phasalazine treatment. Aspirin, ibuprofen, 
naproxen, oxaprozin, and piroxicam increase 
bleeding tendency which manifests in subcon-
junctival hemorrhages and hemorrhagic retinopa-
thies following trauma.
Biologics are a new class of drugs which have 
become recently a choice to treat immune- 
mediated diseases. Abatacept is a biologic agent 
which causes eye irritation, allergic conjunctivi-
tis, blurry vision, visual disturbance, and eye pru-
ritus involving less than 1% of the drug users. 
Another biologic agent is rituximab. In a clinical 
study concerning the efficacy of rituximab in 222 
patients with lymphoma, 9 of them reported ocu-
lar side effects, including conjunctivitis, transient 
ocular edema, a burning sensation, and a tran-
sient or permanent loss of visual function [20]. 
Interferon alfa is an antiviral which is used as 
immunomodulator and has shown effectiveness 
in treating rheumatic diseases. Side effects of 
interferon alfa include retinal vascular abnormal-
ities (retinal microvascular changes, presence of 
cotton wool spots, intraretinal hemorrhages, reti-
nal detachment). Mostly, the ocular changes are 
transient and asymptomatic [21].
Methotrexate is an antimetabolite which is 
used to treat several rheumatic diseases. Ocular 
side effects of methotrexate include periorbital 
edema, ocular pain, blurred vision, photophobia, 
conjunctivitis, blepharitis, decreased reflex tear 
secretion, and non-arteritic ischemic optic neu-
ropathy. Bisphosphonates are used in patients 
with chronic inflammatory diseases or patients 
with osteoporosis. Their use has been reported to 
cause uveitis and scleritis.
Antimalarials such as chloroquine and 
hydroxychloroquine cause keratopathy, ciliary 
body dysfunction, lens opacities, outer retinal 
damage, and pigmentary retinopathy.
19.10  Antimalarial-Related 
Retinopathy
19.10.1  Approach to Antimalarial- 
Related Retinopathy
19.10.1.1  History
There are many factors that may contribute to 
hydroxychloroquine retinopathy. These factors 
include daily and cumulative dosage which is the 
most important, duration of treatment, renal or 
liver disease, patient’s age, and prior retinal dis-
ease. The great majority of case reports of 
hydroxychloroquine toxicity occurred in individu-
als taking more than 6.5 mg/kg/day or chloroquine 
at 3 mg/kg/day, and most of the reports of hydroxy-
chloroquine toxicity at lower doses occurred in 
individuals who took the drug for at least 5 years.
19.10.1.2  Eye Examination
Consists of a dilated posterior-segment examina-
tion, along with Amsler grid testing or automated 
perimetry. Baseline fundus photographs and flu-
orescein angiography (FA) are helpful in patients 
with preexisting macular pigmentary changes. 
The patients should repeat visual acuity testing 
every 6 months, screen the visual field, use the 
Amsler grid, and have a detailed funduscopy. 
Central threshold visual field testing is recom-
mended for suspected optic neuropathy.
19.10.1.3  Treatment
The only treatment for antimalarial related reti-
nopathy is stopping the offending medication 
with consultation of the rheumatologist who is 
taking care of the patient.
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20.1  Learning Objectives
By the end of this chapter, you should be able to:
 – Discuss pathologic mechanisms underlying 
vasculitis.
 – Review classification and nomenclature of 
vasculitis.
 – Compose a diagnostic approach to a patient 
with vasculitis.
 – Describe major forms of vasculitis.
Vasculitis is a clinicopathologic process char-
acterized by inflammation and damage of blood 
vessels by leucocytes which leads to bleeding. 
Compromise of vascular lumen results in isch-
emia and necrosis of the tissues supplied by the 
involved vessels. Vasculitis can be a primary dis-
ease process, or it may be secondary to another 
underlying disease [1].
20.1.1  Pathologic Mechanisms 
Underlying Vasculitis
The exact mechanisms are unclear. However, 
three different models have been advanced [2]:
 1. Pathogenic immune-complex formation and/
or deposition
(IgA vasculitis, hepatitis C-associated vas-
culitis, hepatitis B-associated vasculitis)
 2. Production of antineutrophil cytoplasmic anti-
bodies (ANCA)
(Microscopic polyangiitis, granulomatosis 
with polyangiitis, eosinophilic granulomato-
sis with polyangiitis)
 3. Pathogenic T lymphocytic responses and 
granuloma formation
(Giant cell arteritis, Takayasu’s arteritis, 
granulomatosis with polyangiitis, eosinophilic 
granulomatosis with polyangiitis)
The end result of these immunopathologic 
pathways is endothelial cell activation, with 
subsequent vessel obstruction and ischemia of 
dependent tissue. This may cause hemorrhage 
in the surrounding tissues and, in some cases, 
weakening of the vessel wall, which leads to 
the formation of aneurysms. For almost all 
forms of vasculitis, the triggering event initiat-
ing and driving this inflammatory response is 
unknown.
20.1.2  Classification of Vasculitis
Vasculitis is classified based on the predominant 
size of vessels affected. Types of vessels are 
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defined in the (CHCC) 2012 [3, 4]. This is illus-
trated in Fig. 20.1.
20.1.3  The 2012 Chapel Hill 
Consensus Conference (CHCC) 
on Nomenclature of Vasculitis
The CHCC is a nomenclature system. It is neither 
a classification system nor a diagnostic system. It 
specifies the name that should be used for a spe-
cifically defined disease process. The following 
names are adopted by the CHCC 2012 on the 
nomenclature of vasculitides [4], and their defini-
tions are presented in Table 20.1.
Large Vessel Vasculitis (LVV):
 1. Takayasu’s arthritis (TA).
 2. Giant cell arthritis (GCA).
Medium Vessel Vasculitis (MVV):
 1. Polyarteritis nodosa (PAN).
 2. Kawasaki disease (KD).
Small Vessel Vasculitis (SVV):
 1. Antineutrophil cytoplasmic antibodies 
(ANCA)-associated vasculitis:
 (a) Granulomatosis with polyangiitis (GPA).
 (b) Microscopic polyangiitis (MPA).
 (c) Eosinophilic granulomatosis with polyan-
giitis (EGPA).
 2. Immune-complex-associated vasculitis:
 (a) Anti-glomerular basement membrane 
(Anti-GBM) disease.
 (b) Cryoglobulinemic vasculitis (CV).
 (c) IgA vasculitis (IgAV).
 (d) Hypocomplementemic urticarial vasculi-
tis (HUV) (Anti-C1q).
Variable Vessel Vasculitis (VVV):
 1. Behcet’s disease (BD).
 2. Cogan’s syndrome (CS).
Single Organ Vasculitis (SOV):
 1. Cutaneous leukocytoclastic angiitis.
 2. Cutaneous arteritis.
 3. Primary central nervous system vasculitis.
 4. Isolated aortitis.
Vasculitis Associated with Systemic 
Disease:
 1. Lupus vasculitis.
 2. Rheumatoid vasculitis.
 3. Sarcoid vasculitis.
Vasculitis Associated with Probable 
Etiology:
 1. Hepatitis C-associated cryoglobulinemic 
vasculitis.
 2. Hepatitis B-associated vasculitis.
 3. Syphilis-associated vasculitis.
 4. Drug-associated immune-complex vasculitis.
 5. Drug-associated ANCA-associated vasculitis.
 6. Cancer-associated vasculitis.
A AB C B
Fig. 20.1 Types of vessels that are defined by the 2012 
Chapel Hill Consensus Conference nomenclature system. 
(a) Large vessels represents the aorta, its major branches 
and their corresponding veins. (b) Medium vessels are the 
visceral arteries, veins and their main branches. (c) Small 
vessels consist of interparenchymal arteries, arterioles, 
capillaries, venules and veins
W. Hafiz
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Table 20.1 Definitions adopted by the 2012 CHCC on the nomenclature of vasculitides [4]
CHCC2012 name CHCC2012 definition
Large vessel vasculitis 
(LVV)
“Vasculitis affecting large arteries more often than other vasculitides. Large arteries are 
the aorta and its major branches. Any size artery may be affected. Page no. 6”
Takayasu arteritis
(TAK)
“Arteritis, often granulomatous, predominantly affecting the aorta and/or its major 
branches. Onset usually inpatients younger than 50 years. Page no. 6”
Giant cell arteritis
(GCA)
“Arteritis, often granulomatous, usually affecting the aorta and/or its major branches, with 
a predilection for the branches of the carotid and vertebral arteries. Often involves the 
temporal artery. Onset usually in patients older than 50 years and often associated with 
polymyalgia rheumatica. Page no. 6”
Medium vessel 
vasculitis (MVV)
“Vasculitis predominantly affecting medium arteries defined as the main visceral arteries 
and their branches. Any size artery may be affected. Inflammatory aneurysms and 
stenoses are common. Page no. 6”
Polyarteritis nodosa
(pan)
“Necrotizing arteritis of medium or small arteries without glomerulonephritis or vasculitis 
in arterioles, capillaries, or venules, and not associated with antineutrophil cytoplasmic 
antibodies (ANCAs). Page no. 6”
Kawasaki disease
(KD)
“Arteritis associated with the mucocutaneous lymph node syndrome and predominantly 
affecting medium and small arteries. Coronary arteries are often involved. Aorta and large 
arteries may be involved. Usually occurs in infants and young children. Page no. 6”
Small vessel vasculitis
(SVV)
“Vasculitis predominantly affecting small vessels, defined as small intraparenchymal 





“Necrotizing vasculitis, with few or no immune deposits, predominantly affecting small 
vessels (i.e., capillaries, venules, arterioles, and small arteries), associated with 
myeloperoxidase (MPO)ANCA or proteinase 3 (PR3) ANCA. Not all patients have 
ANCA. Add a prefix indicating ANCA reactivity, e.g., MPO- ANCA, PR3-ANCA, ANCA 




“Necrotizing vasculitis, with few or no immune deposits, predominantly affecting small 
vessels (i.e., capillaries, venules, or arterioles). Necrotizing arteritis involving small and 
medium arteries may be present. Necrotizing glomerulonephritis is very common. 
Pulmonary capillaritis often occurs. Granulomatous inflammation is absent. Page no. 6”
Granulomatosis with 
polyangiitis (GPA)
“Necrotizing granulomatous inflammation usually involving the upper and lower 
respiratory tract, and necrotizing vasculitis affecting predominantly small to medium 
vessels (e.g., capillaries, venules, arterioles, arteries and veins). Necrotizing 





“Eosinophil-rich and necrotizing granulomatous inflammation often involving the 
respiratory tract, and necrotizing vasculitis predominantly affecting small to medium 
vessels, and associated with asthma and eosinophilia. ANCA is more frequent when 
glomerulonephritis is present. Page no. 6”
Immune complex 
vasculitis
“Vasculitis with moderate to marked vessel wall deposits of immunoglobulin and/or 
complement components predominantly affecting small vessels (i.e., capillaries, venules, 





“Vasculitis affecting glomerular capillaries, pulmonary capillaries, or both, with GBM 
deposition of anti-GBM autoantibodies. Lung involvement causes pulmonary 
hemorrhage, and renal involvement causes glomerulonephritis with necrosis and 
crescents. Page no. 6”
Cryoglobulinemic 
vasculitis (CV)
“Vasculitis with cryoglobulin immune deposits affecting small vessels (predominantly 
capillaries, venules, or arterioles) and associated with serum cryoglobulins. Skin, 
glomeruli, and peripheral nerves are often involved. Page no. 6”
IgA vasculitis (IgAV) “Vasculitis, with IgA1- dominant immune deposits, affecting small vessels (predominantly 
capillaries, venules, or arterioles). Often involves skin and gastrointestinal tract, and 
frequently causes arthritis. Glomerulonephritis indistinguishable from IgA nephropathy 




20.1.4  How to Approach a Patient 
with Vasculitis?
20.1.4.1  A Case Scenario
A lady comes to the clinic with a rash over her 
legs. She is aged 32  years and for the last 
6  months has been unwell, with intermittent 
fevers, loss of appetite, and fatigue. Recent blood 
tests show elevated erythrocyte sedimentation 
rate (ESR; 83  mm/h) and C-reactive protein 
(CRP; 46  mg/dL). Today she has palpable pur-
pura on her lower legs. Urinalysis is positive for 
blood and protein.
What are the clinical clues to vasculitis?
What investigations will assist with a precise 
diagnosis?
How should the condition be treated and 
monitored?
Tables 20.2, 20.3 and 20.4 summarize history, 
physical examination findings (Fig.  20.3), and 
work-up of a patient presenting with suspected 
vasculitis. Figure 20.2 summarizes history taking 
from a patient presenting with suspected vasculi-
tis. This includes review of systems, past medical 
history, and medication history. Figures  20.4, 
20.5 and 20.6 show different mucocutaneous 
finding that can be present in a patient with 
vasculitis.
20.1.5  Major Forms of Vasculitis
20.1.5.1  Takayasu’s Arteritis (TA)
TA primarily affects the aorta and its primary 
branches [5]. It is an uncommon form of vasculi-
tis. Up to 90% of the cases are women of repro-
ductive age, and it is more prevalent in Asia [6]. 
Table 20.1 (continued)





“Vasculitis accompanied by urticaria and hypocomplementemia affecting small vessels 
(i.e., capillaries, venules, or arterioles), and associated with anti-C1qantibodies. 
Glomerulonephritis, arthritis, obstructive pulmonary disease, and ocular inflammation are 




“Vasculitis with no predominant type of vessel involved that can affect vessels of any size 
(small, medium, and large) and type (arteries, veins, and capillaries). Page no. 6”
Behcet’s disease
(BD)
“Vasculitis occurring in patients with Behcet’s disease that can affect arteries or veins. 
Behcet’s disease is characterized by recurrent oral and/or genital aphthous ulcers 
accompanied by cutaneous, ocular, articular, gastrointestinal, and/or central nervous 
system inflammatory lesions. Small vessel vasculitis, thromboangiitis, thrombosis, 
arteritis, and arterial aneurysms may occur. Page no. 6”
Cogan’s syndrome
(CS)
“Vasculitis occurring in patients with Cogan’s syndrome. Cogan’s syndrome characterized 
by ocular inflammatory lesions, including interstitial keratitis, uveitis, and episcleritis, and 
inner ear disease, including sensorineural hearing loss and vestibular dysfunction. 
Vasculitic manifestations may include arteritis (affecting small, medium, or large 
arteries), aortitis, aortic aneurysms, and aortic and mitral valvulitis. Page no. 6”
Single-organ vasculitis
(SOV)
“Vasculitis in arteries or veins of any size in a single organ that has no features that 
indicate that it is a limited expression of a systemic vasculitis. The involved organ and 
vessel type should be included in the name (e.g., cutaneous small vessel vasculitis, 
testicular arteritis, central nervous system vasculitis). Vasculitis distribution may be 
unifocal or multifocal (diffuse) within an organ. Some patients originally diagnosed as 
having SOV will develop additional disease manifestations that warrant redefining the 
case as one of the systemic vasculitides (e.g., cutaneous arteritis later becoming systemic 




“Vasculitis that is associated with and maybe secondary to (caused by) a systemic disease. 
The name (diagnosis) should have a prefix term specifying the systemic disease (e.g., 




“Vasculitis that is associated with a probable specific etiology. The name (diagnosis) 
should have a prefix term specifying the association (e.g., hydralazine-associated 
microscopic polyangiitis, hepatitis B virus–associated vasculitis, hepatitis C virus-
associated cryoglobulinemic vasculitis, etc.). Page no. 7”
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The inflammation is characterized by thickening 
of the arterial wall. This can lead to narrowing, 
occlusion, or dilatation of the arteries [7].
The pathogenesis of TA is not clear. Presence 
of mononuclear cells is thought to cause active 
inflammation that leads to granuloma formation 
[8]. Aneurysms are formed due to laminal 
destruction. Arterial plaques were also found in 
patients with TA [9].
Systemic symptoms are manifested early in 
TA [10]. As the disease progresses, vascular 
involvement becomes evident. Subclavian artery 
stenosis proximal to the origin of the vertebral 
artery can lead to the so-called subclavian steal 
syndrome [11]. Ischemic ulcerations and gan-
grene may develop as results of vascular 
occlusion.
The differential diagnosis of TA includes 
fibromuscular dysplasia, excess ergotamine 
intake, Ehlers-Danlos syndrome, and GCA.





Fever, weight loss, malaise, loss 
of appetite, and fatigue
Skin Rash, palpable purpura, nodules, 
ulcers, and cutaneous or nailfold 
infarctions
Ocular symptoms Pain, redness, diplopia, and 
visual loss
Neurological Numbness, weakness, pain 
consistent with mononeuritis 
multiplex, transient ischemic 
attacks, and symptoms suggestive 
of stroke
Cardiac Chest pain and dyspnea
Pulmonary Chest pain, dyspnea, cough, and 
hemoptysis
Gastrointestinal Abdominal pain and upper or 
lower gastrointestinal bleeding




Systemic rheumatic diseases 
(systemic lupus erythematosus, 








Bronchial asthma, hyperactive 
airways





thiazide, allopurinol, penicillin, 
gold, phenytoin, and sulfonamide
Table 20.3 What to look for when physically examining 
a patient with suspected vasculitis?
Skin Palpable purpura, nodules, 
papules, ulcers, and digital 
ischemia
Pulse and blood 
pressure
Unequal pulses and high blood 
pressure (especially diastolic)
Face Pallor, conjunctivitis, septal nasal 
perforation, and saddle nose 
deformity
Oral cavity and 
neck





Musculoskeletal Arthritis and migratory 
polyarthritis
Table 20.4 What are the laboratory tests that help ascer-
tain the type of vasculitis?
CBC Anemia, leukocytosis, 
leukopenia, thrombocytosis, 
and thrombocytopenia
Renal profile Hyperkalemia and elevated 
creatinine
Hepatic profile Abnormal if there is an 
underlying hepatitis






Hepatitis and HIV 
serology
Rule out hepatitis B or C and 
HIV infection




Elevated ESR and/or CRP
Chest X-ray Pulmonary involvement 
(nodules, infiltrates, cavities, 
etc.)




irregularities, stenosis, and 
post-stenotic dilatation










Pulse and blood pressure 
Unequal pulse
























Finger and toe discoloration

























Past Medical History Systemic rheumatic diseases, malignancies, hematological conditions,
bronchial asthma, hyperactive airways and Infections.
Medication History Hydralazine, propylthiouracil, thiazide, allopurinol, penicillin, Gold,
phenytoin and sulphonamide.
Fig. 20.2 History taking from a patient presenting with suspected vasculitis. This includes review of systems, past 
medical history and medication history
W. Hafiz
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Glucocorticoids are the mainstay treatment. 
They reduce both systemic symptoms and dis-
ease progression [12]. Azathioprine, mycopheno-
late, methotrexate, tocilizumab, or leflunomide 
can be used in glucocorticoid-resistant cases, 
while cyclophosphamide is for those who have 
continued disease activity despite those medica-
tions [13, 14]. Percutaneous transluminal angio-
plasty or bypass grafts may be considered in late 
cases when irreversible arterial stenosis has 
occurred and when significant ischemic 
 symptoms develop [15].
Table 20.5 summarizes CHCC12 definition, epi-
demiology, clinical manifestation, diagnostic stud-
ies, American College of Rheumatology (ACR) 
1990 classification criteria, and treatment of TA.
20.1.5.2  Giant Cell Arteritis (GCA)
GCA is a vasculitis of large-sized vessels. Up to 
90% of cases are above the age of 60 [16]. It 
affects the aorta and its major branches, mainly 
the carotid and vertebral arteries [17].
The pathogenesis of GCA is poorly under-
stood. It is thought that an initial trigger (e.g., 
viral infection or other factor) activates mono-
cytes in a susceptible host. These monocytes 
cause systemic symptoms. Release of inflamma-
tory mediators and tissue injury may lead to 
fibrosis, scarring, and narrowing or occlusion of 
the arteries [18].
Symptoms of GCA start gradually but may 
manifest acutely in some patients. An efficient 
history should include questions about sys-
temic symptoms, such as fever, fatigue, and 
weight loss; headache; jaw claudication, which 
is the most specific symptom of GCA; visual 
symptoms; and symptoms of polymyalgia 
rheumatica [19–21].
Fig. 20.4 Erythema nodosum in polyarteritis nodosa. 
Courtesy of Prof. Hani Almoallim
Fig. 20.5 Leukocytoclastic vasculitis with palpable pur-
pura in a patient with immune-complex-associated small 
vessel vasculitis. Courtesy of Prof. Hani Almoallim
Fig. 20.6 Oral ulcer in a patient with Behcet’s disease. 
Courtesy of Dr. Lujain Homeida
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Temporal artery biopsy is the gold standard 
modality for the diagnosis of GCA. However, if 
the clinical suspicion is high or vision is threat-
ened, high-dose glucocorticoid therapy should be 
started immediately. Appropriate measures to 
prevent glucocorticoid-induced osteoporosis 
should be taken [22]. Methotrexate is moderately 
effective as a glucocorticoid-sparing agent. 
Tocilizumab was recently granted a breakthrough 
designation status by the US Food and Drug 
Association for GCA based on positive results 
from a phase 3 clinical trial [23].
Table 20.6 summarizes CHCC12 definition, 
epidemiology, clinical manifestation, diagnostic 
Table 20.5 Takayasu’s arteritis (pulseless disease)
CHCC 2012 
definition
Arteritis, often granulomatous, 
predominantly affecting the aorta 
and/or its major branches. Onset 
usually in patients younger than 
50 years [4]
Epidemiology Most common in Asia and in young 
women of reproductive age
Clinical 
manifestation
Phase 1: Inflammatory period 
(fever, arthralgias, weight loss)
Phase 2: Vessel pain and 
tenderness, unequal pulses in 
extremities, bruits, limb 
claudication, hypertension, aortic 
aneurysm, and insufficiency
Phase 3: Vessel fibrosis
Diagnostic 
studies
Elevated ESR (75%) and CRP
Angiography and MRI/MRA: 
Stenosis, occlusion, irregularity, 
and aneurysms
Biopsy: Pan arteritis, cellular 





  1.  Age less than 40 at disease 
onset.
  2. Claudication of extremities.
  3.  Decrease in brachial artery 
pulse.
  4.  Systolic BP difference by 
more than 10 mmHg between 
both arms.
  5.  Bruit over subclavian artery or 
aorta.
  6.  Arteriographic narrowing or 
occlusion.
Presence of 3 out of 6 is 90.5% 
sensitive (se) and 97.8% specific 
(Sp) [3]
Treatment Steroids: 40–60 mg/day initially, 
then slow tapering based on clinical 
and radiological response. 
Methotrexate, leflunomide, 
azathioprine, or tocilizumab for 
resistant cases.
May consider antiplatelet therapy 
or surgical/endovascular 
revascularization
Table 20.6 Giant cell arteritis
CHCC 2012 
definition
Arteritis, often granulomatous, 
usually affecting the aorta and/or its 
major branches, with a predilection 
for the branches of the carotid and 
vertebral arteries. Often involves the 
temporal artery. Onset usually in 
patients older than 50 years and often 
associated with polymyalgia 
rheumatica [4]
Epidemiology 90% are above 60 years, rare below 
50 years, female/male ratio is 2:1
Clinical 
manifestation
Constitutional symptoms, headache, 
tender and pulseless temporal arteries, 
optic neuritis, diplopia, amaurosis 
fugax, blindness, jaw claudication, 




Elevated ESR and CRP. Anemia
Angiography, MRI/MRA: If aortic 
aneurysm is suspected





  1.  Age more than 50 at disease 
onset.
  2. New headache.
  3.  Temporal artery tenderness or 
decreased pulse.
  4. ESR more than 50 mm/h.
  5.  Biopsy: Vasculitis and 
granulomas.
Presence of 3 out of 5 is 93.5% Se 
and 91.2% Sp [3]
Polymyalgia 
rheumatica
Seen in 50% of patients with GCA, 
15% of patients with PMR develop 
GCA.
Bilateral aching and morning 
stiffness for more than 30 min for 
more than 1 month, involving two of 
the following areas: Neck or torso, 
shoulders or proximal arms, hips or 
proximal thighs, and night time pain. 
Age at onset is usually more than 40
Treatment Steroids: 40 to 60 mg/day and 10 to 
20 mg/day for polymyalgia 
rheumatica.
Taper down treatment based on 
clinical response. Monitor ESR and 
CRP
Methotrexate and tocilizumab can be 
added as steroid-sparing agents
W. Hafiz
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studies, ACR 1990 classification criteria, and 
treatment of GCA.
20.1.5.3  Polyarteritis Nodosa (PAN)
PAN is a systemic necrotizing arteritis of the 
medium-sized muscular arteries, with occasional 
involvement of small muscular arteries. It is not 
associated with the presence of ANCA. It is more 
common in men in the sixth decade of life [24].
PAN is mostly idiopathic, although hepatitis B 
virus infection, hepatitis C virus infection, and 
hairy cell leukemia are important in the patho-
genesis of some cases. The pathogenesis is poorly 
understood. It is characterized by segmental 
transmural inflammation of muscular arteries 
which leads to fibrinoid necrosis and disruption 
of the elastic lamina. Unlike other forms of sys-
temic vasculitis, it does not involve veins [25].
Like most types of vasculitis, patients with 
PAN present with systemic symptoms (fatigue, 
weight loss, weakness, fever, arthralgias) and 
signs of multisystem involvement (skin lesions, 
hypertension, renal insufficiency, neurologic dys-
function, and abdominal pain). PAN has a strik-
ing tendency to spare the lungs.
The differential diagnosis of PAN is broad, 
including infectious diseases that affect the vas-
culature or that are complicated by systemic vas-
culitis; noninfectious disorders, particularly 
those that can cause widespread arterial embo-
lism, thrombosis, or vasospasm; and other sys-
temic vasculitides.
Treatment of PAN depends on the severity of 
the disease. Mild disease can be treated with 
prednisolone at a dose of 1 mg/kg per day (maxi-
mum 60 to 80 mg/day) for approximately 4 weeks 
and then to be tapered based on clinical improve-
ment [26]. Moderate to severe disease is treated 
with methotrexate, azathioprine, mycophenolate, 
or cyclophosphamide [26].
Table 20.7 summarizes CHCC12 definition, 
epidemiology, clinical manifestation, diagnostic 
studies, ACR 1990 classification criteria, and 
treatment of PAN.
Table 20.7 Polyarteritis nodosa
CHCC 2012 
definition
Necrotizing arteritis of medium or small arteries without glomerulonephritis or vasculitis in 
arterioles, capillaries, or venules and not associated with antineutrophil cytoplasmic antibodies 
(ANCAs) [4]
Epidemiology More common in men. Average age at onset is 50. Strongly associated with HBV
Clinical 
manifestation
Constitutional symptoms, myalgias, arthralgias, arthritis, active urinary sediment, hypertension, 
renal impairment, peripheral neuropathy, mononeuritis multiplex, abdominal pain, GI bleeding, 




Elevated ESR and CRP. Leukocytosis. HbsAg is positive in about 30%
ANCA is negative
Angiography or CTA: Microaneurysms and focal vessel narrowing




  1. More than 4 kilograms of weight loss.
  2. Livedo reticularis.
  3. Testicular pain or tenderness.
  4. Myalgias, weakness, and leg tenderness.
  5. Mono or polyneuropathy.
  6. Diastolic BP more than 90 mmHg.
  7. Elevated BUN more than 40 mg/dL or Cr more than 1.5 mg/dL.
  8. HBV.
  9. Arteriographic abnormality.
  10. Vasculitis on biopsy.
Presence of 3 out of 10 is 82% Se and 87% Sp [3]
Treatment Steroids: 40–60 mg/day initially and then slow tapering based on clinical and radiological 
response. Steroid- sparing agents for resistant cases. Antiviral therapy for HBV-related disease
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20.1.5.4 Granulomatosis with Polyangiitis 
(GPA) and Microscopic 
Polyangiitis (MPA)
These are types of vasculitis that affect small ves-
sels. They occur mostly in older adults, and both 
genders are equally affected. Both types are asso-
ciated with ANCA and have similar features on 
renal histology (crescentic, pauci-immune glo-
merulonephritis) [27].
An initiating event (e.g., infection or drug) 
causes tissue injury and immune response [28]. 
This leads to production of ANCA. Up to 80% of 
the antigens observed in granulomatosis with 
polyangiitis are proteinase 3 (PR3) (c-ANCA), 
while myeloperoxidase (MPO) (p-ANCA) is 
observed in 10% of patients. About 70% of 
microscopic polyangiitis patients have positive 
ANCA which is mostly p-ANCA.
Patients typically present with constitutional 
symptoms that may last for weeks to months with-
out evidence of specific organ involvement. Both 
types affect multiple systems including pulmonary, 
renal, ocular, neurologic, and hematologic [29].
The distinction of these types of small vessel 
vasculitis from other systemic rheumatic diseases 
is challenging. Differential diagnosis includes 
diseases with similar general clinical features 
like EGPA, similar lung and/or renal signs like 
anti-GBM disease, and/or positive ANCA serolo-
gies like renal-limited vasculitis.
Therapy has two components: induction of 
remission with initial immunosuppressive ther-
apy and maintenance immunosuppressive ther-
apy for a variable period to prevent relapse. 
Choice of drug regimen in induction of remission 
depends on the severity of the disease. Mild dis-
ease can be treated by a combination therapy 
with glucocorticoids and methotrexate, while 
cyclophosphamide or rituximab [30] is required 
to treat severe disease. Plasma exchange is added 
in case of glomerulonephritis or pulmonary hem-
orrhage [31, 32].
Tables 20.8 and 20.9 summarize CHCC12 
definition, epidemiology, clinical manifestation, 
diagnostic studies, ACR 1990 classification crite-
ria, and treatment of GPA and MPA.
Table 20.8 Granulomatosis with polyangiitis
CHCC 2012 
definition
Necrotizing granulomatous inflammation usually involving the upper and lower respiratory tract 
and necrotizing vasculitis affecting predominantly small to medium vessels (e.g., capillaries, 
venules, arterioles, arteries, and veins). Necrotizing glomerulonephritis is common [4]
Epidemiology Can occur at any age, but mostly in young and middle-aged adults
Clinical 
manifestation
Pulmonary: Sinusitis, rhinitis, nasal mucosal ulceration, saddle nose deformity, pleurisy, 
pulmonary infiltrates, nodules, hemorrhage, and hemoptysis
Renal: Hematuria and glomerulonephritis
Ocular: Episcleritis, uveitis, proptosis, corneal ulcers
Neurological: Cranial and peripheral neuropathies and mononeuritis multiplex
Hematological: Increase incidence of DVT/PE
Diagnostic 
studies
90% have positive ANCA (80 to 95% c-ANCA, remainder p-ANCA)
CXR or CT chest: Nodules, infiltrates, cavities. CT sinus: Sinusitis
Elevated BUN and creatinine, hematuria, proteinuria, and sediment with RBC casts




  1. Nasal or oral inflammation: Oral ulcers, purulent or bloody nasal discharge.
  2. CXR showing nodules, fixed infiltrates or cavities.
  3. Microscopic hematuria or urinary red cell casts.
  4. Granulomatous inflammation on biopsy.
Presence of 2 out of 4 is 88% Se and 92% Sp [3]
Treatment Induction: Cyclophosphamide PO (2 mg/kg/day for 3 to 6 months or pulse 15 mg/kg/day every 2 
to 3 weeks) or IV rituximab 375 mg/m2 per week for 4 weeks and prednisolone 1 to 2 mg/kg/day 
taper over 6 to 18 months. If rapidly progressive glomerulonephritis, add plasma exchange




20.1.5.5  Eosinophilic Granulomatosis 
with Polyangiitis (EGPA)
EGPA is a multisystem disease characterized by 
allergic rhinitis, asthma, and prominent periph-
eral blood eosinophilia [33].
In this disease, ANCA is detected in about 
50% of patients. The etiology of EGPA is 
unknown. However, genetic factors such as HLA- 
DRB4 are thought to play a role. Presence of 
ANCA produces an immune response, which 
then leads to eosinophilic infiltration and necro-
tizing granuloma [34].
Clinical features of EGPA develop in several 
phases: the prodromal phase which is character-
ized by presence of asthma and allergic rhinitis; 
the eosinophilic phase with eosinophilic infiltra-
tion of multiple organs; and the vasculitis phase 
that may be heralded by nonspecific constitu-
tional symptoms [35].
Differential diagnosis includes aspirin- 
exacerbated respiratory disease, the eosinophilic 
pneumonias, allergic bronchopulmonary asper-
gillosis, the hyper-eosinophilic syndrome, and 
other ANCA-associated vasculitides.
Treatment of EGPA consists of induction of 
remission and maintenance of remission. For 
mild disease, induction can be achieved with 
high-dose glucocorticoids. Cyclophosphamide is 
added to glucocorticoids in severe disease. For 
maintenance of remission, azathioprine or meth-
otrexate can be used [36].
Table 20.10 summarizes CHCC12 definition, 
epidemiology, clinical manifestation, diagnostic 
studies, ACR 1990 classification criteria, and 
treatment of EGPA.
20.1.5.6  IgA Vasculitis (IgAV)
IgA vasculitis, also previously called Henoch- 
Schönlein Purpura, is the most common 
systemic.
vasculitis of childhood. Up to 10% of IgA vas-
culitis occur in adults.
It is a self-limited disease and is characterized 
by the presence of the following: palpable pur-
pura without thrombocytopenia and coagulopa-
thy, arthralgias and/or arthritis, abdominal pain, 
and renal disease [37].
The underlying cause of IgA vasculitis is 
unknown. It is thought that IgA vasculitis repre-
sents an immune-mediated vasculitis that may be 
triggered by a variety of antigens, including vari-
ous infections or immunizations [38].
Treatment of IgA vasculitis is supportive and 
should be directed toward adequate oral hydra-
tion, bed rest, and symptomatic relief of joint and 
abdominal pain. Nonsteroidal anti-inflammatory 
drugs can be used to alleviate joint or abdominal 
pain. Glucocorticoids are used for more severe 
cases [39].
Table 20.9 Microscopic polyangiitis
CHCC 2012 
definition
Necrotizing vasculitis, with few or 
no immune deposits, predominantly 
affecting small vessels (i.e., 
capillaries, venules, or arterioles). 
Necrotizing arteritis involving small 
and medium arteries may be present. 
Necrotizing glomerulonephritis is 
very common. Pulmonary capillaritis 
often occurs. Granulomatous 
inflammation is absent [4]
Epidemiology Not associated with HBV
Clinical 
manifestation
Similar to granulomatosis with 
polyangiitis but renal involvement is 




70% have positive ANCA (almost all 
p-ANCA)
CXR or CT chest: Nodules, 
infiltrates, cavities
Elevated BUN and creatinine, 
hematuria, proteinuria, sediment 







Treatment Induction: Cyclophosphamide PO 
(2 mg/kg/day for 3 to 6 months or 
pulse 15 mg/kg/day every 2 to 
3 weeks) or IV rituximab 375 mg/m2 
per week for 4 weeks and 
prednisolone 1 to 2 mg/kg/day taper 
over 6 to 18 months. If rapidly 
progressive glomerulonephritis, add 
plasma exchange
Maintenance: Methotrexate or 
azathioprine for 2 years. Bactrim 
may prevent respiratory infections
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Table 20.11 summarizes CHCC12 definition, 
epidemiology, clinical manifestation, diagnostic 
studies, ACR 1990 classification criteria, and 
treatment of IgA vasculitis.
20.1.5.7  Cutaneous Leukocytoclastic 
Angiitis
Cutaneous leukocytoclastic angiitis, also previ-
ously called hypersensitivity vasculitis, is a form 
of single-organ vasculitis that involves cutaneous 
vessels of any size with no evidence of systemic 
vasculitis [4].
It is the most common type of vasculitis. It 
may be idiopathic, but it may be directly caused 
by drugs, infections, tumor antigens, and serum 
sickness.
It is difficult to distinguish cutaneous leukocy-
toclastic angiitis from other forms of vasculitis, 
particularly when confined to the skin. Many 
types of systemic vasculitis may present initially 
with cutaneous involvement, so careful evalua-
tion is required.
Treatment of the underlying cause or with-
drawal of the offending agent lead to resolution 
within a period of days to a few weeks. 
Glucocorticoids are preserved for progressive 
disease [40].




Eosinophil-rich and necrotizing 
granulomatous inflammation often 
involving the respiratory tract, and 
necrotizing vasculitis predominantly 
affecting small to medium vessels, 
and associated with asthma and 
eosinophilia. ANCA is more 
frequent when glomerulonephritis is 
present [4]
Epidemiology Rare condition, can present at any 
age. Associated with HLA-DRB4
Clinical 
manifestation
Asthma and allergic rhinitis
Eosinophilic infiltrative disease or 
pneumonia
Systemic small vessel vasculitis 
with granuloma
Neuropathy, glomerulonephritis
Cardiac involvement: Coronary 
arteritis, myocarditis, and vascular 
insufficiency
Dermatological: Palpable purpura, 
petechiae, and subcutaneous nodules
Diagnostic 
studies
50% have positive ANCA (c-ANCA 
or p-ANCA). Eosinophilia
CXR: Shifting pulmonary infiltrates
Elevated BUN and creatinine, 
hematuria, proteinuria, and sediment 
with RBC casts





  1. Asthma.
  2. Eosinophilia more than 10%.
  3. Mono- or polyneuropathy.
  4.  Migratory or transitory 
pulmonary infiltrates.
  5. Paranasal sinus abnormality.
  6.  Extravascular eosinophils on 
biopsy.
Presence of 4 out of 6 is 85% Se and 
99.7% Sp [3]
Treatment Induction: High-dose 
corticosteroids. Cyclophosphamide 
can be used if necessary
Maintenance: Azathioprine or 
methotrexate
Table 20.11 IgA vasculitis
CHCC 2012 
definition
Vasculitis, with IgA1-dominant 
immune deposits, affecting small 
vessels (predominantly capillaries, 
venules, or arterioles). Often 
involves skin and gastrointestinal 
tract and frequently causes arthritis. 
Glomerulonephritis 
indistinguishable from IgA 
nephropathy may occur [4]
Epidemiology Males are affected more than 




Palpable purpura on extensor 
surfaces and buttocks
Polyarthralgias, abdominal pain, GI 





Skin biopsy: Leukocytoclastic 
vasculitis with IgA and C3 
deposition in vessel wall





  1. Palpable purpura.
  2.  Age less than 20 at disease 
onset.
  3. Bowel angina.
  4.  Skin biopsy: Leukocytoclastic 
vasculitis with IgA and C3 
deposition in vessel wall.
Presence of 2 out of 4 is 87% Se and 
88% Sp [3]
Treatment Supportive, steroids, and disease- 
modifying antirheumatic drugs for 
renal involvement or severe disease
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Table 20.12 summarizes CHCC12 definition, 
epidemiology, clinical manifestation, diagnostic 
studies, ACR 1990 classification criteria, and 
treatment of cutaneous leukocytoclastic angiitis.
20.1.5.8  Behcet’s Disease (BD)
It is a type of vasculitis that can affect blood ves-
sels of all sizes. It is characterized by recurrent 
oral aphthae and any of several systemic mani-
festations including genital aphthae, ocular dis-
ease, skin lesions, gastrointestinal involvement, 
neurologic disease, vascular disease, or arthritis. 
It is more common along the ancient silk road, 
which extends from Eastern Asia to the 
Mediterranean. It typically affects adults between 
the age of 20 and 40 with a similar prevalence 
between both genders [41].
The underlying cause of BD is unknown. It is 
thought that the immune response is triggered by 
exposure to an agent (e.g., infection, chemicals). 
It is also found to be associated with HLA-B51 
[42]. Both cellular and humoral immunity 
responses are activated [43]. Endothelial dys-
function leads to inflammation and thrombus for-
mation in BD [43].
Ocular, vascular, and neurological manifesta-
tions account for the greatest morbidity and mor-
Table 20.12 Cutaneous leukocytoclastic angiitis
CHCC 2012 
definition
A form of single-organ vasculitis, 
involves arteries or veins of any size 
in the skin that has no features 
indicating that it is a limited 
expression of systemic vasculitis [4]
Epidemiology Most common type of vasculitis. 
Caused by drugs (e.g., penicillin, 
cephalosporins, phenytoin, 
allopurinol, aspirin, amphetamine, 
thiazide, chemicals and 
immunizations), by infections (e.g., 
streptococcal throat infection, 
bacterial endocarditis, and TB), 
tumor antigens, and serum sickness
Clinical 
manifestation
Palpable purpura, ulceration, 




Elevated ESR and eosinophils. Low 
complements
Skin biopsy: Leukocytoclastic 





  1. Age more than 16.
  2. Medication taken at disease onset.
  3. Palpable purpura.
  4. Maculopapular rash.
  5.  Skin biopsy: Leukocytoclastic 
vasculitis with neutrophils.
Presence of 3 out of 5 is 71% Se and 
84% Sp [3]
Treatment Withdrawal of the offending agent 
and rapid prednisolone taper
Table 20.13 Behcet’s disease
CHCC 2012 
definition
Vasculitis occurring in patients with Behcet’s disease that can affect arteries or veins. Behcet’s 
disease is characterized by recurrent oral and/or genital aphthous ulcers accompanied by 
cutaneous, ocular, articular, gastrointestinal, and/or central nervous system inflammatory lesions. 
Small vessel vasculitis, thromboangiitis, thrombosis, arteritis, and arterial aneurysms may occur [4]
Epidemiology Associated with HLA-B51. Highest prevalence in Turkey and other Asian countries
Classification 
criteria
  1. Recurrent oral aphthous ulceration (at least 3 times a year).
  2. Recurrent genital ulceration.
  3. Eye lesion (uveitis, scleritis, optic neuritis).
  4. Skin lesions (pustules, papules, erythema nodosum).
  5. Positive pathergy test (skin prick with a sterile needle will produce a pustule).
Presence of first criteria plus two or more of the others is 91% se and 96% Sp
Other clinical 
manifestation




Slit lamp and fundoscopic eye examination
Treatment Mucocutaneous
Mild: Colchicine, topical steroids, and dapsone
Severe: Oral steroids, azathioprine, methotrexate, cyclosporine, and anti-TNF
Arthritis: NSAIDs, colchicine, steroids, and anti-TNF
Ocular: Steroids, azathioprine, infliximab, cyclosporine, and cyclophosphamide
Vascular: High-dose steroids and cyclophosphamide. Then azathioprine for maintenance. 
Anticoagulation for venous thrombosis
Neurological: Steroids, methotrexate, azathioprine, cyclophosphamide, and adalimumab. 
Anticoagulation for dural sinus thrombosis
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tality in BD. Cutaneous and articular involvement 
are also common [44].
Treatment of BD depends on the severity of 
the disease. Mild disease can be treated with col-
chicine and oral glucocorticoids. Severe disease 
requires addition of immunosuppressive therapy 
such as cyclophosphamide, TNF-alpha blockers, 
and azathioprine [45].
Table 20.13 summarizes CHCC12 definition, 
epidemiology, clinical manifestation, diagnostic 
studies, ACR 1990 classification criteria, and 
treatment of BD.
The author of this chapter is grateful to Prof. 
Hani Almoallim and Dr. Lujain Homeida for pro-
viding some clinical images from their own 
collection.
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Diabetes mellitus (DM) is a chronic disease char-
acterized by persistent hyperglycaemia that hap-
pens as a result of a pancreatic insulin deficiency 
and/or insulin resistance. Its morbidity and mor-
tality are primarily related to the resultant micro-
vascular and macrovascular complications. Its 
prevalence has grown widely, which will result in 
higher rates of diabetic complications including 
rheumatic manifestations.
An improved understanding of the mecha-
nisms through which diabetes alters connective 
tissue metabolism should lead to better preven-
tive and therapeutic interventions. In this chap-
ter, a brief summary about the pathophysiology 
of rheumatological manifestations in diabetes is 
outlined. A schematic classification of rheuma-
tological manifestations in diabetic patients is 
demonstrated according to the region and 
according to the presence or absence of pain. 
This is followed by summarized review of these 
rheumatological manifestations of diabetes mel-
litus. It is obvious that these are not unique to 
diabetes mellitus as it may affect normal indi-
viduals, as well.
21.1.1  Objectives
The reader of this chapter should be able to:
 1. Identify different diabetes related rheumatic 
complications.
 2. Differentiate between rheumatic complica-
tions related to diabetes and those associated 
with other diseases.
 3. Classify these rheumatic diseases based on the 
involved region and the underlying 
pathophysiology.
 4. Assess diabetic patients with rheumatic com-
plications clinically and select the appropriate 
diagnostic tests.
 5. Manage diabetic patients with rheumatic 
complications.
21.2  Pathophysiology
The high glucose, high insulin milieu of diabetes 
affects many of the key cells and matrix compo-
nents of connective tissues. For example, reac-
tive oxygen species are increased in diabetes and 
certainly may mediate tissue damage [1]. 
Advanced glycosylation end products (AGEs) 
tend to accumulate in the long-lived proteins of 
connective tissues and may alter both extracel-
lular matrix structure and function as well as cell 
viability [2]. Early glycosylation of skin colla-
gen can be decreased by improving glycaemic 
A. Monjed (*) 





control [3, 4]. However, the long-term, cumula-
tive damage due to the binding of advanced gly-
cosylation end products to collagen is probably 
irreversible.




Rheumatological diseases associated with diabe-
tes mellitus can be classified according to:
 1. The involved musculoskeletal structures as 
shown in the Fig. 21.1.
 2. Painful or painless rheumatic diseases as 
shown in the Fig. 21.2.
21.3  Carpal Tunnel Syndrome
Carpal tunnel syndrome (CTS) is an entrapment 
neuropathy caused by compression of the median 
nerve resulting in pain and/or paraesthesia in 
thumb, index and middle finger.
21.3.1  Epidemiology
• In diabetic patients: CTS is common and esti-
mated to occur in 14% in patients without dia-
betic polyneuropathies and up to 30% in those 
with diabetic polyneuropathies [5].
• It may be more common in those with predia-
betes [6].
• More common in women than men [7].
• In nondiabetics with life expectancy of 
70 years: 3–5% in Men and 11% in women 
are expected to develop CTS [7].
21.3.2  Approach to CTS
21.3.2.1  History
• Numbness and tingling sensation: it should be 
localized to the palmer aspect of the first to the 
fourth fingers and the distal palm. These 
symptoms usually happen at night and resolve 
by shaking (shake sign).
• Pain: usually at night, and over the ventral 
aspect of the wrist and radiated distally to the 
palm and fingers or proximally to the ventral 
forearm, resolved by flicking (flicking sign).












  e.g, Charcot joint
• Diffuse idiopathic
  skeletal
  hyperostosis (DISH)
• Diabetic muscle





  (Stiff-hand syndrome)
• Limited joint mobility
Hand Shoulder Lower Limb Spine
Fig. 21.1 The musculoskeletal structures involved in diabetes-associated rheumatological diseases
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• Autonomic symptoms: temperature and colour 
changes in the hand.
• Weakness of thumb abduction and opposition.
To exclude other causes of CTS, the following 
should be assessed for establishing the diagnosis 
(Table 21.1):
21.3.2.2  Physical Examination
• Motor Examination: wasting and weakness 
of the median-innervated hand muscles 
(LOAF); first and second lumbricales, oppo-
nens pollicis, abductor pollicis brevis and 
flexor pollicis brevis may be detectable and 
resulting in weak thumb abduction.
• Sensory Examination:
 – Decreased sensation in the median nerve 
distribution (from thumb through the mid-
dle of the fourth finger).
 – Semmes-Weinstein monofilament testing or 
2-point discrimination, which may be more 
sensitive in picking up the sensory 
abnormality.
• Special tests:
 – Phalen test (87% specificity and 84% sen-
sitivity): the patient has to hold his hands 
against each other in full palmer flexion; 
paraesthesia will happen within 30 to 120 s 
in this position.
 – Tinel sign (89% specificity and 82% sensi-
tivity): gentle tapping over the median 
nerve in the carpal tunnel area causes tin-
gling in the nerve’s distribution.
 – The carpal compression test (sensitivity 
84%, specificity 82%): applying firm pres-
sure directly over the carpal tunnel, usually 
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• Stiffness → Diabetic
  cheiroarthropathy
• Locking finger → Flexor 
  tenosynovitis
• Contracture of 4th and
  5th digits →
  Dupuytren’s
No
Fig. 21.2 Painful and painless rheumatic diseases associated with diabetes mellitus
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 – Hand elevation test (89% specificity and 
87% sensitivity): asking the patient to raise 
the affected hand and holding it in that 
position for 1 min. The test is positive when 
tingling and numbness happen in the 
median nerve distribution area.
21.3.2.3  Investigations
• Carpal tunnel syndrome is a clinical 
diagnosis.
• Lab tests are usually not helpful except for 
assessing glycaemic control.
• Nerve conduction studies (NCS) and electro-
myography (EMG): are the diagnostic tests 
that usually used to confirm the diagnosis, 
assess severity and rule out other abnormali-
ties or conditions such as polyneuropathy, 
plexopathy and radiculopathy.
• Imaging studies are not routinely used:
 – Ultrasound (sensitivity 64%):
It can demonstrate the thickening of the 
median nerve, the flattening of the nerve 
within the tunnel and the bowing of the 
flexor retinaculum, which are all fea-
tures that indicate the presence of CTS.
 – MRI (sensitivity 96%):
It demonstrates swelling of the median 
nerve and increased signal intensity on 
T2-weighted images, indicating accu-
mulation of the axonal transportation, 
myelin sheath degeneration or oedema, 
which are suggestive of CTS.
21.3.3  Treatment
• Conservative treatment:
 – Splinting: splinting the wrist at night-time 
for a minimum of 3 weeks. Many off-the- 
shelf wrist splints seem to help.
 – Steroid injection, nonsteroid anti- 
inflammatory drug and vitamin B6: 
effective in reducing inflammation and 
oedema [8, 9].
• Surgical release of carpal tunnel:
 – This is performed more frequently among 
patients with DM and is estimated to be 
4–14 times higher than the general 
population.
 – Success rate is more than 90%.
Causes Important Differentiating Tips
Diabetes




Constitutional symptoms, polyarthritis, morning stiffness, positive RF and ACPA
Gout
Monoarthritis, hyperuricemia, monosodium urate crystals in synovial fluid,
negative culture of joint fluid for microorganisms
Heart failure
Orthopnea, PND, ischemic heart disease, diabetes, 
Hypertension
Hyperthyroidism Palpitation, heat intolerance, weight loss, goitre, suppressed TSH  
Colles' fracture History of trauma 
Over use syndrome Work related e.g. computer Users, typists, and musicians
Abbreviations: RF: Rheumatiod factor, ACPA: Anti-citrullinated protein antibodies, PND: Paroxysmal nocturnal
dyspnea, TSH: Thyroid stimulating hormone
Table 21.1 Causes of Carpal Tunnel Syndrome
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21.4  Reflex Sympathetic 
Dystrophy
Reflex sympathetic dystrophy (RSD), also known 
as complex regional pain syndrome I (CRPS I), is 
characterized by localized or diffuse neuropathic 
pain of the upper or lower extremity usually asso-
ciated with swelling, vasomotor disturbances and 
trophic skin changes which include loss of hair, 
skin colour changes, temperature changes and 
skin thickening (autonomic involvement) [10].
21.4.1  Pathogenesis
The pathogenesis of RSD is unclear, but there are 
some theories that may explain it:
• Sympathetic nervous system dysfunction.
• Neurogenic inflammation.
• Central nervous system sensitization.
• Autoimmune condition.
• Limb ischaemia or ischaemia reperfusion 
injury.
21.4.2  Epidemiology
Incidence of RSD is 26.2 per 100,000person year 
in Netherlands 1996–2005, the highest incidence 
in women aged 61–70  years, with a female to 
male ratio 3.4:1 [11].
21.4.3  Approach to RSD
21.4.3.1  History
• Neuropathic pain following an injury (tissue 
trauma or bony fracture). It is described as 
burning, throbbing, aching, squeezing or 
shooting pain.
• Vasomotor and sudomotor changes in the 
affected limb (colour changes, temperature 
changes and excessive sweating).
• Ask about the possible precipitating factors or 
causes such as:
 – Trauma kor immobilization following 
trauma to limb.
 – Bone fractures of extremities.
 – Diabetes mellitus.
 – Hyperthyroidism.
 – Hyperparathyroidism.
 – Nerve injury.
 – Medications, e.g. ACE inhibitors.
21.4.3.2  Physical Examination
• Skin: may be shiny, swollen, thinned, ery-
thematous or cyanotic, with scaling. 
Temperature may be increased or decreased.
• Extremities:
 – Joint may be stiff with decreased range of 
motion.
 – Signs of chronic lymphoedema.
• Neurologically:
 – Sensory changes and weakness may be 
present.
 – Tremor or dystonia in the affected limb.
21.4.4  Diagnosis Criteria (Table. 21.2)
21.4.5  Treatment
There are different medical and surgical treat-
ment modalities, but they have no strong evi-
dence to support their use.
• The best treatment of RSD is prevention by 
early mobilization following an injury or stroke 
and use of supplemental vitamin C for patients 
with wrist fractures [14, 15]. A typical dose is 
500–1500 mg daily, and the duration is 50 days.
• Physical therapy.
• Medical therapy:
 – Analgesics, e.g., topical capsaicin cream.
 – Bisphosphonates.
 – Anticonvulsants, e.g., gabapentin.
 – Tricyclic antidepressant.
 – Vasodilator medication or percutaneous 
sympathetic blockades.
 – Glucocorticoids.
• Invasive therapy for non-improving on non- 
invasive therapy.
 – Regional sympathetic nerve block.




 – Spinal cord stimulation.
21.5  Flexor Tenosynovitis
Flexor tenosynovitis, also known as trigger finger, 
is a non-infectious inflammation of the flexor ten-
don sheath of the finger leading to finger blocking 
in flexion with failure of active extension.
21.5.1  Pathogenesis
Inflammation causes thickening of flexor tendon 
of the digit over metacarpal head and resistance to 
its entrance into the base of flexor tendon sheath, 
accompanied by constriction of the sheath. 
Flexors are stronger than extensors, so finger gets 
locked in a flexed position, as extensors cannot 
overcome the resistance of constriction.
21.5.2  Epidemiology
The prevalence of flexor tenosynovitis is esti-
mated at 11% in diabetic patients, compared with 
less than 1% in nondiabetics [16]. The occur-
rence of flexor tenosynovitis correlates signifi-
cantly with the duration of DM, but not with 
glycaemic control [16].
Bruehl's criteria[12]
Continuing pain disproportionate to any inciting event.
1. Patient must report at least 1 symptom in each of the 4 following categories
a) Sensory: hyperesthesia
b) Vasomotor: temperature asymmetry, skin color changes or skin color
    asymmetry
c) Sudomotor/edema: edema, sweating changes or sweating asymmetry
d) Motor/trophic: decreased range of motion, motor dysfunction (weakness,
    tremor, dystonia) or trophic changes (hair, nail, skin) 
2. Must display at least 1 sign in 2 or more of the following categories
e) Sensory: evidence of hyperalgesia (to pinprick) or allodynia (to light touch)
f) Vasomotor: evidence of temperature asymmetry, skin color changes or asymmetry 
g) Sudomotor/edema: evidence of edema, sweating changes or sweating asymmetry
h) Motor/trophic: evidence of decreased range of motion, motor dysfunction
  (weakness, tremor, dystonia) or trophic changes (hair, nail, skin)
Veldman's criteria[13]
1. Presence of 4 out of 5 symptoms:
a) Diffuse pain during exercise
b) Temperature differences between affected and unaffected extremity 
c) Color differences between affected and unaffected extremity
d) Volume differences between affected and unaffected extremity
e) Limitations in active range of movement of the affected extremity
2. Occurrence or increase of symptoms during or after use
3. Symptoms in an area larger than the area of the primary injury




21.5.3  Approach to Flexor 
Tenosynovitis
21.5.3.1  History
• Locking of finger in a flexed position with a 
resistance to re-extension. It commonly 
involves thumb, the middle and ring fingers.
• Clicking of the locked digit and finger pain.
21.5.3.2  Physical Examination
• Local tenderness and palpable swelling at the 
base of the finger, where the tendon crosses 
over the metacarpal head.
• Pain usually gets worse by stretching the ten-
don in extension or by resisting flexion 
isometrically.
• Prayer sign test: the ability to flatten the hands 
together as in prayer, facilitating recognition 
of contractures in the metacarpophalangeal, 
proximal interphalangeal and distal interpha-
langeal joints.
• Table top test: assesses the ability to flatten the 
palm against the surface of a table, facilitating 
recognition of contractures in the metacarpo-
phalangeal joints.
21.5.3.3  Investigations
• It is a clinical diagnosis.
• Plain radiographs are rarely done unless there 
is a history of trauma or inflammatory dis-
eases. They may show calcification of the ten-
don but rarely occurs.
21.5.4  Treatment [17]
• Activity modifications to avoid the triggers.
• Splinting.
• NSAIDs.
• Steroid injections into tendon sheath.
• Surgical release.
21.6  Diabetic Muscular Infarction
It refers to spontaneous ischemic necrosis of 
skeletal muscles, unrelated to athero-embolism 
or occlusion of major arteries. Diabetic muscle 
infarction (DMI) is a rare but life threatening 
complication seen in patients with long-standing 
and poorly controlled diabetes. It is considered as 
one of the micro- and macrovascular complica-
tions of Diabetes.
21.6.1  Pathophysiology
DMI is more common in type I diabetes and 
most of the affected patients have multiple 
microvascular complications. Hyperglycaemia, 
with or without insulin resistance, has many 
potentially adverse effects on the arterial vas-
culature. It may also affect platelets functions 
and the levels of coagulation and thrombolytic 
factors leading to occlusion of arterioles and 
capillaries resulting in muscles necrosis and 
oedema.
21.6.2  Epidemiology
• More common with type I diabetes.
• Usually affecting women more than men.
• Usually associated with other complications 
of diabetes as nephropathy (70%), retinopathy 
(57%) and neuropathy (55%) [18]
21.6.3  Approach to DMI
21.6.3.1  History
• Tender and swollen leg.
• Pain of an acute onset in the thigh and less 
commonly in the calf muscles over days.
• Autonomic symptoms: mild fever.
• Ask about trauma: usually there is no history 
of trauma in DMI.
• Ask about suspected complications as recur-
rence or staph sepsis.
• Ask about the diabetes control and medication 
use.
• Ask about symptoms of nephropathy and reti-




21.6.3.2  Physical Examination
• Assessing the leg swelling: site, size, shape, 
tenderness and temperature.
• Any associated leg ulcers?
• Check the leg and upper limb arterial pulses.
• Look for signs of DM-related micro- and mac-
rovascular complications such as retinopathy, 
neuropathy and cardiovascular abnormalities.
21.6.3.3  Imaging Studies
• MRI:
 – Shows a high intensity in the involved mus-
cle as well as subcutaneous oedema and 
subfascial fluid (in T2-weighted 
sequences), in addition to loss of the nor-
mal fatty intramuscular septa with 
T1-weighted images (common finding) 
[19].
 – It is the diagnostic test of choice.
• Ultrasonography:
 – Finding of internal linear echogenic struc-
tures, absence of a predominant anechoic 
area and no evidence of internal motion can 
discriminate a diabetic muscle infarction 
from an abscess.
 – Venous Doppler ultrasound with compres-
sion to rule out venous thrombosis.
• Arteriography:
 – It may show atherosclerotic luminal nar-
rowing. Generally, it is not used for 
diagnosis.
21.6.3.4  Muscle Biopsy (for 
Confirmation)
The primary pathological findings are muscle 
necrosis and oedema, but occlusion of arterioles 
and capillaries by fibrin may also be seen. It 
should be reserved for patients with atypical pre-
sentation, uncertain diagnosis or those who do 
not improve with medical treatment [20].
21.6.4  Treatment
• Rest and analgesics.
• Anti-platelet agents (ASA) and/or anti- 
inflammatory drugs.
• Surgical excision.
21.7  Adhesive Capsulitis (Frozen 
Shoulder)
Adhesive capsulitis, also known as frozen shoul-
der, is characterized by progressive painful 
restriction of the shoulder movements, especially 
external rotation and abduction. Typically, the 
pain of frozen shoulder in diabetics is less than 
that of nondiabetic patients.
21.7.1  Pathogenesis
The exact mechanism is unknown. It is thought 
that hyperglycaemia can lead to a faster rate of 
collagen glycosylation and cross-linking in the 
shoulder capsule, which will cause thickening 
and contraction of the capsule that result in a sub-
stantial decrease in capsular volume capacity.
21.7.2  Epidemiology
• The prevalence of frozen shoulder is esti-
mated to be 2 to 5% of the general population 
[21, 22].
• Patients with diabetes mellitus are at a greater 
risk of developing frozen shoulder, with prev-
alence of 10 to 20% [23–25].
• Bilateral involvement is more frequent in dia-
betic patients than in nondiabetic subjects (33 
to 42% vs. 5 to 20%) [26].
• Women are more often affected than men 
[27].
21.7.3  Approach to Frozen Shoulder
21.7.3.1  History
• Shoulder stiffness.
• Diffuse severe pain, even at night.
• Limitation of shoulder motion.
• The followings should be obtained:
 – Duration and location of pain.
 – Precipitating and relieving factors.
 – One shoulder or both are affected.
 – Any other joints involved.
 – Any strain, overuse or trauma.
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 – Prolonged immobilization.
 – Neck pain or radiation of pain into arms.
 – Neurologic symptoms in arms.
Frozen Shoulder May Progress Through Three 
Theoretical Phases [22, 28] (Table. 21.3).
21.7.3.2  Physical Examination
A stiff and painful glenohumeral joint makes it 
difficult to perform a complete shoulder 
examination.
• Look for swelling, redness and warmth.
• Check distal strength, sensation and pulses.
• Check for diffuse tenderness over anterior and 
posterior aspect of the shoulder.
• Lock for loss of active and passive motion in 
all planes especially on external rotation and 
abduction.
• Diagnosis is unlikely if complete abduction 
present on passive motion.
21.7.3.3  Imaging
• Plain radiographs are usually normal, so had 
limited diagnostic use.
• Ultrasonography is used either to confirm the 
diagnosis of frozen shoulder or to rule out 
other pathology of the rotator cuff and bursa. 
Findings associated with frozen shoulder may 
include [29]:
 – Thickening of the coracohumeral ligament 
and the soft-tissue structures in the rotator 
cuff interval.
 – Increased fluid in the tendon sheath of the 
long head of the biceps.
 – Increased vascularity around the intra- 
articular portion of the biceps tendon and 
the coracohumeral ligament.
• MRI shows a thickening of the joint capsule 
and the coracohumeral ligament. It is useful in 
some conditions like rotator cuff tendinopathy 
and concomitant glenohumeral osteoarthritis 
for accurate diagnosis.
21.7.4  Treatment
In most cases, frozen shoulder is a self-limited 
condition, although a complete resolution does 
not occur in many patients.
• Physical therapy.
• Nonsteroidal anti-inflammatory drugs 
(NSAIDs) and analgesics.
• Intra-articular steroid injections.
• Surgery in severe non-responding cases.
21.8  Neuropathic 
Osteoarthropathy (Charcot 
Joint)
Neuropathic osteoarthropathy, also known as 
Charcot osteoarthropathy, is a progressive 
destructive process affecting the bone and joint 
structures associated with various diseases in 
Painful freezing phase Adhesive phase Resolution phase
 10-36 weeks
 Pain and stiffness around 
the shoulder with no
history of injury 
 Constant pain with little
response to NSAIDs 
 4-12 months
 Pain gradually subsides
but still apparent at
extremes
 Stiffness continues





range of motion  
 Mean duration of
overall impairment
> 30 months
Table 21.3 Frozen shoulder progression phases [22, 28]
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which neuropathy occurs. However, DM is by far 
the most common aetiology.
21.8.1  Pathogenesis
The pathogenesis remains uncertain, but it is 
probably due to an underlying diabetic peripheral 
neuropathy and a combination of mechanical 
trauma and vascular factors. It may result from 
repeated trauma, often minor, in the setting of 
decreased sensation due to a sensory neuropathy, 
which results in increased damage with micro-
fractures (Fig. 21.3).
21.8.2  Epidemiology
• Among the general diabetic population, 
neuroarthropathy is uncommon, affecting 
approximately 1  in 700 diabetic patients 
[30, 31].
Motor Neuropathy Sensory Neuropathy
Decrease muscles strength Loss of proprioception
Autonomic Neuropathy




Decrease perfusion to skin,
bone, and surrounding joint
Fig. 21.3 Pathogenesis of diabetic neuropathic arthropathy
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• Patients at risk are usually those who have 
longstanding diabetes (average duration 
15 years) with peripheral neuropathy and are 
in their sixth or seventh decade [30, 31].
21.8.3  Approach to Charcot Joint
21.8.3.1  History
• Arthritis and swollen foot or ankle (although 
may occur in any joint).
• The modified Eichenholtz system was devel-
oped to stage the progression of Charcot joint 
and to recommend treatment based on the 
clinical stage and radiographic changes [32] 
(Table. 21.4).
21.8.3.2  Physical Examination
• Serial X-rays with different findings 
according to the stage.
 – Inflammatory stage: no radiological 
abnormalities.
 – Development stage: joint effusion, sublux-
ation, bone destruction and osteochondral 
fragmentation.
 – Coalescence stage: periosteal new bone 
formation, subchondral sclerosis, resorp-
tion of debris, marginal osteophytes.
 – Remodelling stage: ankylosis or rounded 
bone ends, decreased sclerosis, decreased 
swelling.
• MRI: may show bone marrow oedema, bone 
bruising or microfractures.
21.8.4  Treatment
• Avoidance of weight bearing is the mainstay 
of treatment. It should be for at least 3 months 
or until erythema and oedema resolve accom-
panied by radiographic improvements.
• NSAIDs.
• Calcitonin and bisphosphonates may be added 
on to limb offloading. Their use has not been 
approved yet in the treatment of Charcot neu-
roarthropathy [35, 36].
• Surgical treatment may only be required when 
the conservative treatment fails or severe 
deformities developed.
(Table 21.5) Summary of the Most Common 
Rheumatological Diseases/Complications in 
Diabetic Patients.
21.9  Diabetes and Osteoporosis
Both diabetes and osteoporosis are prevalent dis-
eases with significantly associated mortalities 
and morbidities. It has been well established that 
diabetic patients are at increased risk of osteopo-
rosis and fractures, particularly at the hip.
Osteoporosis is defined as a combination of 
reduced bone mass and altered bone quality, with 
microarchitectural abnormalities, resulting in 
decreased bone strength with an increased risk of 
fractures [37, 38]. At present, the diagnosis of 










     erythema, and
     warmth 
 No radiological
     abnormalities 
 Persistent
     swelling, redness, and
     warmth 
 Bony changes
     such as fracture,
     subluxation,
     dislocation
 Bony debris
     starts to appear
     radiologically
 Inflammatory
     signs decrease 
 Radiological
     signs of 
     fracture
     healing, bony
     debris
     resorption    
 New bone
      formation 
 Clinical
      inflammatory
      signs have
      settled   
 Bony deformity
 Radiologically,
     may show
     mature fracture
     and decreased
     sclerosis 
Table. 21.4 The Modified Eichenholtz System to Stage Charcot Joint Progression
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(BMD) measurement using dual-energy X-ray 
absorptiometry (DXA). The results are reported 
as the difference, in standard deviations (SDs), 
with the peak bone mass (−score). The World 
Health Organization (WHO) defines osteoporosis 
as a BMD -score of −2.5 or less [37–39].
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- Finger stiffness, 
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Ischemic injury from a 
non-systemic micro 
vasculitis
- Acute local pain, 
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weakness in the 
proximal leg
- Autonomic failure 
and weight loss
- CBC, FBS, HbA1C
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- EMG, nerve 
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• Etiology: unknown, 
could be due to 
abnormal osteoblastic 
activity at the enthesis.
• Insulin-like growth 
factor-1, insulin,
glucose, and growth 
hormone are involved 
in the pathogenesis of 
osteoblastic activity in 
DISH.
• Other factors :
prolonged exposure to 




• Neck, thoracic 
spine, low back, 
or extremities 
pain
• Disability and 
spinal morning 
stiffness
















































Criteria for diagnosis of DISH:
• Resnick and Niwayama Criteria:[31]
1. Presence of longitudinal ossification and calcification on the anterior surface of at least, 4 consecutive
   vertebral bodies.
2. Absence of degenerative radiological changes in discs involved with preservation of intervertebral space.
3. Absence of apophyseal joint bony ankylosis and sacroiliac joint erosion or sclerosis.
• Utsinger Criteria:[32]
1. Ossification, fine and ribbon-like wave, along the anterolateral aspect of at least 4 consecutive vertebrae.
2. Ossification on the anterolateral aspect of at least 2 consecutive vertebral bodies.
3. Presence of peripheral and symmetrical entheses pathology, involving heel, patella and olecranon, with
    new bone formation.




















adverse effects on arterial
vasculature as well as
platelets and coagulation
factors leading to

















• Muscle biopsy 










ASA, asprin, CBC, complete blood count; CK, creatinine kinase; CT, computed tomography; EMG, electromyography;
ESR, erythrocyte sedimentation rate; FBG, fasting blood glucose; MRI, magnetic resonance imaging; NSAIDs,





Type I diabetes is associated with bone fragility 
and loss of bone mass, while type II diabetes, 
despite having a normal or an increased bone 
mineral density (BMD), is associated with bone 
quality deterioration that cannot be diagnosed 
by using dual-energy X-ray absorptiometry 
(DXA).
21.9.2  Challenges in Diagnosing 
and Treating Diabetes-Related 
Osteoporosis
Although the risk has been well established, it 
remains underappreciated in the major interna-
tional diabetes guidelines and by most clinicians 
caring for diabetic patients. There have been also 
insufficient studies evaluating the effectiveness 
and long-term safety of the available therapeutic 
antiporotic modalities to reduce the risk of frac-
ture in patients with diabetes.
21.9.3  Approach to Diabetes-Related 
Osteoporosis
21.9.3.1  History
• Type of diabetes and glycaemic control (fre-
quency of hyper- and hypoglycaemia).
• Symptoms of diabetes-related microvascular 
complications.
• Assess any risk for falls.
• Ask about any of the following risk factors 
that might increase the risk of osteoporotic 
fractures:
 – Previous history of fracture.
 – Parental history of hip fracture.
 – Smoking.
 – Alcoholism.
 – Steroid use.
 – Hyperthyroidism, celiac disease, hyper-
parathyroidism, vitamin D deficiency or 
rheumatoid arthritis.
21.9.3.2  Physical Exam
• Height measurement for any loss of height.
• Body mass index (low BMI < 19 kg/m2).
• Back examination for kyphosis or point ten-
derness over a vertebra suggesting a compres-
sion fracture.
• Signs that may indicate increased fall risk 
(difficulty with balance or gait, orthostatic 
hypotension, lower extremity weakness and or 
neuropathy, poor vision or hearing).
21.9.3.3  Diagnosis
• Use the current osteoporosis guidelines for 
screening in patients with diabetes through 
using dual-energy X-ray absorptiometry 
(DXA) to measure the bone mineral density 
(BMD), but keep in mind the fracture risk is 
high in type II diabetes despite having normal 
or increased bone mineral density (BMD).
• Use the fracture risk assessment (FRAX) 
algorithm (www.shef.ac.uk/FRAX/), which is 
a validated tool used to estimate 10-year risks 
for major osteoporotic and hip fractures even 
if BMD is not measured [41]. It has been 
developed by the metabolic bone disease unit 
at the University of Sheffield.
Box 21.1 Risk Factors for Fractures in 
Diabetic Patients [37, 40]
 1. Type of diabetes I or II, poor glycaemic 
control, and risk of drug-induced 
hypoglycaemia.
 2. Microvascular complications of diabe-
tes, especially nephropathy and 
neuropathy.
 3. Type I diabetes-associated diseases such 
as autoimmune hyperthyroidism, amen-
orrhea, eating disorders and celiac 
disease.
 4. Increased risk of falls due to diabetes- 
related complications such as hypogly-
caemia, poor vision and/or balance, 
autonomic orthostatic hypotension and 
arthropathy.
 5. Vitamin D deficiency, which is more 




21.9.3.4  Management 
of Osteoporosis on Diabetic 
Patients
• Maintain a good glycaemic control.
• Minimize hypoglycaemia as possible.
• Screening and prevention of diabetes-related 
complications.
• Avoid glitazones (TZDs).
• Identify patients with high risk of falls and 
prevent falls.
• Good supplementation with calcium (600–
1200  mg/day) and vitamin D (at least 800–
1000 IU/day).
• Use of specific antiporotic medication 
(bisphosphonates, denosumab or anabolic 
agent teriparatide) based on the recommenda-
tions of good clinical practice and the patients’ 
factors.
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Soft Tissue Rheumatic Disorders
Roaa Mahroos and Hani Almoallim
22.1  Introduction
Soft tissue disorders are common focal pathologi-
cal syndromes affecting soft tissue structures like 
tendons, ligaments, bursa, fascia, and the site of 
insertions of these structures to bones (enthesis). 
They are commonly encountered disorders in 
daily clinical practice particularly in outpatient 
settings. A systemic disease does not always 
accompany them;, however, they can be associated 
with spondyloarthritis. They are most likely 
caused by overuse, repetitive trauma, and occupa-
tional history. This chapter will present in a simpli-
fied approach different types of bursitis, tendinitis, 
enthesitis, and fasciitis encountered in clinical 
practice. The emphasis will be placed on diagnos-
tic workup based on comprehensive history- taking 
skills and musculoskeletal (MSK) examination 
findings. Outlines of management principles will 
be reviewed as most of these disorders respond to 
conservative therapy (pain management, physio-
therapy, and avoidance of aggravating movements) 
and it rarely needs surgical intervention. There are 
other soft tissue disorders discussed in “Diabetes 
and Rheumatology” Chap. 21. Detailed techniques 
of MSK examination of several of these disorders 
are discussed in Chap. 2.
22.1.1  Learning Objectives
By the end of this chapter, you should be able to:
• Discuss the anatomy and classification of 
common soft tissue disorders (bursa, liga-
ments, tendons, and fascia) that cause local-
ized pain syndromes.
• Describe the clinical presentation of the most 
common types of soft tissue disorders.
• Construct a diagnostic approach for different 
types of soft tissue disorders.
• Outline management principles of these 
disorders.
22.1.2  Classification of Soft Tissue 
Disorders
A selective group of soft tissue disorders will be 
reviewed in this chapter based on the following 
classification (Fig. 22.1). It is based on the site of 
involvement of these structures. It is important to 
consider soft tissue disorders in the differential 
diagnosis of regional pain syndromes.
R. Mahroos (*) 




























Achilles tendinitis Rotator cuff tendinitis
3. Enthesitis
Epicondylitis Achilles tendinitis Planter fasciitis
4. Fasciitis
Palmar fasciitis Eosinophilic fasciitis Planter fasciitis
Fig. 22.1 Classification of soft tissue disease in rheumatology
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22.1.3  Bursitis
It is important to realize the anatomical definition 
of a bursa in order to recognize the clinical pre-
sentation of bursitis. A bursa is simply the sac 
structure that is formed of two layers filled with 
synovial fluid that protects other structure under-
neath it from injuries caused by pressure. This 
sac acts as cushions. Bursitis is simply inflamma-
tion of this sac.
The most common sites are shoulder (subdeltoid, 
olecranon), hip (ischial tuberosity, trochanteric), 
knee (prepatellar bursa), and foot (retrocalcaneal) 
[1–9]. Table  22.1 represents a comprehensive a 
 general review of the clinical presentation, investiga-
tion, and treatment of  bursitis. Table 22.2 represents 
a review of specific types of bursitis.
22.1.4  Tendinitis
A tendon is a thick fibrous cord that attaches 
muscle to bone. Inflammation in the tendon is 
called tendinitis. The most common sites for ten-
(continued)
Table 22.1 Review of the Bursitis history, physical examination, investigation, and treatment
History   •  Pain: Assess duration, site, localization, increases with movement, relation to position, 
interferes with activity, recurrence, other joint pains, stiffness, and functional disability (at 
home, work, and leisure activities)
  •  Occupation: Repetitive movement disorder that increase pressure in the joint and its 
surrounding soft tissue structures. For example, overhead lifting, pushing up elbows when 
arising from bed, carrying heavy objects, prolong sitting on hard surface, and repeated 
kneeling
  •  History of trauma: Systemic review for evidence of a systemic disease (see Chap. 1) like 
rheumatoid arthritis (RA), crystal-induced arthritis (gout, pseudogout) and uremia
  •  History suggestive of infection: Fever, (infective endocarditis, cellulitis), skin abrasions in 
superficial bursae (olecranon and prepatellar bursa) wounds, and diabetic, alcoholic [5–7] 
and immunosuppressed patients are at increased risk of septic bursitis [8, 9]
  • Obesity
Physical 
examination
  • Swelling: Mainly superficial
  • Tenderness: With active range of motion (ROM) testing
  • Reduced active ROM: With less or no pain with passive ROM
  • Local tenderness: With palpation over the bursa
  • In septic bursitis: Fever, swelling, redness, tenderness, and hotness [10]
Investigations   1. If history and physical examination suggest septic bursitis
  a. CBC, blood culture, and glucose
  2. Bursa fluid aspiration: [11]
Deep bursa use US or MRI guided aspiration, and fluid for
  a. Cell count:
   Normal WBC: less than 200/ L.
   Noninflammatory WBC: 200–2000/ L.
   Inflammatory WBC: 2000–100, 000/ L.
   Septic bursitis WBC: may be exceeding 100, 000/ L
  b. Gram stain and culture in liquid media: [10] It is
Positive in two-thirds of patients with septic bursitis [8].
    The most common organisms: Staphylococcus aureus In about 80% of cases, [8, 9, 12, 
13] streptococci beta-hemolytic strain, rare coagulase negative staph, Enterococcus, E. 
coli, and Brucella, or TB in subacute and chronic endemic areas
  c. Crystal analysis utilizing compensated polarized microscopy
  d. Bursa fluid glucose: Serum glucose ratio of <50% [14]
  3. Imaging typically not helpful in acute superficial bursitis:
  a.  Plain X-ray: When there is history of trauma or foreign body and to exclude crystal- 
induced arthritis particularly chondrocalcinosis
  b.  CT or MRI: Particularly in septic bursitis to confirm the presence of abscesses or fluid 
collection
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Table 22.1 (continued)
Treatment   1. Patient education
  a. Avoid aggravating factors that increase joints pressure
  b. Joint protection program using cushion and pads
  c. Rest joint position to decrease pressure
  d. Weight reduction
  2. Pain control and decrease inflammation:
  a. NSAIDs (see Chap. 4):
    selective cyclooxygenase 2 inhibitor (celecoxib 200 mg twice daily) or nonselective 
(naproxen 500 mg twice daily for few days in acute bursitis)
  b. Local glucocorticoid injection:
   after ruling out septic bursitis with negative culture
    there is limited data on efficacy and safety;, in general it is more effective than NSAID in 
speeding recovery, relieving pain, and preventing recurrence of olecranon and 
subacromial bursitis [7]
    long-acting glucocorticoid (methylprednisolone 40 mg for large bursa,  subacromial or 
trochanteric, and 10 mg for small bursa,  anserine or Ischia) mixed with equal amount of 
1% lidocaine
   injection should not be repeated for 6–8 weeks
  c. Apply ice for 20 min 6–4 times per day
  d. Heat not more than 20 min
Septic bursitis:
   treatment in immunocompetent or nondiabetic patients:
    Oral antibiotic (dicloxacillin or second-generation cephalosporin or clindamycin) for 10 
days if there is improvement
   frequent aspiration of the bursa and continue antibiotic for 5 days post sterilization
   in severe cases and in immunosuppressed patients:
    IV broad-spectrum antibiotic to cover pseudomonal plus anti-methicillin-resistant S. 
aureus (MRSA) (vancomycin) for 2–3 weeks, till the culture and sensitivity results are 
available [15]
   repeat bursa drain and debridement or open surgical drain in deep bursitis
Table 22.2
Subacromial bursitis
Anatomy Subacromial bursa lies between acromion process and supraspinatus muscle at top of the 
humorous




Abduction of the shoulder
Symptoms   • severe pain at rest and movement of the affected shoulder
  • prevent active movement
Signs   • tenderness over the bursa just below the acromion
  • this may extend over deltoid muscle
  • tender and possibly restricted active ROM, while passive abduction is harmless with 
possibility of mild tenderness
Treatment Pain is markedly relieved after injecting local anesthesia, immobilization, rest of the joint, and use 
of NSAIDs
If not improving after 72 h, inject methylprednisolone 40 mg with lidocaine
Comment It is associated with:
  • rotator cuff tear that presents with supraspinatus muscle weakness
  • polymyalgia rheumatic when it is usually bilateral
Scapulothoracic bursitis [2–4]
Anatomy The bursa is located in medial angle of scapula and adjacent to second and seventh ribs
Symptoms Pain and popping sensation with scapulothoracic movement
It increases with working overhead, pushing up, reaching up, and shoulder shrugging
Signs Localize tenderness and crepitus with movement




Treatment   • spontaneous regression in most of the patients [1]
  • physiotherapy: Postural and scapular strengthening exercise [2]
  • US heat stretching test might help
  • if pain persists, glucocorticoid injections under fluoroscopy might be considered
  • surgery might be indicated in refractory cases [3]
Olecranon bursitis (student’s elbow) [9–12]
Anatomy The bursa is located just over the extensor aspect of the extreme proximal end of the ulna
Aggravated 
positions
Leaning on elbow, repetitive forward leaning position, or any position where pressure
is exerted on the bursa
Symptoms Pain in the posterior point of the elbow with normal ROM
Signs Tenderness, worsening of pain with elbow flexion, and swelling in posterior point of the elbow
Treatment Consider bursal fluid aspiration if swollen to rule out septic and/or crystal-induced bursitis
Treat underlying condition if sepsis or crystal-induced bursitis have been confirmed. 
Glucocorticoid injection is superior to NSAIDs in preventing recurrent bursitis [4]
Referral to orthopedic surgery if recurrent with thick synovium
Ischiogluteal bursitis (Weaver’s bottom)
Anatomy The bursa is located between gluteus medius muscle and ischial tuberosity
Symptoms Pain in sitting and lying position. Also, pain in lower buttock after prolonged sitting
On hard surfaces
Signs Tenderness over ischial tuberosity
Treatment NSAIDs, glucocorticoid injection, foam rubber cushion, and stretching with knee to chest exercise
Greater trochanteric bursitis
Anatomy The bursa is located between the tendon of gluteus medius and posterolateral prominence of 
greater trochanter
This bursitis is more common in females rather than males
Symptoms Night pain, lateral hip pain, 40% radiate to the lateral site of the thigh, worsening if lying on 
affected side, and patient cannot walk in severe case
Iliotibial band syndrome (snapping hip) and leg length discrepancy predispose patients to develop 
trochanteric bursitis
Signs   • tenderness on lateral hip joint pain region over the greater trochanter
  • hip joint resisted hip abduction may reproduce symptoms
  • antalgic gait
Notes:
The differences between greater trochanteric bursitis and gluteus medius tendinopathy are gluteus 
medius tendinopathy causes pain and tenderness superior to the greater trochanter, positive 
Trendelenburg test, significant muscle weakness, and positive one—Leg mini-squat test,  patient 
cannot complete a single repetition squat on affected leg to 60°
Recommended X-ray: Lateral, anteroposterior, and frog-leg views to rule out other causes 
affecting hip joint itself
Treatment Radiating radicular pains from the lower back need to be ruled out as well.
Heat and passive stretching exercise with hip adduction can be tried with weight reduction and 
avoiding stairs
Some resistant cases may need to be injected with glucocorticoid and lidocaine
Spinal needles should be used in obese patients
Prepatellar bursitis (Housemaid’s knee) [1–9]
Anatomy The bursa is located between the patella and the skin
Symptoms Positive history of kneeling down frequently and/or history of trauma
Anterior knee pain that increases with flexion
Swelling may be observed
Signs Tenderness over the patella. Swelling, hotness, and redness particularly in septic or crystal-
induced bursitis
Treatment Rule out septic bursitis and/or crystal-induced bursitis with bursal fluid aspiration
Rest joint and avoid trauma. Glucocorticoid injection may be considered
In refractory cases refer to surgery
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dinitis are around shoulder, elbow, and ankle 
joints. One of the pathophysiological mecha-
nisms for tendinitis is micro-tears, affecting these 
tendons from repeated stressors like in overuse, 
or in traumatic situations.
In some situations where there is inflamma-
tion of the tendon sheath, the condition is called 
tenosynovitis. Table  22.3 represents a compre-
hensive, general review of the clinical presenta-
tion, investigation, and treatment of tendinitis.
Table 22.4 represents a review of rotator cuff 
tendinitis.
Tendinosis is a chronic proses associated with 
an atrophic and degenerative change of the ten-
don caused by recurrent tendinitis. US or MRI is 
required to diagnose it and to differentiate 
between different causes.
22.1.5  Rotator Cuff Tendinitis 
and Rotator Cuff Tear
Rotator cuff tendinitis (RCT) is a common type 
of tendinitis that affects the shoulder. The patient 
usually presents with lateral shoulder pain and 
limited active ROM. It is the most common cause 
of shoulder pain in clinical practice. A brief 
approach to shoulder pain is presented in Chap. 
2. Table  22.4 represents a comparison between 
RCT and rotator cuff tear (RCTr) in terms of defi-
nition, diagnostic, and therapeutic interventions.
Table 22.2 (continued)
Anserine bursitis (Goose’s foot)
Anatomy The bursa is located medially around 6 cm below the joint line at the attachment of medial 
collateral ligament to medial tibia
It is the site of insertion of three tendons: gracilis, sartorius, and semitendinosus muscles
Symptoms Risk factors: Positive history of repeated knee flexion in excessive running, stair climbing.  
More common in obese elderly females and/or with valgus knee alignment
Pain at night over the upper tibia around 6 cm below medial joint line
It is important to ask the patient to point with one finger the area of pain
Signs Local tenderness over the exact anatomical location of the bursa. Rule out medial collateral 
ligament instability (see Chap. 2)
Treatment Rest. Repeated knee bending should be avoided;, also avoid crossing the leg or frequent squatting positions
Use pillow under the knee as a relaxation technique. Ice bags may be applied. NSAIDs can be used, 
and if there is no improvement after 6–8 weeks, local glucocorticoid injection can be considered.
Gastrocnemius semimembranosus bursitis (Baker’s cyst)
Anatomy The bursa is located between gastrocnemius and semimembranosus muscles on the medial side 
distal to the crease in the popliteal fossa back of the knee
Most common in adult from 35–70 years old, and it increases with age because the 
communications between the knee and bursa increase [16]
Symptoms Asymptomatic accidental finding during physical examination or radiological investigation
Posterior knee pain and stiffness that increase with activity
Swelling or discomfort in prolong that standing and hyperflexion
Signs Swelling in posterior aspect of the knee, more marked with knee extension
Absence of swelling on knee flexion up to 45° (Foucher’s sign)
Ecchymosis below the medial malleolus (cresent’s sign) in rupture baker’s cyst
Causes One third of causes is due to trauma. Two thirds of the causes are due to other diseases 
(osteoarthritis, rheumatoid arthritis, septic arthritis and meniscal tear)
Complication Pseudothrombophlebitis, leg ischemia, compartment syndrome, nerve entrapment, and ruptured [17]
Treatment Investigation by US or MRI
Treat underlying disease
If asymptomatic no treatment
In arthrocentesis and intra-articular corticosteroid injection result in decrease size after 4 weeks by 
US follow-up [18]
Direct cyst injection if it does not communicate with the joint
Surgery is indicated in recurrences and lack of response to glucocorticoid injection
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Table 22.3 Review of the tendonitis history, examination, diagnosis, treatment, and prevention
History  • Localized pain over the tendon with active movement particularly
 • Limited activity
 • Occupation: overuse and/or sporting activity, usually in middle age group of patients
Risk factors Intrinsic
 • Age over 35 years and obesity
 •  Biomechanical abnormalities: Mostly located in lower limbs (pes planus [flat foot], pes cavus, 
reduced planter dorsiflexion, pelvic inequality and kyphosis)
 • Previous tendinitis or rupture
 • Fluoroquinolones use [19]
Extrinsic
 • Training error (sudden increase and inadequate rest)
 • Environmental (hard gym floors, frozen turf)
 • Poor equipment (inappropriate footwear)
 • Poor ergonomics excessive movement
Examination  • Localized tendon pain
 • Pain with tendon loading
 • Pain with passive stretching
 • Pain with active movement
 • Normal ROM on passive test
 • Muscle weakness in chronic tendinitis and tendon tear
Diagnosis US and MRI:
 • Help to diagnose partial or complete tendon tear
 • Tendon thickness
 • To rule out other causes particularly if patient did not improve on treatment
Treatment  • Avoid aggravating activity
 • Apply ice over the tendon for 15 min 4–6 times daily
 • NSAIDs and local glucocorticoid injection in severe cases
 •  Physiotherapy: Range of motion stretching and strengthening exercises, eccentric exercise, and 
aerobic fitness
 • Surgery: probably after 6 months if no improvement or acute tendon rupture
Table 22.4 Review of the tendonitis history, examination, diagnosis, treatment, and prevention [21, 22]
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Definition Rotator cuff tendinitis Rotator cuff tear
Inflammation in the tendon Injury in the tendon can be partial or complete tear
Risk factors Excessive overhead activity, repetitive stressful movement, obesity, anatomic variants, scapular 
instability, dyskinesia or hypermobility, old age, Chronic diseases (such as diabetes and 
hyperlipidemia), and Lifting heavy objects [19]. Acute tear can also occur with a fall or forceful 
injury.
Symptoms • Shoulder pain increasing with overhead activity
• Shoulder pain could be laterally or posteriorly. It depends on the muscle involved
• Limited shoulder movement particularly active ROM.
• In the case of rotator cuff tear, muscle weakness is more pronounced, and patients can be 
asymptomatic.
Signs See (Chap. 2)
Special tests See (Chap. 2)
(continued)
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Table 22.5 History, examination, diagnosis, and treatment of enthesitis
Sites The common sites for enthesitis are in planter fascia at calcaneus and Achilles tendon in the heel. 
However, there is a scoring system to measure the extent of enthesitis in different body sites
Causes Ankylosing spondylitis, reactive arthritis, psoriatic arthritis, inflammatory bowel disease (IBD), 
celiac disease, Whipple disease, acne-associated arthritis, fracture, trauma, and idiopathic 
secondary usually to repetitive trauma or mechanical misalignment or over weight
History suggestive of SpA (see Chap. 1): Red eyes, pain with eyes movement, oral or genital ulcer, 
genital discharge, back pain or other joint pain, diarrhea or bloody diarrhea resent gastroenteritis, 
history of psoriasis, or family history of psoriasis
Symptoms Pain that increases with activity and possibly swelling
Signs   • local tenderness increase with movement
  • swelling
  • warmth
  • decrease active ROM and stiffness
  •  other sites: Iliac crest, greater trochanter, medial and lateral epicondyles in elbow, tibial 
tuberosities, plantus, costochondral junction, and humeral tuberosities
  • Most enthesitis in SpA is not detected at clinical examination
Investigations Special test: HLA B 27
X-ray: Nonspecific finding: like intra-tendon focal edema, calcific deposit spars, soft tissue 
swelling, and thickening
US: Better than clinical examination in the detection of enthesitis of the lower limbs in SpA. There 
are specific radiographic definitions for enthesitis at different body sites
Treatment Exercise program
Proper shoe wearing using custom made devices
Occupation-related measures
Local steroid injection in severe and resistant cases
In SpA: NSAIDs can be tried first, no clear evidence of efficacy for sulfasalazine [23]  
and/or methotrexate [24] in enthesitis mainly presentation in SpA. However, several studies 
showed efficacy of anti-TNF-alpha therapy and IL-17 antagonists in severe enthesitis [25]
22.1.6  Enthesitis
It is inflammation at the site of insertion of ligaments, 
tendons, fascia, and articular capsules into the bone. 
It might be associated with pain at free nerve ending. 
It is the hallmark of spondyloarthritis (SpA) particu-
larly when paravertebral ligaments are involved caus-
ing spondylitis. Extensive search for a systemic 
spondyloarthritic disease (see Chap. 1) should be 
sought in patients presenting with common enthesitis 
like Achilles tendinitis and plantar fasciitis [21, 22]. 
However, most of these enthesitis disorders have no 
systemic correlation, and they are induced by regional 
pathophysiological mechanisms. Table  22.5 repre-
sents a review about enthesitis. Tables 22.6, 22.7 and 
22.8 summarize common enthesitis encountered in 
clinical practice: Achilles tendinitis, epicondylitis, 
and plantar fasciitis (Table 22.6).
Investigations Radiology: X-rays for tendon calcifications or bone deformation.
US high sensitivity and/or MRI to confirm diagnosis, asses rotator cuff tear and degeneration.
Treatment Acutely—if there is significant tear refer the patient to orthopedic surgery.
In partial tear or tendinitis consider conservative therapy:
 • Avoid aggravating activity.
 • Apply ice over tendon for 15 mins 4–6 times daily.
 • NSAIDs. Local glucocorticoid inject with lidocaine may be considered.
 • Physiotherapy: Range of motion stretching and strengthening exercises.
Subacute treatment—If no improvement is achieved within two to three months:
 •  Glucocorticoids—subacromial glucocorticoid injection is a common treatment to controlling 
the symptoms [20].
Table 22.4 (continued)
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Table 22.6 Achilles Tendonitis [21, 22]
Anatomy It is the largest tendon in the body formed by the union of tendons of soleus and gastrogenemius 
muscles to form Achilles tendon. It inserts posteriorly at the calcaneus
Muscles action Plantar flexion
Epidemiology   • patients are usually 30–40 years of age
  • males are equally affected like females
  • rupture Achilles tendon is five times more common in males
Risk factors Excessive supination, increase intensity of training program and increasing time in training 
(basketball and football players), repetitive stress, obesity, male gender, previous history, 
mechanical factors: Pes planus and pes cavus deformities, over pronation of foot, and drugs—
Fluoroquinolone or local glucocorticoid use
Symptoms   • pain with activity relieved after rest
  • pain 2–6 cm above insertion of the tendon, swelling, and possibly redness
  • in rupture Achilles tendon patient feels struck violently in the back of ankle or hears loud 
popping sound with severe pain
  • absence of pain dose not rule out Achilles tendon rupture
Signs   • gait and excessive foot supination. This is common with genu varaus deformity in the knee
  • examine the patient in prone position with feet hanging off at the end of the bed
  • inspect for bruising, swelling, and foot misalignment
  • palpation: Hotness, thick tendon or defect, edema, hematoma, tenderness
2–6 cm above calcaneus and compare it with the other side
  •  palpate the tendon in while in dorsiflexion of the ankle, plantar flexion, and
Neutral position
  • assess retrocalcaneal bursitis as one of the differential diagnosis for heel pain
  • crepitus in chronic tendinitis
  • assess for peripheral vascular disease (pulse, capillary refill, hair loss, and edema)
Notes:
The retrocalcaneal bursitis causes pain, fullness, or swelling proximal and anterior to the 
insertion of Achilles tendon in to the calcaneus
The posterior tibial tendinitis causes pain in medial side of the ankle
Special tests   •  calf squeeze or (Thompson test): Sensitivity of 96% and specificity of 93% [21] (see 
Chap. 2)
  • Matles test: Sensitivity of 88% and specificity of 85%: [21]
The patient lies prone with knees flexed to 90°. Observe whether the affected foot is 
dorsiflexed or neutral (both are abnormal) compared with the uninjured side, where the foot 
should appear plantar-flexed
Investigations Radiology: US and/or MRI to confirm diagnosis, monitor treatment response, and/or to assess 
why the patient is not responding if another diagnosis is missing
Treatment Avoid aggravating activity, support Achilles tendon with bandage, apply ice, NSAIDs can be 
used, avoid glucocorticoid at it is associated with high risk of tendon rupture [22]. Consider 
corrections of mechanical defects by providing custom-made orthotics that provide arch support
Consider rehabilitation and occupational therapy programs with eccentric exercise for around 12 
weeks. Air heel brace cast can be used in severe cases
Superficial heat and cold compressors
Deep heat by (US and iontophoresis)
Surgery can be considered in refractory cases after 3–6 months if no improvement all measures
Acute tendon rupture: Apply ice, analgesic, rest the ankle, and consider immobilization trial in 
few degrees of plantarflexion. Consider surgical referral for partial ruputure: there is still no 
clear rule for surgical intervention
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Table 22.7 Lateral and medial epicondylitis
Types Lateral epicondylitis (tennis elbow):
15 times more common than medial epicondylitis
Females are equally affected like males
Medial epicondyle (golfer 
elbow):
Less common
Definition It is inflammation at bony origin for wrist extensors muscles 
(extensor carpi radialis brevis “inserted in posterior base of 
third metacarpal” and extensor digitorum communis), due to 
overuse. The elbow of the dominant arm is affected more
It is inflammation at bony origin 
for wrist flexors muscles (pronator 
teres and flexor carpi radialis)
Muscles 
action
Extensor and abductor of the hand at wrist joint Flexors of fingers and thumb. 
Also, flexors and pronators of the 
wrist
Risk factors Age: Player 30 years or older, smoking, obese,
Tennis ball player , Occupation: Computer user and repeat 
movement for 2 h daily [27, 28]
Physical 
exam
  • localize tenderness in lateral epicondyle
  • pain on resisted wrist extension while elbow in flexion
  • pain in resisted supination and hand shaking
  • pain in resisted middle finger extension
  • Normal ROM of the elbow except in severe cases
  • few degrees of extension might be affected
  • examine radial nerve
  • in compression neuropathy the pain diffuses distally to 
epicondyle and is associated with muscle weakness
  •  Localized tenderness in medial 
epicondyle
  •  Pain on resisted wrist flexion 
while elbow in extension
  •  pain with resisted forearm 
pronation
  • examine ulnar nerve
Investigation It is a clinical diagnosis and investigations are usually not required
X-rays if indicated to look for osteophytes and calcification in epicondyle
Treatment Phase 1: Symptom less than 6 weeks
  • rest the joint and use splint
  • physiotherapy (eccentric exercise)
  •  NSAID: There is limited evidence, oral NSAIDs helps to reduce pain and improve the function 
in 6 weeks [27], and there is limited benefit of topical NSAIDs in acute epicondylitis [29]
Phase 2: If symptoms do not improve for 6–12 weeks
  • repeat 3 views X-ray to identify other possible causes
  • continue eccentric exercise
  •  local injection of corticosteroid. If no improvement, repeat in 2–4 weeks for total of 2
Doses. Use of local corticosteroid injection in lateral epicondylitis improves many patient
Symptoms in 6 weeks but does not prevent recurrences and long-term outcome worseness 
[30, 31]
Phase 3: If symptoms do not improve after 12 weeks
  • do US and/or MRI
Alternate treatment option might be considered as platelet-rich plasma injections, autologous blood 
injections, prolotherapy, extracorporeal shock wave therapy, and percutaneous needle tenotomy [32]
  • surgery if more than 6 months with failed conservative therapy including corticosteroid 
injection
  • 1. debridement +_ arthroscopic drain
  • 2. open debridement
  • 3. Pericutanous tenotomy
22.1.7  Achilles Tendinitis
See Table 22.6.
22.1.8  Epicondylitis [26, 27]
See Table 22.7
22.1.9  Fasciitis
A fascia is a layer of fibrous connective tissue 
(collagen) below the skin that covers underly-
ing tissues (muscles, blood vessels, and 
nerves). Fasciitis is the inflammation of the 
fascia that causes fibrosis and loss of elastic-
ity. The most common types of fasciitis are 
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planter fasciitis, palmar fasciitis, and eosino-
philic fasciitis (these types can be secondary 
to autoimmune rheumatological diseases and 
malignancies).
22.1.10  Plantar Fasciitis
See Table 22.8.
22.1.11  Palmar Fasciitis
See Table 22.9.
22.1.12  Eosinophilic Fasciitis
See Table 22.10.
Table 22.8 Planter fasciitis anatomy, history, physical exam, investigation and treatment
Planter fasciitis
Anatomy It is a thick white tissue with longitudinal fibers attach to medial process of calcaneal tuberosity 
divide to five slips continuing forward to form fibrous of flexor sheathes on plantar aspect one for 
each toe
History Age 40–60 years old
Pain in planter region that worse when initiate walking during the first few steps in morning
Aggravating factors: prolong standing or jumping, flat foot, high arch foot, heel spurs, running, 
excessive training during aerobic exercise and obesity [33, 34]
Symptoms suggestive of SpA (see Chap. 1) [35]
Physical 
examination
  • local tenderness
  • limited ankle dorsiflexion
The examiner should dorsiflex the patient toes with one hand, then pull the plantar
Fascia tight, and then palpate with thumb or index finger of other hand, the fascia
From heel particularly the medial aspect where the plantar fascia originates to the
Forefoot: Tenderness can be elicited
Investigations   • HLA-B27 and CRP if SpA is suspected
  •  X-rays: Lateral and axial films to detect thickness, fat pad abnormality, heel spur
And to rule out other causes
  • MRI in resistant cases [36]
  • US: 80% sensitivity and 88, 5% specificity to detect fascia thickening and edema [37]
Treatment   • 80% resolve spontaneously by 12 months
  • decrease physical activity and consider stretching exercise
  • arch support with custom made orthotics and avoid flat shoes
  • ice massage
  • NSAIDs can be tried for 2–3 weeks
  •  inject with local glucocorticoid and lidocaine in resistant cases
Mechanical defects should be corrected otherwise symptoms may recur
  • botulinum toxin injection might be considered
  •  for resistant cases refer to surgery for cast and possible splint extracorporeal shock wave 
therapy
  • if still no response fasciotomy can be considered as 5–10% of cases ultimately required it
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Table 22.10 Eosinophilic fasciitis definition, risk factors, symptoms, physical exam, investigation and treatment
Eosinophilic Fasciitis (Shulman’s syndrome or diffuse fasciitis with eosinophilic)
Definition Inflammation of the fascia with eosinophils infiltration causes fibrosis in early stages
Risk factors Hematological malignancy leukemia, myelodysplasia, and aplastic anemia [39]
Symptoms Stage 1:
  • pitting edema bilaterally most involving both arms and legs with sparing fingers and toes
  • proximal area more than distal in the extremities
  • no Raynaud’s phenomenon
Stage 2:
  • sever induration of the skin and subcutaneous tissue with peau d’s orange appearance
  •  Groove sign is an induration due to retraction of the subcutaneous tissue along the 
superficial veins
  •  mild myositis with normal CK level
Stage3:
  • Neuropathy like carpal tunnel syndrome
  • flexion deformity of the digits
  • muscle atrophy
  • no sclerodactyly and normal nailfold capillary
Investigations   • CBC and peripheral blood film look for hematological malignancy
  •  peripheral eosinophilia in 80% of the cases and the degree of eosinophilia does not correlate 
with disease activity
  • elevated ESR and CRP
  • aldolase can be elevated with normal CK
  • presence of polyclonal hypergammagloblinemia
  •  tissue biopsy shows inflammation and fibrosis in all skin layers except the epidermis and 
eosinophils infiltration can be seen in early stages
  • MRI findings fascial thickening with enhancement
Treatment   • treat underlying causes
  • some patients may experience spontaneous improvement as the disease can be self-limited
  • complete remission can be seen after 2 years or more
  • high dose of prednisolone 20–60 mg/ day
  • in resistant cases use hydroxychloroquine and methotrexate
Poor prognostic 
factors
  • young age at onset of the disease
  • trunk involvement
Table 22.9 Palmar fasciitis: definition, risk factors, symptoms, physical exam, investigation and treatment
Palmar fasciitis (palmar fibromatosis)
Definition Inflammation of the palmar fascia which causes fibrosis
Risk factors Malignancy most common as ovarian cancer but can also be associated with breast, lung, 
pancreas, stomach, colon, and metastasis [38]
Symptoms   •  Pain in palm with swelling: inability to close hands resulting in limitation of activity and 
function
  • joints pain
  • vasomotor symptoms
  • symptoms suggestive malignancy
Physical 
examination
  • tenderness and swelling of bilateral palms with tight fascia and fibrosis (woody hands)
  • symmetrical polyarthritis and flexion deformity of the fingers
  • Nailfold capillary is normal
Investigations   • tissue biopsy shows extensive fibrosis with fibroblast and mononuclear cell infiltration
  • screening for malignancy
Treatment   • treat underlying malignancy if patient has metastasis and has poor prognosis
  • NSAIDs
  • corticosteroid
  • ganglion blockade
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• To describe gastrointestinal manifestations in 
rheumatic diseases.
• To construct a diagnostic and systemic 
approach to gastrointestinal symptoms in 
rheumatic diseases.
• To interpret laboratory, radiological, and 
endoscopic finding in patients with rheumatic 
diseases presenting with gastrointestinal 
manifestations.
23.2  Gastrointestinal 
Manifestations of Systemic 
Lupus Erythematosus (SLE)
SLE may involve any part of the gastrointestinal 
(GI) tract as well as the liver.
Some patients may develop GI manifestation 
at onset of the disease (42%), which may delay 
the diagnosis of SLE in those patients. Patients 
with SLE who present with GI symptoms may 
have these symptoms secondary to active disease, 
side effects with medications, or secondary to 
infectious process. The most common symptoms 
are nausea and vomiting (53%), anorexia (49%), 
and abdominal pain (19%) [1]. The prognosis in 
such cases depends on early recognition and 
proper management [2].
23.2.1  Oral Cavity Manifestations 
of SLE
Oral cavity manifestations can happen in 7–52% 
of SLE patients and are necessarily associated 
with disease activity. The abnormalities which 
are secondary to active lupus are usually erythe-
matosus, discoid, and ulcerative and can be pain-
ful or painless [3].
There are no high-quality evidences to guide 
in the management of oral lupus lesions using 
systemic therapy.
Antimalarials, azathioprine, and corticoste-
roid are frequently used for the treatment of 
severe cases. Furthermore, thalidomide and 
cyclosporine are commonly used as alternative 
therapy as shown in some studies from Europe 
[3] (Fig. 23.1).
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23.2.2  Esophageal Manifestations 
of SLE
Dysphagia, heartburn, and regurgitation are com-
mon among SLE patients.
Dysphagia may result from dysmotility disor-
der, heartburn, or reduced saliva production in 
case the patient has a secondary Sjogren’s syn-
drome. The esophageal dysmotility may present 
in 21% to 72% of SLE patients [1].
Multiple factors may play a role in the motil-
ity changes which include inflammatory process 
in esophageal muscles, muscle atrophy, or isch-
emic vasculitis. Motility abnormalities may not 
be correlated to the symptoms or lupus [1]. SLE 
patients are at an increased risk of developing 
infectious esophagitis secondary to immunosup-
pression and pill-induced esophagitis. There are 
no high-quality evidences guiding the manage-
ment of dysphagia and reflux in patients with 
SLE. Pharmacological agents, such as antacids, 
proton pump inhibitors, H2 blockers, or pro- 
motility agents, may play a therapeutic role [3].
23.2.3  Gastric Manifestations of SLE
In SLE patients who present with acute abdomi-
nal pain, perforating peptic ulcer may happen in 
6% to 8% out of them. Physicians should consider 
H. pylori testing before initiating treatment with 
NSAIDs. Additionally, those patients may require 
to be on continuous gastroprotective agents such 
as proton pump inhibitors and H2 blocker.
23.2.4  Colonic and Small Bowel 
Manifestations of SLE
It is always challenging for physicians if SLE 
patients present with acute abdominal pain. The 
majority of SLE patients are taking corticosteroid 
and/or other immunosuppressive medications, 
which could mask some clinical signs of perfora-
tion and ischemia [3].
The most prevalent etiologies of acute abdom-
inal pain in patients with SLE are mesenteric vas-
culitis, hepatobiliary disease, pancreatitis, 
gastroenteritis, and appendicitis. Acute abdomi-
nal pain in SLE patients is associated with rela-
tively high mortality reaching 9.4% to 11% [1].
During flare of SLE, 53% of the patients who 
present with acute abdominal pain may have 
intestinal vasculitis, and their initial symptoms 
may include acute abdominal pain, nausea, and 
vomiting.
Intestinal vasculitis may lead to ischemic 
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range from superficial ulcerations to deeper lay-
ers which may cause penetration of the submu-
cosa; in some cases GI bleeding may happen.
There are certain clinical and radiological 
signs that may alert physician for the possibility 
of bowel perforation which include low blood 
pressure, metabolic acidosis, high levels of serum 
lactate dehydrogenase, distended abdomen, and 
dilated intestines in abdominal radiograph.
Thumb printing represents edema of the sub-
mucosa or bleeding on a barium enema; this 
sign is considered specific for intestinal isch-
emia [3]. Colonoscopic findings may reveal 
inflammatory changes and/or ulcers, which may 
be irregular in shape or punched out. Three-
phase abdominal Tc-99 m pyrophosphate scin-
tigraphy can be utilized to show areas of active 
vasculitis. Mesenteric angiography may be used 
to rule out distinct type of vasculitis like polyar-
teritis nodosa which may be associated with dif-
fuse irregularities of the small arteries in the 
intestine and renal arteries [1].
Treatment of lupus vasculitis includes treat-
ment of underlying SLE and high doses of ste-
roids, but in advanced cases, cyclophosphamide 
is usually given. Patient must be referred to gen-
eral surgery because they should have a low 
threshold for early laparotomy in cases of acute 
abdomen [1].
In SLE patients, infection is considered one of 
the most common causes of mortality which 
could reach up to 28.5% [1, 3]. The majority of 
SLE patients are considered immunocompro-
mised because of immune dysregulation associ-
ated with the disease itself and because most of 
the patient are being managed with immunosup-
pressant medications. Thus, they are at risk of 
certain kinds of infections such as CMV, 
Salmonella infection, pneumatosis cystoides 
intestinalis, and others.
In infection with Salmonella, the bacteria is 
usually isolated from blood rather than the stool 
sample. It is usually associated with febrile ill-
ness and abdominal pain and infrequently diar-
rhea [1].
Patients with pneumatosis cystoides intestina-
lis could have benign pneumoperitoneum. 
Conservative management may be sufficient, and 
some patients may require corticosteroids or 
intravenous cyclophosphamide [1].
Because of the similarity between clinical 
symptoms of SLE flares and those associated 
with infections, early identifications of underly-
ing infections among SLE patients can be chal-
lenging [3].
One of the rare GI complications in patients 
with SLE is intestinal pseudo-obstruction (IPO), 
and it is defined as having symptoms and signs of 
intestinal obstruction with the absence of actual 
mechanic obstruction.
IPO can be diagnosed based on the clinical 
findings, abdominal radiograph, and manometry 
findings [4]. Management usually starts with 
conservative measures; in case of insufficient 
response, steroids and/or immunosuppressive 
drugs can be given as well as antibiotics specially 
the ones with prokinetic properties such as eryth-
romycin. Octreotide may be used in refractory 
cases [1].
Protein-losing gastroenteropathy (PLE) is 
described as the presence of low levels of serum 
albumin secondary to losing proteins from the GI 
tract, and it’s usually considered in patients with 
hypoalbuminemia with the absence of marked 
proteinuria, advanced hepatic disorders, impaired 
absorption, or poor oral intake [4]. The small 
intestines are commonly affected rather than the 
large intestines [1]. It commonly manifested as 
mild edema and may progress to ascites and pleu-
ral and pericardial effusions [4]. Radiological 
features of PLE may include prominent mucosal 
pattern (due to edema), speculation, and frag-
mentation or clumping of barium. Histological 
features may be normal or may show blunted villi 
or lymphangiectasia. Management of PLE 
includes corticosteroids, and some patients may 
require the use of cytotoxic medications; octreo-
tide is occasionally used [1].
23.2.5  Pancreatic and Gallbladder 
Manifestations of SLE
Acute pancreatitis is an uncommon complication 
of SLE, and it might occur in 8% of patients with 
SLE, and patient may develop abdominal pain [1].
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SLE patients with pancreatitis have a mortal-
ity rate of 27%. It is associated specially with 
neuropsychiatric and cardiac manifestations, 
hypocalcemia, low levels of the complements, 
and complications of pancreatitis [1]. The man-
agement of SLE-related pancreatitis, as with 
other causes of acute pancreatitis, is with intrave-
nous fluids, pain control, and electrolyte 
correction.
Primary sclerosing cholangitis and autoim-
mune cholangiopathy have been reported in SLE 
patients. Acute acalculous cholecystitis may 
occur secondary to vasculitis or serositis, and it is 
commonly managed with surgical intervention 
[1] (Fig. 23.2).
23.2.6  Hepatic Manifestations of SLE
It was estimated in some studies after several 
years of follow-up periods that 9.3% to 59.7% of 
SLE patients may have an abnormal liver func-
tion test (LFT) [5]. Transaminitis is common 
among SLE patients and may be developed due 
to several etiologies which may include side 
effects of medications, infectious viral hepatitis, 
fatty liver disease associated with steroid use, 
hepatic congestion, primary liver disease, auto-
immune hepatitis (lupoid hepatitis), or lupus 
hepatitis [6]. During SLE flare, 20% of the 
patients may have abnormal liver enzymes, while 
in 23% of the patients, the etiology of the abnor-
mal liver tests is unknown [7]. SLE patients may 
have hepatomegaly in 39% to 40% of the cases, 
while splenomegaly may present in 6% of 
patients with SLE [1].
Autoimmune hepatitis (AIH) should be 
always considered in SLE patient with persistent 
elevated liver enzymes; undiagnosed AIH may 
progress rapidly to hepatic cirrhosis. Both dis-
eases are associated with positive ANA; how-
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with AIH and can help in distinguishing between 
AIH and lupus-associated hepatitis. On the other 
hand, anti-ribosomal P antibody was found to be 
positive in many patients (69%) with lupus hepa-
titis [7].
Patients with AIH are usually managed with 
corticosteroid initially, and some of them require 
other immunosuppressant medications [8].
Based on the current understanding of lupoid 
hepatitis, it can be defined as the presence of 
pathologic liver injury fitting a picture of chronic 
hepatitis, having a negative serum serology of the 
common viral infections associated with chronic 
hepatitis and the presence of positive ANA or LE 
cell preparation [9].
Luckily, there are some histological findings 
seen in liver biopsies which may be helpful for dis-
tinguishing lupus hepatitis from AIH. For instances, 
in AIH, interface hepatitis associated with lobular 
activity, rosetting of liver cells, or lymphoplasma 
cell infiltration can be seen in liver biopsy. On the 
other hand, in lupus hepatitis, the inflammation is 
usually lobular and occasionally periportal, with a 
paucity of lymphoid infiltrate [6].
SLE patient may have a secondary antiphos-
pholipid syndrome (APS), which is described as 
the presence of antiphospholipid antibodies and 
recurrent arterial or venous thrombosis. Patients 
with APS have GI involvement such as Budd- 
Chiari syndrome, hepatic ischemia, and esopha-
geal varices (secondary to portal vein thrombosis); 
esophageal involvement may occur as well which 
include necrosis with perforation (due to throm-
bosis), bowel ischemia, colonic ulcers, and pan-
creatitis [10].
Overlap syndrome can occur in which patient 
may have SLE with AIH or PBC with similar 
prevalence (2.7% to 15%) [7, 11].
23.2.7  Gastrointestinal Malignancies 
in Systemic Lupus 
Erythematosus
Several studies have looked at the malignancy 
rate among SLE patients. An international study 
which involved 16,409 SLE patients noted a 
modest increased risk of malignancy in SLE 
patients [12]. Multiple factors are possibly con-
tributing to this slight increase of overall malig-
nancy risk in those patients which include 
immune dysregulation in SLE which may lead to 
disturbance in abnormal proliferations and acti-
vation of T and B cells. Thus, abnormality in B 
cell proliferation may explain the presence of 
non-Hodgkin’s lymphoma, a type of B cell lym-
phoma, in some SLE patients. Other factors are 
the use of immunosuppressive medications as 
well as the chronic inflammation associated with 
the disease itself [13].
The most frequently noted malignancies in 
SLE patients are non-Hodgkin’s lymphoma, lung 
cancer, hepatobiliary malignancy, vulvar/vaginal 
malignancy, and thyroid malignancies, as well as 
cervical dysplasia [12].
On the other hand, there are some malignan-
cies found to be decreased among patients with 
SLE such as breast and prostate cancer. Some 
proposed reason for this decrease in the rate of 
these malignancies may be related to circulating 
anti-DNA autoantibodies as well as certain cyto-
kines mediated by HSP-27 [12].
23.3  Gastrointestinal 
Manifestations 
of Rheumatoid Arthritis (RA)
23.3.1  Dysphagia and Other 
Esophageal Manifestations 
of Rheumatoid Arthritis
Almost half of RA patients may have temporo-
mandibular joint (TMJ) arthritis. Patients with 
TMJ arthritis may complain of pain and crepitus 
during chewing secondary to TMJ involvement 
which may correlate with RA activity. 
Atlantoaxial subluxation with evidences of spinal 
cord involvement may result in dysphagia; physi-
cians should be aware of the high risk associated 
with endoscopy in such patients. Patients with 
juvenile RA (JRA) may complain of dysphagia 
secondary to cervical spine abnormality or to 
micrognathia, which occurs as a result of the loss 
of the mandibular condyles and retraction of the 
jaw [14]. Methotrexate, the cornerstone of treat-
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ment of RA, can cause oral ulcers which might 
contribute to the difficulty in initiating swallow-
ing or dysphagia.
Esophageal manifestations in RA may include 
esophageal dysmotility, reflux esophagitis, amy-
loidosis, and, rarely, esophageal varices due to 
Felty’s syndrome.
Abnormal esophageal motility with a low per-
istaltic pressure in the lower two-thirds of the 
esophagus and reduced pressure in the lower 
esophageal sphincter lead to impaired peristalsis 
in patients with RA.  These manifestations may 
occur in up to 62.5% of RA patients and can be 
associated with heartburn, dysphagia, and esoph-
agitis. Esophageal dysmotility may be attributed 
to amyloidosis or to GI vasculitis, which occa-
sionally can cause esophageal strictures from 
local ischemia [10, 14].
23.3.2  Gastric Manifestations 
of Rheumatoid Arthritis
Most of GI abnormalities in patient with RA are 
associated with the chronic use of NSAIDs and 
steroids. In 20% to 40% of the patients on 
NSAIDs, abnormal changes can be seen during 
endoscopic evaluations. Those patients are con-
sidered at a high risk of peptic ulcer disease and 
ulcerations in both small and large bowels [10].
In 30% and 60% of patients with RA, biopsy 
samples may show chronic superficial and atro-
phic gastritis. In addition, chronic atrophic gastri-
tis can also be seen in patients with RA and 
associated secondary Sjogren’s syndrome. Those 
patients may develop vitamin B12 deficiency 
and/or pernicious anemia [14]. NSAIDs are com-
monly prescribed for RA patient because of their 
effect for pain relief and for their anti- 
inflammatory properties; however, their use is 
associated with a wide range of GI manifesta-
tions, and patients may present with relatively 
mild symptoms such as dyspepsia and gastroduo-
denal ulcerations to a life-threatening ones such 
as GI bleeding, perforations, or obstructions. 
Gastropathy associated with NSAID use may 
direct physicians toward the use of a selective 
type of NSAIDs known as cyclooxygenase 2 
inhibitors (COX-2), which in many trials proven 
its efficacy in reducing GI complications such as 
bleeding, perforations, or obstructions. 
Physicians may use alternative methods for GI 
protection with NSAID use such as prescribing 
proton pump inhibitor (PPI) or misoprostol com-
bined with NSAIDs [15, 16].
23.3.3  Intestinal and Colonic 
Manifestations of Rheumatoid 
Arthritis
Small bowel findings in patients with RA may 
manifest as inflammatory changes which could 
result in blood and protein loss, ulcerations, and 
strictures. However, colonic and rectal involve-
ment includes nonspecific colitis and rectitis, 
ulcerations, blood loss, diverticular complica-
tions, and perforation. The cecum and the right 
colon are the common sites of colon ulcerations 
which may complicate with a bleeding or perfo-
rations [10].
RA-associated vasculitis is an uncommon 
complication of RA; it can happen in 1% of the 
patients. Among RA patients with associated vas-
culitis, 20% of them may develop intestinal 
involvement. Patients at risk of RA vasculitis are 
those with long-standing erosive arthritis, posi-
tive rheumatoid factor with a high titer, and the 
presence of subcutaneous nodules.
Surprisingly, RA vasculitis may occur in 
patients with inactive joint disease. Furthermore, 
it can complicate with GI bleeding, ulcerations, 
bowel perforations, and small and large intestine 
infarctions [10, 15]. The prognosis in such 
patients is commonly poor, and the consequences 
may be fatal [17].
Long-standing RA may complicate with sec-
ondary amyloidosis which involves the GI tract 
as well as the liver. GI involvement may manifest 
as protein-losing enteropathy, colon ulcers, or 
esophageal strictures [18].
Pneumatosis cystoides intestinalis is rarely 
associated with RA [19]. GI side effects associ-
ated with use of NSAIDs do not merely involve 
the upper GI tract; it also can involve the lower 
GI tract [15].
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Anti-gliadin IgG may be found in up to 47% 
of patients, specially in those with positive rheu-
matoid factor (IgA). Duodenal villous atrophy 
may present in some patients; however there are 
insufficient evidences to support the association 
between RA and celiac disease.
23.3.4  Hepatic Manifestations 
of Rheumatoid Arthritis
Enlarged liver may be seen in up to 22% of RA 
patients using scintigraphy scan, and it may be 
associated with elevated RF.
Spontaneous rupture of the spleen may occur 
with or without splenomegaly. RA may involve 
the capsule which could lead to this complica-
tion. Regarding laboratory investigations, 
patients with RA usually have normal levels of 
transaminases and bilirubin; however, alkaline 
phosphatase may be elevated in up to 18%–46%, 
while gamma glutamyl transaminase (GGT) may 
be elevated in 23%–77% of RA patient and it 
may correlate with RA activity.
In autopsy study, abnormal liver histology was 
found to be in 92% of RA patients and 65% of 
patients in a clinical study. The most prevalent 
histologic findings are periportal fibrosis, inflam-
matory changes in the portal tract, sinusoidal 
dilatation, amyloid, and rarely cirrhosis. These 
changes are usually mild and might correlate 
with RA activity.
RA has been commonly reported after an 
infection with hepatitis B or C. However, it is still 
unclear as to whether the virus triggers RA or the 
infections and RA occur at the same time. After 
following levels of HCV viral loads and liver 
function tests, it was found that the use of anti- 
TNF biological therapy in the treatment of RA 
may not cause a reactivation of chronic infection 
with HCV.  On the other hand, anti-TNF may 
cause a reactivation of HBV. It is recommended 
for all patients with HBV who are planning to get 
anti-TNF to be started on the treatment for HBV 
at least 2  weeks before the initiation of 
anti-TNF.
In RA patients presenting with liver abnor-
malities, physicians should broaden the differen-
tial diagnosis to include side effects of a drug 
with hepatotoxicity, viral hepatitis, fatty liver, 
and autoimmune hepatitis (AIH).
Sulfasalazine can cause reversible liver injury 
but might recur if the drug was reintroduced.
Methotrexate hepatotoxicity was extensively 
reviewed and can cause steatosis, stellate cell 
hypertrophy, and hepatic fibrosis. Hepatic dam-
age may increase with recurrent hepatic infec-
tions and concomitant use of the hepatotoxic 
drugs or alcohol [20].
23.3.5  Other Gastrointestinal 
Manifestations of Rheumatoid 
Arthritis
Rheumatoid vasculitis is classified as vasculitis 
associated with a systemic disease. It usually 
involves small- and medium-sized vessels affect-
ing 1–5% of RA patients.
Intestinal involvement in rheumatoid vasculi-
tis was described in another section (see Intestinal 
and Colonic Manifestations of Rheumatoid 
Arthritis).
In case of ruptured aneurysm, patients may 
develop abdominal pain and syncope. Regarding 
hepatic manifestations, rheumatoid vasculitis 
may lead to intrahepatic or subcapsular hemato-
mas, infarction, or rupture [10, 21]. Management 
of rheumatoid vasculitis is based on only small 
observational studies and case reports.
The most commonly used agents are high- 
dose steroids, cyclophosphamide, and biological 
therapies.
Secondary amyloidosis can be caused by sev-
eral diseases; however, RA is the most common 
cause of secondary amyloidosis. Patients at risk 
are those with poorly controlled and long- 
standing disease usually more than 5  years. 
Secondary amyloidosis may involve the GI tract 
in up to 22% of the cases. It may manifest as 
refractory diarrhea, malabsorption, protein- 
losing enteropathy, and abdominal pain [22–24].
Presence of splenomegaly, neutropenia, and 
RA makes the classic trial of Felty’s syndrome 
which may present in 1% of RA patients. It is 
characterized by severe destructive arthritis, 
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rheumatoid nodules, enlarged lymph nodes, vas-
culopathy, skin ulcers, and hepatic abnormality 
which may include hepatomegaly in up to 68% 
of the cases and abnormal liver function tests in 
up to 56% of the patients which is a higher per-
centage compared to the one seen in uncompli-
cated RA.
23.4  Gastrointestinal 
Manifestations 
of Inflammatory Myositis
Inflammatory myopathies are distinct category of 
rheumatic diseases which usually present with a 
proximal myopathy; however they have different 
skeletal and other organ manifestations; dermato-
myositis (DM), polymyositis (PM), and inclusion 
body myositis (IBM) are the main diseases in this 
category.
23.4.1  Symptomatology
Gastrointestinal manifestations of inflammatory 
myopathies include dysphagia, heartburn, bloat-
ing, nausea, and chronic constipation. Severe GI 
manifestations maybe secondary to inflammatory 
changes in bowel mucosa, resulting in erosions, 
ulcers, and perforations, are uncommonly seen in 
adult DM [25, 26].
23.4.2  Esophageal Manifestations 
of Inflammatory Myositis
Patients with inflammatory myopathies and 
esophageal involvement may develop uncoordi-
nated swallowing, uncoordinated esophageal 
peristalsis, and hiatus hernia with reflux and 
stricture formation [27].
The most common GI symptoms in patients 
with inflammatory myositis are dysphagia—to 
solids and liquids—and heartburns [25]. They 
occur secondary to abnormalities in the pharynx 
and esophagus and in up to 32–84% of patients 
with myositis. The highest type of inflammatory 
myositis in the percentage is inclusion body 
myositis, and it is unfortunately the most refrac-
tory one [28]. The patient might present with 
symptoms including nasal speech, hoarseness of 
the voice, nasal regurgitation, and an inability to 
swallow a food bolus while the patient is on 
recumbent position due to the elimination of the 
effect of gravity; physical exam will be signifi-
cant for tongue weakness, flaccid vocal cords, 
and poor palatal motion [27, 28]. The presence of 
esophageal manifestations is linked to unfavor-
able prognosis and a more severe disease.
Patients with reflux symptoms might respond 
to anti-reflux measures as well as treatment of 
inflammatory myopathy [25]. The use of steroids 
may improve esophageal dysfunction. In PM and 
DM, plasmapheresis may be effective for the 
treatment of dysphagia [29]. Intravenous immu-
noglobulin (IVIG) is usually considered in the 
refractory inflammatory myopathy, with consis-
tent remission maintained in almost half of suc-
cessfully treated patients with PM after 
discontinuation of therapy [30]. In IBM, IVIG 
may be effective as well if given with or without 
steroid in cases of severe dysphagia. Surgical 
intervention is usually needed in case of obstruc-
tive causes.
Cricopharyngeal myotomy is the most benefi-
cial intervention for dysphagia in inflammatory 
myopathy [28], but dilatation may be attempted 
if surgery is contraindicated. Injection of botuli-
num toxin A into the cricopharyngeus may also 
eliminate the need for surgical myotomy [27, 
29–31].
23.4.3  Gastric Manifestations 
of Inflammatory Myositis
Esophageal as well as gastric emptying can be 
delayed in PM and DM. Manometry may reveal 
reduced distal esophageal/gastric emptying 
implying malfunction of the smooth muscle of 
the upper GI tract [25]. Delayed gastric empty-
ing, constipation, and boating all are common in 
patient with inflammatory myopathy which can 
be attributed to dysmotility disorders. Patients 
with inflammatory myopathies (6–60%)—spe-
cially DM—are at high risk of certain types of 
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malignancy [10]. There is a threefold increased 
risk for cancer of the stomach, pancreas, and 
colon [32]. The most common GI malignancies 
are gastric and colorectal adenocarcinoma [10].
23.4.4  Intestinal Manifestations 
of Inflammatory Myositis
Vasculitis may lead to ulcerations in the mucosa 
and possibly intestinal perforation. This is more 
common in childhood type of DM rather than 
adult type, in which all these features have been 
described throughout the GI tract from the esoph-
agus to the large intestine. Pneumatosis cystoides 
intestinalis has been reported in DM and 
PM. There have been also some reports linking 
between PM and small bowel pseudo-obstruction 
and pseudomonal necrotizing enterocolitis [25] 
(Fig. 23.3).
23.4.5  Hepatic Manifestations 
of Inflammatory Myositis
Inflammatory myositis is occasionally misdiag-
nosed as a liver abnormality. Thus, this could 
result in a delay in delivering the appropriate 
management. Active muscle inflammation is 
commonly associated with an elevation of the 
levels of CK, aldolase, ALT, AST, and 
LDH. Higher levels of these enzymes are com-
monly seen in PM compared to DM and in 
males compared to females. Liver abnormality 
or biliary diseases should be suspected in case 
the levels of transaminases are higher than CK 
levels or when patients develop cholestatic pic-
ture [33] [9].
There are some case reports associating 
between PM and primary biliary cirrhosis (PBC); 
physicians may pay attention for patients with 
elevated alkaline phosphatase in light of the pos-
sible association [9].
23.5  Gastrointestinal 
Manifestations of Systemic 
Sclerosis
Gastrointestinal manifestations of systemic scle-
rosis are common, and they have an effect on 
prognosis, morbidity, mortality, and quality of 
life. They result from fibrosis and can affect sev-
eral portions of the GI tract. GI involvement is 
the most frequent internal complication and 
accounts for about 10% of the presenting features 
in systemic sclerosis [34]. Furthermore, it is pos-
sibly the second most prevalent site of systemic 
sclerosis visceral damage [35]. In systemic scle-
rosis, women are affected 4.6 times more than 
men [36].The pathophysiology of SSc of the GIT 
is known only to a limited extent. It is due to 
fibrotic changes caused by an increase in the col-
lagen deposition and other extracellular matrix 
components in the upper and lower GIT leading 
to dysmotility, malabsorption, malnutrition and 
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dilation of the intestine [36], and alteration of the 
microvasculature, the autonomic nervous system, 
and the immune system. Sjogrin proposed a pro-
gression of sclerodermatous GI involvement: 
vascular damage (grade 0), neurogenic impair-
ment (grade1), and myogenic dysfunction 
(grade2) with the replacement of normal smooth 
muscle by collagenous fibrosis and atrophy [35]. 
The most common organ involved in GI manifes-
tation is the esophagus, followed by the anorec-
tum and small bowel [34], but any portion of the 
tact can be involved in both limited and diffused 
SSc. Physicians should have a high level of suspi-
cion for GI abnormality in SSc, because patients 
with SSc may have subclinical GI abnormalities, 
in 50% of patients with esophageal involvement 
and 20% of small intestine involvement [2]. The 
mortality rate secondary to GI complications is 
estimated in 6–12% of the cases [35].
The oropharyngeal involvement in patients 
with systemic sclerosis includes skin thicken-
ing, xerostomia, and swallowing difficulties 
(Fig. 23.4).
23.5.1  Esophageal Manifestations 
of Systemic Sclerosis
Esophageal manifestations in SSc may occur in 
up to 70 to 90% [2]. Asymptomatic esophageal 
changes may happen in 50% of the cases, Thus, 
early recognition is crucial in order to avoid the 
complications.
Esophageal manifestations of SSc may not 
always be symptomatic, but early diagnosis 
remains important as the delay may increase the 
risk of complications [35]. All the symptoms are 
related to esophageal motility disorder and gas-
troesophageal reflux. Symptomatic patients may 
complain of heartburn, dysphagia, or odynopha-
gia and, with advanced dysphagia, may complain 
of food and fluid regurgitation. Gastric reflux 
may lead to esophageal damage through mild 
peptic esophagitis, and it could progress to ero-
sions, bleeding, and prominent ulcerations.
Patients with SSc may develop esophageal 
stricture formation and fistulae, and an achalasia- 
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developing Barrett’s esophagus [35] and esopha-
geal adenocarcinoma [34].
Barrett’s esophagus happens when the normal 
stratified squamous epithelial lining of the distal 
esophagus undergoes metaplasia, with normal 
epithelial cells being replaced by an abnormal 
columnar epithelium including goblet cells. It 
has an incidence rate of 6.8–12.7% compared 
with that of the general population (less than 1%) 
[35]. Evaluation for esophageal involvement is 
guided by the patient’s symptoms. EGD should 
be done in any patient with refractory heartburn, 
dysphagia, and odynophagia. Treatment with 
proton pump inhibitors for 6 months may result 
in complete resolution of inflammation [34].
23.5.2  Gastric Manifestations 
of Systemic Sclerosis (SSc)
Patients with SSc may have gastric involvement 
of the disease in 10–75% of the cases [37]. The 
most common finding among these patients with 
SSc is delayed gastric emptying [2] followed by 
iron deficiency anemia which may be found in 
96% of patients with SSc, and it is mostly due to 
gastric antral vascular ectasia (GAVE); it is also 
called watermelon stomach [37]. GAVE has been 
found more in patients with early diffuse cutane-
ous SSc and late-onset anticentromere-positive 
limited cutaneous SSc [37]. The diagnosis of 
delayed gastric emptying is made by electrogas-
tric graphic recording or by scintigraphy follow-
ing a radiolabelled meal. GAVE can be diagnosed 
endoscopically with two unique findings, i.e., (i) 
classic “watermelon stomach” with prominent, 
flat, or raised erythematous stripes, radiating in a 
spoke-like fashion from the antrum to the pylo-
rus, and (ii) “honeycomb stomach “where a 
coalescence of many round angiodysplastic 
lesions are formed in the antrum [37]. Prokinetic 
agents such as metoclopramide and domperidone 
are commonly used because of their effect on 
increasing the tone of contraction of gastric mus-
cles. Patients who have insufficient response to 
these medications may be offered a low dose of 
erythromycin [35].
In patients with GAVE, in addition to mea-
sures for correcting anemia such as blood trans-
fusion if indicated and iron supplementation, 
endoscopic laser ablation is found to be effective 
in up to 75% of cases [35]. Surgical antrectomy is 
usually not indicated. In refractory cases intrave-
nous cyclophosphamide has been used with suc-
cessful results [34].
23.5.3  Intestinal Manifestations 
of Systemic Sclerosis
SSc can involve the small and large bowel as 
well, including the rectum and the anus. Small 
intestine manifestations, in conjunction with 
hypomotility, cause malabsorption contributing 
to an increased incidence of bacterial overgrowth 
and pseudo-obstruction which can lead to severe 
malnutrition. Colonic involvement may include 
diarrhea, fecal incontinence, and bleeding [35]. 
Another complication which is associated with 
morbidity and mortality among SSc patients is 
the malabsorption syndrome, which is also linked 
to high disease activity. Small bowel bacterial 
overgrowth can be diagnosed by a positive breath 
test or jejuna aspirate cultures. In addition, the 
basic laboratory tests should be acquired for all 
SSc patients, including serum hemoglobin 
because it could indicate the presence of vitamin 
B12, folic acid, or iron deficiencies. In SIBO, lev-
els of serum folic acid may be elevated due to the 
synthesis of folates by bacterial flora in the 
 intestines. Additionally, serum albumin is fre-
quently used to look for evidences of malnutri-
tion; however, this might not be entirely accurate, 
because it is a negative phase reactant, which has 
poor sensitivity and specificity for malnutrition. 
Carotene levels in the serum may be utilized to 
screen for fat malabsorption [34].
The diagnosis of pseudo-obstruction can be 
done by scintigraphy or wireless motility capsule. 
Dilatation of intestinal loops is the most prominent 
radiographic feature in SSc when absence of peri-
stalsis affects the duodenum and proximal jeju-
num. Teamwork among rheumatologists, 
nutritionists, and gastroenterologists is crucial in 
SSc patients with malnutrition and complicated GI 
disease. In case a patient with SSc present with 
picture of SIBO, a trial of appropriate antibiotics 
should be started for 10  days, regardless of the 
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result of breath testing. In patients with pseudo-
obstruction, metoclopramide and domperidone 
can be tried. Subcutaneous octreotide may be con-
sidered for patients with refractory GI symptoms. 
In case patients failed all to abovementioned medi-
cations, parenteral nutrition or enteral feeding 
through jejunostomy might be considered [34].
23.5.4  Colonic and Anorectal 
Manifestations of Systemic 
Sclerosis
Constipation may occur in patients with SSc dur-
ing early phase of colonic disease. Colonic telan-
giectasia and pseudodivirticula are common 
incidental findings and may cause anemia. 
Therapeutic options during early phases of con-
stipation include bulk-forming laxatives which 
also might be helpful in the management of fecal 
incontinence. Reduction of rectal compliance 
may occur secondary to the deposition of colla-
gen; this might complicate with anismus which 
can manifest as diarrhea. Patient may complain 
of severe urgency, and incontinence could occur 
which is usually mildly improved in medical 
therapy such as loperamide [35].
The anorectum can be affected in up to 50–70% 
of SSc patients, and 20% of cases may complicate 
with fecal incontinence. A recent study confirmed 
the involvement of the IAS in SSc patients, find-
ing the IAS of SSc patients to be thin and atrophic 
compared with that of incontinent controls. Based 
on this finding, the most effective management of 
anorectal symptoms could be with sacral neuro-
modulation, which may be worth considering 
early in patients with SSc [34].
23.6  Gastrointestinal 
Manifestations of Behcet’s 
Disease (BD)
Gastrointestinal manifestations of Behçet’s dis-
ease are of great importance because they have 
been associated with morbidity and mortality. 
They follow the development of oral ulcers by 
3.5 to 6 years [38].
23.6.1  Esophageal Manifestations 
of Behçet’s Disease
Esophageal manifestations in BD are uncom-
mon; it may occur in 2%–11% of the patients 
[38]. When the esophagus is involved, other GI 
parts may be involved as well in more than 50% 
of cases [39]. The most frequent symptoms 
include retrosternal chest pain, dysphagia, odyn-
ophagia, and upper and lower GI bleeding [40, 
41]. Endoscopy may show single or multiple 
ulcers. Several complications may happen includ-
ing stenosis and perforations [42]. Esophageal 
varices have also been reported [43].
Esophageal dysmotility may also occur in 
BD.  In comparison to age-matched group, 
patients with BD may have a significantly lower 
esophageal pressure and relaxation [44]. In 
patients with BD, upper GI endoscopy is not rou-
tinely done; however, in some cases physicians 
may consider upper GI endoscopy and/or 
manometry for patients with symptoms sugges-
tive of underlying esophageal abnormality.
23.6.2  Gastric Manifestations 
of Behçet’s Disease
Gastric involvement in BD is uncommon. Patients 
may complain of abdominal pain or dyspepsia 
[43]. Ulcerations may be found during endo-
scopic evaluation; they may be isolated gastric 
ulcers, isolated duodenal ulcers, or mixed [45].
Uncommon findings may include Dieulafoy’s 
lesions and gastric non-Hodgkin’s lymphoma 
[43]. Gastroparesis has also been associated to 
BD in few case reports.
23.6.3  Intestinal and Colonic 
Manifestations of Behcet’s 
Disease
Intestinal involvements in BD can be classified 
into two categories: small vessel disease in which 
ulcers are formed secondary to mucosal inflam-
mation and large vessel disease which may result 
in bowel ischemia and infarction.
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The ileocecal area is the most common site for 
intestinal lesions [45]. The rectum and anus are 
rarely involved [46].
Typically, intestinal lesions in BD are 
described as large (> 1 cm), round−/oval-shaped, 
deep ulcers in the ileocecal area [43]; this is 
based on the findings from a landmark study 
from Korea where a total of 94 patients with BD 
complicated with intestinal involvement were 
studied. Terminal ileum, ileocecal valve, and 
cecum were the most common sites for intestinal 
involvement representing 96% of the cases. The 
pattern of intestinal involvement includes local-
ized single ulcer in 67% and localized multiple 
ulcers in 27% of the cases, while multiple seg-
ments and colonic involvement are found in only 
6% of cases [47].
There are some other rare abnormalities in BD 
which may include the presence of strictures, for-
mation of abscess and fistula, and bowel perfora-
tions [43]. Because the management is completely 
different and the presentation may be confused 
with BD, tuberculosis (TB) should be ruled out in 
patients living in geographic areas which are 
endemic with TB. In cases where it is difficult to 
differentiate between BD and intestinal TB, some 
experts recommend beginning 8-week trial of 
anti-tuberculosis antibiotics. Another mimicker 
of BD is Crohn’s disease (CD), which is some-
times challenging for physicians to differentiate 
between the two, since both of them may present 
in young patients. However, colonoscopy may 
help reaching the diagnosis. Endoscopic findings 
in 235 patients with CD and BD were studied; the 
most predictive findings of BD using multivariate 
analysis were round-shaped ulcers, focal single 
and focal multiple ulcers “less than 6,” and 
absence of cobblestone appearances [48].
In contrast, the lesions in CD are characteristi-
cally described as segmental, diffuse, and longi-
tudinal, with the presence of cobblestone 
appearance. Both diseases (BD and CD) may 
have colitis and transmural enteritis, formation of 
fistulae, intestinal perforation, and GI bleeding, 
but if there are any signs of vasculitis in the speci-
men, this might indicate the presence of BD 
rather than CD [49]. One of the rare complica-
tions that may also affect the GI tract in patients 
with BD is AA amyloidosis, usually manifested 
with diarrhea and malabsorption. Involvement of 
the renal system with proteinuria could also 
occur and may progress to renal failure. In such 
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Fig. 23.5 Etiologies of gastrointestinal bleeding
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23.6.4  Pancreatic Manifestations 
of Behcet’s Disease
Pancreatic manifestation in BD is very rare. Only 
limited case reports of acute pancreatitis have 
been linked to BD.  Chronic pancreatitis was 
reported in a patient with BD—however, this 
finding might be due to other etiology since the 
same patient was consuming high amount of 
alcohol [43, 50]. Because of the lack of sufficient 
evidence to associate BD with pancreatitis, in a 
patient with BD who presents with pancreatitis, 
workup for other etiologies must be done [45].
23.6.5  Hepatic Manifestations 
of Behcet’s Disease
Budd-Chiari syndrome (BCS) is the most com-
mon hepatic manifestation in BD. It causes high 
mortality rate secondary to venous thrombosis that 
resulted from endothelial dysfunction. Its preva-
lence rates are between 1.3% and 3.2% [43–45].
The patient can present right upper quadrant 
abdominal pain, ascites, and hepatosplenomeg-
aly. The course of disease can be acute, subacute, 
or chronic [39].
Acute BCS is associated with poor prognosis 
due to extensive venous thrombosis.
Budd-Chiari syndrome (BCS) can be treated 
medically, surgically, and /or by interventional 
radiology. Ascites can be treated by salt restric-
tion and diuretics. Endoscopy is indicated for 
screening and treatment of varices. 
Cyclophosphamide and corticosteroids are the 
cornerstone for treatment of BCS in patients with 
BD. Anticoagulation is still controversial and is 
not recommended in the most recent European 
League Against Rheumatism guidelines [39, 43].
Other hepatic manifestations of BD include 
liver abscess, sclerosing cholangitis, and chronic 
hepatitis [43].
23.6.6  Visceral Arterial Involvement 
in Patients with Behcet’s 
Disease
BD can involve arteries and veins of all sizes. The 
incidence of vascular involvement is 7%–29% 
with males predominant. Arterial involvement is 
rare, and patients can present fever, abdominal 
pain, pulsatile mass, or complications such as 
intestinal infarction or gastrointestinal bleeding 
[43, 51].
23.7  Gastrointestinal 
Manifestations of Vasculitis
23.7.1  Polyarteritis Nodosa (PAN)
23.7.1.1  Gastrointestinal 
Manifestations 
of Polyarteritis Nodosa
Polyarteritis nodosa (PAN) is a necrotizing vas-
culitis that affects medium-sized arteries. It is 
associated with hepatitis B virus (HBV) in about 
7% of cases [52].
Gastrointestinal manifestations occur in 14% 
to 65% of patients with PAN, and it is a major 
cause of morbidity and mortality [53, 54].
The small bowel and gallbladder are 
most commonly affected from the GI tract 
[53]. The most common symptom is chronic 
abdominal pain which usually develops over 
weeks or months [52]. The pain is usually 
post-prandial, and it is caused by mesenteric 
ischemia and can be associated with nausea, 
vomiting, GI bleeding, or change in bowel 
habits. Ischemic colitis presents with abdomi-
nal pain and bloody diarrhea. If the ischemia 
was limited to the mucosa; submucosa ulcer-
ation and bleeding may occur, but transmural 
ischemia will cause necrosis of the bowel wall 
which may be complicated by infarction and 
perforation, and this is associated with a poor 
prognosis [55].
Patients should be referred to surgery if they 
developed signs of acute abdomen in the form of 
rebound, rigidity, or persistent tenderness.
Multiple hemorrhagic refractory ulcers 
involving the stomach, duodenum, and jejunum 
have also been reported. Colon involvement is 
manifested by deep ulcers complicated by per-
foration or ischemic pseudomembranous colitis. 
Systemic vasculitis involving the appendix is 
also reported, and it is most often caused by 
PAN [56].
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23.7.1.2  Hepatic and Biliary 
Manifestations 
of Polyarteritis Nodosa
Liver can be involved in 16% to 56% of patients 
[52]. Clinical manifestations of liver diseases 
are rare in patients with PAN. In the liver biopsy, 
necrotizing vasculitis may be found. Hepatic 
arteriograms may show caliber changes with 
corkscrew vessels and distal microaneurysms. If 
the portal vein and hepatic arteries are involved, 
it can lead to liver infarction, atrophy of a liver, 
acute liver failure, or nodular regenerative 
hyperplasia. Rarely, hemobilia and subcapsular 
or intrahepatic hemorrhage occur if aneurysmal 
rupture occurs in the liver.
Ascites has been reported, and it is secondary 
to serositis rather than to liver diseases 
[56–58].
Vasculitis of the arteries supplying the small 
bile ducts causes intrahepatic sclerosing cholan-
gitis which is characterized by periductal inflam-
mation, fibrous collar around the ducts, and 
ductal proliferation. Acalculous gangrenous cho-
lecystitis can be a complication of arteritis as 
well. Biliary strictures and intracholecystic hem-
orrhage occur rarely from the rupture of an aneu-
rysm of the cystic arteries into the gallbladder 
lumen [52, 58].
23.7.1.3  Pancreatic Manifestations 
of Polyarteritis Nodosa
The pancreatic diseases are involved in 35% to 
37% of the PAN cases.
Acute pancreatitis, pseudocysts, masses, and 
pancreatic infarcts were reported [52].
Diagnostic Modalities of Polyarteritis 
Nodosa
Arteriography is the initial modality that is used 
in the diagnosis of PAN, and it is positive in more 
than 60% of patients [53]. Typical arteriographic 
lesions in PAN are arterial saccular and fusiform 
microaneurysms, which are usually associated 
with stenotic lesions in the kidney and mesenteric 
and hepatic artery branches. The diagnosis of 
PAN can be established when characteristic angi-
ographic changes are detected within the appro-
priate clinical picture, even without histologic 
confirmation [59].
Treatment
Corticosteroids along with cyclophosphamide 
are the cornerstone of treatment for hepatitis B- 
and C-negative PAN. Adding cyclophosphamide 
has shown to decrease the incidence of relapse, 
but it does not change the 10-year survival rate 
[60]. For life-threatening PAN, plasma exchanges 
can be used [61]. In patients with HBV-associated 
vasculitis, the use of anti-viral therapy in combi-
nation with corticosteroid and plasma exchanges 
is effective in controlling disease activity and in 
viral seroconversion.
The control of the viremia is also proven to 
help in preventing the development of cirrhosis 
and hepatocellular carcinoma.
Relapses are rare in HBV-related PAN and 
never occur when seroconversion has been 
achieved [62, 63].
Surgery is required for the complications, 
such as perforation/rupture, ischemia, or bleed-
ing of the gastrointestinal organs or kidneys [59].
23.7.2  Granulomatosis 
with Polyangiitis—GPA 
(Formerly Named Wegener’s 
Granulomatosis)
Granulomatosis with polyangiitis is manifested 
by necrotizing vasculitis and granulomatosis.
The disease can affect the upper and lower 
respiratory tract and the kidneys, with systemic 
involvement. GI tract can be involved in 10% to 
24% of patients with GPA and is detected in an 
autopsy [64].
Vasculitis can cause local or diffuse patho-
logic changes including mesenteric ischemia, 
bleeding, submucosal edema, paralytic ileus, 
ulcerations, bowel obstruction, and perforation.
Upon studying a group of 62 patients with 
systemic small- and medium-sized vessel vascu-
litis and gastrointestinal tract manifestations, 
Pagnoux et  al. found that the most frequent GI 
symptoms in patients with GPA were abdominal 
pain (97%), nausea or vomiting (34%), diarrhea 
(27%), GI bleeding in the form of hematemesis 
(6%), and hematochezia or melena (16%) [65].
Any part of the GI tract could be affected. The 
most commonly described pathologies are ulcer-
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ations, intestinal ischemia, and perforations. 
Gastrointestinal manifestations can be the pre-
senting symptom of GPA before the respiratory 
or renal involvement [64, 66, 67].
23.7.3  Eosinophilic Granulomatosis 
with Polyangiitis—EGPA 
(Formerly Named Churg- 
Strauss Syndrome)
The respiratory tract is almost constantly affected, 
but it can be a multi-systemic disease. GI involve-
ment can be the presenting symptoms or present 
concurrently with the vasculitic phase, but it has 
a negative prognostic factor, especially if mesen-
teric ischemia or bowel perforation is present 
[68]. GI manifestations occur in 50% of patients 
with EGPA.  Patients may present with nonspe-
cific symptoms such as abdominal pain, vomit-
ing, and diarrhea [69]. Pathologic findings 
include ulcers, mesenteric perforation, obstruc-
tion, and paralytic ileus with evidence of eosino-
philia and granulomatosis. Because of the 
collateral blood supply in the GI tract, ischemic 
changes are rarely documented. Histologic vas-
culitis is rarely seen on endoscopic biopsy 
because submucosal vessels are too superficial to 
get adequate sample [68, 70].
Small bowel is the most commonly involved 
followed by the stomach and the colon [71]. 
Treatment of vasculitis includes steroids with 
cytotoxic medications for induction of remis-
sion. Depending on the degree of GI involve-
ment, patients may require surgical interventions 
[68, 70].
23.7.4  Henoch-Schonlein Purpura 
(HSP)
Henoch-Schonlein purpura is a small-vessel IgA- 
dominant vasculitis involving the capillaries, 
venules, or arterioles [72]. It can affect adults but 
more commonly affect children and typically 
after upper respiratory tract infection. GI involve-
ment occurs in 75–85% of HSP patients [72, 73]. 
The most common presenting symptom is 
abdominal pain and usually is peri-umbilical 
pain. Other GI manifestations include vomiting, 
GI bleeding, and paralytic ileus. Abdominal pain 
occurs because of extravasations of blood and 
fluid into the bowel wall, which can cause ulcer-
ation of the bowel mucosa and bleeding into the 
lumen. Upper gastrointestinal endoscopy should 
be considered in patients who develop GI bleed-
ing. Fifty percent of patients may develop melena, 
and 15% hematemesis [74]. Endoscopy may 
show hemorrhagic erosions, ulcerations, or more 
commonly red, small ring-like petechiae in the 
second part of the duodenum. Petechiae in the 
descending colon is commonly seen in colonos-
copy [74]. Computed tomography (CT) scan may 
reveal wall thickening with skipped areas, mes-
enteric edema, and vascular engorgement [75].
Severe GI complications of HSP are rare. 
Intussusception secondary to submucosal hema-
toma is the most common (1% to 5%). 
Intussusception should be suspected if the patient 
develops colicky abdominal pain that has sud-
denly increased in intensity and that is associated 
with bloody stools, and it can be diagnosed by 
abdominal ultrasonography [72, 74].
Other GI manifestations in HSP patients are 
protein-losing enteropathy, esophageal and ileal 
stricture, gastric and small bowel perforations, 
bowel ischemia, pancreatitis, cholecystitis, and 
appendicitis [73].
The prognosis for HSP is good with the excep-
tion of those patients who developed end-stage 
renal disease. Treatment of HSP with gastrointes-
tinal involvement, including intussusception, 
bowel perforation or infarction, and severe bleed-
ing, usually requires surgical intervention. 
Corticosteroids and immunosuppressive drugs 
can be used especially in patients with severe 
glomerulonephritis.
23.7.5  Behcet’s Disease
Gastrointestinal involvement in Behcet’s disease 
was discussed separately in a previous section of 
this chapter.
H. Halabi et al.
491




Spondyloarthritis (SpA) is a group of diseases 
sharing the clinical, radiological, and serological 
manifestations in addition to having a familial 
and genetic link. It consists of ankylosing spon-
dylitis (AS), reactive arthritis, psoriatic arthritis 
(PsA), and SpA associated with IBD (IBD- 
associated SpA), as well as forms that do not 
meet the criteria of the definite categories of SpA 
and are thus known as undifferentiated SpA. The 
incidence of SpA in patients with IBD ranges 
between 17% and 39%. It is the most common 
extra-intestinal manifestation in IBD patients 
[76, 77]. Most importantly, the chronic type of 
inflammation may be considered as a risk factor 
for developing CD over time. Around 20% of the 
patients with chronic GI inflammation on base-
line ileocolonoscopy evolved into overt IBD in a 
5-year period [78].
23.8.1  Ankylosing Spondylitis (AS)
The pathogenesis of both SpA and IBD is a result 
of a complex interplay between the host (genetic 
predisposition), the immune system, and envi-
ronmental factors [78].
There is a strong genetic link between HLA- 
B27 and AS. More than 90% of patients with AS 
are HLA-B27 positive. Furthermore, 25–78% of 
patients with IBD and AS are HLA-B27 positive. 
Recently, interleukin 23 receptor (IL23R) vari-
ants and the major histocompatibility complex 
(MHC) have been shown to be associated with 
AS and Crohn’s disease [79].
Up to two-thirds of AS patients have sub-
clinical GI involvement which is diagnosed 
either by endoscopy or histology features, and 
up to 5%–10% of cases of AS are associated 
with IBD [80].
Tumor necrosis factor inhibition (infliximab, 
adalimumab, etanercept, golimumab) can 
improve symptoms, signs, and the quality of life 
in several forms of SpA.
NSAIDs are widely used for the treatment of 
AS. The distal part of small bowel and colon are 
the major sites of side effects of NSAIDs, 
although the incidence of NSAID enteropathy or 
colopathy is lower than the upper GI tract and 
usually it is subclinical. However intestinal inju-
ries induced by NSAIDs, including erosions, 
ulcerations, strictures, and intestinal perforations, 
are common. A randomized, controlled trial 
found that the mucosal breaks in a group who 
used NSAIDs plus omeprazole are more than the 
other group who used COX-2 inhibitors. This 
study showed a relative protection of using 
COX-2 inhibitors compared with non-selective 
NSAIDs plus omeprazole against small bowel 
injury [81]. Symptoms and signs are nonspecific 
such as bleeding from ulcers, anemia, hypoalbu-
minemia, bloody diarrhea, and signs of acute 
abdomen [80].
23.8.2  Psoriatic Arthritis (PsA)
Psoriatic arthritis (PsA) is a joint inflammation 
associated with skin manifestations and extra- 
articular involvement that affect the quality of 
life. PsA is considered as seronegative spondylo-
arthritis (SpA) [82, 83]. GI involvement such as 
ulcerative colitis and Crohn’s disease is reported 
in 5–10% of the patients with subclinical course 
in up to two-thirds of the patients [82, 85]. Other 
GI manifestations such as GERD were also 
reported in some retrospective studies [82].
23.8.3  Reactive Arthritis
Reactive arthritis can occur after an enteric infec-
tion due to Shigella, Salmonella, Yersinia, and 
Campylobacter species with an incidence rate 
ranging from 2% to 33%. The presence of HLA- 
B27 genotype and Yersinia infection increase the 
risk of arthritis. Arthritis develops within 
2–3 weeks after diarrhea and mainly involves the 
knee, ankle, wrist, and sacroiliac joints. It is diag-
nosed based on the clinical presentation and con-
firmed by positive stool culture or by rising of 
antibody titers.
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Antibiotic treatment may be effective for diar-
rhea but not for arthritis [80, 84]. Steroids and 
azathioprine can be used in refractory cases.
23.8.4  IBD-Associated SpA
The onset of IBD can be preceded by SpA mani-
festations, but in some cases the intestinal inflam-
mation is silent. Based on the European 
Spondyloarthropathy Study Group criteria, IBD 
is considered as a diagnostic criterion of SpA. The 
musculoskeletal involvement in patients with 
IBD can be divided into two clinical categories: 
axial (including sacroiliitis) and peripheral. Both 
categories can coexist in the same patient [85]. 
Other SpA manifestations such as enthesitis, 
tenosynovitis, dactylitis, or extra-articular mani-
festations (such as anterior uveitis) can also occur 
in IBD-associated SpA.
Axial involvement is present in 2–16% of 
patients with IBD and more common in Crohn’s 
disease patients than in ulcerative colitis patients.
Axial manifestations are inflammatory back 
pain, isolated sacroiliitis, ankylosing spondylitis 
(AS), and non-radiographic spondyloarthritis. 
Inflammatory back pain is diagnosed clinically 
using the ASAS criteria. It is usually difficult to 
localize the pain, insidious in onset, and starts 
usually at rest, relieved by movement and associ-
ated with stiffness. It can be exacerbated by 
cough or sneezing. Patients with IBD-associated 
ankylosing spondylitis are found to be HLA-B27 
positive in 50–80% of cases, which is less com-
mon than those with primary ankylosing spondy-
litis [79, 86, 87]. The clinical course is 
characterized by progressive spine involvement 
with syndesmophyte (bony growth) development 
and vertebral ankylosis. Isolated sacroiliitis is 
diagnosed by pelvic radiograph anteroposterior 
(AP) views or by MRI.
Physical exercise and physiotherapy have a 
role in maintaining the function and relieving 
symptoms. Medical treatment such as anti- 
inflammatory drugs (NSAIDs/COX-2 inhibitors) 
are the first-line treatment for symptomatic AS; 
however, TNFa inhibitors (adalimumab or inflix-
imab) are usually used as a second line of 
 treatment when there is inadequate control of the 
disease by NSAID [86, 87].
The peripheral manifestations of SpA can be 
seen in both Crohn’s disease and ulcerative coli-
tis with prevalence rate of 0.4–34.6% of IBD 
patients. It is more common in individuals with 
Crohn’s disease. Peripheral arthropathies in 
inflammatory bowel disease (IBD) include arthri-
tis, dactylitis, enthesitis, and arthralgia. Peripheral 
arthritis can be classified as type 1 and type 2 
arthritis and can coexist with axial involvement.
Type 1 is an oligoarticular (<5 joints) periph-
eral arthritis usually affecting four or fewer joints 
that is usually persistent for 10 weeks and often 
associated with IBD relapses. In contrast, type 2 
is a polyarticular arthritis (≥5 joints) affecting 
five or more small joints with persistent symp-
toms for months to years and not associated with 
IBD activity [79, 84, 87, 88].
Peripheral arthropathies are diagnosed clini-
cally; on examination, signs of active arthritis in 
form of swelling and pain can be found. Erythema 
nodosum is usually associated with the type 1 
arthritis, whereas uveitis is the most common 
extra-articular manifestation in patients with type 
2 arthritis. Laboratory tests, such as C-reactive 
protein (CRP) and white blood cell count, reflect 
the bowel activity and cannot be used as a diag-
nostic tool. Furthermore, peripheral arthritis is 
not associated with HLA-B27 positivity.
The treatment of active IBD should always 
bring the attention to arthropathies, which usu-
ally occur during a relapse.
The treatment includes pain management such 
as paracetamol, non-steroidal anti-inflammatory 
drugs (NSAIDs), and/or cyclooxygenase-2 
(COX-2) inhibitors.
Steroid injection can be used into the affected 
joint. For resistant peripheral arthritis in patients 
with IBD, sulfasalazine and tumor necrosis factor 
a (TNFa) inhibitors can be used [79, 86, 87].
23.9  Gastrointestinal 
Manifestations of Sjogren’s 
Syndrome (SS)
SS is a chronic inflammatory disorder associated 
with autoimmune destruction of the exocrine 
glands, which leads to diminished glandular 
secretions causing a mucosal dryness. SS is clas-
sified to either primary or secondary. The primary 
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form accounts for approximately 50% of the 
cases. The secondary form occurs in association 
with other autoimmune diseases, most commonly 
RA. Because of the wide distribution of exocrine 
glands in the GI tract, SS can involve any part of 
the digestive system, including the salivary 
glands, mouth, esophagus, stomach, pancreas, 
hepatobiliary organs, small bowel, and colon.
23.9.1  Oral Manifestations 
of Sjogren’s Syndrome
Oral involvement in SS is characterized mainly 
by dryness, causing a wide spectrum of symp-
toms, including mild-to-severe xerostomia with 
dysgeusia and tooth decay. SS patients report 
sensitivity to acid and spicy foods, parched 
mouth, difficulty chewing and swallowing dry 
food, fissures, atrophy, and papillae of the tongue 
and might present with accelerated or unusual 
tooth decay or tooth loss, hoarseness of voice, 
oral candidiasis, and nasal dryness. On examina-
tion, the oral mucous membranes might appear 
dull, parchment-like, adhering to the examining 
finger. Angular cheilitis and reduction in infralin-
gual salivary pooling could be seen. Parotid and/
or submandibular gland enlargement could be 
appreciated [89].
Treatment of dry mouth includes secreta-
gogues and topical agents, which stimulate mus-
carinic receptors (pilocarpine and cevimeline) 
[90, 91].
23.9.2  Esophageal Manifestations 
of Sjogren’s Syndrome
Dysphagia occurs in 30% to 81% of patients with 
SS. It is usually localized to the cervical esopha-
gus/pharynx or midthoracic region [92].
Saliva is required for pharyngoesophageal 
transfer of a food bolus, and saliva reduction in 
SS might contribute to dysphagia. However, most 
authors find no relationship between dysphagia 
and salivary flow rates when tested and measured 
by the change in weight of a sponge after it is 
chewed [93].
Esophageal manometry is the key investiga-
tion and usually showed upper esophageal 
sphincter pressure. Some studies showed 
increased nonspecific motility abnormalities in 
SS [94, 95]. During endoscopy, mucosal atrophy 
can be seen throughout the entire length of the 
esophagus.
23.9.3  Gastric Manifestations 
of Sjogren’s Syndrome
Dyspepsia is found in 15.6% to 23% of patients 
with primary Sjogren’s syndrome. Chronic atro-
phic gastritis was found in 25% to 81% of patients 
with SS who underwent endoscopy. Consistent 
with this finding, hypopepsinogenemia was 
found in 69% of patients, with half of them hav-
ing elevated serum gastrin [96, 97]. One of the 
main concerns in SS is the increased risk of the 
development of lymphoma, such as mucosa- 
associated lymphoid tissue lymphomas (MALT 
lymphoma), within the GI tract. Evaluation for 
malignancy by endoscopic studies is crucial 
whenever the SS patient reported symptoms of 
abdominal fullness or epigastric pain [98].
Treatment of H. pylori does not prove to 
reduce gastric lymphocytic infiltration, gastric 
atrophy, or dyspepsia in SS. B cell clonality was 
noted in both the parotid and gastric tissue from 
six patients with primary SS and gastric MALT 
lymphoma [96, 97].
Chronic inflammation and/or glandular atro-
phy study by immunohistochemistry might 
reveal a predominance of CD3+ T lymphocytes, 
mostly CD4 + 0.31 These findings are similar to 
that found in the salivary glands, suggesting that 
SS is a systemic disease affecting multiple 
organs [98].
23.9.4  Bowel and Colonic 
Manifestations of Sjogren’s 
Syndrome
Documented intestinal involvement is rare to 
absent in large series. Abdominal discomfort 
occurs in up to 37% of patients with SS, nausea 
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5%, constipation 23%, diarrhea in 9%, and iron 
deficiency anemia due to malabsorption in up 
to5% [99, 100]. Duodenal ulcers, likely related 
to a decrease in saliva production and duodenal 
gland secretion reduction, both of them have 
been described in SS. Celiac disease occurred in 
4.5% to 15% of patients as observed in two 
cohorts of primary SS [101].
An occasional association of inflammatory 
bowel disease (IBD) with SS was suggested in 
case reports [102]. A study that evaluated the 
presence of SS among a large cohort of IBD 
patients found that the prevalence of SS was 
4.2% to 5.7%; SS was diagnosed 6 years after the 
diagnosis of IBD.
SS has been associated with intestinal pseudo- 
obstruction, colon cancer, and pneumatosis cys-
toides intestinalis. Vasculitis in SS is rare and can 
be associated with cryoglobulins, and it is often 
life-threatening, presenting with ischemic or 
infarcted bowel, leading to bowel gangrene and 
acute surgical abdomen [103, 104] (Fig. 23.6).
23.9.5  Pancreatic Manifestations 
of Sjogren’s Syndrome
Pancreatitis was documented in 7% of patients 
with SS. It might present as autoimmune pancre-
atitis or chronic pancreatitis. There are multiple 
reported cases of SS with pancreatic calcifica-
tions. Enlarged pancreatic head suggestive of 
neoplasm and increased serum CA 19-9 antibod-
ies in benign pancreatic processes had been also 
reported. Pancreatic exocrine insufficiency is not 
uncommon, and it is related to reduced gastric 
secretions and/or abnormal gallbladder function.
Primary sclerosing cholangitis (PSC) and sec-
ondary sclerosing cholangitis are associated with 
chronic pancreatitis and SS or sicca syndrome. 
Treatment depends on sclerosing cholangitis sta-
tus and the degree of extrahepatic involvement. 
Immunomodulators (including steroids, azathio-
prine, and rituximab) are the mainstay of treat-
ment for autoimmune sclerosing cholangitis with 
or without autoimmune pancreatitis. Endoscopic 
treatment is directed to therapeutic intervention 
to release the biliary obstruction and for tissue 
sampling. Liver transplantation is the treatment 
for end-stage liver disease due to sclerosing chol-
angitis or recurrent cholangitis [89, 105, 106].
23.9.6  Hepatic Manifestations 
of Sjogren’s Syndrome
Liver involvement is the most common non- 
exocrine feature in primary SS.  Hepatomegaly 
was found in 11–21% of patients with primary 
SS at the time of diagnosis. Abnormal liver func-
tion tests (LFTs) mainly cholestatic biochemical 
picture are detected in 30–60% of cases, but 
hepatocellular or mixed patterns may also be 
observed. The most common causes of liver dis-
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ease in SS are primary biliary cholangitis (PBC), 
autoimmune hepatitis (AIH), nonalcoholic fatty 
liver disease, and HCV. AIH or PBC is associated 
with pSS in 50% of cases [9, 107].
Iron overload might cause functional damage 
of the salivary glands leading to sicca syndrome, 
which responds to iron chelation. Idiopathic 
granulomatous hepatitis can also occur in asso-
ciation with SS [108].
B cell clonality was detected in the liver of 
77.8% of the patients with SS who were specifi-
cally evaluated for this. There is no increased 
incidence of hepatic lymphoma in SS (except for 
SS-HCV), suggesting that the B cell clonality is a 
benign antigen-driven expansion [9, 108].
In regard to PBC, sicca complex is found in 
35% to 77% of patients with PBC; in contrast, SS 
is found in 18% to 38% of patients. The degree of 
sicca components does not correlate with the 
duration or degree of liver disease or the presence 
of autoantibodies [107, 109].
It is worth mentioning that the salivary gland 
ducts of patients with PBC—independent of the 
presence of sicca symptoms—manifest a PBC- 
like immunohistochemical monoclonal AMA 
staining specific for the self-antigen pyruvate 
dehydrogenase. More recently, PBC was diag-
nosed in 7% of patients with pSS. Furthermore, 
with respect to the 92% of primary SS patients 
that were shown to have a positive test for anti- 
mitochondrial antibody (AMA), histopathology 
demonstrated histologic features consistent with 
PBC, suggesting the importance of AMA screen-
ing for SS patients, especially when clinically 
warranted, such as in the case of elevated alkaline 
phosphatase (ALP) and aminotransferases [110].
Autoimmune hepatitis is another concern in 
patients with SS as several studies have reported a 
higher prevalence of primary autoimmune liver 
diseases among patients with pSS [111, 112]. 
Autoimmune hepatitis is found in 1.7% of patients 
with primary SS. ANA titers of >1/80 are associ-
ated with the presence of anti-Ro/SSA and anti-
La/SSB, whereas titers of 1/320 are associated 
with presence of anti-smooth muscle and anti-
ribonuclear protein antibodies. SS has also been 
associated with autoimmune cholangiopathy, 
including IgG4 and non IgG4 diseases [111, 112].
HCV infection has an important link with SS; 
xerostomia is found in up to 35.7% of HCV 
patients. Patients with sicca syndrome and HCV 
are more expected to have neurological involve-
ment, elevated transaminase levels, rheumatoid 
factor, and cryoglobulins and less likely to have 
anti-SSA/SSB antibodies compared with SS 
patients without HCV [113, 114].
Neoplasia is more common in SS-HCV, 
including both hepatocellular carcinoma and 
lymphoproliferative tumors. The most frequent 
involved organs of lymphoma in SS-HCV 
patients are the liver and exocrine glands, which 
are infrequently involved in patients with B cell 
non-Hodgkin’s lymphoma [114].
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Musculoskeletal (MSK) complaints in children 
are common. However, not all MSK complaints 
are due to rheumatic diseases. Etiologies range 
from benign conditions to serious conditions 
requiring prompt attention. Therefore, a com-
plete history and physical examination, in addi-
tion to essential investigations and imaging, is 
essential to distinguish rheumatic conditions 
from other diseases (Fig. 24.1). Most of the dif-
ferential diagnoses have been covered in other 
chapters; however, besides trauma and infectious 
causes including septic arthritis and reactive 
arthritis, some common causes of non-rheumatic 
joint pain in children include the following:
Toxic synovitis of the hips is a common self- 
limited form of reactive arthritis usually occurs 
after an upper respiratory tract infection com-
monly affecting boys younger than 8 years. The 
child presents with painless limp or complains of 
pain in the groin, anterior thigh, or knee (referred 
pain). Unlike patients with septic arthritis, the 
child appears well, while the affected limb is held 
in a position of external rotation and flexion. 
Investigations are normal or show mild increases 
in inflammatory markers. Management is sup-
portive with rest and analgesia.
Growing pain is benign short-lived vague 
pain limited to calf, thigh, and shin commonly 
affecting children between the ages of 3 to 
10 years. Pain is severe in intensity, often occurs 
late in the day, or awakens the child at night. The 
child is otherwise well and asymptomatic during 
the day, having no functional limitations. The 
pain is intermittent in nature, with symptom-free 
intervals lasting days to months. There is often a 
family history of growing pains. Importantly, the 
physical examination, laboratory data, and radio-
logical investigations are normal. Management 
consists of reassurance and supportive analgesia.
Childhood malignancies, such as leukemia, 
lymphoma, and neuroblastoma, may present with 
daytime and nighttime joint pain. Clinical char-
acteristics include severe pain that is out of pro-
portion to clinical findings, lack of morning 
stiffness, and the ability to localize the pain to the 
bone on palpation. Patient may have constitu-
tional symptoms including fever, weight loss, 
and night sweats. Similarly, the presence of 
thrombocytopenia and high LDH may indicate 
the presence of malignancy.
Slipped capital femoral epiphysis (SCFE) is 
a condition in which the femoral head is dis-
placed from femoral neck. It commonly affects 
overweight boys between the ages of 10 and 
14  years or children with endocrine problems 
such as hypothyroidism or growth hormone defi-
ciency. The complaint of hip pain may be acute 
or insidious and can frequently present with knee 
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pain. Examination reveals a flexed and externally 
rotated hip with painful and limited passive inter-
nal rotation. Diagnosis is radiological and 
patients should be placed on non-weight-bearing 
crutches until an urgent orthopedic consultation 
for a surgical intervention is made.
Legg Calve Perthes disease is self-limiting 
avascular necrosis of the femoral capital epiphy-
sis commonly affecting boys from 4 to 10 years. 
Children present with painful limp and limited 
range of motion of the hip joint. Initial radio-
graphs may be normal; therefore, MRI is more 
sensitive in detecting early disease. Patients 
should be kept non-weight-bearing until an 
urgent orthopedic referral. Treatment is aimed at 
maintaining the femoral head within the acetabu-
lum, which can be achieved conservatively with 
abduction splints or casts or surgically with an 
osteotomy of the proximal femur.
24.2  Learning Objectives
By the end of this chapter, you should be able to:
• List common causes of non-rheumatic joint 
pain in children.
• Recognize some of the similarities and differ-
ences between childhood and adult onset 
rheumatic diseases.
• Distinguish the characteristic clinical features 
of juvenile idiopathic arthritis subtypes.
• Explore the classification criteria of pediatric 
vasculitis with emphasis on the clinical pre-
sentation and management of Kawasaki 
disease.
• Discuss the spectrum of autoinflammatory 
syndromes.
24.3  Pediatric Rheumatic 
Diseases
Children are not little adults. By acknowledging 
the similarities and difference between adult and 
childhood types of rheumatic diseases, it will be 
easier to identify those features that are characteris-
tic of or specific to children. Many pediatric rheu-
matic diseases have different disease phenotypes, 
outcome measures, investigations, and treatment 
that are distinct from adult rheumatic diseases. The 
next sections will highlight the clinical features that 
are specific to pediatric rheumatic diseases.
24.4  Childhood Onset SLE
The diagnosis and treatment of childhood onset 
SLE (cSLE) is similar in many aspects to adult 
SLE (aSLE). However, differences in disease 
demographics, clinical presentation, disease 
course, and outcome exist between cSLE and 
aSLE.
Onset of SLE during childhood period occurs 
in 10–20% of all SLE cases. There is less female 
prediction in cSLE as the female to male ratio 
with pediatric SLE changes from 4:3 with dis-
ease onset during the first decade of life to 4:1 
during the second decade to 9:1  in aSLE [1]. 
cSLE often presents with more acute and severe 
disease manifestation at the time of diagnosis 
with a higher frequency of renal, neurological, 
and hematological involvement, while cutaneous 
and musculoskeletal features are more common 
at disease onset in aSLE [2]. SLE Disease 
Activity Index (SLEDAI), at diagnosis and over 
disease course, tends to be much higher in cSLE 
[3]. Comparative studies support that cSLE is 
more often treated with high doses of corticoste-
roids and immunosuppressive medications than 
aSLE [4]. Despite improved survival rates in SLE 
patients, there remains substantial morbidity due 
to disease damage. cSLE is associated with more 
rapid accrual of damage than is SLE in adults, 
and it involves mostly ocular, renal, and muscu-
loskeletal damages [4].
24.5  Juvenile Dermatomyositis
Adult and juvenile onset dermatomyositis share 
the hallmark clinical presentation of patho-
gnomic skin rash and muscle weakness described 
in Chap. 8; however, each has distinct demo-




JDM is rare, with incidence of 2–4 per million 
children [6]. The mean age of onset of JDM is 
7 years with 25% of patients presenting younger 
than 4 years of age [7]. The rash of JDM can be 
atypical, occurring anywhere in the body, and is 
more frequently associated with ulcerative 
change than in adults. Anti-p155/140 autoanti-
body is the most prevalent myositis specific anti-
body found in 30% of patients with JDM and is 
associated with cutaneous rash with skin ulcer-
ation, generalized lipodystrophy, low creatinine 
kinase levels, and a chronic course of disease [8].
The clinical course in JDM is monophasic 
(40–60%), chronic (40–60%), and polyphasic 
(>5%).
Predictors of chronic course include delay in 
treatment, higher skin disease activity at base-
lines, ongoing Gottron’s papules and periungual 
nail fold capillary changes beyond 3 months of 
treatment [9]. In addition, the presence of subcu-
taneous edema on MRI at diagnosis and exten-
sive myopathic and severe arteropathic changes 
on the initial muscle biopsy are predictors of a 
chronic illness course [9]. Approximately 
20–47% of patients with JDM develop calcinosis 
at presentation or after many years of illness [10]. 
JDM has not been clearly associated with the 
development of malignancy which is a significant 
cause of mortality in adults with DM.
Treatment of JDM consists of combination of 
corticosteroids (2  mg/kg) with slow taper and 
methotrexate 15  mg/m2 s/c. Other treatment 
modalities include cyclophosphamide for inter-
stitial lung disease or vasculitis. IVIG, cyclospo-
rine, mycophenolate mofetil, and rituximab are 
used in refractory cases.
24.6  Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA) is comprised of 
a heterogeneous group of several disease sub-
types that are characterized by the onset of arthri-
tis prior to the age of 16  years with symptoms 
that persist for more than 6 weeks after exclusion 
of other causes of juvenile arthritis Fig.  24.1. 
Arthritis is diagnosed in the presence of joint 
effusion or two or more of the following: limited 
range of movement, joint line tenderness, or 
painful range of movement and warmth. The cur-
rent classification system by the International 
League of Associations for Rheumatology 
(ILAR) recognizes seven distinct subtypes of 
JIA, based on their presentation within the first 
6  months [11]. The categories of JIA and their 
diagnostic criteria are defined in Fig. 24.2. There 
is evident heterogeneity with respect to demo-
graphic, genetic, and clinical features among the 
JIA subtypes, translating into heterogeneity in 
the responses to treatment.
Oligoarticular JIA is the most common sub-
type with relative frequency of 30–60% in 
Caucasian population with peak age at 1–3 years 
[11]. It is divided into two further subsets: persis-
tent, if arthritis remains confined to four or fewer 
joints during the whole disease course, and 
extended, if arthritis spreads to more than four 
joints after the initial 6  months of illness. The 
arthritis affects medium to large size joints with 
the knee being most common joint affected fol-
lowed by ankle and wrist. Both wrist and ankle 
arthritis in addition to elevated inflammatory 
markers (ESR) at disease onset have been recog-
nized as predictors of an extended course [12]. The 
classic disease phenotype includes asymmetric 
arthritis, early disease onset, female predilection, 
high frequency of positive ANA, and high risk of 
uveitis [13]. Positive ANA represents a high-risk 
factor for development of chronic uveitis which 
occurs in 20–30% of oligoarticular JIA [14]. 
Chronic uveitis can be asymptomatic until the 
point of visual loss, making it crucial to undergo 
regular ophthalmologic screening (Fig. 24.3) [15].
Polyarticular JIA, subdivided into rheuma-
toid factor positive and rheumatoid factor nega-
tive, accounts for 10–30% of JIA cases occurring 
most commonly in young girls with an early 
peak between ages 1–4 years and a later peak of 
6–12 years [11]. It is likely that the older group 
with rheumatoid factor positivity represents dis-
ease that is similar to adult rheumatoid arthritis. 
The arthritis tends to be symmetrical and 
involves large and small joints [16]. In contrast 
to oligoarticular JIA, systemic manifestation 
including low grade fever, anorexia, malaise, 
and growth failure can be present [16]. Chronic 
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asymptomatic uveitis develops less frequently 
and is more common in RF negative polyarticu-
lar JIA [11]. Children with RF positive polyar-
thritis can develop similar complication to adult 
disease including rheumatoid nodules, Felty 
syndrome, rheumatoid vasculitis, and pulmonary 
disease in rare cases [17].
Systemic onset JIA accounts for 10% of cases 
of JIA with a broad peak of onset between 1 and 
5  years, and it also occurs in adolescence and 
adulthood [ 11]. Children of both sexes are equally 
affected. [18] The systemic symptoms of fever, 
fatigue, and anemia may overshadow or proceed 
the arthritis by 6 weeks to 6 months. The arthritis 
is typically symmetrical and polyarticular and can 
be extensive and resistant to treatment. The sys-
temic manifestation include fever spikes >38.5 °C 
occurring once or twice daily, which return to 
baseline or below temperatures. This inflamma-
tion is accompanied by a salmon colored evanes-
Systemic-onset JIA
Systemic arthritis is diagnosed if there is arthritis in 1 or more joints with, or 
preceded by, fever of at least 2 weeks' duration. Signs or symptoms must 
have been documented daily for at least 3 days and accompanied by 1 or 
more of the following: evanescent rash, generalised lymphadenopathy, 
hepato/splenomegaly, serositis. (Exclusions are A, B, C, and D from the 
exclusion list below.)
Persistent or extended 
oligoarthritis
Oligoarthritis is diagnosed if there is arthritis affecting 1 to 4 joints during 
the first 6 months. Persistent oligoarthritis affects up to 4 joints throughout 
the course of the disease, and extended oligoarthritis affects more than 4 
joints after the first 6 months of disease. (Exclusions are A, B, C, D, and E 
from the exclusion list below.)
RF-negative polyarthritis
Polyarthritis (RF-negative) is diagnosed if there is rheumatoid factor (RF)-
negative arthritis affecting 5 or more joints during the first 6 months of 
disease. (Exclusions are A, B, C, D, and E from the exclusion list below.) 
RF–positive polyarthritis
Polyarthritis (RF-positive) is diagnosed if there is RF-positive arthritis 
affecting 5 or more joints during the first 6 months of disease. Two or more 
RF tests (taken at least 3 months apart) are positive during the first 6 
months of disease. (Exclusions are A, B, C, and E from the exclusion list 
below.)
Psoriatic JIA
Psoriatic arthritis is diagnosed if there is arthritis and psoriasis, or arthritis 
and at least 2 of the following: dactylitis, nail pitting, onycholysis, and/or 
family history of psoriasis (in a first-degree relative). (Exclusions are B, C, 
D, and E from the exclusion list below.)
Undifferentiated
Undifferentiated arthritis is diagnosed if there is arthritis that does not fulfil 
criteria in any of the above categories or that fulfils criteria for 2 or more of  
the above categories.
A Psoriasis or history of psoriasis in patients or first-degree relatives.
B Arthritis in HLA B27 positive males beginning after the age of 6 years.
C Ankylosing spondylitis, enthesitis-related arthritis, sacroiliitis with inflammatory bowel 
disease, Reiter's syndrome, acute anterior uveitis, or history ofoneof these disorders in 
first-degree relatives.
D Presence of IgM rheumatoid factor on at least 2 occasions at least 3 months apart. 
E Presence of systemic JIA in patients.
International League of Associations for Rheumatology (ILAR) classification of JIA
Exclusions
Fig. 24.2 International League of Associations for Rheumatology (ILAR) classification of JIA
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cent macular rash accompanying fever spikes. 
Extra-articular manifestation include serositis, 
hepatosplenomegaly, and lymphadenopathy. An 
infectious workup and a bone marrow aspirate are 
strongly considered before starting treatment. 
Systemic JIA is associated with macrophage acti-
vation syndrome (MAS), a potentially life-threat-
ening complication which can manifest as a 
change in the fever pattern from intermittent to 
continuous and improvement in arthritis [19]. A 
recent classification criteria for MAS has been 
proposed [20] (Fig. 24.4).
Psoriatic JIA (PsA) affects 5% of patients 
with JIA and has a bimodal age of distribution in 
preschool years and in late childhood [11]. 
Psoriasis often begins after the onset of arthritis 
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Fig. 24.3 Modified recommended guidelines for ophthalmologic screening in JIA
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in children and may not be evident [ 21]. The pat-
tern of joint inflammation is clinically diverse 
[22, 23]. Disease at younger age of onset tends to 
have asymmetric involvement of large and small 
joints of hand and feet, which differentiates it 
from oligoarticular JIA [14]. Dactylitis, a clinical 
hallmark of the disease is also a common mani-
festation of younger children. Children with 
older age of onset, who are often HLA B27 posi-
tive, tend to develop enthesitis, spinal, and sacro-
iliac disease [22, 23]. Asymptomatic chronic 
anterior uveitis occurs in 15–20% of children 
with PsA and is associated with the presence of 
ANA [ 25]. Acute symptomatic anterior uveitis 
observed in adult patients, is rare in children [25].
Enthesitis-related arthritis (ERA) affects 
<5% of patients with JIA, characterized by the 
presence of arthritis and enthesitis, typically 
occurs in boys older than 6 years of age with pos-
itive HLA B27 [11]. In contrast to adult ankylos-
ing spondylitis at presentation, axial involvement 
is not common, while sacroiliitis can be silent 
[26]. However, axial disease with symptomatic 
sacroiliitis becomes common within 5  years of 
diagnosis [27, 28]. Peripheral arthritis of the 
lower limbs and predominantly the hips is com-
monly seen [29]. The hallmark of ERA is enthesi-
tis, with resultant pain and swelling at entheseal 
sites. Other distinguishing manifestation is tarsi-
tis. Symptomatic anterior uveitis may develop in 
children with ERA, and this usually presents with 
significant eye pain and redness, which may be 
unilateral [20]. Although cardiopulmonary 
involvement is uncommon, aortic insufficiency 
has been reported.
Undifferentiated arthritis does not represent 
a distinct subset but includes patients who do not 
meet the criteria for any category or who meet the 
criteria for more than one subtype of JIA [30].
Laboratory and Imaging Studies: Most 
children with JIA have no laboratory abnormali-
ties. Preliminary investigations should be aimed 
at excluding differential diagnosis (Fig.  24.5). 
Children with systemic JIA and polyarticular JIA 
commonly show evidence of inflammation with 
elevated inflammatory markers and anemia of 
chronic disease. A complete blood count and 
peripheral should be performed to exclude leuke-
mia which can present as low WBC and platelet 
count. ANA should be performed to identify 
patients at higher risk for developing uveitis, 
while RF should be performed in polyarticular 
JIA to identify patients with worse prognosis.
Plain radiographs have limited ability to iden-
tify early erosive changes and have poor sensitiv-
ity to identify active synovitis. Ultrasound is well 
suited to assess synovitis, capture erosions, and 
guide local injections. MRI is able to identify 
early changes and most sensitive indicator of 
joint inflammation.
Treatment: The main stay of treatment of JIA 
aims at controlling inflammation, maintaining 
PRINTO diagnostic criteria for 
Macrophage Activation 
Syndrome
Platelet count < 181 × 109/l
Aspartate
aminotransferse > 48 units/l
Triglycerides > 156 mg/dl
Fibrinogen < 360 mg/dl
A febrile patient with systemic
JIA with the following criteria:
Ferritin > 684 ng/ml
and any 2 of the following:
Fig. 24.4 New Classification Criteria for Diagnosis of Macrophage Activation Syndrome
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function, and preventing joint damage and blind-
ness. This can be achieved through a multidisci-
plinary team comprising a pediatric 
rheumatologist, ophthalmologist, orthopedic sur-
geon, specialist nurse, physical therapist, occupa-
tional therapist, and psychologist. ACR treatment 
recommendations for JIA categories are outlined 
(Figs. 24.6 and 24.7).
First-line therapy in JIA consists of nonsteroi-
dal anti-inflammatory drugs (NSAIDs). Only a 
few NSAIDs are approved for use in children: the 
most common are naproxen (15–20 mg/kg), ibu-
profen (30–50  mg/kg), and indomethacin 
(1–4 mg/kg). There is limited data on the safety 
and efficacy of Cox 2 inhibitors [31]. Intra- 
articular corticosteroids (IAC) may also be used 
as first line in the treatment of Oligoarticular JIA 
[32]. Triamcinolone hexacetonide (TH) is the 
drug of choice for IAC. Due to its lower solubility, 
it has longer lasting duration of action than other 
Fig. 24.5 Preliminary investigation to be considered for evaluation of Juvenile Idiopathic Arthritis
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Low disease activity 
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4 or fewer active joints
ESR or CRP normal
Physicians GADA < 4 of 10
Parent/Patient GAWB  < 
2 of 10
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low or high activity)
1 or more features greater 
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High disease activity
(satisfy at least 3)
8 or more active joints
ESR or CRP > twice upper  
limit of normal
Physician GADA ≥ 7 of 10





Low disease Moderate/High disease
A B
Fig. 24.6 Adopted from 2011 and 2019 American 
College of Rheumatology Recommendations for 
Treatment of Oligoarticular JIA (A) and Polyarticular JIA 
(B). CRP: C reactive protein; ESR: erytherocyte sedimen-
tation rate; GADA: global assessement of overall disease 
activity; GAWB: global assessement of overall well-
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Fig. 24.7 Management of systemic juvenile idiopathic arthritis 
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preparations [33]. The dose of TH administered 
is1mg/kg (max 40 mg) for the knee joint or half of 
this dose for ankle and wrist [24]. The role of sys-
temic corticosteroids is limited to the extra- 
articular manifestations of systemic arthritis and 
as a bridging therapy in severe polyarthritis await-
ing the therapeutic effects of second-line agents 
or biologics.
Second-line therapy includes conventional dis-
ease modifying antirheumatic drugs (DMARDs). 
Methotrexate remains the most widely used at a 
dose of 10–15 mg/m2 per week either orally or 
subcutaneously. There is increased bioavailability 
of the drug in the subcutaneous route at higher 
doses, and increased efficacy after switching from 
oral to subcutaneous administration has been 
reported [34, 35]. Methotrexate should be contin-
ued for at least 6–12 months after achieving dis-
ease remission. No difference in the relapse rate 
was found between patients who were discontin-
ued from methotrexate at 12 months vs. 6 months 
of disease remission [36]. Experience with leflu-
nomide in JIA is limited but is an alternative 
option in case of intolerance [37].
Biologic DMARDs are shown to be highly 
safe and effective in the treatment of JIA as dem-
onstrated in various randomized controlled stud-
ies with anti-TNF inhibitors (etanercept, 
adalimumab, infliximab), anti-CLA4 (abatacept), 
anti-IL1 (anakinra), and anti-IL-6 (tocilizumab) 
[38–42]. Stepwise treatment algorithms have 
been proposed by the ACR for treatment of oligo-
articular JIA, polyarticular JIA, and systemic 
onset JIA. However, there is recent evidence to 
demonstrate the benefits of early aggressive ther-
apy with both conventional and biologic 
DMARDs in treatment of JIA such as TREAT, 
STOP JIA, and BeST for Kids studies [43–45].
24.7  Childhood Vasculitis
Childhood vasculitis is often a challenging and 
complex as the diagnosis can be primary or sec-
ondary to infections, drugs, and other rheumatic 
diseases. If vasculitis is suspected, then the 
approach to history, physical examination, 
workup, and classification is similar to the 
approach used in adult vasculitis.
The EULAR/Pediatric Rheumatology 
European Society (PReS) consensus criteria for 
childhood onset vasculitis are listed in 
(Table  24.1) [46]. Of the primary vasculitides, 
Henoch Schönlein purpura (HSP) and Kawasaki 
disease (KD) are the most common, while the 
other vasculitides are observed rarely in child-
hood [46]. As other types of vasculitides have 
been previously described in Chap. 19, this sec-
tion will focus on KD which is of particular inter-
est to pediatric age group.
24.8  Kawasaki Disease
Kawasaki disease is an acute, self-limiting sys-
temic vasculitis predominantly affecting the cor-
onary arteries, causing coronary artery aneurysms 
(CAA) in 15–25% of untreated patients [47]. The 
disease has a diverse distribution worldwide with 
an ethnic bias toward Asians.
KD predominantly affects children younger 
than 5  years of age with peak age incidence at 
2 years. Patients at extreme end of ages, younger 
than 3 months, or older than 5 years are affected 
less often but are at increased risk for CAA for-
mation. Pathogenesis of KD is thought to be due 
to genetic factors and infectious triggers due to 
disease characteristics which include winter and 
spring seasonal variation, community outbreaks, 
increased risk in siblings, and higher risk in 
Asians even if they migrate to western countries 
[48, 49].
KD presents in children as unexplained fever 
for ≥5 days with the additional four out of the 
five characteristic clinical features described 
in Fig.  24.8. The diagnosis of incomplete KD 
can be made in children in presence of two to 
three of the principal clinical features, com-
monly occurring in young children. The evalu-
ation algorithm of incomplete KD requires the 
presence of supportive laboratory evidence 
and echo cardiac findings (Fig. 24.9) [50]. The 
supplementary supporting laboratory criteria 
include three of the following: hypoalbumin-
emia <30  mg/dl, anemia for age, elevation of 
alanine aminotransferase, thrombocytosis after 
7 days, leukocytosis >15,000/mm3, and sterile 
pyuria ≥10 WBC/HPF.  Diagnostic challenge 
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Henoch-Schönlein purpura/IgA vasculitis 
• Purpura or petechiae with lower limb predominance and at least one of the following:
1. Arthritis or arthralgias 
2. Abdominal pain
3. Histopathology demonstrating IgA deposition
4. Renal involvement 
Kawasaki disease
• Fever that persists for at least 5 days plus at least 4 of the following:
1. Conjunctivitis
2. Changes of the lips and oral cavity
3. Cervical lymphadenopathy
4. Rash
5. Extremity changes 
Childhood Polyarteritis Nodosa
• Histopathological or angiographic abnormalities plus one of the following:




5. Renal involvement 
Childhood-onset Takayasu arteritis
• Aneurysm or dilatation in the aorta or its main branches and pulmonary artery shown by angiography plus one of the following.
1. Absent peripheral pulses or claudication
2. Blood pressure discrepancy in any limb
3. Bruits
4. Hypertension
5. Elevated acute phase reactants
Childhood-onset Granulomatosus with polyangiitis
• Diagnosis requires 3 of the following 6 criteria:
1. Histopathological evidence of granulomatous inflammation
2. Upper airway involvement
3. Laryngo-tracheo-bronchial involvement
4. Pulmonary involvement 
5. ANCA positivity
6. Renal involvement 
Primary CNS vasculitis
• Acquired neurological or psychiatric finding which can not be explained by other causes
• Histopathological or angiographic changes indicating vasculitis in CNS
• Absence of systemic vasculitis or any disease which could cause pathological changes 






Changes in oral mucosa
Changes of extremities
Description
Duration > 5 days PLUS 4 of 5 of
the following
Bilateral, bulbar, non suppurative
Cervical, often >1.5 cm 
Polymorphous, no vesicles or curst
Red cracked lips, strawberry tongue or
diffuse erythema of oropharynx 
Initial phase: erythema and edema of
palms and soles; Convalescent phase:
peeling of skin from fingers and
perianal region   
Fig. 24.8 Diagnostic 




often arises given the significant overlap in 
clinical feature with other pediatric illnesses 
in (Fig.  24.10). Treatment of KD as per the 
American Heart Association (AHA) treat-
ment guidelines includes intravenous immune 
globulin (IVIG) 2gm/kg as single infusion and 
aspirin (30–50 mg/kg) [50]. Aspirin is then con-
tinued until resolution of fever by 48–72 hours 
before switching to low dose ASA (5  mg/kg) 
for 6 weeks and until inflammatory parameters 
normalize. However, approximately 20% of 
patients with KD fail to respond to initial treat-
ment with IVIG. [50–52] The RAISE study has 
demonstrated that treatment of selected high- 
risk KD patients with IVIG/aspirin was associ-
ated with the development of CAA in 23% [53]. 
The Kobayashi scoring system has been devel-
oped in Japan to predict IVIG resistance and to 
identify children at highest risk of developing 
CAA (Table  24.2) [54]. Treatment of severe 
high- risk KD patients with IVIG/aspirin and 

























Fig. 24.10 Differential diagnosis of KD:






for 2 days Fever resolves ECHO
Treat and obtain
ECHO 














z scores of LAD or
RCA of 2-2.5













Assess patient characteristics for KD
(Figure 8) and consider alternative diagnosis
CRP < 3.0 mg/DL
And ESR ≤ 40 mm/hr
CRP > 3.0 mg/DL






criteria   
Fig. 24.9 American Heart Association Guidelines for Treatment of KD
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nificantly reduced the development of CA [ 53, 
55]. The United Kingdom has developed recent 
guidelines for the treatment of KD including 
patients with high-risk features (Fig.  24.11) 
suggesting a role for anti-TNF- α if systemic 
inflammation persists despite IVIG, aspirin, 
and corticosteroids. [56] Live vaccines should 
be delayed for at least 3 months following treat-
ment with IVIG, mainly due potential lack of 
effectiveness and potential detrimental immune 
activation [7].
24.9  Autoinflammatory 
Syndromes
Autoinflammatory syndromes (AIS) are a grow-
ing cluster of heterogeneous disorders, character-
ized by recurrent attacks of unprovoked 
self-limited fever and systemic inflammation 
involving different sites such as skin, joints, gas-
trointestinal, or central nervous system. AA amy-
loidosis is the most serious long-term 
complication. AIS is secondary to abnormal acti-
vation of the innate immune system leading to 
overproduction of pro-inflammatory cytokines, 
such as interleukin (IL)-1𝛽, and tumor necrosis 
factor (TNF)-𝛼, which leads to pathological delay 
of inactivation of inflammatory response [57]. 
The spectrum of monogenic AIS, share 
 overlapping wide range of clinical features as 
described in (Fig. 24.12) [58].
These syndromes should be suspected in 
patients, especially young children, typically 
with recurrent fever and/or with episodic multi-
system inflammation, in the absence of infection. 
Table 24.2 Kobayashi Scoring System for Predicting 
IVIG Resistance
Kobayashi
Na  < 133 mmol/L (2 points)
≤ 4 days of illness (2 points)
AST ≥ 100 U/L (1 point)
Platelet ≤ 30.0 x 104/mm3 (1 point)
CRP ≥ 10 mg/dL (1 point)
Age ≤ 12 months (1 point)
≥ 80% neutrophils (2 points)
High Risk: ≥ 5 points
Establish diagnosis of Kawasaki disease*
High risk features i.e.
1. already failed IVIG?
2. severe disease: the very young (<12mo); those with markers of severe inflammation (including: persistently elevated C reactive protein despite IVIG, liver   
dysfunction, hypoalbuminemia and anemia.
3. features of KLK or shock.
4. already have evolving coronary and/or peripheral aneurysms with ongoing inflammation.
5. Kobayashi risk score ≥ 5**
IF DOUBT SEEK EXPERT ADVICE
NO YES
IVIG 2g/kg as a single infusion over 12 hours.
Aspirin 30-50 mg/kg/day in four divided doses.
Perform echocardiography, and ECG as soon as possible but do not 
delay therapy while awaiting echo.
IVIG 2g/kg; aspirin as per non-high risk group; AND
Corticosteroid e.g methylprednisolone 0.8 mg/kg BD IV for 5-7 days 
OR until CRP normalize; then convert to prednisolone 2mg/kg/day 
PO and wean off over next 2-3 weeks.
Perform echocardiography, and EC G as soon as possible but do not 
delay therapy prior to obtaining echo.
Disease defervescence (fever settled for 48 hours, clinical improvement 
and falling CRP)
Reduce Aspirin to 2-5 mg/kg/day and continue for a minimum of 6 weeks.
No disease defervescence within 48 hours, or disease recrudescence. 
no clinical concerns of systemaic inflammation
Seek expert to consider:
* Corticosteroids as above if not already 
received.
* Second dose of IVIG at 2g/kg over 12 
hours
* Infliximab (6mg/kg) IV 1-2 doses 
(2weeks apart if 2 doses).
Repeat echocardiography at 2 weeks and 6
NO CAA
* Stop aspirin at 6 weeks.
* Follow up for 12 months and d/c if 
well after that.
CAA <8mm, no stenosis
* Continue aspirin until aneurysms resolve.
* Resolve echocardiography & ECG at 6 monthly intervals.
* Consider stopping aspirin if aneurysms resolve.
* Consider exercise stress test.
* Lifelong follow up and advice on reduction of cardiovascular risk 
factors.
* Consider imaging be MR or CT angiogram.
(See also table 4)
CAA >8mm; or for infants Z score >7;  and/or stenosis
* Lifelong aspirin 2-5 mg/kg/day
* Wafarin (with initial full heparinisation to prevent 
paradoxical thrombosis)
* Consider coronary angiography (catheter, MR or CT; if 
catheter wait at least 6 months from disease onset), and 
exercise stress testing.
* Repeat echocardiography & ECG at 6 monthly intervals.
* Lifelong follow up and advice on reduction of 
cardiovascular risk factors. (See also table 4) 
If first echo is normal and CRP within normal range at one week after IVIG and 




























































Fever, pigmented skin lesions, hypertrichosis, insulin 
dependent diabetes mellitus, pancreatic insufficiency, 
cardiomyopathy, lipodystrophy, scleroderma like 
lesion, short status, and delayed puberty
Fever, long clubbed fingers and toes with joint 
contracture, lipomuscular atrophy, pernio like rash in 
hands and feet, heliotrope rash, nodular skin lesions, 
basal ganglia calcification and hepatosplenomegaly
Recurrent fever, arthralgia, purplish skin lesion, 
abnormal growth of lips, lipodystrophy, hypertrichosis, 
acanthosis nigricans, alopecia areata, nodular 
episcleritis, conjunctivitis, chondritis of the nose and 
ear, aseptic meningitis, and basal ganglia calcification
Pauciarticular pyogenic arthritis, joint erosions, 
cystic acne, ulcerative lesion of lower limb, and 
pyogenic abscess
Neonatal multifocal osteomyelitis, periostitis 
with osteolytic lesions, pustulosous and 
icthyyosis skin rash
Fever, pustulous skin lesion on the palms and 
soles, glossitis, arthritis, severe bone pain and 
asthenia
Recurrent multifocal osteomyelitis, congenital 
dyserythropoietic anemia, neutrophilic 
dermatosis with palmoplantar pustulosis or 
pyoderma gangrenosum
Osteomyelitis, bon pain with localized osteolysis, 
potential association with Sweet Syndrome, acne 




anti TNF  agents, anti IL  
1 agents 
rticosteroids, anti TNF a 
agents, anti IL 6 receptor 
antagonist and baricitinib

































































Fever, serositis, arthralgia, erysipelas like 
eruption,  at risk of amyloidosis 
Fever, polymorphous rash, arthralgia, 
abdominal pain, diarrhea, lymph node 
enlargement, splenomegaly and aphthosis
Fever, migratory muscle and joint 
involvement, conjunctivitis, periorbital edema, 
arthralgia, serositis, attacks responsive to 
corticosteroids, at risk of amyloidosis
Fever, cold induced urticarial like rash, 
conjunctivitis and arthralgia, 
Fever, urticarial like rash, conjunctivitis 
and episcleritis, arthralgia, sensineural 
deafness and at risk of amyloidosis
Subcutaneous fever, urticarial rash, clubbing, corneal 
clouding, uveitis, papilledema, retinopathy, optic 
nerve atrophy, aseptic chronic meningitis, increased 
intracranial pressure, inner ear inflammation with 
sensineural deafness, deforming osteoarthritis, bony 
overgrowth, joint contractures, severe growth 
retardation with facial dysmorphic features and 
amyloidosis
Fever, arthralgia, cold induced urticarial 
rash, abdominal complaint and risk of 
sensineural deafness
Intermittent fever, granulomatous dermatitis 
with icthyosis like changes, symmetrical 
granulomatous polyarthritis, recurrent 


























TNF a agents, thalidomide 
Fig. 24.12 Spectrum of autoinflammatory disease syn-
dromes. AD: autosomal dominant, AR: autosomal recessive, 
BLAUs: Blau syndrome, CANDLEs: Chronic atypical neutro-
philic dermatosis with lipodystrophy and elevated tempera-
ture, CINCAs: chronic infantile neurologic cutenous articular 
syndrome. CRMO chronic recurrent multifocal osteomyelitis, 
DIRA: deficiency of interleukin-1-receptor antagonist, 
DITRA: deficiency of IL-36 receptor antagonist, FCAS: 
familial cold auto-inflammatory syndrome; FMF: familial 
Mediterranean fever, MAJEEDs: Majeed syndrome, MKD: 
mevalonate kinase deficiency syndrome, MWS: Muckle-
Wells syndrome, MLRP12-AD: NLRP12 associated auto-
inflammatory disease, NNS: Nakojo-Nishimura syndrome, 
NSAIDs: non-steroidal anti-inflammatory drugs, PAPA: pyo-
genic arthritis, poderma gangrenosum and acne syndrome, 
PHID: pigmentary hypertrichosis and non-autoimmune insu-
lin dependent diabetes mellitus syndrome, TRAPS: tumor 




Table 24.3 Clues that help differentiate auto inflammatory syndromes
Age of onset
At birth NOMID, DIRA, FCAS
Infancy and first year of life HIDS, FCAS, NLRP12
Toddler PFAPA
Late childhood PAPA
Most common of auto inflammatory syndromes to have onset in 
adulthood
TRAPS, DITRA
Variable (mostly in childhood) All others
Ethnicity and geography
Armenians, Turks, Italian, Sephardic Jaws FMF
Arabs FMF, DITRA (Arab Tunisian)
Dutch, French, German, Western Europe HIDS, MWS, NLRP12
United States FCAS
Can occur in blacks (West Africa origin) TRAPS




Cold exposure FCAS, NLRP12
Stress, menses FMF, TRAPS, MWS, PAPA, DITRA
Minor trauma PAPA, MWS, TRAPS, HIDS
Exercise FMF, TRAPS
Pregnancy DITRA
Infections All, especially DITRA
Attack duration
< 24 h FCAS, FMF
1-3 d FMF, MWS, DITRA (fever)
3-7 d HIDS, PFABA
> 7 d TRAPS, PAPA
Almost always “in attack” NOMID, DIRA
Interval between attacks
3-6 wk PFAPA, HIDS
> 6 wk TRAPS
Mostly unpredictable All others
Truly periodic PFAPA, cyclic neutropenia
Useful laboratory tests
Acute-phase reactants must be normal between attacks PFAPA
Urine mevalonic acid is attack HIDS
IgD > 100 mg/dL HIDS
However, some occasionally AIS manifest as 
inflammation without fever and the inflammation 
can be persistent rather than episodic. The inter-
val between attacks is variable, and the child 
remains completely well between febrile epi-
sodes. During attacks, laboratory tests are char-
acterized by leukocytosis and elevation of acute 
phase reactants that normalize in the periods 
between fever episodes. A family history of these 
syndromes is often but not always obtained, 
including a history of unexplained deafness, 
renal failure, or amyloidosis. Initial workup for 
patients with AIS should be focused on ruling out 
serious conditions such as infection, malignan-
cies, or immunodeficiency disorders. However, 
repeated attacks typically four to six attacks over 
an observation period of 9–12  months would 
require further genetic testing for AIS. Diagnosis 
of AIS can be challenging due to overlapping 
clinical features; however, AIS can be differenti-
ated by age of onset, ethnicity, attack triggers, 
duration of attacks, disease-free intervals between 
attacks, clinical manifestations, and the response 
to therapy as described in (Table 24.3) [59, 60].
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Rheumatic diseases have many classification cri-
teria and management guidelines that are contin-
uously being updated in order to improve the 
quality of healthcare provision. With these ever- 
evolving criteria and guidelines, practicing clini-
cians need an easy way to get to the core of these 
updates and to retain them in an easy and memo-
rable way. Classification criteria are meant to dif-
ferentiate between similar diseases and also to 
confirm or rule out a certain disease based on 
inclusion and exclusion criteria. The diagnosis of 
rheumatic diseases can be challenging since 
many clinical signs and symptoms as well as 
many laboratory markers are not specific and can 
be positive in many diseases.
There is an important concept that should be 
addressed. It is that the use of these criteria is 
meant to be a guide rather than a sole diagnostic 
tool. It is an established practice that the diagno-
sis of rheumatic diseases relies heavily on clini-
cal grounds. The importance of basic skills in 
rheumatology, namely, the comprehensive his-
tory and meticulous musculoskeletal (MSK) 
examination, cannot be overemphasized. This is 
obvious as there are no specific diagnostic tests 
for most rheumatic diseases. For this reason, it is 
essential to correlate the findings in history and 
MSK examination with laboratory, radiological, 
and sometimes histopathological findings to 
establish the diagnosis.
Guidelines and recommendations for the man-
agement of rheumatic diseases were developed to 
provide guidance based on the best available evi-
dence. It cannot be applied in all situations since 
the availability of the equipment and medications 
as well as the patient’s condition and ability plays 
a major role in the application of these guide-
lines. The physician has to apply the recommen-
dations and guidelines in light of available 
circumstances and local health authorities’ 
instructions. Such multifaceted decision-making 
may result in different guideline groups giving 
different strengths of recommendations for the 
same treatment. Therefore, all types of evidence, 
including evidence-based guidelines, need to be 
examined with care and common sense.
In this section, we will explain how to use the 
classification criteria for rheumatic diseases in 
clinical practice, the importance of having clas-
sification criteria and the advantage of updating 
the old ones. We will also cover the most recent 
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guidelines and recommendations for the 
 management of the most common rheumatic dis-
eases. This will be aided by the use of tables, 
graphs, and figures for simplification purposes to 
help in their application in research and clinical 
practice and to enhance the accessibility and 
practicality of this section.
25.2  Rheumatoid Arthritis 
Classification Criteria 
and Management Guidelines
25.2.1  Classification Criteria 
(Fig. 25.1)
Rheumatoid arthritis (RA) is the most common 
inflammatory arthritis. If left without treatment, 
RA can result in joint damage and functional dis-
ability. It is diagnosed clinically after the exclu-
sion of other diseases if the symptoms and signs 
are suggestive. It should be suspected if patients 
present with inflammatory polyarthritis, after 
which a detailed history and physical examina-
tion, along with appropriate laboratory tests, will 
help in aiding or excluding this diagnosis.
The initial American College of Rheumatology 
(ACR) classification criteria for RA were devel-
oped in 1987. It was based on patients with estab-
lished disease. To classify as having RA, the 
presence of four out of the seven items and the 
presence of symptoms for more than 6 weeks are 
required. There was limited practical value in this 
classification especially for diagnosing early dis-
ease. This limitation was corrected in the new 
(2010) ACR/EULAR (European League Against 
Rheumatism) classification criteria [1] which 
was formulated to increase the specificity and 
sensitivity in diagnosing early RA. These criteria 
take prognostic markers into account, which 
were not included in its predecessor. Patients can 
be identified earlier and started promptly on treat-
Diagnosis of Rheumatoid Arthritis
a score of 6/10 is needed to definite diagnosis of RA
Joints involved
2-10 large joints 
1 point  
1-3 small joints 
2 points 
4-10 small joints 
3 points 
More than 10 joints 
5 points 
Serology
RF and ACPA 
Low positive
(above the ULN) 
2 points 
High positive (greater 











More than 6 weeks  
1 point 
Less than 6 weeks 
0 point 
• Erosive disease typical of RA with a history of prior fulfillment of 
the criteria above 
• Longstanding disease with a history of prior fulfillment of the 
criteria above 
OR
Fig. 25.1 Rheumatoid arthritis new classification criteria
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ment with disease-modifying antirheumatic 
drugs (DMARDs), or they can be entered into 
clinical trials for promising new agents. It is the 
hope that these new criteria will help rheumatolo-
gists to care for patients with early arthritis and to 
tailor treatment according to their needs.
25.2.2  Management Guidelines [2] 
(Fig. 25.2)
The general approach to RA treatment has evolved 
remarkably in the last 10 years as there are an 
increasing number of effective DMARDs. The 
early introduction of DMARDs has become stan-
dard of care and depends upon early diagnosis 
that is facilitated by the 2010 ACR/EULAR clas-
sification criteria of RA to reach the target remis-
sion or in the very least low disease activity.
The 2013 International Task Force recommen-
dations were designed to be based on evidence. 
They determined 14 recommendations instead of 
the 15 that were mentioned in the previous 2010 
paper, published by the same institute. These rec-
ommendations addressed the use of methotrexate 
or a combination of DMARDs in the first phase, 
the use of anti-TNF or abatacept or tocilizumab 
in the second phase, and the use of tofacitinib 
after the use of at least one DMARD in the third 
phase.
Both 2010 and 2013 guidelines agreed on:
• The use of low-dose steroids initially.
• Early treatment with DMARD within the first 
3–6 months and assessment every 3–6 months.
• Adjustment of treatment according to disease 
activity scales using the treat-to-target 
approach.
We have to consider the following in the appli-
cation of the guidelines:
• Presence of poor prognostic factors.
• Presence of contraindications to methotrexate 
or other agents.
• The aim is to control the disease and to reach 
remission or low disease activity.
The 2016 update in the EULAR recommenda-
tions for the management of rheumatoid arthritis 
with synthetic and biological disease-modifying 
antirheumatic drugs Fig. 25.2.
Management of Rheumatoid Arthritis
Adjusting  the therapy 
Step 1-A: Change the csDMARD with
other csDMARD
Step 1-B: If unfavorable factors present,
add a b DMARD or a Jak-inhibitor  
Step 2: Change the bDMARD with other
b DMARD or use a Jak-inhibitor 
Short-term glucocorticoid should be 
considered while changing the therapy and
should be tapered when clinically possible
Follow up  
A follow up every 1-3 months is recommended in active disease  Improvement must be seen in 3 months, and the target must be reached in 6 months. If not therapy must be adjusted.
At diagnosis 
Start with csDMARDs as soon as the diagnosis is made If the patient has contraindications to methotrexate, 
leflunomide or sulfasalazine should be considered
Short-term glucocorticoids is considered 
Fig. 25.2 Management of rheumatoid arthritis
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25.3.1  Classification Criteria 
of Systemic Lupus 
Erythematosus (Fig. 25.3)
Systemic lupus erythematosus (SLE) is a multi-
system disease that affects nearly every organ in 
the body. It can present with a wide array of clini-
cal symptoms and signs and with variable disease 
courses. If left untreated in its early stages, the 
disease carries significant morbidity and mortal-
ity rates.
The Systemic Lupus International 
Collaborating Clinics (SLICC) represents a con-
sensus group of SLE experts, who amended and 
validated the 1997 American College of 
Rheumatology classification criteria in 2012, to 
address many of the former’s limitations (e.g., 
patients with biopsy-proven lupus nephritis still 
fail to fulfill the 1997 criteria). The first version 
Fig. 25.3 The 2012 SLE SLICC criteria [4].
SLE
o Fulfil 4/17 criteria with at least 1 clinical and 
1 immunologic  OR
o Biopsy proven lupus nephritis in the presence 
of +ve ANA or anti dsDNA
o Malar rash
o Bullous rash
o Maculopapular rash 
o Photosensitive rash
o Toxic epidermal 
necrolysis (variant of 
SLE)
Subacute cutaneous lupus 
erythematosus
(they are erythematous, 
annular/polycyclic 
papulosquamous lesions 
that are photosensitive 
and resemble psoriasis, 


























1. Synovitis ≥ 2 joints
2. Tender ≥ joints + 
morning stiffness for 






R. Hassan et al.
525
of the ACR criteria was introduced in 1982; it 
was last updated in 1997. These new criteria 
(SLICC) had greater sensitivity when compared 
to the 1997 criteria (97% vs 83%) but lower spec-
ificity (84% vs 96%) [3, 4]. Both the ACR and the 
SLICC criteria were initially developed as a way 
to categorize patients for research purposes, as its 
use by clinicians for diagnosis is limited by its 
imperfect sensitivity and specificity.
The 2012 SLICC criteria require the fulfill-
ment of 4 out of the 17 criteria with a minimum 
of at least one clinical and one immunologic cri-
terion. Lupus nephritis confirmed by biopsy with 
positive autoantibodies is also sufficient for clas-
sification [4].
The absence of an SLE diagnostic criteria and 
the wide variety of clinical manifestations make 
the diagnosis challenging and by exclusion. It 
Renal
Urine protein/creatinine 
ratio or 24-hour urine 
collection:







Platelets <100 000Hemolytic anemia
Immunology
Anti SmDSDNAANA
Direct Coombs test 





SOURCE: THE 2012 SLICC CRITERIA FOR DIAGNOSIS OF SLE
10 11
Fig. 25.3 (continued)
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requires the appropriate gathering and interpreta-
tion of the patient’s symptoms, physical signs, 
and diagnostic tools.
The recommendations for the treatment of 
SLE are based on an approach combining evi-
dence as well as the opinions of experts in the 
field. Currently, the only major improvement 
was to create better protocols based on the use 
of existing medications, both traditional and 
biological. There is a newly approved drug for 
SLE by the name of belimumab. However, it has 
very limited post-marketing experience as 
patients with severe renal and central nervous 
system diseases were excluded from its original 
studies. It is expected that treatment algorithms 
will be changed in the future by biologic 
therapies.
It is important to point out that disease presen-
tations and clinical manifestations vary widely in 
SLE and that treatment protocols should be 
thought out carefully and fitted to each patient’s 
unique disease course and needs.
25.3.2  Management Guidelines 
for Systemic Lupus 
Erythematosus
The goals of treatment of systemic lupus erythe-
matosus are the following:
 1. Induction of remission: aiming to rapidly control 
disease activity for prolonged periods of time.
 2. Maintenance therapy: aiming to retain remis-
sion or low disease activity and to prevent 
flares.
 3. Adjunctive therapy: aiming to reduce the side 
effects of drugs employed to control disease 
activity and to control other SLE-associated 
conditions.
25.3.2.1  General Management 
Recommendations
The 2019 European League Against Rheumatism 
guidelines for the treatment of SLE without renal 
involvement include [5] the following (Figs. 25.4 
and 25.5):
• Hydroxychloroquine (HQ) should be given to 
all SLE patients with a maximum dose of 5 
mg/kg/day.
• Ophthalmological examination should be con-
ducted at diagnosis time, after 5 years and 
then every year to screen for retinal toxicity 
associated with HQ.
• Oral steroids are to be given in cases of mild 
disease, while intravenous steroids are to be 
given in moderate/severe disease.
• It is recommended to keep chronic prednisone 
use under 7.5 mg daily (or its equivalent) and 
to stop it whenever possible.
• In patients who are not sufficiently controlled 
on HQ or those who need further steroid- 
sparing agents, immunosuppressive agents 
can be added. Methotrexate (MTX) is recom-
mended for mild disease activity. Azathioprine 
(AZT), calcineurin inhibitors (CNI), and 
mycophenolate mofetil (MMF) are to be given 
for moderate disease activity, both as steroid- 
sparing agents and as initial therapies, while 
belimumab is used for refractory cases. MMF 
and cyclophosphamide (CYC) are recom-
mended for induction of remission in severe 
disease activity, while rituximab (RTX) is 
used when disease response is poor.
• For cutaneous manifestations of SLE, first- 
line management includes topical steroids and 
CNI; systemic steroids can also be used, along 
with HQ. If patients do not respond to initial 
treatment, further choices should include 
MTX, retinoids, dapsone, and MMF. Rescue 
therapy with thalidomide can be considered 
after failure of all previous lines.
• Acute management of thrombocytopenia due 
to SLE (Plt < 30,000) includes the use of mod-
erate−/high-dose steroids in combination with 
either AZT, MMF, or CYC.  Intravenous 
immunoglobulins can also be used in case of 
poor initial response to steroids. For refractory 
cases, RTX therapy can be attempted. Last 
resort choices include thrombopoietin and 
splenectomy.
• Immunization against seasonal influenza yearly 
and pneumococcal vaccine (both PCV13 and 
PPSV23) every 3–5 years is recommended.
R. Hassan et al.
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Recognizing certain clinical manifestations in 
SLE is crucial as proper treatment should be 
started promptly to salvage organ function. Lupus 
nephritis and neuropsychiatric lupus are consid-
ered to be the two most serious clinical manifes-
tations of SLE.  In the next section, we will 
introduce the latest published classification crite-
ria and management guidelines for lupus nephri-
tis and neuropsychiatric lupus.
25.3.2.2  Lupus Nephritis (LN)
It is estimated that during the first 10 years of 
diagnosis, 50–60% of SLE patients will develop 
renal disease. Kidney biopsy should be executed 
in most patients with SLE who have evidence of 
kidney involvement in order to establish the diag-
nosis of lupus nephritis and to classify the 
patient’s renal disease according to its histopa-
thology. This will help determine the disease’s 
prognosis and the proper line of therapy that 
should ensue (see chapter “Renal System and 
Rheumatology”) [6].
The lupus nephritis classification system was 
developed by the International Society of 
Nephrology (ISN) in 2003 [7]. This system 
appears to be associated with increased reproduc-
Mild SevereModerate
ο Major organ threatening 
disease
ο Plt <20
ο TTP like disease
ο HLH
ο SLED AI > 12
ο BILAG A  ≥ 1
ο RA like arthritis




ο SLED AI 7 -12
ο BILAG B ≥ 2
ο Mild arthritis
ο Rash ≤ 9% of BSA
ο Plt 50-100
ο SLED AI ≤ 6




















SLED AI = Systemic Lupus Eythematosusactivity index; BILAG = British Isle Lupus Assessment 
Group; TTP = thrombotic thrombocytopenic purpura; HLH = hemophagocytic lymphohistocytosis.
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Fig. 25.4 Management of systemic lupus erythematosus without kidney involvement [5]
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ibility compared with the modified 1974 WHO 
system [8]. The ISN classification system divides 
glomerular disorders associated with SLE into 
six different patterns (or classes) [7], each carry-
ing distinct histopathological, clinical, and prog-
nostic characteristics (Fig. 25.6).
The 2012 American College of Rheumatology 
guidelines for treatment of SLE with renal 
involvement include the following (Figs.  25.7, 
25.8, 25.9, 25.10 and 25.11):
• Renal function monitoring should be done 
every 3 months in patients deemed at high risk 
of developing LN, including male patients, 
juvenile-onset SLE, and seropositivity for 
anti-C1q antibodies [5].
• The use of either MMF or low-dose CYC 
along with glucocorticoids is recommended 
for the induction of remission in Class III and 
IV LN. Both are equally efficient in control-
ling the disease with no clear superiority for 
one over the other [6].
• Higher doses of CYC can be used in LN if 
there is an increased risk of progressing to 
end-stage renal disease (decreased glomer-
ular filtration rate, the presence of cres-
cents or fibrinoid necrosis in the kidney 
biopsy) [5].
• Maintenance therapy with MMF or AZT is 
recommended for Class III and IV LN [6].
• Use of RTX or CNI along with glucocorti-
coids is recommended to treat resistant cases 
of Class III and IV LN that failed traditional 
therapy [6].
• Class V LN patients are recommended to use 
MMF only as the induction drug of choice 
with either MMF or AZT serving as mainte-
nance therapy [6].
• Resistant cases of Class V LN are recom-
mended to use CYC with glucocorticoids [6].
• Evaluation of disease activity every 6 months 
with modification of treatment options accord-

























Management of Specific Systemic Lupus Erythematosus 
Manifestations
Source: The 2016 Update of the EULAR Recommendations for the Management of Systemic 
Lupus Erythematosus
Fig. 25.5 Management 
of specific systemic 
lupus erythematosus 
manifestations [5]
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• Early decrease in urine protein (≤1 gram at 6 
months or ≤ 800 mg at 12 months) carries a 
favorable long-term prognosis [5].
• There are special considerations for lupus 
nephritis during pregnancy [6].
• There are special recommendations for 
adjunctive treatment of lupus nephritis [6].
25.3.2.3  Neuropsychiatric Lupus [10]
SLE is known to affect both the central ner-
vous system (CNS) and peripheral nervous 
system. It is one of the most confusing mani-
festations of the disease, and it also carries 
one of the highest risks of morbidity and mor-
tality. These manifestations may occur prior or 
during the disease course, with the commonest 
symptoms including headaches, psychiatric 
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SOURCE: THE ISN/RPS 2003 CLASSIFICATION OF LUPUS 
NEPHRITIS
Fig. 25.6 The ISN/RPS 





















SOURCE: THE 2012 ACR GUIDELINES FOR SCREENING, TREATMENT 
AND MANAGEMENT OF LUPUS NEPHRITIS
Fig. 25.7 The 2012 American College of Rheumatology 
indications for kidney biopsy in SLE patients [6]
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Fig. 25.8 The 2012 
American College of 
Rheumatology 
guidelines for treatment 
of lupus nephritis [6]
Class III, IV Lupus Nephritis 
Mycophenolate 




Pulse steroids for 3 days
Then
Prednisone 0.5-1 mg/kg/day 
(taper to lowest dose needed for suppression) 
MMF 1-2 gm/day
OR
AZA 2 mg/kg/day +
low dose Prednisone
Change the regimen
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SOURCE: THE 2012 ACR GUIDELINES FOR SCREENING, TREATMENT 
AND MANAGEMENT OF LUPUS NEPHRITIS
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No treatment Hydroxychloroquine 200-400 mg/day
Class III, IV, V Lupus 
Nephritis in Pregnancy
Prednisone(lowest dose to 
suppress activity)
Avoid dexamethasone & 
betamethasone
AZA if still uncontrolledOR
need to decrease need for 
steroids (max 2 mg/kg/day)
SOURCE: THE 2012 ACR GUIDELINES FOR SCREENING, TREATMENT 







Fig. 25.9 The 2012 American College of Rheumatology guidelines for treatment of class III, IV, and V lupus nephritis 
in patients who are pregnant [6]
Hydroxychloroquine
Proteinuria
ACE/ARBS preferred in patients with 
proteinuria > 500 mg/day
Target BP is 130/80
Hyperlipidemia





SOURCE: THE 2012 ACR GUIDELINES FOR SCREENING, TREATMENT,
AND MANAGEMENT OF LUPUS NEPHRITIS
Fig. 25.10 The 2012 American College of Rheumatology 
guidelines for the adjunctive therapy of lupus nephritis [6]
mood disorders, and cognitive dysfunction. 
Neuropsychiatric lupus encompasses 19 neu-
rologic and psychiatric syndromes; these were 
all classified and defined by the 
ACR. Recommendations for diagnostic testing 
were also included in these criteria (Figs. 25.12 
and 25.13).
The pathogenesis, clinical manifestations, and 
assessments of neuropsychiatric lupus are very 
complex which make it difficult to design proper 
controlled trials; therefore, the treatment is 
strongly based on physicians’ clinical experi-
ence. Treatment tends to vary with the manifesta-
tion, for example, stroke due to antiphospholipid 
antibodies is treated with anticoagulants, while 
cognitive defects may respond to steroids, antide-
pressants, and/or anxiolytics. There are no ran-
domized clinical trials that have specifically 
examined these treatments. Principle of man-
agement of NPSLE (see Box 25.1, Figs. 25.14 
and 25.15) [11].
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Fig. 25.11 The 2006 American College of Rheumatology response criteria for proliferative and membranous renal 
disease in SLE [9]






























Fig. 25.13 Neuropsychiatric manifestations of systemic lupus erythematosus (peripheral nervous system)
1-Sympomatic therapy include anticonvulsants, antidepressants and treatment of
 any aggravating factors
2-Antiplatelet/anticoagulation therapy:Indicated when manifestations are
related to antiphospholipid antibodies
3-Glucocorticoids and immunosuppressive therapy are indicated after the 
exclusion of non-SLE causes if the neuropsychiatric manifestations were felt to 
reflect an immune inflammatory process (eg: acute confusional state, aseptic 
meningitis) after exclusionof non-SLE-related causes
Box 25.1 Principle of 
management of NPSLE
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1. 2010 EULAR recommendation for the management of NPSLE
Recommendation
General NPSLE :Neuropsychatric events may proceed, coincide, or follow the diagnosis of SLE but commonly (50-
60%)occur within the first year after SLE diagnosis, in the presence of generalized disease activity (40-50%) , (COE 2,SOR 
B,AGS 8.2).
Cumulative incidence: Common (5-15% cumulative incidence) manifestations include CVD and seizure;  
relatively uncommon (1-5%) include severe cognitive dysfunction, major depression, ACS and peripheral nervous disorder; 
rare (<1%) are  psychosis, myelitis, chorea, cranial neuropathies and aseptic meningitis. (COE2,SOR B,AGS 8.4)
1-Generalized SLE activity  





primary NPSLE  
are 
It is a diagnosis of exclusion. Initial workup should be similar to what would be done 
in a non-SLE patient, including lumbar puncture, EEG, NCS and a brain MRI.Diagnostic 
Work up
1-Sympomatic therapy include anticonvulsants, antidepressants and treatment of any aggravating factors 
(COE 3,SOR D,AGS 9.8)
2-Antiplatelet/anticoagulation therapy : Indicated when manifestations are related to 
antiphospholipid antibodies ,e.g. thrombotic CVD (COE 2,SOR B,AGS 9.6) 
Antiplatelets let may be considered for primary prevention in SLE patients with persistently positive,   
moderate or high, antiphosph olipid titers (COE 2,SOR D,AGS 8.8)
3-Glucocorticoids and immunosuppressive therapy are indicated after the exclusion of non-SLE causes 
if the neuropsychiatric manifestations were felt to reflect an immune inflammatory process 
(eg: acute confusional state, aseptic meningitis ) afterexclusion of non-SLE-related causes
(COE 1,SOR A,AGS 9.1)   
Therapy
Severe and antiphospholipid (especially for CVD, seizures and chorea).
(COE 2,SOR B,AGS 9.1) 
(COE 2,SOR D,AGS 9.7)
Fig. 25.14 EULAR Recommendation for the manage-
ment of NPSLE. ACS, acute confusion state; AED, anti-
epileptic drugs; CNS, central nervous system; CSF, 
cerebrospinal fluid; CVD, cerebrovascular disease; DWI, 
diffusion-weighted imaging; FLAIR, fluid-attending 
inversion recovery sequence; NCS, nerve conduction 
studies; NPSLE, neuropsychiatric systemic lupus erythe-
matosus; SLE, systemic lupus erythematosus; COE, cate-
gory of evidence; SOR, strength of recommendation; 
AGS, agreement score
25.4  Antiphospholipid Syndrome 
Classification Criteria 
and Management Guidelines
25.4.1  Classification Criteria
Antiphospholipid syndrome (APS) is an autoim-
mune disease that mainly causes thrombosis of 
the patient’s arteries and veins and may also lead 
to poor pregnancy outcomes. The presence of 
antiphospholipid antibodies (aPL) is associated 
with this disease. However, these antibodies can 
also be found in healthy individuals.
The definition has been discussed in several 
international meetings involving experts from 
different specialties (rheumatology, obstetrics, 
neurology, hematology, nephrology, etc.). 
Classification criteria were proposed in 1998  in 
Japan. It required positive antibodies testing and 
at least one clinical manifestation of APL. These 
criteria were initially intended to be used in 
research settings; however, they were also used 
by clinicians to decrease the rates of overdiag-
nosing this disease. Although these criteria 
helped to classify a homogenous group of patients 
for research purposes, they had some limitations 
when used in a clinical setting, as some patients 
who had clinically evident APL still failed to ful-
fill these classification criteria. The same group 
subsequently modified these criteria in 2006, in 
Sydney. The most significant modifications are 
outlined below [12]:
 (a) Time between two positive antibodies results 
was lengthened to 12 weeks. This was done 
to detect persistent positivity.
 (b) For the antibody anti-beta-2 glycoproteins, 
both IgG and IgM antibodies were added to 
the criteria.
There is a need to further understand the under-
lying pathogenic mechanisms that cause 
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APL. Further studies that develop more specific 
laboratory techniques to be able to detect those 
who are most at risk of developing thrombosis 
and poor pregnancy outcomes are also imperative. 
These techniques could also help with the recruit-
ment of patients in clinical trials (see Fig. 25.16).
25.4.2  Management Guidelines
In the absence of solid guidelines derived from 
clinical trials, using prophylaxis as a manage-
ment strategy is still controversial. The treatment 
of non-obstetric manifestations of APS is mostly 
the same regardless of the classification of APS 
(primary vs secondary). Current treatment of 
APS includes heparin and warfarin. Many 
patients with coexisting SLE are also treated with 
hydroxychloroquine, which may have some ben-
efit for patients at risk of thrombosis; this is based 
on evidence from retrospective studies that sug-
gest the presence of an association between the 
use of hydroxychloroquine and a reduced risk of 
thrombosis.
There are special recommendations regarding 
the treatment of catastrophic APS as well as for 
the management of APS during pregnancy. More 
well-designed, prospective research that tackles 
the management options for APL is required 
(Fig. 25.17) [13].
Fig. 25.15 EULAR Recommendation for the 
Management of Specific NPSLE disorder. ACS, acute 
confusion state; AED, antiepileptic drugs; CNS, central 
nervous system; CSF, cerebrospinal fluid; CVD, cerebro-
vascular disease; DWI, diffusion-weighted imaging; 
FLAIR, fluid-attending inversion recovery sequence; 
NCS, nerve conduction studies; NPSLE, neuropsychiatric 
systemic lupus erythematosus; SLE, systemic lupus ery-
thematosus; COE, category of evidence; SOR, strength of 
recommendation; AGS, agreement score
Cerebrovascular 
disease
• Atherosclerotic, embolic and thrombotic cerebrovascular disease is common while hemorrhagic stroke is rare. Stroke caused by vasculitis is very rare in SLE patients.  
(COE2,SOR B,AGS9.1) 








• In SLE cognitive dysfunction is common but severe cognitive impairment resulting in functional compromise is relatively uncommon and should be confirmed by 
neuropsychological tests in collaboration with a clinical neuropsychologist when available.(COE 2,SOR B,AGS 9.3) 
Seizure 
disorder
• Single isolated seizures are common in SLE patients. They are related to disease activity. Chances of recurrence are comparable to that of the general population. (COE 
2,SOR B,AGS8.4) 
• In the absence of MRI lesions that are related to the seizures and definite epileptic abnormalities on EEG, withholding of AEDs after a single seizure should be 
considered. AEDs should be used if high risk features are present, such as two or more unprovoked seizures occurring with at least 24 hours between them, 




• Secondary causes of chorea should be excluded.
• Symptomatic therapy with dopamine antagonists is usually effective and glucocorticoids in combination with immunosuppressive agents may be used to control NPSLE  




• Major depression attributed to SLE is relatively uncommon. Psychosis either due to SLE itself or due to steroid therapy is rare. Glucocorticoids and immunosuppressive 
therapy may be considered especially in the presence of generalized disease activity (COE 2,SOR B,AGS 9.1)  
Myelopathy
• SLE myelopathy presents as rapidly evolving transverse myelitis but ischaemic/thrombotic myelopathy can also occur. (COE 2,SOR D,AGS 9.5) 
• Induction therapy with high dose glucocorticoid followed  by intravenous cyclophosphamide should be instituted (SOR A,AGS 9.4) 
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At least one clinical and one laboratory criteria should be met*
Clinical criteria
Vascular thrombosis: one or more 
clinical episodes of arterial, venous 
or small vessel thrombosis in any 
tissue or organ.
For histopathologic confirmation, 
thrombosis should be present 
without significant evidence of 
inflammation in the vessel wall.
Pregnancy morbidity***:
1- One or more unexplained deaths of a morphologically normal fetus at or beyond the 
10th week of gestation.   Or 
2- One or more premature births of a morphologically normal neonate before the 34th  
week of gestation.        Or
3-Three or more unexplained consecutive spontaneous abortions before the 10th  
week of gestation, with exclusion of maternal anatomic or hormonal abnormalities 
and paternal or maternal chromosomal abnormalities.
Laboratory criteria
1-Lupus anticoagulant positive on 2 or more occasions at  
least 12 weeks apart. 
2-Anticardiolipin antibody (IgG and or IgM) in medium or 
high titer on 2 or more occasions at least 12 weeks  
apart. 
3-Anti -B2-glycoprotein-I antibody (IgG and or lgM) in 
medium or high titer on 2 or more occasions at least 12  
weeks apart.
-Antibodies measured by a standardized ELISA . 
Fig. 25.16 Classification criteria for antiphospholipid syndrome (APS)
Headache
• Headache alone in an SLE patient requires no further investigation beyond the evaluation, if any, that would have been performed 
for non-SLE patients. Unless there are high risk feature from the medical history and the physical examination
Aseptic 
meningitis




• Can be a clinically isolated syndrome or may overlap with another CNS demyelinating syndrome. However, it should be noted that 




• Optic neuropathy includes inflammatory optic neuritis and ischaemic/thrombotic optic neuropathy. Optic neuritis is commonly 
bilateral. The diagnostic work up include complete ophthalmological evaluation. 
• Glucocorticoids alone or in combination with immunosuppresive therapy should be considered. However failure of therapy is common 
(COE1,SOR A,AGS9.1)  
Fig. 25.15 (continued)
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25.5  Vasculitis Classification 
Criteria and Management 
Guidelines
25.5.1  Classification Criteria 
(Fig. 25.18)
Vasculitides encompasses a group of heteroge-
neous yet uncommon conditions that can either 
occur secondary to another disease or arise on its 
own. Classification criteria of vasculitis generally 
include several organizing principles like the size 
of the involved vessel, type of involved vessel 
(artery, vein, capillary, etc.), underlying patho-
physiology (primary vs secondary vasculitis), 
type of immune damage, and others.
There are no validated criteria for the diagno-
sis of vasculitis. However, the ACR presented 
classification criteria in 1990 for seven types of 
vasculitis. These criteria’s main limitation was 
Fig. 25.17 Summary of Management Guideline for Antiphospholipid syndrome(APS)
1-General measures for aPL
carriers 
Thromboprophylaxis with usual
dose of LMWH in all patents
with aPL carriers in highrisk
situations such as surgery,
prolong immobilization &
puerperium. (GOR,1C)




Hydroxychloroquine & low dose
aspirin in patients with SLE &
positive LA or isolated persistent
aCL at medium-high titer. (GOR,1B) 
2- Primary thromboprophylaxis
    in SLE patients with aPL 
3- Primary thromboprophylaxis
    in aPL-positive patient witout
    SLE
    Hydroxychloroquine with long term
    low dose aspirin in patients Without
    history of thrombosis or high risk
    aPL profile. (GOR,2C)
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that it did not include microscopic polyangiitis 
or antineutrophil cytoplasmic antibodies 
(ANCA) [14].
The most widely used nomenclature system is 
the one introduced in 1994 and revised in 2012 
by the Chapel Hill Consensus Conference 
(CHCC) [15], which included microscopic poly-
angiitis and replaced disease eponyms with 
names that were more representative of the dis-
ease’s underlying pathophysiology. However, 
unlike the previously mentioned ACR criteria, 
the CHCC was not meant to be a classification or 
diagnostic criteria. Although, the ACR and 
CHCC definitions are widely used, there is no 
agreement about how it should be applied. 
Another set of classification criteria is the 
European Medicines Agency (EMA) criteria, 
which attempted to produce a consensus method 
for the application of both the ACR’s and the 
CHCC’s definitions of ANCA-associated vascu-
litis and polyarteritis nodosa in a clinical setting. 
They developed an algorithm which incorporates 
the ACR and CHCC definitions with both ANCA 
and surrogate markers to successfully classify 
this population of patients [16].
The most notable changes suggested by the 
2012 CHCC are:
• Use of the term eosinophilic granulomatosis 
with polyangiitis (EGPA) instead of Churg- 
Strauss syndrome.
• Adoption of the term antineutrophil cytoplas-
mic antibody (ANCA)-associated vasculitis 
(AAV) instead of three disorders: microscopic 
4-Secondary
thromboprophylaxis
Patients with definite APS & first
venous event→ oral
anticoagulation therapy to a
target INR 2.0-3.0. (GOR,1B)
Patients with definite APS &
arterial thrombosis→ warfarin to a
target INR>3.0 or combined
antiplatelet -anticoagulant (INR
2.0-3.0) therapy. (Nongraded)   
Non-SLE patients with a first non-
cardioembolic cerebral arterial
event with a low risk aPL profile &
presence of reversible trigger 
factors→ antiplatelet
therapy. (Nongraded)
Patients with either arterial or
venous thrombosis & aPL who do
not fulfill criteria for APS →
management as in aPL
negative. (GOR,1C)
5- Duration of treatment 
Patients with first venous
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polyangiitis (MPA), granulomatosis with 
polyangiitis (GPA) (Wegener’s), and EGPA.
• Use of the term immunoglobulin A (IgA) vas-
culitis instead of Henoch-Schönlein purpura.
• Use of the term cryoglobulinemic vasculitis in 
place of essential cryoglobulinemic 
vasculitis.
• Introducing a definition for hypocomplement-
emic urticarial vasculitis (HUV) (anti-C1q 
vasculitis).
(See chapter “Vasculitis and Rheumatology.”)
Physicians should use these criteria with an 
understanding that they are still a work in prog-
ress and that they currently have limited value in 
clinical practice for diagnosing patients. The 
diagnosis of vasculitis should also always be con-
firmed by a tissue biopsy.
25.5.2  Management Guidelines
Management of vasculitis relies on the extent of 
involvement and severity of the vasculitis. For 
example, a mild drug-induced vasculitis would 
only require discontinuation of the offending drug. 
Systemic or more severe forms of vasculitis may 
require a short or more sustained course of gluco-
corticoids, a cytotoxic agent, or other medications.
Significant progress has been achieved over 
the last 30 years in terms of refining the manage-
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ment guidelines of immunosuppressive medica-
tions while keeping toxicities at a minimum. 
These advances have made diseases like ANCA- 
associated vasculitis (AAV) treatable and less 
fatal. Further advances are needed as there are still 
a proportion of patients that are going to develop 
symptoms that are refractory to all available ther-
apies. Half of this patient population will also 
develop a relapse within 5 years of diagnosis, and 
toxicity from treatments given is still a significant 
contributor to mortality and chronic disability.
The introduction of biomarkers has also made 
it possible to determine disease activity and 
 estimate risks of relapse. However, the key to 
adequately managing these patients should be by 
tailoring their immunosuppressive regimens to 
their individual needs.
The 2016 European League Against 
Rheumatism (EULAR)/European Renal 
Association (ERA)- European Dialysis and 
Transplant Association (EDTA) recommenda-
tions for the management of ANCA-associated 
vasculitis include the following [17] (Fig. 25.19):
• It is recommended to do a biopsy for all patients 
who are suspected to have vasculitis, or patients 
who are suspected to have relapsing vasculitis.
• Induction therapy of non-organ-threatening 















Drug inducedANCA vasculitis 





SOURCE: THE 2012 INTERNATIONAL CHAPEL HILL
CONSENSUS CONFERENCE ON THE NOMENCLATURE OF
VASCULITIDES 
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glucocorticoids and either methotrexate or 
mycophenolate mofetil.
• Induction therapy of organ-threatening vasculitis 
should include a combination of glucocorticoids 
and either cyclophosphamide or rituximab.
• Relapsing disease with organ-threatening vas-
culitis should be treated the same as new-onset 
organ-threatening vasculitis.
• Rapidly progressive glomerulonephritis, both 
new in onset and relapsing, should be treated 
with plasma exchange.
• Severe diffuse alveolar hemorrhage should 
also be treated with plasma exchange.
• For disease maintenance, it is recommended 
to use a combination of glucocorticoids with 
either azathioprine, methotrexate, mycophe-
nolate mofetil, or rituximab. This treatment 
should be continued for a minimum of 24 
months.
• For refractory cases, it is recommended to 
switch from cyclophosphamide to rituximab 
or from rituximab to cyclophosphamide.
Management of ANCA-Associated Vasculitis  
No organ or life
threatening disease
























SOURCE: THE 2016 EULAR/ERA-EDTA RECOMMENDATIONS FOR THE
MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS
Fig. 25.19 The 2016 Eular/ERA-EDTA recommendations for the management of anca-associated vasculitis [17].
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25.5.3  Classification Criteria [18]
Polymyalgia rheumatica (PMR) is an inflamma-
tory disorder that is mainly characterized by 
neck, shoulder, and hip girdle pain and morning 
stiffness. An association between PMR and 
giant cell arteritis (GCA) was found, which may 
represent a shared underlying pathogenic 
process.
In April of 2012, the ACR and EULAR con-
vened and proposed PMR classification criteria 
that were designed to define its most important 
manifestations. [18].
Scoring-based criteria were made that out-
lined the following components:
 – The presence of morning stiffness for more 
than 45 minutes (2 points).
 – Pain in the hips with limited range of motion 
(1 point).
 – The absence of rheumatoid factor and/or anti- 
citrullinated protein antibody (2 points).
 – The absence of pain in the peripheral joints (1 
point).
The interpretation of the PMR scoring algo-
rithm after ruling out alternative conditions:
• The scoring scale is 0–6 (without ultrasound) 
and 0–8 (with ultrasound).
• A score of ≥4 (without ultrasound) or ≥ 
5(with ultrasound) is suggestive of PMR.
• A score of >5 increases the sensitivity to 66% 
and specificity to 81%.
• Patients with a score of <4 make them less 
likely to have PMR.
Ultrasounds are the imaging of choice for 
PMR, as they are a great tool to discern between 
PMR and other non- inflammatory conditions. 
They also increase the specificity of diagnosis. 
These criteria need to be validated by other 
cohort studies as it is important to distinguish 
PMR from other conditions (see Table 25.1).
There are no clear guidelines for the treat-
ment of PMR. The role of the early introduction 
of DMARDs in PMR is not entirely known. 
Currently, corticosteroids are the mainstay of 
treatment for PMR, although some randomized 
controlled trials have studied the use of immu-
nosuppressant therapy. New trials are also 
studying the use of biologics with PMR (see 
Table 25.2) [19].
25.6  Spondyloarthritis 
Classification Criteria 
and Management Guidelines
25.6.1  Classification Criteria 
(Figs. 25.20, 25.21 and 25.22) 
(Table 25.3)
Spondyloarthritis (SpA) is an umbrella term that 
encompasses the following interconnected dis-
eases: ankylosing spondylitis (AS), psoriatic 
arthritis (PsA), reactive arthritis, 
 enteropathic- related spondylitis and arthritis, and 
Table 25.1 Summary of EULAR/ACR 2012 classification criteria for Polymyalgia Rheumatica (PMR)
Criteria
Points without 
US(0-6) Points with US (0-8)
Morming stifness duration >45 min Two points Two points
Hip pain or limited range of motion One point One point
 Absence of RF or ACPA Two point Two points
 Absence of other joint involvement One point One point
 At least one shoulder with subdeltoid bursitis and/or biceps 
tenosynovitis and/or glenohumeral synovitis (either posterior or axillary) 
and at least one hip with synovitis and/or trochanteric bursitis
Not applicable One point
 Both shoulders with subdetoid burstis, biceps tenosynovitis or 
glenohumeral synovitis
Not applicable One point
aA score of 4 or more is categorized as PMR in the algorithm without US and a score of 5 or more is categorized as PMR 
in the algorithm with US
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In patients with ≥3 months back






≥2 other SpA features 
OR
SpA features
1.   Inflammatory back pain
2.   Arthritis
3.   Enthesitis 
4.   Uveitis
5.   Dactylitis
6.   Psoriasis
7.   Crohn’s/colitis
8.   Good response to NSAID
9.   Family history for SpA
10. HLA-B27
11. Elevated CRP
Fig. 25.20 ASAS 
classification criteria for 
axial spondyloarthritis 
(SpA)
undifferentiated SpA. There are many proposed 
classification criteria for SpA; however, they are 
more geared to be used in research contexts 
rather than clinical settings.
The most recent classification criteria devel-
oped by the Assessment of SpondyloArthritis 
international Society (ASAS) have determined 
that MRIs are the imaging modality of choice for 
the detection of axial and sacroiliac affection, as 
they are more sensitive than radiographs, espe-
cially for early disease. These changes were not 
mentioned in the modified New York criteria, the 
European Spondyloarthropathy Study Group cri-
teria, and the Amor criteria for AS [20].
The ASAS group also proposed a definition for 
inflammatory back pain and criteria for classifying 
axial and peripheral spondyloarthritis. These crite-
ria were designed to provide a diagnosis for patients 
in the early phases of their disease. The above 
 mentioned advances were made to aid research into 
the use of biologic agents in early disease. ASAS 
also defined non- radiographic axial spondyloar-
thritis (nr-axSpA); this entity shares the same 
underlying genetic factors, disease course, and 
prognosis as the radiographic variant; however, it 
differs in its absence from detection by plain radio-
graphs as well as a lesser degree of ossification and 
inflammation found both clinically and on MRIs.
Table 25.2 Summary of EULAR/ACR 2015 recommendation of management for Polymyalgia Rheumatica (PMR)
Management of Polymyalgia Rheumatica
Initial glucocorticoid therapy: Prednisone 15mg daily with clinical response in 1 week and resolution of acute 
phase reactant in 3-4 weeks
If no response Dose may be increased by 5 mg day increments each week up to 30 mg/day
Follow up in 
4-6 weeks
Gradual steroid tapering.
Once the dose has fallen to 10 mg day, reduce the dose no faster than 1 mg per month
Relapse   •  In patients who relapse while on glucocorticoids→increase glucocorticoid dose to lowest 
effective dose.
  •  Relapse following discontinuation of glucocorticoids→resumption of glucocorticoids at the 
original dose at which control was achieved.
  •  In patients who relapse several times→ interval between dose reductions should be increased 
to every two or three months.
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25.6.2  Management Guidelines
Diagnosis of SpA is often delayed with many 
patients not receiving the appropriate treatment. 
Biological agents were found to halt the disease’s 
progression and improve its prognosis. Treatment, 
however, should be tailored to each patient’s spe-
cific needs [21].
ASAS-EULAR Recommendations for 
Management of SpA (2016 Update) [22] 
(Figs. 25.23 and 25.24).
The management of patients with AS should 
be specifically individualized for each patient 
according to the disease’s severity and activity as 
well as the patient’s general condition, function, 
disability, wishes, and expectations.
Monitoring of the patient’s disease includes 
assessment by history, physical examination, lab-
oratory investigation, and imaging modalities. 
Management options are then tailored based on 
this assessment and assigned to either non- 
pharmacologic, pharmacologic, or surgical 
approaches.
Nonpharmacologic strategy:
Education, regular exercise, and physiother-
apy should be considered.
Pharmacologic strategy:
• Anti-inflammatory drugs are the first-line 
agents in patients complaining of pain and/or 
stiffness.
• Pain killers like paracetamol and opioids.
• Local steroid injections can be used if the 
patient is still in pain despite using anti- 
inflammatory medications.
• DMARDs can be used in extra-axial inflam-
matory joint pain.
• Anti-tumor necrosis factor (anti-TNF): for 
patients with axial disease, the use of the com-
bination of DMARDs and anti-TNF is not 
necessary.
• Interleukin 17 and interleukin 12/23 inhibi-
tors: they have been introduced in the recent 
ASAS-EULAR guidelines based on recent 
randomized controlled trials that show their 
efficacy in SpA.
Surgical strategy:
Total hip replacement and spinal surgery 
should be contemplated in patients with pain or 
disability that are refractory to treatment.








    imaging  
≥ 2 other SpA features
7.   Arthritis 
8.   Enthesitis
9.   Dactylitis
10. IBP (ever)
11. Family history for
      SpA
OR
Fig. 25.22 ASAS 








with rest  
Pain at night
(improve upon
getting up)  
Age at onset <
40 
Fig. 25.21 Inflammatory back pain assessment ASAS 
expert criteria)
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Table 25.3 Definition of SpA features in the ASAS classification criteria for peripheral SpA
SpA feature Definition
Entry criteria:
Arthritis Current peripheral arthritis compatible with SpA (usually asymmetric and/or predominant
involvement of the lower limb), diagnosed clinically by a physician
Enthesitis Current enthesitis, diagnosed clinically by a doctor
Dactylitis Current dactylitis, diagnosed clinically by a doctor
Additional SpA features:
IBP in the 
pasta
IBP in the past according to the rheumatologist’s judgement
Arthritis Past or present peripheral arthritis compatible with SpA (usually asymmetric and/or predominant
involvement of the lower limb), diagnosed clinically by a physician
Enthesisb Enthesitis: Past or present spontaneous pain or tenderness on examination of an enthesis
Uveitis Past or present uveitis anterior, confi rmed by an ophthalmologist
Dactylitis Past or present dactylitis, diagnosed by a physician
Psoriasis Past or present psoriasis, diagnosed by a physician
IBD Past or present Crohn’s disease or ulcerative colitis diagnosed by a physician
Preceding 
infection




Presence in first-degree (mother, father, sisters, brothers, children) or second-degree
(maternal and paternal grandparents, aunts, uncles, nieces, and nephews) relatives
of any of the following: ankylosing spondylitis, psoriasis, acute uveitis,
reactive arthritis or IBD
HLA-B27 Positive testing according to standard laboratory techniques
sacroiliitis by 
imaging
Bilateral grade 2–4 or unilateral grade 3–4 sacroiliitis on plain radiographs, according
to the modified New York criteria, or active sacroiliitis on MRI according to the
ASAS consensus definition
ASAS, Assessment of SpondyloArthritis International Society; HLA-B27, human leucocyte antigen B27; IBD, inflam-
matory bowel disease; IBP, inflammatory back pain; SpA, spondyloarthritis.
aHere, only IBP in the past is considered. In patients with current IBP (and concomitant peripheral manifestations), the 
ASAS classifi cation criteria for axial SpA should be applied























Fig. 25.23 ASAS- 
EULAR 
recommendations for the 




recommendations for the 
treatment of patients 
with axSpA with 
bDMARDs.
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25.7.1  Classification Criteria
Psoriatic arthritis (PsA) is an inflammatory joint 
disease with heterogeneous presentation pat-
terns representing different clinical subcatego-
ries. Many classification criteria have been put 
forth but they were not used widely and have not 
been validated. The presence of these different 
presentation patterns has made it difficult to 
propose and validate classification criteria for 
the diagnosis of PsA, especially with disease 
patterns like seronegative polyarthritis and 
psoriasis.
Diagnosis of axial SpA by a rheumatologist
Failure of standard treatment:
all patients
1. at least 2 NSAIDs over 4 weeks (in total)
patients with predominant peripheral manifestations
1. one local steroid injection if appropriate
2. normally a therapeutic trial of sulfasalazine






High CRP and/or positive MRI and/or radiographic sacroiliitis*
Fig. 25.24 ASAS- 
EULAR 
recommendations for the 
treatment of patients 
with axSpA with 
bDMARDs)
Table 25.4 Classification Criteria for Psoriatic Arthritis (CASPAR)
Classification criteria for psoriatic arthritis (CASPAR)
Inflammatory articular disease (joint, spine or entheseal) with ≥ 3 of the following:
  1.  Evidence of psoriasis:
 (one of a,b,c)
  a.  Current 
psoriasis
Psoriatic skin or scalp disease present today as judged
by a rheumatologist or dermatologist
  b.  Personal 
history of 
psoriasis
A history of psoriasis that may be obtained from
patient, family doctor, dermatologist, rheumatologist,
or other qualified health-care provider
  c.  Family 
history
A history of psoriasis in a first or second degree relative
according to the patient’s reporting
  2.   Psoriatic nail dystrophy Typical psoriatic nail dystrophy including onycholysis,
pitting and hyperkeratosis observed on current physical
examination
  3.  A negative rheumatoid 
factor
By any method except latex but preferably by ELISA or
nephelometry, according to the local laboratory
reference range
  4. Dactylitis (a or b)   a. Current swelling of entire digit
  b. A history of dactylitis recorded by a rhematologist
  5.   Radiological evidence 
of juxta-articular new 
bone formation
III-defined ossification near joint margins (but excluding osteophyte formation) on 
plain X-rays of hands or feet
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Older criteria, such as the Moll and Wright 
classification criteria for PsA that were proposed 
in 1973, do not offer a clear distinction between 
RA and PsA. The Fourni criteria that were pro-
posed in 1999 were the first to be formulated 
based on patients’ data; however, they require 
HLA-B27 positivity which excludes around 24% 
of patients who have the disease but test negative 
for HLA-B27. ClASsification for Psoriatic 
ARthritis (CASPAR) criteria are a congregation 
of international authorities who were successful 
in creating validated classification criteria in 
2004. These criteria are highly sensitive and spe-
cific (specificity 99% and sensitivity 92%) and 
have allowed for the diagnosis of PsA even in the 
absence of arthritis if manifestations like dactyli-
tis and enthesitis are present. PsA can also be 
diagnosed despite the presence of low RF posi-
tivity. The absence of psoriasis is allowed as 
these criteria incorporate family history; there-
fore, a diagnosis can be established if other typi-
cal features are present [23].
25.7.2  Management Guidelines
A list of ten recommendations were proposed for 
the management of articular and extra-articular 
features of PsA. Treatments mentioned comprise 
of NSAIDs, synthetic DMARDs, and biological 
therapies. These recommendations are aimed to 
give a combined evidence-based and expert 
opinion approach to tackle this disease in the 
most optimal way and to provide the best 
outcomes.
Summary of European League Against 
Rheumatism recommendations for the manage-
ment of psoriatic arthritis with pharmacological 
therapies (2015) [24] (Fig. 25.26).
25.8  Systemic Sclerosis 
Classification Criteria 
and Management Guidelines
25.8.1  Classification Criteria 
of Systemic Sclerosis (Tables 
25.5, 25.6 and 25.7)
ACR developed classification criteria for systemic 
sclerosis (SSc) in 1980. One major and two minor 
criteria are required to diagnose SSc. As these cri-
teria had a strong emphasis on skin manifestations 
Articular



















current dactylitis history of dactylitis
Fig. 25.25 Summary of the Classification Criteria of Psoriatic Arthritis
Table 25.5 The old ACR classification criteria for sys-
temic sclerosis [26])
Criterion Definition
Major criterion Proximal scleroderma
Or two of the minor criterions:
Minor criteria   1. Sclerodactyly
  2.  Digital pitting scars of 
fingers or loss of the 
distal finger pad
  3.  Bilateral basilar 
pulmonary fibrosis
The proposed criteria had a 97% sensitivity for 
definite systemic sclerosis and a 98% specificity




• If there is adverse prognostic factors, with or without major skin involvement,
  go directly to phase II
• Start NSAIDs +/–local glucocorticoid injection. Achieve target within 3–6 months,
• If there is major skin involvement: dermatology consultation 
Phase II
if failed
• If prodominantly axial disease or severe enthesitis: go directly to phase III
• Start methotrexate, or -if contraindicated-start leflunomide or sulfasalazine.
• Achieve target within 3-6 months.
Phase III
if failed
• Arthritis without adverse prognostic factors: start a second sDMARD or
  combination therapy.
• Arthritis with adverse prognostic factors (+ Axial disease) : start a TNF-Inhibitor, if
  contraindicated an IL-17 of or IL-12/23 inhibitors may be used.
• Achieve target within 3-6 months.
Phase IV
• Change the biological treatment: switch to another TNF-inhibitor or other
  mode of actions +/–DMARD
Fig. 25.26 Summary of EULAR 2015 recommendations for the management of psoriatic arthritis
Table 25.6 The American College of Rheumatology/European League Against Rheumatism criteria for the classifica-
tion of systemic sclerosis (SSc)a
Manifestation Additional manifestation Weight/
scoreb
Skin thickening of the fingers of both hands extending 
proximal to the metacarpophalangeal joints (sufficient 
criterion)
- 9
Skin thickening of the fingers
 (only count the higher score)
Puffy fingers 2
Sclerodactyly of the fingers
(distal to the metacarpophalangeal joints but 
proximal to the proximal interphalangeal 
joints)
4
Fingertip lesions  (only count the higher score) Digital tip ulcers 2
Fingertip pitting scars 3
Telangiectasia - 2
Abnormal nailfold capillaries 2
Pulmonary arterial hypertension and/or interstitial lung 
disease (maximum score is 2)
- 2
Raynaud phenomenon - 3
SSc-related autoantibodies (anticentromere, 
antitopoisomerase I [anti-Scl-70], anti-RNA 
polymerase III) (maximum score is 3)
- 3
aThese criteria are applicable to any patient considered for inclusion in an SSc study. The criteria are not applicable to 
patients with skin thickening sparing the fingers or to patients who have a scleroderma-like disorder that better explains their 
manifestations (e.g., nephrogenic sclerosing fibrosis, generalized morphea, eosinophilic fasciitis, scleredema diabeticorum, 
scleromyxedema, erthromyaglis, porphyria, lichen sclerosis, graft-versus-host disease, diabetic cheiroarthropathy)
bThe total score is determined by adding the maximum weight (score) in each category. Patients with a total score ≥ 9 
are classified as having definite SSc
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rather than the vascular or immunologic features 
that predate Raynaud’s phenomenon, it became 
evident that it lacked proper sensitivity and speci-
ficity when it came to diagnosing early disease.
The ACR and EULAR collaborated to develop 
a revised classification criteria in 2013 to improve 
the older criteria’s lower sensitivity and specific-
ity rates in diagnosing early SSc and limited cuta-
neous SSc [25]. These criteria may be used for 
the inclusion of patients in SSc trials; however, it 
may be less efficient in patients with scleroderma- 
like syndromes.
25.8.2  Management Guidelines 
of Systemic Sclerosis 
(Table 25.8)
There is still a lot to be discovered in terms of the 
pathogenesis of SSc disorders. Treatment is chal-
lenging and no cure has yet been found. Previously, 
SSc trials were found to be subpar, with many 
based on single centers with insufficient recruit-
ment numbers and poor randomization and con-
trol. They also did not take into account the many 
variable subsets and stages of the disease.
The past 10 years has witnessed significant 
advances in the field of SSc treatment, and many 
clinical trials have been documenting the efficacy 
of different treatment modalities. However, there 
are many obstacles that still stand in the way of 
conducting quality clinical trials, they include the 
following:
• SSc is an uncommon disease and can present 
with variable features.
• Progression rates vary between the different 
subsets of the disease.
• Treatment varies based on the organ that is 
involved.
• Disease monitoring measures are not very accu-
rate in detecting slower incremental changes.




There have been many proposed classification 
criteria for dermatomyositis (DM) and polymy-
ositis (PM). Brohan and Peter executed one of 
Table 25.7 Definitions of manifestations in the American College of Rheumatology/European League Against 
Rheumatism criteria of the classification of systemic sclerosis (SSc)
Manifestation Definition
Skin thickening Skin thickening or hardening not due to scarring after injury, trauma, etc.
Puffy fingers Swollen digits: a diffuse, usually nonpitting increase in soft tissue mass of the digits extending 
beyond the normal confines of the joint capsule. Normal digits are tapered distally with the 
tissues following the contours of the digital bone and joint structures. Swelling of the digits 
obliterates these contours. Not due to other causes such as inflammatory dactylitis.
Fingertip ulcers or 
pitting scars
Ulcers or scars distal to or at the proximal interphalangeal joint not thought to be due to 
trauma or exogenous causes.
    Telangiectasiae Telangiectasiae are visible macular dilated superficial blood vessels, which collapse upon 
pressure and fill slowly when pressure is released. Telangiectasiae in a scleroderma-like 
pattern are round and well demarcted and founds on hands, lips, inside of the mouth, and/or 
are large mat-like telangiectasiae. Distinguishable from rapidly filling spider angiomas with 





Enlarged capillaries and/or capillary loss with or without pericapillary hemorrhages at the 








Pulmonary fibrosis seen on high-resolution computed tomography or chest radiography, most 
pronounced in the basilar portions of the lungs, or occurrence of “Velcro” crackles on 
examination.
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the earliest criteria in 1975, which had been 
used to aid in research for several decades. 
These criteria demanded the presence of typical 
skin manifestations and at least three out of four 
other criteria to meet the diagnosis of 
DM. Patients who were diagnosed with PM had 
to have met all four criteria in addition to the 
cutaneous features. As there are no highly spe-
cific autoantibodies, biopsy and histological 
proof remain important diagnostic tools. There 
are limitations with these criteria as research 
studies conducted on PM/DM are scarce, mak-
ing the classification of these diseases difficult 
in addition to the poor understanding of the rela-
tionship between DM and PM.
The discovery of at least eight antisynthetase 
autoantibodies had allowed for significant 
advances in diagnosing DM and PM, especially 
as these autoantibodies were all associated with 
different manifestations of the disease (see 
chapter “Diagnostic Approach to Proximal 
Myopathy”).
Table 25.8 Summary of 2016 EULAR recommendations for treatment of systemic sclerosis, according to the organ 
involvement [26]
Digital ulcers 
in patients with 
SSc
Intravenous iloprost should be considered in the treatment of digital ulcers in patients 
with SSc.
A
PDE-5 inhibitors should be considered in the treatment of digital ulcers in patients with 
SSc.
A
Bosentan should be considered for reduction of the number of new digital ulcers in SSc, 
especially in patients with multiple digital ulcers despite use of calcium channel 
blockers, PDE-5 inhibitors or iloprost therapy.
A
SSc-PAH Several ERA (ambrisentan, bosentan and macitentan), PDE-5 inhibitors (sildenafil, 
tadalafil) and riociguat have been approved in the treatment of PAH associated with 
CTDs. ERA, PDE-5 inhibitors or riociguat should be considered to treat SSc-related 
PAH.
B
Intravenous epoprostenol should be considered for the treatment of patients with severe 
SSc-PAH (class III and IV).
A







Methotrexate may be considered for treatment of skin manifestations of early diffuse 
SSc.
A
Despite its known toxicity, cyclophosphamide should be considered for treatment of 
SSc-ILD, in particular for patients with SSc with progressive ILD.
A
HSCT should be considered for treatment of selected patients with rapidly progressive 
SSc at risk of organ failure.
In view of the high risk of treatment-related side effects and of early treatment-related 






Experts recommend immediate use of ACE inhibitors in the treatment of SRC. C
Because several retrospective studies suggest that glucocorticoids are associated with a 
higher risk of SRC, blood pressure and renal function should be carefully monitored in 





Experts recommend that PPI should be used for the treatment of SSc-related GERD and 
for the prevention of oesophageal ulcers and strictures
C
Experts recommend that prokinetic drugs should be used for the management of 
SSc-related symptomatic motility disturbances (dysphagia, GERD, early satiety, 
bloating, pseudo- obstruction, etc).
C
Experts recommend the use of intermittent or rotating antibiotics to treat symptomatic 
small intestine bacterial overgrowth in patients with SSc.
D
CTD, connective tissue disease; ERA, endothelin receptor antagonists; EULAR, European League against Rheumatism; 
GERD, gastro-oesophageal reflux disease; HSCT, haematopoietic stem cell transplantation; PAH, pulmonary arterial 
hypertension; PDE-5, phosphodiesterase type 5; PPI, proton pump inhibitor; SRC, scleroderma renal crisis; SSc, sys-
temic sclerosis; SSc-RP, Raynaud’s phenomenon in patients with SSc
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25.8.4  Summary of Polymyositis 
and Dermatomyositis 
Classification Criteria [27] 
(Fig. 25.27)
Management of inflammatory myositis is diffi-
cult due to the scarcity of randomized controlled 
trials and the fact that the disease is very uncom-
mon. Treatment includes:
• Glucocorticoids, immunoglobulins, and the 
newly included mycophenolate mofetil.
• Mycophenolate mofetil and rituximab 
which were found to be efficient in refrac-
tory cases.
• Anti-tumor necrosis factor (anti-TNF) inhibi-
tors which were also found to be useful in 
treating resistant cases.
In general, there are limited data upon which 
the base treatment recommendations for DM and 
PM are provided.




The ACR proposed classification criteria for 
Sjögren’s syndrome (SS). These criteria were 
based on evidence from the Sjogren’s 
International Collaborative Clinical Alliance 
(SICCA) and also on the knowledge of field 
authorities; it is easily applicable and based 
mostly on objective testing.
At least two of the following items need to be 
present to diagnose SS:
• Positive serum anti-SSA and/or anti-SSB or 
positive rheumatoid factor plus antinuclear 
antibodies ≥1:320.
• Ocular staining score ≥ 3.
• Labial salivary gland biopsy showing focal 
lymphocytic sialadenitis with a focus score ≥ 
1 foci/4 mm2 [28].
Criteria of Sjogren disease 
Labial salivary gland with focal lymphocytic sialadenitis & focus score ≥13
Positive anti Ro/La3
Ocular staining score ≥51
Schirmer’s test ≤ 5mm/ 5minutes in at least 1 eye1
Unstimulated whole saliva flow rate ≤0.1 ml /minute1
• The criteria applies to those who meet the inclusion criteria with a score of at least 5 and to those who do not 
fulfil any of the exclusion criteria
• Exclusion criteria include:
• History of head and neck radiation treatment




• Graft-verus-host diease 
• IgG4-related diease 
Table 25.9 ACR classification criteria for Sjogren’s syndrome
25 Classification Criteria and Clinical Practice Guidelines for Rheumatic Diseases
552
There is no single medication available that 
has been proven to be effective in SS in random-
ized controlled trials. Treatment at this moment is 
mainly symptomatic, supportive, and empiric.
In a subset of patients in which arthralgia is a 
major symptom, some clinicians prescribe anti-
malarials (hydroxychloroquine). More recently, 
biological therapies are studied for their potential 
efficacy in early SS.  Therefore, proper patient 
detection in the early stages of the disease is 
important.
B-cell targeting with either rituximab or beli-
mumab has been studied, and a study with epratu-
zumab is planned for the near future [29]. Until 
now, no immunomodulatory drugs have been 
proved to be effective in primary SS.
25.8.6  Behcet’s Disease Classification 
Criteria and Management 
Guidelines
Behcet’s disease (BD) is an inflammatory disease 
that runs a relapsing and remitting course. The 
pathogenesis is not entirely known and no con-
clusive diagnostic tests have been found. The 
diagnosis relies on clinical grounds.
A group of physicians responsible for the 
treatment of large numbers of patients with BD 
formed the International Study Group (ISG) and 
published the ISG criteria for diagnosis in 1990. 
The utility of the criteria is dependent on the 
prevalence of the syndrome in the background 
population; there may also be atypical patients 
Inclusion
criteria: 
Symmetrical proximal muscle weakness
Elevated muscle enzymes
Characteristic EMG abnormalities
Necrosis, phagocytosis, regeneration and inflammtion in the muscle biopsy
Gottron's sign or heliotrope rash or papules in dermatomyositis
Exclusion
criteria:
















No rash +   
Fig. 25.27 Criteria for the diagnosis of polymyositis and dermatomyositis
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who do not fulfill the criteria. These criteria are 
meant for the classification of groups of patients 
participating in research programs to ensure 
comparability of the groups, and not for the diag-
nosis of the individual patients in clinical 
situations.
25.8.7  Diagnostic Criteria 
for Behcet’s Disease, 
International Study Group 
for Behcet’s Disease (1990) 
(Tables 25.10 and 25.11)
Treatment of BD is mainly based on evidence 
that were gleaned from case reports and case 
series with a paucity of randomized controlled 
trials. Management relies both on organ dysfunc-
tion and on the degree of dysfunction. As patients 
mostly have multisystemic dysfunction, manage-
ment is thus dictated by the most critical organ 
that is involved.
Since 1998, there have been only a small num-
ber of advances in the quality of BD literature. 
These include significant benefits found in ran-
domized trials of colchicine, mucocutaneous dis-
ease, and the introduction of anti-TNF-alpha 
therapy. Most current approaches with other 
medications are dictated primarily by extrapola-
tion of the use of certain medications from their 
efficacy in other inflammatory conditions.
The EULAR and the task force of the EULAR 
Standing Committee for Clinical Affairs 
(ESCCA) proposed a list of treatment recom-
mendations in 2008. This list was primarily 
derived from a systematic review that was con-
ducted in 2006. The treatments of all facets of 
BD were outlined in nine recommendations. 
Recommendations regarding the management of 
ocular, mucocutaneous, and musculoskeletal 
were based on stringent evidence. However, 
manifestations that affect the vascular, neurologi-
cal, and gastrointestinal systems were derived 
from data that is of a lesser quality, including 
open trials, observational studies, and expert 
opinions. There is a significant need for more 
research to cover all areas that are deficient in this 
disease [30].
25.8.8  Gout Classification Criteria 
and Management Guidelines 
[31] (Box 25.2)
Gout is considered to be one of the most common 
inflammatory arthritis. It is characterized by the 
deposition of monosodium urate crystals in the 
extracellular fluid. The diagnosis of gout is sug-








• *4 points or more diagnose Behcet diease  
Table 25.10 Diagnosis criteria for Behcet’s disease
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gested by the presence of typical clinical features 
along with increased urate levels in the serum. 
However, coincidentally found high serum urate 
concentrations could also occur in other causes 
of acute arthritis.
The 2014 guidelines [31] provide practical 
recommendations which are supported by 
evidence- based practice in addition to the opin-
ions of a large number of multinational expert 
rheumatologists. This is called the 3e (Evidence, 
Expertise, Exchange) Initiative.
In these recommendations, they emphasize 
the finding of monosodium urate crystals in syno-
vial fluid as a crucial step for definitive diagnosis 
of gout.
The 3e Initiative differs from the 2012 ACR 
guidelines in two recommendations:
 1. Kidney function should be assessed in patients 
with high uric acid levels and/or gout. 
Measurements of the patient’s cardiovascular 
risk factors are also suggested. In the previous 
2012 guideline, it was not necessary to assess 
for cardiovascular risk factors or renal func-
tion status.
 2. It was suggested that allopurinol be used as 
the first-line urate-lowering therapy.
All xanthine oxidase inhibitors were previ-
ously considered as first-line choices for therapy. 
However, now allopurinol is the first-line agent 
with alternatives including uricosurics or febuxo-
stat. The use of uricase on its own can be used in 
severe and refractory cases where other lines 
were either exhausted or contraindicated.
It is important to mention the limitations of 
these guidelines. Three limitations were men-
tioned: first, there were no participants from other 
specialties like nephrology so, the applicability of 
these recommendations is not clear. Second, many 
recommendations have different statements with 
variable degrees of supporting evidence. Lastly, 
agreement on these recommendations was vari-
able which suggests some degree of dispersion. 
However, around more than 80% of rheumatolo-
gists voted in support of these recommendations.




Corticosteriod & azathioprine(AZA)Posterior eye diease 





Sulfasalazine, corticosteriod, azathioprine, TNFα antagonist before surgery GI involvment 
Corticosteriod, AZA, TNFα antagonist cyclophosphamide
Ciclosporin A not recomended 
CNS inlvoment
AZA, IFNα and TNFα antagonistResistant cases 
• *2008 EULAR recommendations of management for Behcet disease 
Table 25.11 EULAR recommendations for the management of Behcet’s disease
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Mangment of GOUT
treatment of gout 
Nonpharamocgical
• Education about pathophysiology of the diease 
• Weight loss
• Avoidance of alcohol and suger-sweetened drinks 
• Reduce intake of meat and sea food 
• Regular excerice 
• Stop loop or thiazide diureics
flare of gout 
acute 
• Start treatment as early as possible and the choice of drugs depends on pateint's comorbidites.
• Colchicine is the first line treatment; to be started at a loading dose of 1 mg to be followed 1 hour later by 0.5 mg 
• NSAID 
• Oral coricosteroid (30-35 mg/day for 3-5 days)
• Articular injecion of corticosteroids. 
treatment of gout Prophylactic
• Urate lowering therapy (ULT) is indicated in patients with recurrent flares, tophi, urate arthropathy and /or
   renal stones.
• Allopurinol first line therapy, to be started at a low dose (100mg/day) and increased every 2-4 weeks as needed
• Febuxostat or a uricosuric agent are indicated if allopurinol cannot be tolerated.
• For patents on ULT, SUA level should be monitored and maintained to <6 mg/dL 360 umol/L).
• All ULTs should be started at a low dose and then titrated upwards until the SUA target is reached.
• Pegloticase is indicated in patients with crystal proven, severe chronic tophaceous gout in whom 
  the maximum dosage of first line drugs had been reached without improvement











Diagnosis management of Gout artheritis 
Box 25.2: 2016 EULAR recommendation of gout management
2016 EULAR recommendation of gout management
Box 25.2 Multinational Recommendations on the Diagnosis and Management of Gout
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25.9  Osteoarthritis Classification 
Criteria and Management 
Guidelines
25.9.1  Classification Criteria 
(Fig. 25.28)
Osteoarthritis (OA) is a chronic musculoskeletal 
disease that often leaves the patients suffering 
from pain and disability. OA may be classified as 
primary or secondary. Optimal management 
requires early diagnosis.
The ACR formulated classification criteria for 
OA, and although they are highly specific when 
applied and allow for the discernment between 
patients with inflammatory arthritis and patients 
with osteoarthritis, they have lower sensitivity 
rates, especially if the differentiation between 
1 or more of the following 
Knee osteoarthritis (OA)
Criteria of knee OA
Age more than 50 years
Morning stiffness






Criteria of Hand OA
Enlargement of 2 or more 
of 10 *selected joints
Enlargement of 2 or more
DIP joints
3 swollen MCP joints or less
Deformity of 1 of 10
*selected joints 
Hand pain
3 or more of the following 
*The 10 joints are the 2nd and 3rd DIP, the 2nd and 3rd PIP 
and the first CMC joints
Hip osteoarthritis (OA)
Criteria of Hip OA







2 or more of the following 
Fig. 25.28 ACR classification criteria for osteoarthritis (OA) [32, 33, 34]
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patients who are in the early stages of their dis-
ease and healthy subjects is sought.
Another set of recommendations was devel-
oped by the EULAR which showed that hand and 
knee OA can be diagnosed using clinical assess-
ment alone. The EULAR guidelines include ten 
recommendations which were derived from a 
systematic review of literature and the opinions 
of experts in the field. They stipulate that the 
presence of symptoms including knee pain, brief 
morning stiffness, and disturbances in functional-
ity along with clinical signs including knee crepi-
tus, limitation of range of motion, and enlargement 
of bones would suffice to make a diagnosis with-
out the need to proceed for any imaging modali-
ties. This approach would benefit primary care 
physicians the most. However, plain radiographs 
and further imaging can be done if the presenta-
tion is atypical or other differentials are 
considered.
25.9.2  Osteoarthritis Management 
Guidelines [35] (Figs. 25.29, 
25.30 and 25.31)
Research regarding the management of osteoar-
thritis is still scarce. The disease is primarily 
managed using a consensus of opinions from 
experts in the field. The EULAR has formulated 
a list of treatment recommendations in 2010 
which was derived from both experts’ opinions 
and research evidence. The list covers the treat-
ment of the hand, hip, and knee OA. In determin-
ing the strength of recommendation for any 
treatment, many factors other than efficacy need 
to be considered, including safety, cost, logistics 
of delivery, and the individual patient’s 
acceptability.
25.9.2.1  Osteoporosis Classification 
Criteria and Management 
Guidelines [36–41] 
(Table 25.12) (Box 25.3) 
(Fig. 25.32)
Osteoporosis is characterized by decreased bone 
mass and disruption in musculoskeletal microar-
chitecture leading to bone fragility and higher 
risks of fracture. The disease often remains unde-
tected until a fracture develops. Osteoporosis is 
confirmed either by the occurrence of a fragility 
fracture in the hip or spine or by confirmation of 
decreased bone density by bone mineral density 
(BMD) measurements. The definitions of osteo-
penia and osteoporosis based on BMD testing 
were defined by the World Health Organization 
(WHO).
Risk stratification for osteoporosis is impera-
tive in all adults. BMD-independent factors that 
should be kept in consideration include older age, 
previous occurrences of fragility fractures, use of 
steroids, smoking and alcohol consumption, and 
a positive family history of fracture. There are 
recommendations about when to do BMD screen-
ing to detect osteoporosis and when to repeat 
BMD testing.
The Fracture Risk Assessment Tool (FRAX) 
was proposed by the WHO in 2008; this tool 
helps to determine the 10-year risk of hip frac-
tures or major fragility fractures. However, as the 
association between decreased bone mass and 
fractures in premenopausal women is not as well 
studied as the one in postmenopausal women, 
bone mineral density criteria and management 
guidelines may not be as useful in the premeno-
pausal women population.
Ruling out secondary causes of osteoporosis 
is imperative. Management guidelines include 
non-pharmacological lines of therapy and phar-










• Manual therapy in combination with supervised exercise
• Psychosocial interventions
• Directed patellar taping or wedged insoles
• Walking aids/Tai chi programs


















• Intraarticular hyaluronic acid
• Duloxetine
• Opioid
Non pharmacologic recommendations for the management of Knee OA
Pharmacologic recommendations for the management of Knee OA
Fig. 25.29 Nonpharmacologic and pharmacological recommendations for the management of knee OA*




• Ability to perform activities of daily living
• Joint protection techniques
• Assistive devices, thermal modalities











Nonpharmacologic recommendations for the management of Hand OA
Pharmacologic recommendations for the management of Hand OA
Fig. 25.30 Nonpharmacologic and pharmacological recommendations for the management of hand OA




• Cardiovascular (aerobic) and/or resistance land-based exercise
• Aquatic exercise




• Manual therapy in combination with supervised exercise
• Psychosocial interventions
























Nonpharmacologic recommendations for the management of Hip OA
Pharmacologic recommendations for the management of Hip OA
Fig. 25.31 Nonpharmacologic and pharmacological recommendations for the management of hip OA*
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Table 25.12 Defining osteoporosis by BMD WHO definition of osteoporosis based on BMD
Classification Normal Osteopenia Osteoporosis Severe Osteoporosis




1 to 2.5 below 
the SD
2.5 or more below 
the SD
2.5 or more below the 
SD
T-score -1 and 
above
-1 to -2.5 -2.5 and below -2.5 and below with a 
fracture
Risk Factors of Osteoporosis   
• Age above 65 years
• Low body weight 
• Early menopause 
• Fractures: vertebral compression fracture, fragility fracture, family history of
  osteoporotic fracture. 
• Disease: malabsorption syndromes, primary hyperparathyrodism,
  hypogonadism, rheumatoid arthritis, clinical hyperthyroidism.
• Medications: systemic glucocorticoid disease for more than 3 months,
  prolonged anticonvulsant therapy, chronic heparin therapy. 
• Dietary: low calcium intake, excessive alcohol intake, excessive caffeine intake.
• Smoker 
• Propensity to fall
Box 25.3 Factors That 
Identify People Who 
Should Be Assessed for 
Osteoporosis












Low bone mass or
bone loss    
Age
Women ≥ 65
Men ≤ 70 or > 50 
with clinical risk
factors for fracture 
Fig. 25.32 Indications 
for BMD testing
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DXA of ≤ -2.5  
Fig. 25.33 Consider 


















Fig. 25.34 Consider 
nonmedical therapeutic 
interventions
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Regular follow up for patients
not receiving medical therapy
Vertebral imaging if there was 
back pain, height loss, postural
changes or suspicious changes
on chest x-ray 
Two years follow up for patients
receiving medications with
appropriate laboratory and bone
density re-evaluation 




Fig. 25.35 Follow-up recommendations












or major fracture  
Clinical judgment
on Treatment Follow up





Fracture in vertebra 
1st line : Bisphosphonate
2nd line : Denosumab
Raloxifene
(if low risk for peripheral
fracture)
Teriparatide







1st line : Bisphosphonate 
2nd line : Denosumab
Teriparatide




Fig. 25.37 Pharmacological treatment of postmeno-
pausal osteoporosis
macological agents. Assessment and treatment of 
preventable risk factors is also advised.
Universal recommendations for all patients 
(Figs. 25.33, 25.34, 25.35, 25.36 and 25.37) (Box 
25.4) include:
• Proper calcium and vitamin D dietary intake.
• Management of vitamin D deficiency.
• Weight-bearing exercises and exercises to 
improve muscle strength.
• Prevention of fall.
• Smoking cessation and limitation of alcohol 
consumption.
The treatment guidelines mentioned should be 
thought of as a guide in clinical practice. A thor-
ough consideration of each patient’s situation is 
imperative in making proper management deci-
sions. These treatment guidelines should not stop 
physicians from offering therapies to those who do 
not meet the BMD (T-score ≤ −2.5) and FRAX 
diagnostic scores, or are not at a high enough risk 
of fracture despite decreased BMD, as every 
patient’s needs should be assessed individually.
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